The	O
XTT	O
-	O
test	O
was	O
carried	O
according	O
to	O
the	O
protocol	O
of	O
Scudiero	O
et	O
al	O
.	O
.	O
The	O
activity	O
of	O
cytochrome	B
P450	I
1A2	O
was	O
determined	O
by	O
means	O
of	O
O	O
-	O
demethylation	O
of	O
7	O
-	O
ethoxyresorufine	O
to	O
resorufin	O
.	O

Moreover	O
,	O
liver	O
cells	O
show	O
a	O
high	O
level	O
of	O
cytochrome	B
P450	I
activity	O
and	O
often	O
are	O
the	O
main	O
site	O
of	O
metabolic	O
transformation	O
.	O

The	O
results	O
obtained	O
will	O
allow	O
predicting	O
metabolic	O
pathways	O
of	O
target	O
compounds	O
in	O
patients	O
differing	O
in	O
the	O
level	O
of	O
cytochrome	B
P450	I
isoenzymes	O
and	O
,	O
in	O
turn	O
,	O
can	O
probably	O
be	O
helpful	O
in	O
designing	O
personalized	O
antibacterial	O
treatments	O
including	O
these	O
drugs	O
.	O

This	O
is	O
in	O
agreement	O
with	O
the	O
general	O
knowledge	O
that	O
this	O
group	O
of	O
cytochrome	B
P450	I
isoenzymes	O
participates	O
in	O
metabolism	O
of	O
numerous	O
drugs	O
.	O

Besides	O
cytochrome	B
P450	I
,	O
other	O
important	O
elements	O
of	O
microsomal	O
fraction	O
of	O
liver	O
cells	O
include	O
flavin	O
monooxigenase	O
(	O
FMO	O
)	O
and	O
glucuronosyltransferase	O
(	O
UDP	O
)	O
.	O

One	O
can	O
assume	O
that	O
LIN	O
and	O
CEF	O
,	O
owing	O
to	O
their	O
chemical	O
structure	O
and	O
pharmacological	O
properties	O
,	O
do	O
not	O
constitute	O
a	O
substrate	O
for	O
any	O
of	O
the	O
tested	O
isoenzymes	O
of	O
cytochrome	B
P450	I
.	O

It	O
is	O
thus	O
possible	O
that	O
other	O
isoenzymes	O
belonging	O
to	O
cytochrome	B
P450	I
play	O
a	O
part	O
in	O
the	O
metabolism	O
of	O
the	O
studied	O
drugs	O
.	O

Among	O
the	O
multiple	O
microsomal	O
fraction	O
enzymes	O
of	O
liver	O
cells	O
,	O
the	O
ones	O
most	O
involved	O
in	O
biotransformations	O
of	O
foreign	O
substances	O
are	O
isoenzymes	O
of	O
cytochrome	B
P450	I
;	O
ca	O
.	O

Besides	O
,	O
the	O
presence	O
and	O
the	O
appropriate	O
level	O
of	O
NADPH	O
-	O
dependent	O
cytochrome	B
P450	I
reductase	O
in	O
liver	O
cells	O
is	O
a	O
necessary	O
condition	O
for	O
proper	O
physiological	O
actions	O
of	O
its	O
isoenzymes	O
.	O

All	O
the	O
postulated	O
phase	O
I	O
metabolic	O
reactions	O
are	O
typical	O
for	O
processes	O
catalyzed	O
by	O
isoenzymes	O
of	O
the	O
cytochrome	B
P450	I
group	O
.	O

We	O
took	O
into	O
account	O
drug	O
elimination	O
in	O
cardiac	O
tissue	O
as	O
cytochrome	B
P450	I
enzymes	I
were	O
detected	O
in	O
human	O
cardiovascular	O
tissue	O
.	O

In	O
addition	O
,	O
because	O
PHT	O
and	O
CBZ	O
are	O
subjected	O
to	O
hepatic	O
metabolism	O
,	O
cytochrome	B
P450	I
(	O
CYP450	O
)	O
isoenzymes	O
could	O
have	O
an	O
important	O
role	O
,	O
affecting	O
drug	O
exposure	O
in	O
brain	O
tissue	O
,	O
these	O
include	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP3A4	B
,	O
CYP3A5	B
,	O
CYP1B1	O
and	O
CYP2E1	B
proteins	O
.	O

Sex	O
-	O
dependent	O
alteration	O
of	O
cardiac	O
cytochrome	B
P450	I
gene	O
expression	O
by	O
doxorubicin	O
in	O
C57Bl	O
/	O
6	O
mice	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
Doxorubicin	O
alters	O
the	O
expression	O
of	O
several	O
cytochrome	B
P450	I
enzymes	I
in	O
the	O
hearts	O
of	O
male	O
rats	O
.	O

We	O
have	O
demonstrated	O
that	O
acute	O
DOX	O
-	O
induced	O
cardiotoxicity	O
alters	O
the	O
expression	O
of	O
several	O
cytochrome	B
P450	I
enzymes	I
in	O
the	O
H9c2	O
cardiomyoblasts	O
in	O
vitro	O
and	O
in	O
the	O
hearts	O
of	O
male	O
Sprague	O
Dawley	O
rats	O
in	O
vivo	O
.	O

A	O
revelation	O
from	O
the	O
first	O
genome	O
sequence	O
of	O
M	O
.	O
tuberculosis	O
(	O
that	O
for	O
the	O
virulent	O
H37Rv	O
strain	O
)	O
was	O
that	O
20	O
different	O
cytochrome	B
P450	I
(	O
CYP	O
or	O
P450	O
)	O
enzymes	O
were	O
encoded	O
.	O

TF6	O
cytochrome	B
P450	I
alkane	O
hydroxylase	O
,	O
were	O
predicted	O
.	O

N	O
-	O
benzyl	O
-	O
N	O
-	O
cyclopropylamine	O
(	O
BCA	O
)	O
has	O
been	O
attracting	O
great	O
interests	O
for	O
decades	O
for	O
its	O
partial	O
suicide	O
inactivation	O
role	O
to	O
cytochrome	B
P450	I
(	O
P450	O
)	O
via	O
a	O
ring	O
-	O
opening	O
mechanism	O
besides	O
acting	O
as	O
a	O
role	O
of	O
normal	O
substrates	O
.	O

Besides	O
,	O
discovery	O
of	O
such	O
inhibitors	O
for	O
an	O
enzyme	O
,	O
eg	O
,	O
cytochrome	B
P450	I
,	O
whose	O
mechanisms	O
are	O
not	O
well	O
-	O
characterized	O
should	O
provide	O
an	O
equally	O
specific	O
and	O
effective	O
probe	O
.	O

Cyclopropylamines	O
are	O
one	O
kind	O
of	O
such	O
prototypical	O
inhibitors	O
for	O
cytochrome	B
P450	I
enzymes	I
(	O
P450s	O
)	O
,	O
which	O
are	O
widely	O
found	O
in	O
biologically	O
active	O
natural	O
products	O
,	O
synthetic	O
drugs	O
and	O
also	O
widely	O
used	O
as	O
mechanistic	O
probes	O
to	O
reveal	O
elusive	O
reaction	O
mechanisms	O
,	O
such	O
as	O
that	O
involved	O
in	O
P450	O
-	O
catalyzed	O
amine	O
oxidations	O
(	O
Bhakta	O
and	O
Wimalasena	O
,	O
;	O
Ortiz	O
de	O
Montellano	O
and	O
De	O
Voss	O
,	O
;	O
Totah	O
and	O
Hanzlik	O
,	O
;	O
Bhakta	O
et	O
al	O
.	O
,	O
.	O

Furthermore	O
,	O
according	O
to	O
Hanzlik	O
,	O
the	O
incubation	O
of	O
1	O
with	O
microsomes	O
indeed	O
caused	O
a	O
time	O
-	O
,	O
concentration	O
-	O
and	O
cofactor	O
-	O
dependent	O
loss	O
of	O
cytochrome	B
P450	I
activity	O
,	O
which	O
was	O
,	O
however	O
,	O
not	O
vanished	O
completely	O
but	O
instead	O
remained	O
25	O
-	O
30	O
%	O
of	O
it	O
(	O
Cerny	O
and	O
Hanzlik	O
,	O
.	O

recently	O
investigated	O
the	O
mechanism	O
-	O
based	O
inactivation	O
of	O
cytochrome	B
P450	I
by	O
1	O
,	O
1	O
-	O
dimethylhydrazine	O
(	O
UMDH	O
)	O
(	O
Hirao	O
et	O
al	O
.	O
,	O
)	O
,	O
they	O
examined	O
four	O
possible	O
reaction	O
pathways	O
including	O
H	O
-	O
abstractions	O
from	O
the	O
primary	O
amine	O
moiety	O
and	O
the	O
methyl	O
moiety	O
,	O
as	O
well	O
as	O
the	O
direct	O
oxidations	O
on	O
two	O
nitrogen	O
atoms	O
.	O

In	O
other	O
words	O
,	O
the	O
present	O
N	O
-	O
H	O
bond	O
activation	O
should	O
be	O
achieved	O
via	O
a	O
PCET	O
(	O
ET	O
)	O
mechanism	O
as	O
the	O
findings	O
of	O
Usharani	O
et	O
al	O
.	O
.	O
As	O
mentioned	O
by	O
Cerny	O
and	O
Hanzlik	O
,	O
cytochrome	B
P450	I
activity	O
was	O
not	O
vanished	O
completely	O
but	O
instead	O
remained	O
25	O
-	O
30	O
%	O
during	O
the	O
incubation	O
with	O
BCA	O
.	O

For	O
decades	O
,	O
the	O
mechanism	O
-	O
based	O
inactivation	O
role	O
of	O
N	O
-	O
benzyl	O
-	O
N	O
-	O
cyclopropylamine	O
to	O
cytochrome	B
P450	I
has	O
been	O
attracting	O
great	O
interests	O
.	O

A	O
foliar	O
application	O
of	O
methyl	O
jasmonate	O
caused	O
a	O
higher	O
expression	O
level	O
of	O
HMGR	O
and	O
the	O
farnesyl	O
diphosphate	O
synthase	O
gene	O
in	O
leaves	O
and	O
stems	O
of	O
treated	O
S	O
.	O
album	O
seedlings	O
compared	O
to	O
untreated	O
plants	O
at	O
4	O
h	O
,	O
but	O
expression	O
of	O
cytochrome	B
P450	I
showed	O
no	O
change	O
in	O
both	O
leaves	O
and	O
stems	O
.	O

Docetaxel	O
is	O
mainly	O
metabolized	O
by	O
hepatic	O
cytochrome	B
P450	I
isoenzymes	O
,	O
whereas	O
Monoclonal	O
Antibodies	O
are	O
primarily	O
eliminated	O
through	O
large	O
-	O
capacity	O
,	O
non	O
-	O
specific	O
,	O
Fc	O
receptor	O
-	O
mediated	O
IgG	O
clearance	O
mechanisms	O
and	O
through	O
specific	O
,	O
target	O
-	O
mediated	O
drug	O
disposition	O
pathways	O
.	O

In	O
this	O
section	O
,	O
we	O
highlight	O
the	O
diversity	O
of	O
SM	O
production	O
in	O
the	O
aspergilli	O
and	O
the	O
role	O
of	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
genes	O
in	O
secondary	O
metabolism	O
.	O

A	O
cytochrome	B
P450	I
nor	O
(	O
nitric	O
oxide	O
reductase	O
)	O
that	O
reduces	O
NO	O
to	O
N_2O	O
was	O
found	O
in	O
Fusarium	O
oxysporum	O
.	O

This	O
analysis	O
revealed	O
that	O
P	O
-	O
Coumaroyl	O
Ester	O
3	O
-	O
Hydroxylase	O
is	O
a	O
member	O
of	O
the	O
cytochrome	B
P450	I
family	O
,	O
an	O
oxireductase	O
acting	O
as	O
monooxygenase	O
(	O
InterPro	O
)	O
.	O

With	O
respect	O
to	O
environmental	O
stress	O
,	O
we	O
note	O
a	O
proliferation	O
of	O
various	O
detoxification	O
genes	O
,	O
including	O
glutatione	O
-	O
S	O
-	O
transferases	O
and	O
those	O
in	O
the	O
cytochrome	B
P450	I
families	O
.	O

Most	O
CYP450	O
genes	O
in	O
ant	O
genomes	O
are	O
members	O
of	O
cytochrome	B
P450	I
9th	O
,	O
6th	O
and	O
4th	O
families	O
(	O
Fig	O
.	O

We	O
studied	O
the	O
cytochrome	B
P450	I
superfamily	I
in	O
detail	O
,	O
as	O
it	O
is	O
known	O
for	O
its	O
crucial	O
role	O
in	O
resistance	O
to	O
xenobiotics	O
[	O
,	O
.	O

L	O
.	O
niger	O
and	O
C	O
.	O
floridanus	O
,	O
which	O
belong	O
to	O
the	O
subfamily	O
Formicinae	O
,	O
contain	O
approximately	O
the	O
same	O
number	O
of	O
cytochrome	B
P450	I
genes	O
,	O
and	O
this	O
number	O
is	O
higher	O
than	O
that	O
in	O
other	O
species	O
of	O
ants	O
.	O

It	O
is	O
possible	O
that	O
the	O
large	O
set	O
of	O
cytochrome	B
P450	I
genes	O
provide	O
for	O
polyphagia	O
by	O
enabling	O
specific	O
and	O
nonspecific	O
neutralization	O
of	O
various	O
phyto	O
and	O
mycotoxins	O
(	O
phytotoxin	O
resistance	O
would	O
enable	O
L	O
.	O
niger	O
to	O
feed	O
on	O
nectar	O
and	O
resistance	O
to	O
mycotoxins	O
would	O
enable	O
it	O
to	O
feed	O
on	O
dead	O
insects	O
)	O
.	O

Some	O
cytochrome	B
P450	I
genes	O
can	O
oxidize	O
some	O
of	O
these	O
chemicals	O
,	O
eg	O
,	O
benzo	O
(	O
a	O
)	O
pyren	O
.	O

^	O
CYP2J2	O
comes	O
from	O
a	O
superfamily	O
of	O
monooxygenases	O
of	O
cytochrome	B
P450	I
(	O
CYP450	O
)	O
enzymes	O
,	O
and	O
we	O
choose	O
its	O
gene	O
as	O
candidate	O
to	O
investigate	O
the	O
relationship	O
between	O
CYP2J2	O
and	O
IS	O
in	O
Chinese	O
Han	O
population	O
.	O

Similar	O
to	O
other	O
toxic	O
effects	O
of	O
TCDD	O
,	O
DNA	O
oxidation	O
damage	O
and	O
oxidative	O
stress	O
have	O
been	O
assumed	O
to	O
be	O
connected	O
with	O
the	O
AhR	O
and	O
activation	O
of	O
cytochrome	B
P450	I
superfamily	I
of	O
enzymes	O
,	O
especially	O
CYP1A1	B
.	O

DNA	O
oxidation	O
damage	O
in	O
rodents	O
exposed	O
to	O
DLCs	O
is	O
probably	O
induced	O
through	O
upregulation	O
of	O
cytochrome	B
P450	I
superfamily	I
of	O
enzymes	O
,	O
mediated	O
by	O
AhR	O
-	O
dependent	O
pathways	O
.	O

^	O
However	O
,	O
MMF	O
is	O
of	O
possible	O
concern	O
and	O
its	O
combination	O
with	O
drugs	O
,	O
environmental	O
pollutants	O
,	O
or	O
food	O
constituents	O
,	O
which	O
activate	O
cytochrome	B
P450	I
transcriptional	O
factor	O
,	O
may	O
represent	O
a	O
significant	O
toxicological	O
risk	O
.	O

P	O
-	O
glycoprotein	O
(	O
Pgp	O
)	O
and	O
cytochrome	B
P450	I
3A4	I
have	O
been	O
recognized	O
as	O
determinants	O
of	O
the	O
bioavailability	O
of	O
widely	O
used	O
immunosuppressants	O
such	O
as	O
CsA	O
,	O
tacrolimus	O
,	O
and	O
sirolimus	O
.	O

Proliferation	O
signal	O
inhibitors	O
such	O
as	O
sirolimus	O
and	O
EVR	O
are	O
substrates	O
of	O
cytochrome	B
P450	I
3A4	I
and	O
Pgp	O
and	O
have	O
a	O
macrolide	O
structure	O
very	O
similar	O
to	O
tacrolimus	O
,	O
which	O
explains	O
why	O
common	O
drug	O
interactions	O
with	O
proliferation	O
signal	O
inhibitors	O
are	O
comparable	O
to	O
those	O
with	O
CNIs	O
.	O

suggested	O
that	O
DIO	O
induces	O
anticancer	O
activity	O
in	O
MCF7	O
breast	O
cancer	O
cells	O
by	O
causing	O
cytochrome	B
P450	I
bioactivation	O
.	O

While	O
the	O
contribution	O
of	O
some	O
dietary	O
polyphenols	O
in	O
the	O
management	O
of	O
Benign	O
Prostatic	O
Hyperplasia	O
has	O
been	O
indicated	O
in	O
this	O
review	O
as	O
supported	O
by	O
clinical	O
findings	O
,	O
it	O
must	O
also	O
be	O
emphasized	O
that	O
non	O
-	O
regulated	O
and	O
long	O
-	O
lasting	O
supplementation	O
with	O
some	O
dietary	O
polyphenols	O
could	O
lead	O
to	O
potential	O
harmful	O
effects	O
due	O
to	O
possible	O
interactions	O
with	O
cytochrome	B
P450	I
enzymes	I
.	O

Acetaminophen	O
is	O
metabolically	O
activated	O
to	O
form	O
a	O
reactive	O
metabolite	O
by	O
several	O
types	O
of	O
cytochrome	B
P450	I
such	O
as	O
cytochromes	O
2E1	O
,	O
1A2	O
,	O
3A4	O
,	O
and	O
2A6	O
via	O
a	O
direct	O
two	O
-	O
electron	O
oxidation	O
.	O

Of	O
These	O
,	O
Acetaminophen	O
is	O
metabolized	O
by	O
cytochrome	B
P450	I
to	O
form	O
a	O
reactive	O
metabolites	O
,	O
NAPQI	O
,	O
which	O
then	O
reacts	O
with	O
hepatic	O
glutathione	O
(	O
GSH	O
)	O
causing	O
the	O
latter	O
depletion	O
by	O
approximately	O
90	O
%	O
.	O

Although	O
lipids	O
can	O
be	O
oxidized	O
by	O
lipoxygenases	O
,	O
cyclooxygenases	O
,	O
and	O
cytochrome	B
P450	I
to	O
generate	O
signaling	O
molecules	O
,	O
Reactive	O
Oxygen	O
Species	O
(	O
eg	O
,	O
hydroxyl	O
radical	O
-	O
HO	O
^	O
and	O
hydroperoxyl	O
-	O
HO2	O
.	O
)	O

The	O
inhibitory	O
potentials	O
of	O
dimethyllirioresinol	O
,	O
epimagnolin	O
A	O
,	O
eudesmin	O
,	O
fargesin	O
,	O
and	O
magnolin	O
on	O
eight	O
major	O
human	O
cytochrome	B
P450	I
enzyme	I
activities	O
in	O
human	O
liver	O
microsomes	O
were	O
evaluated	O
using	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
to	O
determine	O
the	O
inhibition	O
mechanisms	O
and	O
inhibition	O
potency	O
.	O

Herbal	O
drugs	O
(	O
eg	O
,	O
Hypericum	O
perforatum	O
,	O
Ginkgo	O
biloba	O
,	O
Camellia	O
sinensis	O
,	O
Glycyrrhiza	O
glabra	O
,	O
Allium	O
sativum	O
,	O
Rhizoma	O
Coptidis	O
,	O
and	O
Fructus	O
Silybi	O
)	O
and	O
their	O
constituents	O
cause	O
herb	O
-	O
drug	O
interactions	O
via	O
the	O
induction	O
or	O
inhibition	O
of	O
major	O
drug	O
-	O
metabolizing	O
enzymes	O
,	O
cytochrome	B
P450	I
and	O
result	O
in	O
the	O
toxicity	O
and	O
therapeutic	O
failure	O
of	O
various	O
concomitant	O
drugs	O
.	O

For	O
example	O
,	O
the	O
cytochrome	B
P450	I
enzymes	I
are	O
a	O
class	O
of	O
phase	O
I	O
enzymes	O
.	O

Here	O
we	O
demonstrate	O
the	O
feasibility	O
of	O
dynamic	O
nuclear	O
polarization	O
(	O
DNP	O
)	O
magic	O
-	O
angle	O
-	O
spinning	O
NMR	O
techniques	O
,	O
along	O
with	O
a	O
judiciously	O
designed	O
stable	O
isotope	O
labeling	O
scheme	O
,	O
to	O
measure	O
atomistic	O
-	O
resolution	O
transmembrane	O
-	O
transmembrane	O
interactions	O
of	O
full	O
-	O
length	O
mammalian	O
~	O
72	O
-	O
kDa	O
cytochrome	B
P450	I
-	O
cytochrome	B
b5	I
complex	O
in	O
lipid	O
bilayers	O
.	O

These	O
are	O
particularly	O
notable	O
drawbacks	O
for	O
bitopic	O
proteins	O
that	O
contain	O
bulky	O
soluble	O
domains	O
,	O
such	O
as	O
the	O
membrane	O
-	O
anchored	O
catalytic	O
enzymes	O
like	O
mammalian	O
cytochrome	B
P450	I
,	O
cytochrome	B
b_5	I
,	O
and	O
cytochrome	B
P450	I
reductases	O
^	O
,	O
-	O
-	O
.	O

For	O
a	O
complete	O
understanding	O
of	O
their	O
active	O
interactions	O
,	O
it	O
is	O
crucial	O
to	O
obtain	O
the	O
structural	O
information	O
of	O
the	O
biologically	O
active	O
full	O
-	O
length	O
forms	O
with	O
both	O
transmembrane	O
and	O
extramembranous	O
domains	O
,	O
especially	O
in	O
the	O
case	O
of	O
membrane	O
-	O
bound	O
cytochrome	B
P450	I
complexes	O
^	O
,	O
-	O
,	O
-	O
,	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
feasibility	O
of	O
ssNMR	O
spectroscopy	O
^	O
-	O
for	O
probing	O
transmembrane	O
interactions	O
of	O
membrane	O
-	O
bound	O
bitopic	O
proteins	O
,	O
namely	O
the	O
intact	O
mammalian	O
cytochrome	B
P450	I
-	O
cytochrome	B
b_5	I
complex	O
,	O
in	O
lipid	O
bilayers	O
.	O

As	O
a	O
key	O
step	O
in	O
their	O
catalytic	O
cycles	O
,	O
their	O
oxidation	O
of	O
substrates	O
requires	O
two	O
electrons	O
to	O
be	O
transferred	O
to	O
the	O
heme	O
-	O
containing	O
reaction	O
center	O
of	O
cytochromes	O
P450	O
from	O
their	O
redox	O
partners	O
,	O
such	O
as	O
cytochromes	O
b_5	O
,	O
and	O
cytochrome	B
P450	I
reductases	O
^	O
,	O
.	O

This	O
crucial	O
transmembrane	O
-	O
transmembrane	O
interaction	O
of	O
the	O
full	O
-	O
length	O
liver	O
microsomal	O
cytochrome	B
P450	I
2B4	O
with	O
its	O
full	O
-	O
length	O
redox	O
partner	O
,	O
cytochrome	B
b_5	I
,	O
is	O
investigated	O
in	O
this	O
study	O
.	O

Depending	O
on	O
the	O
substrates	O
,	O
the	O
cytochrome	B
P450	I
isozymes	O
and	O
/	O
or	O
the	O
experimental	O
conditions	O
,	O
cytochrome	B
b_5	I
can	O
significantly	O
enhance	O
the	O
enzymatic	O
turnover	O
of	O
cytochrome	B
P450	I
by	O
up	O
to	O
100	O
-	O
fold	O
,	O
in	O
some	O
cases	O
,	O
however	O
,	O
cytochrome	B
b_5	I
does	O
not	O
affect	O
or	O
even	O
inhibits	O
the	O
catalytic	O
activities	O
of	O
cytochromes	O
P450	O
.	O

In	O
the	O
case	O
of	O
rabbit	O
cytochrome	B
P450	I
2B4	O
,	O
a	O
55	O
.	O
7	O
kDa	O
protein	O
,	O
when	O
metabolizing	O
benzphetamine	O
and	O
methoxyflurane	O
stoichiometrically	O
,	O
cytochrome	B
b_5	I
stimulates	O
the	O
enzymatic	O
activities	O
of	O
cytochrome	B
P450	I
2B4	O
predominantly	O
by	O
reducing	O
the	O
amount	O
of	O
the	O
side	O
-	O
product	O
superoxide	O
^	O
,	O
.	O

In	O
order	O
to	O
fully	O
understand	O
the	O
molecular	O
mechanism	O
of	O
these	O
key	O
roles	O
of	O
cytochrome	B
b_5	I
,	O
elucidating	O
the	O
atomic	O
-	O
resolution	O
structure	O
of	O
the	O
full	O
-	O
length	O
form	O
of	O
cytochrome	B
P450	I
-	O
cytochrome	B
b_5	I
complex	O
is	O
quintessential	O
.	O

Despite	O
the	O
physiological	O
importance	O
of	O
their	O
full	O
-	O
length	O
forms	O
for	O
their	O
complete	O
catalytic	O
functions	O
,	O
the	O
X	O
-	O
ray	O
and	O
solution	O
NMR	O
structures	O
of	O
both	O
membrane	O
-	O
bound	O
eukaryotic	O
cytochrome	B
P450	I
and	O
cytochrome	B
b_5	I
have	O
been	O
determined	O
only	O
for	O
the	O
truncated	O
forms	O
of	O
hydrophilic	O
heme	O
-	O
containing	O
cytosolic	O
catalytic	O
domains	O
,	O
in	O
which	O
the	O
hydrophobic	O
transmembrane	O
domains	O
were	O
removed	O
to	O
overcome	O
the	O
difficulties	O
in	O
overexpression	O
,	O
solubilization	O
,	O
purification	O
,	O
and	O
crystallization	O
^	O
,	O
with	O
the	O
exception	O
of	O
recent	O
solution	O
-	O
and	O
solid	O
-	O
state	O
NMR	O
studies	O
from	O
our	O
group	O
on	O
full	O
-	O
length	O
rabbit	O
cytochrome	B
b_5	I
and	O
cytochrome	B
P450	I
2B4	O
^	O
,	O
-	O
-	O
,	O
as	O
well	O
as	O
an	O
X	O
-	O
ray	O
crystallography	O
study	O
on	O
cytochrome	B
P450	I
51A1	O
^	O
.	O

These	O
high	O
-	O
resolution	O
full	O
-	O
length	O
structures	O
are	O
significant	O
breakthroughs	O
towards	O
the	O
complete	O
understanding	O
of	O
the	O
functional	O
aspects	O
of	O
membrane	O
-	O
bound	O
mammalian	O
cytochromes	O
,	O
as	O
it	O
is	O
known	O
that	O
the	O
lack	O
of	O
transmembrane	O
anchors	O
reduces	O
to	O
only	O
40	O
%	O
of	O
all	O
enzymatic	O
activities	O
in	O
the	O
case	O
of	O
cytochrome	B
P450	I
2B4	O
,	O
and	O
results	O
in	O
a	O
total	O
loss	O
of	O
electron	O
transfer	O
capability	O
to	O
cytochromes	O
P450	O
in	O
the	O
case	O
of	O
cytochrome	B
b_5	I
^	O
,	O
-	O
-	O
.	O

A	O
recent	O
solution	O
NMR	O
study	O
from	O
our	O
group	O
revealed	O
the	O
first	O
full	O
-	O
length	O
dynamic	O
interactions	O
of	O
the	O
membrane	O
-	O
bound	O
complex	O
between	O
rabbit	O
cytochrome	B
P450	I
2B4	O
and	O
cytochrome	B
b_5	I
reconstituted	O
in	O
isotropic	O
bicelles	O
and	O
the	O
electron	O
transfer	O
pathway	O
between	O
catalytic	O
domains	O
of	O
the	O
complex	O
.	O

However	O
,	O
these	O
traditional	O
solution	O
NMR	O
techniques	O
could	O
not	O
have	O
explained	O
the	O
importance	O
of	O
the	O
transmembrane	O
domains	O
for	O
the	O
catalytic	O
activities	O
of	O
the	O
cytochrome	B
P450	I
complex	O
due	O
to	O
the	O
experimental	O
limitations	O
of	O
solution	O
NMR	O
spectroscopy	O
,	O
which	O
are	O
attributed	O
to	O
the	O
intermediate	O
time	O
scale	O
of	O
dynamics	O
of	O
transmembrane	O
helices	O
^	O
.	O

The	O
combination	O
of	O
these	O
developments	O
have	O
enabled	O
us	O
to	O
report	O
the	O
DNP	O
solid	O
-	O
state	O
NMR	O
spectroscopy	O
probing	O
transmembrane	O
-	O
transmembrane	O
interactions	O
of	O
the	O
cytochrome	B
P450	I
-	O
cytochrome	B
b_5	I
complex	O
embedded	O
in	O
lipid	O
bilayers	O
at	O
an	O
atomic	O
-	O
level	O
for	O
the	O
first	O
time	O
.	O

The	O
overexpression	O
and	O
purification	O
of	O
selectively	O
^	O
13C	O
-	O
labeled	O
cytochrome	B
b_5	I
and	O
uniformly	O
^	O
15N	O
-	O
labeled	O
cytochrome	B
P450	I
were	O
reported	O
previously	O
^	O
,	O
.	O

Five	O
milligrams	O
of	O
DMPC	O
powder	O
was	O
hydrated	O
using	O
10	O
l	O
of	O
2	O
.	O
98	O
mM	O
selectively	O
^	O
13C	O
-	O
labeled	O
cytochrome	B
b_5	I
in	O
a	O
DNP	O
solution	O
(	O
or	O
10	O
l	O
of	O
1	O
.	O
2	O
mM	O
selectively	O
^	O
13C	O
-	O
labeled	O
cytochrome	B
b_5	I
-	O
uniformly	O
^	O
15N	O
-	O
labeled	O
cytochrome	B
P450	I
complex	O
in	O
a	O
DNP	O
solution	O
)	O
,	O
[	O
D_8	O
]	O
glycerol	O
,	O
and	O
stock	O
biradical	O
solutions	O
.	O

The	O
selectively	O
^	O
13C	O
-	O
labeled	O
cytochrome	B
b_5	I
(	O
or	O
selectively	O
^	O
13C	O
-	O
labeled	O
cytochrome	B
b_5	I
-	O
uniformly	O
^	O
15N	O
-	O
labeled	O
cytochrome	B
P450	I
complex	O
)	O
reconstituted	O
in	O
DMPC	O
multilamellar	O
vesicles	O
with	O
a	O
10	O
mM	O
DNP	O
polarizing	O
agent	O
and	O
were	O
packed	O
into	O
3	O
.	O
2	O
mm	O
sapphire	O
MAS	O
rotors	O
.	O

Rabbit	O
cytochrome	B
b_5	I
and	O
cytochrome	B
P450	I
were	O
overexpressed	O
and	O
purified	O
from	O
E	O
.	O
Coli	O
^	O
,	O
and	O
then	O
reconstituted	O
^	O
,	O
into	O
1	O
,	O
2	O
-	O
dimyristoyl	O
-	O
sn	O
-	O
glycero	O
-	O
3	O
-	O
phosphocholine	O
(	O
DMPC	O
)	O
lipid	O
bilayers	O
hydrated	O
with	O
biradical	O
solutions	O
of	O
[	O
D_8	O
]	O
glycerol	O
/	O
D_2O	O
/	O
H_2O	O
(	O
60	O
:	O
30	O
:	O
10	O
volume	O
ratio	O
)	O
containing	O
DNP	O
polarizing	O
agents	O
,	O
AMUPol	O
^	O
or	O
TOTAPOL	O
(	O
1	O
-	O
(	O
TEMPO	O
-	O
4	O
-	O
oxy	O
)	O
-	O
3	O
-	O
(	O
TEMPO	O
-	O
4	O
-	O
amino	O
)	O
propan	O
-	O
2	O
-	O
ol	O
)	O
^	O
,	O
as	O
described	O
in	O
the	O
previous	O
section	O
.	O

In	O
fact	O
,	O
the	O
yield	O
of	O
isotopically	O
labeled	O
full	O
-	O
length	O
cytochrome	B
P450	I
is	O
extremely	O
low	O
,	O
which	O
is	O
unfavorable	O
for	O
traditional	O
ssNMR	O
-	O
based	O
structural	O
studies	O
which	O
generally	O
require	O
large	O
sample	O
quantities	O
.	O

In	O
the	O
previous	O
studies	O
,	O
high	O
-	O
resolution	O
structural	O
interactions	O
between	O
the	O
soluble	O
domains	O
of	O
the	O
cytochrome	B
P450	I
-	O
cytochrome	B
b_5	I
complex	O
have	O
been	O
investigated	O
,	O
and	O
structure	O
of	O
the	O
complex	O
was	O
reported	O
^	O
,	O
.	O

In	O
the	O
lipid	O
bilayer	O
environment	O
,	O
based	O
on	O
the	O
membrane	O
interaction	O
between	O
the	O
linker	O
region	O
cytochrome	B
b_5	I
and	O
the	O
lipid	O
bilayer	O
,	O
it	O
is	O
predicted	O
that	O
the	O
soluble	O
domain	O
of	O
cytochrome	B
b_5	I
can	O
adapt	O
certain	O
orientations	O
,	O
which	O
will	O
result	O
in	O
a	O
productive	O
complex	O
formation	O
with	O
cytochrome	B
P450	I
^	O
,	O
.	O

Particularly	O
,	O
it	O
is	O
known	O
that	O
the	O
soluble	O
domain	O
(	O
particularly	O
,	O
the	O
F	O
-	O
G	O
loop	O
region	O
)	O
of	O
cytochrome	B
P450	I
is	O
tightly	O
bound	O
to	O
the	O
lipid	O
membrane	O
due	O
to	O
its	O
hydrophobicity	O
;	O
therefore	O
,	O
its	O
redox	O
binding	O
partners	O
,	O
like	O
cytochrome	B
b_5	I
,	O
have	O
to	O
be	O
suitably	O
oriented	O
to	O
form	O
a	O
productive	O
complex	O
^	O
,	O
.	O

Thus	O
,	O
restricting	O
the	O
motions	O
of	O
redox	O
partners	O
of	O
cytochrome	B
P450	I
,	O
including	O
cytochrome	B
b_5	I
and	O
cytochrome	B
P450	I
-	O
reductase	O
,	O
to	O
produce	O
productive	O
orientations	O
would	O
be	O
one	O
of	O
the	O
biological	O
roles	O
of	O
the	O
relatively	O
flexible	O
linker	O
domain	O
that	O
connects	O
the	O
soluble	O
domain	O
and	O
the	O
transmembrane	O
ALPHA	O
-	O
helix	O
domain	O
in	O
the	O
redox	O
partner	O
^	O
,	O
.	O

Furthermore	O
,	O
our	O
previous	O
studies	O
of	O
oriented	O
ssNMR	O
experiments	O
concluded	O
that	O
,	O
upon	O
the	O
full	O
-	O
length	O
cytochrome	B
P450	I
-	O
cytochrome	B
b_5	I
complex	O
formation	O
in	O
membrane	O
,	O
the	O
ALPHA	O
-	O
helical	O
structure	O
and	O
the	O
topology	O
of	O
the	O
transmembrane	O
domain	O
of	O
cytochrome	B
b_5	I
are	O
not	O
altered	O
^	O
.	O

For	O
decades	O
,	O
it	O
has	O
been	O
widely	O
recognized	O
that	O
the	O
transmembrane	O
domains	O
of	O
cytochrome	B
P450	I
and	O
cytochrome	B
b_5	I
are	O
essential	O
for	O
catalytic	O
activities	O
of	O
cytochrome	B
P450	I
^	O
-	O
,	O
.	O

In	O
this	O
experiment	O
,	O
the	O
natural	O
-	O
abundance	O
^	O
13C	O
magnetizations	O
of	O
U	O
-	O
^	O
15N	O
cytochrome	B
P450	I
selected	O
by	O
the	O
^	O
15N	O
-	O
^	O
13C	O
REDOR	O
scheme	O
,	O
which	O
are	O
encoded	O
during	O
the	O
t	O
_1	O
evolution	O
,	O
and	O
are	O
subsequently	O
correlated	O
to	O
the	O
neighboring	O
^	O
13C	O
nuclei	O
of	O
selectively	O
^	O
13C	O
-	O
labeled	O
cytochrome	B
b_5	I
during	O
a	O
long	O
PDSD	O
mixing	O
time	O
(	O
~	O
3	O
s	O
)	O
in	O
order	O
to	O
obtain	O
the	O
^	O
13C	O
-	O
^	O
13C	O
chemical	O
shift	O
correlation	O
shown	O
in	O
Fig	O
.	O

The	O
full	O
-	O
length	O
cytochrome	B
P450	I
2B4	O
is	O
known	O
to	O
form	O
the	O
functional	O
complex	O
with	O
the	O
second	O
electron	O
donor	O
,	O
cytochrome	B
b_5	I
,	O
in	O
lipid	O
bilayer	O
environments	O
as	O
confirmed	O
by	O
the	O
alternation	O
of	O
spin	O
states	O
,	O
termed	O
type	O
I	O
spectral	O
changes	O
under	O
the	O
sample	O
preparation	O
in	O
this	O
study	O
^	O
,	O
.	O

It	O
is	O
also	O
known	O
that	O
cytochrome	B
P450	I
is	O
relatively	O
unstable	O
at	O
ambient	O
temperatures	O
;	O
however	O
,	O
the	O
use	O
of	O
DNP	O
spectroscopy	O
under	O
frozen	O
conditions	O
can	O
circumvent	O
this	O
shortcoming	O
^	O
,	O
.	O

These	O
structural	O
constraints	O
from	O
transmembrane	O
-	O
transmembrane	O
interactions	O
obtained	O
from	O
DNP	O
-	O
MAS	O
-	O
ssNMR	O
spectroscopy	O
allow	O
us	O
to	O
construct	O
a	O
structural	O
model	O
for	O
the	O
full	O
-	O
length	O
cytochrome	B
P450	I
-	O
cytochrome	B
b_5	I
complex	O
,	O
as	O
shown	O
in	O
Fig	O
.	O

In	O
this	O
structural	O
model	O
,	O
high	O
-	O
resolution	O
NMR	O
structure	O
of	O
the	O
full	O
-	O
length	O
rabbit	O
cytochrome	B
b_5	I
in	O
lipid	O
bilayers	O
,	O
soluble	O
domain	O
interactions	O
,	O
and	O
the	O
transmembrane	O
ALPHA	O
-	O
helix	O
of	O
cytochrome	B
P450	I
were	O
obtained	O
from	O
our	O
previous	O
studies	O
^	O
,	O
.	O

In	O
fact	O
,	O
based	O
on	O
our	O
reported	O
complex	O
structural	O
model	O
in	O
the	O
soluble	O
domain	O
,	O
some	O
labeled	O
positions	O
(	O
eg	O
,	O
Leu41	O
,	O
Ala59	O
,	O
Val66	O
,	O
Ala72	O
,	O
and	O
Leu75	O
)	O
can	O
be	O
close	O
to	O
the	O
cytochrome	B
P450	I
-	O
cytochrome	B
b_5	I
complex	O
interface	O
^	O
.	O

Furthermore	O
,	O
the	O
helical	O
wheel	O
diagram	O
of	O
Supplementary	O
Figure	O
suggests	O
that	O
cytochrome	B
P450	I
2B4	O
contains	O
many	O
leucine	O
residues	O
in	O
the	O
N	O
-	O
terminal	O
transmembrane	O
ALPHA	O
-	O
helix	O
region	O
.	O

Based	O
on	O
these	O
leucine	O
residues	O
present	O
in	O
the	O
transmembrane	O
ALPHA	O
-	O
helices	O
of	O
cytochrome	O
b_5	O
and	O
cytochrome	B
P450	I
,	O
a	O
leucine	O
zipper	O
-	O
like	O
structure	O
can	O
be	O
found	O
in	O
the	O
transmembrane	O
interactions	O
of	O
the	O
cytochrome	B
P450	I
-	O
cytochrome	O
b_5	O
complex	O
^	O
,	O
-	O
,	O
.	O

Herein	O
,	O
possible	O
driving	O
forces	O
for	O
the	O
transmembrane	O
complex	O
formation	O
in	O
cytochrome	B
P450	I
-	O
cytochrome	O
b_5	O
would	O
be	O
a	O
combination	O
of	O
:	O
(	O
i	O
)	O
van	O
der	O
Waals	O
-	O
London	O
interactions	O
^	O
,	O
(	O
ii	O
)	O
electrostatic	O
attraction	O
,	O
estimated	O
by	O
1	O
-	O
3	O
kcal	O
,	O
between	O
oppositely	O
charged	O
electric	O
dipolar	O
moments	O
in	O
the	O
association	O
of	O
C	O
-	O
and	O
N	O
-	O
terminal	O
ALPHA	O
-	O
helices	O
^	O
,	O
and	O
(	O
iii	O
)	O
hydrophobic	O
interactions	O
of	O
ALPHA	O
-	O
helices	O
near	O
the	O
surface	O
of	O
the	O
lipid	O
bilayer	O
based	O
on	O
the	O
leucine	O
zipper	O
-	O
like	O
motifs	O
^	O
,	O
-	O
,	O
.	O

These	O
types	O
of	O
specific	O
transmembrane	O
dimerization	O
motifs	O
can	O
be	O
found	O
in	O
the	O
amino	O
acid	O
sequences	O
of	O
both	O
cytochrome	O
b_5	O
and	O
cytochrome	B
P450	I
;	O
however	O
,	O
the	O
transmembrane	O
region	O
of	O
cytochrome	B
P450	I
reductase	O
does	O
not	O
possess	O
such	O
type	O
of	O
dimerization	O
motifs	O
^	O
.	O

This	O
observation	O
suggests	O
that	O
the	O
roles	O
of	O
transmembrane	O
interaction	O
in	O
the	O
complex	O
formation	O
of	O
cytochrome	B
P450	I
-	O
cytochrome	B
P450	I
reductase	O
could	O
be	O
different	O
.	O

Such	O
NMR	O
studies	O
of	O
cytochrome	B
P450	I
-	O
cytochrome	B
P450	I
reductase	O
are	O
currently	O
under	O
investigation	O
in	O
our	O
laboratory	O
.	O

This	O
study	O
represents	O
the	O
first	O
experimental	O
report	O
revealing	O
the	O
topology	O
and	O
structure	O
of	O
the	O
transmembrane	O
domains	O
of	O
membrane	O
-	O
bound	O
cytochrome	B
P450	I
-	O
cytochrome	O
b_5	O
complex	O
in	O
the	O
functional	O
full	O
-	O
length	O
form	O
.	O

Inter	O
-	O
individual	O
variability	O
of	O
cytochrome	B
P450	I
enzymes	I
(	O
CYP1A2	B
,	O
CYP3A4	B
,	O
CYP2C19	B
,	O
CYP2D6	B
)	O
has	O
been	O
attributed	O
to	O
substantial	O
differences	O
in	O
clozapine	O
plasma	O
concentrations	O
and	O
in	O
drug	O
response	O
.	O

Various	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
(	O
CYP1A2	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP3A4	B
)	O
have	O
been	O
demonstrated	O
to	O
be	O
involved	O
in	O
clozapine	O
metabolism	O
;	O
however	O
,	O
the	O
clinical	O
relevance	O
of	O
these	O
enzymes	O
has	O
to	O
be	O
clarified	O
.	O

The	O
cytochrome	B
P450	I
superfamily	I
is	O
involved	O
in	O
the	O
metabolism	O
of	O
a	O
diverse	O
range	O
of	O
xenobiotics	O
and	O
endogenous	O
compounds	O
.	O

This	O
reaction	O
is	O
catalyzed	O
by	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
,	O
including	O
CYP2C19	B
,	O
CYP3A	B
,	O
CYP2B6	B
,	O
CYP1A2	B
,	O
and	O
CYP2C9	B
.	O

This	O
is	O
a	O
two	O
-	O
step	O
oxidation	O
reaction	O
catalyzed	O
by	O
cytochrome	B
P450	I
enzymes	I
.	O

Nano	O
-	O
sized	O
cytochrome	B
P450	I
3A4	I
inhibitors	O
to	O
block	O
hepatic	O
metabolism	O
of	O
docetaxel	O
.	O

Most	O
drugs	O
are	O
metabolized	O
by	O
hepatic	O
cytochrome	B
P450	I
3A4	I
,	O
resulting	O
in	O
their	O
reduced	O
bioavailability	O
.	O

Taxotere	O
^	O
(	O
docetaxel	O
)	O
is	O
a	O
chemotherapy	O
agent	O
used	O
in	O
clinic	O
,	O
injected	O
intravenously	O
,	O
for	O
several	O
indications	O
,	O
such	O
as	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
,	O
breast	O
cancer	O
,	O
gastric	O
cancer	O
and	O
prostate	O
cancer	O
.	O
,	O
Docetaxel	O
is	O
extensively	O
metabolized	O
by	O
cytochrome	B
P450	I
3A4	I
,	O
resulting	O
in	O
low	O
systemic	O
bioavailability	O
.	O
-	O
Recently	O
,	O
docetaxel	O
was	O
administered	O
with	O
oral	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potent	O
Cytochrome	B
P450	I
3a4	I
inhibitors	O
to	O
increase	O
its	O
bioavailability	O
and	O
to	O
enable	O
its	O
oral	O
administration	O
,	O
especially	O
by	O
the	O
inhibition	O
of	O
intestinal	O
CYP34A	O
.	O
,	O
However	O
,	O
on	O
top	O
of	O
their	O
own	O
pharmacological	O
activity	O
,	O
these	O
orally	O
administered	O
inhibitors	O
of	O
Cytochrome	B
P450	I
3a4	I
generally	O
have	O
a	O
wide	O
biodistribution	O
.	O

The	O
role	O
of	O
cytochrome	B
P450	I
drug	O
metabolizing	O
enzymes	O
in	O
the	O
efficacy	O
of	O
tamoxifen	O
treatment	O
of	O
breast	O
cancer	O
is	O
subject	O
to	O
substantial	O
interest	O
and	O
controversy	O
.	O

The	O
complex	O
tamoxifen	O
metabolism	O
is	O
primarily	O
catalyzed	O
by	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
,	O
which	O
are	O
subject	O
to	O
substantial	O
differences	O
in	O
inter	O
-	O
individual	O
expression	O
and	O
activity	O
^	O
-	O
.	O

Apart	O
from	O
CYP3A4	B
,	O
constituents	O
of	O
Gr	O
,	O
for	O
example	O
,	O
furanocoumarins	O
or	O
bergamottin	O
,	O
can	O
inhibit	O
other	O
cytochrome	B
P450	I
isoenzymes	O
(	O
CYP3A4	B
,	O
CYP2C9	B
,	O
and	O
CYP2D6	B
)	O
and	O
transporters	O
in	O
the	O
intestine	O
such	O
as	O
P	O
-	O
glycoproteins	O
.	O

We	O
found	O
that	O
this	O
sequence	O
has	O
an	O
extra	O
long	O
(	O
~	O
29	O
amino	O
acids	O
)	O
N	O
terminus	O
with	O
no	O
functional	O
annotations	O
when	O
compared	O
with	O
most	O
other	O
CYP152	O
members	O
including	O
those	O
cytochrome	B
P450	I
family	O
proteins	O
from	O
other	O
Staphylococcus	O
species	O
(	O
Additional	O
file	O
:	O
Figure	O
S1	O
)	O
.	O

A	O
widely	O
accepted	O
criterion	O
for	O
the	O
identification	O
of	O
cytochrome	B
P450	I
is	O
a	O
Soret	O
peak	O
at	O
around	O
450	O
nm	O
in	O
the	O
reduced	O
CO	O
difference	O
spectrum	O
.	O

Furthermore	O
,	O
analysis	O
of	O
mRNA	O
sequences	O
of	O
cytochrome	B
P450	I
family	O
proteins	O
from	O
other	O
Staphylococcus	O
species	O
such	O
as	O
S	O
.	O
agnetis	O
(	O
GenBank	O
:	O
JPRT01000001	O
.	O
1	O
)	O
and	O
S	O
.	O
pseudintermedius	O
(	O
GenBank	O
:	O
CP002439	O
.	O
1	O
)	O
also	O
revealed	O
a	O
similar	O
pattern	O
of	O
the	O
strong	O
5	O
-	O
6	O
G	O
-	O
C	O
pairs	O
of	O
Shine	O
-	O
Dalgarno	O
complementarity	O
preceding	O
a	O
GUG	O
start	O
codon	O
.	O

P420	O
species	O
was	O
generally	O
thought	O
to	O
be	O
an	O
inactive	O
form	O
of	O
cytochrome	B
P450	I
enzymes	I
.	O

Duplications	O
of	O
members	O
of	O
enzyme	O
families	O
(	O
eg	O
cytochromes	O
P450	O
,	O
glycosyltransferases	O
,	O
methyltransferases	O
,	O
BAHD	O
acyltransferases	O
)	O
also	O
play	O
major	O
roles	O
in	O
generating	O
chemical	O
novelty	O
,	O
with	O
biosynthesis	O
of	O
>	O
40	O
,	O
000	O
structurally	O
diverse	O
terpenoids	O
-	O
produced	O
partly	O
due	O
to	O
genomic	O
clustering	O
of	O
terpene	O
synthases	O
and	O
cytochrome	B
P450	I
enzymes	I
-	O
as	O
an	O
extreme	O
example	O
.	O

Indeed	O
,	O
the	O
structural	O
diversity	O
in	O
a	O
single	O
individual	O
could	O
be	O
a	O
reflection	O
of	O
promiscuous	O
enzyme	O
activities	O
,	O
given	O
large	O
enzyme	O
families	O
such	O
as	O
BAHDs	O
,	O
cytochrome	O
P450s	O
,	O
glycosyltransferases	O
play	O
a	O
role	O
in	O
the	O
biosynthesis	O
of	O
several	O
specialized	O
metabolite	O
classes	O
.	O

In	O
fact	O
,	O
mitochondria	O
appear	O
uniquely	O
susceptible	O
to	O
toxicants	O
as	O
a	O
result	O
of	O
:	O
1	O
)	O
accumulation	O
of	O
toxicants	O
due	O
to	O
the	O
high	O
lipid	O
content	O
of	O
the	O
mitochondrial	O
membranes	O
,	O
slight	O
negative	O
charge	O
of	O
the	O
mitochondrial	O
matrix	O
,	O
and	O
presence	O
of	O
metal	O
cation	O
transporters	O
;	O
2	O
)	O
ability	O
to	O
activate	O
organic	O
compounds	O
via	O
mitochondrial	O
cytochrome	O
P450s	O
;	O
3	O
)	O
the	O
presence	O
of	O
the	O
reactive	O
oxygen	O
species	O
generating	O
electron	O
transport	O
chain	O
;	O
4	O
)	O
reduced	O
repair	O
mechanisms	O
for	O
mitochondrial	O
DNA	O
in	O
comparison	O
to	O
the	O
nuclear	O
genome	O
,	O
and	O
5	O
)	O
the	O
potential	O
for	O
toxicant	O
exposure	O
to	O
increase	O
the	O
endogenous	O
level	O
of	O
production	O
of	O
reactive	O
oxygen	O
species	O
.	O

The	O
receptor	O
panel	O
profiling	O
and	O
cytochrome	B
P450	I
inhibition	O
assays	O
on	O
S2218	O
were	O
conducted	O
at	O
Eurofins	O
PanlabsTaiwan	O
Ltd	O
.	O
,	O
Taipei	O
,	O
Taiwan	O
.	O

Independent	O
of	O
the	O
effect	O
of	O
any	O
antiparasitic	O
potential	O
of	O
compounds	O
,	O
they	O
were	O
evaluated	O
using	O
a	O
panel	O
of	O
early	O
-	O
toxicity	O
assays	O
comprising	O
cytotoxicity	O
(	O
A549	O
,	O
human	O
lung	O
adenocarcinoma	O
epithelial	O
cell	O
line	O
and	O
WI	O
-	O
38	O
,	O
human	O
lung	O
fibroblasts	O
)	O
,	O
mitochondrial	O
toxicity	O
(	O
786	O
-	O
O	O
,	O
human	O
renal	O
carcinoma	O
cell	O
line	O
)	O
,	O
hERG	O
inhibition	O
,	O
^	O
cytochrome	B
P450	I
inhibition	O
(	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
)	O
,	O
^	O
and	O
Aurora	O
B	O
kinase	O
inhibition	O
.	O

For	O
the	O
two	O
compounds	O
active	O
against	O
TbPTR1	O
(	O
4m	O
and	O
4o	O
)	O
,	O
IC_50	O
against	O
hERG	O
,	O
cytochrome	B
P450	I
,	O
and	O
mitochondrial	O
toxicity	O
were	O
determined	O
(	O
reported	O
in	O
Supporting	O
Information	O
)	O
.	O

Obes	O
Rev	O
17	O
:	O
42941	O
[	O
PMID	O
:	O
26997580	O
]	O
The	O
cytochrome	B
P450	I
enzyme	I
family	O
(	O
CYP450	O
)	O
,	O
E	O
.	O
C	O
.	O

(	O
2017	O
)	O
Pharmacogenomics	O
of	O
the	O
cytochrome	B
P450	I
2C	O
family	O
:	O
impacts	O
of	O
amino	O
acid	O
variations	O
on	O
drug	O
metabolism	O
.	O

(	O
2017	O
)	O
Spectroscopic	O
studies	O
of	O
the	O
cytochrome	B
P450	I
reaction	O
mechanisms	O
.	O

(	O
2017	O
)	O
Keeping	O
the	O
spotlight	O
on	O
cytochrome	B
P450	I
.	O

In	O
vitro	O
experiments	O
indicate	O
that	O
the	O
endocannabinoids	O
are	O
also	O
substrates	O
for	O
oxidative	O
metabolism	O
via	O
cyclooxygenase	O
,	O
lipoxygenase	O
and	O
cytochrome	B
P450	I
enzyme	I
activities	O
[	O
11	O
,	O
154	O
,	O
488	O
]	O
.	O

Oxidative	O
metabolism	O
of	O
arachidonic	O
acid	O
is	O
conducted	O
through	O
three	O
major	O
enzymatic	O
routes	O
:	O
cyclooxygenases	O
;	O
lipoxygenases	O
and	O
cytochrome	O
P450like	O
epoxygenases	O
,	O
particularly	O
CYP2J2	O
.	O

Subsequent	O
to	O
the	O
formation	O
of	O
PGH_2	O
,	O
the	O
cytochrome	B
P450	I
activities	O
thromboxane	O
synthase	O
(	O
CYP5A1	O
,	O
TBXAS1	O
,	O
P24557	O
,	O
EC	O
5	O
.	O
3	O
.	O
99	O
.	O
5	O
)	O
and	O
prostacyclin	O
synthase	O
(	O
CYP8A1	O
,	O
PTGIS	O
,	O
Q16647	O
,	O
EC	O
5	O
.	O
3	O
.	O
99	O
.	O
4	O
)	O
generate	O
thromboxane	O
A_2	O
and	O
prostacyclin	O
(	O
PGI_2	O
)	O
,	O
respectively	O
(	O
see	O
Cytochrome	O
P450s	O
)	O
.	O

Cytochrome	O
b5	O
plays	O
a	O
dual	O
role	O
in	O
the	O
reaction	O
cycle	O
of	O
cytochrome	B
P450	I
3A4	I
during	O
oxidation	O
of	O
the	O
anticancer	O
drug	O
ellipticine	O
.	O

Ellipticine	O
is	O
an	O
anticancer	O
agent	O
that	O
forms	O
covalent	O
DNA	O
adducts	O
after	O
enzymatic	O
activation	O
by	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
,	O
mainly	O
by	O
CYP3A4	B
.	O

This	O
enzymatic	O
system	O
also	O
contains	O
other	O
enzymes	O
such	O
as	O
NADPH	O
:	O
cytochrome	B
P450	I
oxidoreductase	O
(	O
POR	O
)	O
and	O
cytochrome	B
b	I
_5	I
accompanied	O
with	O
its	O
reductase	O
,	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
.	O

Establishment	O
of	O
a	O
novel	O
hepatocyte	O
model	O
that	O
expresses	O
four	O
cytochrome	B
P450	I
genes	O
stably	O
via	O
mammalian	O
-	O
derived	O
artificial	O
chromosome	O
for	O
pharmacokinetics	O
and	O
toxicity	O
studies	O
.	O

The	O
utility	O
of	O
HepG2	O
cells	O
to	O
assess	O
drug	O
metabolism	O
and	O
toxicity	O
induced	O
by	O
chemical	O
compounds	O
is	O
hampered	O
by	O
their	O
low	O
cytochrome	B
P450	I
activities	O
.	O

;	O
Chiangsom	O
et	O
al	O
.	O
.	O
Several	O
studies	O
have	O
evaluated	O
the	O
inhibitory	O
potential	O
of	O
R	O
.	O
rosea	O
toward	O
cytochrome	B
P450	I
enzymes	I
.	O

)	O
,	O
and	O
metyrapone	O
on	O
Ndemethylation	O
of	O
aminopyrine	O
by	O
mixed	O
function	O
oxidase	O
cytochrome	B
P450	I
in	O
rat	O
(	O
Roots	O
and	O
Hildebrandt	O
.	O

Prediction	O
of	O
cytochrome	B
P450	I
-	O
mediated	O
drug	O
clearance	O
in	O
humans	O
based	O
on	O
the	O
measured	O
activities	O
of	O
selected	O
CYPs	O
.	O

Determining	O
drug	O
-	O
metabolizing	O
enzyme	O
activities	O
on	O
an	O
individual	O
basis	O
is	O
an	O
important	O
component	O
of	O
personalized	O
medicine	O
,	O
and	O
cytochrome	B
P450	I
enzymes	I
play	O
a	O
principal	O
role	O
in	O
hepatic	O
drug	O
metabolism	O
.	O

Microsomal	O
protein	O
per	O
gram	O
of	O
liver	O
contents	O
were	O
determined	O
using	O
cytochrome	B
P450	I
oxidoreductase	O
activity	O
as	O
measured	O
in	O
homogenates	O
and	O
microsomes	O
obtained	O
from	O
the	O
same	O
liver	O
tissue	O
sample	O
;	O
The	O
liver	O
weight	O
was	O
calculated	O
by	O
multiplying	O
the	O
liver	O
volume	O
by	O
the	O
liver	O
density	O
,	O
where	O
liver	O
volume	O
(	O
ml	O
)	O
=	O
12	O
.	O
5	O
Body	O
Weight	O
+	O
536	O
.	O
4	O
and	O
the	O
liver	O
density	O
was	O
1	O
.	O
001	O
g	O
/	O
ml	O
.	O

This	O
study	O
aims	O
to	O
observe	O
TSG	O
-	O
provided	O
the	O
aggravation	O
on	O
acetaminophen	O
(	O
APAP	O
)	O
-	O
induced	O
hepatotoxicity	O
in	O
mice	O
by	O
inducing	O
hepatic	O
expression	O
of	O
cytochrome	B
P450	I
enzymes	I
.	O

A	O
series	O
of	O
stilbene	O
derivatives	O
were	O
synthesized	O
to	O
study	O
their	O
role	O
in	O
inhibiting	O
human	O
recombinant	O
cytochrome	B
P450	I
(	O
CYPs	O
)	O
:	O
CYP1B1	O
,	O
CYP1A1	B
,	O
CYP1A2	B
.	O

Although	O
insects	O
have	O
detoxification	O
mechanisms	O
(	O
eg	O
,	O
cytochrome	B
P450	I
monooxygenases	O
,	O
glutathione	O
S	O
-	O
transferases	O
,	O
and	O
esterases	O
)	O
,	O
some	O
symbionts	O
within	O
the	O
host	O
-	O
associated	O
bacterial	O
community	O
are	O
responsible	O
for	O
the	O
detoxification	O
of	O
plant	O
secondary	O
metabolites	O
.	O

Human	O
cytochrome	B
P450	I
3A4	I
is	O
the	O
most	O
abundant	O
isoform	O
of	O
P450	B
enzyme	I
in	O
the	O
liver	O
.	O

Based	O
on	O
previous	O
in	O
vitro	O
studies	O
,	O
cytochrome	B
P450	I
3A4	I
(	O
CYP3A4	B
)	O
has	O
been	O
regarded	O
as	O
the	O
main	O
CYP	O
isoform	O
responsible	O
for	O
the	O
de	O
-	O
ethylation	O
of	O
lidocaine	O
to	O
its	O
primary	O
metabolite	O
,	O
MEGX	O
.	O
,	O
CYP3A4	B
,	O
as	O
a	O
member	O
of	O
P450	B
enzyme	I
superfamily	O
,	O
is	O
the	O
most	O
important	O
drug	O
-	O
metabolizing	O
enzyme	O
in	O
human	O
liver	O
and	O
gastrointestinal	O
tract	O
.	O

One	O
of	O
the	O
most	O
important	O
mechanisms	O
through	O
which	O
interactions	O
occur	O
is	O
via	O
the	O
interference	O
of	O
herbal	O
products	O
with	O
human	O
hepatic	O
drug	O
metabolizing	O
enzyme	O
activities	O
particularly	O
the	O
cytochrome	B
P450	I
enzymes	I
.	O

Human	O
thromboxane	O
synthase	O
belongs	O
to	O
the	O
cytochrome	B
P450	I
superfamily	I
(	O
CYP5A1	O
)	O
.	O

Sort	O
=	O
Bait	O
also	O
performs	O
other	O
functions	O
:	O
catalyze	O
monooxygenase	O
reactions	O
characteristic	O
of	O
cytochrome	B
P450	I
and	O
involving	O
redox	O
partners	O
.	O

Sort	O
=	O
Bait	O
and	O
cytochrome	B
P450	I
reductase	O
(	O
http	O
:	O
/	O
/	O
hdl	O
.	O
handle	O
.	O

Sort	O
=	O
Bait	O
using	O
a	O
LC	O
-	O
MS	O
/	O
MS	O
-	O
analysis	O
,	O
one	O
of	O
which	O
was	O
cytochrome	B
P450	I
(	O
CYP2E1	B
)	O
.	O

Other	O
well	O
known	O
cytochrome	B
P450	I
protein	O
partners	O
(	O
CYB5A	O
,	O
Cytochrome	B
P450	I
Reductase	O
,	O
Nadph	O
-	O
Adrenodoxin	O
Reductase	O
,	O
ADX	O
)	O
and	O
several	O
proteins	O
unrelated	O
to	O
the	O
cytochrome	B
P450	I
monooxygenase	O
system	O
(	O
FECH	O
,	O
SMAD4	O
,	O
RAB27B	O
,	O
RBP4	O
)	O
were	O
also	O
used	O
for	O
the	O
specificity	O
test	O
.	O

Sort	O
=	O
Bait	O
interacts	O
with	O
cytochrome	B
P450	I
CYP2E1	B
and	O
CYP11B2	O
,	O
while	O
the	O
affinity	O
of	O
TBXAS1CYP2E1	O
complex	O
formation	O
is	O
fivefold	O
higher	O
in	O
the	O
presence	O
of	O
low	O
-	O
molecular	O
-	O
weight	O
non	O
-	O
peptide	O
endogenous	O
bioregulator	O
isatin	O
(	O
2	O
,	O
3	O
-	O
dioxindole	O
)	O
.	O

Methicillin	O
-	O
Resistant	O
Staphylococcus	O
Aureus	O
infection	O
can	O
modulate	O
the	O
effects	O
of	O
drugs	O
,	O
which	O
may	O
occur	O
through	O
an	O
influence	O
on	O
cytochrome	B
P450	I
,	O
the	O
drug	O
-	O
metabolizing	O
enzyme	O
in	O
the	O
liver	O
.	O

There	O
are	O
many	O
causes	O
for	O
change	O
in	O
the	O
expression	O
of	O
liver	O
drug	O
metabolic	O
enzymes	O
;	O
the	O
most	O
important	O
is	O
the	O
inflammation	O
and	O
oxidative	O
stress	O
caused	O
by	O
pathogenic	O
microbial	O
infection	O
.	O
-	O
Studies	O
have	O
shown	O
that	O
a	O
component	O
of	O
the	O
gut	O
microbiome	O
,	O
Citrobacter	O
rodentium	O
,	O
the	O
hepatitis	O
C	O
virus	O
,	O
and	O
other	O
infectious	O
agents	O
modulate	O
the	O
expression	O
of	O
hepatic	O
cytochrome	B
P450	I
.	O
-	O
Matsumoto	O
et	O
al	O
reported	O
that	O
Methicillin	O
-	O
Resistant	O
Staphylococcus	O
Aureus	O
infections	O
influenced	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
teicoplanin	O
in	O
patients	O
.	O

We	O
speculated	O
that	O
this	O
effect	O
was	O
a	O
result	O
of	O
changes	O
in	O
the	O
expression	O
of	O
the	O
cytochrome	B
P450	I
enzyme	I
caused	O
by	O
Methicillin	O
-	O
Resistant	O
Staphylococcus	O
Aureus	O
infection	O
.	O

Importantly	O
,	O
however	O
,	O
the	O
results	O
with	O
the	O
various	O
strains	O
indicate	O
that	O
the	O
genetic	O
cytochrome	B
P450	I
manipulations	O
in	O
these	O
mice	O
did	O
not	O
compromise	O
overall	O
long	O
-	O
term	O
survival	O
of	O
these	O
mice	O
relative	O
to	O
their	O
WT	O
founder	O
strain	O
or	O
to	O
CD	O
-	O
1	O
mice	O
.	O

A	O
cytochrome	B
P450	I
,	O
CYP73	O
,	O
with	O
cinnamate	O
4	O
-	O
hydroxylase	O
(	O
C4H	O
)	O
activity	O
,	O
catalyzes	O
the	O
first	O
plant	O
-	O
specific	O
and	O
rate	O
-	O
limiting	O
step	O
in	O
this	O
pathway	O
.	O

Our	O
extensive	O
mining	O
of	O
the	O
most	O
recent	O
sequencing	O
data	O
is	O
in	O
line	O
with	O
the	O
hypothesis	O
that	O
the	O
CYP73	O
family	O
of	O
cytochrome	B
P450	I
enzymes	I
evolved	O
upon	O
plant	O
colonization	O
of	O
land	O
.	O

As	O
a	O
control	O
,	O
experimental	O
N	O
-	O
terminal	O
helical	O
segments	O
of	O
ScErg11p	O
(	O
CYP51	O
)	O
,	O
the	O
first	O
crystal	O
structure	O
for	O
any	O
full	O
-	O
length	O
cytochrome	B
P450	I
enzyme	I
showing	O
resolution	O
of	O
the	O
membrane	O
spanning	O
helix	O
available	O
in	O
PDB	O
,	O
were	O
also	O
submitted	O
to	O
PPM	O
server	O
.	O

Fg02458	O
and	O
Fg00012	O
are	O
members	O
of	O
the	O
CYP63	O
family	O
,	O
which	O
is	O
predicted	O
to	O
take	O
part	O
in	O
the	O
degradation	O
of	O
fatty	O
acids	O
,	O
and	O
members	O
of	O
the	O
subfamily	O
CYP537A2	O
(	O
Fg12737	O
)	O
are	O
known	O
to	O
be	O
related	O
to	O
benzoate	O
4	O
-	O
monooxygenase	O
cytochrome	B
P450	I
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
summarize	O
and	O
evaluate	O
what	O
is	O
currently	O
known	O
about	O
cytochrome	B
P450	I
genetic	O
variation	O
in	O
Indigenous	O
populations	O
in	O
North	O
America	O
and	O
to	O
highlight	O
the	O
importance	O
of	O
including	O
these	O
groups	O
in	O
future	O
pharmacogenetic	O
studies	O
for	O
implementation	O
of	O
personalized	O
drug	O
therapy	O
.	O

While	O
much	O
work	O
has	O
been	O
conducted	O
investigating	O
the	O
clinical	O
importance	O
of	O
the	O
cytochrome	B
P450	I
(	O
P450	O
)	O
gene	O
variants	O
,	O
there	O
is	O
relatively	O
little	O
data	O
specifically	O
addressing	O
P450	O
variation	O
and	O
its	O
consequences	O
in	O
Indigenous	O
populations	O
.	O

A	O
search	O
of	O
PubMed	O
was	O
performed	O
using	O
the	O
keywords	O
Alaska	O
Native	O
,	O
American	O
Indian	O
,	O
Native	O
American	O
,	O
Canadian	O
Native	O
Indian	O
,	O
First	O
Nations	O
,	O
Canadian	O
Inuit	O
,	O
Mexico	O
Amerindian	O
,	O
Mexico	O
Indigenous	O
,	O
cytochrome	B
P450	I
polymorphisms	O
,	O
Pharmacogenetics	O
,	O
and	O
CYP450	O
allele	O
frequencies	O
,	O
drug	O
disposition	O
,	O
and	O
drug	O
metabolism	O
.	O

Additional	O
analysis	O
of	O
the	O
gene	O
using	O
InterproScan	O
found	O
it	O
to	O
be	O
a	O
cytochrome	B
P450	I
domain	O
containing	O
gene	O
.	O

For	O
example	O
,	O
the	O
g5566t	O
.	O
1	O
gene	O
that	O
was	O
identified	O
to	O
represent	O
the	O
highest	O
degree	O
of	O
connectivity	O
was	O
initially	O
identified	O
as	O
uncharacterized	O
and	O
containing	O
cytochrome	B
P450	I
domain	O
information	O
.	O

While	O
multiple	O
genes	O
have	O
been	O
identified	O
to	O
be	O
involved	O
with	O
cytochrome	B
P450	I
and	O
pathogenicity	O
for	O
other	O
pathogens	O
,	O
the	O
protein	O
sequence	O
would	O
have	O
been	O
initially	O
missed	O
because	O
it	O
was	O
returned	O
as	O
uncharacterized	O
during	O
the	O
initial	O
BLAST	O
analysis	O
against	O
F	O
.	O
graminearum	O
.	O

Through	O
this	O
tool	O
,	O
metabolism	O
using	O
certain	O
cytochrome	B
P450	I
enzymes	I
was	O
evaluated	O
comparing	O
whether	O
the	O
compounds	O
were	O
substrates	O
for	O
cytochromes	O
CYP450	O
2D6	O
,	O
CYP450	O
3A4	O
,	O
and	O
CYP450	O
2C9	O
;	O
whether	O
they	O
were	O
inhibitors	O
of	O
cytochrome	O
CYP450	O
1A2	O
,	O
CYP450	O
2C9	O
,	O
CYP450	O
2D6	O
,	O
CYP450	O
2C19	O
,	O
and	O
CYP450	O
3A4	O
;	O
and	O
whether	O
there	O
was	O
cytochrome	O
inhibition	O
promiscuity	O
.	O

An	O
elevated	O
production	O
of	O
Nitric	O
Oxide	O
decreases	O
regulation	O
of	O
cytochrome	B
P450	I
;	O
it	O
triggers	O
suppression	O
of	O
hepatic	O
proteins	O
and	O
the	O
synthesis	O
of	O
DNA	O
and	O
thus	O
induces	O
apoptosis	O
and	O
necrosis	O
[	O
,	O
.	O

^	O
While	O
MCF	O
-	O
7	O
cells	O
used	O
to	O
develop	O
the	O
ER	O
-	O
Luc	O
cells	O
express	O
metabolic	O
enzymes	O
from	O
the	O
cytochrome	B
P450	I
superfamily	I
(	O
and	O
thus	O
possess	O
the	O
ability	O
for	O
endogenous	O
biotransformation	O
of	O
chemicals	O
)	O
,	O
formation	O
of	O
MBP	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
S9	O
enzymes	O
.	O

We	O
undertook	O
an	O
in	O
-	O
depth	O
assessment	O
of	O
extracts	O
of	O
Hyptis	O
verticillata	O
Jacq	O
.	O
,	O
via	O
its	O
impact	O
on	O
activities	O
of	O
key	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
(	O
CYPs	O
1A1	O
,	O
1A2	O
,	O
1B1	O
,	O
3A4	O
and	O
2D6	O
)	O
,	O
its	O
antioxidant	O
properties	O
(	O
determined	O
by	O
DPPH	O
assays	O
)	O
and	O
chemical	O
characterisation	O
(	O
using	O
LC	O
-	O
MS	O
)	O
.	O

to	O
screen	O
natural	O
products	O
for	O
cytochrome	B
P450	I
inhibition	O
potential	O
with	O
a	O
particular	O
emphasis	O
on	O
the	O
P450	B
enzymes	I
,	O
CYPs	O
1A1	O
,	O
1A2	O
,	O
1B1	O
,	O
3A4	O
and	O
2D6	O
.	O

Plant	O
extracts	O
and	O
various	O
phytochemicals	O
were	O
evaluated	O
for	O
their	O
ability	O
to	O
inhibit	O
the	O
catalytic	O
activity	O
of	O
human	O
cytochrome	B
P450	I
enzymes	I
by	O
means	O
of	O
high	O
throughput	O
fluorometric	O
inhibition	O
assays	O
conducted	O
in	O
96	O
well	O
microtitre	O
plates	O
as	O
described	O
by	O
Crespi	O
et	O
al	O
.	O
,	O
BD	O
Gentest	O
and	O
Murray	O
et	O
al	O
.	O
.	O
7	O
-	O
Ethoxy	O
-	O
3	O
-	O
cyanocoumarin	O
(	O
CEC	O
)	O
was	O
used	O
as	O
a	O
substrate	O
for	O
detecting	O
the	O
activities	O
of	O
CYPs	O
1A1	O
,	O
and	O
1A2	O
,	O
7	O
-	O
ethoxyresorufin	O
(	O
ERes	O
)	O
for	O
CYP1B1	O
,	O
7	O
-	O
benzyloxy	O
-	O
4	O
-	O
trifluoromethylcoumarin	O
(	O
BFC	O
)	O
for	O
CYP3A4	B
,	O
and	O
3	O
-	O
[	O
2	O
-	O
(	O
N	O
,	O
N	O
-	O
diethyl	O
-	O
N	O
-	O
methylammonium	O
)	O
-	O
ethyl	O
]	O
-	O
7	O
-	O
methoxy	O
-	O
4	O
-	O
methylcoumarin	O
(	O
AMMC	O
)	O
for	O
CYP2D6	B
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
multiplication	O
of	O
cytochrome	B
P450	I
variants	O
within	O
the	O
CYP71AZ	O
subfamily	O
has	O
contributed	O
to	O
the	O
diversification	O
of	O
these	O
molecules	O
.	O

This	O
approach	O
may	O
explain	O
the	O
evolution	O
of	O
this	O
cytochrome	B
P450	I
family	O
regarding	O
the	O
appearance	O
of	O
FCs	O
in	O
parsnip	O
and	O
possibly	O
in	O
the	O
Apiaceae	O
.	O

Beside	O
dioxygenases	O
,	O
the	O
cytochrome	O
P450s	O
(	O
P450s	O
)	O
are	O
the	O
most	O
diversified	O
enzyme	O
family	O
in	O
plants	O
and	O
are	O
estimated	O
to	O
represent	O
up	O
to	O
1	O
%	O
of	O
the	O
annotated	O
genes	O
in	O
plant	O
genomes	O
.	O

In	O
summary	O
,	O
the	O
data	O
provided	O
unequivocal	O
evidence	O
that	O
the	O
SRS	O
regions	O
of	O
CYP71AZs	O
are	O
intimately	O
involved	O
in	O
the	O
specificities	O
of	O
these	O
enzymes	O
and	O
confirm	O
the	O
relevance	O
commonly	O
assigned	O
to	O
SRSs	O
in	O
cytochrome	O
P450s	O
.	O

Here	O
,	O
we	O
provide	O
a	O
new	O
example	O
of	O
the	O
importance	O
of	O
cytochrome	O
P450s	O
,	O
which	O
have	O
already	O
been	O
identified	O
to	O
be	O
deeply	O
involved	O
in	O
this	O
diversification	O
,	O
and	O
suggest	O
how	O
they	O
can	O
be	O
involved	O
in	O
the	O
appearance	O
of	O
new	O
molecules	O
to	O
meet	O
further	O
challenges	O
for	O
an	O
ecological	O
function	O
(	O
;	O
.	O

Buried	O
active	O
sites	O
in	O
cytochrome	B
P450	I
enzymes	I
are	O
connected	O
to	O
the	O
solvent	O
by	O
a	O
network	O
of	O
channels	O
exiting	O
at	O
the	O
distal	O
surface	O
of	O
the	O
protein	O
.	O

For	O
a	O
rather	O
long	O
period	O
,	O
besides	O
the	O
ribosomal	O
tunnel	O
of	O
the	O
nascently	O
synthesized	O
polypeptide	O
,	O
cytochrome	O
P450s	O
and	O
haloalkane	O
dehalogenases	O
were	O
the	O
only	O
known	O
enzymes	O
with	O
a	O
deeply	O
buried	O
active	O
site	O
with	O
no	O
easily	O
visible	O
pathway	O
leading	O
from	O
the	O
protein	O
surface	O
to	O
the	O
catalytic	O
cavity	O
.	O

Historically	O
,	O
the	O
first	O
attempt	O
to	O
identify	O
access	O
channels	O
in	O
cytochrome	B
P450	I
was	O
made	O
twenty	O
years	O
ago	O
by	O
Rebecca	O
Wade	O
and	O
her	O
coworkers	O
on	O
cytochrome	O
P450cam	B
(	O
CYP101A1	O
)	O
.	O

Detailed	O
stopped	O
-	O
flow	O
kinetics	O
of	O
binding	O
of	O
camphor	O
to	O
cytochrome	O
P450cam	O
have	O
been	O
studied	O
for	O
site	O
-	O
directed	O
mutants	O
of	O
P450cam	O
.	O

The	O
authors	O
have	O
identified	O
all	O
of	O
the	O
channels	O
in	O
the	O
network	O
that	O
this	O
enzyme	O
,	O
which	O
is	O
not	O
a	O
cytochrome	B
P450	I
,	O
exhibits	O
.	O

Secnidazole	O
is	O
rapidly	O
and	O
completely	O
absorbed	O
following	O
oral	O
administration	O
and	O
demonstrates	O
a	O
longer	O
terminal	O
elimination	O
halflife	O
of	O
approximately	O
17	O
to	O
29	O
hours	O
vs	O
other	O
drugs	O
in	O
its	O
class	O
.	O
,	O
It	O
is	O
metabolized	O
by	O
oxidation	O
in	O
the	O
liver	O
to	O
a	O
hydroxyethyl	O
metabolite	O
without	O
any	O
effects	O
,	O
neither	O
induction	O
nor	O
inhibition	O
,	O
on	O
cytochrome	B
P450	I
enzymes	I
,	O
;	O
elimination	O
is	O
mainly	O
through	O
the	O
urinary	O
route	O
,	O
with	O
approximately	O
50	O
%	O
excreted	O
by	O
96	O
hours	O
.	O

This	O
review	O
collects	O
available	O
information	O
of	O
which	O
-	O
taken	O
with	O
great	O
caution	O
because	O
of	O
the	O
still	O
very	O
limited	O
data	O
-	O
the	O
most	O
salient	O
points	O
are	O
:	O
in	O
the	O
skin	O
of	O
all	O
animal	O
species	O
and	O
skin	O
-	O
derived	O
in	O
vitro	O
systems	O
considered	O
in	O
this	O
review	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
-	O
dependent	O
monooxygenase	O
activities	O
(	O
largely	O
responsible	O
for	O
initiating	O
xenobiotica	O
metabolism	O
in	O
the	O
organ	O
which	O
provides	O
most	O
of	O
the	O
xenobiotica	O
metabolism	O
of	O
the	O
mammalian	O
organism	O
,	O
the	O
liver	O
)	O
are	O
very	O
low	O
to	O
undetectable	O
.	O

A	O
notable	O
example	O
of	O
this	O
is	O
many	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
-	O
dependent	O
activities	O
.	O
In	O
many	O
(	O
actually	O
in	O
most	O
)	O
cases	O
in	O
the	O
original	O
literature	O
crucial	O
details	O
are	O
not	O
given	O
.	O

The	O
effect	O
of	O
non	O
-	O
synonymous	O
single	O
nucleotide	O
polymorphisms	O
on	O
cytochrome	B
P450	I
drug	O
metabolism	O
is	O
currently	O
poorly	O
understood	O
due	O
to	O
the	O
large	O
number	O
of	O
polymorphisms	O
,	O
the	O
diversity	O
of	O
potential	O
substrates	O
and	O
the	O
complexity	O
of	O
Cytochrome	B
P450	I
function	O
.	O

Single	O
amino	O
acid	O
substitutions	O
can	O
affect	O
haem	O
binding	O
,	O
substrate	O
access	O
and	O
binding	O
,	O
interactions	O
with	O
redox	O
partner	O
cytochrome	B
P450	I
reductase	O
,	O
oligomerisation	O
and	O
/	O
or	O
the	O
conformation	O
and	O
structural	O
stability	O
of	O
the	O
enzyme	O
.	O

To	O
account	O
for	O
direct	O
effects	O
of	O
mutations	O
on	O
protein	O
function	O
,	O
a	O
cytochrome	B
P450	I
SNP	O
map	O
was	O
created	O
which	O
combined	O
information	O
from	O
previous	O
functional	O
studies	O
to	O
delineate	O
regions	O
important	O
for	O
substrate	O
recognition	O
^	O
,	O
,	O
haem	O
binding	O
,	O
interactions	O
with	O
CPR	O
^	O
-	O
and	O
residues	O
implicated	O
in	O
the	O
gating	O
of	O
substrate	O
and	O
product	O
access	O
/	O
egress	O
tunnels	O
^	O
-	O
.	O

In	O
addition	O
,	O
a	O
real	O
-	O
time	O
reverse	O
transcription	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
study	O
was	O
performed	O
to	O
study	O
the	O
regulatory	O
role	O
of	O
the	O
biosynthetic	O
genes	O
HMG	O
-	O
CoA	O
reductase	O
,	O
farnesyl	O
diphosphate	O
synthase	O
,	O
epikunzeaol	O
synthase	O
(	O
TgTPS2	O
)	O
and	O
the	O
cytochrome	B
P450	I
(	O
TgCYP76AE2	O
)	O
of	O
stem	O
,	O
leaf	O
and	O
callus	O
tissues	O
.	O

This	O
study	O
aimed	O
to	O
illustrate	O
the	O
effects	O
of	O
protoberberines	O
on	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
activation	O
and	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
1	O
in	O
the	O
estrogen	O
receptor	O
(	O
ER	O
)	O
ALPHA	O
(	O
+	O
)	O
MCF	O
-	O
7	O
breast	O
cancer	O
cells	O
.	O

The	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
downstream	O
targets	O
,	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
1	O
isoforms	O
,	O
play	O
very	O
important	O
roles	O
in	O
the	O
detoxification	O
and	O
bioactivation	O
of	O
environmental	O
pollutants	O
,	O
carcinogens	O
and	O
physiological	O
compounds	O
,	O
such	O
as	O
benzo	O
(	O
a	O
)	O
pyrene	O
(	O
B	O
(	O
a	O
)	O
P	O
)	O
and	O
estradiol	O
(	O
E2	O
)	O
.	O

By	O
using	O
univariate	O
analysis	O
,	O
human	O
hepatic	O
cytochrome	B
P450	I
(	O
P450	O
,	O
CYP	O
)	O
1A1	O
protein	O
levels	O
were	O
negatively	O
correlated	O
with	O
miR	O
-	O
21	O
-	O
5p	O
(	O
mature	O
miR	O
-	O
21	O
)	O
,	O
miR	O
-	O
132	O
and	O
miR	O
-	O
142	O
-	O
3p	O
levels	O
.	O

Although	O
there	O
have	O
been	O
studies	O
on	O
the	O
biological	O
activities	O
of	O
selaginellins	O
,	O
their	O
modulatory	O
potential	O
of	O
cytochrome	B
P450	I
(	O
P450	O
)	O
and	O
uridine	O
5	O
-	O
diphosphoglucuronosyltransferase	O
activities	O
have	O
not	O
been	O
previously	O
evaluated	O
.	O

Among	O
the	O
numerous	O
drug	O
-	O
metabolizing	O
enzymes	O
,	O
cytochrome	O
P450s	O
(	O
P450s	O
)	O
and	O
uridine	O
5	O
-	O
diphosphoglucuronosyltransferases	O
,	O
which	O
are	O
responsible	O
for	O
the	O
metabolic	O
clearance	O
of	O
90	O
%	O
of	O
commercial	O
drugs	O
,	O
have	O
been	O
shown	O
to	O
a	O
play	O
key	O
roles	O
in	O
drug	O
metabolism	O
and	O
drug	O
interactions	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
inhibitory	O
effect	O
of	O
two	O
selaginellins	O
against	O
ten	O
cytochrome	B
P450	I
isoforms	O
and	O
six	O
Uridine	O
5	O
-	O
Diphosphoglucuronosyltransferase	O
isoforms	O
using	O
human	O
liver	O
microsomes	O
.	O

Thus	O
,	O
interconversion	O
of	O
7OH	O
-	O
DHEA	O
via	O
7	O
-	O
oxo	O
-	O
DHEA	O
is	O
probably	O
specific	O
only	O
to	O
these	O
animals	O
cytochrome	O
P450s	O
.	O

Firstly	O
,	O
the	O
behavior	O
as	O
substrate	O
or	O
inhibitor	O
of	O
the	O
target	O
molecules	O
in	O
the	O
most	O
important	O
isoforms	O
of	O
the	O
cytochrome	B
P450	I
participants	O
in	O
the	O
metabolism	O
of	O
therapeutic	O
drugs	O
was	O
evaluated	O
.	O

Evaluation	O
of	O
the	O
target	O
molecules	O
as	O
substrates	O
of	O
Cytochrome	B
P450	I
shows	O
that	O
1	O
-	O
4	O
act	O
as	O
non	O
-	O
substrates	O
of	O
the	O
2C9	O
and	O
2D6	O
isoforms	O
of	O
cytochrome	B
P450	I
.	O

Levels	O
of	O
other	O
xenobiotics	O
,	O
including	O
caffeine	O
,	O
are	O
also	O
reported	O
to	O
increase	O
in	O
older	O
subjects	O
,	O
possibly	O
reflecting	O
decreased	O
activity	O
of	O
hepatic	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
.	O

A	O
number	O
of	O
PhM	O
studies	O
have	O
focused	O
on	O
the	O
prediction	O
of	O
individual	O
drug	O
metabolism	O
by	O
measuring	O
the	O
cytochrome	B
P450	I
activity	O
of	O
drug	O
-	O
metabolizing	O
enzymes	O
.	O

Pyrethroid	O
/	O
permethrin	O
resistant	O
mosquitoes	O
exhibit	O
insecticide	O
resistance	O
through	O
elevated	O
levels	O
of	O
multiple	O
detoxification	O
enzymes	O
,	O
including	O
Glutathion	O
S	O
-	O
Transferases	O
,	O
ATP	O
-	O
binding	O
cassette	O
transporters	O
,	O
carboxylesterase	O
,	O
and	O
cytochrome	B
P450	I
.	O

These	O
transcripts	O
encoded	O
one	O
alcohol	O
dehydrogenase	O
,	O
two	O
aldehyde	O
oxidases	O
,	O
one	O
aldo	O
-	O
keto	O
reductase	O
,	O
two	O
Carboxy	O
/	O
choline	O
esterases	O
,	O
one	O
core	O
1	O
UDP	O
-	O
galactose	O
galactosyltransferase	O
,	O
33	O
cytochrome	B
P450	I
,	O
one	O
d	O
-	O
amino	O
acid	O
oxidase	O
,	O
one	O
epoxide	O
hydrolase	O
,	O
seven	O
glucosyl	O
/	O
glucuronosyl	O
transferases	O
,	O
one	O
glutamate	O
semialdehyde	O
dehydrogenase	O
,	O
three	O
n	O
-	O
acetylgalactosaminyltransferases	O
,	O
one	O
prophenoloxidase	O
,	O
four	O
short	O
-	O
chain	O
dehydrogenases	O
,	O
one	O
sterol	O
desaturase	O
,	O
and	O
one	O
thioredoxin	O
peroxidase	O
.	O

Four	O
cytochrome	B
P450	I
(	O
AAEL009018	O
,	O
AAEL014609	O
,	O
AAEL014617	O
,	O
and	O
AAEL014893	O
)	O
were	O
reported	O
as	O
associated	O
with	O
insecticide	O
resistance	O
in	O
several	O
populations	O
of	O
Ae	O
.	O

In	O
vitro	O
studies	O
have	O
suggested	O
that	O
UVB	O
enhances	O
B	O
[	O
a	O
]	O
P	O
genotoxicity	O
by	O
activating	O
the	O
AhR	O
pathway	O
and	O
overexpressing	O
the	O
cytochrome	B
P450	I
enzymes	I
responsible	O
for	O
the	O
conversion	O
of	O
B	O
[	O
a	O
]	O
P	O
into	O
DNA	O
damaging	O
metabolites	O
.	O

We	O
found	O
that	O
topically	O
applied	O
B	O
[	O
a	O
]	O
P	O
strongly	O
induced	O
expression	O
of	O
cutaneous	O
cytochrome	B
P450	I
genes	O
and	O
formation	O
of	O
DNA	O
adducts	O
.	O

However	O
,	O
metabolization	O
via	O
phase	O
I	O
enzymes	O
,	O
mainly	O
cytochrome	B
P450	I
oxygenases	O
,	O
convert	O
Polycyclic	O
Aromatic	O
Hydrocarbons	O
into	O
reactive	O
metabolite	O
intermediaries	O
^	O
.	O

The	O
purpose	O
of	O
this	O
research	O
was	O
to	O
study	O
the	O
microbial	O
structural	O
complexes	O
of	O
the	O
pesticide	O
-	O
contaminated	O
soils	O
in	O
these	O
dumping	O
zones	O
,	O
and	O
to	O
search	O
for	O
and	O
select	O
microorganisms	O
destructors	O
with	O
cytochrome	B
P450	I
genes	O
for	O
pesticide	O
degradation	O
.	O

The	O
universal	O
primer	O
set	O
for	O
the	O
16S	O
ribosomal	O
RNA	O
(	O
rRNA	O
)	O
gene	O
and	O
the	O
specific	O
primer	O
set	O
P450R	O
were	O
used	O
to	O
amplify	O
the	O
cytochrome	B
P450	I
hydroxylase	O
gene	O
.	O

;	O
Qureshi	O
et	O
al	O
.	O
.	O
Among	O
oxidoreductases	O
,	O
the	O
most	O
frequent	O
are	O
monooxygenases	O
like	O
cytochrome	B
P450	I
,	O
dioxygenases	O
,	O
peroxidases	O
,	O
and	O
oxidases	O
;	O
hydrolases	O
like	O
A	O
-	O
esterase	O
are	O
involved	O
in	O
biodegradation	O
pathways	O
.	O

The	O
main	O
purpose	O
of	O
this	O
research	O
is	O
to	O
study	O
the	O
microbial	O
structural	O
complexes	O
of	O
pesticide	O
-	O
contaminated	O
soils	O
in	O
these	O
dumping	O
zones	O
,	O
and	O
to	O
search	O
for	O
and	O
select	O
microorganism	O
destructors	O
with	O
cytochrome	B
P450	I
genes	O
for	O
pesticide	O
degradation	O
.	O

The	O
primer	O
set	O
alkB	O
-	O
F	O
and	O
alkB	O
-	O
R	O
was	O
used	O
to	O
amplify	O
the	O
alkane	O
hydroxylase	O
,	O
and	O
P450R	O
was	O
used	O
to	O
amplify	O
the	O
cytochrome	B
P450	I
alkane	O
hydroxylase	O
.	O

;	O
Matsumoto	O
et	O
al	O
.	O
.	O
Most	O
of	O
the	O
DNA	O
samples	O
extracted	O
from	O
the	O
soil	O
in	O
the	O
enrichment	O
culture	O
were	O
amplified	O
with	O
P450	O
fw1	O
and	O
P450	O
rv3	O
primers	O
,	O
demonstrating	O
the	O
presence	O
of	O
cytochrome	B
P450	I
genes	O
(	O
Fig	O
.	O

The	O
presence	O
of	O
such	O
microorganisms	O
involved	O
in	O
the	O
biodegradation	O
process	O
was	O
proved	O
by	O
amplification	O
of	O
the	O
cytochrome	B
P450	I
genes	O
that	O
encode	O
this	O
process	O
.	O

Steroidogenesis	O
in	O
ovarian	O
follicular	O
cells	O
is	O
mediated	O
by	O
a	O
number	O
of	O
well	O
-	O
known	O
enzymes	O
such	O
as	O
,	O
for	O
example	O
,	O
steroidogenic	O
acute	O
regulatory	O
protein	O
STAR	O
,	O
cytochrome	B
P450	I
side	O
chain	O
cleavage	O
CYP450scc	O
,	O
3	O
-	O
beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
HSD3BETA	O
,	O
and	O
CYP450	O
aromatase	O
in	O
theca	O
and	O
granulosa	O
cells	O
.	O

75	O
%	O
of	O
the	O
enzymes	O
that	O
metabolize	O
drugs	O
in	O
the	O
human	O
body	O
are	O
cytochrome	O
P450s	O
.	O

Five	O
cytochrome	O
P450s	O
account	O
for	O
90	O
%	O
of	O
the	O
drug	O
metabolism	O
.	O

Thus	O
,	O
they	O
reach	O
systemic	O
circulation	O
as	O
aglycones	O
,	O
and	O
as	O
such	O
are	O
exposed	O
to	O
the	O
cytochrome	B
P450	I
enzymes	I
.	O

Further	O
studies	O
of	O
chrysin	O
dimethylether	O
,	O
isorhamnetin	O
,	O
pinocembrin	O
,	O
and	O
tangeretin	O
inhibition	O
of	O
CYP3A4	B
are	O
needed	O
to	O
determine	O
inactivation	O
kinetics	O
and	O
steps	O
of	O
the	O
catalytic	O
cycle	O
of	O
cytochrome	B
P450	I
3A4	O
that	O
are	O
affected	O
by	O
the	O
inhibitor	O
or	O
potential	O
reactive	O
intermediate	O
products	O
/	O
metabolites	O
.	O

The	O
recombinant	O
baculosomes	O
with	O
hyperexpressed	O
CYP3A4	B
and	O
coexpressed	O
NADPH	O
cytochrome	B
P450	I
reductase	O
and	O
cytochrome	O
b_5	O
,	O
was	O
used	O
as	O
source	O
of	O
enzyme	O
.	O

Besides	O
serving	O
as	O
a	O
simple	O
model	O
for	O
the	O
first	O
step	O
of	O
the	O
cytochrome	B
P450	I
catalytic	O
cycle	O
,	O
the	O
spin	O
switch	O
can	O
be	O
used	O
to	O
switch	O
the	O
spin	O
-	O
lattice	O
relaxation	O
time	O
T1	O
of	O
the	O
water	O
protons	O
by	O
a	O
factor	O
of	O
15	O
.	O

Substrate	O
binding	O
to	O
cytochrome	B
P450	I
triggers	O
a	O
change	O
in	O
the	O
spin	O
state	O
of	O
the	O
heme	O
-	O
bound	O
Fe	O
(	O
III	O
)	O
from	O
the	O
resting	O
state	O
,	O
low	O
spin	O
(	O
S	O
=	O
^	O
1	O
/	O
_2	O
)	O
,	O
to	O
high	O
spin	O
(	O
S	O
=	O
^	O
5	O
/	O
_2	O
)	O
.	O

The	O
active	O
center	O
of	O
cytochrome	B
P450	I
contains	O
a	O
low	O
spin	O
Fe	O
(	O
III	O
)	O
porphyrin	O
in	O
its	O
resting	O
state	O
.	O

Here	O
,	O
using	O
a	O
microarray	O
-	O
based	O
genome	O
-	O
wide	O
transcription	O
and	O
qRT	O
-	O
PCR	O
analysis	O
,	O
we	O
showed	O
that	O
metabolic	O
resistance	O
mechanisms	O
through	O
over	O
-	O
expression	O
of	O
cytochrome	B
P450	I
and	O
glutathione	O
S	O
-	O
transferase	O
genes	O
(	O
GSTs	O
)	O
are	O
a	O
major	O
contributor	O
to	O
DDT	O
and	O
permethrin	O
resistance	O
in	O
Anopheles	O
funestus	O
from	O
Kpome	O
.	O

Metabolic	O
resistance	O
is	O
the	O
main	O
resistance	O
mechanism	O
recorded	O
,	O
and	O
cytochrome	B
P450	I
genes	O
are	O
playing	O
a	O
major	O
role	O
while	O
target	O
-	O
site	O
resistance	O
like	O
the	O
knockdown	O
resistance	O
(	O
kdr	O
)	O
is	O
absent	O
.	O

In	O
this	O
study	O
,	O
using	O
a	O
genome	O
-	O
wide	O
microarray	O
-	O
based	O
transcription	O
analysis	O
,	O
the	O
underlying	O
molecular	O
mechanisms	O
conferring	O
DDT	O
and	O
permethrin	O
resistance	O
in	O
Kpome	O
were	O
characterised	O
revealing	O
that	O
both	O
glutathione	O
S	O
-	O
transferases	O
,	O
notably	O
the	O
GSTe2	O
,	O
and	O
cytochrome	B
P450	I
genes	O
are	O
the	O
main	O
drivers	O
of	O
resistance	O
.	O

Among	O
these	O
genes	O
,	O
the	O
transcripts	O
for	O
glycogenin	O
(	O
Afun000500	O
)	O
and	O
CYP6M7	O
,	O
belonging	O
to	O
the	O
cytochrome	B
P450	I
gene	O
family	O
,	O
were	O
the	O
most	O
commonly	O
overexpressed	O
detoxification	O
gene	O
in	O
R_perm	O
-	O
S	O
(	O
FC	O
of	O
36	O
.	O
2	O
for	O
Afun000500	O
and	O
34	O
.	O
6	O
for	O
CYP6M7	O
)	O
and	O
C	O
-	O
S	O
(	O
FC	O
of	O
38	O
.	O
1	O
for	O
Afun000500	O
and	O
28	O
.	O
9	O
for	O
CYP6M7	O
)	O
.	O

The	O
cytochrome	B
P450	I
gene	O
CYP307A1	O
was	O
also	O
upregulated	O
with	O
FC	O
3	O
.	O
3	O
in	O
R_DDT	O
-	O
S	O
and	O
FC	O
2	O
.	O
2	O
in	O
C	O
-	O
S	O
.	O

These	O
genes	O
include	O
alcohol	O
dehydrogenase	O
Afun013475	O
(	O
FC	O
3	O
.	O
2	O
)	O
,	O
the	O
most	O
upregulated	O
gene	O
(	O
FC	O
3	O
.	O
2	O
)	O
as	O
well	O
as	O
CYP302A1	O
(	O
FC	O
2	O
.	O
6	O
)	O
,	O
CYP4D15	O
(	O
FC	O
2	O
.	O
4	O
)	O
,	O
CYP4J5	O
(	O
FC	O
2	O
.	O
2	O
)	O
,	O
gb	O
-	O
CYP12F3	O
(	O
FC	O
2	O
.	O
1	O
)	O
and	O
the	O
cytochrome	B
P450	I
(	O
Afun010630	O
)	O
(	O
FC	O
2	O
.	O
1	O
)	O
.	O

funestus	O
from	O
Kpome	O
notably	O
through	O
overexpression	O
of	O
genes	O
involved	O
in	O
insecticide	O
detoxification	O
such	O
as	O
cytochrome	B
P450	I
genes	O
,	O
GSTs	O
,	O
aldehyde	O
oxidases	O
,	O
and	O
other	O
gene	O
families	O
previously	O
associated	O
with	O
resistance	O
of	O
An	O
.	O

The	O
cytochrome	B
P450	I
,	O
CYP6M7	O
was	O
the	O
most	O
overexpressed	O
detoxification	O
gene	O
in	O
permethrin	O
exposed	O
mosquitoes	O
compared	O
to	O
the	O
FANG	O
susceptible	O
strain	O
as	O
well	O
as	O
to	O
the	O
unexposed	O
mosquitoes	O
from	O
microarrays	O
analysis	O
.	O

The	O
two	O
duplicated	O
cytochrome	B
P450	I
genes	O
,	O
CYP6P9a	O
(	O
FC	O
=	O
3	O
.	O
7	O
)	O
and	O
CYP6P9b	O
(	O
FC	O
=	O
3	O
.	O
9	O
)	O
,	O
which	O
confer	O
pyrethroid	O
resistance	O
in	O
southern	O
African	O
populations	O
of	O
An	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
if	O
DN	O
,	O
GO	O
and	O
GN	O
affect	O
three	O
isoforms	O
of	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
,	O
namely	O
,	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP3A4	B
,	O
expressed	O
in	O
the	O
liver	O
.	O

The	O
major	O
enzymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
xenobiotics	O
are	O
members	O
of	O
the	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
family	O
.	O

However	O
,	O
no	O
cytochrome	B
P450	I
involved	O
in	O
downstream	O
in	O
the	O
alkaloid	O
biosynthetic	O
pathway	O
has	O
been	O
cloned	O
or	O
identified	O
in	O
Dendrobium	O
plants	O
.	O

Characterization	O
of	O
kinetics	O
of	O
human	O
cytochrome	O
P450s	O
involved	O
in	O
bioactivation	O
of	O
flucloxacillin	O
:	O
inhibition	O
of	O
CYP3Acatalysed	O
hydroxylation	O
by	O
sulfaphenazole	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
human	O
cytochrome	O
P450s	O
(	O
CYPs	O
)	O
involved	O
in	O
oxidative	O
bioactivation	O
of	O
flucloxacillin	O
to	O
5hydroxymethyl	O
flucloxacillin	O
,	O
a	O
metabolite	O
with	O
high	O
cytotoxicity	O
towards	O
biliary	O
epithelial	O
cells	O
.	O

Nonrenal	O
clearance	O
of	O
flucloxacillin	O
occurs	O
predominantly	O
by	O
cytochrome	O
P450mediated	O
hydroxylation	O
of	O
flucloxacillin	O
to	O
5HMFLX	O
and	O
partly	O
by	O
hydrolysis	O
to	O
the	O
corresponding	O
penicilloic	O
acid	O
,	O
showed	O
that	O
CYP3A4	O
was	O
able	O
to	O
catalyse	O
the	O
5hydroxylation	O
of	O
flucloxacillin	O
.	O

The	O
current	O
study	O
aimed	O
to	O
investigate	O
the	O
impact	O
of	O
co	O
-	O
administration	O
of	O
pomegranate	O
peel	O
and	O
guava	O
leaves	O
extracts	O
,	O
including	O
their	O
quality	O
markers	O
namely	O
;	O
ellagic	O
acid	O
and	O
quercetin	O
,	O
respectively	O
,	O
on	O
warfarins	O
in	O
vivo	O
dynamic	O
activity	O
and	O
pharmacokinetic	O
actions	O
,	O
in	O
addition	O
to	O
potential	O
in	O
vitro	O
cytochrome	B
P450	I
enzymes	I
inhibition	O
.	O

For	O
example	O
,	O
St	O
Johns	O
wort	O
induces	O
microsomal	O
cytochrome	B
P450	I
enzyme	I
-	O
mediated	O
metabolism	O
of	O
warfarin	O
,	O
particularly	O
CYP2C9	O
and	O
increases	O
warfarin	O
clearance	O
.	O

Progesterone	O
Receptor	O
Membrane	O
Component1	O
is	O
also	O
involved	O
in	O
diverse	O
biological	O
functions	O
,	O
such	O
as	O
regulation	O
of	O
cytochrome	B
P450	I
,	O
progesterone	O
signaling	O
,	O
vesicle	O
trafficking	O
,	O
steroidogenesis	O
,	O
cell	O
cycle	O
regulation	O
,	O
anchorage	O
-	O
independent	O
growth	O
,	O
invasive	O
growth	O
,	O
angiogenesis	O
,	O
hypoxic	O
biology	O
,	O
and	O
autophagy	O
promotion	O
^	O
,	O
.	O

Common	O
variation	O
in	O
the	O
CYP2B6	B
gene	O
,	O
encoding	O
the	O
cytochrome	B
P450	I
2B6	O
enzyme	O
,	O
is	O
associated	O
with	O
substratespecific	O
altered	O
clearance	O
of	O
multiple	O
drugs	O
.	O

We	O
further	O
attempted	O
to	O
measure	O
cytochrome	O
P450mediated	O
nicotine	O
metabolism	O
in	O
human	O
brain	O
microsomes	O
,	O
where	O
FMO	O
activity	O
was	O
previously	O
demonstrated	O
,	O
,	O
using	O
nicotine	O
and	O
other	O
CYP2B6	B
probe	O
substrates	O
.	O

Extensive	O
evidence	O
demonstrates	O
that	O
functional	O
variation	O
in	O
cytochrome	B
P450	I
genes	O
can	O
significantly	O
affect	O
the	O
metabolism	O
of	O
many	O
small	O
molecules	O
including	O
pharmaceuticals	O
and	O
toxins	O
.	O

This	O
provided	O
an	O
opportunity	O
to	O
further	O
investigate	O
possible	O
cytochrome	O
P450related	O
nicotine	O
metabolism	O
in	O
postmortem	O
samples	O
known	O
to	O
retain	O
detectable	O
microsomal	O
enzyme	O
activity	O
.	O

We	O
therefore	O
conclude	O
that	O
the	O
iminium	O
ion	O
detected	O
was	O
not	O
due	O
to	O
cytochrome	O
P450s	O
or	O
any	O
typical	O
enzymatic	O
activity	O
.	O

Hepatocyte	O
spheroids	O
formed	O
in	O
this	O
device	O
were	O
subjected	O
to	O
different	O
flow	O
rates	O
,	O
of	O
which	O
a	O
flow	O
rate	O
of	O
50	O
L	O
/	O
min	O
provided	O
the	O
optimal	O
microenvironment	O
for	O
spheroid	O
formation	O
,	O
maintained	O
significantly	O
higher	O
rates	O
of	O
albumin	O
and	O
urea	O
synthesis	O
,	O
yielded	O
higher	O
CYP3A1	O
(	O
cytochrome	B
P450	I
3A1	O
)	O
and	O
CYP2C11	O
(	O
cytochrome	B
P450	I
2C11	O
)	O
enzyme	O
activities	O
for	O
metabolism	O
,	O
and	O
demonstrated	O
higher	O
expression	O
levels	O
of	O
liver	O
-	O
specific	O
genes	O
.	O

The	O
cytochrome	B
P450	I
enzymes	I
might	O
be	O
the	O
most	O
significant	O
class	O
of	O
enzyme	O
to	O
study	O
the	O
metabolic	O
behavior	O
of	O
lead	O
compounds	O
.	O

Most	O
antidepressant	O
and	O
antipsychotic	O
drugs	O
are	O
metabolized	O
by	O
cytochrome	B
P450	I
enzymes	I
and	O
,	O
where	O
cytochrome	B
P450	I
inhibitors	O
are	O
co	O
-	O
ingested	O
,	O
serial	O
plasma	O
concentrations	O
should	O
optimally	O
be	O
obtained	O
in	O
order	O
to	O
assess	O
a	O
suitable	O
time	O
for	O
reintroduction	O
of	O
the	O
psychoactive	O
drugs	O
.	O

Consequently	O
,	O
search	O
terms	O
used	O
included	O
names	O
of	O
individual	O
drugs	O
AND	O
overdose	O
,	O
toxicokinetics	O
,	O
pharmacokinetics	O
,	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzyme	O
,	O
metabolism	O
,	O
or	O
active	O
metabolites	O
.	O

Function	O
,	O
essentiality	O
,	O
and	O
expression	O
of	O
cytochrome	B
P450	I
enzymes	I
and	O
their	O
cognate	O
redox	O
partners	O
in	O
Mycobacterium	O
tuberculosis	O
:	O
are	O
they	O
drug	O
targets	O
?	O
.	O

This	O
review	O
covers	O
the	O
current	O
knowledge	O
of	O
the	O
cytochrome	B
P450	I
enzymes	I
(	O
CYPs	O
)	O
of	O
the	O
human	O
pathogen	O
Mycobacterium	O
tuberculosis	O
(	O
Mtb	O
)	O
and	O
their	O
endogenous	O
redox	O
partners	O
,	O
focusing	O
on	O
their	O
biological	O
function	O
,	O
expression	O
,	O
regulation	O
,	O
involvement	O
in	O
antibiotic	O
resistance	O
,	O
and	O
suitability	O
for	O
exploitation	O
as	O
antitubercular	O
targets	O
.	O

Genome	O
mapping	O
revealed	O
that	O
Mtb	O
encodes	O
a	O
high	O
number	O
of	O
cytochrome	B
P450	I
enzymes	I
(	O
CYPs	O
or	O
P450s	O
)	O
.	O

Moreover	O
,	O
seventy	O
-	O
eight	O
cytochrome	O
P450s	O
and	O
multiple	O
transcription	O
factors	O
(	O
five	O
MYB	O
,	O
two	O
bHLH	O
,	O
and	O
three	O
WD40	O
family	O
genes	O
)	O
may	O
be	O
associated	O
with	O
the	O
regulation	O
of	O
the	O
flavonoid	O
biosynthesis	O
process	O
.	O

In	O
addition	O
,	O
glycosyltransferases	O
and	O
cytochrome	O
P450s	O
also	O
contribute	O
to	O
flavonoid	O
regulation	O
in	O
plants	O
.	O

These	O
enzymes	O
belong	O
to	O
three	O
pathways	O
,	O
namely	O
(	O
a	O
)	O
the	O
COX	O
pathway	O
(	O
COX1	O
,	O
COX2	O
)	O
resulting	O
in	O
production	O
of	O
prostaglandins	O
,	O
(	O
b	O
)	O
the	O
Lipoxygenases	O
pathway	O
(	O
5	O
-	O
LOX	O
,	O
1LOX	O
,	O
15LOX	O
)	O
resulting	O
in	O
production	O
of	O
leukotrienes	O
and	O
lipoxins	O
,	O
and	O
(	O
c	O
)	O
the	O
cytochrome	B
P450	I
pathway	O
which	O
forms	O
the	O
hydroxyeicosotetranoic	O
acids	O
and	O
the	O
epoxyeicosotrienoic	O
acids	O
(	O
Hanna	O
and	O
Hafez	O
,	O
.	O

The	O
MPB	O
genome	O
contains	O
86	O
different	O
cytochrome	B
P450	I
genes	O
,	O
and	O
three	O
of	O
these	O
P450s	O
have	O
previously	O
been	O
shown	O
to	O
function	O
in	O
terpenoid	O
metabolism	O
or	O
terpenoid	O
pheromone	O
biosynthesis	O
in	O
the	O
MPB	O
.	O

Second	O
,	O
an	O
oxidative	O
cyclisation	O
cascade	O
consisting	O
typically	O
of	O
three	O
to	O
four	O
cytochrome	B
P450	I
(	O
Oxy	O
)	O
enzymes	O
(	O
one	O
enzyme	O
per	O
ring	O
formed	O
,	O
see	O
Fig	O
)	O
is	O
then	O
recruited	O
to	O
the	O
NRPS	O
-	O
bound	O
heptapeptide	O
in	O
order	O
to	O
perform	O
the	O
stepwise	O
cyclisation	O
of	O
the	O
peptide	O
into	O
a	O
rigid	O
,	O
active	O
antibiotic	O
^	O
,	O
.	O

Strikingly	O
,	O
the	O
biosynthetic	O
gene	O
cluster	O
of	O
this	O
GPA	O
encodes	O
only	O
two	O
cytochrome	B
P450	I
enzymes	I
(	O
KisN	O
and	O
KisO	O
)	O
implicated	O
in	O
the	O
crosslinking	O
of	O
the	O
aromatic	O
side	O
chains	O
of	O
the	O
peptide	O
,	O
despite	O
there	O
being	O
three	O
crosslinks	O
in	O
kistamicin	O
.	O

For	O
isoflavones	O
,	O
the	O
gut	O
microbiome	O
and	O
phase	O
I	O
cytochrome	B
P450	I
enzymes	I
in	O
human	O
liver	O
microsome	O
were	O
responsible	O
for	O
O	O
-	O
demethylation	O
at	O
4	O
carbon	O
;	O
hence	O
formononetin	O
is	O
converted	O
to	O
daidzein	O
and	O
biochanin	O
A	O
to	O
genistein	O
Anthocyanidins	O
,	O
or	O
their	O
monoglucosides	O
of	O
anthocyanins	O
,	O
remained	O
unchanged	O
when	O
incubated	O
with	O
rat	O
liver	O
microsomes	O
in	O
the	O
presence	O
of	O
NADPH	O
,	O
which	O
suggests	O
that	O
anthocyanidins	O
are	O
not	O
affected	O
by	O
phase	O
I	O
enzymes	O
.	O

Markers	O
of	O
pharmacokinetics	O
/	O
toxicity	O
:	O
(	O
1	O
)	O
Sofarenib	O
metabolism	O
:	O
The	O
metabolism	O
of	O
sorafenib	O
is	O
well	O
-	O
established	O
and	O
occurs	O
mainly	O
in	O
the	O
liver	O
through	O
two	O
pathways	O
:	O
Phase	O
I	O
oxidation	O
mediated	O
by	O
cytochrome	B
P450	I
3A4	O
,	O
and	O
phase	O
II	O
conjugation	O
mediated	O
by	O
UDP	O
glucuronosyltransferase	O
1A9	O
.	O

Insects	O
have	O
employed	O
cytochrome	B
P450	I
monooxygenases	O
(	O
P450s	O
)	O
that	O
promote	O
more	O
a	O
rapid	O
metabolism	O
to	O
defer	O
the	O
cost	O
of	O
a	O
counter	O
-	O
defence	O
against	O
toxic	O
plant	O
compounds	O
.	O

The	O
AhR	O
/	O
ARNT	O
heterodimer	O
binds	O
the	O
xenobiotic	O
responsive	O
elements	O
in	O
the	O
promoter	O
,	O
leading	O
to	O
the	O
transcription	O
of	O
genes	O
that	O
encode	O
xenobiotic	O
metabolism	O
enzymes	O
,	O
such	O
as	O
cytochrome	B
P450	I
genes	O
,	O
which	O
in	O
mammals	O
include	O
CYP1A1	B
,	O
CYP1A2	B
,	O
and	O
CYP1B1	O
.	O

The	O
expression	O
of	O
cytochrome	B
P450	I
,	O
sodA	O
(	O
encoding	O
Fe	O
/	O
Mn	O
superoxide	O
dismutase	O
)	O
,	O
recA	O
,	O
and	O
superoxide	O
anion	O
radical	O
generation	O
rate	O
increased	O
after	O
the	O
addition	O
of	O
all	O
studied	O
hydrocarbons	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
expression	O
of	O
genes	O
,	O
cytochrome	B
P450	I
,	O
superoxide	O
dismutases	O
A	O
and	O
C	O
,	O
recA	O
,	O
as	O
well	O
as	O
generation	O
of	O
superoxide	O
anion	O
radical	O
and	O
hydrogen	O
peroxide	O
under	O
the	O
influence	O
of	O
hydrocarbons	O
on	O
Rhodococcus	O
.	O

It	O
is	O
well	O
known	O
that	O
in	O
the	O
course	O
of	O
enzymatic	O
reactions	O
of	O
cytochrome	B
P450	I
the	O
socalled	O
disjunction	O
of	O
the	O
cycle	O
may	O
occur	O
when	O
the	O
flow	O
of	O
electrons	O
derived	O
from	O
NAD	O
(	O
P	O
)	O
H	O
to	O
P450	O
molecules	O
leads	O
to	O
the	O
generation	O
of	O
superoxide	O
anion	O
radical	O
and	O
/	O
or	O
hydrogen	O
peroxide	O
instead	O
of	O
the	O
products	O
of	O
monooxygenase	O
reaction	O
(	O
Guengerich	O
,	O
;	O
Goeptar	O
,	O
Scheerens	O
,	O
&	O
Vermeulen	O
,	O
.	O

The	O
ROS	O
produced	O
by	O
cytochrome	B
P450	I
are	O
likely	O
to	O
cause	O
DNA	O
damage	O
.	O

A	O
growing	O
amount	O
of	O
data	O
have	O
demonstrated	O
the	O
biosynthesis	O
of	O
flavonoids	O
through	O
multienzyme	O
complexes	O
of	O
which	O
the	O
membrane	O
-	O
bounded	O
cytochrome	B
P450	I
supergene	O
family	O
shares	O
a	O
crucial	O
part	O
.	O

The	O
ER	O
-	O
bound	O
enzyme	O
complex	O
belongs	O
to	O
the	O
cytochrome	B
P450	I
superfamily	O
.	O

In	O
most	O
of	O
the	O
plant	O
species	O
,	O
cytochrome	B
P450	I
is	O
found	O
abundantly	O
and	O
produces	O
multiple	O
groups	O
of	O
secondary	O
metabolites	O
through	O
hydroxylation	O
and	O
monooxygenation	O
reactions	O
.	O

CYP701	O
,	O
a	O
member	O
of	O
cytochrome	B
P450	I
encoding	O
ent	O
-	O
kaurene	O
oxidase	O
,	O
is	O
essential	O
for	O
the	O
biosynthesis	O
of	O
gibberellins	O
.	O

Furthermore	O
,	O
several	O
other	O
studies	O
have	O
discovered	O
the	O
pharmacological	O
importance	O
of	O
the	O
cytochrome	B
P450	I
supergene	O
family	O
by	O
stimulating	O
plant	O
immunity	O
against	O
various	O
pathogens	O
.	O

Though	O
the	O
diversity	O
of	O
flavonoid	O
biosynthesis	O
has	O
been	O
reported	O
in	O
Arabidopsis	O
thaliana	O
seeds	O
,	O
the	O
mechanism	O
of	O
stress	O
-	O
responsive	O
cytochrome	B
P450	I
genes	O
encoding	O
a	O
single	O
or	O
group	O
of	O
enzymes	O
promoting	O
the	O
flavonoid	O
biosynthesis	O
pathway	O
in	O
Arabidopsis	O
remains	O
unexplained	O
.	O

As	O
a	O
point	O
of	O
paramount	O
significance	O
,	O
it	O
is	O
important	O
to	O
focus	O
on	O
studies	O
related	O
to	O
identification	O
and	O
characterization	O
of	O
putative	O
cytochrome	B
P450	I
genes	O
promoting	O
the	O
flavonoid	O
biosynthetic	O
pathway	O
in	O
plants	O
.	O

Based	O
on	O
predicted	O
open	O
-	O
reading	O
frames	O
,	O
the	O
unigenes	O
were	O
further	O
subjected	O
to	O
cytochrome	B
P450	I
database	O
(	O
http	O
:	O
/	O
/	O
drnelson	O
.	O
uthsc	O
.	O
edu	O
/	O
CytochromeP450	O
.	O
html	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
also	O
predicted	O
the	O
computational	O
structure	O
of	O
rutin	O
against	O
a	O
comprehensive	O
metabolite	O
prediction	O
tool	O
(	O
GLORY	O
)	O
that	O
contained	O
the	O
cytochrome	B
P450	I
prediction	O
module	O
according	O
to	O
the	O
instructions	O
of	O
.	O

These	O
findings	O
provide	O
a	O
theoretical	O
and	O
practical	O
basis	O
for	O
identifying	O
the	O
intrinsic	O
relation	O
of	O
a	O
stress	O
-	O
responsive	O
cytochrome	B
P450	I
gene	O
during	O
flavonoid	O
biosynthesis	O
in	O
plants	O
.	O

Heme	O
enzymes	O
,	O
such	O
as	O
the	O
cytochrome	O
P450s	O
,	O
are	O
involved	O
in	O
the	O
metabolism	O
/	O
breakdown	O
of	O
approximately	O
90	O
%	O
of	O
small	O
-	O
molecule	O
drugs	O
,	O
and	O
are	O
more	O
generally	O
themselves	O
drug	O
targets	O
in	O
yeast	O
,	O
fungi	O
and	O
tuberculosis	O
infections	O
(	O
McLean	O
&	O
Munro	O
,	O
2017	O
;	O
Guengerich	O
et	O
al	O
.	O
,	O
2016	O
;	O
Rendic	O
&	O
Guengerich	O
,	O
2015	O
)	O
.	O

Two	O
major	O
functional	O
classes	O
of	O
enzymes	O
are	O
involved	O
in	O
the	O
biosynthesis	O
of	O
all	O
steroid	O
hormones	O
,	O
namely	O
the	O
cytochrome	B
P450	I
and	O
hydroxysteroid	O
dehydrogenase	O
enzymes	O
.	O

Cytochrome	B
P450	I
type	O
II	O
enzymes	O
are	O
found	O
in	O
the	O
Endoplasmic	O
Reticulum	O
and	O
are	O
dependent	O
on	O
the	O
electron	O
donor	O
enzyme	O
cytochrome	B
P450	I
oxidoreductase	O
for	O
electron	O
delivery	O
.	O

Phenobarbital	O
metabolism	O
is	O
highly	O
dependent	O
upon	O
the	O
cytochrome	B
P450	I
and	O
genetic	O
polymorphisms	O
can	O
lead	O
to	O
variability	O
in	O
active	O
drug	O
levels	O
.	O

The	O
sequences	O
for	O
all	O
promoters	O
in	O
CYP2C19	B
gene	O
are	O
as	O
follows	O
:	O
CYP2C19	B
-	O
201	O
identified	O
in	O
chromosome	O
position	O
at	O
94762681	O
(	O
ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG	O
)	O
,	O
CYP2C19	B
-	O
202	O
chromosome	O
position	O
94842926	O
(	O
ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA	O
)	O
,	O
and	O
CYP2C19	B
-	O
203	O
chromosome	O
position	O
94775489	O
(	O
ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG	O
)	O
In	O
addition	O
,	O
we	O
identified	O
the	O
following	O
Kyoto	O
Encyclopedia	O
Of	O
Genes	O
And	O
Genomes	O
pathways	O
of	O
CYP2C19	B
which	O
include	O
arachidonic	O
acid	O
metabolism	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
chemical	O
carcinogenesis	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
drug	O
metabolism	O
(	O
cytochrome	B
P450	I
)	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
linoleic	O
acid	O
metabolism	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
metabolic	O
pathways	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
and	O
serotonergic	O
synapse	O
.	O

Celastrol	O
biosynthesis	O
likely	O
adheres	O
to	O
the	O
common	O
triterpenoid	O
scheme	O
that	O
starts	O
with	O
cycloisomerization	O
of	O
2	O
,	O
3	O
-	O
oxidosqualene	O
by	O
an	O
oxidosqualene	O
cyclase	O
(	O
OSC	O
)	O
and	O
continues	O
with	O
oxidative	O
decoration	O
(	O
s	O
)	O
of	O
the	O
30	O
-	O
carbon	O
triterpenoid	O
core	O
structure	O
by	O
cytochrome	B
P450	I
enzymes	I
[	O
,	O
.	O

Nevertheless	O
,	O
the	O
sex	O
-	O
dependent	O
effect	O
of	O
Doxorubicin	O
on	O
the	O
expression	O
of	O
Cytochrome	B
P450	B
enzymes	I
is	O
still	O
not	O
known	O
.	O

Since	O
cardiac	O
Cytochrome	B
P450	B
enzymes	I
metabolize	O
several	O
endogenous	O
compounds	O
to	O
biologically	O
active	O
metabolites	O
,	O
sex	O
-	O
dependent	O
alteration	O
of	O
Cytochrome	B
P450	I
genes	O
may	O
play	O
a	O
role	O
in	O
the	O
sexual	O
dimorphism	O
of	O
acute	O
DOX	O
-	O
induced	O
cardiotoxicity	O
.	O

DOX	O
-	O
induced	O
alteration	O
of	O
Cytochrome	B
P450	B
enzymes	I
may	O
have	O
important	O
toxicological	O
implications	O
,	O
due	O
to	O
the	O
role	O
of	O
Cytochrome	B
P450	B
enzymes	I
in	O
the	O
metabolism	O
of	O
several	O
biologically	O
active	O
endogenous	O
compounds	O
including	O
arachidonic	O
acid	O
and	O
sex	O
steroids	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
effect	O
of	O
acute	O
Doxorubicin	O
exposure	O
on	O
the	O
gene	O
expression	O
of	O
Cytochrome	B
P450	B
enzymes	I
in	O
the	O
hearts	O
of	O
both	O
male	O
and	O
female	O
C57Bl	O
/	O
6	O
mice	O
to	O
determine	O
the	O
interaction	O
between	O
sex	O
and	O
Doxorubicin	O
exposure	O
in	O
regulating	O
Cytochrome	B
P450	I
gene	O
expression	O
.	O

A	O
growing	O
body	O
of	O
evidence	O
suggests	O
an	O
important	O
role	O
of	O
Cytochrome	B
P450	B
enzymes	I
in	O
the	O
pathogenesis	O
of	O
DOX	O
-	O
induced	O
cardiotoxicity	O
[	O
,	O
.	O

Cytochrome	B
P450	B
enzymes	I
play	O
important	O
roles	O
in	O
metabolizing	O
sex	O
steroids	O
and	O
other	O
endogenous	O
compounds	O
,	O
such	O
as	O
arachidonic	O
acid	O
that	O
have	O
significant	O
biological	O
effects	O
on	O
the	O
cardiovascular	O
system	O
.	O

Interestingly	O
,	O
there	O
is	O
a	O
significant	O
sex	O
-	O
divergent	O
expression	O
of	O
several	O
Cytochrome	B
P450	B
enzymes	I
in	O
both	O
humans	O
and	O
experimental	O
animals	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
Doxorubicin	O
alters	O
Cytochrome	B
P450	B
enzymes	I
in	O
a	O
sex	O
-	O
dependent	O
manner	O
to	O
mediate	O
sexual	O
dimorphism	O
of	O
DOX	O
-	O
induced	O
cardiotoxicity	O
.	O

This	O
position	O
is	O
consistent	O
with	O
those	O
seen	O
in	O
other	O
P450	B
enzymes	I
(	O
eg	O
the	O
fatty	O
acid	O
/	O
fatty	O
acyl	O
-	O
ACP	O
oxidizing	O
P450	O
BioI	O
(	O
CYP107H1	O
)	O
at	O
1090	O
nm	O
and	O
CYP121A1	O
at	O
1125	O
nm	O
)	O
(	O
,	O
.	O

The	O
dimer	O
interface	O
is	O
made	O
by	O
the	O
BC	O
-	O
and	O
FG	O
-	O
loop	O
regions	O
,	O
both	O
of	O
which	O
are	O
associated	O
with	O
substrate	O
entry	O
into	O
P450	B
enzymes	I
.	O

Amongst	O
the	O
Cytochrome	B
P450	B
enzymes	I
which	O
are	O
responsible	O
for	O
the	O
metabolism	O
of	O
a	O
wide	O
array	O
of	O
endogenous	O
substances	O
,	O
(	O
example	O
-	O
steroids	O
,	O
hormones	O
,	O
lipids	O
,	O
and	O
bile	O
acids	O
)	O
,	O
xenobiotics	O
(	O
example	O
-	O
drugs	O
and	O
pollutants	O
from	O
the	O
environment	O
)	O
,	O
and	O
dietary	O
products	O
and	O
/	O
dietary	O
polyphenols	O
,	O
Cytochrome	B
P450	I
3A4	O
has	O
been	O
shown	O
to	O
be	O
the	O
major	O
enzyme	O
that	O
is	O
involved	O
in	O
the	O
metabolism	O
of	O
drugs	O
and	O
xenobiotics	O
in	O
the	O
liver	O
and	O
gut	O
.	O

One	O
thing	O
most	O
of	O
these	O
studies	O
reporting	O
on	O
the	O
interaction	O
of	O
polyphenols	O
with	O
Cytochrome	B
P450	B
enzymes	I
have	O
shown	O
is	O
the	O
need	O
for	O
controlled	O
/	O
regulated	O
use	O
of	O
polyphenols	O
for	O
therapeutic	O
purposes	O
.	O

Intriguingly	O
,	O
a	O
large	O
part	O
of	O
the	O
reducing	O
substrates	O
are	O
employed	O
by	O
eukaryotic	O
P450	B
enzymes	I
to	O
generate	O
Reactive	O
Oxygen	O
Species	O
,	O
while	O
the	O
efficiency	O
and	O
coupling	O
of	O
P450	B
enzymes	I
are	O
regulated	O
by	O
cofactors	O
,	O
such	O
as	O
cytochrome	B
b_5	I
,	O
or	O
by	O
post	O
-	O
translational	O
modifications	O
,	O
such	O
as	O
phosphorylation	O
.	O

In	O
vitro	O
inhibitory	O
effects	O
of	O
the	O
pharmacologically	O
active	O
lignans	O
such	O
as	O
aschantin	O
,	O
honokiol	O
,	O
machilin	O
A	O
,	O
phyllantin	O
,	O
hypophyllantin	O
,	O
and	O
podophyllotoxin	O
on	O
Cytochrome	B
P450	B
enzymes	I
have	O
been	O
reported	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
on	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
inhibitory	O
effects	O
of	O
the	O
bioactive	O
tetrahydrofurofuranoid	O
lignans	O
such	O
as	O
dimethyllirioresinol	O
,	O
epimagnolin	O
A	O
,	O
eudesmin	O
,	O
fargesin	O
,	O
and	O
magnolin	O
on	O
human	O
Cytochrome	B
P450	B
enzymes	I
.	O

The	O
reversible	O
and	O
time	O
-	O
dependent	O
inhibitory	O
potencials	O
(	O
IC_50	O
values	O
)	O
of	O
dimethyllirioresinol	O
,	O
epimagnolin	O
A	O
,	O
eudesmin	O
,	O
fargesin	O
,	O
and	O
magnolin	O
on	O
8	O
major	O
human	O
Cytochrome	B
P450	B
enzymes	I
were	O
investigated	O
in	O
human	O
liver	O
microsomes	O
.	O

Magnolin	O
,	O
epimagnolin	O
A	O
,	O
and	O
eudesmin	O
negligibly	O
inhibited	O
CYP1A2	B
,	O
CYP2A6	O
,	O
CYP2B6	B
,	O
CYP2C8	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
activities	O
at	O
100	O
M	O
in	O
human	O
liver	O
microsomes	O
did	O
not	O
cause	O
the	O
IC_50	O
value	O
shift	O
of	O
eight	O
Cytochrome	B
P450	B
enzymes	I
,	O
indicating	O
that	O
dimethyllirioresinol	O
,	O
magnolin	O
,	O
epimagnolin	O
A	O
,	O
or	O
eudesmin	O
may	O
not	O
be	O
mechanism	O
-	O
based	O
inhibitors	O
.	O

In	O
this	O
study	O
,	O
the	O
in	O
vitro	O
inhibitory	O
effects	O
of	O
bioactive	O
tetrahydrofurofuranoid	O
lignans	O
such	O
as	O
dimethyllirioresinol	O
,	O
epimagnolin	O
A	O
,	O
eudesmin	O
,	O
fargesin	O
,	O
and	O
magnolin	O
on	O
8	O
major	O
Cytochrome	B
P450	B
enzymes	I
were	O
,	O
for	O
the	O
first	O
time	O
,	O
evaluated	O
in	O
pooled	O
human	O
liver	O
microsomes	O
.	O

Gene	O
expression	O
profiles	O
of	O
P450	B
enzymes	I
change	O
in	O
the	O
developing	O
liver	O
and	O
the	O
normal	O
adult	O
P450	O
expression	O
is	O
not	O
established	O
in	O
mice	O
until	O
a	O
specific	O
postnatal	O
age	O
.	O

The	O
formation	O
of	O
active	O
tamoxifen	O
metabolites	O
in	O
patients	O
carrying	O
reduced	O
or	O
increased	O
CYP2C19	B
function	O
alleles	O
may	O
be	O
sufficiently	O
compensated	O
through	O
parallel	O
and	O
serial	O
metabolic	O
pathways	O
catalyzed	O
by	O
other	O
P450	B
enzymes	I
.	O

P450	O
fatty	O
acid	O
decarboxylases	O
represented	O
by	O
the	O
unusual	O
CYP152	O
peroxygenase	O
family	O
member	O
OleTJE	O
have	O
been	O
receiving	O
great	O
attention	O
recently	O
since	O
these	O
P450	B
enzymes	I
are	O
able	O
to	O
catalyze	O
the	O
simple	O
and	O
direct	O
production	O
of	O
1	O
-	O
alkenes	O
for	O
potential	O
applications	O
in	O
biofuels	O
and	O
biomaterials	O
.	O

As	O
a	O
result	O
,	O
while	O
the	O
control	O
P450	O
monooxygenase	O
P450_BM3	O
was	O
successfully	O
reduced	O
by	O
the	O
addition	O
of	O
NADPH	O
and	O
exhibited	O
an	O
almost	O
complete	O
transition	O
to	O
P450	O
spectrum	O
in	O
the	O
presence	O
of	O
lauric	O
acid	O
(	O
LA	O
)	O
substrate	O
(	O
Additional	O
file	O
:	O
Figure	O
S4	O
)	O
,	O
neither	O
CYP	O
-	O
Aa162	O
nor	O
CYP	O
-	O
Sm4629	O
showed	O
a	O
P450	O
chromophore	O
after	O
incubation	O
with	O
the	O
redox	O
partner	O
proteins	O
CamAB	O
(	O
ie	O
,	O
putidaredoxin	O
reductase	O
and	O
putidaredoxin	O
that	O
are	O
able	O
to	O
support	O
the	O
in	O
vitro	O
activity	O
of	O
both	O
P450	B
enzymes	I
,	O
see	O
below	O
)	O
and	O
their	O
optimal	O
cofactor	O
NADH	O
in	O
the	O
presence	O
of	O
LA	O
.	O

This	O
may	O
suggest	O
that	O
the	O
substrate	O
binding	O
pocket	O
of	O
the	O
two	O
P450	B
enzymes	I
could	O
accommodate	O
more	O
than	O
one	O
C_12	O
molecules	O
and	O
that	O
the	O
binding	O
of	O
one	O
C_12	O
molecule	O
could	O
facilitate	O
the	O
binding	O
of	O
the	O
other	O
to	O
the	O
same	O
P450	B
enzyme	I
,	O
particularly	O
at	O
low	O
to	O
medium	O
substrate	O
concentrations	O
(	O
10	O
-	O
80	O
M	O
)	O
.	O

Whether	O
the	O
failure	O
of	O
observing	O
a	O
P450	O
species	O
in	O
CYP	O
-	O
Sm4629	O
is	O
due	O
to	O
the	O
instability	O
of	O
the	O
thiolate	O
-	O
ligated	O
P450	O
species	O
that	O
quickly	O
reverts	O
to	O
a	O
P420	O
form	O
as	O
with	O
EpoK	O
,	O
or	O
an	O
alternative	O
proximal	O
ligand	O
-	O
coordinated	O
species	O
as	O
in	O
P420_cam	O
,	O
P450	B
enzymes	I
that	O
undergo	O
peroxide	O
shunt	O
pathway	O
are	O
insensitive	O
to	O
the	O
nature	O
of	O
the	O
proximal	O
ligand	O
as	O
they	O
do	O
not	O
require	O
electron	O
transfer	O
to	O
the	O
heme	O
iron	O
.	O

Spectra	O
of	O
the	O
CO	O
-	O
bound	O
NAD	O
(	O
P	O
)	O
H	O
-	O
reduced	O
forms	O
of	O
the	O
P450	B
enzymes	I
were	O
subsequently	O
recorded	O
.	O

In	O
addition	O
,	O
none	O
of	O
the	O
aforementioned	O
benzothiadiazine	O
analogs	O
significantly	O
inhibit	O
the	O
major	O
Cytochrome	B
P450	B
enzymes	I
indicating	O
that	O
these	O
compounds	O
should	O
not	O
affect	O
the	O
metabolism	O
of	O
drug	O
substances	O
.	O

In	O
vitro	O
studies	O
using	O
both	O
rat	O
and	O
human	O
liver	O
microsomes	O
have	O
shown	O
that	O
these	O
benzothiadiazine	O
derivatives	O
themselves	O
are	O
resistant	O
to	O
oxidative	O
metabolism	O
by	O
Cytochrome	B
P450	B
enzymes	I
with	O
>	O
97	O
%	O
of	O
the	O
parent	O
compounds	O
remaining	O
after	O
a	O
60	O
min	O
incubation	O
with	O
microsomes	O
of	O
either	O
species	O
.	O

To	O
overcome	O
this	O
limitation	O
,	O
we	O
established	O
HepG2	O
cell	O
lines	O
expressing	O
major	O
Cytochrome	B
P450	B
enzymes	I
involved	O
in	O
drug	O
metabolism	O
(	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
)	O
and	O
Cytochrome	B
P450	I
oxidoreductase	O
(	O
POR	O
)	O
using	O
the	O
mammalian	O
-	O
derived	O
artificial	O
chromosome	O
vector	O
.	O

The	O
commercial	O
R	O
.	O
rosea	O
industry	O
is	O
large	O
,	O
with	O
over	O
46	O
registered	O
international	O
companies	O
,	O
giving	O
the	O
herb	O
a	O
global	O
distribution	O
(	O
Galambosi	O
;	O
Edwards	O
et	O
al	O
.	O
.	O
CYP2C9	B
is	O
a	O
part	O
of	O
the	O
CYP2C	O
family	O
of	O
enzymes	O
,	O
which	O
accounts	O
for	O
about	O
20	O
%	O
of	O
all	O
P450	B
enzymes	I
in	O
the	O
human	O
liver	O
(	O
Niwa	O
and	O
Yamazaki	O
.	O

The	O
inhibition	O
of	O
Cytochrome	B
P450	B
enzymes	I
can	O
broadly	O
be	O
divided	O
into	O
two	O
types	O
;	O
reversible	O
and	O
irreversible	O
.	O

When	O
comparing	O
our	O
observed	O
32	O
%	O
inhibition	O
of	O
CYP2C9	B
at	O
1	O
%	O
ethanol	O
with	O
the	O
investigated	O
Cytochrome	B
P450	B
enzymes	I
at	O
similar	O
ethanol	O
concentration	O
in	O
the	O
study	O
by	O
Busby	O
et	O
al	O
.	O
,	O
we	O
found	O
that	O
the	O
CYP2C9	B
inhibition	O
was	O
more	O
potent	O
than	O
for	O
CYP1A2	B
,	O
CYP2A6	O
,	O
CYP2C8	B
,	O
and	O
CYP3A4	B
,	O
and	O
weaker	O
than	O
for	O
CYP1A1	B
,	O
CYP2B6	B
,	O
CYP2C19	B
,	O
and	O
CYP2D6	B
.	O

Liver	O
Cytochrome	B
P450	B
enzymes	I
is	O
the	O
most	O
important	O
drug	O
metabolizing	O
enzymes	O
and	O
responsible	O
for	O
more	O
than	O
80	O
%	O
of	O
drug	O
metabolism	O
^	O
,	O
.	O

N	O
-	O
acetyl	O
p	O
-	O
benzoquinoneimine	O
,	O
a	O
hepatotoxic	O
metabolite	O
of	O
APAP	O
,	O
is	O
metabolized	O
by	O
Cytochrome	B
P450	B
enzymes	I
in	O
livers	O
,	O
specifically	O
isoforms	O
such	O
as	O
CYP2E1	B
,	O
CYP3A4	B
and	O
CYP1A2	B
^	O
,	O
.	O

Cytochrome	B
P450	B
enzymes	I
are	O
responsible	O
for	O
metabolizing	O
APAP	O
into	O
its	O
reactive	O
metabolite	O
N	O
-	O
Acetyl	O
P	O
-	O
Benzoquinoneimine	O
,	O
and	O
of	O
which	O
CYP1A2	B
,	O
CYP2E1	B
and	O
CYP3A4	B
are	O
the	O
main	O
Cytochrome	B
P450	B
enzymes	I
for	O
the	O
metabolic	O
activation	O
of	O
APAP	O
in	O
liver	O
^	O
,	O
,	O
,	O
.	O

Previous	O
studies	O
showed	O
that	O
some	O
chemical	O
agents	O
were	O
reported	O
to	O
exacerbate	O
APAP	O
-	O
induced	O
liver	O
injury	O
by	O
enhancing	O
its	O
liver	O
metabolism	O
via	O
inducing	O
the	O
expression	O
of	O
Cytochrome	B
P450	B
enzymes	I
^	O
-	O
.	O

Cytochrome	B
P450	B
enzymes	I
constitute	O
a	O
superfamily	O
of	O
proteins	O
that	O
play	O
an	O
important	O
role	O
in	O
the	O
metabolism	O
and	O
detoxification	O
of	O
xenobiotics	O
(	O
Brown	O
et	O
al	O
.	O
,	O
.	O

Cytochrome	B
P450	B
enzymes	I
were	O
isolated	O
and	O
prepared	O
by	O
differential	O
centrifugation	O
and	O
analyzed	O
for	O
their	O
activity	O
by	O
the	O
use	O
of	O
liver	O
microsomes	O
.	O
.	O
The	O
liver	O
was	O
excised	O
,	O
rinsed	O
with	O
ice	O
-	O
cold	O
saline	O
(	O
0	O
.	O
9	O
%	O
NaCl	O
w	O
/	O
v	O
)	O
,	O
weighed	O
,	O
and	O
homogenized	O
in	O
0	O
.	O
05	O
mM	O
Tris	O
/	O
KCl	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
.	O

NF	O
-	O
B	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
P450s	O
through	O
interaction	O
with	O
their	O
induction	O
mechanisms	O
.	O
-	O
Our	O
results	O
demonstrated	O
that	O
Methicillin	O
-	O
Resistant	O
Staphylococcus	O
Aureus	O
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
the	O
mRNA	O
levels	O
and	O
enzyme	O
activities	O
of	O
Cytochrome	B
P450	B
enzymes	I
.	O

This	O
inhibition	O
of	O
Cytochrome	B
P450	B
enzymes	I
was	O
also	O
accompanied	O
by	O
an	O
increase	O
in	O
oxidative	O
stress	O
in	O
the	O
livers	O
of	O
mice	O
infected	O
with	O
Methicillin	O
-	O
Resistant	O
Staphylococcus	O
Aureus	O
.	O

All	O
three	O
enzymes	O
showed	O
high	O
and	O
very	O
similar	O
dissociation	O
constants	O
(	O
in	O
the	O
M	O
range	O
)	O
for	O
the	O
binding	O
of	O
cinnamate	O
,	O
and	O
high	O
catalytic	O
efficiencies	O
,	O
around	O
100	O
min	O
^	O
1	O
M	O
^	O
1	O
,	O
for	O
the	O
conversion	O
of	O
cinnamate	O
into	O
p	O
-	O
coumarate	O
,	O
which	O
are	O
among	O
the	O
best	O
reported	O
for	O
membrane	O
-	O
bound	O
P450	B
enzymes	I
.	O

Some	O
mammalian	O
P450	B
enzymes	I
with	O
a	O
single	O
TMH	O
have	O
been	O
reported	O
to	O
enter	O
the	O
secretory	O
pathway	O
and	O
to	O
be	O
targeted	O
to	O
the	O
plasma	O
membrane	O
,	O
some	O
of	O
them	O
facing	O
the	O
extracellular	O
space	O
.	O

The	O
following	O
data	O
were	O
abstracted	O
from	O
selected	O
studies	O
:	O
number	O
of	O
individuals	O
in	O
the	O
study	O
,	O
the	O
study	O
population	O
,	O
P450	B
enzymes	I
,	O
method	O
for	O
genotyping	O
and	O
phenotyping	O
,	O
allele	O
frequencies	O
and	O
conclusions	O
from	O
the	O
study	O
.	O

CHO	O
-	O
K1	O
cells	O
do	O
not	O
metabolize	O
steroid	O
hormones	O
,	O
^	O
and	O
no	O
expression	O
of	O
CYP	O
P450	B
enzymes	I
was	O
detected	O
in	O
CHO	O
cells	O
;	O
^	O
this	O
indicates	O
that	O
metabolites	O
were	O
exclusively	O
formed	O
by	O
enzymes	O
provided	O
by	O
the	O
S9	O
-	O
mix	O
.	O

Various	O
studies	O
have	O
reported	O
the	O
pivotal	O
role	O
of	O
P450	B
enzymes	I
in	O
the	O
synthesis	O
of	O
FCs	O
(	O
,	O
;	O
,	O
.	O

Amino	O
acid	O
residues	O
at	O
the	O
entrance	O
of	O
the	O
channels	O
may	O
participate	O
to	O
a	O
first	O
global	O
ligand	O
recognition	O
of	O
ligands	O
by	O
P450	B
enzymes	I
before	O
they	O
reach	O
the	O
buried	O
active	O
site	O
.	O

Moreover	O
,	O
different	O
P450	B
enzymes	I
show	O
different	O
networks	O
of	O
predicted	O
channels	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
all	O
P450	B
enzymes	I
,	O
except	O
a	O
few	O
ones	O
,	O
is	O
to	O
catalyze	O
molecular	O
dioxygen	O
reduction	O
by	O
splitting	O
the	O
dioxygen	O
molecule	O
in	O
two	O
,	O
one	O
oxygen	O
atom	O
is	O
inserted	O
in	O
the	O
substrate	O
to	O
yield	O
the	O
oxidized	O
product	O
,	O
and	O
the	O
second	O
is	O
reduced	O
to	O
water	O
,	O
a	O
typical	O
monooxygenase	O
activity	O
.	O

Two	O
biochemical	O
properties	O
characterize	O
P450	B
enzymes	I
among	O
other	O
hemoproteins	O
.	O

The	O
P450	B
enzymes	I
,	O
which	O
are	O
divided	O
into	O
gene	O
families	O
and	O
subfamilies	O
on	O
the	O
basis	O
of	O
the	O
amount	O
of	O
identity	O
between	O
amino	O
acid	O
sequences	O
,	O
can	O
be	O
broadly	O
classified	O
in	O
two	O
main	O
classes	O
depending	O
on	O
their	O
global	O
substrate	O
specificity	O
.	O

A	O
first	O
class	O
includes	O
P450	B
enzymes	I
that	O
have	O
a	O
strong	O
preference	O
for	O
a	O
single	O
substrate	O
.	O

The	O
second	O
class	O
comprises	O
P450	B
enzymes	I
featuring	O
a	O
broad	O
specificity	O
for	O
substrates	O
,	O
often	O
very	O
different	O
in	O
size	O
and	O
chemical	O
nature	O
,	O
mostly	O
comprising	O
the	O
P450s	O
that	O
are	O
involved	O
in	O
the	O
drug	O
and	O
pollutant	O
metabolism	O
in	O
vertebrates	O
.	O

Consequently	O
,	O
P450	B
enzymes	I
are	O
frequently	O
designated	O
as	O
unspecific	O
monooxygenases	O
(	O
EC1	O
.	O
14	O
.	O
14	O
.	O
1	O
)	O
.	O

P450	B
enzymes	I
of	O
either	O
classes	O
share	O
the	O
same	O
similar	O
catalytic	O
cycle	O
and	O
a	O
similar	O
folding	O
.	O

This	O
plant	O
P450	O
exhibits	O
a	O
crystal	O
structure	O
that	O
is	O
highly	O
similar	O
to	O
any	O
other	O
P450	B
enzymes	I
,	O
such	O
as	O
that	O
of	O
human	O
CYP2B6	B
,	O
which	O
reduces	O
molecular	O
dioxygen	O
and	O
reacts	O
with	O
hundreds	O
of	O
different	O
substrates	O
.	O

The	O
extraordinary	O
chemical	O
ability	O
of	O
P450	B
enzymes	I
is	O
mainly	O
based	O
on	O
three	O
features	O
that	O
all	O
of	O
these	O
enzymes	O
share	O
.	O

This	O
iron	O
-	O
cysteinate	O
bond	O
is	O
at	O
the	O
heart	O
of	O
the	O
different	O
redox	O
states	O
that	O
the	O
iron	O
ion	O
may	O
access	O
during	O
P450	O
catalysis	O
,	O
leading	O
to	O
the	O
sophisticated	O
catalytic	O
cycle	O
of	O
P450	B
enzymes	I
.	O

Besides	O
these	O
common	O
features	O
,	O
all	O
of	O
the	O
P450	B
enzymes	I
also	O
present	O
a	O
typical	O
structural	O
feature	O
,	O
the	O
absence	O
of	O
a	O
clear	O
visible	O
access	O
between	O
the	O
protein	O
surface	O
and	O
the	O
active	O
site	O
that	O
is	O
always	O
buried	O
deep	O
in	O
the	O
protein	O
core	O
.	O

Differences	O
in	O
the	O
networks	O
of	O
channels	O
among	O
P450	B
enzymes	I
may	O
account	O
for	O
the	O
differences	O
in	O
ligand	O
selectivity	O
,	O
and	O
hence	O
,	O
for	O
the	O
ways	O
that	O
P450	B
enzymes	I
control	O
at	O
several	O
levels	O
their	O
substrate	O
selectivity	O
.	O

have	O
classified	O
and	O
named	O
the	O
different	O
access	O
channels	O
that	O
were	O
found	O
by	O
CAVER	O
on	O
structurally	O
characterized	O
P450	B
enzymes	I
in	O
a	O
systematic	O
manner	O
.	O

The	O
different	O
ligand	O
access	O
channels	O
that	O
were	O
identified	O
in	O
P450	B
enzymes	I
were	O
each	O
named	O
by	O
a	O
different	O
number	O
(	O
channels	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
W	O
,	O
and	O
S	O
)	O
.	O

P450cam	B
(	O
CYP101	O
)	O
,	O
which	O
is	O
one	O
of	O
the	O
best	O
characterized	O
of	O
all	O
P450	B
enzymes	I
,	O
is	O
considered	O
as	O
a	O
model	O
for	O
P450s	O
with	O
narrow	O
substrate	O
specificity	O
.	O

It	O
appears	O
that	O
the	O
inhibitor	O
metyrapone	O
binds	O
the	O
heme	O
iron	O
ion	O
by	O
one	O
of	O
its	O
pyridine	O
nitrogen	O
,	O
and	O
that	O
the	O
progesterone	O
is	O
bound	O
on	O
the	O
CYP3A4	B
surface	O
to	O
a	O
pocket	O
made	O
by	O
the	O
F	O
/	O
G	O
region	O
,	O
and	O
which	O
colocalized	O
with	O
the	O
mouth	O
of	O
either	O
CAVER	O
channel	O
3	O
or	O
4	O
in	O
P450	B
enzymes	I
.	O

For	O
all	O
mammalian	O
P450	B
enzymes	I
that	O
were	O
considered	O
,	O
a	O
network	O
of	O
several	O
access	O
channels	O
linking	O
the	O
catalytic	O
cavity	O
to	O
the	O
distal	O
face	O
of	O
the	O
protein	O
is	O
consistently	O
predicted	O
.	O

However	O
,	O
in	O
P450	B
enzymes	I
,	O
discrete	O
side	O
chains	O
reorganizations	O
and	O
some	O
secondary	O
elements	O
are	O
also	O
prone	O
to	O
conformational	O
change	O
,	O
both	O
types	O
of	O
protein	O
dynamics	O
seem	O
to	O
take	O
place	O
.	O

This	O
result	O
suggests	O
that	O
in	O
P450	B
enzymes	I
preliminary	O
ligand	O
recognition	O
takes	O
place	O
at	O
the	O
surface	O
of	O
the	O
enzyme	O
before	O
channeling	O
it	O
to	O
the	O
catalytic	O
cavity	O
.	O

This	O
was	O
the	O
first	O
study	O
to	O
demonstrate	O
that	O
phospholipids	O
were	O
not	O
just	O
playing	O
a	O
structural	O
role	O
bymaking	O
the	O
membrane	O
,	O
but	O
also	O
could	O
play	O
a	O
role	O
in	O
the	O
function	O
of	O
the	O
P450	B
enzymes	I
.	O

It	O
is	O
known	O
,	O
though	O
surprisingly	O
enough	O
not	O
much	O
worked	O
,	O
that	O
phospholipids	O
indeed	O
play	O
a	O
role	O
in	O
modulating	O
the	O
activity	O
of	O
membrane	O
-	O
bound	O
P450	B
enzymes	I
.	O

This	O
work	O
thus	O
shows	O
that	O
the	O
dynamic	O
of	O
channels	O
in	O
P450	B
enzymes	I
may	O
also	O
be	O
influenced	O
by	O
the	O
nature	O
of	O
phospholipids	O
present	O
in	O
their	O
vicinity	O
.	O

All	O
of	O
these	O
results	O
indicate	O
that	O
at	O
least	O
two	O
notions	O
have	O
to	O
be	O
kept	O
in	O
mind	O
when	O
looking	O
at	O
channels	O
and	O
ligand	O
selectivity	O
in	O
P450	B
enzymes	I
.	O

The	O
association	O
to	O
the	O
membrane	O
and	O
the	O
F	O
/	O
G	O
cassette	O
are	O
key	O
elements	O
in	O
the	O
relationships	O
between	O
channels	O
and	O
ligand	O
selectivity	O
in	O
P450	B
enzymes	I
.	O

The	O
F	O
/	O
G	O
region	O
of	O
P450	B
enzymes	I
have	O
not	O
only	O
been	O
highlighted	O
by	O
molecular	O
dynamics	O
simulations	O
,	O
but	O
also	O
by	O
biochemical	O
and	O
biophysical	O
experiments	O
,	O
and	O
this	O
,	O
both	O
for	O
bacterial	O
and	O
eukaryotic	O
P450s	O
.	O

Whether	O
a	O
given	O
channel	O
opens	O
up	O
depends	O
on	O
the	O
physicochemical	O
properties	O
of	O
the	O
interface	O
between	O
the	O
F	O
/	O
G	O
structural	O
block	O
and	O
the	O
rest	O
of	O
the	O
P450	O
molecule	O
,	O
and	O
also	O
on	O
structural	O
features	O
,	O
such	O
as	O
the	O
extent	O
of	O
the	O
F	O
/	O
G	O
loop	O
and	O
the	O
arrangement	O
of	O
F	O
and	O
G	O
helices	O
within	O
the	O
F	O
/	O
G	O
region	O
in	O
mammalian	O
P450	B
enzymes	I
.	O

This	O
result	O
points	O
out	O
how	O
Nature	O
may	O
use	O
a	O
few	O
specific	O
sequence	O
motifs	O
to	O
modulate	O
the	O
channel	O
opening	O
of	O
the	O
different	O
P450	B
enzymes	I
,	O
and	O
thus	O
their	O
associated	O
ligand	O
specificity	O
,	O
by	O
using	O
local	O
flexibility	O
of	O
some	O
definite	O
secondary	O
structure	O
elements	O
.	O

This	O
motion	O
was	O
observed	O
both	O
when	O
comparing	O
the	O
crystal	O
structures	O
of	O
the	O
same	O
P450	O
complexed	O
with	O
different	O
ligands	O
and	O
in	O
silicoby	O
revealing	O
the	O
malleability	O
of	O
this	O
region	O
in	O
P450	B
enzymes	I
.	O

In	O
this	O
respect	O
,	O
it	O
is	O
interesting	O
to	O
note	O
that	O
two	O
of	O
the	O
less	O
-	O
studied	O
channels	O
that	O
were	O
seen	O
with	O
CAVER	O
in	O
P450	B
enzymes	I
,	O
namely	O
channels	O
3	O
and	O
4	O
,	O
have	O
their	O
opening	O
right	O
in	O
-	O
between	O
the	O
F	O
and	O
the	O
G	O
helices	O
,	O
one	O
being	O
very	O
close	O
to	O
the	O
F	O
/	O
G	O
helices	O
(	O
channel	O
4	O
)	O
and	O
the	O
other	O
close	O
to	O
the	O
F	O
/	O
F	O
loop	O
.	O

It	O
thus	O
appears	O
that	O
P450	B
enzymes	I
show	O
structural	O
regions	O
with	O
major	O
differences	O
in	O
flexibility	O
.	O

The	O
atomic	O
models	O
of	O
six	O
human	O
P450	B
enzymes	I
including	O
CYP3A4	B
anchored	O
to	O
a	O
lipid	O
bilayer	O
were	O
constructed	O
and	O
investigated	O
by	O
molecular	O
dynamics	O
simulations	O
for	O
the	O
position	O
and	O
orientation	O
of	O
the	O
P450	O
protein	O
on	O
the	O
model	O
membrane	O
.	O

The	O
P450	B
enzymes	I
seem	O
to	O
not	O
have	O
the	O
same	O
affinity	O
for	O
these	O
cholesterol	O
-	O
rich	O
microdomains	O
.	O

Using	O
wild	O
-	O
type	O
and	O
artificial	O
chimeras	O
between	O
human	O
CYP1A1	B
and	O
human	O
CYP1A2	B
,	O
conclusive	O
evidence	O
were	O
presented	O
showing	O
that	O
,	O
despite	O
a	O
82	O
%	O
sequence	O
identity	O
between	O
them	O
,	O
these	O
two	O
human	O
P450	B
enzymes	I
have	O
a	O
totally	O
different	O
affinity	O
for	O
the	O
lipid	O
rafts	O
in	O
mammalian	O
cells	O
.	O

The	O
accessibility	O
of	O
the	O
occluded	O
catalytic	O
cavity	O
of	O
P450	B
enzymes	I
originates	O
from	O
the	O
analyses	O
of	O
crystal	O
structures	O
,	O
which	O
offer	O
only	O
a	O
static	O
view	O
,	O
and	O
it	O
is	O
known	O
that	O
shortcomings	O
,	O
such	O
as	O
crystal	O
packing	O
causing	O
non	O
-	O
native	O
contacts	O
and	O
constraints	O
,	O
may	O
affect	O
conclusions	O
that	O
are	O
deduced	O
from	O
the	O
comparison	O
of	O
crystal	O
structures	O
.	O

This	O
important	O
work	O
was	O
also	O
showing	O
that	O
different	O
substrates	O
may	O
use	O
different	O
channels	O
to	O
access	O
the	O
active	O
site	O
in	O
P450	B
enzymes	I
.	O

This	O
opens	O
the	O
way	O
to	O
a	O
study	O
of	O
the	O
relationships	O
between	O
the	O
functions	O
and	O
the	O
composition	O
of	O
the	O
channel	O
networks	O
,	O
as	O
they	O
are	O
systematically	O
observed	O
in	O
P450	B
enzymes	I
.	O

A	O
combination	O
between	O
the	O
substrate	O
access	O
channel	O
and	O
the	O
F	O
-	O
helix	O
break	O
could	O
act	O
as	O
a	O
structural	O
determinant	O
of	O
substrate	O
specificity	O
in	O
this	O
family	O
of	O
P450	B
enzymes	I
.	O

The	O
network	O
of	O
channels	O
observed	O
in	O
all	O
P450	B
enzymes	I
is	O
thus	O
likely	O
involved	O
in	O
the	O
control	O
of	O
their	O
substrate	O
specificity	O
.	O

Channels	O
are	O
an	O
element	O
of	O
the	O
structural	O
determinants	O
of	O
the	O
substrate	O
specificity	O
in	O
P450	B
enzymes	I
.	O

Future	O
prospects	O
on	O
channels	O
in	O
P450	B
enzymes	I
could	O
include	O
the	O
possibility	O
to	O
transfer	O
a	O
specific	O
channel	O
from	O
a	O
P450	O
to	O
another	O
,	O
in	O
which	O
this	O
specific	O
channel	O
is	O
missing	O
.	O

All	O
of	O
these	O
future	O
studies	O
will	O
rely	O
on	O
extensive	O
and	O
specific	O
multiple	O
mutations	O
in	O
P450	B
enzymes	I
,	O
and	O
,	O
for	O
the	O
moment	O
,	O
their	O
feasibility	O
and	O
outcome	O
are	O
hardly	O
predictable	O
.	O

The	O
electron	O
leakage	O
in	O
the	O
electron	O
transport	O
chain	O
during	O
respiration	O
is	O
generally	O
considered	O
as	O
the	O
main	O
source	O
of	O
mitochondrial	O
Reactive	O
Oxygen	O
Species	O
but	O
other	O
mitochondrial	O
enzymatic	O
systems	O
,	O
such	O
as	O
monoamine	O
oxidase	O
and	O
cytochrome	O
b5	O
reductase	O
in	O
the	O
outer	O
membranes	O
,	O
cytochromes	O
P450	B
enzymes	I
in	O
the	O
inner	O
membranes	O
,	O
or	O
several	O
matrix	O
enzymes	O
such	O
as	O
aconitase	O
,	O
can	O
also	O
produce	O
Reactive	O
Oxygen	O
Species	O
(	O
Andreyev	O
,	O
Kushnareva	O
,	O
Murphy	O
,	O
&	O
Starkov	O
,	O
;	O
Andreyev	O
,	O
Kushnareva	O
,	O
&	O
Starkov	O
,	O
.	O

Cytochrome	B
P450	B
enzymes	I
,	O
arguably	O
natures	O
most	O
versatile	O
catalysts	O
,	O
are	O
a	O
superfamily	O
of	O
haem	O
-	O
thiolate	O
proteins	O
found	O
across	O
all	O
lineages	O
of	O
life	O
^	O
.	O

While	O
there	O
are	O
more	O
than	O
57	O
different	O
Cytochrome	B
P450	B
enzymes	I
in	O
humans	O
,	O
only	O
a	O
small	O
number	O
of	O
highly	O
polymorphic	O
isoforms	O
are	O
responsible	O
for	O
the	O
majority	O
of	O
drug	O
metabolism	O
^	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
provides	O
for	O
the	O
first	O
time	O
an	O
extensive	O
picture	O
of	O
the	O
impact	O
of	O
Simulated	O
Sunlight	O
,	O
namely	O
a	O
combination	O
of	O
both	O
UVB	O
and	O
UVA	O
components	O
,	O
on	O
the	O
metabolism	O
and	O
genotoxicity	O
of	O
B	O
[	O
a	O
]	O
P	O
.	O
In	O
contrast	O
to	O
previous	O
data	O
obtained	O
in	O
vitro	O
with	O
pure	O
UVB	O
,	O
solar	O
Ultraviolet	O
radiation	O
appears	O
to	O
have	O
a	O
strong	O
repressive	O
effect	O
on	O
B	O
[	O
a	O
]	O
P	O
-	O
induced	O
gene	O
induction	O
of	O
Cytochrome	B
P450	B
enzymes	I
and	O
delays	O
formation	O
of	O
BPDE	O
-	O
DNA	O
adducts	O
in	O
skin	O
.	O

Cytochrome	B
P450	B
enzymes	I
are	O
the	O
major	O
heme	O
-	O
containing	O
enzyme	O
family	O
and	O
the	O
most	O
important	O
drug	O
-	O
metabolizing	O
enzymes	O
.	O

Cytochrome	B
P450	B
enzymes	I
,	O
CYP2C8	B
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
,	O
are	O
important	O
in	O
the	O
metabolism	O
of	O
hypoglycemic	O
drugs	O
,	O
such	O
as	O
thiazolidinediones	O
(	O
TZDs	O
)	O
and	O
sulfonylureas	O
,	O
and	O
hypocholesterolemic	O
drugs	O
,	O
such	O
as	O
atorvastatin	O
.	O

Molecules	O
more	O
soluble	O
in	O
water	O
do	O
not	O
make	O
good	O
substrates	O
for	O
P450	B
enzymes	I
.	O

These	O
results	O
indicate	O
that	O
rooibos	O
extracts	O
may	O
potentially	O
cause	O
herb	O
-	O
drug	O
interactions	O
when	O
co	O
-	O
administered	O
with	O
substrates	O
or	O
drugs	O
metabolized	O
by	O
these	O
P450	B
enzymes	I
.	O

This	O
study	O
includes	O
the	O
quantitative	O
measurement	O
of	O
drug	O
-	O
like	O
properties	O
such	O
as	O
,	O
lipophilicity	O
,	O
solubility	O
,	O
pKa	O
(	O
negative	O
logarithmic	O
measure	O
of	O
acid	O
dissociation	O
constant	O
)	O
,	O
permeability	O
,	O
absorption	O
,	O
bioavailability	O
,	O
blood	O
-	O
brain	O
barrier	O
penetration	O
,	O
transporters	O
,	O
dermal	O
and	O
ocular	O
penetration	O
,	O
plasma	O
-	O
protein	O
binding	O
,	O
metabolism	O
and	O
drug	O
-	O
drug	O
interaction	O
,	O
volume	O
of	O
distribution	O
(	O
V_d	O
)	O
,	O
clearance	O
,	O
half	O
-	O
life	O
,	O
p	O
-	O
glycoprotein	O
efflux	O
and	O
inhibition	O
as	O
well	O
as	O
inhibition	O
of	O
the	O
hepatic	O
organic	O
anion	O
transporting	O
polypeptide	O
(	O
OATP	O
-	O
1B1	O
)	O
transporter	O
,	O
cytochromes	O
P450	B
enzymes	I
,	O
and	O
UDP	O
-	O
glucuronosyltransferases	O
.	O

In	O
identifying	O
the	O
affinity	O
of	O
studies	O
compound	O
with	O
CYP	O
-	O
P450	B
enzymes	I
in	O
quantitative	O
terms	O
,	O
the	O
Michaelis	O
-	O
Menten	O
constant	O
(	O
K_m	O
)	O
,	O
maximum	O
metabolic	O
rate	O
(	O
V_max	O
)	O
and	O
intrinsic	O
clearance	O
(	O
C_Lint	O
)	O
calculated	O
,	O
which	O
provide	O
the	O
knowledge	O
of	O
the	O
rate	O
of	O
metabolism	O
.	O

The	O
lipophilic	O
sterol	O
metabolites	O
produced	O
by	O
IFN	O
signaling	O
including	O
oxysterols	O
are	O
substrates	O
for	O
Cytochrome	B
P450	B
enzymes	I
and	O
they	O
profoundly	O
influence	O
cellular	O
metabolism	O
(	O
Newmark	O
et	O
al	O
.	O
,	O
)	O
which	O
in	O
turn	O
has	O
been	O
shown	O
to	O
influence	O
Mycobacterium	O
Tuberculosis	O
replication	O
inside	O
cells	O
(	O
Huang	O
et	O
al	O
.	O
,	O
.	O

The	O
Cytochrome	B
P450	B
enzymes	I
are	O
heme	O
containing	O
monooxygenases	O
involved	O
in	O
the	O
pathways	O
associated	O
with	O
the	O
metabolism	O
of	O
fatty	O
acids	O
,	O
steroids	O
and	O
other	O
lipophilic	O
molecules	O
(	O
Pikuleva	O
,	O
.	O

The	O
loss	O
of	O
Cytochrome	B
P450	B
enzymes	I
prevents	O
Apolipoprotein	O
(	O
Apo	O
)	O
A1	O
synthesis	O
thus	O
affecting	O
the	O
removal	O
of	O
cholesterol	O
from	O
the	O
cells	O
to	O
the	O
liver	O
for	O
biliary	O
excretion	O
(	O
Rubin	O
et	O
al	O
.	O
,	O
;	O
Nebert	O
and	O
Russell	O
,	O
;	O
Guan	O
et	O
al	O
.	O
,	O
.	O

Since	O
the	O
activity	O
of	O
the	O
Cytochrome	B
P450	B
enzymes	I
can	O
be	O
modulated	O
post	O
-	O
translationally	O
,	O
they	O
are	O
targets	O
to	O
manipulate	O
cholesterol	O
homeostasis	O
(	O
Luoma	O
,	O
.	O

For	O
example	O
,	O
Mycobacterium	O
Tuberculosis	O
has	O
about	O
20	O
different	O
Cytochrome	B
P450	B
enzymes	I
,	O
and	O
several	O
Cytochrome	B
P450	I
genes	O
have	O
been	O
associated	O
with	O
mycobacterial	O
viability	O
(	O
Mclean	O
et	O
al	O
.	O
,	O
.	O

have	O
reported	O
that	O
the	O
Mycobacterium	O
Tuberculosis	O
genome	O
sequence	O
has	O
a	O
very	O
high	O
number	O
of	O
Cytochrome	B
P450	B
enzymes	I
,	O
with	O
Cyp128	O
contributing	O
to	O
synthesis	O
of	O
cell	O
wall	O
sulpholipid	O
and	O
being	O
necessary	O
for	O
in	O
-	O
vitro	O
growth	O
of	O
the	O
bacterium	O
(	O
Cole	O
et	O
al	O
.	O
,	O
;	O
Holsclaw	O
et	O
al	O
.	O
,	O
;	O
Sogi	O
et	O
al	O
.	O
,	O
.	O

Cytochrome	B
P450	B
enzymes	I
(	O
P450s	O
)	O
of	O
the	O
MPB	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
metabolism	O
of	O
at	O
least	O
some	O
of	O
these	O
defense	O
compounds	O
.	O

The	O
active	O
site	O
heme	O
iron	O
is	O
coordinated	O
by	O
the	O
thiolate	O
of	O
the	O
conserved	O
,	O
proximal	O
Cys332	O
residue	O
,	O
whilst	O
the	O
I	O
-	O
helix	O
that	O
runs	O
across	O
the	O
top	O
of	O
the	O
heme	O
contains	O
the	O
Glu	O
/	O
Gln	O
pair	O
of	O
residues	O
(	O
Glu228	O
,	O
Gln229	O
)	O
that	O
are	O
required	O
in	O
P450	B
enzymes	I
to	O
maintain	O
an	O
effective	O
protonation	O
cascade	O
during	O
oxygen	O
activation	O
.	O

Cytochrome	B
P450	B
enzymes	I
,	O
responsible	O
for	O
the	O
biotransformation	O
of	O
more	O
than	O
85	O
%	O
of	O
existing	O
drugs	O
,	O
may	O
contain	O
genetic	O
variants	O
that	O
result	O
in	O
poor	O
,	O
intermediate	O
,	O
extensive	O
or	O
ultra	O
-	O
rapid	O
metabolic	O
rates	O
^	O
,	O
.	O

The	O
values	O
of	O
mean	O
microsomal	O
fractions	O
of	O
the	O
human	O
heart	O
for	O
CYP	O
enzymes	O
(	O
CYP2C8	B
,	O
CYP2C9	B
,	O
and	O
CYP2J2	O
)	O
were	O
used	O
in	O
computing	O
total	O
cardiac	O
clearance	O
in	O
Equations	O
and	O
.	O

where	O
:	O
CL_int2C8_per_mgC8_per_mg	O
-	O
intrinsic	O
clearance	O
per	O
mg	O
of	O
protein	O
[	O
mcL	O
/	O
min	O
/	O
mg	O
]	O
,	O
CL_int2C8_per_pmolC8_per_pmol	O
-	O
intrinsic	O
clearance	O
per	O
pmol	O
of	O
CYP2C8	B
isoform	O
[	O
mcL	O
/	O
min	O
/	O
pmol	O
]	O
,	O
CYP2C8	B
-	O
Mean	O
CYP2C8	B
enzyme	O
abundance	O
in	O
the	O
human	O
heart	O
[	O
pmol	O
/	O
mg	O
]	O
,	O
CL_int	O
2C8C8	O
-	O
Intrinsic	O
clearance	O
for	O
CYP2C8	B
in	O
the	O
human	O
heart	O
[	O
L	O
/	O
h	O
]	O
,	O
W_he	O
-	O
average	O
heart	O
weight	O
[	O
g	O
]	O
,	O
CLu_int	O
2C8C8	O
-	O
intrinsic	O
clearance	O
for	O
CYP2C8	B
based	O
on	O
unbound	O
fraction	O
of	O
compound	O
[	O
L	O
/	O
h	O
]	O
,	O
fu_mic	O
-	O
fraction	O
of	O
drug	O
unbound	O
in	O
an	O
in	O
vitro	O
microsomal	O
preparation	O
,	O
ISEF_2C8C8	O
-	O
Inter	O
System	O
Extrapolation	O
Factor	O
for	O
CYP2C8	B
.	O

Fargesin	O
inhibited	O
CYP2C9	B
-	O
catalyzed	O
diclofenac	O
4	O
-	O
hydroxylation	O
with	O
a	O
Ki	O
value	O
of	O
16	O
.	O
3	O
M	O
,	O
and	O
it	O
exhibited	O
mechanism	O
-	O
based	O
inhibition	O
of	O
CYP2C19	B
-	O
catalyzed	O
[	O
S	O
]	O
-	O
mephenytoin	O
4	O
-	O
hydroxylation	O
(	O
Ki	O
,	O
3	O
.	O
7	O
M	O
;	O
kinact	O
,	O
0	O
.	O
102	O
min1	O
)	O
,	O
CYP2C8	B
-	O
catalyzed	O
amodiaquine	O
N	O
-	O
deethylation	O
(	O
Ki	O
,	O
10	O
.	O
7	O
M	O
;	O
kinact	O
,	O
0	O
.	O
082	O
min1	O
)	O
,	O
and	O
CYP3A4	B
-	O
catalyzed	O
midazolam	O
1	O
-	O
hydroxylation	O
(	O
Ki	O
,	O
23	O
.	O
0	O
M	O
;	O
kinact	O
,	O
0	O
.	O
050	O
min1	O
)	O
in	O
human	O
liver	O
microsomes	O
.	O

Dimethyllirioresinol	O
weakly	O
inhibited	O
CYP2C19	B
and	O
CYP2C8	B
with	O
IC50	O
values	O
of	O
55	O
.	O
1	O
and	O
85	O
.	O
0	O
M	O
,	O
respectively	O
,	O
without	O
inhibition	O
of	O
CYP1A2	B
,	O
CYP2A6	O
,	O
CYP2B6	B
,	O
CYP2C9	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
activities	O
at	O
100	O
M	O
.	O
Epimagnolin	O
A	O
,	O
eudesmin	O
,	O
and	O
magnolin	O
showed	O
no	O
the	O
reversible	O
and	O
time	O
-	O
dependent	O
inhibition	O
of	O
eight	O
major	O
Cytochrome	B
P450	I
activities	O
at	O
100	O
M	O
in	O
human	O
liver	O
microsomes	O
.	O

These	O
in	O
vitro	O
results	O
suggest	O
that	O
it	O
is	O
necessary	O
to	O
investigate	O
the	O
potentials	O
of	O
in	O
vivo	O
fargesin	O
-	O
drug	O
interaction	O
with	O
CYP2C8	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
and	O
CYP3A4	B
substrates	O
.	O

Dimethyllirioresinol	O
weakly	O
inhibited	O
CYP2C19	B
-	O
catalyzed	O
[	O
S	O
]	O
-	O
mephenytoin	O
4	O
-	O
hydroxylation	O
and	O
CYP2C8	B
-	O
catalyzed	O
amodiaquine	O
N	O
-	O
deethylation	O
with	O
IC_50	O
values	O
of	O
55	O
.	O
1	O
and	O
85	O
.	O
0	O
M	O
,	O
respectively	O
,	O
without	O
inhibition	O
of	O
CYP1A2	B
-	O
catalyzed	O
phenacetin	O
O	O
-	O
deethylation	O
,	O
CYP2A6	O
-	O
catalyzed	O
coumarin	O
7	O
-	O
hydroxylation	O
,	O
CYP2B6	B
-	O
catalyzed	O
bupropion	O
hydroxylation	O
,	O
CYP2C9	B
-	O
catalyzed	O
diclofenac	O
4	O
-	O
hydroxylation	O
,	O
CYP2D6	B
-	O
catalyzed	O
bufuralol	O
1	O
-	O
hydroxylation	O
,	O
and	O
CYP3A4	B
-	O
catalyzed	O
midazolam	O
1	O
-	O
hydroxylation	O
activities	O
at	O
100	O
M	O
in	O
human	O
liver	O
microsomes	O
.	O

However	O
,	O
30	O
min	O
pre	O
-	O
incubation	O
of	O
human	O
liver	O
microsomes	O
with	O
fargesin	O
and	O
NADPH	O
lowered	O
the	O
IC_50	O
values	O
of	O
CYP2C8	B
-	O
catalyzed	O
amodiaquine	O
N	O
-	O
deethylation	O
,	O
CYP2C19	B
-	O
catalyzed	O
[	O
S	O
]	O
-	O
mephenytoin	O
4	O
-	O
hydroxylation	O
,	O
and	O
CYP3A4	B
-	O
catalyzed	O
midazolam	O
1	O
-	O
hydroxylation	O
activities	O
by	O
more	O
than	O
2	O
.	O
5	O
-	O
fold	O
in	O
comparison	O
with	O
the	O
IC_50	O
values	O
obtained	O
without	O
pre	O
-	O
incubation	O
(	O
34	O
.	O
9	O
versus	O
4	O
.	O
0	O
M	O
for	O
CYP2C8	B
,	O
30	O
.	O
2	O
versus	O
1	O
.	O
6	O
M	O
for	O
CYP2C19	B
,	O
and	O
>	O
100	O
versus	O
17	O
.	O
9	O
M	O
for	O
CYP3A4	B
)	O
,	O
indicating	O
that	O
fargesin	O
causes	O
potent	O
mechanism	O
-	O
based	O
inhibition	O
of	O
CYP2C8	B
,	O
CYP2C19	B
,	O
and	O
CYP3A4	B
enzymes	O
in	O
human	O
liver	O
microsomes	O
.	O

Fargesin	O
decreased	O
CYP2C8	B
-	O
catalyzed	O
amodiaquine	O
N	O
-	O
deethylation	O
,	O
CYP2C19	B
-	O
catalyzed	O
[	O
S	O
]	O
-	O
mephenytoin	O
4	O
-	O
hydroxylation	O
,	O
and	O
CYP3A4	B
-	O
catalyzed	O
midazolam	O
1	O
-	O
hydroxylation	O
in	O
pre	O
-	O
incubation	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manners	O
in	O
human	O
liver	O
microsomes	O
.	O

The	O
apparent	O
K_i	O
and	O
maximal	O
inactivation	O
rate	O
(	O
k_inact	O
)	O
values	O
of	O
fargesin	O
were	O
10	O
.	O
7	O
M	O
and	O
0	O
.	O
082	O
min	O
^	O
1	O
for	O
CYP2C8	B
-	O
catalyzed	O
amodiaquine	O
N	O
-	O
deethylation	O
,	O
3	O
.	O
7	O
M	O
and	O
0	O
.	O
102	O
min	O
^	O
1	O
for	O
CYP2C19	B
-	O
catalyzed	O
[	O
S	O
]	O
-	O
mephenytoin	O
4	O
-	O
hydroxylation	O
,	O
and	O
23	O
.	O
0	O
M	O
and	O
0	O
.	O
050	O
min	O
^	O
1	O
for	O
CYP3A4	B
-	O
catalyzed	O
midazolam	O
1	O
-	O
hydroxylation	O
,	O
respectively	O
,	O
in	O
human	O
liver	O
microsomes	O
.	O

Dimethyllirioresinol	O
exhibited	O
weak	O
inhibition	O
of	O
CYP2C8	B
and	O
CYP2C19	B
activities	O
without	O
inhibition	O
of	O
CYP1A2	B
,	O
CYP2A6	O
,	O
CYP2B6	B
,	O
CYP2C9	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
in	O
human	O
liver	O
microsomes	O
.	O

Magnolin	O
,	O
epimagnolin	O
A	O
,	O
and	O
eudesmin	O
showed	O
no	O
the	O
reversible	O
and	O
time	O
-	O
dependent	O
inhibition	O
of	O
CYP1A2	B
,	O
CYP2A6	O
,	O
CYP2B6	B
,	O
CYP2C8	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
activities	O
at	O
100	O
M	O
in	O
human	O
liver	O
microsomes	O
and	O
the	O
potent	O
time	O
-	O
dependent	O
inhibition	O
of	O
CYP2C19	B
,	O
CYP2C8	B
,	O
and	O
CYP3A4	B
activities	O
(	O
IC_50	O
values	O
of	O
1	O
.	O
6	O
,	O
4	O
.	O
0	O
,	O
and	O
17	O
.	O
9	O
M	O
,	O
respectively	O
)	O
in	O
human	O
liver	O
microsomes	O
.	O

Aschantin	O
,	O
a	O
chemical	O
derivative	O
of	O
fargesin	O
,	O
with	O
a	O
methylenedioxyphenyl	O
moiety	O
also	O
exhibited	O
the	O
reversible	O
and	O
time	O
-	O
dependent	O
inhibition	O
of	O
CYP2C8	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
and	O
CYP3A4	B
activities	O
in	O
human	O
liver	O
microsomes	O
.	O

Fargesin	O
showed	O
mechanism	O
-	O
based	O
inhibition	O
of	O
CYP2C8	B
-	O
catalyzed	O
amodiaquine	O
N	O
-	O
deethylation	O
,	O
CYP2C19	B
-	O
catalyzed	O
[	O
S	O
]	O
-	O
mephenytoin	O
4	O
-	O
hydroxylation	O
,	O
and	O
CYP3A4	B
-	O
catalyzed	O
midazolam	O
1	O
-	O
hydroxylation	O
in	O
pooled	O
human	O
liver	O
microsomes	O
.	O

The	O
inactivation	O
potency	O
(	O
k_inact	O
/	O
K_i	O
ratio	O
)	O
of	O
fargesin	O
against	O
CYP2C8	B
(	O
7	O
.	O
66	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
was	O
comparable	O
to	O
that	O
of	O
aschantin	O
(	O
k_inact	O
/	O
K_i	O
=	O
5	O
.	O
49	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
but	O
was	O
higher	O
than	O
those	O
of	O
mechanism	O
-	O
based	O
CYP2C8	B
inhibitors	O
such	O
as	O
amiodarone	O
(	O
0	O
.	O
57	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
phenelzine	O
(	O
3	O
.	O
17	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
and	O
gemfibrozil	O
(	O
1	O
.	O
24	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
in	O
human	O
liver	O
microsomes	O
,	O
indicating	O
that	O
fargesin	O
may	O
be	O
a	O
potent	O
mechanism	O
-	O
based	O
inhibitor	O
of	O
CYP2C8	B
.	O

The	O
degree	O
of	O
inhibition	O
(	O
IC_50	O
values	O
)	O
of	O
dimethyllirioresinol	O
,	O
epimagnolin	O
A	O
,	O
eudesmin	O
,	O
fargesin	O
,	O
and	O
magnolin	O
toward	O
CYP1A2	B
,	O
CYP2A6	O
,	O
CYP2C8	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
activities	O
in	O
pooled	O
human	O
liver	O
microsomes	O
were	O
evaluated	O
following	O
our	O
previous	O
method	O
using	O
Cytochrome	B
P450	I
cocktail	O
substrates	O
and	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
.	O

The	O
mechanism	O
-	O
based	O
inhibition	O
potency	O
of	O
fargesin	O
against	O
human	O
liver	O
microsomal	O
CYP2C8	B
,	O
CYP2C19	B
,	O
and	O
CYP3A4	B
activities	O
was	O
evaluated	O
.	O

Aliquots	O
(	O
10	O
L	O
)	O
of	O
the	O
pre	O
-	O
incubation	O
mixtures	O
were	O
collected	O
at	O
5	O
,	O
10	O
,	O
15	O
,	O
and	O
20	O
min	O
after	O
the	O
pre	O
-	O
incubation	O
and	O
transferred	O
to	O
new	O
tubes	O
containing	O
Cytochrome	B
P450	I
substrates	O
(	O
2	O
M	O
amodiaquine	O
for	O
CYP2C8	B
,	O
100	O
M	O
[	O
S	O
]	O
-	O
mephenytoin	O
for	O
CYP2C19	B
,	O
or	O
2	O
M	O
midazolam	O
for	O
CYP3A4	B
)	O
,	O
10	O
mM	O
MgCl_2	O
,	O
1	O
mM	O
NADPH	O
,	O
and	O
50	O
mM	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
in	O
90	O
L	O
reaction	O
mixtures	O
.	O

Fargesin	O
competitively	O
inhibited	O
CYP2C9	B
-	O
catalyzed	O
diclofenac	O
4	O
-	O
hydroxylation	O
with	O
K_i	O
value	O
of	O
16	O
.	O
3	O
M	O
and	O
exhibited	O
the	O
mechanism	O
-	O
based	O
inhibition	O
of	O
CYP2C19	B
-	O
catalyzed	O
[	O
S	O
]	O
-	O
mephenytoin	O
4	O
-	O
hydroxylation	O
,	O
CYP2C8	B
-	O
catalyzed	O
amodiaquine	O
N	O
-	O
deethylation	O
,	O
and	O
CYP3A4	B
-	O
catalyzed	O
midazolam	O
1	O
-	O
hydroxylation	O
with	O
K_i	O
values	O
of	O
3	O
.	O
7	O
,	O
10	O
.	O
7	O
,	O
and	O
23	O
.	O
0	O
M	O
,	O
respectively	O
,	O
in	O
human	O
liver	O
microsomes	O
.	O

Fargesin	O
negligibly	O
inhibited	O
CYP1A2	B
,	O
CYP2A6	O
,	O
CYP2B6	B
,	O
and	O
CYP2D6	B
activities	O
at	O
100	O
M	O
.	O
Dimethyllirioresinol	O
weakly	O
inhibited	O
CYP2C19	B
and	O
CYP2C8	B
with	O
IC_50	O
values	O
of	O
55	O
.	O
1	O
and	O
85	O
.	O
0	O
M	O
,	O
respectively	O
,	O
without	O
inhibition	O
of	O
CYP1A2	B
,	O
CYP2A6	O
,	O
CYP2B6	B
,	O
CYP2C9	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
activities	O
at	O
100	O
M	O
in	O
human	O
liver	O
microsomes	O
.	O

These	O
in	O
vitro	O
results	O
suggest	O
that	O
it	O
is	O
necessary	O
to	O
investigate	O
fargesin	O
-	O
induced	O
in	O
vivo	O
drug	O
interaction	O
studies	O
via	O
the	O
inhibition	O
of	O
CYP2C8	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
and	O
CYP3A4	B
activities	O
.	O

The	O
taxane	O
paclitaxel	O
for	O
instance	O
is	O
metabolized	O
by	O
both	O
Cytochrome	B
P450	I
3a4	I
and	O
CYP2C8	B
.	O

More	O
specifically	O
,	O
the	O
V_max	O
of	O
CYP2A6	O
could	O
be	O
predicted	O
based	O
on	O
the	O
V_max	O
of	O
CYP2C19	B
,	O
the	O
V_max	O
of	O
CYP2D6	B
could	O
be	O
predicted	O
by	O
the	O
V_max	O
of	O
CYP2C9	B
,	O
the	O
V_max	O
of	O
CYP2E1	B
could	O
be	O
predicted	O
by	O
the	O
V_max	O
of	O
CYP1A2	B
,	O
the	O
V_max	O
of	O
CYP2C8	B
could	O
be	O
predicted	O
based	O
on	O
the	O
V_max	O
values	O
of	O
CYP2C9	B
and	O
2B6	O
,	O
and	O
the	O
V_max	O
values	O
of	O
CYP3A4	B
/	O
5	O
could	O
be	O
predicted	O
based	O
on	O
the	O
V_max	O
values	O
of	O
CYP2B6	B
and	O
2C19	O
.	O

For	O
CL_int	O
,	O
CYP2A6	O
could	O
be	O
predicted	O
based	O
on	O
CYP2C19	B
,	O
CYP2C8	B
could	O
be	O
predicted	O
based	O
on	O
CYP2C9	B
,	O
CYP2D6	B
could	O
be	O
predicted	O
based	O
on	O
CYP2B6	B
,	O
CYP2E1	B
could	O
be	O
predicted	O
based	O
on	O
CYP1A2	B
and	O
2C19	O
,	O
CYP3A4	B
/	O
5	O
could	O
be	O
predicted	O
based	O
on	O
CYP1A2	B
,	O
2B6	O
,	O
and	O
2C19	O
.	O

Taken	O
together	O
,	O
the	O
activity	O
of	O
CYP2A6	O
could	O
be	O
predicted	O
based	O
on	O
the	O
activity	O
of	O
CYP2C19	B
,	O
CYP2C8	B
and	O
2D6	O
could	O
be	O
predicted	O
based	O
on	O
CYP2B6	B
and	O
2C9	O
,	O
CYP2E1	B
could	O
be	O
predicted	O
based	O
on	O
CYP2C19	B
and	O
1A2	O
,	O
CYP3A4	B
/	O
5	O
could	O
be	O
predicted	O
based	O
on	O
CYP1A2	B
,	O
2B6	O
,	O
and	O
2C19	O
.	O

The	O
biggest	O
individual	O
variations	O
in	O
predicted	O
CL_int	O
took	O
place	O
in	O
the	O
CYP3A4	B
/	O
5	O
,	O
reaching	O
to	O
4	O
.	O
1	O
-	O
fold	O
,	O
followed	O
by	O
that	O
of	O
CYP2D6	B
,	O
CYP2C8	B
,	O
CYP2E1	B
,	O
and	O
CYP2A6	O
,	O
demonstrating	O
the	O
fold	O
-	O
change	O
of	O
3	O
.	O
1	O
,	O
2	O
.	O
9	O
,	O
2	O
.	O
6	O
,	O
and	O
1	O
.	O
6	O
respectively	O
.	O

Selaginellin	O
and	O
selaginellin	O
M	O
had	O
high	O
inhibitory	O
potential	O
for	O
CYP2C8	B
-	O
mediated	O
amodiaquine	O
O	O
-	O
demethylation	O
with	O
IC50	O
values	O
of	O
0	O
.	O
5	O
and	O
0	O
.	O
9	O
M	O
,	O
respectively	O
.	O

Selaginellin	O
and	O
selaginellin	O
M	O
had	O
high	O
inhibitory	O
potential	O
for	O
CYP2C8	B
-	O
mediated	O
amodiaquine	O
O	O
-	O
demethylation	O
,	O
respectively	O
,	O
indicating	O
that	O
herbal	O
drugs	O
containing	O
selaginellins	O
may	O
be	O
used	O
carefully	O
with	O
drugs	O
metabolized	O
by	O
CYP2C8	B
,	O
such	O
as	O
anti	O
-	O
cancer	O
drugs	O
(	O
paclitaxel	O
and	O
sorafenib	O
)	O
,	O
antidiabetics	O
(	O
repaglinide	O
)	O
,	O
and	O
diuretics	O
(	O
torsemide	O
)	O
in	O
order	O
to	O
avoid	O
drug	O
interactions	O
.	O

The	O
inhibitory	O
potential	O
of	O
these	O
two	O
selaginellins	O
on	O
CYP2C8	B
(	O
IC_50	O
<	O
1	O
M	O
)	O
were	O
lower	O
than	O
that	O
of	O
troglitazone	O
(	O
IC_50	O
=	O
2	O
.	O
3	O
M	O
)	O
and	O
quercetin	O
(	O
IC_50	O
=	O
7	O
.	O
2	O
M	O
)	O
.	O

Their	O
inhibitory	O
potentials	O
,	O
however	O
,	O
were	O
less	O
potent	O
than	O
montelukast	O
,	O
an	O
strong	O
CYP2C8	B
inhibitor	O
(	O
IC_50	O
=	O
0	O
.	O
019	O
M	O
)	O
.	O

CYP2C8	B
,	O
CYP2C9	B
,	O
and	O
CYP2J2	O
metabolize	O
approximately	O
4	O
.	O
7	O
,	O
12	O
.	O
8	O
,	O
and	O
3	O
%	O
of	O
clinically	O
used	O
drugs	O
(	O
n	O
=	O
248	O
)	O
,	O
respectively	O
.	O

Therefore	O
,	O
it	O
might	O
be	O
used	O
with	O
anticancer	O
or	O
antidiabetic	O
drugs	O
which	O
are	O
metabolized	O
by	O
CYP2C8	B
(	O
paclitaxel	O
)	O
,	O
CYP2C9	B
(	O
tolbutamide	O
)	O
,	O
or	O
UGT1A1	O
(	O
irinotecan	O
)	O
.	O

Phenacetin	O
O	O
-	O
deethylase	O
,	O
coumarin	O
7	O
-	O
hydroxylase	O
,	O
bupropion	O
4	O
-	O
hydroxylase	O
,	O
amodiaquine	O
N	O
-	O
deethylase	O
,	O
tolbutamide	O
4	O
-	O
hydroxylase	O
,	O
omeprazole	O
5	O
-	O
hydroxylase	O
,	O
dextromethorphan	O
O	O
-	O
demethylase	O
,	O
chlorzoxazone	O
6	O
-	O
hydroxylase	O
and	O
midazolam	O
1	O
-	O
hydroxylase	O
activities	O
were	O
determined	O
as	O
probe	O
activities	O
for	O
CYP1A2	B
,	O
CYP2A6	O
,	O
CYP2B6	B
,	O
CYP2C8	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP2E1	B
and	O
CYP3A2	O
,	O
respectively	O
,	O
using	O
substrate	O
cocktail	O
incubation	O
and	O
tandem	O
mass	O
spectrometry	O
.	O

Unfermented	O
(	O
GRT	O
)	O
and	O
fermented	O
(	O
FRE	O
)	O
rooibos	O
extracts	O
inhibited	O
the	O
activity	O
of	O
CYP2C8	B
(	O
7	O
.	O
69	O
8	O
.	O
85	O
g	O
/	O
mL	O
and	O
8	O
.	O
93	O
8	O
.	O
88	O
g	O
/	O
mL	O
,	O
respectively	O
)	O
and	O
CYP3A4	B
(	O
31	O
.	O
33	O
4	O
.	O
69	O
g	O
/	O
mL	O
and	O
51	O
.	O
44	O
4	O
.	O
31	O
g	O
/	O
mL	O
,	O
respectively	O
)	O
based	O
on	O
their	O
respective	O
IC50	O
concentrations	O
.	O

Both	O
extracts	O
dose	O
-	O
and	O
time	O
-	O
dependently	O
inhibited	O
CYP2C8	B
activity	O
,	O
but	O
only	O
time	O
-	O
dependently	O
inhibited	O
CYP2C9	B
.	O

Metformin	O
,	O
a	O
first	O
-	O
line	O
anti	O
-	O
diabetic	O
drug	O
,	O
is	O
metabolized	O
by	O
CYP2C11	O
,	O
CYP2D1	O
,	O
and	O
CYP3A1	O
/	O
2	O
,	O
while	O
glyburide	O
and	O
pioglitazone	O
,	O
other	O
known	O
hypoglycemic	O
drugs	O
,	O
are	O
metabolized	O
by	O
CYP2C9	B
,	O
CYP3A4	B
,	O
and	O
CYP2C8	B
.	O

Flavonoids	O
,	O
common	O
in	O
the	O
diet	O
,	O
are	O
responsible	O
for	O
the	O
modulation	O
of	O
the	O
clinically	O
relevant	O
CYP2C8	B
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
enzymes	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
,	O
therefore	O
,	O
to	O
investigate	O
the	O
inhibitory	O
effects	O
of	O
polyphenol	O
-	O
enriched	O
unfermented	O
rooibos	O
extract	O
(	O
GRT	O
)	O
,	O
and	O
fermented	O
rooibos	O
extract	O
(	O
FRE	O
)	O
,	O
(	O
Z	O
-	O
2	O
-	O
(	O
BETA	O
-	O
d	O
-	O
glucopyranosyloxy	O
)	O
-	O
3	O
-	O
phenylpropenoic	O
acid	O
(	O
PPAG	O
)	O
and	O
aspalathin	O
(	O
ASP	O
)	O
on	O
Vivid	O
^	O
recombinant	O
CYP450	O
enzymes	O
CYP2C8	B
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
.	O

Qualitative	O
screening	O
of	O
extracts	O
and	O
compounds	O
was	O
used	O
to	O
identify	O
potential	O
inhibitory	O
effects	O
on	O
CYP2C8	B
,	O
CYP2C9	B
and	O
CYP3A4	B
.	O

Quercetin	O
,	O
sulfaphenazole	O
,	O
and	O
ketoconazole	O
were	O
the	O
selected	O
positive	O
inhibitors	O
for	O
CYP2C8	B
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
,	O
respectively	O
.	O

GRT	O
and	O
FRE	O
inhibited	O
the	O
reaction	O
rate	O
of	O
CYP2C8	B
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
as	O
measured	O
over	O
30	O
min	O
(	O
a	O
-	O
c	O
)	O
.	O

GRT	O
and	O
FRE	O
showed	O
strong	O
inhibition	O
of	O
CYP2C8	B
activity	O
(	O
7	O
.	O
69	O
8	O
.	O
85	O
g	O
/	O
mL	O
and	O
8	O
.	O
93	O
8	O
.	O
88	O
g	O
/	O
mL	O
,	O
respectively	O
)	O
(	O
a	O
)	O
.	O

GRT	O
and	O
FRE	O
reduced	O
the	O
remaining	O
CYP2C8	B
activity	O
in	O
a	O
moderate	O
to	O
strong	O
concentration	O
-	O
dependent	O
manner	O
from	O
25	O
g	O
/	O
mL	O
(	O
70	O
.	O
1	O
%	O
and	O
82	O
.	O
1	O
%	O
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
50	O
g	O
/	O
mL	O
(	O
31	O
%	O
and	O
39	O
.	O
7	O
%	O
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
100	O
g	O
/	O
mL	O
(	O
15	O
.	O
9	O
%	O
and	O
18	O
.	O
1	O
%	O
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
(	O
a	O
)	O
.	O

ASP	O
significantly	O
inhibited	O
CYP2C8	B
activity	O
,	O
albeit	O
that	O
the	O
percentage	O
remaining	O
activity	O
at	O
50	O
and	O
100	O
g	O
/	O
mL	O
was	O
still	O
at	O
84	O
.	O
4	O
%	O
and	O
85	O
.	O
5	O
%	O
,	O
respectively	O
.	O

Both	O
GRT	O
and	O
FRE	O
showed	O
time	O
-	O
dependent	O
inhibition	O
of	O
CYP2C8	B
activity	O
(	O
a	O
)	O
.	O

Therefore	O
,	O
in	O
the	O
current	O
study	O
,	O
we	O
screened	O
for	O
the	O
inhibitory	O
potential	O
of	O
the	O
extracts	O
and	O
compounds	O
using	O
co	O
-	O
incubation	O
(	O
reversible	O
inhibition	O
)	O
and	O
pre	O
-	O
incubation	O
(	O
time	O
-	O
dependent	O
inhibition	O
)	O
with	O
CYP2C8	B
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
Vivid	O
^	O
@	O
recombinant	O
enzymes	O
.	O

Plant	O
extracts	O
containing	O
high	O
levels	O
of	O
polyphenols	O
are	O
expected	O
to	O
have	O
inhibitory	O
effects	O
on	O
various	O
CYPs	O
including	O
CYP2C8	B
,	O
CYP2C9	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
.	O

A	O
strong	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
inhibition	O
of	O
CYP2C8	B
activity	O
was	O
observed	O
for	O
both	O
GRT	O
and	O
FRE	O
.	O

However	O
,	O
ASP	O
and	O
PPAG	O
had	O
no	O
effect	O
on	O
CYP2C8	B
.	O

This	O
study	O
demonstrates	O
that	O
GRT	O
and	O
FRE	O
inhibited	O
CYP2C8	B
and	O
CYP3A4	B
activity	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
,	O
whilst	O
inhibiting	O
CYP2C9	B
activity	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
only	O
.	O

Vivid	O
^	O
CYP2C8	B
Green	O
Screening	O
Kit	O
with	O
Vivid	O
^	O
substrate	O
,	O
di	O
-	O
[	O
benzyl	O
-	O
O	O
-	O
methyl	O
]	O
-	O
fluorescein	O
(	O
DBOMF	O
)	O
and	O
Vivid	O
^	O
CYP3A4	B
and	O
CYP2C9	B
Blue	O
Screening	O
Kits	O
with	O
Vivid	O
^	O
substrate	O
,	O
7	O
-	O
benzyl	O
-	O
oxymethyloxy	O
-	O
3	O
-	O
cyanocoumarin	O
(	O
BOMCC	O
)	O
were	O
purchased	O
from	O
Life	O
Technologies	O
^	O
(	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
effect	O
of	O
organic	O
solvents	O
such	O
as	O
methanol	O
,	O
acetonitrile	O
and	O
DMSO	O
on	O
Vivid	O
^	O
recombinant	O
CYP2C8	B
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
assays	O
was	O
determined	O
.	O

A	O
mixture	O
containing	O
0	O
.	O
1	O
%	O
of	O
organic	O
solvent	O
,	O
reaction	O
buffer	O
(	O
200	O
mM	O
potassium	O
phosphate	O
(	O
reaction	O
buffer	O
I	O
)	O
or	O
100	O
mM	O
potassium	O
phosphate	O
(	O
reaction	O
buffer	O
II	O
)	O
)	O
and	O
regeneration	O
system	O
(	O
333	O
mM	O
glucose	O
-	O
6	O
-	O
phosphate	O
and	O
30	O
U	O
/	O
mL	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
in	O
100	O
mM	O
potassium	O
phosphate	O
,	O
pH	O
8	O
.	O
0	O
)	O
solution	O
with	O
the	O
addition	O
of	O
each	O
enzyme	O
(	O
CYP2C8	B
,	O
CYP2C9	B
,	O
or	O
CYP3A4	B
)	O
was	O
prepared	O
.	O

Compounds	O
,	O
PPAG	O
and	O
ASP	O
,	O
and	O
the	O
rooibos	O
extracts	O
,	O
GRT	O
and	O
FRE	O
,	O
were	O
screened	O
for	O
their	O
inhibitory	O
effects	O
on	O
CYP2C8	B
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
using	O
one	O
-	O
point	O
screening	O
kinetics	O
.	O

Briefly	O
,	O
inhibitors	O
,	O
extracts	O
,	O
and	O
compounds	O
were	O
pre	O
-	O
incubated	O
with	O
either	O
CYP2C8	B
or	O
CYP2C9	B
at	O
a	O
concentration	O
of	O
100	O
g	O
/	O
mL	O
,	O
or	O
CYP3A4	B
at	O
a	O
concentration	O
of	O
200	O
g	O
/	O
mL	O
.	O

As	O
per	O
the	O
manufacturers	O
instruction	O
,	O
50	O
L	O
of	O
Vivid	O
^	O
Master	O
Pre	O
-	O
Mix	O
(	O
BACULOSOMES	O
^	O
enzymes	O
(	O
CYP2C8	B
,	O
CYP2C9	B
or	O
CYP3A4	B
)	O
,	O
regeneration	O
system	O
,	O
reaction	O
buffer	O
(	O
I	O
/	O
II	O
)	O
,	O
and	O
NADP	O
^	O
+	O
)	O
was	O
added	O
to	O
each	O
well	O
.	O

After	O
incubation	O
,	O
10	O
L	O
reconstituted	O
DBOMF	O
(	O
CYP2C8	B
)	O
or	O
BOMCC	O
(	O
CYP2C9	B
and	O
CYP3A4	B
)	O
and	O
NADP	O
^	O
+	O
in	O
Vivid	O
^	O
reaction	O
buffer	O
I	O
/	O
II	O
were	O
added	O
to	O
each	O
well	O
and	O
incubated	O
for	O
30	O
min	O
at	O
37	O
C	O
.	O
Fluorescence	O
was	O
measured	O
on	O
a	O
SpectraMax	O
i3	O
plate	O
reader	O
at	O
5	O
min	O
intervals	O
to	O
determine	O
reaction	O
kinetics	O
.	O

Enzyme	O
activity	O
was	O
measured	O
by	O
formation	O
of	O
the	O
metabolites	O
at	O
excitation	O
and	O
emission	O
wavelengths	O
of	O
485	O
/	O
530	O
nm	O
(	O
CYP2C8	B
)	O
and	O
406	O
/	O
460	O
nm	O
(	O
CYP2C9	B
and	O
CYP3A4	B
)	O
,	O
respectively	O
.	O

A	O
three	O
-	O
fold	O
serial	O
dilution	O
of	O
PPAG	O
,	O
ASP	O
,	O
GRT	O
,	O
and	O
FRE	O
was	O
added	O
to	O
CYP2C8	B
and	O
CYP2C9	B
(	O
concentration	O
range	O
100	O
-	O
0	O
.	O
41	O
g	O
/	O
mL	O
)	O
and	O
CYP3A4	B
(	O
concentration	O
range	O
200	O
-	O
0	O
.	O
82	O
g	O
/	O
mL	O
)	O
to	O
determine	O
their	O
respective	O
IC_50	O
concentrations	O
.	O

CYP2C8	B
,	O
CYP2C9	B
,	O
or	O
CYP3A4	B
BACULOSOMES	O
^	O
plus	O
reagent	O
and	O
regeneration	O
system	O
in	O
Vivid	O
^	O
reaction	O
buffer	O
I	O
/	O
II	O
added	O
to	O
a	O
black	O
Costar	O
96	O
-	O
well	O
plate	O
containing	O
test	O
extracts	O
and	O
compounds	O
were	O
incubated	O
for	O
15	O
min	O
at	O
37	O
C	O
.	O
Thereafter	O
,	O
as	O
previously	O
described	O
,	O
the	O
reaction	O
was	O
initiated	O
by	O
adding	O
a	O
mixture	O
of	O
reconstituted	O
DBOMF	O
(	O
CYP2C8	B
)	O
or	O
BOMCC	O
(	O
CYP2C9	B
and	O
CYP3A4	B
)	O
and	O
NADP	O
^	O
+	O
in	O
Vivid	O
^	O
reaction	O
buffer	O
I	O
/	O
II	O
and	O
incubated	O
for	O
30	O
min	O
at	O
37	O
C	O
.	O
After	O
addition	O
of	O
the	O
stop	O
solution	O
to	O
terminate	O
the	O
reaction	O
,	O
fluorescence	O
was	O
determined	O
at	O
the	O
relative	O
excitation	O
/	O
emission	O
wavelengths	O
described	O
in	O
.	O

Time	O
-	O
dependent	O
inhibition	O
(	O
TDI	O
)	O
using	O
the	O
respective	O
serial	O
dilutions	O
employed	O
for	O
IC_50	O
determination	O
(	O
CYP2C8	B
and	O
CYP2C9	B
;	O
100	O
-	O
0	O
.	O
41	O
g	O
/	O
mL	O
and	O
for	O
CYP3A4	B
;	O
200	O
-	O
0	O
.	O
82	O
g	O
/	O
mL	O
)	O
was	O
performed	O
.	O

The	O
extracts	O
and	O
compounds	O
were	O
pre	O
-	O
incubated	O
with	O
CYP2C8	B
,	O
CYP2C9	B
,	O
or	O
CYP3A4	B
BACULOSOMES	O
^	O
and	O
NADPH	O
for	O
30	O
min	O
.	O

Inhibition	O
of	O
CYP2C8	B
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
BACULOSOMES	O
^	O
was	O
quantified	O
,	O
as	O
described	O
in	O
.	O

The	O
data	O
generated	O
were	O
exported	O
to	O
an	O
Excel	O
(	O
Microsoft	O
Headquarters	O
,	O
One	O
Microsoft	O
Way	O
,	O
Redmond	O
,	O
WA	O
,	O
USA	O
)	O
worksheet	O
and	O
the	O
amount	O
of	O
metabolite	O
formed	O
at	O
various	O
concentrations	O
relative	O
to	O
the	O
control	O
was	O
calculated	O
using	O
the	O
following	O
equation	O
:	O
The	O
relative	O
percentage	O
activity	O
was	O
plotted	O
against	O
the	O
log	O
transformed	O
concentrations	O
of	O
the	O
extracts	O
,	O
compounds	O
and	O
positive	O
controls	O
,	O
ie	O
quercetin	O
(	O
positive	O
CYP2C8	B
inhibitor	O
)	O
,	O
sulfaphenazole	O
(	O
positive	O
CYP2C9	B
inhibitor	O
)	O
,	O
and	O
ketoconazole	O
(	O
positive	O
CYP3A4	B
inhibitor	O
)	O
.	O

This	O
in	O
vitro	O
study	O
indicated	O
that	O
combining	O
nutraceuticals	O
containing	O
rooibos	O
extracts	O
with	O
drugs	O
metabolized	O
by	O
CYP2C8	B
and	O
CYP3A4	B
could	O
potentially	O
alter	O
the	O
pharmacodynamics	O
and	O
safety	O
of	O
these	O
drugs	O
.	O

456255	O
)	O
,	O
CYP2C8	B
(	O
Lot	O
No	O
.	O

Flucloxacillin	O
was	O
incubated	O
at	O
substrate	O
concentrations	O
of	O
10	O
and	O
100	O
M	O
with	O
0	O
.	O
5	O
mgmL	O
^	O
1	O
HLM	O
,	O
as	O
described	O
above	O
,	O
and	O
in	O
the	O
absence	O
or	O
presence	O
of	O
the	O
following	O
inhibitors	O
:	O
10	O
M	O
ALPHAnaphtoflavone	O
(	O
CYP1A2	B
)	O
,	O
3	O
M	O
ticlopidine	O
(	O
CYP2B6	B
)	O
,	O
15	O
M	O
quercetin	O
(	O
CYP2C8	B
)	O
,	O
10	O
M	O
sulfaphenazole	O
(	O
CYP2C9	B
)	O
,	O
10	O
M	O
fluvoxamine	O
(	O
CYP2C9	B
/	O
CYP1A2	B
)	O
,	O
1	O
M	O
(	O
+	O
)	O
N3benzylnirvanol	O
(	O
CYP2C19	B
)	O
,	O
2	O
M	O
quinidine	O
(	O
CYP2D6	B
)	O
,	O
20	O
M	O
diethylthiocarbamate	O
(	O
CYP2E1	B
)	O
,	O
3	O
M	O
troleandomycin	O
(	O
CYP3A4	O
)	O
;	O
2	O
M	O
miconazole	O
(	O
CYP3A4	O
/	O
CYP2C9	B
)	O
and	O
0	O
.	O
1	O
M	O
(	O
CYP3A4	O
)	O
and	O
1	O
M	O
(	O
CYP3A	B
)	O
ketoconazole	O
respectively	O
.	O

To	O
determine	O
the	O
variability	O
of	O
5hydroxylation	O
of	O
flucloxacillin	O
,	O
the	O
substrate	O
was	O
incubated	O
(	O
10	O
and	O
100	O
M	O
)	O
with	O
a	O
panel	O
of	O
individual	O
HLM	O
fractions	O
from	O
16	O
donors	O
(	O
0	O
.	O
5	O
mgmL	O
^	O
1	O
)	O
which	O
were	O
phenotyped	O
with	O
respect	O
to	O
activities	O
of	O
CYP1A2	B
(	O
phenacetin	O
Odeethylation	O
)	O
,	O
CYP2A6	O
(	O
coumarin	O
7hydroxylation	O
)	O
,	O
CYP2B6	B
(	O
bupropion	O
hydroxylation	O
)	O
,	O
CYP2C8	B
(	O
amodiaquine	O
Ndeethylation	O
)	O
,	O
CYP2C9	B
(	O
diclofenac	O
4hydroxylation	O
)	O
,	O
CYP2C19	B
(	O
mephenytoin	O
4hydroxylation	O
)	O
,	O
CYP2D6	B
(	O
bufuralol	O
1hydroxylation	O
)	O
,	O
CYP2E1	B
(	O
chlorzoxazone	O
6hydroxylation	O
)	O
and	O
CYP3A4	O
(	O
midazolam	O
1hydroxylation	O
and	O
testosterone	O
6BETAhydroxylation	O
)	O
using	O
the	O
concentrations	O
described	O
previously	O
(	O
den	O
BraverSewradj	O
et	O
al	O
.	O
,	O
.	O

Low	O
activities	O
of	O
5HMFLX	O
formation	O
were	O
observed	O
,	O
in	O
decreasing	O
order	O
,	O
in	O
incubations	O
with	O
CYP2C9	B
,	O
CYP2J2	O
,	O
CYP2C8	B
,	O
CYP2E1	B
,	O
CYP3A5	B
,	O
CYP1A1	B
,	O
CYP2D6	B
and	O
CYP1A2	B
.	O

At	O
100	O
M	O
flucloxacillin	O
,	O
low	O
activities	O
were	O
also	O
observed	O
with	O
CYP1A1	B
,	O
CYP1A2	B
,	O
CYP2C8	B
,	O
CYP2E1	B
,	O
CYP2J2	O
and	O
CYP3A5	B
.	O

Significant	O
reduction	O
in	O
CYP2C8	B
,	O
2C9	O
,	O
and	O
3A4	O
was	O
seen	O
upon	O
concomitant	O
use	O
of	O
warfarin	O
with	O
ellagic	O
acid	O
,	O
guava	O
leaves	O
and	O
quercetin	O
,	O
unlike	O
pomegranate	O
that	O
insignificantly	O
affected	O
Cytochrome	B
P450	I
Enzymes	O
activities	O
.	O

Combination	O
of	O
ellagic	O
acid	O
with	O
warfarin	O
significantly	O
inhibited	O
activities	O
of	O
CYP2C8	B
,	O
2C9	O
and	O
3A4	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
however	O
treatment	O
of	O
cells	O
with	O
ellagic	O
acid	O
alone	O
presented	O
significant	O
inhibition	O
on	O
CYP2C9	O
activity	O
despite	O
other	O
CYPs	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Although	O
guava	O
leaves	O
extract	O
showed	O
an	O
insignificant	O
effect	O
on	O
CYP2C8	B
when	O
used	O
alone	O
,	O
it	O
significantly	O
reduced	O
its	O
activity	O
when	O
combined	O
with	O
warfarin	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
however	O
,	O
inhibited	O
the	O
activities	O
of	O
CYP2C9	O
and	O
3A4	O
when	O
used	O
alone	O
and	O
concomitantly	O
with	O
warfarin	O
(	O
p	O
-	O
values	O
are	O
marked	O
in	O
Figs	O
.	O

We	O
genotyped	O
119	O
SNPs	O
in	O
ABCB1	O
,	O
ABCC2	O
,	O
CYP1A1	B
,	O
CYP1A2	B
,	O
CYP1B1	O
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP2E1	B
,	O
CYP3A4	B
,	O
and	O
CYP3A5	B
genes	O
.	O

Similarly	O
,	O
SNPs	O
in	O
CYP2C9	B
(	O
rs1799853	O
and	O
rs1057910	O
)	O
have	O
been	O
associated	O
with	O
PHT	O
dose	O
requirement	O
,	O
and	O
SNPs	O
in	O
CYP2C19	B
(	O
rs12248560	O
)	O
and	O
CYP2D6	B
have	O
been	O
considered	O
pharmacogenomic	O
biomarkers	O
for	O
neurologic	O
and	O
psychiatric	O
therapeutic	O
drugs	O
,	O
including	O
clobazam	O
(	O
CLB	O
)	O
and	O
diazepam	O
,	O
receiving	O
approval	O
for	O
use	O
by	O
the	O
U	O
.	O
S	O
.	O

In	O
this	O
context	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
SNPs	O
in	O
the	O
following	O
genes	O
-	O
ABCB1	O
,	O
ABCC2	O
,	O
CYP1A1	B
,	O
CYP1A2	B
,	O
CYP1B1	O
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP2E1	B
,	O
CYP3A4	B
,	O
and	O
CYP3A5	B
-	O
could	O
improve	O
the	O
accuracy	O
of	O
predicting	O
poor	O
response	O
to	O
AED	O
therapy	O
in	O
patients	O
with	O
MTLE	O
.	O

In	O
addition	O
,	O
LD	O
was	O
observed	O
between	O
rs2153628	O
and	O
rs9332168	O
(	O
r	O
^	O
2	O
=	O
0	O
.	O
88	O
)	O
in	O
the	O
CYP2C9	B
gene	O
,	O
and	O
between	O
rs11597626	O
and	O
rs12268020	O
(	O
r	O
^	O
2	O
=	O
0	O
.	O
84	O
)	O
in	O
CYP2C19	B
in	O
the	O
remaining	O
SNP	O
set	O
.	O

In	O
addition	O
,	O
the	O
most	O
important	O
variables	O
in	O
the	O
prediction	O
model	O
include	O
SNPs	O
in	O
ABCC2	O
,	O
CYP1A2	B
,	O
CYP1B1	O
,	O
CYP2E1	B
,	O
CYP3A4	B
,	O
and	O
CYP3A5	B
,	O
as	O
well	O
as	O
CYP2C9	B
and	O
CYP2C19	B
,	O
both	O
of	O
which	O
have	O
been	O
previously	O
proposed	O
as	O
pharmacogenetic	O
biomarkers	O
.	O

However	O
,	O
SNPs	O
in	O
CYP2C9	B
and	O
CYP2D6	B
present	O
an	O
average	O
MAF	O
=	O
0	O
.	O
06	O
,	O
significantly	O
limiting	O
their	O
use	O
in	O
clinical	O
practice	O
,	O
since	O
they	O
can	O
only	O
be	O
detected	O
in	O
a	O
small	O
fraction	O
of	O
the	O
population	O
.	O

in	O
their	O
study	O
,	O
showed	O
the	O
inhibitory	O
effects	O
of	O
polyphenols	O
on	O
human	O
CYP3A4	B
and	O
CYP2C9	B
activity	O
in	O
vitro	O
which	O
inhibitory	O
actions	O
were	O
reported	O
by	O
the	O
authors	O
to	O
involve	O
the	O
formation	O
of	O
a	O
covalent	O
bond	O
between	O
the	O
polyphenol	O
and	O
the	O
CYP3A4	B
molecule	O
,	O
leading	O
to	O
the	O
inactivation	O
of	O
the	O
enzyme	O
,	O
or	O
reversible	O
binding	O
that	O
causes	O
reversible	O
inhibition	O
.	O

Fargesin	O
exhibited	O
competitive	O
inhibition	O
of	O
CYP2C9	B
-	O
catalyzed	O
diclofenac	O
4	O
-	O
hydroxylation	O
with	O
a	O
K_i	O
value	O
of	O
16	O
.	O
3	O
M	O
(	O
,	O
.	O

Fargesin	O
exhibited	O
competitive	O
inhibition	O
of	O
CYP2C9	B
-	O
catalyzed	O
diclofenac	O
4	O
-	O
hydroxylation	O
(	O
K_i	O
,	O
16	O
.	O
3	O
M	O
)	O
,	O
but	O
aschantin	O
showed	O
mechanism	O
-	O
based	O
inhibition	O
of	O
CYP2C9	B
(	O
K_i	O
,	O
3	O
.	O
7	O
M	O
;	O
k_inact	O
,	O
0	O
.	O
044	O
min	O
^	O
1	O
)	O
.	O

Other	O
pharmacologically	O
active	O
lignans	O
such	O
as	O
honokiol	O
,	O
deoxypodophyllotoxin	O
,	O
and	O
podophyllotoxin	O
potently	O
inhibited	O
CYP2C9	B
activity	O
with	O
K_i	O
values	O
of	O
0	O
.	O
54	O
,	O
3	O
.	O
5	O
,	O
and	O
2	O
.	O
0	O
M	O
,	O
respectively	O
.	O

To	O
determine	O
the	O
K_i	O
values	O
and	O
inhibition	O
mode	O
of	O
fargesin	O
for	O
CYP2C9	B
,	O
various	O
concentrations	O
of	O
fargesin	O
(	O
0	O
-	O
16	O
M	O
)	O
and	O
diclofenac	O
(	O
2	O
-	O
20	O
M	O
)	O
were	O
incubated	O
with	O
human	O
liver	O
microsomes	O
(	O
0	O
.	O
1	O
mg	O
/	O
mL	O
)	O
,	O
10	O
mM	O
MgCl_2	O
,	O
1	O
mM	O
NADPH	O
,	O
50	O
mM	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
in	O
a	O
total	O
volume	O
of	O
100	O
L	O
for	O
10	O
min	O
at	O
37	O
C	O
.	O
The	O
reaction	O
was	O
stopped	O
by	O
adding	O
100	O
L	O
of	O
ice	O
-	O
cold	O
d_9	O
-	O
1	O
-	O
hydroxybufuralol	O
in	O
methanol	O
(	O
10	O
ng	O
/	O
mL	O
)	O
,	O
and	O
the	O
mixtures	O
were	O
centrifuged	O
at	O
13	O
,	O
000	O
g	O
for	O
4	O
min	O
.	O

Furanocoumarins	O
inhibit	O
several	O
CYP450	O
(	O
CYP3A4	B
,	O
CYP1A2	B
,	O
CYP1B1	O
,	O
CYP2C9	B
,	O
CYP2C19	B
and	O
CYP2D6	B
)	O
,	O
,	O
but	O
other	O
CYP450	O
are	O
involved	O
in	O
common	O
drug	O
metabolism	O
.	O

The	O
complex	O
metabolism	O
of	O
tamoxifen	O
,	O
which	O
include	O
catalytic	O
activity	O
of	O
CYP2C19	B
,	O
CYP1A2	B
,	O
CYP3A4	B
/	O
5	O
,	O
CYP2D6	B
,	O
CYP2B6	B
and	O
CYP2C9	B
,	O
may	O
explain	O
the	O
null	O
-	O
association	O
found	O
in	O
this	O
study	O
.	O

cDNA	O
of	O
four	O
CYPs	O
expressed	O
in	O
human	O
hepatocytes	O
(	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP3A4	B
)	O
and	O
Cytochrome	B
P450	I
oxidoreductase	O
(	O
POR	O
)	O
were	O
obtained	O
as	O
artificial	O
synthetic	O
genes	O
(	O
Invitrogen	O
)	O
.	O

Next	O
,	O
the	O
HS4	O
-	O
CAG	O
-	O
CYP2C9	B
plasmid	O
was	O
digested	O
with	O
NheI	O
/	O
AscI	O
site	O
and	O
ligated	O
with	O
the	O
HS4	O
-	O
CAG	O
-	O
CYP2C19	B
,	O
which	O
was	O
digested	O
with	O
AscI	O
/	O
AvrII	O
,	O
for	O
the	O
construction	O
of	O
HS4	O
-	O
CAG	O
-	O
CYP2C19	B
-	O
HS4	O
-	O
CAG	O
-	O
CYP2C9	B
plasmid	O
.	O

Then	O
,	O
the	O
HS4	O
-	O
CAG	O
-	O
CYP2C19	B
-	O
HS4	O
-	O
CAG	O
-	O
CYP2C9	B
and	O
the	O
HS4	O
-	O
CAG	O
-	O
CYP3A4	B
-	O
HS4	O
-	O
CAG	O
-	O
CYP2D6	B
plasmids	O
were	O
digested	O
with	O
AscI	O
/	O
AvrII	O
and	O
ligated	O
in	O
sequence	O
to	O
the	O
HS4	O
-	O
HPRT	O
-	O
loxP	O
-	O
PAC	O
vector	O
,	O
which	O
was	O
digested	O
with	O
NheI	O
/	O
AscI	O
,	O
for	O
the	O
construction	O
of	O
the	O
P1	O
-	O
Derived	O
Artificial	O
Chromosome	O
vector	O
containing	O
all	O
four	O
CYPs	O
.	O

Analysis	O
by	O
RT	O
-	O
qPCR	O
confirmed	O
the	O
expression	O
of	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP3A4	B
,	O
and	O
POR	O
,	O
and	O
representative	O
three	O
clones	O
were	O
selected	O
.	O

Genomic	O
PCR	O
determined	O
that	O
all	O
of	O
these	O
clones	O
expressed	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP3A4	B
,	O
and	O
POR	O
genes	O
.	O

The	O
inhibitors	O
used	O
in	O
these	O
experiments	O
included	O
CYP3A4	B
inhibitors	O
ethinylestradiol	O
,	O
ritonavir	O
,	O
mifepristone	O
,	O
erythromycin	O
,	O
clarithromycin	O
,	O
and	O
roxithromycin	O
;	O
CYP2C9	B
inhibitor	O
tienilic	O
acid	O
;	O
CYP2C19	B
inhibitor	O
ticlopidine	O
;	O
and	O
CYP2D6	B
inhibitor	O
paroxetine	O
.	O

Between	O
the	O
WGS	O
and	O
targeted	O
genotyping	O
data	O
sets	O
,	O
there	O
were	O
six	O
discordant	O
genotypes	O
in	O
three	O
genes	O
(	O
one	O
in	O
CYP2C9	B
,	O
one	O
in	O
HLA	O
-	O
A	O
and	O
four	O
in	O
IFNL3	O
)	O
limited	O
a	O
complete	O
comparison	O
of	O
these	O
platforms	O
.	O

Overall	O
,	O
six	O
discordant	O
genotype	O
calls	O
(	O
both	O
false	O
positive	O
and	O
false	O
negative	O
)	O
were	O
observed	O
between	O
WGS	O
(	O
Complete	O
Genomics	O
)	O
and	O
our	O
targeted	O
genotyping	O
panel	O
in	O
three	O
different	O
genes	O
(	O
CYP2C9	B
,	O
HLA	O
-	O
A	O
,	O
and	O
IFNL3	O
)	O
,	O
which	O
are	O
currently	O
being	O
investigated	O
,	O
we	O
were	O
able	O
to	O
manually	O
inspect	O
the	O
ratios	O
of	O
reference	O
and	O
alternate	O
allele	O
reads	O
at	O
informative	O
positions	O
in	O
the	O
whole	O
-	O
genome	O
data	O
to	O
deduce	O
the	O
duplicated	O
allele	O
.	O

^	O
We	O
used	O
the	O
Human	O
Cytochrome	B
P450	I
Allele	O
Nomenclature	O
Database	O
^	O
to	O
define	O
variant	O
alleles	O
in	O
CYP2D6	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
and	O
CYP3A5	B
genes	O
and	O
their	O
effect	O
on	O
their	O
respective	O
CYP	O
protein	O
.	O

Noncompetitive	O
inhibition	O
of	O
human	O
CYP2C9	B
in	O
vitro	O
by	O
a	O
commercial	O
Rhodiola	O
rosea	O
product	O
.	O

A	O
commercial	O
Rhodiola	O
rosea	O
(	O
R	O
.	O
rosea	O
)	O
product	O
has	O
previously	O
demonstrated	O
CYP2C9	B
inhibition	O
in	O
humans	O
.	O

Another	O
aim	O
was	O
to	O
examine	O
the	O
in	O
vitro	O
influence	O
of	O
ethanol	O
on	O
the	O
CYP2C9	B
activity	O
.	O

Human	O
CYP2C9	B
(	O
wild	O
type	O
)	O
isolated	O
from	O
a	O
baculovirusinfected	O
cell	O
system	O
was	O
incubated	O
with	O
0	O
.	O
8	O
mol	O
/	O
L	O
losartan	O
for	O
20	O
min	O
.	O

Formation	O
of	O
the	O
CYP2C9produced	O
losartan	O
metabolite	O
EXP3174	O
was	O
determined	O
by	O
validated	O
LCMS	O
/	O
MS	O
methodology	O
.	O

CYP2C9	B
was	O
inhibited	O
by	O
Arctic	O
Root	O
with	O
an	O
IC	O
50	O
(	O
extract	O
concentration	O
yielding	O
50	O
%	O
reduction	O
in	O
enzyme	O
activity	O
)	O
of	O
19	O
.	O
2	O
2	O
.	O
7	O
g	O
/	O
mL	O
.	O

The	O
presence	O
of	O
ethanol	O
inhibited	O
CYP2C9	B
activity	O
in	O
a	O
concentrationdependent	O
manner	O
.	O

In	O
conclusion	O
,	O
the	O
commercial	O
R	O
.	O
rosea	O
product	O
Arctic	O
Root	O
demonstrated	O
noncompetitive	O
inhibition	O
of	O
CYP2C9	B
in	O
vitro	O
.	O

CYP2C9	B
metabolizes	O
more	O
than	O
20	O
%	O
of	O
all	O
therapeutic	O
drugs	O
,	O
including	O
drugs	O
with	O
a	O
narrow	O
therapeutic	O
index	O
,	O
such	O
as	O
phenytoin	O
and	O
warfarin	O
(	O
Miners	O
and	O
Birkett	O
;	O
Danielson	O
;	O
Niwa	O
and	O
Yamazaki	O
.	O

Inhibition	O
of	O
CYP2C9	B
activity	O
has	O
been	O
shown	O
clinically	O
relevant	O
for	O
numerous	O
drug	O
inhibitors	O
like	O
amiodarone	O
,	O
trimethoprim	O
,	O
and	O
sulfaphenazole	O
(	O
Miners	O
and	O
Birkett	O
.	O

Inhibition	O
studies	O
by	O
these	O
drugs	O
,	O
and	O
also	O
by	O
herbal	O
supplement	O
extracts	O
,	O
have	O
shown	O
that	O
CYP2C9	B
can	O
be	O
subject	O
to	O
different	O
types	O
of	O
inhibition	O
,	O
including	O
competitive	O
inhibition	O
(	O
St	O
.	O

evaluated	O
the	O
influence	O
of	O
50	O
mg	O
/	O
kg	O
R	O
.	O
rosea	O
extracts	O
on	O
CYP2C9	B
metabolism	O
of	O
warfarin	O
in	O
rats	O
.	O

This	O
result	O
was	O
opposed	O
by	O
Spanakis	O
et	O
al	O
.	O
,	O
who	O
found	O
an	O
almost	O
twofold	O
increase	O
in	O
Area	O
Under	O
The	O
Curve	O
of	O
the	O
CYP2C9	B
substrate	O
losartan	O
after	O
a	O
50	O
mg	O
/	O
kg	O
concurrent	O
administration	O
of	O
a	O
commercial	O
R	O
.	O
rosea	O
extract	O
to	O
six	O
rabbits	O
in	O
a	O
twoway	O
crossover	O
study	O
,	O
concluding	O
that	O
R	O
.	O
rosea	O
could	O
be	O
categorized	O
as	O
a	O
moderate	O
in	O
vivo	O
inhibitor	O
and	O
that	O
a	O
study	O
in	O
humans	O
was	O
needed	O
.	O

Recently	O
,	O
our	O
group	O
published	O
a	O
study	O
evaluating	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
interaction	O
in	O
man	O
by	O
a	O
commercially	O
available	O
R	O
.	O
rosea	O
product	O
similar	O
to	O
that	O
used	O
by	O
Spanakis	O
et	O
al	O
.	O

In	O
this	O
study	O
,	O
using	O
a	O
twophase	O
,	O
randomized	O
crossover	O
cocktail	O
study	O
in	O
13	O
males	O
,	O
we	O
found	O
a	O
21	O
%	O
reduction	O
in	O
the	O
EXP3174	O
/	O
losartan	O
ratio	O
,	O
indicating	O
a	O
significant	O
inhibition	O
of	O
CYP2C9	B
enzyme	O
activity	O
(	O
Thu	O
et	O
al	O
.	O
.	O
For	O
herbal	O
products	O
with	O
identified	O
bioactive	O
constituents	O
,	O
in	O
vitro	O
studies	O
are	O
usually	O
performed	O
with	O
isolated	O
constituents	O
only	O
,	O
yielding	O
specific	O
data	O
,	O
which	O
can	O
be	O
extrapolated	O
to	O
herbal	O
products	O
with	O
similar	O
constituent	O
concentration	O
.	O

Given	O
the	O
previous	O
studies	O
,	O
where	O
Arctic	O
Root	O
was	O
found	O
to	O
be	O
the	O
most	O
potent	O
in	O
vitro	O
inhibitor	O
among	O
a	O
selection	O
of	O
commercially	O
available	O
R	O
.	O
rosea	O
products	O
and	O
also	O
was	O
displaying	O
CYP2C9	B
inhibition	O
in	O
humans	O
,	O
this	O
study	O
was	O
undertaken	O
with	O
the	O
aim	O
to	O
provide	O
CYP2C9	B
in	O
vitro	O
inhibition	O
data	O
,	O
including	O
the	O
classification	O
of	O
the	O
type	O
of	O
inhibition	O
,	O
using	O
this	O
particular	O
R	O
.	O
rosea	O
product	O
.	O

Baculovirus	O
expressed	O
human	O
wildtype	O
CYP2C9	B
*	O
1	O
(	O
cat	O
.	O

The	O
CYP2C9	B
*	O
1	O
enzyme	O
preparation	O
used	O
was	O
a	O
recombinant	O
cDNAexpressed	O
wildtype	O
CYP2C9	B
*	O
1	O
prepared	O
from	O
a	O
baculovirusinfected	O
insect	O
cell	O
system	O
.	O

CYP2C9	B
*	O
1	O
content	O
was	O
278	O
pmol	O
/	O
mg	O
protein	O
.	O

CYP2C9	B
(	O
12	O
.	O
5	O
nmol	O
/	O
L	O
)	O
was	O
incubated	O
in	O
conical	O
glass	O
tubes	O
in	O
a	O
shaking	O
water	O
bath	O
for	O
15	O
min	O
at	O
37C	O
in	O
a	O
0	O
.	O
1	O
mmol	O
/	O
L	O
potassiumphosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
containing	O
losartan	O
(	O
0	O
.	O
8	O
mol	O
/	O
L	O
)	O
and	O
a	O
NADPH	O
regenerating	O
system	O
(	O
1	O
.	O
25	O
mmol	O
/	O
L	O
NADP	O
^	O
+	O
,	O
3	O
.	O
3	O
mmol	O
/	O
L	O
Glucose6phosphate	O
,	O
3	O
.	O
3	O
mmol	O
/	O
L	O
MgCl_2	O
,	O
and	O
0	O
.	O
4	O
U	O
/	O
mL	O
glucose6phosphate	O
dehydrogenase	O
)	O
.	O

The	O
formation	O
of	O
EXP3174	O
was	O
linear	O
from	O
5	O
to	O
20	O
min	O
with	O
CYP2C9	B
concentrations	O
up	O
to	O
at	O
least	O
30	O
nmol	O
/	O
L	O
and	O
a	O
losartan	O
concentration	O
ranging	O
from	O
0	O
.	O
05	O
to	O
40	O
mol	O
/	O
L	O
.	O

In	O
the	O
timedependent	O
assay	O
,	O
CYP2C9	B
was	O
preincubated	O
at	O
37C	O
with	O
R	O
.	O
rosea	O
in	O
the	O
presence	O
of	O
the	O
NADPH	O
regenerating	O
system	O
,	O
but	O
without	O
substrate	O
.	O

The	O
NADPHdependent	O
assay	O
was	O
performed	O
by	O
preincubating	O
CYP2C9	B
with	O
R	O
.	O
rosea	O
as	O
described	O
above	O
,	O
but	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
NADPH	O
regenerating	O
system	O
for	O
0	O
and	O
45	O
min	O
.	O

The	O
CYP2C9	B
activity	O
was	O
determined	O
from	O
the	O
formation	O
rate	O
of	O
EXP3174	O
from	O
losartan	O
when	O
based	O
on	O
a	O
total	O
CYP2C9	B
amount	O
of	O
5	O
pmol	O
in	O
the	O
incubation	O
solution	O
and	O
an	O
incubation	O
time	O
of	O
15	O
min	O
.	O

Enzyme	O
activity	O
was	O
expressed	O
as	O
pmol	O
EXP3174	O
formed	O
per	O
pmol	O
CYP2C9	B
and	O
min	O
.	O

The	O
IC_50	O
value	O
of	O
Arctic	O
Root	O
was	O
estimated	O
from	O
nonlinear	O
regression	O
of	O
the	O
inhibition	O
plot	O
where	O
CYP2C9	B
activity	O
was	O
plotted	O
against	O
increasing	O
herbal	O
concentrations	O
using	O
Sigmaplot	O
(	O
Sigmaplot	O
,	O
Ver	O
.	O

K_m	O
and	O
V	O
_max	O
values	O
for	O
CYP2C9mediated	O
metabolism	O
of	O
losartan	O
were	O
estimated	O
by	O
incubating	O
CYP2C9	B
with	O
increasing	O
substrate	O
concentrations	O
(	O
0	O
.	O
4	O
-	O
8	O
.	O
0	O
mol	O
/	O
L	O
)	O
,	O
K	O
_m	O
(	O
app	O
)	O
and	O
V	O
_max	O
(	O
app	O
)	O
were	O
obtained	O
in	O
the	O
presence	O
of	O
control	O
inhibitor	O
and	O
R	O
.	O
rosea	O
.	O

A	O
twosample	O
ttest	O
was	O
used	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
herbal	O
preparation	O
and	O
inhibitor	O
control	O
on	O
CYP2C9	B
enzyme	O
activity	O
and	O
linear	O
regression	O
analyses	O
were	O
performed	O
on	O
standard	O
curves	O
and	O
inhibition	O
plots	O
.	O

CYP2C9	B
mean	O
enzyme	O
reference	O
(	O
control	O
)	O
activity	O
without	O
inhibitor	O
was	O
0	O
.	O
378	O
0	O
.	O
061	O
pmol	O
metabolite	O
/	O
(	O
pmol	O
enzyme	O
min	O
)	O
.	O

Results	O
were	O
CYP2C9	B
activities	O
of	O
49	O
.	O
5	O
0	O
.	O
0	O
,	O
53	O
.	O
8	O
0	O
.	O
1	O
,	O
54	O
.	O
5	O
0	O
.	O
1	O
,	O
and	O
51	O
.	O
2	O
0	O
.	O
1	O
%	O
compared	O
to	O
reference	O
without	O
inhibitor	O
,	O
respectively	O
.	O

NADPH	O
dependency	O
was	O
evaluated	O
by	O
preincubating	O
CYP2C9	B
with	O
Arctic	O
Root	O
extract	O
(	O
20	O
g	O
/	O
mL	O
)	O
with	O
and	O
without	O
NADPH	O
for	O
45	O
min	O
.	O

Results	O
were	O
CYP2C9	B
activities	O
of	O
51	O
.	O
2	O
0	O
.	O
1	O
and	O
52	O
.	O
2	O
0	O
.	O
2	O
%	O
,	O
respectively	O
.	O

The	O
plot	O
indicates	O
that	O
the	O
commercial	O
R	O
.	O
rosea	O
Arctic	O
Root	O
is	O
a	O
noncompetitive	O
inhibitor	O
of	O
the	O
CYP2C9mediated	O
metabolism	O
of	O
losartan	O
.	O

In	O
this	O
study	O
,	O
the	O
in	O
vitro	O
inhibitory	O
potential	O
and	O
inhibition	O
characteristics	O
of	O
the	O
commercial	O
R	O
.	O
rosea	O
product	O
Arctic	O
Root	O
was	O
investigated	O
using	O
cDNA	O
baculovirusexpressed	O
human	O
CYP2C9	B
Supersomes	O
.	O

In	O
addition	O
,	O
we	O
have	O
previously	O
verified	O
the	O
product	O
quality	O
by	O
quantification	O
of	O
the	O
established	O
R	O
.	O
rosea	O
markers	O
salidroside	O
,	O
tyrosol	O
,	O
rosavin	O
,	O
rosarin	O
,	O
and	O
rosin	O
(	O
Thu	O
et	O
al	O
.	O
.	O
The	O
IC_50	O
value	O
of	O
the	O
positive	O
control	O
sulfaphenazole	O
on	O
CYP2C9	B
activity	O
was	O
0	O
.	O
25	O
0	O
.	O
1	O
mol	O
/	O
L	O
,	O
and	O
falls	O
within	O
the	O
range	O
found	O
in	O
studies	O
using	O
similar	O
methodology	O
(	O
Dinger	O
et	O
al	O
.	O
.	O
The	O
influence	O
of	O
ethanol	O
at	O
relevant	O
methodological	O
concentrations	O
presented	O
in	O
Figure	O
demonstrates	O
a	O
strong	O
decrease	O
in	O
activity	O
with	O
increasing	O
ethanol	O
concentration	O
.	O

where	O
only	O
a	O
small	O
inhibition	O
of	O
7	O
6	O
%	O
at	O
3	O
%	O
ethanol	O
concentration	O
was	O
found	O
when	O
quantifying	O
the	O
CYP2C9mediated	O
formation	O
of	O
4hydroxydiclofenac	O
from	O
diclofenac	O
.	O

In	O
fact	O
,	O
the	O
influence	O
of	O
ethanol	O
on	O
CYP2C9	B
activity	O
seems	O
to	O
be	O
substrate	O
dependent	O
,	O
with	O
a	O
significant	O
inhibition	O
on	O
warfarin	O
metabolism	O
at	O
0	O
.	O
1	O
vol	O
%	O
and	O
no	O
inhibition	O
of	O
diclofenac	O
metabolism	O
at	O
1	O
vol	O
%	O
(	O
Tatsumi	O
et	O
al	O
.	O
.	O
In	O
general	O
,	O
the	O
influence	O
of	O
ethanol	O
on	O
CYP2C9	B
differs	O
from	O
that	O
on	O
CYP2D6	B
,	O
where	O
Hellum	O
and	O
Nilsen	O
found	O
a	O
biphasic	O
effect	O
with	O
a	O
small	O
inhibition	O
at	O
0	O
.	O
1	O
%	O
,	O
a	O
significant	O
activation	O
at	O
0	O
.	O
5	O
%	O
,	O
0	O
.	O
8	O
%	O
,	O
1	O
.	O
1	O
%	O
,	O
1	O
.	O
5	O
%	O
,	O
and	O
5	O
%	O
,	O
and	O
a	O
significant	O
inhibition	O
at	O
8	O
%	O
and	O
15	O
%	O
.	O

These	O
findings	O
show	O
that	O
care	O
must	O
be	O
taken	O
when	O
conducting	O
experiments	O
with	O
CYP2C9	B
where	O
ethanol	O
is	O
used	O
as	O
a	O
solvent	O
,	O
to	O
ensure	O
an	O
identical	O
ethanol	O
concentration	O
throughout	O
the	O
experimental	O
setup	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
an	O
in	O
vitro	O
CYP2C9	B
IC_50	O
value	O
of	O
19	O
.	O
2	O
2	O
.	O
7	O
g	O
/	O
mL	O
.	O

In	O
a	O
previous	O
investigation	O
of	O
the	O
inhibition	O
of	O
six	O
commercial	O
R	O
.	O
rosea	O
products	O
including	O
Arctic	O
Root	O
on	O
CYP1A2	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
,	O
IC_50	O
values	O
of	O
19	O
.	O
5	O
5	O
,	O
30	O
.	O
1	O
3	O
.	O
6	O
,	O
and	O
11	O
.	O
6	O
1	O
.	O
1	O
g	O
/	O
mL	O
,	O
respectively	O
,	O
were	O
found	O
(	O
Thu	O
et	O
al	O
.	O
.	O
This	O
places	O
the	O
in	O
vitro	O
CYP2C9	B
inhibition	O
potential	O
in	O
line	O
with	O
our	O
previous	O
study	O
.	O

However	O
,	O
CYP2C9	B
was	O
the	O
only	O
affected	O
enzyme	O
in	O
an	O
in	O
vivo	O
experiment	O
investigating	O
interactions	O
with	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
in	O
man	O
using	O
Arctic	O
Root	O
as	O
test	O
compound	O
(	O
Thu	O
et	O
al	O
.	O
.	O
One	O
would	O
perhaps	O
expect	O
a	O
more	O
potent	O
in	O
vitro	O
CYP2C9	B
inhibition	O
based	O
on	O
the	O
in	O
vivo	O
results	O
,	O
but	O
the	O
present	O
result	O
illustrates	O
the	O
challenges	O
of	O
predicting	O
possible	O
in	O
vivo	O
interactions	O
by	O
interpretation	O
of	O
in	O
vitro	O
inhibitory	O
data	O
.	O

Similar	O
studies	O
have	O
also	O
found	O
a	O
noncompetitive	O
inhibition	O
of	O
CYP2C9	B
by	O
other	O
herbal	O
products	O
like	O
Bacopa	O
monnieri	O
(	O
IC_50	O
/	O
K	O
_i	O
=	O
36	O
.	O
49	O
/	O
12	O
.	O
5	O
g	O
/	O
mL	O
)	O
(	O
Ramasamy	O
et	O
al	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
found	O
a	O
noncompetitive	O
inhibition	O
of	O
CYP2C9	B
by	O
the	O
commercial	O
R	O
.	O
rosea	O
product	O
Arctic	O
Root	O
and	O
adds	O
to	O
the	O
increasing	O
evidence	O
of	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
Cytochrome	B
P450	I
inhibitory	O
potential	O
of	O
R	O
.	O
rosea	O
.	O

According	O
to	O
our	O
previous	O
studies	O
,	O
CYP2D6	B
,	O
CYP2C9	B
and	O
CYP2C19	B
not	O
only	O
exhibit	O
significant	O
genetic	O
polymorphisms	O
between	O
individuals	O
,	O
but	O
also	O
had	O
substrate	O
-	O
specificity	O
,	O
which	O
show	O
marked	O
differences	O
on	O
the	O
metabolism	O
of	O
various	O
clinical	O
drugs	O
.	O
-	O
Similarly	O
,	O
it	O
has	O
been	O
reported	O
that	O
there	O
is	O
approximately	O
a	O
10	O
-	O
fold	O
variation	O
in	O
the	O
metabolism	O
of	O
CYP3A4	B
substrates	O
in	O
vivo	O
,	O
which	O
reveal	O
that	O
CYP3A4	B
may	O
also	O
exhibit	O
a	O
broad	O
substrate	O
specificity	O
.	O
,	O
However	O
,	O
thus	O
far	O
,	O
few	O
studies	O
have	O
been	O
performed	O
on	O
CYP3A4	B
genetic	O
polymorphisms	O
in	O
the	O
Chinese	O
Han	O
population	O
and	O
this	O
is	O
the	O
first	O
report	O
of	O
all	O
these	O
alleles	O
for	O
lidocaine	O
metabolism	O
.	O

These	O
studies	O
reported	O
P450	O
polymorphisms	O
in	O
Indigenous	O
North	O
American	O
populations	O
for	O
CYP1A1	B
,	O
CYP1A2	B
,	O
CYP2A6	O
,	O
CYP2B6	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP2E1	B
,	O
CYP3A4	B
,	O
CYP3A5	B
and	O
CYP4F2	O
.	O

The	O
CYP2C9	B
enzyme	O
metabolizes	O
medications	O
across	O
many	O
therapeutic	O
classes	O
including	O
nonsteroidal	O
anti	O
-	O
inflammatories	O
(	O
eg	O
,	O
naproxen	O
)	O
,	O
angiotensin	O
II	O
blockers	O
(	O
eg	O
,	O
losartan	O
)	O
,	O
as	O
well	O
as	O
narrow	O
therapeutic	O
index	O
drugs	O
such	O
as	O
(	O
S	O
)	O
-	O
warfarin	O
,	O
tolbutamide	O
and	O
phenytoin	O
.	O

This	O
observed	O
difference	O
in	O
warfarin	O
dosing	O
is	O
clinically	O
meaningful	O
and	O
thought	O
to	O
be	O
due	O
,	O
in	O
part	O
,	O
to	O
genetic	O
polymorphisms	O
in	O
the	O
CYP2C9	B
,	O
VKORC1	O
and	O
CYP4F2	O
genes	O
.	O

For	O
example	O
,	O
individuals	O
with	O
CYP2C9	B
*	O
2	O
or	O
CYP2C9	B
*	O
3	O
variant	O
alleles	O
require	O
a	O
lower	O
warfarin	O
dose	O
to	O
achieve	O
therapeutic	O
anticoagulation	O
.	O

In	O
the	O
Indigenous	O
population	O
of	O
Canada	O
,	O
the	O
previously	O
studied	O
CYP2C9	B
variant	O
allele	O
frequencies	O
were	O
found	O
to	O
be	O
distinct	O
from	O
the	O
European	O
and	O
Asian	O
reference	O
groups	O
,	O
particularly	O
for	O
the	O
Inuit	O
population	O
,	O
where	O
CYP2C9	B
*	O
2	O
,	O
*	O
3	O
and	O
*	O
4	O
were	O
absent	O
.	O

The	O
MAF	O
of	O
CYP2C9	B
*	O
2	O
,	O
*	O
3	O
and	O
*	O
4	O
were	O
3	O
.	O
0	O
%	O
,	O
6	O
.	O
0	O
%	O
and	O
0	O
.	O
0	O
%	O
,	O
respectively	O
in	O
the	O
FN	O
population	O
.	O

Through	O
deep	O
resequencing	O
to	O
identify	O
novel	O
variants	O
and	O
subsequent	O
genotyping	O
to	O
establish	O
population	O
frequencies	O
,	O
the	O
prevalence	O
of	O
novel	O
and	O
previously	O
known	O
CYP2C9	B
variants	O
was	O
determined	O
in	O
the	O
Yupik	O
AN	O
,	O
AIAN	O
at	O
Southcentral	O
Foundation	O
(	O
SCF	O
)	O
(	O
with	O
multiple	O
AN	O
sub	O
-	O
cultures	O
and	O
an	O
aggregate	O
of	O
AI	O
tribes	O
)	O
and	O
the	O
Confederated	O
Salish	O
and	O
Kootenai	O
Tribes	O
(	O
CSKT	O
)	O
AI	O
populations	O
.	O

The	O
MAFs	O
of	O
CYP2C9	B
*	O
2	O
and	O
*	O
3	O
were	O
lower	O
in	O
AIAN	O
populations	O
with	O
CYP2C9	B
*	O
2	O
at	O
0	O
.	O
3	O
%	O
,	O
5	O
.	O
2	O
%	O
and	O
5	O
.	O
2	O
%	O
in	O
the	O
Yupik	O
,	O
SCF	O
and	O
CSKT	O
populations	O
,	O
respectively	O
,	O
compared	O
to	O
European	O
populations	O
at	O
15	O
.	O
2	O
%	O
.	O

The	O
prevalence	O
of	O
CYP2C9	B
*	O
3	O
was	O
found	O
to	O
be	O
2	O
.	O
1	O
%	O
,	O
3	O
.	O
4	O
%	O
and	O
2	O
.	O
7	O
%	O
in	O
the	O
Yupik	O
,	O
SCF	O
and	O
CSKT	O
populations	O
,	O
respectively	O
,	O
compared	O
to	O
European	O
populations	O
at	O
6	O
.	O
6	O
%	O
.	O

CYP2C9	B
*	O
29	O
,	O
a	O
rare	O
coding	O
-	O
region	O
variant	O
,	O
was	O
found	O
at	O
2	O
.	O
1	O
%	O
in	O
the	O
Yupik	O
population	O
.	O

In	O
another	O
study	O
of	O
AI	O
youth	O
in	O
the	O
Northwestern	O
United	O
States	O
,	O
the	O
MAFs	O
of	O
CYP2C9	B
*	O
2	O
,	O
*	O
3	O
and	O
*	O
5	O
were	O
5	O
.	O
8	O
%	O
,	O
2	O
.	O
7	O
%	O
and	O
0	O
.	O
4	O
%	O
,	O
respectively	O
.	O

With	O
respect	O
to	O
novel	O
variation	O
,	O
one	O
new	O
novel	O
coding	O
variant	O
,	O
CYP2C9	B
K119T	O
,	O
was	O
identified	O
in	O
the	O
CSKT	O
population	O
at	O
a	O
frequency	O
of	O
0	O
.	O
57	O
%	O
.	O

In	O
addition	O
,	O
two	O
novel	O
coding	O
-	O
region	O
CYP2C9	B
were	O
identified	O
in	O
the	O
Yupik	O
and	O
SCF	O
populations	O
:	O
CYP2C9	B
M1L	O
(	O
M1L	O
)	O
and	O
CYP2C9	B
N218I	O
(	O
N218I	O
)	O
.	O

However	O
,	O
there	O
is	O
increased	O
confidence	O
that	O
individuals	O
who	O
are	O
heterozygous	O
or	O
homozygous	O
for	O
the	O
M1L	O
variant	O
would	O
have	O
a	O
lower	O
warfarin	O
dose	O
requirement	O
,	O
among	O
phenotypic	O
changes	O
for	O
other	O
CYP2C9	B
substrates	O
.	O

determined	O
the	O
CYP2C9	B
*	O
2	O
,	O
*	O
3	O
and	O
*	O
6	O
allele	O
frequencies	O
in	O
eight	O
Amerindian	O
populations	O
from	O
Northwest	O
Mexico	O
:	O
Tepehuano	O
,	O
Mexicanera	O
and	O
Huichol	O
from	O
Durango	O
,	O
Cora	O
from	O
Nayarit	O
,	O
Seri	O
,	O
Guarijo	O
and	O
Mayo	O
from	O
Sonora	O
and	O
Tarahumara	O
from	O
Chihuahua	O
.	O

The	O
MAF	O
of	O
CYP2C9	B
*	O
2	O
in	O
Seris	O
and	O
Mayos	O
was	O
2	O
.	O
6	O
%	O
and	O
5	O
.	O
7	O
%	O
,	O
respectively	O
;	O
this	O
variant	O
was	O
not	O
found	O
in	O
the	O
other	O
six	O
Amerindian	O
populations	O
.	O

With	O
regard	O
to	O
CYP2C9	B
*	O
3	O
,	O
the	O
MAF	O
was	O
10	O
.	O
4	O
%	O
,	O
9	O
.	O
1	O
%	O
,	O
7	O
.	O
5	O
%	O
,	O
6	O
.	O
7	O
%	O
,	O
3	O
.	O
7	O
%	O
and	O
3	O
.	O
3	O
%	O
in	O
Tarahumaras	O
,	O
Mayos	O
,	O
Tepehuanos	O
,	O
Guarijos	O
,	O
Coras	O
and	O
Huicholes	O
,	O
respectively	O
,	O
while	O
it	O
was	O
not	O
detected	O
in	O
Mexicanera	O
or	O
Seri	O
Amerindians	O
.	O

CYP2C9	B
*	O
6	O
was	O
not	O
detected	O
in	O
any	O
of	O
the	O
eight	O
Amerindian	O
groups	O
studied	O
.	O

found	O
that	O
the	O
MAF	O
of	O
CYP2C9	B
*	O
2	O
and	O
*	O
3	O
in	O
the	O
Tepehuano	O
population	O
was	O
1	O
.	O
0	O
%	O
and	O
1	O
.	O
5	O
%	O
,	O
respectively	O
,	O
while	O
CYP2C9	B
*	O
4	O
,	O
*	O
5	O
and	O
*	O
6	O
were	O
not	O
detected	O
.	O

tested	O
for	O
CYP2C9	B
*	O
2	O
and	O
CYP2C9	B
*	O
3	O
in	O
five	O
Amerindian	O
groups	O
:	O
Nahua	O
from	O
Central	O
Mexico	O
,	O
Teenek	O
from	O
the	O
Huasteca	O
Potosina	O
region	O
,	O
Tarahumara	O
from	O
Chihuahua	O
,	O
Purepecha	O
from	O
Michoacan	O
and	O
Huichol	O
from	O
Nayarit	O
.	O

In	O
the	O
Nahua	O
and	O
Teenek	O
groups	O
,	O
the	O
CYP2C9	B
*	O
2	O
MAF	O
was	O
0	O
.	O
7	O
%	O
and	O
0	O
.	O
5	O
%	O
,	O
respectively	O
and	O
the	O
CYP2C9	B
*	O
3	O
MAF	O
was	O
0	O
.	O
4	O
%	O
and	O
0	O
.	O
5	O
%	O
,	O
respectively	O
.	O

The	O
CYP2C9	B
*	O
2	O
and	O
*	O
3	O
alleles	O
were	O
absent	O
from	O
the	O
Tarahumara	O
,	O
Purepecha	O
and	O
Huichol	O
Amerindian	O
groups	O
.	O

With	O
regard	O
to	O
CYP2C9	B
*	O
2	O
in	O
the	O
Tepehuano	O
and	O
Tarahumara	O
populations	O
,	O
the	O
results	O
reported	O
by	O
Dorado	O
et	O
al	O
.	O

However	O
,	O
there	O
is	O
a	O
notable	O
difference	O
in	O
CYP2C9	B
*	O
3	O
allele	O
frequencies	O
reported	O
by	O
these	O
authors	O
for	O
the	O
Tepehuano	O
and	O
Tarahumara	O
populations	O
.	O

The	O
ratio	O
of	O
losartan	O
to	O
losartan	O
carboxylic	O
acid	O
was	O
significantly	O
greater	O
in	O
CYP2C9	B
*	O
2	O
or	O
*	O
3	O
homozygotes	O
or	O
carriers	O
,	O
compared	O
to	O
those	O
with	O
the	O
reference	O
genotype	O
.	O

CYP4F2	O
enzyme	O
catabolizes	O
vitamin	O
K	O
and	O
,	O
along	O
with	O
CYP2C9	B
and	O
vitamin	O
K	O
oxidoreductase	O
(	O
VKOR	O
)	O
,	O
can	O
affect	O
the	O
pharmacological	O
response	O
of	O
warfarin	O
,	O
a	O
VKOR	O
antagonist	O
.	O

With	O
regards	O
to	O
CYP2C9	B
,	O
there	O
was	O
a	O
lack	O
of	O
CYP2C9	B
*	O
2	O
in	O
the	O
Canadian	O
Inuit	O
population	O
as	O
well	O
as	O
many	O
Amerindian	O
groups	O
including	O
the	O
Mexicanera	O
,	O
Huichol	O
,	O
Guarijo	O
,	O
Cora	O
,	O
Tarahumara	O
and	O
Purepecha	O
.	O

CYP2C9	B
*	O
3	O
was	O
also	O
absent	O
from	O
the	O
Canadian	O
Inuit	O
,	O
Mexicanera	O
,	O
Seri	O
,	O
Purepecha	O
and	O
Huichol	O
populations	O
.	O

The	O
allele	O
frequencies	O
of	O
known	O
and	O
recently	O
reported	O
CYP2C9	B
variants	O
in	O
the	O
AN	O
Yupik	O
population	O
illustrate	O
this	O
scenario	O
.	O

The	O
CYP2C9	B
*	O
2	O
and	O
*	O
3	O
alleles	O
that	O
define	O
the	O
CYP2C9	B
PM	O
phenotype	O
in	O
the	O
European	O
population	O
are	O
found	O
at	O
very	O
low	O
frequencies	O
in	O
the	O
Yupik	O
population	O
.	O

The	O
novel	O
and	O
relatively	O
common	O
M1L	O
and	O
N218I	O
variants	O
found	O
in	O
the	O
Yupik	O
population	O
,	O
in	O
addition	O
to	O
CYP2C9	B
*	O
2	O
and	O
*	O
3	O
alleles	O
,	O
that	O
are	O
predicted	O
to	O
confer	O
a	O
CYP2C9	B
PM	O
phenotype	O
.	O

Importantly	O
,	O
if	O
only	O
the	O
allele	O
frequencies	O
known	O
to	O
be	O
clinically	O
relevant	O
in	O
the	O
European	O
population	O
are	O
applied	O
to	O
the	O
Yupik	O
population	O
,	O
an	O
individual	O
homozygous	O
or	O
heterozygous	O
for	O
the	O
M1L	O
or	O
N218I	O
variants	O
would	O
be	O
classified	O
as	O
a	O
CYP2C9	B
EM	O
and	O
improper	O
warfarin	O
dosing	O
could	O
result	O
in	O
adverse	O
events	O
for	O
these	O
individuals	O
.	O

This	O
potential	O
for	O
misclassification	O
and	O
inappropriate	O
drug	O
dosing	O
has	O
also	O
been	O
described	O
of	O
African	O
populations	O
,	O
where	O
the	O
CYP2C9	B
*	O
8	O
allele	O
contributes	O
to	O
the	O
PM	O
phenotype	O
.	O

where	O
the	O
CYP2C9	B
,	O
CYP2C19	B
,	O
or	O
CYP2D6	B
phenotype	O
for	O
some	O
Amerindians	O
could	O
not	O
be	O
accurately	O
predicted	O
based	O
on	O
genotype	O
,	O
possibly	O
due	O
to	O
the	O
presence	O
of	O
novel	O
rare	O
variation	O
in	O
these	O
pharmacogenes	O
.	O

CYP1A1	B
,	O
1A2	O
and	O
CYP2C9	B
are	O
not	O
expressed	O
in	O
human	O
kidney	O
,	O
whereas	O
the	O
CYP3A4	B
expression	O
in	O
kidney	O
is	O
highly	O
variable	O
and	O
remains	O
to	O
be	O
elucidated	O
^	O
.	O

Moreover	O
,	O
the	O
shift	O
of	O
the	O
F	O
-	O
helix	O
and	O
of	O
the	O
F	O
/	O
F	O
loop	O
in	O
CYP2C9	B
in	O
high	O
-	O
temperature	O
molecular	O
dynamics	O
simulations	O
are	O
shown	O
to	O
close	O
the	O
solvent	O
channel	O
and	O
to	O
open	O
the	O
channel	O
2b	O
.	O
.	O
A	O
large	O
conformational	O
shift	O
of	O
the	O
F	O
/	O
F	O
loop	O
is	O
also	O
seen	O
in	O
CYP3A4	B
crystal	O
structures	O
complexed	O
with	O
ketoconazole	O
(	O
a	O
P450	O
inhibitor	O
)	O
or	O
erythromycin	O
(	O
a	O
CYP3A4	B
substrate	O
)	O
.	O

The	O
structure	O
of	O
human	O
CYP2C9	B
is	O
known	O
from	O
X	O
-	O
ray	O
experiments	O
,	O
but	O
its	O
mode	O
of	O
insertion	O
into	O
the	O
membrane	O
remains	O
unsolved	O
.	O

Atomistic	O
models	O
of	O
complete	O
CYP2C9	B
embedded	O
in	O
a	O
bilayer	O
membrane	O
were	O
constructed	O
and	O
evolved	O
by	O
molecular	O
dynamics	O
simulations	O
.	O

The	O
entry	O
of	O
the	O
substrate	O
access	O
channel	O
was	O
found	O
to	O
be	O
facing	O
the	O
membrane	O
interior	O
,	O
while	O
the	O
exit	O
of	O
the	O
product	O
egress	O
channel	O
is	O
found	O
to	O
be	O
located	O
above	O
the	O
interface	O
between	O
phospholipid	O
heads	O
and	O
the	O
water	O
solvent	O
.	O
Moreover	O
,	O
the	O
positions	O
of	O
the	O
mouths	O
of	O
the	O
substrate	O
access	O
and	O
the	O
product	O
egress	O
channels	O
roughly	O
correspond	O
to	O
the	O
positions	O
of	O
energy	O
minima	O
for	O
the	O
location	O
of	O
CYP2C9	B
substrate	O
and	O
its	O
metabolite	O
in	O
the	O
membrane	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
(	O
CYP1	O
-	O
selective	O
)	O
:	O
1	O
.	O
01	O
0	O
.	O
14	O
,	O
PROD	B
(	O
CYP2B	O
-	O
selective	O
)	O
:	O
below	O
detection	O
at	O
an	O
limit	O
of	O
quantification	O
of	O
1	O
.	O
87	O
pmol	O
,	O
tolbutamide	O
4	O
-	O
hydroxylation	O
(	O
CYP2C9	B
-	O
selective	O
)	O
0	O
.	O
47	O
0	O
.	O
04	O
,	O
bufuralol	O
1	O
-	O
hydroxylation	O
(	O
CYP2D6	B
-	O
selective	O
)	O
1	O
.	O
33	O
0	O
.	O
17	O
,	O
chlorzoxazone	O
6	O
-	O
hydroxylation	O
(	O
CYP2E1	B
-	O
selective	O
)	O
below	O
detection	O
at	O
an	O
Limit	O
Of	O
Quantitation	O
of	O
12	O
.	O
8	O
pmol	O
,	O
midazolam	O
1	O
-	O
hydroxylation	O
(	O
CYP3A	B
-	O
selective	O
)	O
0	O
.	O
58	O
0	O
.	O
09	O
(	O
Rolsted	O
et	O
al	O
.	O
.	O
Localization	O
Early	O
studies	O
already	O
tried	O
to	O
differentiate	O
whether	O
the	O
rat	O
skin	O
CYP	O
activities	O
were	O
present	O
in	O
different	O
skin	O
layers	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
95	O
.	O
4	O
4	O
.	O
2	O
,	O
PROD	B
below	O
detection	O
(	O
LOQ	O
1	O
.	O
87	O
pmol	O
)	O
,	O
tolbutamide	O
4	O
-	O
hydroxylation	O
(	O
CYP2C9	B
-	O
selective	O
substrate	O
)	O
below	O
detection	O
,	O
bufuralol	O
1	O
-	O
hydroxylation	O
(	O
CYP	B
2D6	I
-	O
selective	O
substrate	O
)	O
9	O
.	O
23	O
0	O
.	O
67	O
,	O
chlorzoxazone	O
6	O
-	O
hydroxylation	O
(	O
CYP2E1	B
-	O
selective	O
substrate	O
)	O
20	O
.	O
8	O
0	O
.	O
5	O
,	O
midazolam	O
1	O
-	O
hydroxylation	O
(	O
CYP3A	B
-	O
selective	O
substrate	O
)	O
8	O
.	O
70	O
0	O
.	O
28	O
.	O

reported	O
the	O
presence	O
of	O
the	O
following	O
CYPs	O
mRNA	O
in	O
full	O
-	O
thickness	O
human	O
skin	O
biopsies	O
:	O
CYP1B1	O
,	O
CYP2B6	B
(	O
not	O
present	O
in	O
some	O
individuals	O
)	O
,	O
CYP2D6	B
,	O
CYP3A4	B
;	O
low	O
expression	O
:	O
CYP1A1	B
,	O
CYP2C9	B
,	O
CYP2C18	O
,	O
CYP2C19	B
,	O
CYP2E1	B
and	O
CYP3A5	B
mRNAs	O
;	O
not	O
detected	O
:	O
CYP1A2	B
,	O
2A6	O
,	O
and	O
2C8	O
.	O

observed	O
in	O
total	O
human	O
skin	O
,	O
in	O
human	O
epidermis	O
,	O
in	O
EpiSkin	O
^	O
and	O
in	O
EpiskinTMF	O
^	O
mRNAs	O
for	O
the	O
following	O
CYPs	O
:	O
Low	O
levels	O
(	O
below	O
200	O
,	O
000	O
copies	O
/	O
g	O
total	O
RNA	O
)	O
:	O
CYP2B6	B
,	O
2D6	O
,	O
2E1	O
,	O
1A1	O
,	O
1B1	O
,	O
2C8	O
,	O
2C18	O
,	O
2F1	O
and	O
3A5	O
;	O
very	O
low	O
levels	O
(	O
below	O
10	O
,	O
000	O
copies	O
/	O
g	O
total	O
RNA	O
)	O
:	O
CYP2C9	B
,	O
1A2	O
and	O
3A7	O
.	O

)	O
:	O
The	O
major	O
hepatic	O
CYPs	O
,	O
namely	O
CYP1A2	B
,	O
CYP2C9	B
/	O
18	O
/	O
19	O
and	O
CYP3A4	B
were	O
absent	O
or	O
present	O
only	O
at	O
low	O
levels	O
,	O
notably	O
CYP1A2	B
,	O
CYP2B6	B
,	O
CYP3A4	B
and	O
the	O
fetal	O
form	O
CYP3A7	O
were	O
not	O
expressed	O
,	O
while	O
the	O
following	O
were	O
expressed	O
at	O
weak	O
or	O
good	O
levels	O
:	O
CYP1B1	O
,	O
CYP2C18	O
,	O
CYP2R1	O
,	O
CYP2S1	O
,	O
CYP3A5	B
,	O
CYP4B1	O
,	O
CYP4F2	O
,	O
CYP4F3	O
,	O
CYP4F11	O
,	O
CYP7B1	O
,	O
CYP26B1	B
and	O
CYP27B1	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
(	O
CYP1	O
-	O
selective	O
)	O
not	O
detected	O
(	O
LOQ	O
1	O
.	O
87	O
pmol	O
)	O
,	O
PROD	B
(	O
CYP2B	O
-	O
selective	O
)	O
not	O
detected	O
(	O
LOQ	O
1	O
.	O
87	O
pmol	O
)	O
,	O
tolbutamide	O
4	O
-	O
hydroxylation	O
(	O
CYP2C9	B
-	O
selective	O
)	O
0	O
.	O
46	O
0	O
.	O
05	O
pmol	O
/	O
h	O
/	O
mg	O
protein	O
,	O
bufuralol	O
1	O
-	O
hydroxylation	O
(	O
CYP	B
2D6	I
-	O
selective	O
)	O
not	O
detected	O
(	O
LOQ	O
1	O
.	O
08	O
pmol	O
)	O
,	O
chlorzoxazone	O
6	O
-	O
hydroxylation	O
(	O
CYP2E1	B
-	O
selective	O
)	O
2	O
.	O
83	O
0	O
.	O
34	O
pmol	O
/	O
h	O
/	O
mg	O
protein	O
,	O
midazolam	O
1	O
-	O
hydroxylation	O
(	O
CYP3A	B
-	O
selective	O
)	O
2	O
.	O
35	O
0	O
.	O
23	O
pmol	O
/	O
h	O
/	O
mg	O
protein	O
.	O

;	O
Oesch	O
and	O
Arand	O
]	O
and	O
in	O
part	O
by	O
CYP2C9	B
,	O
and	O
CYP3A48	O
;	O
(	O
Gautier	O
et	O
al	O
.	O

CYP2C	O
subfamily	O
In	O
contrast	O
to	O
other	O
CYPs	O
,	O
as	O
pointed	O
out	O
above	O
,	O
the	O
mRNAs	O
coding	O
for	O
the	O
major	O
human	O
CYP2C	O
proteins	O
,	O
CYP2C9	B
,	O
CYP2C18	O
and	O
CYP2C19	B
were	O
found	O
in	O
the	O
skin	O
of	O
all	O
individuals	O
investigated	O
by	O
Yengi	O
et	O
al	O
.	O
.	O
On	O
the	O
other	O
hand	O
,	O
in	O
proliferating	O
human	O
keratinocytes	O
in	O
culture	O
CYP2C19	B
mRNA	O
was	O
found	O
only	O
after	O
induction	O
by	O
clofibrate	O
Gonzalez	O
et	O
al	O
.	O
.	O
In	O
line	O
with	O
the	O
failure	O
of	O
finding	O
constitutive	O
expression	O
in	O
proliferating	O
keratinocytes	O
,	O
the	O
localization	O
of	O
CYP2C	O
mRNAs	O
as	O
well	O
as	O
CYP2C	O
proteins	O
is	O
in	O
most	O
cases	O
in	O
the	O
outer	O
suprabasal	O
cell	O
layers	O
of	O
the	O
epidermis	O
,	O
where	O
differentiated	O
keratinocytes	O
are	O
located	O
(	O
Du	O
et	O
al	O
.	O
.	O
As	O
found	O
in	O
skin	O
or	O
other	O
systems	O
CYP2Cs	O
metabolize	O
:	O
many	O
physiological	O
compounds	O
(	O
CYP2C9	B
:	O
retinoic	O
,	O
arachidonic	O
and	O
linoleic	O
acids	O
,	O
5	O
-	O
alpha	O
-	O
androstane	O
-	O
3	O
-	O
alpha	O
,	O
17	O
-	O
beta	O
-	O
diol	O
;	O
2C18	O
:	O
retinoic	O
acid	O
,	O
progesterone	O
;	O
2C19	O
:	O
progesterone	O
,	O
testosterone	O
,	O
retinal	O
,	O
arachidonic	O
and	O
linoleic	O
acids	O
)	O
;	O
natural	O
compounds	O
(	O
2C9	O
:	O
limonene	O
,	O
capsaicin	O
,	O
nicotine	O
,	O
galangin	O
,	O
genistein	O
4	O
-	O
methyl	O
ether	O
,	O
ochrotoxine	O
A	O
;	O
2C18	O
:	O
limonene	O
;	O
2C19	O
:	O
limonene	O
,	O
capsaicin	O
,	O
nicotine	O
,	O
genistein	O
4	O
-	O
methyl	O
ether	O
,	O
ochratoxin	O
A	O
,	O
tetrahydrocannabinol	O
)	O
;	O
pharmaceutical	O
drugs	O
[	O
2C9	O
:	O
(	O
S	O
)	O
-	O
warfarin	O
,	O
tolbutamide	O
,	O
diclofenac	O
,	O
ibuprofen	O
,	O
indomethacin	O
,	O
phenytoin	O
;	O
2C19	O
:	O
(	O
R	O
)	O
-	O
warfarin	O
,	O
omeprazole	O
,	O
pantoprazole	O
,	O
lansoprazole	O
,	O
(	O
S	O
)	O
-	O
mephenytoin	O
,	O
diazepam	O
,	O
amitryptiline	O
]	O
(	O
Du	O
et	O
al	O
.	O

Effects	O
of	O
polymorphic	O
variation	O
on	O
the	O
thermostability	O
of	O
heterogenous	O
populations	O
of	O
CYP3A4	B
and	O
CYP2C9	B
enzymes	O
in	O
solution	O
.	O

Here	O
we	O
have	O
determined	O
the	O
effect	O
of	O
eight	O
CYP3A4	B
and	O
seven	O
CYP2C9	B
Single	O
Nucleotide	O
Polymorphisms	O
on	O
the	O
thermostability	O
of	O
proteins	O
in	O
solution	O
to	O
test	O
these	O
predictions	O
.	O

Thermostability	O
assays	O
revealed	O
distinct	O
Cytochrome	B
P450	I
sub	O
-	O
populations	O
with	O
only	O
65	O
-	O
70	O
%	O
of	O
wild	O
-	O
type	O
CYP3A4	B
and	O
CYP2C9	B
susceptible	O
to	O
rapid	O
heat	O
-	O
induced	O
P450	O
to	O
P420	O
conversion	O
.	O

CYP3A4	B
mutations	O
G56D	O
,	O
P218R	O
,	O
S222P	O
,	O
I223R	O
,	O
L373F	O
and	O
M445T	O
and	O
CYP2C9	B
mutations	O
V76M	O
,	O
I359L	O
and	O
I359T	O
were	O
destabilising	O
,	O
increasing	O
the	O
proportion	O
of	O
protein	O
sensitive	O
to	O
the	O
rapid	O
heat	O
-	O
induced	O
P450	O
to	O
P420	O
conversion	O
and	O
/	O
or	O
reducing	O
the	O
half	O
-	O
life	O
of	O
this	O
conversion	O
.	O

CYP2C9	B
Q214L	O
was	O
the	O
only	O
stabilising	O
mutation	O
.	O

Over	O
100	O
non	O
-	O
synonymous	O
single	O
amino	O
acid	O
substitutions	O
have	O
been	O
reported	O
for	O
isoforms	O
CYP3A4	B
and	O
CYP2C9	B
alone	O
^	O
,	O
;	O
these	O
two	O
isoforms	O
are	O
jointly	O
responsible	O
for	O
nearly	O
half	O
of	O
Cytochrome	B
P450	I
mediated	O
drug	O
metabolism	O
^	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
our	O
previous	O
in	O
silico	O
stability	O
prediction	O
in	O
vitro	O
,	O
using	O
a	O
selection	O
of	O
recombinantly	O
expressed	O
CYP3A4	B
and	O
CYP2C9	B
mutants	O
.	O

The	O
8	O
CYP3A4	B
and	O
7	O
CYP2C9	B
variants	O
tested	O
included	O
mutations	O
previously	O
predicted	O
to	O
be	O
neutral	O
,	O
stabilising	O
and	O
destabilising	O
,	O
falling	O
within	O
both	O
functional	O
and	O
undefined	O
regions	O
of	O
the	O
protein	O
structure	O
^	O
.	O

The	O
positions	O
of	O
the	O
CYP3A4	B
and	O
CYP2C9	B
variants	O
selected	O
for	O
in	O
vitro	O
testing	O
are	O
shown	O
in	O
Fig	O
.	O

Recombinant	O
wild	O
-	O
type	O
and	O
variant	O
His	O
-	O
tagged	O
CYP3A4	B
and	O
CYP2C9	B
proteins	O
were	O
expressed	O
in	O
E	O
.	O
coli	O
and	O
purified	O
using	O
immobilized	O
metal	O
affinity	O
chromatography	O
.	O

The	O
specific	O
holoprotein	O
content	O
of	O
each	O
CYP3A4	B
and	O
CYP2C9	B
variant	O
protein	O
sample	O
was	O
determined	O
using	O
carbon	O
monoxide	O
P450	O
spectral	O
assays	O
^	O
,	O
.	O

To	O
test	O
the	O
thermostability	O
of	O
the	O
CYP3A4	B
and	O
CYP2C9	B
,	O
Wild	O
-	O
Type	O
and	O
variant	O
proteins	O
,	O
Carbon	O
Monoxide	O
P450	O
difference	O
spectra	O
were	O
used	O
to	O
measure	O
the	O
decrease	O
in	O
P450	O
content	O
at	O
an	O
elevated	O
temperature	O
as	O
a	O
function	O
of	O
time	O
.	O

Different	O
temperatures	O
were	O
tested	O
to	O
ensure	O
the	O
decrease	O
in	O
P450	O
could	O
be	O
monitored	O
at	O
a	O
constant	O
temperature	O
over	O
a	O
30	O
-	O
minute	O
period	O
:	O
34	O
C	O
was	O
chosen	O
for	O
CYP3A4	B
proteins	O
and	O
48	O
C	O
for	O
the	O
more	O
stable	O
CYP2C9	B
proteins	O
.	O

CYP3A4	B
and	O
CYP2C9	B
Wild	O
-	O
Type	O
protein	O
samples	O
both	O
showed	O
an	O
exponential	O
decrease	O
in	O
P450	O
content	O
,	O
although	O
the	O
graphs	O
did	O
not	O
tend	O
to	O
zero	O
,	O
suggesting	O
either	O
the	O
presence	O
of	O
a	O
stable	O
P450	O
sub	O
-	O
population	O
or	O
background	O
signal	O
.	O

Figure	O
shows	O
the	O
thermostability	O
results	O
for	O
the	O
CYP2C9	B
Wild	O
-	O
Type	O
and	O
variant	O
proteins	O
.	O

The	O
one	O
phase	O
exponential	O
decay	O
model	O
was	O
the	O
preferred	O
model	O
for	O
all	O
the	O
CYP2C9	B
proteins	O
.	O

P279T	O
had	O
a	O
half	O
-	O
life	O
of	O
15	O
.	O
3	O
minutes	O
(	O
33	O
%	O
higher	O
than	O
WT	O
)	O
and	O
I359L	O
had	O
a	O
half	O
-	O
life	O
of	O
7	O
.	O
5	O
minutes	O
(	O
35	O
%	O
lower	O
than	O
WT	O
)	O
;	O
however	O
,	O
differences	O
in	O
the	O
half	O
-	O
lives	O
were	O
not	O
significantly	O
different	O
for	O
any	O
of	O
the	O
CYP2C9	B
variants	O
compared	O
to	O
Wild	O
-	O
Type	O
.	O

Size	O
exclusion	O
chromatography	O
was	O
carried	O
out	O
on	O
CYP3A4	B
and	O
CYP2C9	B
Wild	O
-	O
Type	O
protein	O
samples	O
to	O
determine	O
whether	O
protein	O
oligomerisation	O
could	O
provide	O
an	O
explanation	O
for	O
the	O
presence	O
of	O
P450	O
sub	O
-	O
populations	O
with	O
different	O
stabilities	O
in	O
solution	O
.	O

Figure	O
shows	O
the	O
elution	O
profiles	O
for	O
CYP3A4	B
and	O
CYP2C9	B
Wild	O
-	O
Type	O
proteins	O
monitored	O
at	O
410	O
nm	O
,	O
the	O
maximum	O
absorbance	O
wavelength	O
of	O
the	O
haem	O
-	O
bound	O
protein	O
.	O

The	O
data	O
provides	O
evidence	O
that	O
both	O
isoforms	O
do	O
indeed	O
oligomerise	O
in	O
solution	O
;	O
the	O
major	O
peak	O
for	O
both	O
CYP3A4	B
(	O
66	O
kDa	O
in	O
monomeric	O
form	O
)	O
and	O
CYP2C9	B
(	O
63	O
kDa	O
in	O
monomeric	O
form	O
)	O
correspond	O
roughly	O
to	O
oligomeric	O
structures	O
made	O
up	O
of	O
9	O
and	O
8	O
subunits	O
respectively	O
.	O

CYP2C9	B
shows	O
two	O
secondary	O
peaks	O
(	O
~	O
83	O
and	O
32	O
kDa	O
)	O
,	O
which	O
do	O
not	O
correspond	O
well	O
to	O
the	O
expected	O
size	O
of	O
a	O
CYP2C9	B
dimer	O
and	O
monomer	O
,	O
however	O
the	O
columns	O
capability	O
of	O
accurately	O
predicting	O
protein	O
sizes	O
in	O
the	O
lower	O
molecular	O
weight	O
range	O
may	O
be	O
limiting	O
.	O

In	O
order	O
to	O
test	O
previous	O
in	O
silico	O
predictions	O
on	O
the	O
effects	O
of	O
Single	O
Nucleotide	O
Polymorphisms	O
on	O
Cytochrome	B
P450	I
stability	O
,	O
recombinant	O
soluble	O
CYP2C9	B
and	O
CYP3A4	B
Wild	O
-	O
Type	O
and	O
variant	O
proteins	O
,	O
lacking	O
their	O
N	O
-	O
terminal	O
membrane	O
binding	O
region	O
,	O
were	O
expressed	O
in	O
E	O
.	O
coli	O
and	O
purified	O
from	O
the	O
cell	O
lysate	O
.	O

CYP2C9	B
was	O
much	O
more	O
stable	O
than	O
CYP3A4	B
,	O
to	O
the	O
extent	O
that	O
CYP3A4	B
had	O
a	O
shorter	O
half	O
-	O
life	O
at	O
34	O
C	O
than	O
CYP2C9	B
had	O
at	O
48	O
C	O
.	O
The	O
observed	O
differences	O
in	O
stability	O
were	O
consistent	O
with	O
the	O
differences	O
in	O
expression	O
levels	O
and	O
P450	O
:	O
P420	O
ratios	O
.	O

Notably	O
,	O
the	O
P420	O
form	O
of	O
the	O
protein	O
was	O
not	O
detected	O
in	O
any	O
of	O
the	O
CYP2C9	B
samples	O
,	O
while	O
the	O
P420	O
form	O
was	O
present	O
in	O
all	O
CYP3A4	B
samples	O
.	O

Exponential	O
decay	O
curves	O
for	O
both	O
CYP3A4	B
and	O
CYP2C9	B
indicated	O
energetically	O
distinct	O
P450	O
sub	O
-	O
populations	O
that	O
did	O
not	O
interconvert	O
between	O
each	O
other	O
during	O
the	O
course	O
of	O
the	O
assay	O
.	O

In	O
this	O
study	O
we	O
observed	O
similar	O
conformational	O
heterogeneity	O
for	O
both	O
CYP3A4	B
and	O
CYP2C9	B
in	O
solution	O
;	O
only	O
65	O
-	O
70	O
%	O
of	O
the	O
P450	O
was	O
susceptible	O
to	O
rapid	O
heat	O
-	O
induced	O
P450	O
to	O
P420	O
conversion	O
at	O
a	O
constant	O
elevated	O
temperature	O
while	O
the	O
remaining	O
fraction	O
was	O
much	O
more	O
stable	O
,	O
consistent	O
with	O
the	O
literature	O
.	O

Size	O
exclusion	O
chromatography	O
experiments	O
confirmed	O
that	O
both	O
CYP3A4	B
and	O
CYP2C9	B
were	O
predominantly	O
in	O
the	O
oligomeric	O
form	O
in	O
solution	O
.	O

Our	O
Size	O
Exclusion	O
Chromatography	O
results	O
suggest	O
that	O
CYP2C9	B
is	O
predominantly	O
in	O
the	O
octomeric	O
form	O
;	O
this	O
does	O
not	O
readily	O
explain	O
the	O
1	O
:	O
2	O
conformer	O
distribution	O
observed	O
here	O
.	O

Little	O
is	O
known	O
about	O
the	O
quaternary	O
structure	O
of	O
CYP2C9	B
in	O
solution	O
or	O
in	O
the	O
membrane	O
.	O

In	O
some	O
Cytochrome	B
P450	I
structures	O
this	O
region	O
is	O
comprised	O
of	O
two	O
short	O
F	O
and	O
G	O
helixes	O
(	O
eg	O
CYP2C9	B
PDB	O
1OG2	O
^	O
)	O
while	O
in	O
other	O
structures	O
it	O
is	O
a	O
disordered	O
loop	O
region	O
(	O
eg	O
CYP2C9	B
PDB	O
1R9O	O
^	O
)	O
.	O

CYP2C9	B
variant	O
Q214L	O
,	O
another	O
mutation	O
to	O
a	O
buried	O
residue	O
within	O
the	O
F	O
-	O
G	O
loop	O
and	O
substrate	O
recognition	O
site	O
(	O
2	O
,	O
3	O
)	O
,	O
was	O
the	O
only	O
variant	O
predicted	O
to	O
be	O
stabilising	O
by	O
Site	O
Directed	O
Mutator	O
and	O
the	O
only	O
variant	O
that	O
showed	O
a	O
significant	O
increase	O
in	O
thermostability	O
,	O
showing	O
a	O
significant	O
increase	O
in	O
the	O
proportion	O
of	O
stable	O
conformer	O
in	O
solution	O
,	O
but	O
no	O
significant	O
difference	O
in	O
the	O
half	O
-	O
life	O
of	O
the	O
fast	O
phase	O
.	O

I359L	O
and	O
I359T	O
mutations	O
in	O
CYP2C9	B
decrease	O
the	O
proportion	O
of	O
protein	O
making	O
up	O
the	O
stable	O
P450	O
sub	O
-	O
population	O
.	O

Site	O
Directed	O
Mutator	O
correctly	O
predicts	O
that	O
a	O
mutation	O
to	O
threonine	O
at	O
this	O
position	O
will	O
destabilise	O
the	O
protein	O
fold	O
but	O
incorrectly	O
predicts	O
the	O
effect	O
of	O
the	O
conserved	O
mutation	O
to	O
leucine	O
;	O
while	O
isoleucine	O
and	O
leucine	O
are	O
both	O
hydrophobic	O
residues	O
with	O
the	O
same	O
volume	O
and	O
similar	O
properties	O
,	O
the	O
subtle	O
difference	O
between	O
these	O
residues	O
at	O
this	O
position	O
significantly	O
affects	O
the	O
conformation	O
of	O
the	O
CYP2C9	B
fold	O
.	O

I359L	O
and	O
I359T	O
are	O
the	O
non	O
-	O
synonymous	O
amino	O
acid	O
substitutions	O
associated	O
with	O
CYP2C9	B
*	O
3	O
and	O
CYP2C9	B
*	O
4	O
alleles	O
,	O
respectively	O
.	O

CYP2C9	B
variant	O
V76M	O
also	O
showed	O
significantly	O
less	O
P450	O
in	O
the	O
stable	O
sub	O
-	O
population	O
than	O
observed	O
for	O
the	O
Wild	O
-	O
Type	O
protein	O
but	O
was	O
not	O
predicted	O
to	O
be	O
a	O
destabilising	O
mutation	O
by	O
Site	O
Directed	O
Mutator	O
.	O

While	O
Val	O
76	O
is	O
position	O
roughly	O
13	O
from	O
the	O
bound	O
haem	O
,	O
the	O
model	O
of	O
the	O
CYP2C9	B
V76M	O
variant	O
used	O
to	O
generate	O
the	O
Site	O
Directed	O
Mutator	O
data	O
suggests	O
that	O
the	O
substitution	O
of	O
valine	O
for	O
the	O
bulkier	O
methionine	O
residue	O
at	O
this	O
position	O
has	O
a	O
subtle	O
long	O
-	O
range	O
effect	O
on	O
the	O
side	O
chain	O
position	O
of	O
His	O
368	O
,	O
which	O
interacts	O
with	O
the	O
haem	O
propionate	O
via	O
a	O
salt	O
bridge	O
.	O

While	O
CYP2C9	B
R132Q	O
and	O
R150H	O
showed	O
no	O
significant	O
effect	O
on	O
the	O
Cytochrome	B
P450	I
stability	O
in	O
agreement	O
with	O
the	O
in	O
silico	O
predictions	O
,	O
these	O
Single	O
Nucleotide	O
Polymorphisms	O
have	O
both	O
been	O
reported	O
to	O
affect	O
catalytic	O
activity	O
.	O

CYP2C9	B
R132Q	O
,	O
despite	O
showing	O
similar	O
holo	O
P450	O
levels	O
in	O
a	O
baculovirus	O
-	O
insect	O
cell	O
system	O
,	O
showed	O
~	O
90	O
%	O
reduction	O
in	O
catalytic	O
activity	O
towards	O
diclofenac	O
,	O
losartan	O
and	O
glimepiride	O
^	O
,	O
.	O

CYP2C9	B
R150H	O
does	O
not	O
fall	O
within	O
any	O
of	O
the	O
known	O
functional	O
regions	O
.	O

Despite	O
this	O
,	O
it	O
has	O
been	O
reported	O
to	O
affect	O
CYP2C9	B
function	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
CYP2C9	B
*	O
8	O
R150H	O
allele	O
commonly	O
occurs	O
in	O
African	O
Americans	O
and	O
has	O
been	O
associated	O
with	O
decreased	O
warfarin	O
and	O
phenytoin	O
metabolism	O
^	O
,	O
.	O

This	O
work	O
provides	O
new	O
insight	O
into	O
structure	O
-	O
function	O
relationships	O
in	O
CYP3A4	B
and	O
CYP2C9	B
and	O
demonstrates	O
the	O
utility	O
of	O
in	O
silico	O
approaches	O
such	O
as	O
Site	O
Directed	O
Mutator	O
combined	O
with	O
the	O
Cytochrome	B
P450	I
functional	O
map	O
^	O
for	O
predicting	O
the	O
effects	O
of	O
mutations	O
on	O
Cytochrome	B
P450	I
stability	O
and	O
prioritising	O
Single	O
Nucleotide	O
Polymorphisms	O
for	O
experimental	O
testing	O
.	O

pBJW102	O
.	O
2	O
vectors	O
containing	O
the	O
N	O
-	O
terminal	O
truncated	O
CYP3A4	B
and	O
CYP2C9	B
cDNA	O
sequences	O
were	O
a	O
gift	O
from	O
Procognia	O
Ltd	O
,	O
Maidenhead	O
,	O
UK	O
.	O

The	O
translated	O
CYP3A4	B
and	O
CYP2C9	B
proteins	O
had	O
a	O
24	O
amino	O
acid	O
and	O
28	O
amino	O
acid	O
deletion	O
at	O
the	O
N	O
-	O
terminus	O
respectively	O
.	O

Expression	O
plasmids	O
for	O
8	O
CYP3A4	B
and	O
7	O
CYP2C9	B
polymorphic	O
variants	O
were	O
generated	O
from	O
the	O
pBJW102	O
.	O
2	O
+	O
CYP3A4	B
and	O
the	O
pBJW102	O
.	O
2	O
+	O
CYP2C9	B
wild	O
-	O
type	O
expression	O
plasmids	O
by	O
inverse	O
PCR	O
using	O
the	O
5phosphorylated	O
primers	O
listed	O
in	O
Supplementary	O
Table	O
.	O

CYP3A4	B
and	O
CYP2C9	B
holo	O
P450	O
protein	O
content	O
in	O
the	O
enriched	O
protein	O
samples	O
was	O
determined	O
using	O
carbon	O
monoxide	O
spectral	O
assays	O
^	O
.	O

The	O
cuvettes	O
were	O
then	O
placed	O
back	O
into	O
the	O
spectrophotometer	O
maintained	O
at	O
a	O
constant	O
temperature	O
of	O
34	O
C	O
(	O
for	O
CYP3A4	B
samples	O
)	O
or	O
48	O
C	O
(	O
for	O
CYP2C9	B
samples	O
)	O
by	O
circulating	O
water	O
from	O
a	O
heated	O
water	O
bath	O
through	O
the	O
cell	O
holder	O
.	O

CYP3A4	B
and	O
CYP2C9	B
Wild	O
-	O
Type	O
protein	O
samples	O
were	O
separated	O
using	O
the	O
BioSep	O
-	O
SEC	O
-	O
S3000	O
column	O
with	O
exclusion	O
range	O
of	O
5	O
kDa	O
to	O
700	O
kDa	O
.	O

Selaginellin	O
and	O
selaginellin	O
M	O
also	O
showed	O
medium	O
inhibitory	O
potential	O
against	O
CYP2C9	B
,	O
CYP2J2	O
,	O
UGT1A1	O
,	O
and	O
UGT1A3	O
(	O
1	O
M	O
<	O
IC50	O
<	O
5	O
M	O
)	O
.	O

Two	O
selaginellins	O
also	O
showed	O
medium	O
inhibitory	O
potential	O
on	O
CYP2C9	B
-	O
catalyzed	O
tolbutamide	O
hydroxylation	O
,	O
CYP2J2	O
-	O
catalyzed	O
astemizole	O
O	O
-	O
demethylation	O
,	O
UGT1A1	O
-	O
catalyzed	O
SN	O
-	O
38	O
glucuronidation	O
,	O
and	O
UGT1A3	O
-	O
catalyzed	O
chenodeoxycholic	O
acid	O
glucuronidation	O
activities	O
(	O
IC_50	O
<	O
5	O
M	O
)	O
.	O

Therefore	O
,	O
the	O
inhibitory	O
effect	O
of	O
selaginellins	O
might	O
be	O
important	O
for	O
producing	O
potential	O
herb	O
-	O
drug	O
interaction	O
with	O
drugs	O
which	O
undergo	O
CPY2C8	O
,	O
CYP2C9	B
,	O
CYP2J2	O
,	O
and	O
UGT1A1	O
-	O
mediated	O
biotransformation	O
;	O
such	O
drugs	O
include	O
glipizide	O
,	O
irinotecan	O
,	O
losartan	O
,	O
paclitaxel	O
,	O
tolbutamide	O
,	O
and	O
warfarin	O
.	O

The	O
obtained	O
results	O
for	O
these	O
cytochromes	O
can	O
be	O
explained	O
by	O
considering	O
the	O
usual	O
structure	O
of	O
their	O
substrates	O
;	O
CYP2C9	B
substrates	O
possess	O
weakly	O
acidic	O
properties	O
and	O
multiple	O
aromatic	O
rings	O
.	O

Another	O
Cytochrome	B
P450	I
isoform	O
inhibited	O
by	O
the	O
studied	O
molecules	O
is	O
the	O
-	O
CYP2C9	B
,	O
in	O
agreement	O
with	O
result	O
obtained	O
in	O
the	O
substrate	O
behavior	O
studies	O
.	O

Cytochromes	O
CYP2C19	B
,	O
CYP3A4	B
,	O
and	O
CYP1A2	B
(	O
especially	O
CYP2C9	B
)	O
play	O
a	O
major	O
role	O
in	O
the	O
metabolism	O
of	O
warfarin	O
in	O
the	O
human	O
body	O
.	O

The	O
presence	O
in	O
the	O
patients	O
genome	O
of	O
the	O
alleles	O
R144C	O
(	O
CYP2C9	B
*	O
2	O
)	O
and	O
I359L	O
(	O
CYP2C9	B
*	O
3	O
)	O
leads	O
to	O
a	O
steady	O
decrease	O
in	O
cytochrome	O
activity	O
(	O
up	O
to	O
90	O
%	O
for	O
homozygous	O
variants	O
)	O
and	O
alters	O
the	O
drugs	O
half	O
-	O
life	O
.	O

The	O
greatest	O
contributor	O
to	O
the	O
biotransformation	O
of	O
drugs	O
is	O
CYP3A4	B
/	O
5	O
(	O
30	O
.	O
2	O
%	O
)	O
,	O
followed	O
by	O
CYP2D6	B
(	O
20	O
.	O
0	O
%	O
)	O
,	O
CYP2C9	B
(	O
12	O
.	O
8	O
%	O
)	O
,	O
CYP1A2	B
(	O
8	O
.	O
9	O
%	O
)	O
,	O
and	O
others	O
.	O

Approximately	O
80	O
%	O
of	O
conventional	O
drugs	O
are	O
metabolized	O
by	O
specific	O
enzymes	O
(	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP2E1	B
,	O
and	O
CYP3A4	B
)	O
belonging	O
to	O
subfamilies	O
,	O
CYP1	O
,	O
CYP2	O
,	O
and	O
CYP3	O
.	O

ASP	O
showed	O
24	O
%	O
inhibition	O
of	O
CYP2C9	B
at	O
100	O
g	O
/	O
mL	O
and	O
23	O
%	O
inhibition	O
of	O
CYP3A4	B
at	O
200	O
g	O
/	O
mL	O
activity	O
,	O
while	O
PPAG	O
had	O
no	O
effect	O
on	O
any	O
of	O
these	O
enzymes	O
.	O

PPAG	O
,	O
ASP	O
,	O
GRT	O
,	O
and	O
FRE	O
did	O
not	O
significantly	O
affect	O
CYP2C9	B
enzyme	O
activity	O
(	O
b	O
)	O
.	O

GRT	O
showed	O
a	O
slight	O
increase	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
inhibition	O
of	O
CYP2C9	B
activity	O
after	O
approximately	O
15	O
min	O
,	O
however	O
,	O
this	O
inhibitory	O
effect	O
was	O
more	O
noticeable	O
than	O
for	O
the	O
positive	O
inhibitor	O
,	O
sulfaphenazole	O
(	O
b	O
)	O
.	O

CYP2C9	B
plays	O
a	O
role	O
in	O
the	O
oxidation	O
of	O
xenobiotic	O
and	O
endogenous	O
compounds	O
and	O
is	O
responsible	O
for	O
the	O
metabolism	O
of	O
15	O
%	O
-	O
20	O
%	O
of	O
drugs	O
undergoing	O
phase	O
I	O
metabolism	O
.	O

CYP2C9	B
is	O
also	O
involved	O
in	O
the	O
metabolic	O
clearance	O
of	O
therapeutic	O
drugs	O
such	O
as	O
oral	O
hypoglycemics	O
(	O
pioglitazone	O
,	O
glyburide	O
,	O
and	O
tolbutamide	O
)	O
,	O
cyclooxygenase	O
-	O
2	O
anti	O
-	O
inflammatories	O
(	O
celecoxib	O
,	O
ibuprofen	O
,	O
and	O
naproxen	O
)	O
,	O
and	O
oral	O
anti	O
-	O
coagulants	O
(	O
warfarin	O
)	O
.	O

Changes	O
in	O
metabolic	O
activity	O
caused	O
by	O
genetic	O
variants	O
in	O
CYP2C9	B
play	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
caused	O
by	O
adverse	O
drug	O
reactions	O
.	O

Patients	O
with	O
low	O
enzyme	O
activity	O
are	O
at	O
risk	O
of	O
adverse	O
drug	O
reactions	O
from	O
these	O
CYP2C9	B
substrates	O
.	O

However	O
,	O
a	O
partial	O
time	O
-	O
dependent	O
decrease	O
in	O
CYP2C9	B
activity	O
was	O
shown	O
for	O
GRT	O
and	O
FRE	O
with	O
GRT	O
demonstrating	O
stronger	O
inhibitory	O
potential	O
than	O
the	O
competitive	O
CYP2C9	B
inhibitor	O
,	O
sulfaphenazole	O
.	O

Queried	O
databases	O
included	O
,	O
eg	O
,	O
PharmGKB	O
,	O
PharmVar	O
(	O
available	O
only	O
for	O
CYP2C9	B
,	O
2C19	O
,	O
2D6	O
genes	O
)	O
,	O
ADReCS	O
-	O
Target	O
an	O
Adverse	O
Drug	O
Reaction	O
Classification	O
System	O
-	O
Target	O
Profile	O
(	O
http	O
:	O
/	O
/	O
bioinf	O
.	O
xmu	O
.	O
edu	O
.	O
cn	O
/	O
ADReCS	O
-	O
Target	O
)	O
,	O
which	O
provides	O
comprehensive	O
information	O
about	O
ADRs	O
caused	O
by	O
drug	O
interaction	O
with	O
protein	O
,	O
gene	O
and	O
genetic	O
variation	O
,	O
PheWas	O
Resources	O
(	O
phenome	O
-	O
wide	O
association	O
studies	O
with	O
antineoplastic	O
drugs	O
)	O
,	O
Clinvar	O
and	O
dbSNP	O
.	O

Recombinant	O
CYPs	O
showing	O
the	O
highest	O
specific	O
activity	O
were	O
CYP3A4	O
,	O
CYP3A7	O
and	O
to	O
lower	O
extent	O
CYP2C9	B
and	O
CTP2C8	O
.	O

Michaelis	O
-	O
Menten	O
enzyme	O
kinetics	O
were	O
determined	O
for	O
pooled	O
human	O
liver	O
microsomes	O
,	O
recombinant	O
CYP3A4	O
,	O
CYP3A7	O
and	O
CYP2C9	B
.	O

The	O
combined	O
results	O
show	O
that	O
the	O
5hydroxylation	O
of	O
flucloxacillin	O
is	O
primarily	O
catalysed	O
by	O
CYP3A4	O
,	O
CYP3A7	O
and	O
CYP2C9	B
.	O

Quantification	O
of	O
specific	O
activities	O
and	O
enzyme	O
kinetics	O
of	O
flucloxacillin	O
hydroxylation	O
by	O
HLM	O
and	O
14	O
recombinant	O
human	O
CYPs	O
.	O
Next	O
to	O
CYP3A4	O
,	O
CYP3A7	O
and	O
CYP2C9	B
may	O
contribute	O
significantly	O
to	O
flucloxacillin	O
hydroxylation	O
.	O
Sulfaphenazole	O
,	O
considered	O
as	O
a	O
selective	O
CYP2C9	B
inhibitor	O
,	O
strongly	O
inhibits	O
CYP3Amediated	O
flucloxacillin	O
hydroxylation	O
.	O

Interindividual	O
variability	O
and	O
drugdrug	O
interactions	O
at	O
the	O
level	O
of	O
CYP3A4	O
,	O
CYP3A7	O
and	O
CYP2C9	B
may	O
be	O
important	O
factors	O
determining	O
the	O
risk	O
of	O
flucloxacillininduced	O
liver	O
injury	O
.	O

456252	O
)	O
,	O
CYP2C9	B
*	O
1	O
(	O
Arg144	O
)	O
(	O
Lot	O
No	O
.	O

Because	O
these	O
incubations	O
were	O
only	O
performed	O
to	O
identify	O
the	O
most	O
active	O
enzymes	O
,	O
duplicate	O
experiments	O
were	O
deemed	O
sufficient	O
since	O
reproducibility	O
of	O
incubations	O
with	O
recombinant	O
enzymes	O
from	O
the	O
same	O
source	O
was	O
always	O
within	O
5	O
%	O
,	O
For	O
the	O
most	O
active	O
Gentest	O
Supersomes	O
and	O
pooled	O
HLM	O
,	O
the	O
enzyme	O
kinetics	O
of	O
the	O
formation	O
of	O
5HMFLX	O
were	O
determined	O
by	O
incubating	O
with	O
11	O
concentrations	O
of	O
flucloxacillin	O
,	O
ranging	O
from	O
0	O
to	O
500	O
M	O
.	O
Each	O
flucloxacillin	O
concentration	O
was	O
incubated	O
in	O
duplicate	O
for	O
10	O
min	O
with	O
0	O
.	O
5	O
mgmL	O
^	O
1	O
pooled	O
HLM	O
,	O
100	O
nM	O
CYP3A4	O
,	O
CYP3A7	O
and	O
CYP2C9	B
Supersomes	O
in	O
100	O
mM	O
potassium	O
phosphate	O
buffer	O
,	O
pH	O
7	O
.	O
4	O
supplemented	O
with	O
5	O
mM	O
MgCl_2	O
and	O
2	O
mM	O
EDTA	O
.	O

Because	O
the	O
CYP2C9specific	O
inhibitor	O
sulfaphenazole	O
appeared	O
to	O
almost	O
completely	O
block	O
formation	O
of	O
5HMFLX	O
by	O
pooled	O
HLM	O
,	O
it	O
was	O
also	O
added	O
at	O
different	O
concentrations	O
to	O
incubations	O
of	O
CYP3A4	O
and	O
CYP3A7	O
Supersomes	O
with	O
flucloxacillin	O
(	O
10	O
M	O
)	O
and	O
testosterone	O
(	O
50	O
M	O
)	O
.	O

At	O
a	O
flucloxacillin	O
concentration	O
of	O
10	O
M	O
,	O
recombinant	O
CYP3A4	O
,	O
CYP3A7	O
and	O
to	O
a	O
lesser	O
extent	O
CYP2C9	B
showed	O
the	O
highest	O
activity	O
,	O
in	O
terms	O
of	O
the	O
formation	O
of	O
5HMFLX	O
.	O

As	O
CYP3A4	O
,	O
CYP3A7	O
and	O
CYP2C9	B
Supersomes	O
showed	O
highest	O
activity	O
at	O
both	O
concentrations	O
,	O
the	O
enzyme	O
kinetics	O
of	O
5HMFLX	O
formation	O
was	O
also	O
determined	O
for	O
these	O
recombinant	O
CYPs	O
.	O

Using	O
the	O
Michaelis	O
-	O
Menten	O
model	O
,	O
the	O
following	O
enzyme	O
kinetic	O
parameters	O
were	O
determined	O
:	O
CYP3A4	O
,	O
K	O
_M	O
124	O
15	O
M	O
,	O
V_max	O
197	O
9	O
pmolmin	O
^	O
1nmol	O
^	O
1	O
P450	O
;	O
CYP3A7	O
:	O
K	O
_M	O
65	O
8	O
M	O
,	O
V_max	O
193	O
7	O
pmolmin	O
^	O
1nmol	O
^	O
1	O
P450	O
;	O
and	O
CYP2C9	B
:	O
K	O
_M	O
of	O
508	O
82	O
M	O
,	O
V_max	O
67	O
7	O
pmolmin	O
^	O
1nmol	O
^	O
1	O
P450	O
.	O

Although	O
recombinant	O
CYP2C9	B
showed	O
much	O
lower	O
activity	O
when	O
compared	O
to	O
CYP3A4	O
,	O
an	O
almost	O
90	O
%	O
inhibition	O
of	O
5HMFLX	O
formation	O
was	O
observed	O
in	O
the	O
presence	O
of	O
sulfaphenazole	O
,	O
which	O
is	O
considered	O
to	O
be	O
a	O
selective	O
CYP2C9	B
inhibitor	O
.	O

However	O
,	O
fluvoxamine	O
,	O
the	O
other	O
CYP2C9	B
inhibitor	O
used	O
,	O
did	O
not	O
show	O
significant	O
inhibition	O
of	O
5HMFLX	O
formation	O
.	O

At	O
both	O
concentrations	O
of	O
flucloxacillin	O
,	O
the	O
highest	O
correlation	O
coefficients	O
were	O
found	O
with	O
CYP2C9catalysed	O
diclofenac	O
4hydroxylation	O
,	O
with	O
Pearson	O
correlation	O
coefficients	O
of	O
0	O
.	O
78	O
and	O
0	O
.	O
58	O
,	O
respectively	O
,	O
and	O
CYP3Acatalysed	O
6BETAhydroxylation	O
,	O
with	O
correlation	O
coefficients	O
of	O
0	O
.	O
69	O
and	O
0	O
.	O
58	O
respectively	O
.	O

In	O
addition	O
,	O
studies	O
have	O
showed	O
association	O
between	O
rs2606345	O
in	O
CYP1A1	B
gene	O
and	O
North	O
Indian	O
women	O
with	O
epilepsy	O
,	O
and	O
between	O
rs762551	O
in	O
CYP1A2	B
and	O
CBZ	O
pharmacokinetics	O
in	O
children	O
diagnosed	O
with	O
partial	O
or	O
generalized	O
tonic	O
-	O
clonic	O
seizures	O
.	O

In	O
contrast	O
to	O
this	O
finding	O
,	O
we	O
have	O
previously	O
reported	O
that	O
acute	O
DOX	O
-	O
induced	O
cardiotoxicity	O
caused	O
significant	O
induction	O
of	O
CYP1A1	B
in	O
the	O
hearts	O
of	O
male	O
Sprague	O
Dawley	O
rats	O
.	O

^	O
,	O
The	O
dose	O
-	O
response	O
and	O
different	O
time	O
course	O
induction	O
of	O
CYP1A1	B
is	O
well	O
characterized	O
in	O
the	O
liver	O
of	O
female	O
Sprague	O
-	O
Dawley	O
rats	O
following	O
exposure	O
to	O
TCDD	O
and	O
the	O
tertiary	O
mixture	O
^	O
,	O
,	O
,	O
CYP1A1	B
induction	O
occurs	O
in	O
virtually	O
every	O
tissue	O
of	O
the	O
body	O
following	O
exposure	O
to	O
either	O
TCDD	O
or	O
the	O
tertiary	O
mixture	O
.	O

^	O
,	O
By	O
using	O
the	O
continuous	O
nonlinear	O
Hill	O
model	O
,	O
the	O
induction	O
of	O
hepatic	O
CYP1A1	B
was	O
compared	O
in	O
female	O
rats	O
following	O
exposure	O
to	O
TCDD	O
,	O
PCB	O
126	O
,	O
and	O
PeCDF	O
alone	O
or	O
their	O
tertiary	O
mixture	O
with	O
doses	O
or	O
TEQ	O
doses	O
ranging	O
from	O
0	O
-	O
100	O
ng	O
/	O
kg	O
/	O
day	O
for	O
14	O
,	O
31	O
,	O
or	O
53	O
weeks	O
.	O

^	O
In	O
summary	O
,	O
although	O
the	O
importance	O
of	O
CYP1A1	B
in	O
the	O
induction	O
of	O
oxidative	O
DNA	O
damage	O
was	O
implied	O
previously	O
,	O
the	O
complicated	O
association	O
between	O
DNA	O
oxidation	O
damage	O
and	O
induction	O
of	O
CYP1A1	B
by	O
DLCs	O
or	O
their	O
mixtures	O
cannot	O
be	O
completely	O
described	O
in	O
our	O
study	O
and	O
still	O
requires	O
further	O
detailed	O
exploration	O
.	O

DNA	O
oxidation	O
products	O
,	O
oxidative	O
stress	O
biomarkers	O
,	O
CYP1A1	B
induction	O
,	O
and	O
genomic	O
studies	O
consistently	O
suggest	O
that	O
the	O
simple	O
TEF	O
methodology	O
cannot	O
be	O
applied	O
to	O
evaluate	O
the	O
diverse	O
patterns	O
of	O
toxic	O
effects	O
induced	O
by	O
DLCs	O
.	O

Dose	O
-	O
and	O
time	O
-	O
dependent	O
induction	O
of	O
CYP1A1	B
and	O
CYP1A2	B
was	O
detected	O
in	O
the	O
livers	O
of	O
female	O
rats	O
exposed	O
to	O
TCDD	O
or	O
the	O
tertiary	O
mixture	O
,	O
which	O
is	O
also	O
in	O
accordance	O
with	O
our	O
results	O
of	O
DNA	O
oxidation	O
products	O
.	O

Although	O
the	O
2	O
-	O
year	O
tumor	O
incidence	O
data	O
support	O
the	O
application	O
of	O
the	O
TEF	O
approach	O
in	O
the	O
risk	O
assessment	O
of	O
DLCs	O
based	O
on	O
the	O
generation	O
of	O
similar	O
dose	O
-	O
response	O
curves	O
in	O
response	O
to	O
TCDD	O
and	O
the	O
tertiary	O
mixture	O
exposed	O
female	O
rats	O
,	O
^	O
the	O
TEF	O
approach	O
cannot	O
be	O
applied	O
to	O
evaluate	O
the	O
DNA	O
oxidation	O
products	O
in	O
this	O
study	O
,	O
CYP1A1	B
or	O
CYP1A2	B
induction	O
,	O
or	O
oxidative	O
biomarkers	O
.	O

These	O
data	O
suggest	O
the	O
potential	O
involvement	O
of	O
CYP1A1	B
/	O
2	O
in	O
the	O
ribosylation	O
of	O
theophylline	O
,	O
since	O
theonosine	O
production	O
appears	O
to	O
be	O
greater	O
in	O
microsomal	O
tissue	O
from	O
smokers	O
.	O

Recently	O
,	O
we	O
have	O
found	O
that	O
the	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
/	O
cytochrome	B
b	I
_5	I
/	O
NADH	O
system	O
can	O
also	O
substitute	O
the	O
POR	O
/	O
NADPH	O
system	O
and	O
act	O
as	O
an	O
electron	O
donor	O
to	O
another	O
CYP	O
enzyme	O
,	O
CYP1A1	B
,	O
for	O
the	O
oxidation	O
of	O
benzo	O
[	O
a	O
]	O
pyrene	O
(	O
BaP	O
)	O
.	O

This	O
NADH	O
-	O
dependent	O
system	O
can	O
,	O
therefore	O
,	O
function	O
as	O
a	O
sole	O
electron	O
donor	O
for	O
both	O
reduction	O
steps	O
in	O
the	O
reaction	O
cycles	O
of	O
CYP1A1	B
and	O
CYP3A4	B
[	O
,	O
.	O

These	O
results	O
,	O
and	O
those	O
found	O
for	O
the	O
interaction	O
of	O
cytochrome	B
b	I
_5	I
with	O
CYP1A1	B
,	O
demonstrate	O
that	O
the	O
natural	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
cytochrome	B
b	I
_5	I
protein	O
dictates	O
the	O
optimal	O
conformational	O
state	O
of	O
the	O
CYP	O
-	O
cytochrome	B
b	I
_5	I
complex	O
.	O

Our	O
data	O
confirmed	O
previous	O
results	O
found	O
for	O
CYP3A4	B
and	O
for	O
CYP1A1	B
that	O
NADH	O
:	O
cytochrome	B
b	I
_5	O
reductase	O
/	O
cytochrome	B
b	I
_5	O
/	O
NADH	O
can	O
replace	O
NADPH	O
/	O
POR	O
in	O
the	O
catalytic	O
cycle	O
of	O
the	O
CYP	O
reactions	O
in	O
the	O
monooxygenase	O
system	O
[	O
,	O
.	O

Various	O
studies	O
highlighted	O
the	O
interactions	O
between	O
tetramethoxystilbene	O
and	O
the	O
AhR	O
-	O
CYP1A	O
signaling	O
pathway	O
and	O
define	O
as	O
substrates	O
and	O
inhibitors	O
of	O
CYP1A1	B
,	O
CYP1A2	B
and	O
CYP1B1	O
enzymes	O
.	O

Among	O
all	O
the	O
studies	O
,	O
compound	O
tetramethoxystilbene	O
was	O
found	O
to	O
be	O
more	O
potent	O
and	O
selective	O
in	O
inhibiting	O
CYP1A1	B
,	O
CYP1A2	B
and	O
CYP1B1	O
activities	O
.	O

It	O
down	O
regulated	O
the	O
expression	O
of	O
Cyclin	O
D1	O
,	O
cyclin	O
B1	O
and	O
CDK	O
4	O
as	O
well	O
as	O
p27Kip1	O
,	O
and	O
enhanced	O
the	O
level	O
of	O
cyclin	O
E	O
.	O
Furthermore	O
,	O
as	O
3	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
THS	O
was	O
produced	O
by	O
resveratrol	O
during	O
metabolism	O
,	O
so	O
it	O
could	O
also	O
suppress	O
the	O
TCDD	O
-	O
dependent	O
induction	O
of	O
CYP1A1	B
and	O
CYP1B1	O
in	O
HepG2	O
cells	O
.	O

The	O
CYP1A1	B
enzyme	O
plays	O
a	O
role	O
in	O
the	O
metabolism	O
of	O
caffeine	O
as	O
well	O
as	O
the	O
bioactivation	O
of	O
polycyclic	O
aromatic	O
hydrocarbons	O
.	O

The	O
CYP1A1	B
*	O
2A	O
variant	O
located	O
in	O
the	O
3	O
non	O
-	O
coding	O
region	O
confers	O
a	O
restriction	O
endonuclease	O
site	O
for	O
cleavage	O
by	O
Msp1	O
.	O

CYP1A1	B
*	O
2C	O
is	O
characterized	O
by	O
a	O
nonsynonymous	O
base	O
change	O
that	O
results	O
in	O
an	O
amino	O
acid	O
substitution	O
associated	O
with	O
an	O
increase	O
in	O
CYP1A1	B
gene	O
inducibility	O
.	O

The	O
frequencies	O
of	O
CYP1A1	B
*	O
2A	O
and	O
*	O
2C	O
were	O
determined	O
in	O
two	O
Amerindian	O
peoples	O
,	O
the	O
Teenek	O
and	O
Mayos	O
and	O
compared	O
to	O
the	O
Mestizo	O
Mexican	O
population	O
.	O

In	O
the	O
Teenek	O
population	O
,	O
the	O
minor	O
allele	O
frequencies	O
(	O
MAFs	O
)	O
of	O
CYP1A1	B
*	O
2A	O
and	O
*	O
2C	O
were	O
71	O
.	O
4	O
and	O
65	O
.	O
4	O
%	O
,	O
respectively	O
and	O
in	O
the	O
Mayos	O
the	O
MAFs	O
were	O
46	O
.	O
9	O
and	O
54	O
.	O
6	O
%	O
,	O
respectively	O
.	O

Both	O
Amerindian	O
populations	O
had	O
a	O
significantly	O
higher	O
frequency	O
of	O
CYP1A1	B
*	O
2C	O
compared	O
to	O
the	O
Mexican	O
Mestizo	O
population	O
(	O
34	O
.	O
4	O
%	O
)	O
,	O
while	O
only	O
the	O
Teenek	O
had	O
a	O
significantly	O
higher	O
frequency	O
of	O
CYP1A1	B
*	O
2A	O
compared	O
to	O
the	O
Mestizo	O
population	O
(	O
40	O
.	O
1	O
%	O
)	O
.	O

CYP1A1	B
is	O
a	O
well	O
-	O
known	O
AhR	O
target	O
gene	O
,	O
and	O
both	O
compounds	O
BaP	O
and	O
PCB118	O
are	O
potent	O
AhR	O
agonists	O
.	O

Addition	O
of	O
organic	O
pollutants	O
at	O
the	O
early	O
stage	O
of	O
the	O
induction	O
process	O
,	O
ie	O
,	O
Time	O
1	O
led	O
to	O
a	O
lower	O
induction	O
of	O
CYP1A1	B
expression	O
than	O
expected	O
:	O
a	O
low	O
induction	O
following	O
treatment	O
of	O
the	O
cells	O
with	O
BaP	O
and	O
PCB118	O
,	O
and	O
no	O
induction	O
with	O
PCB153	O
.	O

However	O
,	O
when	O
the	O
cells	O
were	O
co	O
-	O
treated	O
with	O
BaP	O
and	O
PCB118	O
,	O
we	O
observed	O
a	O
potentiation	O
of	O
the	O
CYP1A1	B
induction	O
and	O
surprisingly	O
,	O
such	O
a	O
potentiation	O
was	O
also	O
observed	O
in	O
response	O
to	O
the	O
combination	O
of	O
BaP	O
with	O
PCB153	O
.	O

When	O
pollutants	O
were	O
tested	O
at	O
Time	O
2	O
,	O
only	O
BaP	O
induced	O
significantly	O
the	O
CYP1A1	B
expression	O
.	O

Surprisingly	O
,	O
this	O
induction	O
of	O
CYP1A1	B
was	O
partly	O
repressed	O
by	O
a	O
co	O
-	O
addition	O
of	O
PCB118	O
or	O
PCB153	O
.	O

On	O
the	O
other	O
hand	O
,	O
cytochromes	O
P450	O
,	O
notably	O
those	O
belonging	O
to	O
the	O
CYP1	O
family	O
,	O
can	O
induce	O
endoplasmic	O
reticulum	O
stress	O
,	O
and	O
interestingly	O
,	O
our	O
results	O
show	O
that	O
combination	O
of	O
BaP	O
and	O
PCB118	O
induces	O
CYP1A1	B
expression	O
in	O
adipocytes	O
.	O

Previously	O
,	O
we	O
have	O
demonstrated	O
that	O
retinoids	O
decrease	O
the	O
CYP1A1	B
induction	O
.	O

Inversely	O
,	O
concerning	O
the	O
expression	O
of	O
CYP1A1	B
,	O
TNFALPHA	O
,	O
and	O
IL6	O
,	O
we	O
observed	O
that	O
PCB153	O
enhances	O
the	O
effect	O
of	O
BaP	O
in	O
pre	O
-	O
adipocytes	O
(	O
Time	O
1	O
treatment	O
)	O
.	O

CYP1A2	B
,	O
CYP1A1	B
and	O
NQO1	O
have	O
been	O
reported	O
to	O
be	O
the	O
major	O
enzymes	O
involved	O
in	O
AAI	O
metabolism	O
^	O
,	O
,	O
,	O
.	O

To	O
examine	O
whether	O
Glycine	O
N	O
-	O
Methyltransferase	O
participates	O
in	O
AAI	O
-	O
induced	O
nephropathy	O
,	O
the	O
levels	O
of	O
mRNA	O
expression	O
for	O
Glycine	O
N	O
-	O
Methyltransferase	O
,	O
CYP1A1	B
,	O
CYP1A2	B
,	O
and	O
NQO1	O
in	O
mouse	O
livers	O
and	O
kidneys	O
were	O
determined	O
using	O
real	O
-	O
time	O
quantitative	O
PCR	O
analysis	O
.	O

In	O
mice	O
,	O
CYP1A1	B
,	O
CYP1A2	B
and	O
CYP3A44	O
/	O
3A41	O
are	O
almost	O
not	O
expressed	O
in	O
kidney	O
^	O
.	O

CYP1A1	B
is	O
particularly	O
implicated	O
in	O
lung	O
,	O
colorectal	O
,	O
breast	O
,	O
and	O
prostate	O
cancers	O
,	O
CYP1B1	O
in	O
hormone	O
dependent	O
cancers	O
of	O
the	O
prostate	O
,	O
breast	O
,	O
and	O
endometrium	O
,	O
and	O
CYP1A2	B
in	O
colorectal	O
,	O
lung	O
,	O
and	O
breast	O
cancers	O
.	O

Escherichia	O
coli	O
membranes	O
expressing	O
human	O
CYP1A1	B
,	O
CYP1A2	B
,	O
CYP1B1	O
,	O
CYP3A4	B
,	O
and	O
CYP2D6	B
,	O
co	O
-	O
expressed	O
with	O
CYP	O
reductase	O
,	O
were	O
purchased	O
from	O
Cypex	O
Ltd	O
.	O

From	O
benzo	O
[	O
a	O
]	O
pyrene	O
,	O
CYP1A1	B
produces	O
4	O
,	O
5	O
-	O
,	O
7	O
,	O
8	O
-	O
,	O
and	O
9	O
,	O
10	O
-	O
epoxides	O
in	O
significant	O
amounts	O
.	O

The	O
three	O
-	O
residue	O
disruption	O
of	O
helix	O
F	O
in	O
CYP1A2	B
is	O
extended	O
to	O
five	O
residues	O
in	O
CYP1A1	B
.	O

This	O
suggests	O
that	O
this	O
longer	O
break	O
in	O
helix	O
F	O
and	O
a	O
slightly	O
longer	O
helix	O
B	O
are	O
the	O
only	O
secondary	O
structural	O
differences	O
that	O
are	O
observed	O
between	O
CYP1A1	B
and	O
CYP1A2	B
.	O

Moreover	O
,	O
the	O
tilt	O
that	O
was	O
observed	O
in	O
X	O
-	O
ray	O
structures	O
between	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
moieties	O
of	O
helix	O
Fis	O
more	O
pronounced	O
in	O
CYP1A2	B
than	O
in	O
CYP1A1	B
.	O

This	O
causes	O
the	O
mouth	O
of	O
one	O
of	O
the	O
four	O
channels	O
,	O
namely	O
channel	O
3	O
,	O
to	O
be	O
smaller	O
in	O
CYP1A2	B
than	O
in	O
CYP1A1	B
.	O

Similarly	O
,	O
mutation	O
Phe240Ala	O
in	O
rat	O
CYP1A1	B
has	O
changed	O
the	O
selectivity	O
of	O
hydroxylation	O
towards	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachloro	O
-	O
dibenzo	O
-	O
p	O
-	O
dioxin	O
and	O
3	O
,	O
3	O
,	O
4	O
,	O
4	O
-	O
tetrachlorobiphenyl	O
(	O
PCB77	O
)	O
.	O

The	O
F240A	O
mutant	O
presents	O
an	O
activity	O
towards	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
Tetrachloro	O
-	O
Dibenzo	O
-	O
P	O
-	O
Dioxin	O
,	O
whereas	O
the	O
wild	O
-	O
type	O
rat	O
CYP1A1	B
has	O
no	O
activity	O
detectable	O
for	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
Tetrachloro	O
-	O
Dibenzo	O
-	O
P	O
-	O
Dioxin	O
.	O

The	O
molecular	O
dynamics	O
simulation	O
performed	O
on	O
the	O
wild	O
-	O
type	O
and	O
F240A	O
mutant	O
of	O
rat	O
CYP1A1	B
,	O
showed	O
that	O
the	O
preferred	O
channels	O
(	O
those	O
that	O
are	O
open	O
most	O
of	O
the	O
time	O
and	O
are	O
wider	O
at	O
bottleneck	O
during	O
the	O
duration	O
of	O
the	O
simulations	O
)	O
are	O
not	O
the	O
same	O
between	O
the	O
mutant	O
and	O
the	O
wild	O
-	O
type	O
P450	B
enzyme	I
.	O

We	O
have	O
shown	O
that	O
resveratrol	O
does	O
not	O
strongly	O
activate	O
the	O
expression	O
of	O
CYP1A1	B
in	O
a	O
human	O
hepatocellular	O
cell	O
line	O
.	O

observed	O
CYP1A1	B
/	O
A2	O
and	O
CYP2B1	B
/	O
B2	O
protein	O
in	O
the	O
rat	O
epidermal	O
preparations	O
,	O
the	O
former	O
noticed	O
in	O
addition	O
CYP1A1	B
protein	I
after	O
treatment	O
with	O
3	O
-	O
methylcholanthrene	O
(	O
3	O
-	O
MC	O
)	O
,	O
the	O
latter	O
even	O
without	O
pretreatment	O
.	O

CYP1A1	B
,	O
1A2	O
,	O
2C12	O
were	O
not	O
observed	O
in	O
the	O
skin	O
(	O
method	O
:	O
immunoblotting	O
with	O
mono	O
-	O
specific	O
antibodies	O
)	O
.	O

reported	O
cutaneous	O
dealkylase	O
activity	O
for	O
7	O
-	O
ethoxyresorufin	O
(	O
CYP1	O
-	O
selective	O
)	O
,	O
7	O
-	O
pentoxyresorufin	O
(	O
PROD	B
)	O
(	O
CYP2B	O
-	O
selective	O
)	O
,	O
and	O
7	O
-	O
benzyloxyresorufin	O
(	O
BROD	B
)	O
(	O
broader	O
spectrum	O
for	O
rat	O
CYPs	O
including	O
CYP1A1	B
,	O
2B1	O
/	O
2	O
and	O
3A1	O
)	O
.	O

(	O
CYP1A1	B
/	O
A2	O
and	O
CYP2B1	B
/	O
B2	O
localized	O
predominantly	O
in	O
the	O
epidermis	O
and	O
sebaceous	O
glands	O
)	O
,	O
Jugert	O
et	O
al	O
.	O

concluded	O
that	O
CYP1A1	B
converts	O
eugenol	O
to	O
a	O
sensitizing	O
metabolite	O
based	O
on	O
their	O
observation	O
that	O
in	O
contrast	O
to	O
wild	O
-	O
type	O
mice	O
1A1	O
-	O
knockout	O
mice	O
are	O
not	O
sensitized	O
by	O
eugenol	O
.	O

reported	O
that	O
in	O
adult	O
human	O
full	O
-	O
thickness	O
skin	O
biopsies	O
the	O
following	O
CYPs	O
mRNA	O
were	O
increased	O
by	O
treatment	O
with	O
coal	O
tar	O
:	O
CYP1A1	B
,	O
CYP1A2	B
,	O
CYP1B1	O
,	O
CYP2C18	O
;	O
by	O
treatment	O
with	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
:	O
CYP26	O
and	O
NADPH	O
P450	O
reductase	O
(	O
CYP1A1	B
and	O
CYP1A2	B
RNAs	O
decreased	O
)	O
;	O
by	O
treatment	O
with	O
clobetasol	O
17	O
-	O
propionate	O
:	O
CYP3A5	B
.	O

found	O
in	O
cultured	O
keratinocytes	O
CYP1A1	B
,	O
1B1	O
,	O
CYP2C	O
,	O
2E1	O
,	O
3A5	O
and	O
4B1	O
mRNAs	O
,	O
in	O
cultured	O
Langerhans	O
cells	O
CYP1A1	B
,	O
1B1	O
,	O
1E1	O
,	O
3A4	O
and	O
3A7	O
mRNAs	O
,	O
in	O
fibroblasts	O
CYP1A1	B
,	O
1B1	O
,	O
2A6	O
,	O
2C	O
,	O
2D6	O
,	O
2E1	O
,	O
CYP3A5	B
and	O
3A7	O
mRNAs	O
,	O
in	O
cultured	O
melanocytes	O
CYP1A1	B
,	O
1B1	O
,	O
2A6	O
and	O
2E1	O
mRNAs	O
.	O

mRNA	O
coding	O
for	O
CYP1A1	B
,	O
CYP1A2	B
and	O
CYP1B1	O
were	O
increased	O
after	O
treatment	O
with	O
dioxin	O
.	O

mRNAs	O
coding	O
for	O
CYP1A1	B
,	O
1B1	O
,	O
2E1	O
,	O
2J2	O
,	O
3A5	O
,	O
4B1	O
,	O
low	O
levels	O
of	O
RNAs	O
coding	O
for	O
CYP2C18	O
and	O
3A4	O
,	O
but	O
no	O
RNA	O
coding	O
for	O
CYP2B6	B
were	O
recognized	O
by	O
Neis	O
et	O
al	O
.	O

The	O
CYPs	O
mRNA	O
levels	O
were	O
strongly	O
increased	O
by	O
liquor	O
carbonis	O
detergens	O
(	O
except	O
of	O
only	O
a	O
weak	O
increase	O
of	O
CYP1A1	B
mRNA	O
in	O
Phenion	O
^	O
)	O
.	O

found	O
a	O
high	O
concordance	O
(	O
83	O
-	O
86	O
%	O
)	O
of	O
xenobiotic	O
-	O
metabolizing	O
enzymes	O
mRNA	O
levels	O
between	O
Full	O
-	O
Thickness	O
Human	O
Bottom	O
Skin	O
(	O
full	O
-	O
thickness	O
human	O
bottom	O
skin	O
)	O
and	O
EpiDerm	O
^	O
with	O
the	O
exception	O
of	O
mRNAs	O
for	O
CYP1A1	B
,	O
2A6	O
,	O
2E1	O
,	O
4	O
1	O
and	O
8B1	O
which	O
were	O
observed	O
in	O
Full	O
-	O
Thickness	O
Human	O
Bottom	O
Skin	O
,	O
but	O
not	O
in	O
EpiDerm	O
^	O
.	O

CYP1A1	B
which	O
was	O
expressed	O
at	O
very	O
low	O
levels	O
,	O
was	O
dramatically	O
induced	O
by	O
BETANF	O
(	O
133	O
-	O
fold	O
)	O
and	O
3	O
-	O
MC	O
(	O
250	O
-	O
fold	O
)	O
,	O
while	O
CYP1B1	O
was	O
more	O
moderately	O
induced	O
(	O
14	O
-	O
fold	O
by	O
BETA	O
-	O
naphthoflavone	O
and	O
12	O
-	O
fold	O
by	O
3	O
-	O
MC	O
)	O
.	O

reported	O
the	O
presence	O
of	O
CYP1A1	B
/	O
A2	O
and	O
CYP2B1	B
/	O
B2	O
proteins	O
in	O
human	O
skin	O
,	O
localized	O
predominantly	O
in	O
the	O
epidermis	O
and	O
sebaceous	O
glands	O
.	O

in	O
that	O
CYP1A1	B
protein	I
was	O
found	O
predominantly	O
in	O
the	O
basal	O
cells	O
of	O
the	O
(	O
buttock	O
)	O
epidermis	O
,	O
but	O
CYP1B1	O
protein	O
in	O
the	O
epidermal	O
cells	O
other	O
than	O
the	O
basal	O
cells	O
.	O

Exposure	O
to	O
UVB	O
led	O
to	O
an	O
increase	O
of	O
epidermal	O
CYP1A1	B
and	O
1B1	O
mRNA	O
.	O

observed	O
CYP1A1	B
,	O
2B6	O
,	O
2E1	O
and	O
3A	O
protein	O
(	O
in	O
foreskin	O
)	O
predominantly	O
localized	O
in	O
the	O
suprabasal	O
layer	O
of	O
the	O
epidermis	O
.	O

showed	O
in	O
human	O
whole	O
skin	O
increases	O
of	O
CYP1A1	B
protein	I
after	O
pretreatment	O
with	O
benzo	O
[	O
a	O
]	O
pyrene	O
.	O

demonstrated	O
the	O
presence	O
of	O
CYP1A1	B
,	O
2B6	O
,	O
2E1	O
and	O
3A	O
proteins	O
,	O
CYP1A1	B
protein	I
at	O
least	O
in	O
some	O
individual	O
cells	O
.	O

Treatment	O
with	O
benz	O
[	O
a	O
]	O
anthracene	O
led	O
to	O
a	O
large	O
increase	O
in	O
the	O
number	O
of	O
cells	O
containing	O
CYP1A1	B
protein	I
and	O
to	O
a	O
large	O
increase	O
of	O
the	O
level	O
of	O
this	O
protein	O
.	O

)	O
]	O
,	O
6BETA	O
-	O
hydroxytestosterone	O
[	O
produced	O
by	O
CYP1A1	B
/	O
2	O
,	O
CYP3A4	B
/	O
5	O
/	O
7	O
and	O
CYP3A43	O
(	O
Soucek	O
et	O
al	O
.	O

BP	O
was	O
metabolized	O
by	O
ORS	O
-	O
RHE	O
to	O
hydroxy	O
-	O
,	O
diol	O
,	O
catechol	O
and	O
dione	O
metabolites	O
(	O
known	O
to	O
be	O
mainly	O
produced	O
by	O
CYP1B1	O
,	O
CYP1A1	B
and	O
microsomal	O
epoxide	O
hydrolases	O
(	O
Hvastkovs	O
et	O
al	O
.	O

observed	O
that	O
extremely	O
low	O
concentrations	O
(	O
low	O
picomolar	O
)	O
of	O
the	O
And	O
References	O
Therein	O
ligand	O
6	O
-	O
formylindolo	O
[	O
3	O
,	O
2	O
-	O
b	O
]	O
carbazole	O
are	O
sufficient	O
to	O
cause	O
significant	O
increases	O
of	O
the	O
CYP1A1	B
transcript	O
.	O

reported	O
that	O
induction	O
of	O
CYP1A1	B
transcript	O
by	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlorodibenzofuran	O
occurred	O
in	O
human	O
keratinocytes	O
in	O
culture	O
at	O
an	O
EC50	O
of	O
2	O
nM	O
,	O
but	O
only	O
in	O
presence	O
of	O
either	O
serum	O
or	O
high	O
calcium	O
(	O
2	O
mM	O
)	O
concentration	O
.	O

Since	O
these	O
conditions	O
were	O
similar	O
to	O
those	O
required	O
for	O
induction	O
of	O
the	O
transcript	O
coding	O
for	O
the	O
differentiation	O
-	O
specific	O
epidermal	O
transglutaminase	O
it	O
appears	O
that	O
terminal	O
differentiation	O
is	O
a	O
prerequisite	O
for	O
CYP1A1	B
induction	O
by	O
And	O
References	O
Therein	O
ligands	O
to	O
happen	O
in	O
human	O
skin	O
.	O

reported	O
that	O
the	O
occurrence	O
of	O
the	O
CYP1	O
inducer	O
PCB	O
126	O
(	O
3	O
,	O
3	O
,	O
4	O
,	O
4	O
,	O
5	O
-	O
pentachlorobiphenyl	O
)	O
-	O
evoqued	O
increase	O
in	O
CYP1A1	B
mRNA	O
and	O
protein	O
expression	O
was	O
inhibited	O
by	O
hypoxia	O
.	O

reported	O
that	O
mechanisms	O
other	O
than	O
ligand	O
-	O
binding	O
to	O
AhR	O
-	O
dependent	O
events	O
must	O
exist	O
which	O
also	O
lead	O
to	O
CYP1	O
induction	O
,	O
since	O
carbaryl	O
induced	O
CYP1A1	B
expression	O
in	O
HaCaT	O
without	O
being	O
an	O
And	O
References	O
Therein	O
ligand	O
.	O

In	O
monolayer	O
epidermal	O
cells	O
(	O
NHEK	O
)	O
and	O
in	O
monolayer	O
fibroblasts	O
CYP1A1	B
mRNA	O
was	O
weakly	O
,	O
but	O
significantly	O
expressed	O
in	O
cultures	O
derived	O
from	O
all	O
three	O
above	O
-	O
mentioned	O
donors	O
.	O

CYP1A1	B
mRNA	O
was	O
moderately	O
expressed	O
in	O
the	O
three	O
-	O
dimensional	O
epidermal	O
reconstructed	O
model	O
OS	O
-	O
REp	O
from	O
all	O
three	O
above	O
-	O
mentioned	O
donors	O
,	O
but	O
in	O
none	O
of	O
the	O
three	O
-	O
dimensional	O
full	O
skin	O
model	O
Phenion	O
FT	O
Skin	O
(	O
Wiegand	O
et	O
al	O
.	O
.	O
The	O
latter	O
discrepancy	O
between	O
mRNA	O
expression	O
in	O
Phenion	O
FT	O
Skin	O
versus	O
native	O
human	O
skin	O
is	O
in	O
contrast	O
to	O
the	O
expression	O
of	O
mRNAs	O
coding	O
for	O
most	O
other	O
xenobiotica	O
-	O
metabolizing	O
enzymes	O
which	O
are	O
quite	O
well	O
-	O
mirrored	O
in	O
this	O
three	O
-	O
dimensional	O
full	O
skin	O
model	O
,	O
while	O
the	O
mRNA	O
expression	O
in	O
the	O
epidermal	O
three	O
-	O
dimensional	O
model	O
OS	O
-	O
REp	O
also	O
compared	O
quite	O
well	O
with	O
that	O
of	O
the	O
epidermal	O
compartment	O
of	O
the	O
native	O
skin	O
(	O
see	O
in	O
the	O
following	O
chapters	O
)	O
.	O

CYP1A1	B
protein	I
Polycyclic	O
aromatic	O
hydrocarbons	O
,	O
such	O
as	O
BP	O
,	O
dibenzo	O
[	O
a	O
,	O
l	O
]	O
pyrene	O
,	O
7	O
,	O
12	O
-	O
dimethylbenz	O
[	O
a	O
]	O
anthracene	O
,	O
and	O
other	O
Polycyclic	O
Aromatic	O
Hydrocarbon	O
are	O
substrates	O
of	O
CYP1A1	B
generating	O
electrophilically	O
reactive	O
genotoxins	O
including	O
epoxides	O
,	O
but	O
also	O
phenols	O
which	O
are	O
then	O
conjugated	O
yielding	O
glucuronides	O
and	O
sulfates	O
allowing	O
for	O
facilitated	O
excretion	O
.	O

As	O
a	O
consequence	O
of	O
this	O
dual	O
role	O
modulations	O
of	O
CYP1A1	B
activities	O
,	O
eg	O
,	O
by	O
induction	O
may	O
lead	O
to	O
opposite	O
effects	O
after	O
different	O
routes	O
of	O
administration	O
depending	O
whether	O
these	O
lead	O
first	O
-	O
pass	O
effects	O
or	O
to	O
direct	O
exposure	O
of	O
target	O
tissues	O
(	O
Nebert	O
et	O
al	O
.	O
.	O
Schober	O
et	O
al	O
.	O

reported	O
that	O
metabolic	O
activation	O
of	O
dibenzo	O
[	O
a	O
,	O
l	O
]	O
pyrene	O
(	O
as	O
far	O
as	O
hitherto	O
known	O
the	O
most	O
carcinogenic	O
PAH	O
)	O
by	O
heterologously	O
expressed	O
CYPs	O
is	O
most	O
efficient	O
with	O
human	O
CYP1A1	B
as	O
compared	O
to	O
other	O
human	O
CYPs	O
and	O
as	O
compared	O
to	O
any	O
rat	O
CYP	O
.	O

reported	O
that	O
metabolic	O
activation	O
of	O
dibenzo	O
[	O
a	O
,	O
l	O
]	O
pyrene	O
is	O
catalyzed	O
by	O
heterologously	O
expressed	O
CYP1A2	B
,	O
albeit	O
not	O
as	O
well	O
as	O
by	O
human	O
CYP1A1	B
or	O
by	O
CYP1B1	O
,	O
but	O
better	O
than	O
by	O
other	O
human	O
CYPs	O
.	O

showed	O
that	O
metabolic	O
activation	O
of	O
the	O
most	O
carcinogenic	O
member	O
of	O
the	O
Polycyclic	O
Aromatic	O
Hydrocarbon	O
,	O
dibenzo	O
[	O
a	O
,	O
l	O
]	O
pyrene	O
,	O
is	O
efficiently	O
catalyzed	O
by	O
heterologously	O
expressed	O
human	O
CYP1B1	O
,	O
much	O
better	O
than	O
by	O
other	O
human	O
CYPs	O
and	O
by	O
rat	O
CYPs	O
,	O
but	O
less	O
efficiently	O
than	O
by	O
human	O
CYP1A1	B
.	O

In	O
monolayer	O
epidermal	O
cells	O
(	O
NHEK	O
)	O
and	O
in	O
monolayer	O
fibroblasts	O
CYP1A1	B
mRNA	O
was	O
not	O
expressed	O
in	O
cultures	O
derived	O
from	O
any	O
of	O
the	O
three	O
above	O
-	O
mentioned	O
donors	O
.	O

CYP1A1	B
mRNA	O
was	O
weakly	O
to	O
moderately	O
expressed	O
in	O
the	O
three	O
-	O
dimensional	O
epidermal	O
reconstructed	O
model	O
OS	O
-	O
REp	O
derived	O
from	O
any	O
of	O
the	O
three	O
donors	O
,	O
but	O
in	O
the	O
three	O
-	O
dimensional	O
full	O
skin	O
model	O
Phenion	O
FT	O
Skin	O
only	O
weakly	O
and	O
only	O
in	O
one	O
of	O
the	O
three	O
donors	O
(	O
Wiegand	O
et	O
al	O
.	O
.	O
Baron	O
et	O
al	O
.	O

Berberine	O
Activates	O
Aryl	O
Hydrocarbon	O
Receptor	O
but	O
Suppresses	O
CYP1A1	B
Induction	O
through	O
miR	O
-	O
21	O
-	O
3p	O
Stimulation	O
in	O
MCF	O
-	O
7	O
Breast	O
Cancer	O
Cells	O
.	O

Among	O
protoberberines	O
at	O
non	O
-	O
cytotoxic	O
concentrations	O
(	O
10	O
M	O
)	O
,	O
berberine	O
had	O
the	O
most	O
potent	O
and	O
statistically	O
significant	O
effects	O
on	O
AhR	O
activation	O
and	O
CYP1A1	B
/	O
1A2	O
/	O
1B1	O
mRNA	O
induction	O
.	O

The	O
24	O
-	O
h	O
exposure	O
to	O
10	O
M	O
berberine	O
did	O
not	O
change	O
CYP1A1	B
mRNA	O
stability	O
,	O
protein	O
level	O
and	O
function	O
.	O

Berberine	O
significantly	O
increased	O
micro	O
RNA	O
(	O
miR	O
)	O
-	O
21	O
-	O
3p	O
by	O
36	O
%	O
and	O
the	O
transfection	O
of	O
an	O
inhibitor	O
of	O
miR	O
-	O
21	O
-	O
3p	O
restored	O
the	O
induction	O
of	O
CYP1A1	B
protein	I
with	O
a	O
50	O
%	O
increase	O
.	O

While	O
CYP1A1	B
mRNA	O
was	O
elevated	O
,	O
berberine	O
-	O
induced	O
miR	O
-	O
21	O
-	O
3p	O
suppressed	O
the	O
increase	O
of	O
functional	O
CYP1A1	B
protein	I
expression	O
.	O

In	O
the	O
determination	O
of	O
CYP1	O
function	O
,	O
7	O
-	O
ethoxyresorufin	O
is	O
generally	O
used	O
as	O
a	O
common	O
substrate	O
of	O
CYP1s	O
,	O
and	O
CYP1A1	B
has	O
the	O
highest	O
turnover	O
rate	O
in	O
7	O
-	O
ethoxyresorufin	O
O	O
-	O
deethylation	O
(	O
EROD	B
)	O
.	O

CYP1A1	B
and	O
CYP1B1	O
are	O
predominantly	O
expressed	O
in	O
extrahepatic	O
tissues	O
including	O
the	O
breasts	O
(	O
mammaries	O
)	O
.	O

The	O
AhR	O
nuclear	O
translocator	O
(	O
ARNT	O
)	O
carries	O
the	O
AhR	O
-	O
ligand	O
complex	O
to	O
interact	O
with	O
the	O
dioxin	O
-	O
responsive	O
element	O
(	O
DRE	O
)	O
of	O
the	O
CYP1A1	B
,	O
CYP1A2	B
and	O
CYP1B1	O
genes	O
,	O
resulting	O
in	O
transcriptional	O
induction	O
.	O

Compared	O
to	O
the	O
dramatic	O
increase	O
in	O
CYP1A1	B
mRNA	O
by	O
TCDD	O
in	O
estrogen	O
receptor	O
(	O
ER	O
)	O
ALPHA	O
(	O
+	O
)	O
MCF	O
-	O
7	O
(	O
human	O
breast	O
adenocarcinoma	O
)	O
cells	O
,	O
ERALPHAMDA	O
-	O
MB	O
-	O
231	O
(	O
MB	O
-	O
231	O
)	O
(	O
human	O
breast	O
adenocarcinoma	O
)	O
cells	O
carry	O
an	O
ARNT	O
variant	O
with	O
an	O
incomplete	O
glutamine	O
-	O
rich	O
region	O
and	O
transactivation	O
domain	O
,	O
resulting	O
in	O
an	O
inefficient	O
CYP1A1	B
induction	O
.	O

The	O
TCDD	O
-	O
and	O
BETA	O
-	O
naphthoflavone	O
-	O
induced	O
levels	O
of	O
CYP1A1	B
mRNA	O
were	O
reduced	O
in	O
the	O
ERALPHA	O
knockdown	O
mouse	O
mammary	O
epithelial	O
cell	O
line	O
HC11	O
(	O
nontumorigenic	O
)	O
and	O
the	O
liver	O
of	O
ovariectomized	O
ER	O
knockout	O
mice	O
,	O
respectively	O
.	O

However	O
,	O
in	O
the	O
MCF	O
-	O
7	O
cell	O
line	O
,	O
TCDD	O
-	O
induced	O
CYP1A1	B
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
ERALPHA	O
knockdown	O
.	O

In	O
MCF	O
-	O
7	O
cells	O
,	O
concurrent	O
exposure	O
to	O
E2	O
reduced	O
the	O
TCDD	O
-	O
mediated	O
induction	O
of	O
CYP1A1	B
mRNA	O
through	O
the	O
ERALPHA	O
-	O
dependent	O
increase	O
of	O
DNA	O
methylation	O
of	O
DRE	O
.	O

Our	O
previous	O
report	O
demonstrated	O
that	O
these	O
three	O
protoberberines	O
could	O
inhibit	O
recombinant	O
human	O
CYP1A1	B
activity	O
.	O

A	O
CYP1A1	B
inhibitor	O
can	O
activate	O
AhR	O
indirectly	O
through	O
inhibiting	O
the	O
oxidation	O
of	O
a	O
photoproduct	O
of	O
tryptophan	O
,	O
6	O
-	O
formylindolo	O
(	O
3	O
,	O
2	O
-	O
b	O
)	O
carbazole	O
,	O
in	O
cultured	O
cells	O
.	O

Palmatine	O
(	O
10	O
M	O
)	O
activated	O
DRE	O
and	O
increased	O
CYP1A1	B
mRNA	O
and	O
EROD	B
activity	O
in	O
HepG2	O
cells	O
,	O
whereas	O
EROD	B
activity	O
remained	O
the	O
same	O
in	O
the	O
primary	O
culture	O
of	O
human	O
hepatocytes	O
.	O

In	O
HepG2	O
cells	O
,	O
berberine	O
elevated	O
CYP1A1	B
mRNA	O
until	O
it	O
approached	O
TCDD	O
-	O
induced	O
levels	O
.	O

However	O
,	O
the	O
increase	O
of	O
CYP1A1	B
protein	I
by	O
berberine	O
was	O
only	O
~	O
16	O
%	O
of	O
that	O
by	O
TCDD	O
,	O
suggesting	O
that	O
berberine	O
might	O
cause	O
post	O
-	O
transcriptional	O
down	O
-	O
regulation	O
of	O
CYP1A1	B
expression	O
.	O

The	O
influence	O
of	O
miR	O
-	O
21	O
-	O
3p	O
on	O
CYP1A1	B
expression	O
remained	O
unclear	O
.	O

The	O
effects	O
of	O
E2	O
,	O
ERALPHA	O
knockdown	O
and	O
miRs	O
on	O
the	O
berberine	O
-	O
mediated	O
CYP1A1	B
regulation	O
is	O
reported	O
for	O
the	O
first	O
time	O
.	O

In	O
MCF	O
-	O
7	O
cells	O
,	O
24	O
-	O
h	O
exposure	O
to	O
2	O
M	O
B	O
(	O
a	O
)	O
P	O
potently	O
increased	O
CYP1A1	B
,	O
CYP1A2	B
and	O
CYP1B1	O
mRNA	O
levels	O
by	O
8	O
-	O
,	O
3	O
-	O
and	O
6	O
-	O
fold	O
,	O
respectively	O
(	O
A	O
)	O
.	O

The	O
24	O
-	O
h	O
exposure	O
to	O
berberine	O
at	O
1	O
M	O
increased	O
CYP1A1	B
and	O
CYP1B1	O
mRNA	O
levels	O
by	O
3	O
-	O
and	O
2	O
-	O
fold	O
,	O
respectively	O
.	O

By	O
increasing	O
the	O
exposure	O
concentration	O
to	O
10	O
M	O
,	O
berberine	O
significantly	O
elevated	O
the	O
CYP1A1	B
,	O
CYP1A2	B
and	O
CYP1B1	O
mRNA	O
levels	O
by	O
4	O
-	O
fold	O
,	O
28	O
%	O
and	O
3	O
-	O
fold	O
,	O
respectively	O
.	O

Palmatine	O
at	O
10	O
M	O
elevated	O
CYP1A1	B
and	O
CYP1A2	B
mRNA	O
levels	O
by	O
2	O
-	O
fold	O
,	O
whereas	O
CYP1B1	O
mRNA	O
level	O
remained	O
unchanged	O
.	O

Exposure	O
to	O
10	O
M	O
jatrorrhizine	O
decreased	O
CYP1A1	B
mRNA	O
levels	O
by	O
32	O
%	O
without	O
affecting	O
CYP1A2	B
or	O
CYP1B1	O
.	O

Among	O
protoberberines	O
,	O
berberine	O
caused	O
the	O
highest	O
induction	O
of	O
CYP1A1	B
mRNA	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

The	O
24	O
-	O
h	O
exposure	O
to	O
B	O
(	O
a	O
)	O
P	O
(	O
2	O
M	O
)	O
caused	O
4	O
-	O
and	O
2	O
-	O
fold	O
increases	O
in	O
the	O
CYP1A1	B
and	O
CYP1B1	O
mRNA	O
levels	O
,	O
respectively	O
.	O

Berberine	O
,	O
palmatine	O
and	O
jatrorrhizine	O
at	O
a	O
concentration	O
up	O
to	O
10	O
M	O
had	O
no	O
effects	O
on	O
CYP1A1	B
and	O
CYP1B1	O
mRNA	O
in	O
MB	O
-	O
231	O
cells	O
(	O
B	O
)	O
.	O

The	O
differential	O
induction	O
of	O
CYP1A1	B
mRNA	O
by	O
protoberberines	O
in	O
MCF	O
-	O
7	O
cells	O
was	O
further	O
examined	O
using	O
real	O
-	O
time	O
PCR	O
analysis	O
.	O

By	O
using	O
two	O
different	O
primer	O
sets	O
,	O
jatrorrhizine	O
did	O
not	O
cause	O
a	O
significant	O
change	O
of	O
CYP1A1	B
mRNA	O
level	O
.	O

Berberine	O
and	O
palmatine	O
at	O
10	O
M	O
induced	O
CYP1A1	B
mRNA	O
by	O
6	O
-	O
30	O
fold	O
and	O
50	O
%	O
-	O
227	O
%	O
,	O
respectively	O
(	O
C	O
)	O
.	O

Results	O
of	O
PCR	O
analysis	O
consistently	O
demonstrated	O
that	O
berberine	O
caused	O
the	O
most	O
-	O
potent	O
induction	O
of	O
CYP1A1	B
mRNA	O
.	O

Thus	O
,	O
the	O
protein	O
expression	O
levels	O
of	O
CYP1A1	B
and	O
CYP1B1	O
were	O
further	O
examined	O
using	O
immunoblot	O
analysis	O
.	O

The	O
apparent	O
molecular	O
weights	O
of	O
CYP1A1	B
,	O
CYP1B1	O
and	O
CPR	O
were	O
estimated	O
to	O
be	O
53	O
,	O
54	O
and	O
78	O
kDa	O
,	O
respectively	O
.	O

In	O
MCF	O
-	O
7	O
cells	O
,	O
exposure	O
to	O
2	O
M	O
B	O
(	O
a	O
)	O
P	O
for	O
24	O
and	O
48	O
h	O
increased	O
CYP1A1	B
protein	I
level	O
by	O
2	O
-	O
fold	O
and	O
36	O
%	O
,	O
respectively	O
(	O
A	O
)	O
.	O

Neither	O
CYP1A1	B
nor	O
CYP1B1	O
protein	O
level	O
was	O
increased	O
after	O
24	O
h	O
and	O
48	O
h	O
exposure	O
to	O
10	O
M	O
berberine	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

In	O
cells	O
cultured	O
in	O
DCC	O
-	O
stripped	O
FBS	O
(	O
DCCFBS	O
)	O
-	O
supplemented	O
medium	O
,	O
E2	O
alone	O
did	O
not	O
change	O
CYP1A1	B
mRNA	O
level	O
.	O

The	O
berberine	O
-	O
mediated	O
increase	O
in	O
CYP1A1	B
mRNA	O
was	O
not	O
affected	O
by	O
concurrent	O
exposure	O
to	O
E2	O
at	O
a	O
concentration	O
up	O
to	O
10	O
nM	O
(	O
A	O
)	O
.	O

In	O
cells	O
cultured	O
in	O
FBS	O
-	O
supplemented	O
medium	O
,	O
the	O
ER	O
antagonist	O
fulvestrant	O
had	O
no	O
influence	O
on	O
the	O
berberine	O
-	O
mediated	O
CYP1A1	B
mRNA	O
induction	O
(	O
B	O
)	O
.	O

The	O
transfection	O
of	O
siERALPHA	O
resulted	O
in	O
a	O
70	O
%	O
decrease	O
of	O
basal	O
ERALPHA	O
expression	O
,	O
but	O
did	O
not	O
diminish	O
the	O
berberine	O
-	O
mediated	O
CYP1A1	B
mRNA	O
induction	O
(	O
C	O
)	O
.	O

Results	O
revealed	O
that	O
berberine	O
-	O
mediated	O
CYP1A1	B
mRNA	O
induction	O
could	O
not	O
be	O
affected	O
by	O
the	O
ERALPHA	O
signaling	O
.	O

To	O
illustrate	O
post	O
-	O
transcriptional	O
regulation	O
,	O
the	O
stability	O
of	O
CYP1A1	B
mRNA	O
was	O
first	O
determined	O
.	O

The	O
berberine	O
(	O
10	O
M	O
,	O
24	O
h	O
)	O
-	O
mediated	O
change	O
to	O
the	O
half	O
-	O
life	O
of	O
CYP1A1	B
mRNA	O
was	O
minimal	O
(	O
control	O
cells	O
:	O
9	O
.	O
3	O
3	O
.	O
4	O
h	O
;	O
berberine	O
-	O
exposed	O
cells	O
:	O
11	O
.	O
7	O
2	O
.	O
4	O
h	O
)	O
(	O
A	O
)	O
.	O

Transfection	O
of	O
a	O
miR	O
-	O
21	O
-	O
3p	O
hairpin	O
inhibitor	O
restored	O
the	O
berberine	O
-	O
mediated	O
induction	O
of	O
CYP1A1	B
protein	I
with	O
a	O
50	O
19	O
%	O
increase	O
(	O
C	O
)	O
.	O

In	O
miR	O
-	O
21	O
-	O
5p	O
hairpin	O
inhibitor	O
-	O
transfected	O
cells	O
,	O
CYP1A1	B
protein	I
level	O
remained	O
unchanged	O
after	O
berberine	O
exposure	O
.	O

These	O
results	O
revealed	O
that	O
berberine	O
stimulated	O
miR	O
-	O
21	O
-	O
3p	O
,	O
suppressing	O
the	O
elevation	O
of	O
CYP1A1	B
protein	I
.	O

Among	O
protoberberines	O
,	O
berberine	O
caused	O
the	O
most	O
-	O
potent	O
AhR	O
activation	O
and	O
CYP1A1	B
mRNA	O
stimulation	O
in	O
MCF	O
-	O
7	O
cells	O
,	O
but	O
not	O
in	O
MB	O
-	O
231	O
cells	O
.	O

Consistent	O
with	O
the	O
report	O
of	O
the	O
effect	O
of	O
TCDD	O
,	O
the	O
increases	O
in	O
CYP1B1	O
mRNA	O
by	O
berberine	O
and	O
palmatine	O
were	O
less	O
than	O
the	O
elevation	O
of	O
CYP1A1	B
mRNA	O
.	O

The	O
IC_50	O
values	O
for	O
the	O
inhibition	O
of	O
recombinant	O
human	O
CYP1A1	B
were	O
in	O
the	O
following	O
order	O
:	O
berberine	O
(	O
1	O
.	O
38	O
M	O
)	O
<	O
jatrorrhizine	O
(	O
2	O
.	O
17	O
M	O
)	O
<	O
palmatine	O
(	O
8	O
.	O
71	O
M	O
)	O
.	O

Although	O
berberine	O
was	O
predicted	O
to	O
potentially	O
activate	O
AhR	O
through	O
inhibition	O
of	O
CYP1A1	B
in	O
cells	O
,	O
the	O
CYP1A1	B
inhibitory	O
effects	O
of	O
these	O
protoberberines	O
did	O
not	O
correlate	O
with	O
their	O
respective	O
effects	O
on	O
AhR	O
activation	O
in	O
this	O
report	O
.	O

In	O
rats	O
,	O
B	O
(	O
a	O
)	O
P	O
elevated	O
the	O
CYP1A1	B
mRNA	O
level	O
in	O
the	O
ovaries	O
by	O
an	O
amount	O
comparable	O
to	O
that	O
in	O
the	O
liver	O
.	O

However	O
,	O
the	O
CYP1A1	B
protein	I
level	O
and	O
microsomal	O
EROD	B
activity	O
were	O
induced	O
by	O
B	O
(	O
a	O
)	O
P	O
in	O
the	O
liver	O
,	O
but	O
not	O
the	O
ovaries	O
.	O

Elevated	O
levels	O
of	O
miRs	O
,	O
including	O
miR	O
-	O
21	O
,	O
can	O
contribute	O
to	O
the	O
post	O
-	O
transcriptional	O
downregulation	O
of	O
ovary	O
CYP1A1	B
protein	I
expression	O
.	O

Although	O
one	O
immunoblot	O
showed	O
a	O
weak	O
to	O
mild	O
elevation	O
in	O
CYP1A1	B
protein	I
in	O
MCF	O
-	O
7	O
cells	O
exposed	O
to	O
10	O
-	O
40	O
M	O
berberine	O
for	O
48	O
h	O
,	O
the	O
statistical	O
significance	O
has	O
not	O
been	O
proven	O
.	O

Our	O
findings	O
revealed	O
that	O
neither	O
CYP1A1	B
/	O
1B1	O
protein	O
levels	O
nor	O
EROD	B
activity	O
in	O
MCF	O
-	O
7	O
cells	O
were	O
significantly	O
affected	O
by	O
protoberberines	O
at	O
a	O
non	O
-	O
cytotoxic	O
concentration	O
(	O
10	O
M	O
)	O
.	O

CYP1A1	B
protein	O
level	O
was	O
significantly	O
induced	O
by	O
berberine	O
in	O
MCF	O
-	O
7	O
cells	O
after	O
the	O
transfection	O
of	O
a	O
miR	O
-	O
21	O
-	O
3p	O
hairpin	O
inhibitor	O
,	O
demonstrating	O
that	O
miR	O
-	O
21	O
-	O
3p	O
suppressed	O
CYP1A1	B
protein	O
induction	O
.	O

While	O
berberine	O
increased	O
CYP1A1	B
mRNA	O
to	O
a	O
level	O
approaching	O
that	O
of	O
TCDD	O
-	O
exposed	O
HepG2	O
cells	O
,	O
our	O
findings	O
suggested	O
that	O
an	O
increase	O
in	O
miR	O
-	O
21	O
-	O
3p	O
might	O
be	O
the	O
reason	O
for	O
the	O
mild	O
increase	O
in	O
CYP1A1	B
protein	O
level	O
by	O
berberine	O
as	O
compared	O
to	O
that	O
induced	O
by	O
TCDD	O
.	O

While	O
the	O
CYP1A1	B
mRNA	O
was	O
increased	O
,	O
berberine	O
-	O
induced	O
miR	O
-	O
21	O
-	O
3p	O
suppressed	O
the	O
increase	O
in	O
CYP1A1	B
protein	O
and	O
function	O
.	O

Rabbit	O
polyclonal	O
antibody	O
against	O
human	O
CYP1A1	B
(	O
AB10328	O
)	O
,	O
which	O
immunoreacted	O
with	O
CYP1A1	B
in	O
a	O
human	O
thyroid	O
cancer	O
cell	O
line	O
,	O
was	O
purchased	O
from	O
Merck	O
Millipore	O
(	O
Billerica	O
,	O
MA	O
,	O
USA	O
)	O
.	O

After	O
incubation	O
with	O
5	O
%	O
non	O
-	O
fat	O
milk	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
at	O
37	O
C	O
for	O
1	O
h	O
,	O
the	O
membranes	O
were	O
incubated	O
with	O
anti	O
-	O
CYP1A1	B
(	O
1	O
:	O
2500	O
)	O
,	O
anti	O
-	O
CYP1B1	O
(	O
1	O
:	O
200	O
)	O
and	O
anti	O
-	O
CPR	O
(	O
1	O
:	O
2000	O
)	O
in	O
PBS	O
containing	O
1	O
%	O
non	O
-	O
fat	O
milk	O
overnight	O
at	O
4	O
C	O
.	O
In	O
the	O
immunoblot	O
analysis	O
of	O
ERALPHA	O
and	O
caveolin	O
-	O
1	O
,	O
cell	O
lysate	O
was	O
prepared	O
as	O
described	O
previously	O
and	O
subjected	O
to	O
electrophoresis	O
as	O
described	O
above	O
.	O

For	O
CYP1A1	B
*	O
1	O
(	O
NM_000499	O
.	O
4	O
)	O
,	O
primer	O
set	O
1	O
:	O
forward	O
primer	O
5	O
-	O
TAGACACTGATCTGGCTGCAG	O
-	O
3	O
and	O
the	O
reverse	O
primer	O
5	O
-	O
GGGAAGGCTCCATCAGCATC	O
-	O
3	O
was	O
used	O
.	O

The	O
amplification	O
of	O
CYP1A1	B
,	O
CYP1A2	B
,	O
CYP1B1	O
and	O
BETA	O
-	O
actin	O
was	O
carried	O
out	O
for	O
35	O
,	O
40	O
,	O
35	O
and	O
25	O
cycles	O
,	O
respectively	O
.	O

In	O
the	O
real	O
-	O
time	O
PCR	O
analysis	O
of	O
CYP1A1	B
mRNA	O
level	O
,	O
both	O
primer	O
set	O
1	O
and	O
a	O
reported	O
primer	O
set	O
2	O
were	O
used	O
to	O
further	O
examine	O
the	O
differential	O
effects	O
of	O
protoberberines	O
.	O

The	O
relative	O
mRNA	O
expression	O
level	O
was	O
normalized	O
to	O
the	O
GAPDH	O
transcript	O
level	O
,	O
which	O
allowed	O
the	O
target	O
cDNA	O
calculation	O
by	O
2	O
^	O
(	O
Ct	O
CYP1A1Ct	O
GAPDH	O
)	O
CYP1A1Ct	O
GAPDH	O
)	O
.	O

The	O
effects	O
on	O
CYP1A1	B
,	O
CYP2A6	O
,	O
CYP2E1	B
,	O
and	O
UGT1A6	O
activities	O
were	O
assumed	O
to	O
be	O
a	O
negligible	O
(	O
IC_50	O
>	O
25	O
M	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
clinical	O
interactions	O
between	O
these	O
compounds	O
and	O
CYP1A1	B
,	O
CYP2A6	O
,	O
CYP2E1	B
,	O
or	O
UGT1A6	O
would	O
not	O
occur	O
.	O

More	O
recently	O
,	O
in	O
vitro	O
experiments	O
have	O
shown	O
that	O
UVB	O
induced	O
the	O
expression	O
of	O
CYP1A1	B
and	O
favored	O
the	O
formation	O
of	O
DNA	O
adducts	O
upon	O
subsequent	O
exposure	O
to	O
B	O
[	O
a	O
]	O
P	O
^	O
.	O

Expression	O
of	O
the	O
phase	O
I	O
genes	O
CYP1A1	B
,	O
CYP1A2	B
,	O
and	O
CYP1B1	O
was	O
then	O
quantified	O
,	O
using	O
untreated	O
samples	O
as	O
references	O
.	O

Like	O
in	O
skin	O
,	O
CYP1A1	B
was	O
the	O
most	O
over	O
-	O
expressed	O
gene	O
in	O
HNK	O
.	O

Exposure	O
to	O
2	O
MED	O
Simulated	O
Sunlight	O
slightly	O
increased	O
expression	O
of	O
Cytochrome	B
P450	I
genes	O
(	O
fold	O
change	O
2	O
.	O
9	O
,	O
1	O
.	O
4	O
and	O
1	O
.	O
8	O
for	O
CYP1A1	B
,	O
CYP1A2	B
,	O
and	O
CYP1B1	O
,	O
respectively	O
)	O
,	O
but	O
without	O
reaching	O
statistical	O
significance	O
,	O
contrary	O
to	O
skin	O
results	O
.	O

Interestingly	O
,	O
the	O
maximal	O
level	O
of	O
adducts	O
was	O
not	O
observed	O
for	O
the	O
largest	O
concentration	O
investigated	O
(	O
5	O
M	O
)	O
,	O
but	O
rather	O
at	O
1	O
M	O
.	O
Exposure	O
to	O
Simulated	O
Sunlight	O
resulted	O
in	O
a	O
very	O
low	O
overexpression	O
of	O
CYP1A1	B
and	O
1B1	O
by	O
a	O
factor	O
of	O
2	O
,	O
but	O
not	O
of	O
CYP1A2	B
(	O
Supplementary	O
Fig	O
.	O

Over	O
the	O
time	O
period	O
investigated	O
,	O
it	O
was	O
observed	O
that	O
Simulated	O
Sunlight	O
reduced	O
the	O
stimulation	O
of	O
gene	O
expression	O
induced	O
by	O
B	O
[	O
a	O
]	O
P	O
of	O
CYP1A1	B
and	O
CYP1A2	B
,	O
particularly	O
at	O
48	O
hours	O
and	O
to	O
a	O
lesser	O
extent	O
at	O
72	O
hours	O
,	O
regardless	O
of	O
the	O
treatment	O
protocol	O
used	O
(	O
Figs	O
and	O
.	O

Costa	O
et	O
al	O
.	O
^	O
used	O
punch	O
biopsies	O
of	O
abdominal	O
skin	O
to	O
test	O
the	O
effect	O
of	O
B	O
[	O
a	O
]	O
P	O
on	O
expression	O
of	O
CYP1A1	B
.	O

Emphasis	O
was	O
placed	O
on	O
classical	O
metabolic	O
enzymes	O
CYP1A1	B
,	O
CYP1B1	O
,	O
and	O
CYP1A2	B
found	O
in	O
the	O
skin	O
and	O
other	O
organs	O
^	O
,	O
.	O

In	O
agreement	O
with	O
Costa	O
et	O
al	O
.	O
^	O
,	O
our	O
RT	O
-	O
qPCR	O
analyses	O
unambiguously	O
showed	O
that	O
exposure	O
of	O
human	O
skin	O
and	O
NHK	O
^	O
,	O
to	O
B	O
[	O
a	O
]	O
P	O
results	O
in	O
a	O
time	O
-	O
dependent	O
increase	O
of	O
CYP1A1	B
,	O
CYP1A2	B
,	O
and	O
CYP1B1	O
.	O

Katiyar	O
et	O
al	O
.	O
^	O
reported	O
that	O
CYP1A1	B
and	O
CYP1B1	O
were	O
induced	O
following	O
Ultraviolet	O
exposure	O
at	O
both	O
the	O
gene	O
and	O
protein	O
level	O
in	O
human	O
epidermis	O
.	O

Accordingly	O
,	O
we	O
report	O
that	O
Ultraviolet	O
alone	O
increases	O
expression	O
of	O
CYP1A1	B
by	O
a	O
factor	O
approximately	O
5	O
in	O
skin	O
and	O
2	O
in	O
Normal	O
Human	O
Keratinocytes	O
,	O
in	O
the	O
same	O
range	O
of	O
low	O
values	O
observed	O
by	O
others	O
^	O
,	O
,	O
,	O
,	O
,	O
.	O

Our	O
experiments	O
involving	O
irradiation	O
followed	O
by	O
B	O
[	O
a	O
]	O
P	O
treatment	O
rather	O
showed	O
that	O
preliminary	O
irradiation	O
of	O
skin	O
explants	O
strongly	O
inhibited	O
the	O
induction	O
of	O
Phase	O
I	O
CYP1A1	B
,	O
CYP1A2	B
,	O
or	O
CYP1B1	O
metabolism	O
genes	O
.	O

Gene	O
expression	O
analysis	O
was	O
performed	O
on	O
phase	O
I	O
(	O
CYP1A1	B
,	O
CYP1A2	B
,	O
Cytochrome	B
P450	I
1B1	O
,	O
and	O
EPHX1	O
)	O
and	O
phase	O
II	O
(	O
GSTA1	O
and	O
GSTP1	O
)	O
metabolism	O
genes	O
.	O

CYP1A1	B
is	O
an	O
inducible	O
isoform	O
that	O
can	O
be	O
regulated	O
by	O
aryl	O
hydrocarbon	O
receptors	O
.	O

None	O
of	O
the	O
treatments	O
statistically	O
increased	O
the	O
mRNA	O
levels	O
of	O
CYP1A1	B
,	O
although	O
BETA	O
-	O
NF	O
and	O
EtOH	O
showed	O
a	O
1	O
.	O
6	O
-	O
and	O
1	O
.	O
9	O
-	O
fold	O
increase	O
,	O
respectively	O
(	O
c	O
)	O
.	O

The	O
Western	O
Blot	O
results	O
of	O
CYP1A1	B
showed	O
the	O
same	O
non	O
-	O
induction	O
pattern	O
by	O
both	O
treatments	O
,	O
as	O
well	O
as	O
for	O
CYP3A4	B
(	O
c	O
,	O
d	O
)	O
.	O

Neither	O
CYP1A1	B
nor	O
CYP3A4	B
were	O
affected	O
by	O
both	O
treatments	O
in	O
differentiated	O
cells	O
.	O

Fluorescent	O
images	O
of	O
CYP1A1	B
revealed	O
no	O
preferential	O
localization	O
of	O
this	O
isoform	O
at	O
mitochondria	O
or	O
Endoplasmic	O
Reticulum	O
,	O
yet	O
the	O
R	O
values	O
showed	O
to	O
be	O
slightly	O
higher	O
in	O
Endoplasmic	O
Reticulum	O
.	O

Similar	O
to	O
CYP2D6	B
and	O
2E1	O
,	O
the	O
low	O
expression	O
of	O
CYP1A1	B
in	O
the	O
control	O
condition	O
did	O
not	O
allow	O
us	O
to	O
calculate	O
the	O
R	O
Pearson	O
coefficient	O
.	O

On	O
the	O
other	O
hand	O
,	O
CYP1A1	B
was	O
unexpectedly	O
not	O
induced	O
by	O
BETA	O
-	O
NF	O
.	O

On	O
the	O
contrary	O
,	O
in	O
differentiated	O
SH	O
-	O
SY5Y	O
cells	O
,	O
this	O
compound	O
was	O
able	O
to	O
increase	O
the	O
expression	O
of	O
CYP1A1	B
at	O
2	O
.	O
5	O
and	O
5	O
nM	O
.	O

In	O
general	O
terms	O
,	O
these	O
results	O
support	O
the	O
inducibility	O
of	O
CYP2D6	B
and	O
2E1	O
in	O
our	O
in	O
vitro	O
model	O
,	O
in	O
contrast	O
to	O
other	O
isoforms	O
such	O
as	O
CYP1A1	B
and	O
3A4	O
.	O

Several	O
studies	O
indicated	O
that	O
,	O
in	O
human	O
liver	O
microsomes	O
,	O
CYP1A1	B
,	O
1A2	O
,	O
2E1	O
,	O
2A6	O
,	O
and	O
2B6	O
are	O
the	O
major	O
isoforms	O
involved	O
in	O
ethoxycumarin	O
O	O
-	O
dealkylation	O
reaction	O
,	O
although	O
other	O
isoforms	O
such	O
as	O
1B1	O
,	O
2C	O
,	O
and	O
2D6	O
can	O
play	O
a	O
minor	O
role	O
.	O

The	O
localization	O
images	O
of	O
CYP1A1	B
and	O
3A4	O
showed	O
no	O
preferential	O
localization	O
of	O
these	O
isoforms	O
for	O
either	O
mitochondria	O
or	O
Endoplasmic	O
Reticulum	O
,	O
as	O
also	O
shown	O
by	O
other	O
groups	O
in	O
several	O
models	O
.	O

The	O
quantification	O
of	O
relative	O
mRNA	O
levels	O
for	O
the	O
isoforms	O
CYP1A1	B
,	O
2D6	O
and	O
2E1	O
was	O
carried	O
out	O
after	O
incubation	O
of	O
SH	O
-	O
SY5Y	O
cells	O
for	O
48	O
h	O
with	O
BETA	O
-	O
NF	O
(	O
4	O
M	O
)	O
,	O
dissolved	O
in	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
;	O
0	O
.	O
1	O
%	O
maximum	O
final	O
concentration	O
used	O
,	O
v	O
/	O
v	O
)	O
,	O
and	O
EtOH	O
(	O
100	O
mM	O
)	O
,	O
dissolved	O
in	O
water	O
.	O

The	O
following	O
probes	O
for	O
Cytochrome	B
P450	I
isoforms	O
were	O
used	O
,	O
CYP1A1	B
(	O
Life	O
Technologies	O
,	O
Assay	O
ID	O
Hs01054797_g1	O
,	O
#	O
4331182	O
)	O
,	O
CYP2D6	B
(	O
Life	O
Technologies	O
,	O
Assay	O
ID	O
Hs03043790_g1	O
,	O
#	O
4331182	O
)	O
,	O
and	O
CYP2E1	B
(	O
Life	O
Technologies	O
,	O
Assay	O
ID	O
Hs00559368_m1	O
,	O
#	O
4453320	O
)	O
.	O

The	O
analysis	O
of	O
protein	O
levels	O
was	O
performed	O
for	O
isoforms	O
CYP1A1	B
,	O
2D6	O
,	O
2E1	O
,	O
and	O
3A4	O
in	O
both	O
undifferentiated	O
and	O
differentiated	O
SH	O
-	O
SY5Y	O
cells	O
.	O

They	O
were	O
incubated	O
with	O
one	O
of	O
the	O
following	O
primary	O
antibodies	O
overnight	O
,	O
anti	O
-	O
CYP1A1	B
(	O
Life	O
Technologies	O
,	O
#	O
PA515213	O
,	O
1	O
:	O
1000	O
,	O
polyclonal	O
rabbit	O
)	O
,	O
anti	O
-	O
CYP2D6	B
(	O
Life	O
Technologies	O
,	O
#	O
PA535148	O
,	O
1	O
:	O
1000	O
,	O
polyclonal	O
rabbit	O
)	O
,	O
anti	O
-	O
CYP2E1	B
(	O
Life	O
Technologies	O
,	O
#	O
PA535351	O
,	O
1	O
:	O
1000	O
,	O
polyclonal	O
rabbit	O
)	O
,	O
or	O
anti	O
-	O
CYP3A4	B
(	O
Life	O
Technologies	O
,	O
#	O
PA514896	O
,	O
1	O
:	O
1000	O
,	O
polyclonal	O
rabbit	O
)	O
mixed	O
with	O
anti	O
-	O
BETA	O
-	O
actin	O
primary	O
antibody	O
(	O
Life	O
Technologies	O
,	O
#	O
PA516914	O
,	O
1	O
:	O
1000	O
,	O
polyclonal	O
mouse	O
)	O
as	O
an	O
endogenous	O
housekeeping	O
protein	O
.	O

To	O
determine	O
the	O
effect	O
of	O
B	O
[	O
ALPHA	O
]	O
P	O
on	O
the	O
gene	O
signature	O
in	O
human	O
T	O
lymphocytes	O
,	O
primary	O
cultures	O
of	O
T	O
lymphocytes	O
purified	O
from	O
healthy	O
blood	O
donors	O
and	O
activated	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
antibodies	O
for	O
72	O
h	O
,	O
were	O
used	O
and	O
co	O
-	O
exposed	O
to	O
2	O
M	O
B	O
[	O
ALPHA	O
]	O
P	O
for	O
the	O
last	O
48	O
h	O
.	O
We	O
previously	O
reported	O
an	O
early	O
and	O
functional	O
up	O
-	O
regulation	O
of	O
the	O
Aryl	O
Hydrocarbon	O
by	O
such	O
human	O
T	O
lymphocyte	O
activation	O
during	O
24	O
h	O
,	O
followed	O
by	O
a	O
maximal	O
response	O
of	O
target	O
genes	O
such	O
as	O
CYP1A1	B
and	O
CYP1B1	O
after	O
exposure	O
to	O
2	O
M	O
B	O
[	O
ALPHA	O
]	O
P	O
.	O
Such	O
a	O
2	O
M	O
concentration	O
is	O
in	O
the	O
range	O
of	O
B	O
[	O
ALPHA	O
]	O
P	O
concentrations	O
known	O
to	O
lead	O
to	O
maximal	O
response	O
of	O
target	O
genes	O
in	O
cultured	O
human	O
cells	O
.	O

Among	O
these	O
genes	O
,	O
as	O
expected	O
,	O
CYP1A1	B
and	O
CYP1B1	O
,	O
well	O
-	O
known	O
targets	O
of	O
Aryl	O
Hydrocarbon	O
,	O
appear	O
as	O
the	O
top	O
genes	O
over	O
-	O
expressed	O
after	O
exposure	O
to	O
B	O
[	O
ALPHA	O
]	O
P	O
,	O
thus	O
validating	O
our	O
experimental	O
conditions	O
.	O

We	O
thus	O
selected	O
the	O
most	O
significantly	O
affected	O
genes	O
:	O
CYP1A1	B
and	O
1B1	O
,	O
gap	O
junction	O
beta	O
-	O
2	O
and	O
beta	O
-	O
6	O
(	O
GJB6	O
)	O
proteins	O
,	O
TCDD	O
-	O
inducible	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
TIPARP	O
)	O
,	O
transmembrane	O
protein	O
167A	O
,	O
oligodendrocyte	O
transcription	O
factor	O
3	O
,	O
cyclin	O
-	O
dependent	O
kinase	O
-	O
binding	O
protein	O
(	O
CABLES1	O
)	O
,	O
proto	O
-	O
oncogene	O
c	O
-	O
KIT	O
and	O
E3	O
ubiquitin	O
ligase	O
specificity	O
subunit	O
(	O
ASB2	O
)	O
for	O
the	O
10	O
most	O
up	O
-	O
regulated	O
genes	O
;	O
IFN	O
-	O
induced	O
proteins	O
44L	O
,	O
44	O
(	O
IFI44	O
)	O
,	O
p78	O
(	O
MX1	O
)	O
with	O
tetratricopeptide	O
repeats	O
2	O
(	O
IFIT2	O
)	O
,	O
collagen	O
(	O
COL6A3	O
)	O
,	O
microcephalin	O
MCPH1	O
,	O
lysosomal	O
trafficking	O
regulator	O
,	O
enzyme	O
oligoadenylate	O
synthetase	O
like	O
,	O
proteoglycan	O
(	O
PRG4	O
)	O
,	O
and	O
cell	O
surface	O
antigen	O
(	O
THY1	O
)	O
for	O
the	O
10	O
most	O
down	O
-	O
regulated	O
ones	O
.	O

Thus	O
,	O
CYP1A1	B
,	O
CYP1B1	O
,	O
Gap	O
Junction	O
Beta	O
-	O
2	O
,	O
GJB6	O
,	O
TIPARP	O
,	O
Oligodendrocyte	O
Transcription	O
Factor	O
3	O
,	O
CABLES1	O
,	O
KIT	O
and	O
ASB2	O
transcriptional	O
levels	O
were	O
confirmed	O
to	O
be	O
up	O
-	O
regulated	O
after	O
B	O
[	O
ALPHA	O
]	O
P	O
exposure	O
;	O
with	O
inductions	O
reaching	O
a	O
significant	O
level	O
for	O
all	O
these	O
genes	O
except	O
for	O
Oligodendrocyte	O
Transcription	O
Factor	O
3	O
and	O
TIPARP	O
(	O
A	O
)	O
.	O

Among	O
genes	O
belonging	O
to	O
Aryl	O
Hydrocarbon	O
signaling	O
,	O
we	O
recently	O
reported	O
the	O
regulation	O
of	O
CYP1A1	B
,	O
CYP1B1	O
and	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
1A	O
in	O
human	O
T	O
lymphocytes	O
upon	O
exposure	O
to	O
B	O
[	O
ALPHA	O
]	O
P	O
.	O
The	O
Aryl	O
Hydrocarbon	O
repressor	O
,	O
the	O
cyclin	O
E2	O
and	O
the	O
NAD	O
(	O
P	O
)	O
H	O
dehydrogenase	O
(	O
NQO1	O
)	O
have	O
already	O
been	O
reported	O
to	O
be	O
robust	O
targets	O
of	O
B	O
[	O
ALPHA	O
]	O
P	O
but	O
,	O
in	O
different	O
cell	O
types	O
,	O
but	O
not	O
in	O
primary	O
T	O
lymphocytes	O
.	O

We	O
then	O
validated	O
by	O
RT	O
-	O
qPCR	O
assays	O
these	O
changes	O
in	O
Ahr	O
Repressor	O
,	O
Cyclin	O
E2	O
,	O
Cyclin	O
-	O
Dependent	O
Kinase	O
Inhibitor	O
1a	O
,	O
CYP1A1	B
,	O
CYP1B1	O
,	O
and	O
NQO1	O
gene	O
expression	O
changes	O
using	O
the	O
16	O
individual	O
RNA	O
samples	O
isolated	O
from	O
Concentration	O
Of	O
Dmso	O
and	O
B	O
[	O
ALPHA	O
]	O
P	O
-	O
treated	O
T	O
lymphocyte	O
cultures	O
(	O
A	O
)	O
.	O

Additionally	O
,	O
except	O
for	O
the	O
Aryl	O
Hydrocarbon	O
target	O
genes	O
,	O
CYP1A1	B
and	O
CYP1B1	O
,	O
few	O
of	O
the	O
158	O
differentially	O
expressed	O
transcripts	O
displayed	O
strong	O
amplitude	O
in	O
the	O
changes	O
observed	O
.	O

Among	O
genes	O
identified	O
by	O
our	O
study	O
,	O
some	O
have	O
already	O
been	O
described	O
to	O
be	O
targeted	O
by	O
B	O
[	O
ALPHA	O
]	O
P	O
.	O
This	O
is	O
notably	O
true	O
for	O
CYP1A1	B
,	O
CYP1B1	O
,	O
the	O
ferredoxin	O
reductase	O
,	O
NQO1	O
,	O
Cyclin	O
-	O
Dependent	O
Kinase	O
Inhibitor	O
1a	O
,	O
Ahr	O
Repressor	O
,	O
ASB2	O
or	O
TIPARP	O
up	O
-	O
regulated	O
genes	O
and	O
MX1	O
or	O
the	O
solute	O
carrier	O
SLC25A37	O
,	O
regarding	O
the	O
down	O
-	O
regulated	O
ones	O
.	O

Nevertheless	O
,	O
AhR	O
-	O
and	O
p53	O
-	O
target	O
genes	O
such	O
as	O
CYP1A1	B
,	O
CYP1B1	O
,	O
Ahr	O
Repressor	O
,	O
ASB2	O
or	O
Cyclin	O
-	O
Dependent	O
Kinase	O
Inhibitor	O
1a	O
and	O
the	O
ribonucleotide	O
reductase	O
RRM2B	O
were	O
shown	O
to	O
be	O
modulated	O
in	O
both	O
type	O
of	O
cells	O
,	O
all	O
encoding	O
enzymes	O
important	O
in	O
the	O
detoxication	O
and	O
the	O
DNA	O
damage	O
response	O
induced	O
after	O
B	O
[	O
ALPHA	O
]	O
P	O
exposure	O
.	O

Hitoshi	O
et	O
al	O
reported	O
that	O
SWCNT	O
also	O
downregulated	O
genes	O
coding	O
other	O
CYP	O
isoenzymes	O
,	O
namely	O
,	O
CYP1A1	B
and	O
CYP1B1	O
.	O

In	O
other	O
studies	O
by	O
Hitoshi	O
et	O
al	O
,	O
multi	O
-	O
walled	O
carbon	O
nanotubes	O
downregulated	O
CYP1A1	B
and	O
in	O
HepG2	O
cells	O
by	O
repression	O
of	O
AhR	O
binding	O
to	O
the	O
enhancer	O
region	O
.	O

The	O
enzymes	O
used	O
were	O
CYP1A1	B
(	O
Lot	O
No	O
.	O

CYP3A4	O
is	O
the	O
major	O
enzyme	O
responsible	O
for	O
the	O
16ALPHA	O
-	O
hydroxylation	O
of	O
estrone	O
in	O
adults	O
,	O
though	O
CYP1A1	B
,	O
CYP2C19	B
and	O
CYP3A5	O
can	O
also	O
catalyze	O
the	O
reaction	O
.	O

Conversely	O
,	O
CYP1A2	B
is	O
the	O
dominant	O
enzyme	O
catalyzing	O
the	O
16ALPHA	O
-	O
hydroxylation	O
of	O
17BETA	O
-	O
estradiol	O
,	O
with	O
CYP3A4	O
,	O
CYP1A1	B
and	O
CYP1B1	O
also	O
demonstrating	O
this	O
activity	O
.	O

These	O
reactions	O
are	O
catalyzed	O
by	O
a	O
variety	O
of	O
CYPs	O
,	O
including	O
CYP3A4	O
and	O
CYP1A2	B
in	O
the	O
liver	O
,	O
or	O
CYP1A1	B
and	O
CYP3A4	O
in	O
peripheral	O
tissues	O
.	O

CYP1A	O
subfamily	O
contains	O
only	O
two	O
functional	O
genes	O
,	O
CYP1A1	B
and	O
CYP1A2	B
,	O
which	O
are	O
highly	O
conserved	O
among	O
species	O
.	O

Phylogenetic	O
analysis	O
of	O
CYP1A	O
gene	O
shows	O
that	O
the	O
CYP1A2	B
gene	O
may	O
rise	O
from	O
CYP1A1	B
and	O
they	O
have	O
a	O
common	O
5	O
-	O
anking	O
region	O
,	O
which	O
has	O
been	O
proved	O
to	O
contain	O
bidirectional	O
regulators	O
both	O
for	O
CYP1A1	B
and	O
CYP1A2	B
^	O
,	O
.	O

Although	O
the	O
transcriptional	O
regulation	O
of	O
CYP1A1	B
and	O
1A2	O
may	O
be	O
simultaneously	O
controlled	O
by	O
bidirectional	O
gene	O
elements	O
,	O
their	O
expression	O
patterns	O
are	O
different	O
.	O

For	O
example	O
,	O
CYP1A2	B
is	O
constitutively	O
and	O
specifically	O
expressed	O
in	O
the	O
liver	O
,	O
while	O
CYP1A1	B
is	O
mainly	O
expressed	O
outside	O
the	O
liver	O
^	O
,	O
.	O

As	O
illustrated	O
in	O
,	O
SNP	O
rs2472306	O
in	O
CYP1A2	B
was	O
the	O
most	O
important	O
variable	O
in	O
the	O
prediction	O
model	O
(	O
MDA	O
=	O
25	O
.	O
3	O
)	O
,	O
followed	O
by	O
the	O
presence	O
of	O
HS	O
on	O
MRI	O
(	O
MDA	O
=	O
25	O
.	O
2	O
)	O
.	O

Fargesin	O
negligibly	O
inhibited	O
CYP1A2	B
-	O
catalyzed	O
phenacetin	O
O	O
-	O
deethylation	O
,	O
CYP2A6	O
-	O
catalyzed	O
coumarin	O
7	O
-	O
hydroxylation	O
,	O
CYP2B6	B
-	O
catalyzed	O
bupropion	O
hydroxylation	O
,	O
and	O
CYP2D6	B
-	O
catalyzed	O
bufuralol	O
1	O
-	O
hydroxylation	O
at	O
100	O
M	O
in	O
human	O
liver	O
microsomes	O
.	O

Other	O
methylenedioxyphenyl	O
compounds	O
such	O
as	O
myristicin	O
and	O
podophyllotoxin	O
exhibited	O
mechanism	O
-	O
based	O
inactivation	O
of	O
CYP1A2	B
and	O
CYP3A4	B
,	O
respectively	O
,	O
in	O
human	O
liver	O
microsomes	O
.	O

Since	O
a	O
potential	O
role	O
in	O
clozapine	O
metabolism	O
is	O
assigned	O
to	O
CYP1A2	B
,	O
CYP2C19	B
,	O
CYP2D6	B
and	O
CYP3A	B
enzymes	O
,	O
the	O
association	O
between	O
the	O
patients	O
CYP	O
status	O
(	O
CYP	O
genotypes	O
,	O
CYP	O
expression	O
)	O
and	O
clozapine	O
clearance	O
was	O
evaluated	O
in	O
92	O
psychiatric	O
patients	O
.	O

The	O
patients	O
CYP2C19	B
or	O
CYP2D6	B
genotypes	O
and	O
CYP1A2	B
expression	O
seemed	O
to	O
have	O
no	O
effect	O
on	O
clozapine	O
serum	O
concentration	O
,	O
whereas	O
CYP3A4	B
expression	O
significantly	O
influenced	O
the	O
normalized	O
clozapine	O
concentration	O
(	O
185	O
.	O
5356	O
.	O
53	O
in	O
low	O
expressers	O
vs	O
78	O
.	O
0529	O
.	O
57	O
or	O
66	O
.	O
520	O
.	O
25	O
(	O
ng	O
/	O
mL	O
)	O
/	O
(	O
mg	O
/	O
kg	O
)	O
in	O
normal	O
or	O
high	O
expressers	O
,	O
P	O
<	O
.	O
0001	O
)	O
,	O
in	O
particular	O
that	O
the	O
patients	O
expressed	O
CYP1A2	B
at	O
a	O
relatively	O
low	O
level	O
.	O

The	O
patients	O
CYP2C19	B
and	O
CYP2D6	B
genotypes	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
steady	O
-	O
state	O
clozapine	O
concentrations	O
,	O
even	O
as	O
CYP1A2	B
expression	O
influenced	O
neither	O
the	O
clozapine	O
levels	O
nor	O
the	O
norclozapine	O
/	O
clozapine	O
ratio	O
.	O

The	O
relative	O
importance	O
of	O
these	O
enzymes	O
in	O
clozapine	O
clearance	O
seemed	O
to	O
be	O
lower	O
,	O
whereas	O
the	O
patients	O
CYP3A	B
-	O
status	O
(	O
CYP3A4	B
expression	O
and	O
CYP3A5	B
genotype	O
)	O
was	O
found	O
to	O
potentially	O
influence	O
normalized	O
clozapine	O
concentration	O
and	O
dose	O
requirement	O
,	O
in	O
particular	O
that	O
the	O
patients	O
expressed	O
CYP1A2	B
at	O
a	O
relatively	O
low	O
level	O
.	O

CYP1A2	B
and	O
CYP3A4	B
were	O
assumed	O
to	O
be	O
the	O
major	O
enzymes	O
responsible	O
for	O
the	O
N	O
-	O
demethylation	O
pathway	O
,	O
and	O
several	O
clinical	O
reports	O
provided	O
indirect	O
evidence	O
for	O
their	O
participation	O
in	O
clozapine	O
metabolism	O
.	O

Concomitant	O
treatment	O
with	O
fluvoxamine	O
,	O
the	O
potent	O
inhibitor	O
of	O
several	O
CYPs	O
(	O
CYP1A2	B
,	O
CYP2C19	B
,	O
CYP3A4	B
)	O
,	O
significantly	O
decreased	O
the	O
plasma	O
norclozapine	O
/	O
clozapine	O
ratios	O
and	O
patients	O
clozapine	O
dose	O
requirement	O
(	O
;	O
.	O

Cigarette	O
smoking	O
,	O
inducing	O
CYP1A2	B
expression	O
,	O
seems	O
to	O
increase	O
clozapine	O
clearance	O
;	O
however	O
,	O
CYP1A2	B
genetic	O
polymorphisms	O
do	O
not	O
have	O
significant	O
clinical	O
effect	O
.	O

CYP3A4	B
and	O
CYP1A2	B
mRNA	O
levels	O
in	O
leukocytes	O
were	O
proven	O
to	O
inform	O
about	O
the	O
hepatic	O
CYP3A4	B
and	O
CYP1A2	B
activities	O
.	O

Patients	O
CYP	O
status	O
was	O
determined	O
by	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP3A4	B
,	O
and	O
CYP3A5	B
genotyping	O
and	O
by	O
analyzing	O
CYP1A2	B
and	O
CYP3A4	B
expression	O
in	O
leukocytes	O
.	O

Since	O
CYP1A2	B
expression	O
was	O
found	O
to	O
be	O
poorly	O
associated	O
with	O
the	O
presence	O
of	O
CYP1A2	B
SNPs	O
,	O
the	O
patients	O
CYP1A2	B
activity	O
was	O
estimated	O
by	O
CYP1A2	B
mRNA	O
levels	O
in	O
leukocytes	O
,	O
and	O
not	O
by	O
CYP1A2	B
-	O
genotype	O
.	O

The	O
quantities	O
of	O
CYP1A2	B
and	O
CYP3A4	B
mRNAs	O
relative	O
to	O
that	O
of	O
the	O
housekeeping	O
gene	O
glyceraldehyde	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
were	O
determined	O
.	O

The	O
cut	O
-	O
off	O
values	O
for	O
CYP	O
mRNA	O
levels	O
in	O
leukocytes	O
have	O
been	O
previously	O
established	O
on	O
the	O
basis	O
of	O
the	O
cut	O
-	O
off	O
values	O
for	O
the	O
hepatic	O
CYP	O
enzyme	O
activities	O
(	O
CYP1A2	B
:	O
phenacetin	O
O	O
-	O
dealkylation	O
;	O
CYP3A4	B
:	O
nifedipine	O
oxidation	O
or	O
midazolam	O
1	O
-	O
and	O
4	O
-	O
hydroxylation	O
)	O
.	O

The	O
cut	O
-	O
off	O
values	O
for	O
CYP1A2	B
(	O
10	O
^	O
-	O
5	O
and	O
5	O
*	O
10	O
^	O
-	O
4	O
)	O
and	O
CYP3A4	B
(	O
10	O
^	O
-	O
6	O
and	O
10	O
^	O
-	O
4	O
)	O
allowed	O
a	O
distinction	O
between	O
low	O
,	O
normal	O
,	O
and	O
high	O
expressers	O
.	O

The	O
statistical	O
significance	O
of	O
demographic	O
data	O
,	O
CYP1A2	B
and	O
CYP3A4	B
expressions	O
,	O
CYP2C19	B
,	O
CYP2D6	B
and	O
CYP3A5	B
genotypes	O
as	O
covariates	O
of	O
clozapine	O
,	O
norclozapine	O
and	O
clozapine	O
N	O
-	O
oxide	O
concentrations	O
was	O
analyzed	O
by	O
ANOVA	O
using	O
linear	O
model	O
of	O
covariate	O
effects	O
with	O
constant	O
terms	O
.	O

CYP1A2	B
expression	O
assays	O
revealed	O
that	O
a	O
substantial	O
portion	O
of	O
the	O
patients	O
(	O
70	O
.	O
7	O
%	O
)	O
was	O
low	O
CYP1A2	B
expressers	O
and	O
less	O
than	O
one	O
-	O
third	O
of	O
the	O
patients	O
expressed	O
CYP1A2	B
at	O
normal	O
level	O
,	O
whereas	O
no	O
high	O
CYP1A2	B
expresser	O
was	O
found	O
.	O

Smoking	O
is	O
a	O
potent	O
inducer	O
of	O
CYP1A2	B
,	O
increasing	O
CYP1A2	B
expression	O
and	O
enzyme	O
activity	O
;	O
however	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
smoker	O
/	O
nonsmoker	O
ratio	O
was	O
the	O
same	O
in	O
the	O
low	O
and	O
normal	O
CYP1A2	B
expresser	O
groups	O
(	O
10	O
:	O
17	O
vs	O
25	O
:	O
40	O
,	O
P	O
=	O
1	O
.	O
00	O
)	O
.	O

Furthermore	O
,	O
the	O
normalized	O
clozapine	O
concentrations	O
were	O
comparable	O
in	O
the	O
patients	O
expressing	O
CYP1A2	B
at	O
low	O
and	O
normal	O
level	O
(	O
P	O
=	O
.	O
6639	O
)	O
.	O

According	O
to	O
the	O
present	O
results	O
,	O
the	O
patients	O
CYP2C19	B
or	O
CYP2D6	B
genotypes	O
and	O
CYP1A2	B
expression	O
seemed	O
to	O
have	O
no	O
effect	O
on	O
clozapine	O
concentrations	O
,	O
whereas	O
CYP3A4	B
expression	O
significantly	O
influenced	O
the	O
steady	O
-	O
state	O
levels	O
of	O
clozapine	O
.	O

The	O
formation	O
of	O
both	O
principal	O
metabolites	O
widely	O
varied	O
in	O
individuals	O
;	O
however	O
,	O
the	O
serum	O
concentrations	O
of	O
clozapine	O
metabolites	O
appeared	O
to	O
be	O
associated	O
merely	O
with	O
the	O
patients	O
CYP3A4	B
expression	O
and	O
not	O
with	O
CYP1A2	B
mRNA	O
levels	O
.	O

Nevertheless	O
,	O
the	O
norclozapine	O
/	O
clozapine	O
concentration	O
ratios	O
were	O
comparable	O
in	O
patients	O
expressing	O
CYP1A2	B
at	O
a	O
low	O
or	O
normal	O
level	O
(	O
0	O
.	O
69880	O
.	O
2341	O
vs	O
0	O
.	O
70700	O
.	O
1824	O
;	O
P	O
=	O
0	O
.	O
3966	O
)	O
.	O

In	O
vitro	O
studies	O
using	O
cDNA	O
-	O
expressed	O
CYP	O
enzymes	O
have	O
demonstrated	O
the	O
contribution	O
of	O
CYP1A2	B
,	O
CYP2C19	B
,	O
CYP3A4	B
,	O
and	O
CYP2D6	B
to	O
clozapine	O
metabolism	O
;	O
however	O
,	O
hepatic	O
microsomal	O
metabolism	O
hardly	O
supported	O
a	O
significant	O
role	O
of	O
CYP2C19	B
and	O
CYP2D6	B
(	O
;	O
.	O

CYP1A2	B
is	O
considered	O
to	O
be	O
one	O
of	O
the	O
major	O
enzymes	O
responsible	O
for	O
clozapine	O
biotransformation	O
,	O
which	O
was	O
confirmed	O
by	O
several	O
clinical	O
data	O
.	O

Induction	O
of	O
CYP1A2	B
by	O
the	O
components	O
of	O
cigarette	O
smoke	O
seems	O
to	O
increase	O
clozapine	O
dose	O
requirement	O
,	O
primarily	O
of	O
male	O
smokers	O
;	O
however	O
,	O
the	O
patients	O
with	O
the	O
polymorphic	O
CYP1A2	B
*	O
1F	O
allele	O
,	O
resulting	O
in	O
an	O
increase	O
in	O
CYP1A2	B
inducibility	O
,	O
did	O
not	O
require	O
dose	O
adjustment	O
.	O

On	O
the	O
other	O
hand	O
,	O
demonstrated	O
an	O
association	O
between	O
the	O
frequency	O
of	O
clozapine	O
-	O
induced	O
adverse	O
reactions	O
and	O
the	O
occurrence	O
of	O
the	O
low	O
activity	O
CYP1A2	B
*	O
1C	O
allele	O
in	O
patients	O
.	O

The	O
CYP1A2	B
substrate	O
caffeine	O
has	O
been	O
reported	O
to	O
inhibit	O
clozapine	O
metabolism	O
,	O
and	O
caffeine	O
consumption	O
in	O
a	O
daily	O
dose	O
of	O
400	O
to	O
1000	O
mg	O
significantly	O
decreased	O
clozapine	O
clearance	O
(	O
;	O
.	O

The	O
adjunctive	O
fluvoxamine	O
to	O
ongoing	O
clozapine	O
therapy	O
was	O
found	O
to	O
increase	O
clozapine	O
plasma	O
concentration	O
,	O
moreover	O
resulting	O
in	O
toxic	O
serum	O
concentration	O
,	O
which	O
was	O
attributed	O
to	O
CYP1A2	B
inhibition	O
by	O
fluvoxamine	O
(	O
;	O
.	O

It	O
should	O
be	O
noted	O
that	O
fluvoxamine	O
is	O
not	O
a	O
CYP1A2	B
-	O
selective	O
inhibitor	O
,	O
but	O
significantly	O
blocks	O
the	O
activities	O
of	O
other	O
CYPs	O
,	O
notably	O
it	O
irreversibly	O
inhibits	O
CYP3A4	B
by	O
forming	O
a	O
metabolic	O
intermediate	O
complex	O
.	O

The	O
clinical	O
observations	O
on	O
the	O
dominant	O
role	O
of	O
CYP1A2	B
were	O
not	O
confirmed	O
by	O
our	O
findings	O
that	O
the	O
patients	O
CYP3A	B
status	O
rather	O
than	O
their	O
CYP1A2	B
expression	O
was	O
associated	O
with	O
normalized	O
clozapine	O
concentrations	O
.	O

The	O
relative	O
importance	O
of	O
CYP3A4	B
in	O
clozapine	O
clearance	O
,	O
particularly	O
in	O
patients	O
with	O
low	O
CYP1A2	B
activity	O
,	O
may	O
be	O
higher	O
than	O
it	O
has	O
been	O
previously	O
considered	O
(	O
;	O
.	O

suggested	O
further	O
research	O
with	O
the	O
potential	O
to	O
demonstrate	O
the	O
critical	O
roles	O
of	O
CYPs	O
other	O
than	O
CYP1A2	B
for	O
the	O
elucidation	O
of	O
individual	O
differences	O
in	O
clozapine	O
metabolism	O
.	O

Furthermore	O
,	O
provided	O
support	O
for	O
the	O
functional	O
roles	O
of	O
both	O
CYP3A4	B
and	O
CYP1A2	B
in	O
clozapine	O
clearance	O
,	O
and	O
suggested	O
that	O
the	O
relative	O
activities	O
of	O
CYP3A4	B
and	O
CYP1A2	B
in	O
patients	O
might	O
determine	O
the	O
clearance	O
pathways	O
.	O

Although	O
the	O
majority	O
of	O
the	O
patients	O
with	O
schizophrenia	O
were	O
smokers	O
evoking	O
high	O
CYP1A2	B
activity	O
,	O
in	O
the	O
present	O
study	O
,	O
only	O
38	O
%	O
of	O
the	O
patients	O
were	O
current	O
smokers	O
and	O
4	O
subjects	O
(	O
4	O
.	O
3	O
%	O
)	O
were	O
heavy	O
smokers	O
(	O
>	O
20	O
cigarettes	O
/	O
d	O
)	O
.	O

In	O
>	O
70	O
%	O
of	O
the	O
patients	O
,	O
CYP1A2	B
mRNA	O
was	O
expressed	O
at	O
low	O
concentration	O
,	O
whereas	O
a	O
high	O
proportion	O
of	O
the	O
patients	O
(	O
>	O
70	O
%	O
)	O
were	O
CYP3A4	B
normal	O
/	O
high	O
expressers	O
,	O
and	O
additionally	O
3	O
low	O
CYP3A4	B
expressers	O
displayed	O
normal	O
clozapine	O
-	O
metabolizing	O
capacity	O
because	O
of	O
the	O
functional	O
CYP3A5	B
*	O
1	O
allele	O
.	O

The	O
patients	O
caffeine	O
consumption	O
data	O
were	O
not	O
available	O
,	O
and	O
the	O
CYP1A2	B
inhibitory	O
effect	O
on	O
clozapine	O
clearance	O
therefore	O
could	O
not	O
be	O
taken	O
into	O
account	O
.	O

Although	O
the	O
present	O
work	O
involved	O
a	O
limited	O
number	O
of	O
patients	O
and	O
further	O
investigation	O
enrolling	O
larger	O
cohort	O
is	O
required	O
,	O
it	O
clearly	O
demonstrated	O
that	O
CYP3A	B
status	O
could	O
be	O
the	O
major	O
determinant	O
of	O
normalized	O
clozapine	O
concentration	O
and	O
dose	O
requirement	O
,	O
in	O
particular	O
that	O
the	O
patients	O
expressed	O
CYP1A2	B
at	O
a	O
relatively	O
low	O
level	O
.	O

Therefore	O
,	O
considering	O
the	O
toxicity	O
of	O
the	O
compounds	O
at	O
10	O
M	O
,	O
we	O
can	O
extrapolate	O
that	O
only	O
CYP1A2	B
shows	O
around	O
50	O
%	O
of	O
inhibition	O
at	O
4	O
M	O
in	O
the	O
combination	O
studies	O
.	O

A	O
previously	O
published	O
study	O
from	O
our	O
group	O
found	O
an	O
in	O
vitro	O
inhibition	O
of	O
CYP3A4	B
enzyme	O
activity	O
by	O
extracts	O
of	O
six	O
R	O
.	O
rosea	O
clones	O
,	O
with	O
IC_50	O
values	O
(	O
extract	O
concentration	O
yielding	O
50	O
%	O
reduction	O
in	O
enzyme	O
activity	O
)	O
ranging	O
from	O
1	O
.	O
7	O
to	O
3	O
.	O
1	O
g	O
/	O
mL	O
(	O
Hellum	O
et	O
al	O
.	O
.	O
We	O
have	O
also	O
evaluated	O
the	O
in	O
vitro	O
inhibition	O
potential	O
of	O
several	O
commercial	O
R	O
.	O
rosea	O
products	O
on	O
CYP1A2	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
activities	O
,	O
which	O
produced	O
IC_50	O
values	O
ranging	O
from	O
7	O
.	O
2	O
to	O
186	O
g	O
/	O
mL	O
(	O
Thu	O
et	O
al	O
.	O
.	O
The	O
in	O
vivo	O
interaction	O
potential	O
of	O
R	O
.	O
rosea	O
has	O
also	O
been	O
studied	O
by	O
some	O
groups	O
.	O

;	O
Mudge	O
et	O
al	O
.	O
.	O
However	O
,	O
the	O
constituent	O
(	O
s	O
)	O
responsible	O
for	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
Cytochrome	B
P450	I
inhibition	O
by	O
R	O
.	O
rosea	O
remains	O
to	O
be	O
identified	O
and	O
the	O
concentration	O
of	O
these	O
constituents	O
could	O
not	O
be	O
linked	O
to	O
in	O
vitro	O
enzyme	O
inhibition	O
of	O
CYP1A2	B
,	O
CYP2D6	B
,	O
or	O
CYP3A4	B
in	O
a	O
previous	O
experiment	O
(	O
Thu	O
et	O
al	O
.	O
.	O
Consequently	O
,	O
it	O
is	O
of	O
interest	O
to	O
study	O
fullextract	O
solutions	O
of	O
R	O
.	O
rosea	O
,	O
as	O
a	O
full	O
extract	O
provides	O
a	O
more	O
accurate	O
depiction	O
of	O
what	O
the	O
consumers	O
are	O
exposed	O
to	O
when	O
they	O
ingest	O
these	O
products	O
.	O

Moreover	O
,	O
no	O
correlation	O
between	O
the	O
supposed	O
bioactive	O
constituents	O
and	O
in	O
vitro	O
CYP1A2	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
enzyme	O
activities	O
was	O
found	O
in	O
a	O
previous	O
publication	O
from	O
our	O
group	O
(	O
Thu	O
et	O
al	O
.	O
.	O
However	O
,	O
a	O
moderate	O
noncompetitive	O
in	O
vitro	O
CYP2D6	B
inhibition	O
by	O
the	O
relatively	O
unknown	O
R	O
.	O
rosea	O
constituents	O
rhodiosin	O
and	O
rhodionin	O
has	O
recently	O
been	O
published	O
with	O
IC_50	O
values	O
of	O
0	O
.	O
47	O
and	O
0	O
.	O
19	O
g	O
/	O
mL	O
,	O
respectively	O
(	O
Xu	O
et	O
al	O
.	O
.	O
For	O
better	O
prediction	O
of	O
the	O
potential	O
in	O
vivo	O
inhibition	O
of	O
commercial	O
R	O
.	O
rosea	O
products	O
,	O
the	O
specific	O
constituents	O
responsible	O
for	O
the	O
inhibition	O
must	O
be	O
identified	O
.	O

The	O
Vmax	O
,	O
Km	O
,	O
and	O
CLint	O
of	O
six	O
Cytochrome	B
P450	I
Enzymes	I
(	O
CYP2A6	O
,	O
2C8	O
,	O
2D6	O
,	O
2E1	O
,	O
and	O
3A4	O
/	O
5	O
)	O
could	O
be	O
predicted	O
by	O
measuring	O
the	O
activities	O
of	O
four	O
Cytochrome	B
P450	I
Enzymes	I
(	O
CYP1A2	B
,	O
2B6	O
,	O
2C9	O
,	O
and	O
2C19	O
)	O
in	O
Human	O
Liver	O
Microsomes	O
.	O

These	O
findings	O
suggest	O
that	O
measuring	O
the	O
activity	O
of	O
CYP1A2	B
,	O
2B6	O
,	O
2C9	O
,	O
and	O
2C19	O
allowed	O
us	O
to	O
accurately	O
predict	O
CYP2A6	O
-	O
,	O
2C8	O
-	O
,	O
2D6	O
-	O
,	O
2E1	O
-	O
,	O
and	O
3A4	O
/	O
5	O
-	O
mediated	O
activities	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
may	O
possibly	O
be	O
helpful	O
for	O
the	O
assessment	O
of	O
an	O
individuals	O
drug	O
metabolic	O
profile	O
.	O

According	O
to	O
the	O
recent	O
methods	O
,	O
ten	O
CYP	O
-	O
mediated	O
metabolic	O
activities	O
were	O
measured	O
in	O
individual	O
assays	O
by	O
incubating	O
Human	O
Liver	O
Microsomes	O
(	O
0	O
.	O
3	O
mg	O
protein	O
/	O
ml	O
for	O
CYP1A2	B
,	O
2A6	O
,	O
and	O
2E1	O
;	O
0	O
.	O
2	O
mg	O
protein	O
/	O
ml	O
for	O
CYP2D6	B
and	O
3A4	O
/	O
5	O
;	O
0	O
.	O
5	O
mg	O
protein	O
/	O
ml	O
for	O
CYP2B6	B
,	O
2C8	O
,	O
2C9	O
,	O
and	O
2C19	O
)	O
,	O
100	O
mM	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
and	O
1	O
mM	O
reduced	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
with	O
seven	O
or	O
eight	O
concentrations	O
of	O
substrate	O
(	O
6	O
.	O
25	O
-	O
800	O
M	O
for	O
phenacetin	O
,	O
0	O
.	O
156	O
-	O
20	O
M	O
for	O
coumarin	O
,	O
7	O
.	O
8	O
-	O
500	O
M	O
for	O
bupropion	O
,	O
2	O
.	O
5	O
-	O
80	O
M	O
for	O
paclitaxel	O
,	O
31	O
.	O
25	O
-	O
2000	O
M	O
for	O
tolbutamide	O
,	O
3	O
.	O
9	O
-	O
500	O
M	O
for	O
omeprazole	O
,	O
0	O
.	O
625	O
-	O
960	O
M	O
for	O
dextromethorphan	O
,	O
7	O
.	O
8	O
-	O
1000	O
M	O
for	O
chlorzoxazone	O
,	O
and	O
0	O
.	O
39	O
-	O
50	O
M	O
for	O
midazolam	O
)	O
.	O

Using	O
the	O
equations	O
generated	O
and	O
refined	O
above	O
,	O
it	O
was	O
found	O
that	O
the	O
activities	O
of	O
six	O
Cytochrome	B
P450	I
Enzymes	I
(	O
CYP2A6	O
,	O
2C8	O
,	O
2D6	O
,	O
2E	O
,	O
and	O
3A4	O
/	O
5	O
)	O
could	O
be	O
predicted	O
based	O
on	O
the	O
measured	O
activities	O
of	O
four	O
Cytochrome	B
P450	I
Enzymes	I
(	O
CYP1A2	B
,	O
2B6	O
,	O
2C9	O
,	O
and	O
2C19	O
)	O
.	O

The	O
above	O
normal	O
Chinese	O
liver	O
samples	O
were	O
used	O
to	O
measure	O
the	O
ten	O
Cytochrome	B
P450	I
Enzymes	I
(	O
CYP1A2	B
,	O
2A6	O
,	O
2B6	O
,	O
2C8	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
2E1	O
,	O
and	O
3A4	O
/	O
5	O
)	O
-	O
mediated	O
metabolic	O
activities	O
in	O
vitro	O
using	O
probe	O
substrate	O
metabolism	O
assays	O
.	O

The	O
results	O
show	O
that	O
the	O
descriptive	O
models	O
of	O
V_max	O
and	O
CL_int	O
of	O
all	O
ten	O
Cytochrome	B
P450	I
Enzymes	I
and	O
K_m	O
of	O
six	O
Cytochrome	B
P450	I
Enzymes	I
(	O
CYP1A2	B
,	O
2B6	O
,	O
2C9	O
,	O
2C19	O
,	O
and	O
3A4	O
/	O
5	O
)	O
could	O
be	O
developed	O
,	O
and	O
the	O
essential	O
structures	O
of	O
these	O
models	O
consisted	O
of	O
the	O
measured	O
V_max	O
,	O
CL_int	O
,	O
and	O
K_m	O
of	O
Cytochrome	B
P450	I
Enzymes	I
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
results	O
indicate	O
that	O
the	O
six	O
Cytochrome	B
P450	I
Enzymes	I
(	O
CYP2A6	O
,	O
2C8	O
,	O
2D6	O
,	O
2E1	O
,	O
and	O
3A4	O
/	O
5	O
)	O
-	O
mediated	O
metabolic	O
activities	O
in	O
vitro	O
could	O
be	O
predicted	O
if	O
the	O
activities	O
of	O
four	O
Cytochrome	B
P450	I
Enzymes	I
(	O
CYP1A2	B
,	O
2B6	O
,	O
2C9	O
,	O
and	O
2C19	O
)	O
measured	O
in	O
vitro	O
were	O
known	O
.	O

Descriptive	O
models	O
for	O
predicting	O
the	O
activities	O
of	O
Cytochrome	B
P450	I
Enzymes	I
in	O
Human	O
Liver	O
Microsomes	O
were	O
developed	O
first	O
and	O
the	O
activities	O
of	O
six	O
Cytochrome	B
P450	I
Enzymes	I
(	O
CYP2A6	O
,	O
2C8	O
,	O
2D6	O
,	O
2E1	O
,	O
and	O
3A4	O
/	O
5	O
)	O
could	O
be	O
predicted	O
by	O
actually	O
measuring	O
the	O
activities	O
of	O
four	O
Cytochrome	B
P450	I
Enzymes	I
(	O
CYP1A2	B
,	O
2B6	O
,	O
2C9	O
,	O
and	O
2C19	O
)	O
.	O

In	O
summary	O
,	O
we	O
developed	O
descriptive	O
models	O
to	O
predict	O
the	O
activities	O
of	O
six	O
Cytochrome	B
P450	I
Enzymes	I
(	O
CYP2A6	O
,	O
2C8	O
,	O
2D6	O
,	O
2E1	O
,	O
and	O
3A4	O
/	O
5	O
)	O
in	O
Human	O
Liver	O
Microsomes	O
by	O
actually	O
measuring	O
the	O
activities	O
of	O
four	O
Cytochrome	B
P450	I
Enzymes	I
(	O
CYP1A2	B
,	O
2B6	O
,	O
2C9	O
,	O
and	O
2C19	O
)	O
.	O

2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
BETA	O
-	O
D	O
-	O
glucoside	O
exacerbates	O
acetaminophen	O
-	O
induced	O
hepatotoxicity	O
by	O
inducing	O
hepatic	O
expression	O
of	O
CYP2E1	B
,	O
CYP3A4	B
and	O
CYP1A2	B
.	O

2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
increased	O
the	O
expression	O
of	O
CYP2E1	B
,	O
CYP3A4	B
and	O
CYP1A2	B
both	O
in	O
mice	O
and	O
in	O
human	O
normal	O
liver	O
L	O
-	O
02	O
hepatocytes	O
.	O

2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
also	O
enhanced	O
liver	O
catalytic	O
activity	O
of	O
CYP2E1	B
,	O
CYP3A4	B
and	O
CYP1A2	B
in	O
mice	O
.	O

In	O
summary	O
,	O
our	O
results	O
demonstrate	O
that	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
enhances	O
hepatic	O
expression	O
of	O
CYP3A4	B
,	O
CYP2E1	B
and	O
CYP1A2	B
,	O
and	O
thus	O
exacerbates	O
the	O
hepatotoxicity	O
induced	O
by	O
APAP	O
in	O
mice	O
.	O

In	O
this	O
study	O
,	O
the	O
aggravation	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
on	O
APAP	O
-	O
induced	O
liver	O
injury	O
by	O
inducing	O
hepatic	O
expression	O
of	O
CYP2E1	B
,	O
CYP3A4	B
and	O
CYP1A2	B
was	O
investigated	O
.	O

Liver	O
mRNA	O
expression	O
of	O
Cyp1a2	B
,	O
Cyp3a11	O
(	O
human	O
CYP3A4	B
)	O
and	O
Cyp2e1	B
was	O
increased	O
in	O
mice	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
(	O
100	O
,	O
200	O
,	O
400	O
,	O
800	O
mg	O
/	O
kg	O
)	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
liver	O
mRNA	O
expression	O
of	O
Cyp1a2	B
,	O
Cyp2e1	B
and	O
Cyp3a11	O
was	O
increased	O
in	O
mice	O
treated	O
with	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
(	O
800	O
mg	O
/	O
kg	O
)	O
for	O
4	O
h	O
,	O
8	O
h	O
,	O
and	O
12	O
h	O
enhanced	O
hepatic	O
CYP1A2	B
protein	O
expression	O
when	O
mice	O
were	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
increased	O
hepatic	O
CYP1A2	B
expression	O
after	O
treated	O
mice	O
for	O
8	O
h	O
and	O
12	O
h	O
enhanced	O
hepatic	O
CYP2E1	B
protein	O
expression	O
when	O
mice	O
were	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
only	O
increased	O
hepatic	O
CYP2E1	B
expression	O
after	O
treated	O
mice	O
for	O
12	O
h	O
enhanced	O
hepatic	O
CYP3A4	B
protein	O
expression	O
when	O
mice	O
were	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
increased	O
hepatic	O
CYP3A4	B
expression	O
after	O
treated	O
mice	O
for	O
4	O
h	O
,	O
8	O
h	O
and	O
12	O
h	O
(	O
Fig	O
.	O

TSG	O
(	O
400	O
,	O
800	O
mg	O
/	O
kg	O
)	O
enhanced	O
liver	O
CYP2E1	B
catalytic	O
activity	O
when	O
mice	O
were	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
increased	O
liver	O
CYP2E1	B
catalytic	O
activity	O
after	O
treated	O
mice	O
for	O
8	O
h	O
and	O
12	O
h	O
enhanced	O
liver	O
CYP3A4	B
catalytic	O
activity	O
when	O
mice	O
were	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
increased	O
liver	O
CYP3A4	B
catalytic	O
activity	O
after	O
treated	O
mice	O
for	O
4	O
h	O
,	O
8	O
h	O
and	O
12	O
h	O
enhanced	O
liver	O
CYP1A2	B
catalytic	O
activity	O
when	O
mice	O
were	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
increased	O
liver	O
CYP1A2	B
catalytic	O
activity	O
after	O
treated	O
mice	O
for	O
4	O
h	O
,	O
8	O
h	O
and	O
12	O
h	O
(	O
Fig	O
.	O

AHR	O
and	O
Pregnane	O
X	O
Receptor	O
are	O
reported	O
to	O
regulate	O
the	O
expression	O
of	O
CYP1A2	B
and	O
CYP3A4	B
^	O
.	O

In	O
this	O
study	O
,	O
when	O
mice	O
were	O
treated	O
with	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
increased	O
hepatic	O
expression	O
of	O
CYP2E1	B
,	O
CYP1A2	B
and	O
CYP3A4	B
,	O
and	O
also	O
elevated	O
liver	O
catalytic	O
activity	O
of	O
CYP2E1	B
,	O
CYP1A2	B
and	O
CYP3A4	B
.	O

Moreover	O
,	O
when	O
mice	O
were	O
treated	O
with	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
5	O
consecutive	O
days	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
also	O
enhanced	O
hepatic	O
expression	O
of	O
CYP2E1	B
,	O
CYP1A2	B
and	O
CYP3A4	B
.	O

All	O
these	O
results	O
indicate	O
that	O
TSG	O
-	O
induced	O
the	O
increased	O
expression	O
and	O
catalytic	O
activity	O
of	O
CYP1A2	B
,	O
CYP2E1	B
and	O
CYP3A4	B
may	O
contribute	O
to	O
its	O
augmentation	O
on	O
APAP	O
-	O
induced	O
hepatotoxicity	O
via	O
elevating	O
its	O
metabolic	O
activation	O
in	O
liver	O
.	O

Aryl	O
Hydrocarbon	O
Receptor	O
and	O
Pregnane	O
X	O
Receptor	O
are	O
found	O
to	O
be	O
responsible	O
for	O
regulating	O
the	O
transcriptional	O
expression	O
of	O
CYP1A2	B
and	O
CYP3A4	B
^	O
,	O
.	O

In	O
this	O
study	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
promoted	O
the	O
nuclear	O
translocation	O
of	O
Aryl	O
Hydrocarbon	O
Receptor	O
and	O
Pregnane	O
X	O
Receptor	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
expression	O
of	O
CYP1A2	B
and	O
CYP3A4	B
induced	O
by	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
.	O

Additionally	O
,	O
Aryl	O
Hydrocarbon	O
Receptor	O
or	O
Pregnane	O
X	O
Receptor	O
inhibitors	O
reduced	O
the	O
expression	O
and	O
activity	O
of	O
hepatic	O
CYP1A2	B
and	O
CYP3A4	B
in	O
mice	O
.	O

Next	O
,	O
this	O
study	O
showed	O
that	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
augmented	O
APAP	O
-	O
induced	O
liver	O
injury	O
by	O
increasing	O
the	O
expression	O
and	O
catalytic	O
activation	O
of	O
liver	O
CYP3A4	B
,	O
CYP1A2	B
and	O
CYP2E1	B
.	O

Kits	O
for	O
detecting	O
CYP1A2	B
,	O
CYP2E1	B
and	O
CYP3A4	B
catalytic	O
activity	O
were	O
purchased	O
from	O
Shanghai	O
GENMED	O
gene	O
Pharmaceutical	O
Technology	O
Co	O
.	O

Antibodies	O
including	O
anti	O
-	O
CYP1A2	B
,	O
-	O
CYP2E1	B
,	O
-	O
CYP3A4	B
,	O
-	O
AHR	O
and	O
-	O
PXR	O
were	O
all	O
purchased	O
from	O
Beijing	O
biosynthesis	O
biotechnology	O
CO	O
.	O
,	O
LTD	O
(	O
Beijing	O
,	O
China	O
)	O
(	O
all	O
1	O
:	O
1000	O
dilution	O
)	O
.	O

For	O
analyzing	O
the	O
effects	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
on	O
the	O
expression	O
and	O
activity	O
of	O
CYP1A2	B
,	O
CYP2E1	B
and	O
CYP3A4	B
,	O
two	O
batches	O
of	O
mice	O
experiments	O
were	O
implemented	O
.	O

CYP1A2	B
,	O
CYP2E1	B
and	O
CYP3A4	B
catalytic	O
activity	O
were	O
detected	O
by	O
using	O
GENMED	O
CYP1A2	B
,	O
CYP2E1	B
and	O
CYP3A4	B
Kits	O
.	O

The	O
activity	O
of	O
7	O
-	O
methoxyresorufin	O
-	O
O	O
-	O
demethylase	O
is	O
the	O
diagnostic	O
marker	O
of	O
CYP1A2	B
.	O

The	O
activity	O
of	O
CYP1A2	B
was	O
determined	O
by	O
fluorescence	O
value	O
of	O
resorufin	O
conversed	O
from	O
7	O
-	O
methoxyresorufin	O
by	O
7	O
-	O
Methoxyresorufin	O
-	O
O	O
-	O
Demethylase	O
.	O

The	O
activity	O
of	O
CYP1A2	B
,	O
CYP2E1	B
and	O
CYP3A4	B
were	O
measured	O
with	O
kits	O
according	O
to	O
the	O
manufacturers	O
instructions	O
.	O

The	O
propensity	O
to	O
inhibit	O
CYP1A2	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
of	O
the	O
A	O
.	O
Lancea	O
extract	O
was	O
investigated	O
using	O
human	O
liver	O
microsomes	O
.	O

Results	O
showed	O
potent	O
inhibitory	O
activity	O
of	O
A	O
.	O
Lancea	O
on	O
CYP1A2	B
-	O
mediated	O
phenacetin	O
O	O
-	O
deethylation	O
with	O
mean	O
IC_50	O
of	O
0	O
.	O
36	O
g	O
/	O
ml	O
(	O
36	O
-	O
fold	O
of	O
the	O
inhibitor	O
ALPHA	O
-	O
naphthoflavone	O
)	O
.	O

Inhibition	O
of	O
CYP1A2	B
by	O
A	O
.	O
Lancea	O
extract	O
should	O
be	O
beneficial	O
to	O
Compared	O
With	O
Human	O
Embryonic	O
Fibroblast	O
Cell	O
Oums	O
-	O
36t	O
prevention	O
and	O
/	O
or	O
therapy	O
in	O
view	O
of	O
the	O
contribution	O
of	O
CYP1A2	B
in	O
carcinogenesis	O
of	O
Compared	O
With	O
Human	O
Embryonic	O
Fibroblast	O
Cell	O
Oums	O
-	O
36t	O
.	O

CYP1A2	B
is	O
a	O
highly	O
polymorphic	O
enzyme	O
responsible	O
for	O
the	O
metabolism	O
of	O
many	O
drugs	O
including	O
clozapine	O
,	O
mirtazapine	O
,	O
theophylline	O
,	O
tizanidine	O
and	O
triamterene	O
.	O

CYP1A2	B
*	O
1F	O
is	O
associated	O
with	O
increased	O
enzyme	O
activity	O
in	O
the	O
presence	O
of	O
an	O
inducer	O
,	O
such	O
as	O
high	O
caffeine	O
consumption	O
or	O
heavy	O
cigarette	O
use	O
.	O

found	O
that	O
the	O
CYP1A2	B
*	O
1F	O
allele	O
was	O
present	O
at	O
a	O
MAF	O
of	O
66	O
.	O
6	O
%	O
in	O
the	O
Amerindian	O
population	O
(	O
Tarahumara	O
,	O
Tepehuano	O
,	O
Mexicanera	O
,	O
Huichol	O
,	O
Cora	O
,	O
Seri	O
,	O
Mayo	O
and	O
Guarijo	O
)	O
.	O

Using	O
100	O
mg	O
of	O
caffeine	O
,	O
as	O
part	O
of	O
a	O
probe	O
drug	O
cocktail	O
for	O
phenotyping	O
,	O
no	O
association	O
between	O
CYP1A2	B
*	O
1F	O
and	O
higher	O
enzyme	O
activity	O
was	O
observed	O
.	O

However	O
,	O
the	O
CYP1A2	B
*	O
1F	O
variant	O
does	O
not	O
confer	O
high	O
constitutive	O
activity	O
but	O
rather	O
increases	O
enzyme	O
inducibility	O
with	O
exposure	O
to	O
an	O
inducer	O
,	O
so	O
the	O
lack	O
of	O
genotype	O
-	O
phenotype	O
association	O
could	O
be	O
due	O
to	O
the	O
fact	O
that	O
subjects	O
were	O
not	O
stratified	O
by	O
their	O
level	O
of	O
intake	O
of	O
a	O
CYP1A2	B
inducer	O
,	O
such	O
as	O
high	O
dose	O
caffeine	O
.	O

For	O
example	O
,	O
despite	O
the	O
fact	O
that	O
CYP1A2	B
is	O
a	O
highly	O
polymorphic	O
enzyme	O
important	O
for	O
the	O
metabolism	O
of	O
many	O
clinical	O
drugs	O
,	O
no	O
studies	O
to	O
date	O
have	O
assessed	O
the	O
frequencies	O
of	O
CYP1A2	B
allelic	O
variants	O
in	O
Indigenous	O
peoples	O
of	O
Canada	O
or	O
AIAN	O
populations	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
Glycine	O
N	O
-	O
Methyltransferase	O
may	O
participate	O
in	O
and	O
serve	O
as	O
a	O
cofactor	O
for	O
the	O
regulation	O
of	O
detoxification	O
gene	O
expression	O
,	O
such	O
as	O
CYP	B
1A1	I
and	O
CYP1A2	B
,	O
thereby	O
decreasing	O
the	O
formations	O
of	O
BaP	O
-	O
and	O
AFB1	O
-	O
DNA	O
adducts	O
^	O
-	O
.	O

In	O
both	O
sexes	O
,	O
the	O
liver	O
Glycine	O
N	O
-	O
Methyltransferase	O
and	O
CYP1A2	B
mRNA	O
levels	O
decreased	O
and	O
liver	O
NQO1	O
mRNA	O
levels	O
increased	O
significantly	O
after	O
3	O
weeks	O
of	O
AAI	O
exposure	O
.	O

The	O
kidney	O
Glycine	O
N	O
-	O
Methyltransferase	O
,	O
NQO1	O
and	O
CYP1A2	B
mRNA	O
levels	O
were	O
decreased	O
in	O
all	O
groups	O
after	O
AAI	O
treatment	O
(	O
Supplementary	O
Fig	O
.	O

Further	O
analysis	O
of	O
other	O
crude	O
extracts	O
demonstrated	O
potent	O
inhibition	O
of	O
CYP1A2	B
activity	O
for	O
a	O
dried	O
plant	O
ethanol	O
extract	O
(	O
1	O
.	O
5	O
g	O
/	O
mL	O
)	O
,	O
fresh	O
plant	O
ethanol	O
extract	O
(	O
3	O
.	O
9	O
g	O
/	O
mL	O
)	O
,	O
and	O
moderate	O
activity	O
for	O
a	O
fresh	O
plant	O
aqueous	O
extract	O
(	O
27	O
.	O
8	O
g	O
/	O
mL	O
)	O
.	O

Individual	O
screening	O
of	O
these	O
phytochemicals	O
against	O
the	O
activity	O
of	O
CYP1A2	B
identified	O
yatein	O
as	O
a	O
moderate	O
inhibitor	O
(	O
71	O
.	O
9	O
M	O
)	O
,	O
likely	O
to	O
contribute	O
to	O
the	O
plant	O
extracts	O
potent	O
bioactivity	O
.	O

This	O
latest	O
study	O
set	O
out	O
to	O
investigate	O
the	O
inhibitory	O
impact	O
of	O
various	O
extracts	O
of	O
H	O
.	O
verticillata	O
on	O
a	O
number	O
of	O
key	O
drug	O
metabolizing	O
CYP450	O
enzymes	O
,	O
its	O
characterisation	O
and	O
further	O
impact	O
on	O
CYP1A2	B
,	O
representing	O
the	O
first	O
such	O
in	O
vitro	O
evaluation	O
for	O
this	O
plant	O
,	O
and	O
to	O
add	O
to	O
the	O
growing	O
list	O
of	O
screened	O
Caribbean	O
medicinal	O
plants	O
.	O

Both	O
fresh	O
and	O
dry	O
ethanol	O
extracts	O
and	O
the	O
dry	O
aqueous	O
extract	O
demonstrated	O
potent	O
inhibition	O
of	O
CYP1A2	B
activity	O
with	O
the	O
dry	O
plant	O
ethanol	O
extract	O
demonstrating	O
the	O
most	O
potent	O
inhibition	O
(	O
1	O
.	O
5	O
g	O
/	O
mL	O
)	O
.	O

The	O
dry	O
aqueous	O
extract	O
potently	O
inhibited	O
CYP1A2	B
activity	O
and	O
was	O
close	O
in	O
potency	O
at	O
1	O
.	O
9	O
g	O
/	O
mL	O
to	O
the	O
dry	O
plant	O
ethanol	O
extract	O
and	O
was	O
more	O
potent	O
than	O
the	O
fresh	O
plant	O
ethanol	O
extract	O
(	O
3	O
.	O
9	O
g	O
/	O
mL	O
)	O
.	O

The	O
fresh	O
plant	O
aqueous	O
extract	O
moderately	O
inhibited	O
CYP1A2	B
activity	O
(	O
27	O
.	O
8	O
g	O
/	O
mL	O
)	O
.	O

Key	O
phytochemicals	O
were	O
individually	O
assessed	O
for	O
their	O
impact	O
on	O
CYP1A2	B
activity	O
.	O

The	O
mix	O
of	O
five	O
lignans	O
demonstrated	O
moderate	O
inhibition	O
against	O
the	O
activity	O
of	O
CYP1A2	B
(	O
61	O
.	O
8	O
g	O
/	O
mL	O
)	O
.	O

In	O
comparison	O
H	O
.	O
verticillata	O
aqueous	O
extract	O
(	O
dried	O
aerial	O
plant	O
material	O
)	O
demonstrated	O
potent	O
inhibition	O
of	O
CYP1A2	B
activity	O
(	O
1	O
.	O
9	O
g	O
/	O
mL	O
)	O
.	O

The	O
IC_50	O
values	O
determined	O
for	O
-	O
yatein	O
(	O
71	O
.	O
9	O
M	O
)	O
,	O
demonstrated	O
moderate	O
inhibition	O
,	O
and	O
BETA	O
-	O
sitosterol	O
(	O
160	O
.	O
1	O
M	O
)	O
demonstrated	O
weak	O
inhibition	O
against	O
the	O
activity	O
of	O
CYP1A2	B
.	O

In	O
comparison	O
,	O
the	O
plot	O
and	O
the	O
IC_50	O
value	O
for	O
known	O
CYP1A2	B
inhibitor	O
,	O
furafylline	O
(	O
1	O
.	O
4	O
M	O
)	O
,	O
demonstrated	O
potent	O
inhibition	O
.	O

However	O
,	O
it	O
was	O
possible	O
to	O
indicate	O
that	O
IC_50	O
values	O
for	O
both	O
oleanolic	O
and	O
ursolic	O
acid	O
would	O
be	O
>	O
100	O
M	O
and	O
for	O
cadina	O
-	O
4	O
,	O
10	O
(	O
15	O
)	O
-	O
dien	O
-	O
3	O
-	O
one	O
>	O
500	O
M	O
,	O
demonstrating	O
weak	O
inhibition	O
against	O
the	O
activity	O
of	O
CYP1A2	B
.	O

Two	O
phytochemicals	O
,	O
podophyllotoxin	O
and	O
4	O
-	O
demethylpodophyllotoxin	O
demonstrated	O
no	O
impact	O
on	O
the	O
activity	O
of	O
CYP1A2	B
.	O

Broken	O
down	O
,	O
the	O
figures	O
are	O
50	O
%	O
for	O
CYP3A4	B
,	O
25	O
%	O
for	O
CYP2D6	B
,	O
and	O
8	O
%	O
for	O
CYP1A2	B
.	O

CYP1A2	B
is	O
important	O
,	O
as	O
it	O
metabolizes	O
many	O
commonly	O
prescribed	O
drugs	O
including	O
the	O
bronchodilator	O
theophylline	O
,	O
the	O
tricyclic	O
antidepressant	O
imipramine	O
,	O
the	O
beta	O
blocker	O
propranolol	O
and	O
the	O
antipsychotic	O
clozapine	O
.	O

Additional	O
research	O
,	O
undertaken	O
to	O
assess	O
the	O
bioactivity	O
of	O
other	O
traditionally	O
prepared	O
extracts	O
,	O
aqueous	O
(	O
fresh	O
)	O
and	O
ethanol	O
(	O
dry	O
and	O
fresh	O
)	O
,	O
against	O
the	O
activity	O
of	O
the	O
CYP	O
enzyme	O
most	O
potently	O
inhibited	O
,	O
in	O
this	O
case	O
CYP1A2	B
,	O
demonstrated	O
similar	O
results	O
to	O
those	O
originally	O
obtained	O
with	O
the	O
aqueous	O
extract	O
(	O
dry	O
plant	O
material	O
)	O
.	O

CYP1A2	B
is	O
an	O
important	O
enzyme	O
,	O
because	O
it	O
is	O
responsible	O
for	O
metabolizing	O
a	O
number	O
of	O
commonly	O
prescribed	O
drugs	O
,	O
several	O
of	O
which	O
are	O
used	O
in	O
psychiatric	O
medicine	O
-	O
drugs	O
such	O
as	O
fluvoxamine	O
,	O
amitriptyline	O
,	O
clomipramine	O
and	O
clozapine	O
.	O

Further	O
investigations	O
were	O
undertaken	O
to	O
characterise	O
the	O
phytochemicals	O
in	O
the	O
crude	O
aqueous	O
extract	O
of	O
the	O
dried	O
aerial	O
plant	O
material	O
of	O
H	O
.	O
verticillata	O
,	O
to	O
identify	O
the	O
key	O
phytochemical	O
(	O
s	O
)	O
responsible	O
for	O
the	O
inhibition	O
of	O
CYP1A2	B
,	O
and	O
to	O
allow	O
further	O
assessment	O
of	O
the	O
plant	O
preparations	O
potential	O
to	O
impact	O
the	O
activities	O
of	O
CYP	O
enzymes	O
in	O
vivo	O
.	O

Five	O
individual	O
phytochemicals	O
,	O
together	O
with	O
the	O
mixture	O
of	O
five	O
lignans	O
were	O
tested	O
for	O
their	O
impact	O
on	O
the	O
activity	O
of	O
CYP1A2	B
.	O

The	O
two	O
triterpenes	O
,	O
oleanolic	O
acid	O
and	O
ursolic	O
acid	O
,	O
demonstrated	O
weak	O
inhibition	O
,	O
with	O
IC_50	O
values	O
>	O
100	O
M	O
.	O
The	O
remaining	O
two	O
individual	O
phytochemicals	O
,	O
the	O
lignans	O
podophyllotoxin	O
and	O
4	O
-	O
demethylpodophyllotoxin	O
demonstrated	O
no	O
inhibition	O
of	O
CYP1A2	B
activity	O
.	O

Two	O
further	O
phytochemicals	O
,	O
cadina	O
-	O
4	O
,	O
10	O
(	O
15	O
)	O
-	O
dien	O
-	O
3	O
-	O
one	O
and	O
-	O
sitosterol	O
were	O
found	O
to	O
be	O
weak	O
inhibitors	O
of	O
CYP1A2	B
.	O

By	O
way	O
of	O
comparison	O
,	O
an	O
assay	O
with	O
a	O
known	O
CYP1A2	B
inhibitor	O
,	O
furafylline	O
,	O
was	O
tested	O
against	O
the	O
activity	O
of	O
CYP1A2	B
,	O
and	O
an	O
IC_50	O
value	O
of	O
1	O
.	O
4	O
0	O
.	O
15	O
M	O
generated	O
,	O
which	O
was	O
consistent	O
with	O
values	O
previously	O
obtained	O
and	O
published	O
by	O
our	O
laboratory	O
.	O

Only	O
two	O
of	O
the	O
phytochemicals	O
,	O
oleanolic	O
and	O
ursolic	O
acid	O
,	O
appear	O
to	O
have	O
been	O
previously	O
screened	O
against	O
the	O
activity	O
of	O
CYP1A2	B
.	O

Our	O
results	O
,	O
reporting	O
no	O
inhibition	O
by	O
podophyllotoxin	O
and	O
moderate	O
/	O
weak	O
inhibition	O
by	O
-	O
yatein	O
against	O
the	O
activity	O
of	O
CYP1A2	B
for	O
the	O
first	O
time	O
,	O
further	O
strengthens	O
the	O
earlier	O
reports	O
of	O
selectively	O
potent	O
inhibition	O
of	O
CYP3A4	B
by	O
these	O
two	O
phytochemicals	O
.	O

Having	O
confirmed	O
the	O
identity	O
of	O
seven	O
phytochemicals	O
in	O
the	O
aqueous	O
extract	O
of	O
H	O
.	O
verticillata	O
(	O
dried	O
aerial	O
material	O
)	O
,	O
and	O
screened	O
them	O
for	O
their	O
impact	O
on	O
the	O
activity	O
of	O
CYP1A2	B
,	O
it	O
appears	O
that	O
the	O
bioactivity	O
displayed	O
by	O
the	O
crude	O
aqueous	O
extract	O
of	O
the	O
plant	O
(	O
dried	O
aerial	O
material	O
)	O
can	O
be	O
attributed	O
in	O
part	O
to	O
yatein	O
and	O
two	O
of	O
the	O
phytochemicals	O
identified	O
from	O
the	O
mixture	O
of	O
lignans	O
,	O
which	O
displayed	O
moderate	O
/	O
weak	O
and	O
moderate	O
inhibition	O
,	O
respectively	O
,	O
of	O
the	O
same	O
enzyme	O
.	O

In	O
conclusion	O
,	O
this	O
research	O
presents	O
the	O
results	O
of	O
an	O
in	O
-	O
depth	O
assessment	O
of	O
the	O
medicinal	O
plant	O
H	O
.	O
verticillata	O
,	O
its	O
impact	O
on	O
a	O
number	O
of	O
key	O
CYP450	O
enzymes	O
,	O
antioxidant	O
properties	O
,	O
and	O
its	O
characterisation	O
and	O
further	O
impact	O
on	O
CYP1A2	B
.	O

Screening	O
phytochemicals	O
against	O
the	O
activity	O
of	O
CYP1A2	B
identified	O
yatein	O
as	O
a	O
moderate	O
-	O
weak	O
contributor	O
to	O
the	O
plants	O
potent	O
bioactivity	O
,	O
with	O
potential	O
for	O
synergistic	O
activity	O
among	O
other	O
constituents	O
.	O

Positive	O
control	O
experiments	O
were	O
conducted	O
with	O
known	O
inhibitors	O
with	O
varying	O
concentrations	O
of	O
ALPHA	O
-	O
naphthoflavone	O
for	O
CYPs	O
1A1	O
and	O
1B1	O
,	O
furafylline	O
for	O
CYP1A2	B
,	O
quinidine	O
for	O
CYP2D6	B
,	O
and	O
ketoconazole	O
for	O
CYP3A4	B
.	O

Dimethylformamide	O
(	O
DMF	O
)	O
has	O
been	O
identified	O
as	O
one	O
of	O
the	O
least	O
inhibitory	O
solvents	O
towards	O
CYP1A2	B
.	O

Control	O
assays	O
run	O
with	O
DMF	O
confirmed	O
that	O
no	O
inhibition	O
against	O
CYP1A2	B
occurred	O
at	O
concentrations	O
levels	O
below	O
3	O
%	O
,	O
demonstrating	O
the	O
least	O
impact	O
with	O
no	O
significant	O
levels	O
of	O
inhibition	O
or	O
potentiation	O
of	O
fluorescence	O
across	O
the	O
range	O
of	O
concentrations	O
tested	O
.	O

A	O
recent	O
study	O
has	O
also	O
shown	O
in	O
silico	O
that	O
the	O
phospholipids	O
may	O
modulate	O
the	O
dynamics	O
of	O
access	O
channels	O
in	O
human	O
CYP1A2	B
.	O

One	O
of	O
the	O
results	O
presented	O
shows	O
that	O
,	O
during	O
molecular	O
dynamics	O
simulations	O
,	O
a	O
molecule	O
of	O
1	O
,	O
2	O
-	O
dilauroyl	O
-	O
sn	O
-	O
glycero	O
-	O
3	O
-	O
phosphocholine	O
can	O
penetrate	O
in	O
one	O
of	O
the	O
CYP1A2	B
access	O
channels	O
(	O
namely	O
tunnel	O
2d	O
)	O
.	O

The	O
penetration	O
progress	O
,	O
monitored	O
as	O
the	O
time	O
evolution	O
of	O
distance	O
of	O
1	O
,	O
2	O
-	O
Dilauroyl	O
-	O
Sn	O
-	O
Glycero	O
-	O
3	O
-	O
Phosphocholine	O
molecule	O
from	O
heme	O
cofactor	O
,	O
is	O
found	O
to	O
be	O
correlated	O
with	O
opening	O
/	O
closing	O
events	O
of	O
the	O
other	O
important	O
channels	O
of	O
CYP1A2	B
.	O

A	O
natural	O
genetic	O
variant	O
of	O
CYP1A2	B
,	O
namely	O
CYP1A2	B
*	O
11	O
,	O
was	O
characterized	O
for	O
its	O
activity	O
towards	O
two	O
marker	O
substrates	O
,	O
phenacetin	O
and	O
7	O
-	O
ethoxy	O
-	O
resorufin	O
,	O
and	O
was	O
shown	O
to	O
be	O
more	O
impacted	O
for	O
phenacetin	O
O	O
-	O
deethylase	O
activity	O
(	O
10	O
%	O
of	O
that	O
of	O
wild	O
-	O
type	O
CYP1A2	B
)	O
than	O
for	O
ethoxyresorufin	O
O	O
-	O
deethylase	O
activity	O
(	O
30	O
%	O
of	O
that	O
of	O
wild	O
-	O
type	O
CYP1A2	B
)	O
.	O

In	O
a	O
recent	O
work	O
,	O
the	O
aromatic	O
residue	O
186	O
was	O
proposed	O
,	O
based	O
on	O
molecular	O
simulation	O
studies	O
,	O
to	O
exist	O
in	O
two	O
conformational	O
states	O
,	O
corresponding	O
to	O
the	O
open	O
or	O
closed	O
conformation	O
of	O
one	O
of	O
the	O
several	O
access	O
channels	O
of	O
CYP1A2	B
network	O
.	O

In	O
contrast	O
to	O
the	O
further	O
above	O
-	O
mentioned	O
studies	O
CYP1A2	B
,	O
2A7	O
,	O
2B6	O
and	O
3A4	O
mRNAs	O
were	O
not	O
detected	O
in	O
keratinocytes	O
in	O
this	O
investigation	O
(	O
the	O
keratinocytes	O
were	O
cultured	O
for	O
36	O
h	O
only	O
,	O
in	O
presence	O
of	O
1	O
.	O
5	O
mM	O
calcium	O
)	O
.	O

A	O
considerable	O
number	O
of	O
CYPs	O
mRNAs	O
were	O
found	O
in	O
both	O
,	O
Full	O
-	O
Thickness	O
Human	O
Bottom	O
Skin	O
and	O
EpiDerm	O
^	O
:	O
CYP1A2	B
,	O
1B1	O
,	O
2C9	O
,	O
2C18	O
,	O
2J2	O
,	O
2R1	O
,	O
2S1	O
,	O
3A5	O
and	O
4B1	O
and	O
a	O
considerable	O
number	O
of	O
CYPs	O
mRNAs	O
were	O
found	O
in	O
neither	O
Full	O
-	O
Thickness	O
Human	O
Bottom	O
Skin	O
nor	O
EpiDerm	O
^	O
:	O
CYP2B6	B
,	O
2C8	O
,	O
2C19	O
,	O
2F1	O
,	O
3A4	O
and	O
3A7	O
(	O
for	O
further	O
studies	O
on	O
CYPs	O
transcripts	O
expression	O
in	O
reconstructed	O
human	O
skin	O
models	O
see	O
Hayden	O
et	O
al	O
.	O

CYP1A2	B
,	O
2E1	O
and	O
3A4	O
proteins	O
were	O
additionally	O
sought	O
and	O
not	O
found	O
by	O
immunoblotting	O
(	O
LOD	O
2	O
.	O
5	O
pmol	O
/	O
mg	O
microsomal	O
protein	O
)	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
(	O
CYP1	O
-	O
selective	O
)	O
and	O
7	O
-	O
Methoxyresorufin	O
-	O
O	O
-	O
Demethylase	O
(	O
CYP1A2	B
-	O
selective	O
)	O
which	O
was	O
higher	O
in	O
the	O
immortalized	O
cell	O
lines	O
HaCaT	O
and	O
NCTC	O
2544	O
than	O
in	O
the	O
primary	O
keratinocytes	O
NHEK	O
.	O

CYP1A2	B
The	O
following	O
arguments	O
indicate	O
that	O
CYP1A2	B
is	O
present	O
in	O
the	O
human	O
skin	O
:	O
several	O
enzymatic	O
activities	O
which	O
are	O
typical	O
for	O
CYP1A2	B
have	O
been	O
observed	O
in	O
human	O
skin	O
,	O
including	O
7	O
-	O
Methoxyresorufin	O
-	O
O	O
-	O
Demethylase	O
as	O
well	O
as	O
theophylline	O
demethylation	O
(	O
Ademola	O
et	O
al	O
.	O
.	O
Schober	O
et	O
al	O
.	O

Other	O
CYP1A2	B
substrates	O
(	O
as	O
observed	O
in	O
skin	O
or	O
in	O
other	O
systems	O
)	O
include	O
aflatoxin	O
B1	O
,	O
aromatic	O
amines	O
and	O
aromatic	O
amides	O
,	O
caffeine	O
,	O
acetaminophen	O
,	O
phenacetin	O
,	O
imipramine	O
,	O
warfarin	O
(	O
Du	O
et	O
al	O
.	O

Interestingly	O
both	O
CYP2B4	O
and	O
CYP1A2	B
have	O
been	O
shown	O
to	O
exist	O
as	O
hexamers	O
in	O
solution	O
^	O
-	O
.	O

Although	O
CYP1A2	B
is	O
predominantly	O
a	O
hepatic	O
isoform	O
,	O
CYP1A2	B
protein	O
has	O
been	O
identified	O
in	O
breast	O
cancer	O
tissues	O
.	O

In	O
MB	O
-	O
231	O
cells	O
,	O
the	O
CYP1A2	B
mRNA	O
levels	O
were	O
below	O
detectable	O
limits	O
.	O

This	O
finding	O
was	O
consistent	O
with	O
that	O
of	O
a	O
mouse	O
study	O
that	O
showed	O
that	O
liver	O
microsomal	O
EROD	O
activity	O
was	O
unaffected	O
by	O
berberine	O
when	O
CYP1A2	B
mRNA	O
was	O
elevated	O
.	O

The	O
resulting	O
cDNA	O
was	O
subjected	O
to	O
PCR	O
amplification	O
using	O
primer	O
sets	O
for	O
CYP1A2	B
*	O
1	O
(	O
NM_000761	O
.	O
4	O
)	O
,	O
CYP1B1	O
*	O
1	O
(	O
NM_000104	O
.	O
3	O
)	O
and	O
BETA	O
-	O
actin	O
(	O
NM_001101	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
drug	O
interaction	O
potential	O
of	O
two	O
selaginellins	O
on	O
ten	O
P450	O
isoforms	O
(	O
CYP1A2	B
,	O
2A6	O
,	O
2B6	O
,	O
2C8	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
2E1	O
,	O
2J2	O
and	O
3A	O
)	O
and	O
six	O
Uridine	O
5	O
-	O
Diphosphoglucuronosyltransferase	O
isoforms	O
(	O
UGT1A1	O
,	O
1A3	O
,	O
1A4	O
,	O
1A6	O
,	O
1A9	O
and	O
2B7	O
)	O
using	O
human	O
liver	O
microsomes	O
and	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
.	O

These	O
two	O
selaginellins	O
had	O
low	O
inhibitory	O
potential	O
against	O
CYP1A2	B
,	O
CYP2A6	O
,	O
CYP2E1	B
,	O
and	O
UGT1A6	O
(	O
IC50	O
>	O
25	O
M	O
)	O
.	O

Prediction	O
of	O
the	O
ligand	O
effect	O
in	O
CYP1A2	B
show	O
the	O
inhibitory	O
effect	O
of	O
1	O
-	O
4	O
;	O
this	O
result	O
could	O
be	O
explained	O
considering	O
the	O
similitude	O
between	O
the	O
substrates	O
(	O
polar	O
heterocyclic	O
compounds	O
and	O
arylamines	O
)	O
of	O
cytochrome	O
1A2	O
with	O
the	O
indole	O
motif	O
of	O
the	O
target	O
molecules	O
.	O

However	O
,	O
contrary	O
to	O
skin	O
,	O
CYP1B1	O
was	O
more	O
upregulated	O
than	O
CYP1A2	B
.	O

Interestingly	O
,	O
induction	O
of	O
CYP1A2	B
in	O
skin	O
was	O
found	O
to	O
be	O
much	O
larger	O
than	O
that	O
of	O
CYP1B1	O
,	O
whereas	O
an	O
opposite	O
trend	O
was	O
found	O
in	O
Normal	O
Human	O
Keratinocytes	O
,	O
similar	O
to	O
other	O
cell	O
types	O
^	O
.	O

Nanostructures	O
of	O
diamond	O
,	O
graphene	O
oxide	O
and	O
graphite	O
inhibit	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP3A4	B
enzymes	O
and	O
downregulate	O
their	O
genes	O
in	O
liver	O
cells	O
.	O

Other	O
important	O
isoenzymes	O
highly	O
engaged	O
in	O
drug	O
and	O
xenobiotic	O
metabolism	O
are	O
CYP2D6	B
and	O
CYP1A2	B
.	O

The	O
CYP1A2	B
form	O
is	O
relevant	O
not	O
only	O
in	O
drug	O
metabolism	O
(	O
over	O
10	O
%	O
of	O
popular	O
drugs	O
)	O
but	O
also	O
for	O
polycyclic	O
aromatic	O
hydrocarbon	O
(	O
PAH	O
)	O
metabolism	O
,	O
leading	O
to	O
metabolic	O
activation	O
of	O
procarcinogens	O
.	O

We	O
turned	O
our	O
attention	O
to	O
other	O
carbon	O
nanostructures	O
,	O
such	O
as	O
diamond	O
nanoparticles	O
(	O
DN	O
)	O
,	O
graphene	O
oxide	O
(	O
GO	O
)	O
and	O
graphite	O
nanoparticles	O
(	O
GN	O
)	O
,	O
which	O
were	O
previously	O
shown	O
to	O
be	O
nontoxic	O
or	O
low	O
toxic	O
;	O
however	O
,	O
no	O
data	O
are	O
available	O
on	O
their	O
potential	O
interactions	O
with	O
CYP	O
isoenzymes	O
.	O
,	O
,	O
We	O
hypothesized	O
that	O
a	O
physicochemical	O
interaction	O
occurs	O
between	O
employed	O
carbon	O
nanostructures	O
and	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP3A4	O
enzymes	O
.	O

Additionally	O
,	O
the	O
control	O
Baculosomes	O
without	O
CYP450	O
expression	O
were	O
mixed	O
in	O
the	O
same	O
manner	O
as	O
the	O
Baculosomes	O
with	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP3A4	O
expression	O
.	O

Known	O
inhibitors	O
of	O
CYP450	O
enzymes	O
were	O
used	O
as	O
positive	O
controls	O
:	O
miconazole	O
for	O
CYP1A2	B
,	O
quinidine	O
for	O
CYP2D6	B
and	O
ketoconazole	O
for	O
CYP3A4	O
.	O

In	O
the	O
first	O
step	O
,	O
Vivid	O
Substrates	O
(	O
EOMCC	O
for	O
CYP1A2	B
and	O
CYP2D6	B
,	O
BOMCC	O
for	O
CYP3A4	O
)	O
were	O
reconstituted	O
in	O
anhydrous	O
acetonitrile	O
,	O
and	O
then	O
40	O
L	O
of	O
tested	O
compounds	O
(	O
DN	O
,	O
GO	O
,	O
GN	O
or	O
inhibitors	O
)	O
or	O
working	O
buffer	O
(	O
control	O
)	O
was	O
added	O
to	O
each	O
well	O
on	O
96	O
-	O
well	O
black	O
-	O
bottom	O
plate	O
(	O
Corning	O
,	O
New	O
York	O
,	O
NY	O
,	O
USA	O
)	O
.	O

Then	O
,	O
50	O
L	O
of	O
Master	O
Pre	O
-	O
Mix	O
consisting	O
of	O
Baculosomes	O
(	O
containing	O
either	O
CYP1A2	B
,	O
CYP2D6	B
or	O
CYP3A4	O
isoenzyme	O
and	O
NADPH	O
reductase	O
)	O
in	O
working	O
buffer	O
and	O
the	O
regeneration	O
system	O
(	O
consisting	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
and	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
)	O
were	O
added	O
to	O
each	O
well	O
.	O

In	O
the	O
experiment	O
,	O
the	O
expression	O
levels	O
of	O
genes	O
for	O
the	O
previously	O
studied	O
cytochromes	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP3A4	O
,	O
for	O
two	O
other	O
cytochromes	O
vastly	O
expressed	O
in	O
the	O
liver	O
:	O
CYP2B6	B
and	O
CYP2E1	B
,	O
as	O
well	O
as	O
the	O
receptors	O
responsible	O
for	O
cytochrome	O
gene	O
expression	O
regulation	O
:	O
pregnane	O
X	O
receptor	O
(	O
PXR	O
)	O
,	O
constitutive	O
androstane	O
receptor	O
(	O
CAR	O
)	O
and	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
were	O
measured	O
.	O

DN	O
almost	O
did	O
not	O
affect	O
the	O
diameter	O
or	O
zeta	O
potential	O
of	O
the	O
microsomes	O
expressing	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP3A4	O
isoenzymes	O
,	O
whereas	O
GO	O
and	O
GN	O
visibly	O
increased	O
the	O
diameter	O
of	O
the	O
microsomes	O
,	O
especially	O
for	O
the	O
Baculosomes	O
expressing	O
CYP1A2	B
and	O
CYP3A4	O
isoenzymes	O
(	O
>	O
1	O
,	O
000	O
nm	O
in	O
comparison	O
to	O
~	O
300	O
nm	O
in	O
0	O
mg	O
/	O
L	O
samples	O
)	O
.	O

GN	O
also	O
shifted	O
zeta	O
potential	O
of	O
the	O
microsomes	O
from	O
highly	O
negative	O
(	O
37	O
,	O
31	O
and	O
42	O
mV	O
for	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP3A4	O
,	O
respectively	O
)	O
toward	O
more	O
positive	O
values	O
(	O
2	O
,	O
16	O
and	O
30	O
mV	O
for	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP3A4	O
,	O
respectively	O
)	O
and	O
GO	O
shifted	O
the	O
values	O
toward	O
more	O
negative	O
values	O
(	O
43	O
,	O
44	O
and	O
48	O
mV	O
for	O
1A2	O
,	O
2D6	O
and	O
3A4	O
,	O
respectively	O
)	O
,	O
which	O
indicates	O
the	O
impact	O
of	O
GO	O
and	O
GN	O
on	O
the	O
stability	O
of	O
microsome	O
hydrocolloids	O
and	O
the	O
occurrence	O
of	O
physicochemical	O
interactions	O
between	O
the	O
nanostructures	O
and	O
microsomes	O
expressing	O
the	O
CYP	O
enzymes	O
.	O

However	O
,	O
additional	O
measurements	O
performed	O
with	O
the	O
control	O
Baculosomes	O
,	O
which	O
did	O
not	O
express	O
any	O
recombinant	O
CYP	O
isoenzyme	O
,	O
revealed	O
that	O
the	O
binding	O
might	O
not	O
be	O
specific	O
for	O
the	O
CYP1A2	B
,	O
CYP2D6	B
or	O
CYP3A4	O
proteins	O
,	O
since	O
a	O
similar	O
decrease	O
in	O
the	O
protein	O
level	O
was	O
observed	O
.	O

In	O
the	O
enzymatic	O
test	O
based	O
on	O
Baculosomes	O
,	O
all	O
three	O
types	O
of	O
nanostructures	O
inhibited	O
reactions	O
by	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP3A4	O
isoenzymes	O
.	O

Inhibition	O
rate	O
was	O
compared	O
to	O
inhibition	O
in	O
positive	O
control	O
samples	O
with	O
the	O
known	O
specific	O
inhibitors	O
miconazole	O
,	O
quinidine	O
and	O
ketoconazole	O
for	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP3A4	O
,	O
respectively	O
.	O

In	O
the	O
reaction	O
catalyzed	O
by	O
CYP1A2	B
,	O
higher	O
inhibition	O
at	O
a	O
similar	O
level	O
was	O
observed	O
for	O
DN	O
and	O
GN	O
(	O
about	O
70	O
%	O
-	O
80	O
%	O
compared	O
to	O
the	O
control	O
inhibitor	O
,	O
miconazole	O
)	O
than	O
for	O
GO	O
(	O
20	O
%	O
-	O
50	O
%	O
inhibition	O
)	O
.	O

The	O
inhibition	O
rate	O
of	O
CYP3A4	O
was	O
comparable	O
for	O
DN	O
,	O
GO	O
and	O
GN	O
at	O
all	O
concentrations	O
(	O
50	O
%	O
-	O
60	O
%	O
inhibition	O
)	O
;	O
however	O
,	O
at	O
the	O
highest	O
concentration	O
,	O
we	O
observed	O
an	O
effect	O
similar	O
to	O
the	O
one	O
in	O
CYP1A2	B
.	O

CYP1A2	B
expression	O
was	O
significantly	O
decreased	O
in	O
both	O
cell	O
lines	O
in	O
the	O
DN	O
(	O
45	O
.	O
9	O
%	O
and	O
36	O
%	O
of	O
the	O
control	O
in	O
HepG2	O
and	O
HepaRG	O
,	O
respectively	O
)	O
and	O
GO	O
(	O
50	O
.	O
6	O
%	O
and	O
1	O
.	O
7	O
%	O
of	O
the	O
control	O
in	O
HepG2	O
and	O
HepaRG	O
,	O
respectively	O
)	O
groups	O
,	O
but	O
increased	O
in	O
the	O
GN	O
group	O
(	O
55	O
.	O
8	O
%	O
and	O
138	O
.	O
7	O
%	O
more	O
than	O
in	O
the	O
control	O
,	O
HepG2	O
and	O
HepaRG	O
,	O
respectively	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
presented	O
interactions	O
among	O
three	O
nanostructures	O
of	O
different	O
carbon	O
allotropes	O
,	O
namely	O
,	O
DN	O
,	O
GO	O
and	O
GN	O
,	O
and	O
isoenzymes	O
of	O
CYP450	O
,	O
namely	O
,	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP3A4	O
,	O
in	O
the	O
model	O
of	O
Baculosomes	O
.	O

The	O
most	O
important	O
evidence	O
for	O
the	O
direct	O
interaction	O
between	O
CYP	O
-	O
expressing	O
microsomes	O
and	O
DN	O
,	O
GO	O
and	O
GN	O
is	O
inhibition	O
of	O
the	O
catalytic	O
activity	O
of	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP3A4	O
measured	O
separately	O
for	O
all	O
three	O
isoforms	O
and	O
revealing	O
subtle	O
differences	O
among	O
the	O
isoenzymes	O
.	O

Product	O
formation	O
on	O
CYP1A2	B
was	O
highly	O
inhibited	O
by	O
DN	O
and	O
GN	O
,	O
while	O
on	O
CYP2D6	B
and	O
CYP3A4	O
,	O
all	O
nanostructures	O
inhibited	O
the	O
reaction	O
at	O
similar	O
levels	O
.	O

Interestingly	O
,	O
inhibition	O
of	O
CYP1A2	B
and	O
CYP3A4	O
was	O
lower	O
in	O
the	O
presence	O
of	O
the	O
highest	O
concentration	O
of	O
DN	O
and	O
GN	O
(	O
100	O
mg	O
/	O
L	O
)	O
,	O
which	O
could	O
be	O
related	O
to	O
the	O
formation	O
of	O
nanoparticle	O
agglomerates	O
in	O
higher	O
concentrations	O
and	O
then	O
reduction	O
of	O
their	O
surface	O
area	O
available	O
to	O
interact	O
.	O

On	O
the	O
contrary	O
,	O
inhibition	O
of	O
CYP1A2	B
was	O
concentration	O
dependent	O
in	O
the	O
presence	O
of	O
GO	O
.	O

General	O
downregulation	O
of	O
the	O
genes	O
was	O
especially	O
visible	O
in	O
HepaRG	O
cells	O
,	O
which	O
probably	O
results	O
from	O
a	O
weaker	O
expression	O
of	O
genes	O
encoding	O
enzymes	O
of	O
Phases	O
I	O
and	O
II	O
of	O
the	O
xenobiotic	O
metabolism	O
in	O
the	O
HepG2	O
cell	O
line	O
,	O
making	O
HepaRG	O
a	O
more	O
suitable	O
model	O
for	O
drug	O
metabolism	O
studies	O
.	O
-	O
The	O
strongest	O
downregulation	O
of	O
CYP	O
genes	O
was	O
induced	O
by	O
GO	O
,	O
which	O
influenced	O
not	O
only	O
CYP1A2	B
and	O
CYP3A4	O
genes	O
,	O
but	O
also	O
CYP2B6	B
,	O
CYP2E1	B
and	O
AhR	O
,	O
CAR	O
and	O
PXR	O
,	O
which	O
are	O
responsive	O
elements	O
regulating	O
the	O
expression	O
of	O
CYP	O
genes	O
.	O

Interestingly	O
,	O
we	O
observed	O
induction	O
of	O
CYP1A2	B
upon	O
treatment	O
with	O
GN	O
.	O

A	O
known	O
inducer	O
of	O
CYP1A2	B
is	O
cigarette	O
smoke	O
containing	O
a	O
significant	O
amount	O
of	O
nanoparticulated	O
carbon	O
black	O
and	O
PAH	O
.	O
,	O
Thus	O
,	O
it	O
might	O
be	O
related	O
to	O
GN	O
structure	O
,	O
more	O
similar	O
to	O
compounds	O
found	O
in	O
the	O
cigarette	O
smoke	O
,	O
when	O
compared	O
to	O
the	O
DN	O
or	O
GO	O
used	O
in	O
this	O
study	O
,	O
as	O
PAH	O
structure	O
also	O
consists	O
of	O
sp	O
^	O
2	O
-	O
hybridized	O
carbon	O
atoms	O
with	O
delocalized	O
electrons	O
,	O
which	O
is	O
a	O
reason	O
for	O
naming	O
PAH	O
nanographenes	O
or	O
cutouts	O
of	O
graphene	O
.	O

456211	O
)	O
,	O
CYP1A2	B
(	O
Lot	O
No	O
.	O

did	O
not	O
detect	O
5HMFLX	O
in	O
incubations	O
with	O
recombinant	O
CYP1A2	B
,	O
CYP2C9	O
and	O
CYP3A5	B
might	O
be	O
attributed	O
to	O
the	O
less	O
sensitive	O
analytical	O
method	O
used	O
(	O
HPLC	O
-	O
UV	O
detection	O
versus	O
LC	O
-	O
MS	O
)	O
and	O
/	O
or	O
the	O
use	O
of	O
yeastexpressed	O
CYPs	O
with	O
lower	O
specific	O
activity	O
than	O
the	O
Supersomes	O
used	O
in	O
the	O
present	O
study	O
.	O

Mostly	O
all	O
the	O
compounds	O
were	O
found	O
to	O
be	O
a	O
substrate	O
of	O
CYP1A2	B
,	O
except	O
F25	O
,	O
whereas	O
,	O
for	O
CYP2C8	O
,	O
only	O
compound	O
F2	O
was	O
found	O
to	O
be	O
the	O
substrate	O
.	O

Results	O
revealed	O
that	O
for	O
predicting	O
the	O
site	O
of	O
enzyme	O
CYP1A2	B
,	O
the	O
K_m	O
value	O
was	O
28	O
.	O
53	O
,	O
33	O
.	O
79	O
,	O
18	O
.	O
55	O
,	O
16	O
.	O
59	O
,	O
7	O
.	O
42	O
,	O
158	O
.	O
31	O
and	O
49	O
.	O
91	O
M	O
,	O
whereas	O
the	O
V_max	O
constant	O
was	O
1	O
.	O
76	O
,	O
4	O
.	O
22	O
,	O
5	O
.	O
34	O
,	O
1	O
.	O
18	O
,	O
1	O
.	O
99	O
,	O
5	O
.	O
19	O
and	O
8	O
.	O
04	O
nM	O
/	O
min	O
/	O
nM	O
and	O
the	O
C_Lint	O
was	O
3	O
.	O
21	O
,	O
6	O
.	O
49	O
,	O
14	O
.	O
96	O
,	O
3	O
.	O
69	O
,	O
13	O
.	O
92	O
,	O
1	O
.	O
70	O
,	O
and	O
8	O
.	O
37	O
L	O
/	O
min	O
/	O
mg	O
for	O
compounds	O
F2	O
,	O
F3	O
,	O
F8	O
,	O
F11	O
,	O
F13	O
,	O
F20	O
,	O
and	O
F21	O
,	O
respectively	O
.	O

However	O
,	O
results	O
of	O
inhibition	O
studies	O
showed	O
that	O
all	O
the	O
compound	O
might	O
inhibit	O
CYP1A2	B
,	O
CYP2C9	O
,	O
and	O
CYP2D6	B
,	O
except	O
compound	O
F2	O
which	O
did	O
not	O
inhibit	O
the	O
CYP2D6	B
.	O

^	O
,	O
Chronic	O
tobacco	O
smokers	O
have	O
induced	O
hepatic	O
CYP	O
enzymes	O
,	O
particularly	O
CYP1A2	B
.	O

CYP1A2	B
is	O
a	O
relevant	O
enzyme	O
in	O
the	O
metabolism	O
of	O
commonly	O
prescribed	O
psychoactive	O
medications	O
,	O
including	O
clozapine	O
,	O
duloxetine	O
,	O
olanzapine	O
and	O
imipramine	O
are	O
not	O
metabolized	O
by	O
CYP1A2	B
.	O

PharmG	O
+	O
clozapine	O
treated	O
patients	O
with	O
CYP1A2	B
or	O
CYP2C19	B
UM	O
and	O
PMs	O
variants	O
also	O
showed	O
higher	O
reductions	O
in	O
UKU	O
scores	O
than	O
PharmG	O
clozapine	O
patients	O
in	O
general	O
.	O

CYPs	O
are	O
responsible	O
for	O
the	O
biotransformation	O
of	O
widely	O
used	O
antipsychotics	O
such	O
as	O
clozapine	O
(	O
CYP1A2	B
and	O
CYP2C19	B
)	O
,	O
olanzapine	O
(	O
CYP1A2	B
)	O
,	O
risperidone	O
and	O
haloperidol	O
(	O
CYP2D6	B
)	O
,	O
quetiapine	O
and	O
ziprasidone	O
(	O
CYP3A5	B
)	O
amongst	O
others	O
^	O
,	O
.	O

A	O
commercial	O
pharmacogenetic	O
test	O
(	O
Brainchip	O
,	O
Brainco	O
,	O
Bilbao	O
,	O
Spain	O
)	O
was	O
used	O
to	O
characterise	O
common	O
and	O
functional	O
polymorphisms	O
in	O
CYP1A2	B
,	O
CYP2D6	B
,	O
CYP2C19	B
and	O
CYP3A5	O
enzymes	O
,	O
the	O
main	O
metabolic	O
pathways	O
of	O
currently	O
available	O
antipsychotics	O
.	O

Doses	O
were	O
adjusted	O
according	O
to	O
main	O
metabolic	O
pathways	O
:	O
^	O
,	O
clozapine	O
doses	O
were	O
adjusted	O
according	O
to	O
the	O
genotypic	O
variants	O
observed	O
in	O
CYP1A2	B
and	O
CYP2C19	B
;	O
olanzapine	O
doses	O
were	O
adjusted	O
according	O
to	O
CYP1A2	B
polymorphisms	O
;	O
risperidone	O
,	O
aripiprazole	O
,	O
haloperidol	O
,	O
pimozide	O
and	O
trifluoperazine	O
doses	O
were	O
adjusted	O
according	O
to	O
CYP2D6	B
polymorphisms	O
;	O
finally	O
,	O
quetiapine	O
and	O
ziprasidone	O
doses	O
were	O
adjusted	O
according	O
to	O
CYP3A5	O
genetic	O
variants	O
.	O

When	O
analysing	O
patients	O
with	O
functional	O
variants	O
in	O
CYP1A2	B
,	O
CYP2D6	B
and	O
/	O
or	O
CYP2C19	B
(	O
N	O
=	O
155	O
)	O
,	O
no	O
differences	O
were	O
observed	O
between	O
PharmG	O
+	O
and	O
PharmG	O
patients	O
in	O
PANSS	O
improvement	O
,	O
nor	O
was	O
it	O
observed	O
in	O
the	O
subgroups	O
of	O
patients	O
treated	O
with	O
clozapine	O
(	O
p	O
>	O
0	O
.	O
05	O
for	O
all	O
comparisons	O
,	O
see	O
Table	O
.	O

Analyses	O
of	O
patients	O
with	O
functional	O
variants	O
in	O
CYP1A2	B
,	O
CYP2D6	B
or	O
CYP2C19	B
revealed	O
clearer	O
improvements	O
in	O
the	O
profile	O
of	O
side	O
effects	O
in	O
the	O
PharmG	O
+	O
patients	O
in	O
comparison	O
to	O
PharmG	O
patients	O
.	O

However	O
,	O
those	O
differences	O
were	O
not	O
statistically	O
significant	O
,	O
even	O
when	O
considering	O
patients	O
with	O
CYP1A2	B
or	O
CYP2C19	B
UM	O
and	O
PMs	O
variants	O
(	O
p	O
>	O
0	O
.	O
05	O
in	O
all	O
comparisons	O
)	O
.	O

Several	O
studies	O
have	O
proven	O
the	O
clinical	O
value	O
of	O
a	O
commercial	O
array	O
combining	O
genetic	O
information	O
in	O
metabolic	O
enzymes	O
(	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP2C19	B
)	O
and	O
antidepressant	O
targets	O
(	O
serotonin	O
transporter	O
,	O
SLC6A4	O
and	O
serotonin	O
receptor	O
2A	O
,	O
HTR2A	O
)	O
.	O

Regorafenib	O
and	O
its	O
major	O
metabolites	O
are	O
also	O
reported	O
to	O
inhibit	O
a	O
number	O
of	O
cytochromes	O
(	O
CYP2C8	O
,	O
CYP2C9	O
,	O
CYP2B6	O
,	O
Cytochrome	B
P450	I
3a4	O
,	O
CYP2D6	O
)	O
,	O
UGT1A	O
enzymes	O
(	O
UGT1A9	O
,	O
UGT1A1	O
)	O
,	O
and	O
transporters	O
(	O
BCRP	O
)	O
and	O
induce	O
others	O
(	O
CYP1A2	B
,	O
CYP2B6	O
,	O
CYP2C19	B
,	O
CYP3A4	O
)	O
with	O
potential	O
alteration	O
in	O
the	O
exposure	O
of	O
co	O
-	O
administered	O
drugs	O
.	O

There	O
are	O
more	O
than	O
50	O
Cytochrome	B
P450	I
enzymes	I
,	O
but	O
the	O
CYP1A2	B
,	O
CYP2C9	O
,	O
CYP2C19	B
,	O
CYP2D6	O
,	O
CYP3A4	O
,	O
and	O
CYP3A5	O
enzymes	O
metabolize	O
90	O
percent	O
of	O
drugs	O
.	O

Similar	O
serum	O
antibodies	O
to	O
drug	O
-	O
modified	O
and	O
/	O
or	O
unmodified	O
P450s	O
and	O
other	O
native	O
cellular	O
proteins	O
have	O
also	O
been	O
detected	O
in	O
idiosyncratic	O
liver	O
injury	O
upon	O
halothane	O
-	O
exposure	O
(	O
anti	O
-	O
trifluoroacetyl	O
-	O
CYP2E1	O
)	O
,	O
aromatic	O
anti	O
-	O
convulsant	O
(	O
anti	O
-	O
CYP3A	O
)	O
,	O
dihydralazine	O
(	O
anti	O
-	O
CYP1A2	B
)	O
,	O
tienilic	O
acid	O
(	O
anti	O
-	O
tienilic	O
acid	O
-	O
CYP2C9	O
)	O
and	O
/	O
or	O
chronic	O
alcohol	O
intake	O
(	O
anti	O
-	O
acetaldehyde	O
-	O
CYP2E1	O
and	O
anti	O
-	O
hydroxyethyl	O
-	O
CYP2E1	O
)	O
,	O
.	O

CYP1A	O
-	O
catalyzed	O
reactions	O
include	O
hydroxylation	O
and	O
oxidation	O
of	O
aromatic	O
compounds	O
,	O
in	O
which	O
CYP1A1	O
is	O
mainly	O
involved	O
in	O
the	O
metabolism	O
of	O
aromatic	O
hydrocarbon	O
,	O
while	O
CYP1A2	B
prefers	O
aromatic	O
amines	O
and	O
heterocyclic	O
compounds	O
.	O

Compared	O
with	O
CYP1A2	B
,	O
CYP1A1	O
is	O
the	O
main	O
isoform	O
mediating	O
the	O
biotransformation	O
of	O
pregnenolone	O
.	O

Genotyping	O
kits	O
for	O
specific	O
alleles	O
in	O
CYP2C19	B
and	O
CYP2D6	B
genes	O
have	O
been	O
approved	O
by	O
the	O
US	O
-	O
FDA	O
to	O
be	O
used	O
as	O
pharmacogenetic	O
biomarkers	O
(	O
www	O
.	O
fda	O
.	O
gov	O
)	O
.	O

The	O
inactivation	O
potency	O
(	O
k_inact	O
/	O
K_i	O
ratio	O
)	O
of	O
fargesin	O
against	O
CYP2C19	B
(	O
27	O
.	O
57	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
was	O
higher	O
than	O
those	O
of	O
drugs	O
identified	O
as	O
mechanism	O
-	O
based	O
inhibitors	O
of	O
CYP2C19	B
such	O
as	O
aschantin	O
(	O
8	O
.	O
28	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
clopidogrel	O
(	O
3	O
.	O
90	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
and	O
fluoxetine	O
(	O
2	O
.	O
14	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
but	O
was	O
comparable	O
to	O
that	O
of	O
ticlopidine	O
(	O
22	O
.	O
3	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
in	O
human	O
liver	O
microsomes	O
.	O

Hydrolysis	O
single	O
-	O
nucleotide	O
polymorphism	O
analysis	O
for	O
CYP2C19	B
*	O
2	O
,	O
CYP2C19	B
*	O
3	O
,	O
CYP2C19	B
*	O
4	O
,	O
CYP2C19	B
*	O
17	O
,	O
CYP2D6	B
*	O
3	O
,	O
CYP2D6	B
*	O
4	O
,	O
CYP2D6	B
*	O
6	O
,	O
CYP2D6	B
*	O
10	O
,	O
CYP2D6	B
*	O
41	O
,	O
CYP3A4	B
*	O
1B	O
,	O
CYP3A4	B
*	O
22	O
,	O
and	O
CYP3A5	B
*	O
3	O
was	O
performed	O
using	O
TaqMan	O
probes	O
(	O
BioSearch	O
Technologies	O
,	O
Novato	O
,	O
CA	O
)	O
.	O

Of	O
92	O
patients	O
,	O
31	O
carried	O
at	O
least	O
one	O
CYP2C19	B
loss	O
-	O
of	O
-	O
function	O
allele	O
(	O
CYP2C19	B
*	O
2	O
,	O
CYP2C19	B
*	O
3	O
,	O
or	O
CYP2C19	B
*	O
4	O
)	O
,	O
and	O
32	O
carried	O
the	O
gain	O
-	O
of	O
-	O
function	O
CYP2C19	B
*	O
17	O
allele	O
.	O

CYP2C19	B
genotype	O
seemed	O
to	O
influence	O
neither	O
the	O
clozapine	O
concentrations	O
normalized	O
by	O
the	O
dose	O
nor	O
the	O
concentrations	O
normalized	O
by	O
the	O
dose	O
/	O
bodyweight	O
.	O

No	O
significant	O
differences	O
in	O
clozapine	O
concentrations	O
were	O
observed	O
between	O
the	O
carriers	O
of	O
one	O
or	O
two	O
loss	O
-	O
of	O
-	O
function	O
alleles	O
and	O
the	O
patients	O
with	O
CYP2C19	B
*	O
1	O
/	O
*	O
1	O
genotype	O
or	O
those	O
with	O
gain	O
-	O
of	O
-	O
function	O
allele	O
(	O
CYP2C19	B
*	O
17	O
)	O
associated	O
with	O
increased	O
CYP2C19	B
expression	O
(	O
P	O
=	O
.	O
1083	O
)	O
.	O

Our	O
results	O
indicated	O
that	O
CYP2C19	B
and	O
CYP2D6	B
were	O
not	O
likely	O
to	O
have	O
a	O
primary	O
role	O
in	O
clozapine	O
clearance	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
results	O
of	O
previous	O
studies	O
showing	O
that	O
the	O
patients	O
response	O
to	O
clozapine	O
treatment	O
did	O
not	O
correlate	O
with	O
their	O
CYP2D6	B
genotype	O
,	O
and	O
the	O
association	O
between	O
clozapine	O
clearance	O
in	O
patients	O
and	O
the	O
polymorphic	O
expression	O
of	O
either	O
CYP2D6	B
or	O
CYP2C19	B
have	O
failed	O
to	O
be	O
demonstrated	O
.	O

In	O
contrast	O
,	O
reported	O
higher	O
clozapine	O
concentrations	O
in	O
patients	O
with	O
CYP2C19	B
*	O
2	O
/	O
*	O
2	O
genotype	O
than	O
in	O
those	O
carrying	O
non	O
-	O
CYP2C19	B
*	O
2	O
/	O
*	O
2	O
genotypes	O
.	O

CYP2C19	B
*	O
2	O
and	O
CYP2C19	B
*	O
17	O
variants	O
and	O
effect	O
of	O
tamoxifen	O
on	O
breast	O
cancer	O
recurrence	O
:	O
Analysis	O
of	O
the	O
International	O
Tamoxifen	O
Pharmacogenomics	O
Consortium	O
dataset	O
.	O

CYP2D6	B
have	O
been	O
intensively	O
studied	O
,	O
but	O
the	O
role	O
of	O
CYP2C19	B
is	O
less	O
elucidated	O
,	O
and	O
we	O
studied	O
the	O
association	O
of	O
CYPC19	O
genotype	O
and	O
recurrence	O
of	O
breast	O
cancer	O
.	O

CYP2C19	B
genotype	O
data	O
was	O
available	O
for	O
2	O
423	O
patients	O
and	O
the	O
final	O
sample	O
cohort	O
comprised	O
2	O
102	O
patients	O
.	O

CYP2C19	B
*	O
2	O
or	O
*	O
19	O
alleles	O
did	O
not	O
influence	O
DFS	O
.	O

For	O
the	O
CYP2C19	B
*	O
2	O
allele	O
,	O
the	O
HR	O
was	O
1	O
.	O
05	O
(	O
CI	O
0	O
.	O
78	O
-	O
1	O
.	O
42	O
)	O
and	O
0	O
.	O
79	O
(	O
CI	O
0	O
.	O
32	O
-	O
1	O
.	O
94	O
)	O
for	O
hetero	O
-	O
and	O
homozygote	O
carriers	O
,	O
respectively	O
.	O

The	O
corresponding	O
HR	O
for	O
hetero	O
-	O
and	O
homozygote	O
carriers	O
of	O
the	O
CYP2C19	B
*	O
17	O
allele	O
were	O
1	O
.	O
02	O
(	O
CI	O
0	O
.	O
71	O
-	O
1	O
.	O
46	O
)	O
and	O
0	O
.	O
57	O
(	O
CI	O
0	O
.	O
26	O
-	O
1	O
.	O
24	O
)	O
,	O
respectively	O
.	O

We	O
found	O
no	O
evidence	O
to	O
support	O
a	O
clinically	O
meaningful	O
role	O
of	O
CYP2C19	B
polymorphisms	O
and	O
response	O
to	O
tamoxifen	O
in	O
breast	O
cancer	O
patients	O
and	O
,	O
consequently	O
,	O
CYP2C19	B
genotype	O
status	O
should	O
not	O
be	O
included	O
in	O
clinical	O
decisions	O
on	O
tamoxifen	O
treatment	O
.	O

CYP2C19	B
catalyzes	O
the	O
formation	O
of	O
a	O
proportion	O
of	O
tamoxifen	O
metabolites	O
,	O
including	O
the	O
conversion	O
of	O
4	O
-	O
OH	O
-	O
TAM	O
to	O
endoxifen	O
^	O
.	O

The	O
CYP2C19	B
gene	O
is	O
highly	O
polymorphic	O
.	O

Loss	O
of	O
enzyme	O
activity	O
results	O
from	O
the	O
CYP2C19	B
*	O
2	O
(	O
681	O
G	O
>	O
A	O
,	O
rs4244285	O
)	O
^	O
,	O
and	O
CYP2C19	B
*	O
3	O
(	O
636	O
G	O
>	O
A	O
,	O
rs4986893	O
)	O
alleles	O
^	O
,	O
.	O

CYP2C19	B
*	O
17	O
(	O
806C	O
>	O
T	O
,	O
rs12248560	O
or	O
3402C	O
>	O
T	O
,	O
rs11188072	O
)	O
has	O
been	O
implicated	O
in	O
enhanced	O
gene	O
transcription	O
^	O
,	O
.	O

Studies	O
differ	O
with	O
respect	O
to	O
the	O
associations	O
observed	O
between	O
CYP2C19	B
genotypes	O
and	O
clinical	O
outcomes	O
as	O
well	O
as	O
to	O
corresponding	O
levels	O
of	O
tamoxifen	O
and	O
its	O
metabolites	O
^	O
-	O
.	O

In	O
some	O
studies	O
the	O
CYP2C19	B
*	O
17	O
allele	O
is	O
associated	O
with	O
more	O
favorable	O
outcomes	O
in	O
breast	O
cancer	O
patients	O
treated	O
with	O
tamoxifen	O
^	O
,	O
though	O
null	O
results	O
have	O
also	O
been	O
found	O
^	O
,	O
.	O

Given	O
these	O
contradictory	O
findings	O
,	O
we	O
used	O
a	O
large	O
,	O
publicly	O
available	O
dataset	O
to	O
investigate	O
the	O
association	O
of	O
CYP2C19	B
*	O
2	O
and	O
CYP2C19	B
*	O
17	O
variants	O
with	O
breast	O
cancer	O
recurrence	O
in	O
both	O
pre	O
-	O
and	O
postmenopausal	O
women	O
treated	O
with	O
adjuvant	O
tamoxifen	O
therapy	O
for	O
ER	O
-	O
positive	O
breast	O
cancer	O
.	O

We	O
included	O
patients	O
with	O
non	O
-	O
metastatic	O
,	O
ER	O
-	O
positive	O
tumors	O
who	O
had	O
data	O
on	O
at	O
least	O
one	O
CYP2C19	B
variant	O
,	O
whether	O
a	O
recurrence	O
occurred	O
,	O
and	O
follow	O
-	O
up	O
time	O
(	O
Fig	O
.	O

Genotype	O
exposures	O
were	O
CYP2C19	B
*	O
2	O
and	O
CYP2C19	B
*	O
17	O
,	O
with	O
reference	O
to	O
the	O
wild	O
-	O
type	O
CYP2C19	B
*	O
1	O
.	O

In	O
three	O
instances	O
where	O
multiple	O
methods	O
were	O
used	O
for	O
a	O
single	O
individual	O
and	O
the	O
AmpliChip	O
blood	O
genotype	O
did	O
not	O
match	O
the	O
CYP2C19	B
*	O
2	O
genotype	O
obtained	O
with	O
another	O
method	O
,	O
preference	O
was	O
given	O
to	O
the	O
AmpliChip	O
data	O
due	O
to	O
the	O
high	O
sensitivity	O
and	O
specificity	O
of	O
this	O
test	O
^	O
.	O

The	O
CYP2C19	B
*	O
3	O
allele	O
was	O
not	O
assessed	O
in	O
this	O
study	O
because	O
no	O
variants	O
were	O
detected	O
in	O
the	O
included	O
data	O
.	O

We	O
generated	O
a	O
variable	O
designating	O
overall	O
tamoxifen	O
metabolic	O
activity	O
(	O
high	O
,	O
intermediate	O
or	O
low	O
)	O
by	O
combining	O
CYP2D6	B
phenotypes	O
and	O
CYP2C19	B
genotypes	O
according	O
to	O
Schroth	O
^	O
.	O

Final	O
Cox	O
proportional	O
hazards	O
models	O
included	O
age	O
at	O
diagnosis	O
of	O
primary	O
breast	O
cancer	O
(	O
as	O
a	O
continuous	O
variable	O
)	O
,	O
tumor	O
stage	O
,	O
and	O
ethnicity	O
(	O
Caucasian	O
or	O
Asian	O
,	O
for	O
CYP2C19	B
*	O
2	O
only	O
)	O
as	O
covariates	O
.	O

To	O
assess	O
the	O
potential	O
for	O
bias	O
due	O
to	O
the	O
use	O
of	O
complete	O
case	O
analyses	O
,	O
imputation	O
of	O
missing	O
values	O
for	O
CYP2C19	B
*	O
2	O
genotype	O
,	O
CYP2C19	B
*	O
17	O
genotype	O
,	O
ethnicity	O
,	O
age	O
at	O
breast	O
cancer	O
diagnosis	O
,	O
and	O
tumor	O
stage	O
was	O
done	O
in	O
a	O
supplemental	O
analysis	O
.	O

Data	O
on	O
CYP2C19	B
*	O
2	O
were	O
available	O
from	O
all	O
seven	O
study	O
sites	O
for	O
2	O
055	O
women	O
,	O
and	O
data	O
on	O
CYP2C19	B
*	O
17	O
were	O
reported	O
from	O
three	O
sites	O
for	O
1	O
253	O
women	O
.	O

Distributions	O
and	O
Hardy	O
-	O
Weinberg	O
chi	O
-	O
squared	O
statistics	O
within	O
each	O
study	O
site	O
for	O
the	O
CYP2C19	B
*	O
2	O
and	O
CYP2C19	B
*	O
17	O
genotypes	O
and	O
DNA	O
sources	O
are	O
provided	O
for	O
sample	O
and	O
source	O
populations	O
in	O
Supplementary	O
Tables	O
and	O
.	O

Both	O
variants	O
were	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
for	O
each	O
study	O
site	O
,	O
except	O
for	O
CYP2C19	B
*	O
17	O
at	O
site	O
8	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
and	O
CYP2D6	B
*	O
2	O
at	O
site	O
12	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
For	O
the	O
CYP2C19	B
*	O
2	O
allele	O
,	O
adjusted	O
hazard	O
ratios	O
for	O
associations	O
between	O
variant	O
heterozygotes	O
and	O
homozygotes	O
with	O
DFS	O
were	O
1	O
.	O
05	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
78	O
,	O
1	O
.	O
42	O
)	O
and	O
0	O
.	O
79	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
32	O
,	O
1	O
.	O
94	O
)	O
,	O
respectively	O
and	O
0	O
.	O
57	O
(	O
0	O
.	O
26	O
,	O
1	O
.	O
24	O
)	O
,	O
respectively	O
(	O
Table	O
.	O

Stratification	O
by	O
menopausal	O
status	O
and	O
CYP2D6	B
phenotype	O
did	O
not	O
yield	O
any	O
notable	O
associations	O
between	O
CYP2C19	B
genotype	O
and	O
DFS	O
(	O
Supplementary	O
Table	O
.	O

For	O
the	O
CYP2D6	B
phenotype	O
/	O
CYP2C19	B
*	O
2	O
genotype	O
combinations	O
,	O
multivariate	O
DFS	O
hazard	O
ratios	O
for	O
the	O
phenotypically	O
designated	O
high	O
and	O
intermediate	O
tamoxifen	O
metabolic	O
activity	O
groups	O
were	O
0	O
.	O
86	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
45	O
-	O
1	O
.	O
66	O
)	O
and	O
0	O
.	O
89	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
46	O
-	O
1	O
.	O
74	O
)	O
,	O
respectively	O
,	O
compared	O
with	O
the	O
low	O
metabolic	O
activity	O
group	O
.	O

The	O
corresponding	O
adjusted	O
DFS	O
hazard	O
ratios	O
for	O
the	O
CYP2D6	B
phenotype	O
/	O
CYP2C19	B
*	O
17	O
genotype	O
combinations	O
were	O
1	O
.	O
19	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
73	O
-	O
1	O
.	O
94	O
)	O
and	O
1	O
.	O
21	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
80	O
-	O
1	O
.	O
85	O
)	O
.	O

We	O
found	O
no	O
evidence	O
of	O
a	O
clinically	O
meaningful	O
association	O
between	O
CYP2C19	B
*	O
2	O
or	O
CYP2C19	B
*	O
17	O
genotypes	O
and	O
DFS	O
in	O
tamoxifen	O
-	O
treated	O
breast	O
cancer	O
patients	O
in	O
a	O
large	O
dataset	O
.	O

A	O
secondary	O
analysis	O
of	O
CYP2C19	B
genotype	O
accounting	O
for	O
CYP2D6	B
phenotypes	O
resulted	O
in	O
little	O
change	O
to	O
the	O
observation	O
.	O

This	O
study	O
has	O
the	O
largest	O
overall	O
sample	O
size	O
of	O
work	O
on	O
this	O
topic	O
to	O
date	O
and	O
includes	O
a	O
larger	O
number	O
of	O
CYP2C19	B
variants	O
compared	O
with	O
prior	O
studies	O
.	O

Only	O
two	O
other	O
studies	O
have	O
examined	O
the	O
association	O
between	O
CYP2C19	B
genotype	O
and	O
breast	O
cancer	O
recurrence	O
within	O
strata	O
of	O
menopausal	O
status	O
^	O
,	O
and	O
those	O
studies	O
included	O
a	O
combined	O
total	O
of	O
only	O
85	O
premenopausal	O
patients	O
.	O

Combining	O
CYP2D6	B
and	O
CYP2C19	B
*	O
2	O
or	O
CYP2C19	B
*	O
17	O
into	O
singular	O
phenotypes	O
(	O
as	O
suggested	O
by	O
Schroth	O
et	O
al	O
.	O
^	O
)	O
did	O
not	O
suggest	O
that	O
this	O
is	O
of	O
clinical	O
relevance	O
which	O
yielded	O
frequencies	O
of	O
18	O
and	O
35	O
%	O
for	O
*	O
2	O
heterozygosity	O
,	O
respectively	O
.	O

The	O
CYP2C19	B
*	O
17	O
was	O
only	O
assessed	O
at	O
three	O
sites	O
that	O
yielded	O
homogenous	O
and	O
comparable	O
allele	O
frequencies	O
with	O
one	O
gain	O
of	O
function	O
allele	O
frequencies	O
between	O
32	O
-	O
37	O
%	O
.	O

The	O
lack	O
of	O
data	O
on	O
CYP2C19	B
inhibitor	O
use	O
could	O
have	O
biased	O
our	O
estimates	O
towards	O
the	O
null	O
.	O

CYP2C19	B
genotyping	O
using	O
tumor	O
-	O
derived	O
DNA	O
(	O
at	O
three	O
sites	O
)	O
may	O
introduce	O
misclassification	O
due	O
to	O
potential	O
loss	O
-	O
of	O
-	O
heterozygosity	O
in	O
tumor	O
cells	O
^	O
,	O
.	O

Results	O
of	O
chi	O
-	O
squared	O
tests	O
for	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
indicate	O
that	O
loss	O
-	O
of	O
-	O
heterozygosity	O
had	O
a	O
minor	O
impact	O
on	O
observed	O
CYP2C19	B
genotypes	O
in	O
this	O
study	O
.	O

A	O
minor	O
violation	O
of	O
HWE	O
was	O
observed	O
at	O
study	O
site	O
8	O
,	O
which	O
accounted	O
for	O
the	O
majority	O
of	O
samples	O
assessed	O
for	O
CYP2C19	B
*	O
17	O
.	O

A	O
violation	O
of	O
HWE	O
for	O
CYP2C19	B
*	O
2	O
was	O
observed	O
at	O
study	O
site	O
12	O
,	O
but	O
the	O
sample	O
of	O
240	O
subjects	O
contributed	O
little	O
to	O
the	O
overall	O
analysis	O
.	O

While	O
previous	O
reports	O
have	O
found	O
the	O
presence	O
of	O
CYP2C19	B
*	O
2	O
to	O
be	O
associated	O
with	O
superior	O
efficacy	O
of	O
tamoxifen	O
treatment	O
^	O
-	O
,	O
our	O
results	O
support	O
other	O
studies	O
reporting	O
no	O
such	O
association	O
^	O
,	O
-	O
-	O
.	O

The	O
hazard	O
ratio	O
for	O
the	O
association	O
of	O
CYP2C19	B
*	O
17	O
homozygotes	O
with	O
a	O
favorable	O
DFS	O
(	O
HR	O
=	O
0	O
.	O
57	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
26	O
,	O
1	O
.	O
24	O
)	O
is	O
similar	O
to	O
the	O
ratio	O
found	O
previously	O
for	O
the	O
association	O
of	O
carrying	O
CYP2C19	B
*	O
17	O
with	O
relapse	O
-	O
free	O
time	O
(	O
HR	O
=	O
0	O
.	O
45	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
21	O
,	O
0	O
.	O
92	O
)	O
(	O
31	O
)	O
.	O

Despite	O
the	O
biologic	O
plausibility	O
of	O
CYP2C19	B
playing	O
an	O
important	O
role	O
in	O
patients	O
with	O
reduced	O
CYP2D6	B
function	O
,	O
our	O
stratified	O
analyses	O
do	O
not	O
support	O
this	O
hypothesis	O
.	O

This	O
would	O
mitigate	O
the	O
net	O
overall	O
clinical	O
consequence	O
of	O
genomic	O
CYP2C19	B
variants	O
and	O
result	O
in	O
a	O
statistical	O
inference	O
toward	O
the	O
null	O
.	O

Several	O
studies	O
indicate	O
that	O
CYP2C19	B
variants	O
are	O
associated	O
with	O
differences	O
in	O
baseline	O
breast	O
cancer	O
risk	O
,	O
likely	O
due	O
to	O
the	O
inherent	O
role	O
of	O
CYP2C19	B
in	O
the	O
metabolism	O
of	O
estrogen	O
.	O

However	O
,	O
this	O
association	O
has	O
not	O
been	O
consistently	O
observed	O
,	O
and	O
the	O
fact	O
that	O
the	O
minor	O
allele	O
frequencies	O
observed	O
here	O
match	O
population	O
-	O
wide	O
benchmarks	O
argues	O
against	O
CYP2C19	B
genotype	O
as	O
a	O
selection	O
force	O
.	O

In	O
conclusion	O
,	O
we	O
found	O
no	O
evidence	O
to	O
support	O
a	O
clinically	O
meaningful	O
role	O
of	O
CYP2C19	B
polymorphisms	O
and	O
response	O
to	O
tamoxifen	O
in	O
breast	O
cancer	O
patients	O
.	O

In	O
the	O
case	O
of	O
hERG	O
,	O
CYP2D6	B
,	O
CYP2A9	O
,	O
CYP2C19	B
,	O
and	O
mitochondrial	O
toxicity	O
,	O
there	O
is	O
a	O
selectivity	O
index	O
of	O
around	O
3	O
-	O
4	O
fold	O
,	O
thus	O
showing	O
an	O
acceptable	O
profile	O
.	O

Another	O
genomic	O
position	O
(	O
CYP2C19	B
*	O
9	O
,	O
rs17884712	O
)	O
with	O
low	O
-	O
quality	O
calling	O
was	O
observed	O
in	O
a	O
portion	O
of	O
the	O
study	O
samples	O
(	O
17	O
/	O
98	O
)	O
.	O

The	O
potency	O
of	O
inhibitory	O
effects	O
on	O
CYP3A4	B
,	O
CYP2D6	B
,	O
and	O
CYP2C19	B
was	O
low	O
(	O
mean	O
IC_50	O
313	O
.	O
51	O
,	O
54	O
.	O
36	O
,	O
and	O
16	O
.	O
48	O
g	O
/	O
ml	O
,	O
respecies	O
.	O
)	O
.	O

Surface	O
Plasmon	O
Resonance	O
experiments	O
with	O
five	O
control	O
cytochromes	O
P450	O
(	O
CYP2C19	B
,	O
CYP11A1	B
,	O
CYP11B1	B
,	O
CYP3A4	B
,	O
CYP3A5	B
)	O
were	O
negative	O
,	O
indicating	O
the	O
high	O
specificity	O
of	O
the	O
detected	O
PPIs	O
.	O

Sort	O
=	O
Bait	O
,	O
cytochromes	O
P450	O
(	O
limonene	O
6	O
-	O
monooxygenase	O
(	O
CYP2C19	B
)	O
,	O
steroid	O
-	O
20	O
,	O
22	O
-	O
lyase	O
(	O
CYP11A1	B
)	O
,	O
steroid	O
-	O
11BETA	O
-	O
hydroxylase	O
(	O
CYP11V1	O
)	O
,	O
aldosterone	O
synthase	O
(	O
CYP11B2	B
)	O
,	O
taurochenodeoxycholate	O
-	O
6ALPHA	O
-	O
monooxygenase	O
(	O
CYP3A4	B
)	O
,	O
cyclic	O
hydrocarbon	O
hydroxylase	O
(	O
CYP3A5	B
)	O
,	O
4	O
-	O
nitrophenol	O
-	O
2	O
-	O
hydroxylase	O
(	O
CYP2E1	B
)	O
,	O
microsomal	O
cytochrome	O
b5	O
(	O
CYB5A	O
)	O
,	O
NADPH	O
-	O
cytochrome	O
-	O
P450	O
-	O
reductase	O
,	O
NADPH	O
-	O
adrenodoxin	O
reductase	O
,	O
adrenodoxin	O
,	O
and	O
ferrochelatase	O
,	O
SMAD4	O
,	O
RAB27B	O
)	O
were	O
prepared	O
at	O
the	O
Institute	O
of	O
Bioorganic	O
Chemistry	O
(	O
Republic	O
of	O
Belarus	O
)	O
by	O
molecular	O
cloning	O
and	O
heterologous	O
expression	O
in	O
a	O
bacterial	O
system	O
(	O
E	O
.	O
coli	O
)	O
,	O
followed	O
by	O
purification	O
using	O
metal	O
-	O
affinity	O
and	O
ion	O
exchange	O
chromatography	O
[	O
,	O
.	O

Sort	O
=	O
Bait	O
and	O
CYP2E1	B
interaction	O
was	O
tested	O
by	O
running	O
control	O
Surface	O
Plasmon	O
Resonance	O
experiments	O
using	O
both	O
microsomal	O
(	O
CYP2C19	B
,	O
CYP3A4	B
,	O
CYP3A5	B
)	O
and	O
mitochondrial	O
(	O
CYP11A1	B
,	O
CYP11B1	B
,	O
CYP11B2	B
)	O
cytochromes	O
P450	O
as	O
analytes	O
.	O

It	O
is	O
known	O
that	O
indole	O
is	O
oxidized	O
to	O
isatin	O
by	O
some	O
cytochromes	O
P450	O
(	O
CYP2A6	O
,	O
CYP2C19	B
,	O
and	O
CYP2E1	B
)	O
which	O
are	O
responsible	O
for	O
the	O
metabolism	O
of	O
various	O
xenobiotics	O
.	O

The	O
CYP2C19	B
enzyme	O
plays	O
an	O
important	O
role	O
in	O
the	O
metabolism	O
of	O
antiplatelet	O
agents	O
(	O
eg	O
,	O
clopidogrel	O
)	O
,	O
proton	O
pump	O
inhibitors	O
(	O
eg	O
,	O
omeprazole	O
)	O
,	O
tricyclic	O
antidepressants	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
and	O
benzodiazepines	O
.	O

CYP2C19	B
*	O
2	O
and	O
*	O
3	O
alleles	O
define	O
the	O
current	O
PM	O
phenotype	O
status	O
,	O
with	O
markedly	O
different	O
allele	O
frequencies	O
across	O
different	O
ethnic	O
populations	O
.	O

The	O
CYP2C19	B
*	O
17	O
variant	O
is	O
a	O
gain	O
-	O
of	O
-	O
function	O
allele	O
,	O
resulting	O
in	O
higher	O
enzyme	O
activity	O
.	O

CYP2C19	B
catalyzes	O
the	O
4	O
-	O
hydroxylation	O
of	O
(	O
S	O
)	O
-	O
mephenytoin	O
,	O
a	O
probe	O
substrate	O
for	O
CYP2C19	B
.	O

The	O
CYP2C19	B
PM	O
phenotype	O
is	O
associated	O
with	O
a	O
reduced	O
ability	O
to	O
metabolize	O
(	O
S	O
)	O
-	O
mephenytoin	O
.	O

Thus	O
,	O
PMs	O
eliminate	O
racemic	O
mephenytoin	O
more	O
slowly	O
than	O
EMs	O
and	O
urinary	O
4	O
-	O
hydroxymephenytoin	O
and	O
S	O
/	O
R	O
mephenytoin	O
enantiomeric	O
ratio	O
was	O
used	O
in	O
the	O
past	O
to	O
distinguish	O
between	O
CYP2C19	B
EMs	O
and	O
PMs	O
.	O

reported	O
that	O
in	O
FNs	O
,	O
the	O
CYP2C19	B
*	O
2	O
allelic	O
variant	O
was	O
found	O
at	O
19	O
.	O
1	O
%	O
,	O
while	O
CYP2C19	B
*	O
3	O
was	O
not	O
detected	O
.	O

conducted	O
CYP2C19	B
genotyping	O
and	O
phenotyping	O
,	O
based	O
on	O
the	O
mephenytoin	O
S	O
/	O
R	O
enantiomeric	O
ratio	O
,	O
in	O
Inuit	O
peoples	O
in	O
Canada	O
.	O

The	O
CYP2C19	B
*	O
2	O
allele	O
frequency	O
was	O
12	O
%	O
,	O
while	O
CYP2C19	B
*	O
3	O
was	O
not	O
detected	O
in	O
this	O
Inuit	O
population	O
.	O

Clopidogrel	O
is	O
a	O
prodrug	O
that	O
is	O
bioactivated	O
by	O
multiple	O
P450s	O
enzymes	O
(	O
including	O
CYP2C19	B
)	O
to	O
its	O
active	O
metabolite	O
,	O
which	O
acts	O
as	O
an	O
antiplatelet	O
agent	O
by	O
irreversibly	O
inhibiting	O
the	O
P2Y12	O
adenosine	O
diphosphate	O
receptor	O
on	O
platelets	O
.	O

CYP2C19	B
genetic	O
variation	O
has	O
been	O
associated	O
with	O
the	O
fraction	O
metabolized	O
and	O
clinical	O
response	O
to	O
clopidogrel	O
.	O

In	O
the	O
Oglala	O
Sioux	O
Tribe	O
of	O
South	O
Dakota	O
,	O
the	O
MAFs	O
for	O
CYP2C19	B
*	O
2	O
,	O
*	O
3	O
and	O
*	O
17	O
were	O
11	O
.	O
2	O
%	O
,	O
0	O
.	O
0	O
%	O
and	O
8	O
.	O
7	O
%	O
,	O
respectively	O
.	O

In	O
a	O
study	O
examining	O
CYP2C19	B
variant	O
alleles	O
in	O
AI	O
children	O
,	O
the	O
frequencies	O
of	O
CYP2C19	B
*	O
2	O
,	O
*	O
4	O
and	O
*	O
17	O
were	O
11	O
.	O
5	O
%	O
,	O
1	O
.	O
3	O
%	O
and	O
11	O
.	O
1	O
%	O
,	O
respectively	O
.	O

CYP2C19	B
*	O
8	O
and	O
CYP2C19	B
*	O
14	O
were	O
not	O
present	O
in	O
the	O
AI	O
population	O
studied	O
and	O
CYP2C19	B
*	O
3	O
was	O
not	O
tested	O
.	O

With	O
regards	O
to	O
CYP2C19	B
variation	O
in	O
Amerindians	O
of	O
Mexico	O
,	O
Salazar	O
-	O
Flores	O
et	O
al	O
.	O

The	O
CYP2C19	B
*	O
2	O
MAF	O
was	O
reported	O
as	O
31	O
%	O
,	O
5	O
.	O
4	O
%	O
,	O
3	O
.	O
6	O
%	O
,	O
5	O
.	O
6	O
%	O
and	O
0	O
.	O
0	O
%	O
in	O
Tarahumaras	O
,	O
Purepechas	O
,	O
Tojolabales	O
,	O
Tzotziles	O
and	O
Tzeltales	O
,	O
respectively	O
.	O

The	O
high	O
allele	O
frequency	O
in	O
the	O
Tarahumara	O
population	O
is	O
of	O
particular	O
interest	O
clinically	O
,	O
as	O
this	O
predicts	O
that	O
a	O
substantial	O
portion	O
of	O
the	O
population	O
would	O
be	O
CYP2C19	B
PMs	O
.	O

CYP2C19	B
*	O
3	O
,	O
*	O
4	O
and	O
*	O
5	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
Amerindian	O
populations	O
studied	O
.	O

reported	O
the	O
MAFs	O
of	O
CYP2C19	B
*	O
2	O
,	O
*	O
3	O
and	O
*	O
17	O
as	O
12	O
.	O
0	O
%	O
,	O
0	O
.	O
2	O
%	O
and	O
2	O
.	O
2	O
%	O
,	O
respectively	O
.	O

CYP2C19	B
*	O
4	O
and	O
*	O
5	O
were	O
not	O
detected	O
in	O
the	O
population	O
studied	O
.	O

CYP2C19	B
phenotype	O
was	O
determined	O
using	O
omeprazole	O
as	O
a	O
probe	O
substrate	O
as	O
part	O
of	O
a	O
drug	O
cocktail	O
.	O

The	O
ratio	O
of	O
omeprazole	O
to	O
5	O
-	O
hydroxyomeprazole	O
was	O
significantly	O
greater	O
in	O
individuals	O
with	O
the	O
PM	O
conferring	O
variants	O
,	O
CYP2C19	B
*	O
2	O
or	O
*	O
3	O
,	O
compared	O
to	O
those	O
with	O
the	O
reference	O
genotype	O
.	O

In	O
contrast	O
,	O
CYP2C19	B
*	O
2	O
was	O
found	O
at	O
a	O
high	O
MAF	O
in	O
Tarahumaras	O
,	O
compared	O
to	O
other	O
Indigenous	O
peoples	O
of	O
Mexico	O
.	O

In	O
the	O
same	O
way	O
,	O
3	O
and	O
4	O
show	O
inhibitory	O
effects	O
on	O
CYP2C19	B
.	O

456222	O
)	O
,	O
CYP2C19	B
(	O
Lot	O
No	O
.	O

Moreover	O
,	O
only	O
compound	O
F13	O
was	O
found	O
to	O
be	O
the	O
substrate	O
of	O
CYP2C19	B
and	O
compound	O
F25	O
was	O
found	O
to	O
be	O
the	O
substrate	O
of	O
CYP3A4	O
.	O

Additionally	O
,	O
that	O
for	O
predicting	O
the	O
site	O
of	O
enzyme	O
CYP2C19	B
,	O
the	O
K_m	O
value	O
was	O
61	O
.	O
866	O
M	O
,	O
whereas	O
the	O
V_max	O
constant	O
was	O
2	O
.	O
35	O
nM	O
/	O
min	O
/	O
nM	O
and	O
the	O
C_Lint	O
was	O
0	O
.	O
53	O
L	O
/	O
min	O
/	O
mg	O
for	O
compound	O
F13	O
.	O

Whereas	O
no	O
compounds	O
were	O
found	O
to	O
inhibit	O
the	O
CYP2C19	B
.	O

Seven	O
variants	O
of	O
CYP2C19	B
have	O
also	O
been	O
associated	O
with	O
slow	O
metabolism	O
of	O
several	O
antidepressants	O
.	O

Slow	O
recovery	O
after	O
overdoses	O
is	O
anticipated	O
in	O
patients	O
with	O
low	O
-	O
activity	O
CYP2C19	B
.	O

Slow	O
recovery	O
is	O
also	O
anticipated	O
in	O
patients	O
receiving	O
proton	O
-	O
pump	O
inhibitors	O
,	O
particularly	O
omeprazole	O
and	O
esomeprazole	O
,	O
as	O
these	O
are	O
potent	O
inhibitors	O
of	O
CYP2C19	B
.	O

^	O
On	O
the	O
other	O
hand	O
,	O
some	O
patients	O
are	O
ultrafast	O
CYP2C19	B
metabolizers	O
.	O

^	O
,	O
Important	O
pharmacokinetic	O
and	O
pharmacodynamic	O
interactions	O
in	O
the	O
use	O
of	O
MAOIs	O
include	O
inhibitory	O
effects	O
on	O
hepatic	O
CYP	O
enzymes	O
,	O
in	O
particular	O
,	O
CYP2C19	B
and	O
2D6	O
,	O
and	O
a	O
tyramine	O
-	O
induced	O
sympathomimetic	O
response	O
.	O

Genetic	O
polymorphisms	O
of	O
the	O
CYPs	O
contribute	O
to	O
drug	O
clearance	O
,	O
particularly	O
for	O
CYP2D6	B
and	O
CYP2C19	B
.	O

A	O
recent	O
study	O
in	O
which	O
clinicians	O
were	O
provided	O
pharmacogenetic	O
information	O
based	O
on	O
CYP2D6	B
and	O
CYP2C19	B
variants	O
to	O
adjust	O
antipsychotic	O
and	O
antidepressant	O
treatments	O
in	O
80	O
psychiatric	O
patients	O
suggested	O
a	O
favourable	O
opinion	O
on	O
the	O
outcome	O
of	O
the	O
intervention	O
,	O
although	O
no	O
control	O
group	O
was	O
considered	O
in	O
the	O
study	O
^	O
.	O

showed	O
in	O
a	O
previous	O
study	O
that	O
the	O
adjustment	O
of	O
clinical	O
doses	O
according	O
to	O
CYP2D6	B
and	O
CYP2C19	B
polymorphisms	O
resulted	O
in	O
a	O
reduction	O
of	O
treatment	O
costs	O
in	O
schizophrenia	O
patients	O
showing	O
poor	O
or	O
ultra	O
-	O
rapid	O
metabolism	O
^	O
.	O

Carriers	O
of	O
CYP2C19	B
*	O
2	O
(	O
rs4244285	O
;	O
Pro227Pro	O
)	O
or	O
CYP2D6	O
*	O
10	O
(	O
rs1065852	O
,	O
Pro34Ser	O
)	O
had	O
sorafenib	O
plasma	O
levels	O
and	O
associated	O
liver	O
/	O
renal	O
toxicity	O
that	O
were	O
intermediate	O
between	O
those	O
of	O
rats	O
carrying	O
CYP3A5	O
*	O
3	O
or	O
CYP3A4	O
*	O
1	O
genetic	O
variants	O
.	O

In	O
term	O
of	O
pharmacokinetics	O
,	O
tivantinib	O
is	O
metabolized	O
by	O
CYP2C19	B
,	O
CYP3A4	O
/	O
5	O
,	O
Udp	O
Glucuronosyltransferase	O
1a9	O
,	O
and	O
alcohol	O
dehydrogenase	O
isoform	O
4	O
.	O

CYP2C19	B
shows	O
catalytic	O
activity	O
for	O
the	O
formation	O
of	O
the	O
hydroxylated	O
metabolite	O
(	O
M5	O
)	O
,	O
whereas	O
CYP3A4	O
/	O
5	O
catalyzes	O
formation	O
of	O
M5	O
and	O
its	O
stereoisomer	O
(	O
M4	O
)	O
.	O

Between	O
2010	O
and	O
2014	O
,	O
two	O
phase	O
I	O
trials	O
(	O
NCT01069757	O
,	O
NCT01656265	O
)	O
in	O
Japanese	O
patients	O
with	O
advanced	O
solid	O
tumors	O
examined	O
the	O
safety	O
,	O
pharmacokinetics	O
,	O
and	O
preliminary	O
efficacy	O
of	O
tivantinib	O
as	O
a	O
single	O
agent	O
to	O
determine	O
recommended	O
phase	O
II	O
dose	O
according	O
to	O
CYP2C19	B
polymorphisms	O
.	O

In	O
fact	O
,	O
CYP2C19	B
and	O
CYP3A4	O
can	O
21	O
-	O
hydroxylate	O
progesterone	O
and	O
pregnenolone	O
,	O
possibly	O
partially	O
compensating	O
mineralocorticoid	O
deficiency	O
in	O
CAH	O
due	O
to	O
21	O
-	O
hydroxylase	O
deficiency	O
;	O
however	O
,	O
the	O
two	O
enzymes	O
are	O
not	O
capable	O
of	O
catalyzing	O
the	O
21	O
-	O
hydroxylation	O
of	O
17OHP	O
to	O
11	O
-	O
deoxycortisol	O
.	O

The	O
highly	O
polymorphic	O
CYP2C19	B
isozymes	O
are	O
responsible	O
for	O
metabolizing	O
a	O
large	O
portion	O
of	O
routinely	O
prescribed	O
drugs	O
and	O
variants	O
contribute	O
significantly	O
to	O
adverse	O
drug	O
reactions	O
and	O
therapeutic	O
failures	O
.	O

A	O
limited	O
number	O
of	O
CYP2C19	B
single	O
nucleotide	O
polymorphisms	O
are	O
involved	O
in	O
drug	O
metabolism	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
better	O
understand	O
and	O
provide	O
further	O
knowledge	O
about	O
the	O
metabolism	O
and	O
interactions	O
between	O
phenobarbital	O
and	O
CYP2C19	B
polymorphisms	O
in	O
children	O
with	O
epilepsy	O
,	O
interplay	O
between	O
sleep	O
,	O
and	O
Eversus	O
Understanding	O
this	O
interplay	O
between	O
epilepsy	O
and	O
sleep	O
is	O
helpful	O
in	O
the	O
optimal	O
treatment	O
of	O
all	O
patients	O
with	O
epileptic	O
seizures	O
.	O

In	O
the	O
report	O
we	O
will	O
only	O
discuss	O
the	O
CYP2C19	B
gene	O
as	O
outlined	O
in	O
.	O

The	O
Cytochrome	O
P450	O
,	O
family	O
2	O
,	O
subfamily	O
C	O
,	O
polypeptide	O
19	O
(	O
CYP2C19	B
gene	O
)	O
is	O
located	O
within	O
a	O
cluster	O
of	O
Cytochrome	O
P450	O
genes	O
(	O
CYP2C19	B
)	O
on	O
chromosome	O
10q23	O
.	O
33	O
with	O
reference	O
sequence	O
number	O
(	O
NM_000769	O
)	O
and	O
ensemble	O
accession	O
number	O
ENST00000371321	O
.	O
8	O
.	O

CYP2C19	B
is	O
expressed	O
in	O
the	O
liver	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
small	O
intestine	O
,	O
contributing	O
to	O
the	O
metabolism	O
of	O
a	O
large	O
number	O
of	O
clinically	O
relevant	O
drugs	O
and	O
drug	O
classes	O
including	O
phenytoin	O
and	O
phenobarbital	O
.	O

The	O
CYP2C19	B
gene	O
is	O
part	O
of	O
the	O
CYP2C	O
cluster	O
comprising	O
four	O
genes	O
(	O
CYP2C8	O
,	O
CYP2C9	O
,	O
CYP2C18	O
and	O
CYP2C19	B
)	O
.	O

This	O
CYP2C19	B
gene	O
encompasses	O
90	O
,	O
637	O
bases	O
and	O
is	O
composed	O
of	O
nine	O
exons	O
encoding	O
490	O
amino	O
acids	O
.	O

We	O
checked	O
nucleotide	O
human	O
sequence	O
homology	O
of	O
CYP2C19	B
(	O
NP_000760	O
.	O
1	O
)	O
with	O
National	O
Institute	O
of	O
Health	O
databases	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
)	O
,	O
and	O
we	O
found	O
that	O
84	O
%	O
of	O
CYPC29	O
(	O
NP_000760	O
.	O
1	O
)	O
,	O
81	O
%	O
of	O
CYP2C18	O
isoform	O
2	O
precursor	O
(	O
NP_000762	O
.	O
2	O
)	O
,	O
81	O
%	O
of	O
Cytochrome	O
P450	O
2C8	O
isoform	O
c	O
(	O
NP_000763	O
.	O
1	O
)	O
,	O
79	O
%	O
of	O
Cytochrome	O
P450	O
2C8	O
isoform	O
b	O
(	O
NP_001185783	O
.	O
1	O
)	O
,	O
78	O
%	O
Cytochrome	O
P450	O
2C8	O
isoform	O
a	O
precursor	O
(	O
NP_000761	O
.	O
3	O
)	O
,	O
58	O
%	O
Cytochrome	O
P450	O
2E1	O
precursor	O
(	O
NP_000764	O
.	O
1	O
)	O
,	O
56	O
%	O
Cytochrome	O
P450	O
2F1	O
isoform	O
X7	O
(	O
XP_016881875	O
.	O
1	O
)	O
,	O
and	O
48	O
%	O
CYPP450	O
2F1	O
isoform	O
X4	O
(	O
XP_011524855	O
.	O
1	O
)	O
.	O

Understanding	O
the	O
biological	O
function	O
of	O
CYP2C19	B
gene	O
can	O
provide	O
a	O
good	O
foundation	O
for	O
subsequently	O
interpreting	O
the	O
potential	O
influence	O
of	O
genetic	O
associations	O
on	O
a	O
disease	O
phenotype	O
and	O
so	O
can	O
greatly	O
support	O
any	O
identified	O
genetic	O
association	O
.	O

Potential	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
such	O
as	O
GATA	O
proteins	O
,	O
progesterone	O
receptor	O
,	O
TATA	O
box	O
elements	O
and	O
nuclear	O
factors	O
in	O
CYP2C19	B
promoter	O
region	O
has	O
been	O
described	O
.	O

This	O
CYP2C19	B
gene	O
(	O
RefSeq	O
accession	O
number	O
NM_000769	O
.	O
4	O
)	O
has	O
three	O
promoter	O
regions	O
.	O

As	O
shown	O
in	O
,	O
CYP2C19	B
-	O
201	O
has	O
nine	O
exons	O
and	O
eight	O
introns	O
and	O
consists	O
of	O
490	O
amino	O
acids	O
,	O
while	O
CYP2C10	O
-	O
202	O
has	O
162	O
amino	O
acids	O
,	O
however	O
,	O
CYP2C19	B
-	O
203	O
does	O
not	O
produce	O
protein	O
products	O
.	O

For	O
the	O
cellular	O
component	O
,	O
the	O
CYP2C19	B
gene	O
is	O
found	O
in	O
different	O
part	O
of	O
the	O
cells	O
:	O
cytoplasm	O
(	O
GO	O
:	O
0005737	O
)	O
,	O
endoplasmic	O
reticulum	O
(	O
GO	O
:	O
0005783	O
)	O
,	O
endoplasmic	O
reticulum	O
membrane	O
(	O
GO	O
:	O
0005789	O
)	O
,	O
membrane	O
(	O
GO	O
:	O
0016020	O
)	O
,	O
and	O
organelle	O
membrane	O
(	O
GO	O
:	O
0031090	O
)	O
.	O

Next	O
,	O
we	O
used	O
STRING	O
software	O
to	O
build	O
a	O
gene	O
network	O
of	O
the	O
CYP2C19	B
gene	O
and	O
other	O
neighbor	O
genes	O
using	O
https	O
:	O
/	O
/	O
string	O
-	O
db	O
.	O
org	O
/	O
as	O
shown	O
in	O
.	O

This	O
network	O
shows	O
high	O
interaction	O
between	O
CYP2C19	B
and	O
other	O
genes	O
such	O
as	O
glutathione	O
S	O
-	O
transferase	O
mu	O
1	O
,	O
glutathione	O
S	O
-	O
transferase	O
mu	O
2	O
(	O
muscle	O
)	O
,	O
glutathione	O
S	O
-	O
transferase	O
mu	O
3	O
(	O
brain	O
)	O
,	O
glutathione	O
S	O
-	O
transferase	O
theta	O
1	O
.	O

Next	O
,	O
we	O
used	O
genome	O
at	O
USSC	O
to	O
find	O
out	O
the	O
CYP2C19	B
tagged	O
Single	O
Nucleotide	O
Polymorphisms	O
(	O
https	O
:	O
/	O
/	O
genome	O
.	O
ucsc	O
.	O
edu	O
/	O
cgi	O
-	O
bin	O
/	O
hgGateway	O
)	O
.	O

The	O
tagged	O
Single	O
Nucleotide	O
Polymorphisms	O
associated	O
with	O
the	O
CYP2C19	B
gene	O
are	O
shown	O
in	O
.	O

In	O
this	O
report	O
,	O
we	O
will	O
focus	O
only	O
on	O
CYP2C19	B
Single	O
Nucleotide	O
Polymorphisms	O
that	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
drug	O
metabolism	O
as	O
shown	O
in	O
.	O

We	O
identified	O
the	O
position	O
of	O
each	O
amino	O
acid	O
for	O
each	O
Single	O
Nucleotide	O
Polymorphisms	O
and	O
the	O
upstream	O
Single	O
Nucleotide	O
Polymorphisms	O
and	O
downstream	O
Single	O
Nucleotide	O
Polymorphisms	O
including	O
Single	O
Nucleotide	O
Polymorphisms	O
(	O
rs28399504	O
(	O
CYP2C19	B
*	O
4	O
)	O
located	O
on	O
amino	O
acid	O
number	O
1	O
(	O
valine	O
)	O
,	O
rs17878459	O
(	O
CYP2C19	B
*	O
17	O
)	O
,	O
located	O
on	O
amino	O
acid	O
92	O
,	O
(	O
aspartic	O
,	O
D	O
)	O
,	O
rs4986893	O
CYP2C19	B
*	O
3	O
located	O
on	O
amino	O
acid	O
number	O
212	O
(	O
NA	O
)	O
,	O
rs4244285	O
(	O
CYP2C19	B
*	O
2	O
)	O
located	O
on	O
amino	O
acid	O
227	O
(	O
proline	O
)	O
,	O
and	O
rs56337013	O
(	O
CYP2C19	B
*	O
5	O
)	O
located	O
on	O
amino	O
acid	O
number	O
433	O
(	O
tryptophan	O
,	O
W	O
)	O
.	O

CYP2D6	B
*	O
5	O
(	O
gene	O
deletion	O
)	O
and	O
CYP2D6	B
duplication	O
were	O
analyzed	O
by	O
TaqMan	O
Copy	O
Number	O
Assay	O
(	O
ThermoFisher	O
Scientific	O
,	O
Waltham	O
,	O
MA	O
)	O
.	O

Furthermore	O
,	O
no	O
significant	O
association	O
was	O
found	O
between	O
the	O
normalized	O
clozapine	O
concentrations	O
and	O
the	O
patients	O
CYP2D6	B
genotypes	O
(	O
P	O
=	O
.	O
8881	O
)	O
.	O

Haloperidol	O
,	O
risperidone	O
,	O
and	O
propranolol	O
are	O
potent	O
CYP2D6	B
inhibitors	O
that	O
may	O
influence	O
the	O
minor	O
contribution	O
of	O
CYP2D6	B
to	O
clozapine	O
clearance	O
;	O
however	O
,	O
most	O
of	O
the	O
patients	O
who	O
were	O
co	O
-	O
treated	O
with	O
these	O
drugs	O
carried	O
the	O
CYP2D6	B
loss	O
-	O
of	O
-	O
function	O
allele	O
.	O

Genetic	O
factors	O
and	O
/	O
or	O
co	O
-	O
medication	O
therefore	O
could	O
result	O
in	O
CYP2D6	B
poor	O
metabolism	O
.	O

According	O
to	O
the	O
guidance	O
of	O
the	O
Pharmacogenetic	O
Working	O
Group	O
of	O
the	O
Royal	O
Dutch	O
Pharmacists	O
Association	O
,	O
no	O
clozapine	O
dose	O
adjustment	O
is	O
needed	O
for	O
patients	O
with	O
CYP2D6	B
poor	O
metabolism	O
.	O

Accounting	O
for	O
CYP2D6	B
genotype	O
status	O
did	O
not	O
change	O
these	O
estimates	O
.	O

CYP2D6	B
is	O
the	O
principal	O
enzyme	O
catalyzing	O
the	O
conversion	O
of	O
tamoxifen	O
to	O
endoxifen	O
,	O
and	O
the	O
association	O
of	O
genomic	O
variants	O
in	O
the	O
CYP2D6	B
gene	O
to	O
outcome	O
of	O
tamoxifen	O
treatment	O
has	O
been	O
extensively	O
studied	O
^	O
,	O
.	O

Two	O
of	O
the	O
largest	O
datasets	O
reported	O
a	O
null	O
-	O
association	O
,	O
but	O
contradictory	O
findings	O
have	O
led	O
to	O
ongoing	O
controversy	O
over	O
the	O
value	O
of	O
using	O
CYP2D6	B
genotyping	O
to	O
guide	O
the	O
prescription	O
of	O
tamoxifen	O
^	O
-	O
.	O

Potential	O
covariates	O
of	O
interest	O
were	O
:	O
age	O
,	O
ethnicity	O
,	O
menopausal	O
status	O
,	O
tumor	O
grade	O
and	O
stage	O
,	O
progesterone	O
receptor	O
(	O
PR	O
)	O
status	O
,	O
use	O
of	O
other	O
adjuvant	O
therapies	O
(	O
radiation	O
and	O
chemotherapy	O
)	O
,	O
and	O
CYP2D6	B
metabolizer	O
phenotype	O
.	O

A	O
variable	O
encoding	O
individuals	O
CYP2D6	B
metabolizer	O
phenotype	O
(	O
ultra	O
-	O
UM	O
,	O
extensive	O
-	O
EM	O
,	O
intermediate	O
-	O
IM	O
,	O
or	O
poor	O
-	O
PM	O
)	O
was	O
available	O
in	O
the	O
ITPC	O
data	O
,	O
and	O
accounted	O
for	O
both	O
genetic	O
factors	O
and	O
the	O
use	O
of	O
CYP2D6	B
-	O
inhibiting	O
drugs	O
.	O

Supplemental	O
analyses	O
stratified	O
by	O
CYP2D6	B
phenotype	O
and	O
menopausal	O
status	O
were	O
also	O
performed	O
.	O

Our	O
findings	O
for	O
the	O
*	O
17	O
allele	O
are	O
consistent	O
with	O
results	O
from	O
a	O
smaller	O
,	O
similar	O
study	O
,	O
which	O
reported	O
a	O
hazard	O
ratio	O
of	O
0	O
.	O
93	O
(	O
95	O
%	O
CI	O
=	O
0	O
.	O
64	O
,	O
1	O
.	O
37	O
)	O
and	O
found	O
a	O
near	O
-	O
null	O
association	O
among	O
those	O
with	O
impaired	O
CYP2D6	B
^	O
.	O

analyzed	O
the	O
ITPC	O
dataset	O
and	O
reported	O
poorer	O
disease	O
-	O
free	O
survival	O
among	O
CYP2D6	B
poor	O
metabolizers	O
and	O
a	O
weak	O
association	O
between	O
poor	O
metabolizer	O
status	O
and	O
a	O
shorter	O
breast	O
cancer	O
-	O
free	O
interval	O
^	O
.	O

Some	O
compounds	O
in	O
series	O
4	O
showed	O
a	O
liability	O
risk	O
for	O
their	O
effects	O
on	O
hERG	O
,	O
CYP2D6	B
,	O
and	O
WI	O
-	O
38	O
cells	O
,	O
which	O
appears	O
to	O
be	O
due	O
to	O
the	O
introduction	O
of	O
the	O
second	O
nitrogen	O
atom	O
that	O
can	O
induce	O
a	O
toxic	O
effect	O
on	O
the	O
thiadiazole	O
core	O
.	O

Similarly	O
,	O
the	O
HS4	O
-	O
CAG	O
-	O
CYP2D6	B
plasmid	O
was	O
digested	O
with	O
NheI	O
/	O
AscI	O
and	O
ligated	O
with	O
the	O
HS4	O
-	O
CAG	O
-	O
CYP3A4	B
,	O
which	O
was	O
digested	O
with	O
AscI	O
/	O
AvrII	O
,	O
for	O
the	O
construction	O
of	O
HS4	O
-	O
CAG	O
-	O
CYP3A4	B
-	O
HS4	O
-	O
CAG	O
-	O
CYP2D6	B
plasmid	O
.	O

We	O
used	O
targeted	O
genotyping	O
data	O
as	O
a	O
benchmark	O
to	O
assess	O
accuracy	O
of	O
variant	O
calling	O
,	O
and	O
to	O
identify	O
copy	O
number	O
variations	O
of	O
the	O
CYP2D6	B
gene	O
.	O

Concordance	O
of	O
CYP2D6	B
predicted	O
phenotype	O
between	O
estimates	O
of	O
whole	O
-	O
genome	O
sequencing	O
and	O
targeted	O
genotyping	O
panel	O
were	O
90	O
%	O
;	O
a	O
result	O
from	O
a	O
lower	O
coverage	O
depth	O
or	O
variant	O
calling	O
difficulties	O
in	O
our	O
whole	O
-	O
genome	O
sequencing	O
data	O
when	O
copy	O
number	O
variation	O
and	O
/	O
or	O
the	O
CYP2D6	B
*	O
4	O
haplotype	O
were	O
present	O
.	O

We	O
also	O
compared	O
estimates	O
of	O
CYP2D6	B
gene	O
copy	O
number	O
between	O
WGS	O
and	O
targeted	O
genotyping	O
.	O

We	O
used	O
the	O
targeted	O
genotyping	O
data	O
as	O
a	O
benchmark	O
to	O
assess	O
variant	O
calling	O
and	O
to	O
predict	O
copy	O
number	O
status	O
of	O
the	O
CYP2D6	B
gene	O
.	O

We	O
genotyped	O
98	O
subjects	O
with	O
the	O
iPLEX	O
ADME	O
CYP2D6	B
Panel	O
,	O
analyzing	O
29	O
CYP2D6	B
SNP	O
and	O
indel	O
variants	O
,	O
with	O
a	O
99	O
.	O
8	O
%	O
success	O
rate	O
(	O
2835	O
genotypes	O
)	O
.	O

This	O
metric	O
was	O
over	O
99	O
%	O
in	O
non	O
-	O
CYP2D6	B
positions	O
.	O

Seven	O
positions	O
in	O
CYP2D6	B
were	O
missing	O
calls	O
in	O
more	O
than	O
10	O
patients	O
in	O
WGS	O
due	O
to	O
low	O
-	O
confidence	O
calling	O
;	O
rs16947	O
,	O
a	O
common	O
CYP2D6	B
variant	O
found	O
in	O
the	O
CYP2D6	B
*	O
2	O
haplotype	O
among	O
others	O
,	O
was	O
the	O
most	O
frequently	O
missed	O
position	O
(	O
60	O
of	O
the	O
98	O
subjects	O
)	O
.	O

For	O
subjects	O
missing	O
a	O
call	O
for	O
rs16947	O
and	O
/	O
or	O
additional	O
variants	O
,	O
the	O
most	O
likely	O
CYP2D6	B
diplotype	O
was	O
manually	O
and	O
individually	O
assigned	O
by	O
using	O
the	O
CYP2D6	B
star	O
nomenclature	O
^	O
carried	O
rs3892097	O
variant	O
defining	O
the	O
CYP2D6	B
*	O
4	O
haplotype	O
and	O
seven	O
subjects	O
(	O
Patient	O
ID	O
:	O
1039	O
,	O
1053	O
,	O
1063	O
,	O
1086	O
,	O
1090	O
,	O
1093	O
,	O
and	O
1096	O
)	O
had	O
CYP2D6	B
copy	O
number	O
gains	O
or	O
losses	O
(	O
described	O
below	O
)	O
.	O

One	O
sample	O
(	O
Patient	O
ID	O
1093	O
)	O
carried	O
a	O
combination	O
of	O
both	O
(	O
copy	O
number	O
gain	O
+	O
CYP2D6	B
*	O
4	O
)	O
.	O

Lastly	O
,	O
we	O
looked	O
at	O
coding	O
variants	O
in	O
the	O
CYP2D6	B
gene	O
outside	O
of	O
the	O
set	O
examined	O
here	O
were	O
investigated	O
further	O
because	O
of	O
their	O
potential	O
to	O
affect	O
metabolizer	O
status	O
depending	O
on	O
the	O
allele	O
they	O
occur	O
in	O
.	O

CNV	O
in	O
CYP2D6	B
is	O
relatively	O
common	O
,	O
and	O
has	O
been	O
established	O
as	O
important	O
accompanying	O
information	O
in	O
CYP2D6	B
typing	O
.	O

^	O
When	O
we	O
examined	O
CYP2D6	B
-	O
overlapping	O
CNVs	O
in	O
the	O
Complete	O
Genomics	O
cnvSegmentsDiploidBeta	O
and	O
high	O
ConfidenceSVEventsBeta	O
files	O
,	O
only	O
one	O
sample	O
was	O
flagged	O
as	O
having	O
a	O
copy	O
number	O
gain	O
of	O
CYP2D6	B
.	O

We	O
instead	O
extracted	O
relative	O
coverage	O
(	O
defined	O
as	O
normalized	O
coverage	O
level	O
under	O
a	O
diploid	O
model	O
,	O
a	O
value	O
of	O
1	O
being	O
2	O
-	O
copy	O
)	O
for	O
a	O
6	O
kb	O
window	O
containing	O
CYP2D6	B
.	O

A	O
subset	O
of	O
nine	O
samples	O
was	O
inconclusive	O
for	O
copy	O
number	O
by	O
this	O
method	O
,	O
as	O
they	O
exhibited	O
intermediate	O
values	O
of	O
average	O
relative	O
coverage	O
(	O
between	O
0	O
.	O
5	O
and	O
1	O
or	O
between	O
1	O
and	O
1	O
.	O
5	O
)	O
contain	O
the	O
CYP2D6	B
*	O
4	O
variant	O
rs3892097	O
in	O
this	O
way	O
.	O

Of	O
the	O
nine	O
samples	O
(	O
Patient	O
ID	O
:	O
1009	O
,	O
1025	O
,	O
1031	O
,	O
1043	O
,	O
1068	O
,	O
1070	O
,	O
1072	O
,	O
1074	O
,	O
1112	O
)	O
inconclusive	O
for	O
genomic	O
copy	O
number	O
of	O
CYP2D6	B
in	O
WGS	O
data	O
,	O
one	O
sample	O
(	O
Patient	O
ID	O
:	O
1074	O
)	O
was	O
estimated	O
to	O
be	O
one	O
copy	O
while	O
the	O
other	O
eight	O
samples	O
were	O
classified	O
as	O
a	O
two	O
copy	O
using	O
the	O
targeted	O
genotyping	O
panel	O
(	O
Table	O
.	O

In	O
the	O
12	O
WES	O
samples	O
,	O
the	O
67	O
loci	O
were	O
sequenced	O
to	O
an	O
average	O
depth	O
of	O
140X	O
,	O
and	O
there	O
were	O
no	O
missing	O
calls	O
for	O
variants	O
in	O
exonic	O
regions	O
were	O
not	O
covered	O
by	O
this	O
WES	O
data	O
set	O
,	O
however	O
,	O
all	O
other	O
CYP2D6	B
positions	O
were	O
successfully	O
genotyped	O
.	O

However	O
,	O
we	O
also	O
found	O
WGS	O
was	O
not	O
able	O
to	O
accurately	O
genotype	O
several	O
positions	O
in	O
CYP2D6	B
.	O

In	O
particular	O
,	O
genotype	O
information	O
for	O
the	O
rs16947	O
SNP	O
that	O
defines	O
CYP2D6	B
*	O
2	O
-	O
related	O
haplotypes	O
was	O
absent	O
in	O
the	O
majority	O
of	O
subjects	O
(	O
60	O
/	O
98	O
)	O
with	O
WGS	O
data	O
.	O

In	O
a	O
clinical	O
setting	O
,	O
these	O
individuals	O
would	O
require	O
reflexed	O
testing	O
using	O
targeted	O
genotyping	O
of	O
the	O
CYP2D6	B
gene	O
.	O

We	O
found	O
that	O
individuals	O
with	O
an	O
rs3892097	O
variant	O
(	O
CYP2D6	B
*	O
4	O
)	O
were	O
more	O
likely	O
to	O
have	O
ambiguous	O
calling	O
(	O
no	O
call	O
or	O
only	O
one	O
allele	O
confidently	O
called	O
)	O
for	O
several	O
CYP2D6	B
positions	O
.	O

Our	O
findings	O
are	O
also	O
consistent	O
with	O
in	O
silico	O
modeling	O
showing	O
that	O
short	O
reads	O
of	O
CYP2D6	B
multi	O
-	O
align	O
to	O
the	O
highly	O
similar	O
CYP2D7	O
and	O
CYP2D8	O
genes	O
,	O
^	O
leading	O
to	O
the	O
reasonable	O
assumption	O
that	O
WGS	O
variant	O
calling	O
in	O
CYP2D6	B
will	O
be	O
platform	O
-	O
dependent	O
because	O
of	O
variations	O
in	O
sequence	O
coverage	O
due	O
to	O
chemistry	O
,	O
read	O
length	O
and	O
downstream	O
bioinformatics	O
tools	O
.	O

^	O
At	O
this	O
time	O
,	O
we	O
recommend	O
pursuing	O
additional	O
targeted	O
testing	O
for	O
the	O
CYP2D6	B
gene	O
to	O
confirm	O
WGS	O
data	O
.	O

In	O
five	O
samples	O
with	O
a	O
copy	O
number	O
gain	O
(	O
Patient	O
ID	O
:	O
1012	O
,	O
1018	O
,	O
1020	O
,	O
1061	O
,	O
1085	O
)	O
the	O
prediction	O
of	O
CYP2D6	B
metabolizer	O
status	O
changed	O
when	O
compared	O
to	O
an	O
individual	O
of	O
the	O
same	O
genotype	O
without	O
a	O
duplication	O
from	O
12	O
individuals	O
of	O
our	O
patient	O
cohort	O
and	O
compared	O
the	O
variant	O
calling	O
data	O
for	O
the	O
67	O
positions	O
to	O
targeted	O
genotyping	O
data	O
.	O

Although	O
we	O
anticipated	O
similar	O
variant	O
calling	O
issues	O
as	O
observed	O
in	O
the	O
WGS	O
data	O
,	O
interestingly	O
,	O
WES	O
variant	O
calling	O
in	O
CYP2D6	B
was	O
highly	O
concordant	O
to	O
targeted	O
genotyping	O
and	O
no	O
position	O
exhibited	O
similar	O
rates	O
of	O
missing	O
data	O
.	O

Two	O
SNPs	O
outside	O
of	O
exons	O
(	O
rs28735595	O
,	O
rs1080985	O
)	O
that	O
are	O
traditionally	O
examined	O
to	O
assign	O
CYP2D6	B
haplotypes	O
were	O
not	O
captured	O
was	O
covered	O
at	O
a	O
sufficient	O
depth	O
for	O
variant	O
calling	O
(	O
average	O
47X	O
)	O
indicating	O
that	O
some	O
commercial	O
bait	O
sets	O
may	O
be	O
supplemented	O
to	O
capture	O
intronic	O
regions	O
.	O

However	O
,	O
it	O
is	O
important	O
to	O
note	O
that	O
variant	O
calling	O
,	O
especially	O
in	O
the	O
CYP2D6	B
gene	O
,	O
could	O
be	O
challenging	O
depending	O
on	O
sequencing	O
platform	O
used	O
.	O

For	O
CYP2D6	B
,	O
manual	O
interpretation	O
of	O
WGS	O
data	O
in	O
the	O
form	O
of	O
targeted	O
CNV	O
analysis	O
,	O
inspection	O
of	O
allelic	O
read	O
depth	O
and	O
decision	O
-	O
making	O
surrounding	O
missing	O
markers	O
,	O
was	O
necessary	O
here	O
with	O
data	O
generated	O
on	O
the	O
Complete	O
Genomics	O
platform	O
.	O

Further	O
PCR	O
-	O
based	O
testing	O
could	O
also	O
be	O
done	O
on	O
some	O
subjects	O
to	O
determine	O
if	O
they	O
harbor	O
structural	O
variants	O
of	O
CYP2D6	B
not	O
detectable	O
by	O
the	O
methods	O
here	O
.	O

In	O
the	O
case	O
of	O
CYP2D6	B
,	O
the	O
copy	O
number	O
status	O
is	O
an	O
integral	O
part	O
of	O
typing	O
an	O
individual	O
so	O
this	O
testing	O
would	O
need	O
to	O
be	O
done	O
separately	O
via	O
quantitative	O
PCR	O
or	O
other	O
method	O
.	O

Twenty	O
-	O
nine	O
SNP	O
and	O
indel	O
variants	O
as	O
well	O
as	O
copy	O
number	O
status	O
of	O
the	O
CYP2D6	B
gene	O
were	O
analyzed	O
using	O
the	O
Agena	O
iPLEX	O
ADME	O
CYP2D6	B
Panel	O
v1	O
.	O
0	O
,	O
which	O
is	O
a	O
3	O
-	O
well	O
assay	O
combining	O
genotyping	O
for	O
SNP	O
and	O
indel	O
variants	O
as	O
well	O
as	O
five	O
assays	O
to	O
determine	O
genomic	O
copy	O
number	O
.	O

^	O
CYP2D6	B
diplotypes	O
and	O
CNV	O
calling	O
for	O
MassArray	O
data	O
were	O
determined	O
using	O
the	O
Agena	O
PGx	O
Report	O
2	O
.	O
0	O
Reporter	O
plugin	O
for	O
the	O
Typer	O
Analyzer	O
software	O
(	O
Agena	O
Bioscience	O
)	O
.	O

CYP2D6	B
copy	O
number	O
was	O
estimated	O
from	O
the	O
five	O
copy	O
number	O
assays	O
that	O
are	O
integrated	O
in	O
the	O
CYP2D6	B
genotyping	O
panel	O
,	O
which	O
is	O
calculated	O
from	O
informative	O
polymorphisms	O
between	O
CYP2D6	B
and	O
CYP2D7	O
.	O

Furthermore	O
,	O
phenotype	O
assignments	O
such	O
as	O
poor	O
,	O
intermediate	O
,	O
extensive	O
,	O
and	O
ultrarapid	O
metabolizers	O
were	O
determined	O
by	O
utilizing	O
the	O
corresponding	O
published	O
CPIC	O
guidelines	O
^	O
-	O
and	O
for	O
CYP2D6	B
,	O
the	O
activity	O
score	O
system	O
as	O
described	O
elsewhere	O
.	O

Nevertheless	O
,	O
the	O
predicted	O
CL_int	O
values	O
of	O
CYP2D6	B
(	O
P	O
=	O
0	O
.	O
003	O
)	O
and	O
3A4	O
/	O
5	O
(	O
P	O
=	O
0	O
.	O
014	O
)	O
were	O
significantly	O
higher	O
than	O
the	O
measured	O
values	O
.	O

The	O
CYP2D6	B
enzyme	O
metabolizes	O
many	O
basic	O
drugs	O
including	O
opioids	O
,	O
antidepressants	O
(	O
eg	O
,	O
nortriptyline	O
and	O
fluoxetine	O
)	O
,	O
antipsychotics	O
(	O
eg	O
,	O
risperidone	O
)	O
and	O
-	O
blockers	O
(	O
eg	O
,	O
metoprolol	O
)	O
.	O

Individuals	O
homozygous	O
or	O
compound	O
heterozygous	O
for	O
the	O
CYP2D6	B
*	O
3	O
,	O
*	O
4	O
,	O
*	O
5	O
,	O
or	O
*	O
6	O
variants	O
exhibit	O
no	O
enzyme	O
activity	O
,	O
while	O
those	O
with	O
CYP2D6	B
*	O
1	O
or	O
*	O
2	O
gene	O
duplication	O
have	O
more	O
CYP2D6	B
protein	O
with	O
resulting	O
higher	O
enzymatic	O
activity	O
.	O

This	O
is	O
clinically	O
relevant	O
for	O
codeine	O
,	O
which	O
is	O
metabolized	O
to	O
morphine	O
by	O
CYP2D6	B
.	O

CYP2D6	B
PMs	O
may	O
experience	O
an	O
inadequate	O
analgesic	O
effect	O
while	O
UMs	O
are	O
at	O
risk	O
of	O
morphine	O
toxicity	O
.	O

A	O
structurally	O
related	O
drug	O
,	O
dextromethorphan	O
(	O
DEX	O
)	O
,	O
is	O
O	O
-	O
demethylated	O
by	O
CYP2D6	B
to	O
dextrorphan	O
(	O
DXO	O
)	O
and	O
,	O
therefore	O
,	O
the	O
metabolic	O
ratio	O
of	O
DEX	O
/	O
DXO	O
can	O
be	O
used	O
to	O
differentiate	O
between	O
CYP2D6	B
phenotypes	O
.	O

In	O
Inuit	O
peoples	O
in	O
Canada	O
,	O
the	O
allele	O
frequency	O
of	O
CYP2D6	B
*	O
4	O
was	O
6	O
.	O
7	O
-	O
8	O
.	O
3	O
%	O
;	O
the	O
CYP2D6	B
*	O
10	O
MAF	O
was	O
2	O
.	O
2	O
%	O
and	O
the	O
CYP2D6	B
*	O
3	O
and	O
*	O
6	O
alleles	O
were	O
not	O
detected	O
.	O

Phenotype	O
results	O
were	O
in	O
agreement	O
with	O
genotype	O
and	O
furthermore	O
,	O
individuals	O
classified	O
as	O
PMs	O
had	O
lower	O
recoveries	O
of	O
DXO	O
as	O
well	O
as	O
other	O
CYP2D6	B
-	O
mediated	O
metabolites	O
,	O
compared	O
to	O
EMs	O
.	O

Notably	O
,	O
the	O
frequency	O
of	O
the	O
CYP2D6	B
*	O
4	O
allele	O
in	O
the	O
Inuit	O
population	O
was	O
significantly	O
lower	O
than	O
the	O
MAF	O
reported	O
in	O
the	O
European	O
population	O
(	O
23	O
%	O
)	O
and	O
significantly	O
greater	O
than	O
in	O
the	O
Asian	O
population	O
(	O
<	O
1	O
.	O
0	O
%	O
)	O
.	O

CYP2D6	B
genotype	O
,	O
as	O
well	O
as	O
phenotype	O
using	O
the	O
O	O
-	O
demethylation	O
ratio	O
of	O
DEX	O
,	O
was	O
determined	O
in	O
a	O
FN	O
population	O
.	O

The	O
MAFs	O
of	O
CYP2D6	B
*	O
3	O
,	O
*	O
4	O
and	O
*	O
10	O
were	O
0	O
.	O
0	O
,	O
3	O
.	O
0	O
and	O
3	O
.	O
0	O
%	O
,	O
respectively	O
.	O

Interestingly	O
,	O
the	O
one	O
individual	O
identified	O
as	O
a	O
CYP2D6	B
PM	O
by	O
phenotyping	O
with	O
DEX	O
was	O
not	O
found	O
to	O
have	O
a	O
CYP2D6	B
*	O
4	O
/	O
*	O
4	O
genotype	O
.	O

In	O
the	O
CSKT	O
population	O
,	O
the	O
CYP2D6	B
*	O
1	O
frequency	O
was	O
37	O
.	O
6	O
%	O
,	O
CYP2D6	B
*	O
2	O
occurred	O
at	O
a	O
frequency	O
of	O
23	O
.	O
4	O
%	O
and	O
copy	O
number	O
variation	O
conferring	O
UM	O
phenotype	O
had	O
a	O
frequency	O
of	O
1	O
.	O
1	O
%	O
.	O

The	O
reported	O
frequencies	O
of	O
the	O
PM	O
conferring	O
variants	O
CYP2D6	B
*	O
3	O
,	O
*	O
4	O
,	O
*	O
5	O
and	O
*	O
6	O
were	O
0	O
.	O
3	O
%	O
,	O
20	O
.	O
9	O
%	O
,	O
1	O
.	O
3	O
%	O
and	O
0	O
.	O
0	O
%	O
,	O
respectively	O
.	O

The	O
reduced	O
activity	O
variants	O
conferring	O
IM	O
phenotype	O
,	O
CYP2D6	B
*	O
10	O
,	O
*	O
17	O
and	O
*	O
41	O
,	O
had	O
frequencies	O
of	O
1	O
.	O
3	O
%	O
,	O
0	O
.	O
0	O
%	O
and	O
11	O
.	O
2	O
%	O
,	O
respectively	O
.	O

These	O
allele	O
frequencies	O
are	O
similar	O
to	O
the	O
findings	O
of	O
McGrane	O
and	O
Loveland	O
who	O
performed	O
pharmacogenetic	O
testing	O
in	O
Northwest	O
AI	O
youth	O
and	O
reported	O
MAFs	O
of	O
CYP2D6	B
*	O
3	O
,	O
*	O
4	O
,	O
*	O
5	O
,	O
*	O
6	O
,	O
*	O
10	O
,	O
*	O
17	O
and	O
*	O
41	O
as	O
0	O
.	O
0	O
%	O
,	O
14	O
.	O
6	O
%	O
,	O
2	O
.	O
8	O
%	O
,	O
0	O
.	O
8	O
%	O
,	O
2	O
.	O
0	O
%	O
,	O
0	O
.	O
0	O
%	O
and	O
6	O
.	O
9	O
%	O
,	O
respectively	O
.	O

The	O
relatively	O
high	O
frequencies	O
for	O
CYP2D6	B
*	O
4	O
and	O
CYP2D6	B
*	O
41	O
could	O
have	O
clinical	O
implications	O
,	O
particularly	O
with	O
medications	O
that	O
require	O
bioactivation	O
by	O
CYP2D6	B
to	O
an	O
active	O
metabolite	O
to	O
be	O
clinically	O
effective	O
.	O

CYP2D6	B
is	O
the	O
primary	O
enzyme	O
responsible	O
for	O
metabolizing	O
tamoxifen	O
to	O
endoxifen	O
,	O
a	O
major	O
active	O
metabolite	O
responsible	O
for	O
much	O
of	O
tamoxifens	O
therapeutic	O
effect	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
distribution	O
of	O
CYP2D6	B
activity	O
within	O
different	O
patient	O
populations	O
.	O

In	O
the	O
Northwest	O
CSKT	O
and	O
AI	O
youth	O
populations	O
,	O
the	O
overall	O
prevalence	O
of	O
low	O
activity	O
CYP2D6	B
,	O
including	O
both	O
PMs	O
and	O
IMs	O
,	O
was	O
9	O
.	O
1	O
%	O
and	O
20	O
.	O
3	O
%	O
,	O
respectively	O
.	O

performed	O
CYP2D6	B
genotyping	O
in	O
Tarahumaras	O
from	O
Chihuahua	O
,	O
Purepechas	O
from	O
Michoacn	O
,	O
Tojolabales	O
,	O
Tzotziles	O
and	O
Tzeltales	O
from	O
Chiapas	O
and	O
Tepehuanos	O
from	O
Durango	O
.	O

The	O
MAFs	O
reported	O
for	O
CYP2D6	B
*	O
4	O
were	O
7	O
.	O
3	O
%	O
,	O
2	O
.	O
9	O
%	O
,	O
1	O
.	O
2	O
%	O
,	O
2	O
.	O
7	O
%	O
and	O
5	O
.	O
3	O
%	O
for	O
Tarahumaras	O
,	O
Purepechas	O
,	O
Tojolabales	O
,	O
Tzotziles	O
and	O
Tzeltales	O
,	O
respectively	O
.	O

CYP2D6	B
*	O
3	O
,	O
*	O
6	O
,	O
*	O
7	O
and	O
*	O
8	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
Amerindian	O
populations	O
studied	O
.	O

The	O
CYP2D6	B
genotype	O
results	O
from	O
Perez	O
-	O
Paramo	O
et	O
al	O
.	O

in	O
Tepehuanos	O
further	O
support	O
previous	O
findings	O
that	O
the	O
frequency	O
of	O
CYP2D6	B
inactive	O
alleles	O
is	O
low	O
in	O
most	O
Amerindian	O
populations	O
.	O

These	O
MAFs	O
predict	O
a	O
low	O
frequency	O
of	O
CYP2D6	B
PMs	O
in	O
these	O
Amerindian	O
populations	O
.	O

investigated	O
the	O
CYP2D6	B
phenotype	O
in	O
Tepehuanos	O
using	O
DEX	O
/	O
DXO	O
metabolic	O
ratio	O
and	O
found	O
that	O
no	O
Tepehuanos	O
were	O
classified	O
as	O
CYP2D6	B
PMs	O
,	O
as	O
expected	O
based	O
on	O
the	O
allele	O
frequencies	O
reported	O
by	O
multiple	O
studies	O
.	O

The	O
frequency	O
of	O
CYP2D6	B
UMs	O
,	O
based	O
on	O
CYP2D6	B
*	O
1	O
or	O
*	O
2	O
gene	O
duplication	O
,	O
varied	O
depending	O
on	O
the	O
Amerindian	O
population	O
studied	O
and	O
the	O
location	O
of	O
the	O
reference	O
Mestizo	O
population	O
.	O

in	O
an	O
Amerindian	O
population	O
including	O
the	O
Tarahumara	O
,	O
Tepehuano	O
,	O
Mexicanera	O
,	O
Huichol	O
,	O
Cora	O
,	O
Seri	O
,	O
Mayo	O
and	O
Guarijo	O
groups	O
,	O
were	O
consistent	O
with	O
previously	O
published	O
findings	O
that	O
CYP2D6	B
variants	O
conferring	O
PM	O
status	O
are	O
rare	O
in	O
the	O
Amerindian	O
population	O
.	O

Regarding	O
CYP2D6	B
multiplications	O
,	O
the	O
frequency	O
of	O
wtxN	O
,	O
*	O
2xN	O
and	O
*	O
4xN	O
were	O
4	O
.	O
7	O
,	O
1	O
.	O
1	O
and	O
0	O
.	O
1	O
%	O
,	O
respectively	O
.	O

CYP2D6	B
phenotype	O
was	O
also	O
determined	O
using	O
the	O
DEX	O
/	O
DXO	O
ratio	O
,	O
with	O
a	O
significantly	O
greater	O
parent	O
to	O
metabolite	O
ratio	O
for	O
individuals	O
with	O
reduced	O
activity	O
or	O
null	O
CYP2D6	B
variants	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
identify	O
and	O
characterize	O
variants	O
that	O
may	O
impact	O
the	O
activity	O
of	O
important	O
drug	O
metabolizing	O
enzymes	O
including	O
CYP2D6	B
.	O

The	O
relatively	O
high	O
frequencies	O
for	O
CYP2D6	B
*	O
4	O
and	O
CYP2D6	B
*	O
41	O
in	O
the	O
CSKT	O
and	O
AI	O
youth	O
may	O
be	O
important	O
to	O
consider	O
with	O
CYP2D6	B
substrates	O
such	O
as	O
codeine	O
,	O
tamoxifen	O
and	O
antidepressants	O
.	O

Conversely	O
,	O
certain	O
subgroups	O
in	O
the	O
Amerindian	O
population	O
(	O
Tepehuano	O
,	O
Purepecha	O
,	O
Tojolabal	O
,	O
Tzotzil	O
,	O
Mexicanera	O
,	O
Cora	O
and	O
Guarijo	O
)	O
had	O
a	O
low	O
proportion	O
of	O
CYP2D6	B
variants	O
conferring	O
PM	O
status	O
.	O

^	O
,	O
However	O
,	O
incubation	O
of	O
the	O
antiestrogenic	O
precursor	O
drug	O
tamoxifen	O
did	O
not	O
lead	O
to	O
an	O
increased	O
antiestrogenic	O
response	O
(	O
data	O
not	O
shown	O
)	O
despite	O
the	O
presence	O
of	O
CYP2D6	B
in	O
S9	O
-	O
mix	O
which	O
increases	O
the	O
potency	O
of	O
tamoxifen	O
30	O
-	O
100	O
fold	O
through	O
formation	O
of	O
the	O
active	O
metabolite	O
4	O
-	O
hydroxytamoxifen	O
.	O

^	O
,	O
Therefore	O
,	O
formation	O
of	O
4	O
-	O
hydroxytamoxifen	O
by	O
endogenously	O
expressed	O
CYP2D6	B
in	O
MCF	O
-	O
7	O
cells	O
^	O
,	O
could	O
explain	O
the	O
lack	O
of	O
increased	O
potency	O
following	O
treatment	O
with	O
S9	O
-	O
mix	O
.	O

It	O
was	O
not	O
possible	O
to	O
measure	O
the	O
aqueous	O
extracts	O
impact	O
on	O
CYP2D6	B
due	O
to	O
a	O
high	O
level	O
of	O
background	O
fluorescence	O
produced	O
by	O
the	O
extract	O
(	O
A	O
,	O
B	O
)	O
.	O

CYP3A4	B
is	O
the	O
enzyme	O
most	O
implicated	O
in	O
drug	O
interactions	O
,	O
while	O
CYP2D6	B
is	O
important	O
,	O
firstly	O
because	O
of	O
the	O
high	O
percentage	O
of	O
drugs	O
metabolized	O
and	O
secondly	O
,	O
because	O
the	O
enzyme	O
is	O
associated	O
with	O
high	O
levels	O
of	O
polymorphism	O
.	O

Podophyllotoxin	O
and	O
-	O
yatein	O
are	O
reported	O
as	O
potent	O
inhibitors	O
of	O
CYP3A4	B
and	O
-	O
yatein	O
is	O
reported	O
as	O
a	O
moderate	O
/	O
weak	O
inhibitor	O
against	O
the	O
activity	O
of	O
CYP2D6	B
.	O

mRNAs	O
for	O
CYP2D6	B
,	O
2U1	O
and	O
2W1	O
were	O
present	O
in	O
Full	O
-	O
Thickness	O
Human	O
Bottom	O
Skin	O
,	O
but	O
variable	O
between	O
individual	O
EpiDerm	O
^	O
samples	O
.	O

The	O
expression	O
of	O
CYP2D6	B
was	O
very	O
low	O
or	O
nil	O
.	O

reported	O
that	O
they	O
found	O
CYP2D6	B
mRNA	O
in	O
the	O
skin	O
biopsies	O
of	O
all	O
27	O
human	O
individuals	O
investigated	O
,	O
the	O
levels	O
of	O
the	O
CYP2D6	B
mRNA	O
being	O
among	O
the	O
highest	O
of	O
all	O
10	O
CYPs	O
studied	O
.	O

reported	O
that	O
the	O
CYP2D6	B
-	O
catalyzed	O
metabolism	O
of	O
bufuralol	O
did	O
not	O
reach	O
the	O
Limit	O
Of	O
Quantitation	O
of	O
1	O
.	O
08	O
pmol	O
.	O

reported	O
that	O
they	O
observed	O
CYP2D6	B
mRNA	O
in	O
human	O
dermal	O
fibroblasts	O
,	O
but	O
not	O
in	O
proliferating	O
human	O
keratinocytes	O
in	O
culture	O
.	O

CYP2D6	B
mRNA	O
was	O
neither	O
detected	O
in	O
the	O
dermis	O
of	O
native	O
human	O
skin	O
nor	O
in	O
monolayer	O
fibroblasts	O
derived	O
from	O
the	O
same	O
donors	O
nor	O
in	O
the	O
dermis	O
of	O
the	O
three	O
-	O
dimensional	O
full	O
skin	O
model	O
Phenion	O
FT	O
Skin	O
,	O
but	O
was	O
consistently	O
expressed	O
in	O
the	O
three	O
-	O
dimensional	O
epidermal	O
reconstructed	O
model	O
OS	O
-	O
REp	O
derived	O
from	O
any	O
of	O
the	O
three	O
donors	O
.	O

It	O
was	O
not	O
expressed	O
in	O
native	O
human	O
skin	O
,	O
neither	O
in	O
the	O
epidermis	O
nor	O
in	O
the	O
dermis	O
(	O
Wiegand	O
et	O
al	O
.	O
.	O
The	O
substrate	O
specificity	O
of	O
CYP2D6	B
protein	O
(	O
investigated	O
in	O
organs	O
other	O
than	O
the	O
skin	O
)	O
includes	O
:	O
physiological	O
substrates	O
(	O
eg	O
,	O
progesterone	O
,	O
testosterone	O
,	O
retinal	O
,	O
tryptoptamine	O
)	O
,	O
natural	O
compounds	O
(	O
eg	O
,	O
aflatoxin	O
B_1	O
,	O
nicotine	O
,	O
ochratoxin	O
A	O
,	O
capsaicin	O
,	O
curcumin	O
,	O
emetine	O
,	O
genistein	O
4	O
-	O
methyl	O
ether	O
,	O
sparteine	O
)	O
,	O
pharmaceutical	O
drugs	O
(	O
eg	O
,	O
debrisoquine	O
,	O
bufuralol	O
,	O
propranolol	O
,	O
dextromethorphan	O
,	O
fluoxetine	O
)	O
(	O
Du	O
et	O
al	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
compounds	O
1	O
-	O
4	O
did	O
not	O
show	O
inhibitory	O
effect	O
on	O
CYP2D6	B
and	O
CYP3A4	B
.	O

EtOH	O
increased	O
mRNA	O
and	O
protein	O
levels	O
of	O
CYP2D6	B
by	O
73	O
%	O
and	O
60	O
%	O
respectively	O
.	O

Finally	O
,	O
CYP2D6	B
localized	O
at	O
mitochondria	O
and	O
Endoplasmic	O
Reticulum	O
.	O

CYP2D6	B
is	O
one	O
of	O
the	O
most	O
expressed	O
isoforms	O
in	O
brain	O
cells	O
and	O
plays	O
a	O
key	O
role	O
in	O
Central	O
Nervous	O
System	O
homeostasis	O
.	O

CYP2D6	B
is	O
also	O
involved	O
in	O
an	O
alternative	O
anabolic	O
pathway	O
of	O
dopamine	O
,	O
thus	O
taking	O
part	O
in	O
important	O
aspects	O
of	O
brain	O
health	O
and	O
neurotoxicity	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
CYP2D6	B
-	O
polymorphism	O
affects	O
dopamine	O
formation	O
through	O
drug	O
interaction	O
,	O
and	O
therefore	O
,	O
may	O
contribute	O
to	O
neurodegeneration	O
.	O

Individuals	O
with	O
CYP2D6	B
-	O
poor	O
metabolism	O
are	O
related	O
to	O
a	O
higher	O
risk	O
of	O
Parkinsons	O
Disease	O
.	O

Despite	O
that	O
its	O
mRNA	O
expression	O
is	O
lower	O
than	O
that	O
observed	O
for	O
CYP2D6	B
in	O
substantia	O
nigra	O
,	O
CYP2E1	B
is	O
important	O
for	O
many	O
key	O
biological	O
processes	O
.	O

We	O
found	O
that	O
CYP2D6	B
can	O
play	O
an	O
important	O
role	O
in	O
the	O
metabolism	O
of	O
xenobiotics	O
in	O
this	O
cell	O
line	O
.	O

In	O
undifferentiated	O
cells	O
,	O
the	O
mRNA	O
levels	O
of	O
CYP2D6	B
were	O
not	O
significantly	O
affected	O
by	O
BETA	O
-	O
NF	O
treatment	O
,	O
yet	O
EtOH	O
promoted	O
a	O
significative	O
1	O
.	O
7	O
-	O
fold	O
increase	O
(	O
a	O
)	O
.	O

In	O
the	O
undifferentiated	O
phenotype	O
,	O
the	O
protein	O
levels	O
of	O
CYP2D6	B
revealed	O
that	O
EtOH	O
was	O
the	O
most	O
potent	O
inducer	O
,	O
showing	O
a	O
1	O
.	O
6	O
-	O
fold	O
increase	O
compared	O
to	O
control	O
,	O
while	O
BETA	O
-	O
NF	O
did	O
not	O
significantly	O
affect	O
the	O
expression	O
of	O
this	O
protein	O
(	O
a	O
)	O
.	O

The	O
dextromethorphan	O
is	O
metabolized	O
mainly	O
by	O
CYP2D6	B
,	O
which	O
promotes	O
the	O
formation	O
of	O
dextrorphan	O
by	O
an	O
O	O
-	O
demethylation	O
reaction	O
.	O

Interestingly	O
,	O
the	O
expression	O
of	O
CYP2D6	B
after	O
treatments	O
correlated	O
with	O
mitochondria	O
,	O
while	O
it	O
presented	O
less	O
localization	O
in	O
Endoplasmic	O
Reticulum	O
.	O

Localization	O
between	O
CYP2D6	B
and	O
Endoplasmic	O
Reticulum	O
was	O
lower	O
,	O
as	O
observed	O
by	O
their	O
R	O
Pearson	O
coefficients	O
(	O
BETA	O
-	O
NF	O
,	O
0	O
.	O
43	O
;	O
EtOH	O
,	O
0	O
.	O
37	O
)	O
.	O

Similar	O
to	O
CYP2D6	B
,	O
the	O
R	O
Pearson	O
coefficient	O
was	O
not	O
able	O
to	O
be	O
calculated	O
in	O
control	O
conditions	O
due	O
to	O
the	O
low	O
fluorescent	O
intensity	O
.	O

The	O
role	O
of	O
CYP2D6	B
and	O
2E1	O
in	O
neurodegeneration	O
is	O
important	O
for	O
developing	O
new	O
therapeutic	O
approaches	O
.	O

Our	O
results	O
demonstrate	O
that	O
CYP2D6	B
and	O
2E1	O
can	O
be	O
increased	O
in	O
terms	O
of	O
mRNA	O
,	O
proteins	O
,	O
and	O
activities	O
by	O
incubating	O
undifferentiated	O
SH	O
-	O
SY5Y	O
cells	O
with	O
two	O
well	O
-	O
known	O
inducer	O
compounds	O
in	O
the	O
liver	O
,	O
BETA	O
-	O
NF	O
and	O
EtOH	O
.	O

Moreover	O
,	O
different	O
studies	O
suggested	O
that	O
,	O
inconsistent	O
with	O
what	O
has	O
been	O
observed	O
in	O
the	O
liver	O
,	O
CYP2D6	B
is	O
inducible	O
in	O
the	O
brain	O
and	O
in	O
SH	O
-	O
SY5Y	O
.	O

Therefore	O
,	O
we	O
have	O
also	O
investigated	O
the	O
effects	O
of	O
BETA	O
-	O
NF	O
and	O
EtOH	O
on	O
CYP2D6	B
.	O

Under	O
our	O
experimental	O
conditions	O
,	O
CYP2D6	B
seems	O
to	O
be	O
inducible	O
by	O
EtOH	O
in	O
terms	O
of	O
mRNA	O
and	O
protein	O
levels	O
,	O
and	O
not	O
by	O
BETA	O
-	O
NF	O
,	O
while	O
in	O
differentiated	O
cells	O
,	O
both	O
BETA	O
-	O
NF	O
and	O
EtOH	O
were	O
able	O
to	O
increase	O
the	O
protein	O
levels	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
EtOH	O
induction	O
of	O
CYP2D6	B
observed	O
in	O
these	O
results	O
is	O
in	O
agreement	O
with	O
other	O
studies	O
,	O
where	O
an	O
in	O
vitro	O
induction	O
of	O
this	O
isoform	O
by	O
the	O
same	O
compound	O
has	O
been	O
reported	O
.	O

Furthermore	O
,	O
the	O
in	O
vivo	O
treatment	O
of	O
African	O
green	O
monkeys	O
with	O
nicotine	O
also	O
demonstrated	O
that	O
CYP2D6	B
can	O
be	O
inducible	O
in	O
brain	O
while	O
remaining	O
unchanged	O
in	O
the	O
liver	O
.	O

The	O
evidence	O
of	O
the	O
induction	O
of	O
CYP2D6	B
in	O
SH	O
-	O
SY5Y	O
cells	O
,	O
in	O
conflict	O
with	O
that	O
observed	O
in	O
hepatocytes	O
,	O
suggests	O
that	O
this	O
isoform	O
has	O
a	O
different	O
regulation	O
in	O
the	O
neuroblastoma	O
cell	O
line	O
.	O

suggested	O
the	O
involvement	O
of	O
PPARs	O
in	O
the	O
regulation	O
of	O
CYP2D6	B
in	O
brain	O
and	O
SH	O
-	O
SY5Y	O
cells	O
.	O

As	O
shown	O
in	O
Western	O
Blot	O
experiments	O
,	O
the	O
expression	O
of	O
CYP2D6	B
and	O
2E1	O
proteins	O
can	O
be	O
increased	O
by	O
at	O
least	O
one	O
compound	O
used	O
in	O
this	O
study	O
in	O
both	O
undifferentiated	O
and	O
differentiated	O
phenotypes	O
.	O

The	O
role	O
of	O
CYP2D6	B
in	O
Parkinsons	O
Disease	O
is	O
still	O
under	O
debate	O
.	O

In	O
fact	O
,	O
a	O
pharmacogenetic	O
study	O
of	O
70	O
individuals	O
with	O
Parkinsons	O
Disease	O
showed	O
that	O
a	O
lower	O
metabolic	O
rate	O
of	O
CYP2D6	B
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
developing	O
this	O
disease	O
.	O

However	O
,	O
other	O
groups	O
state	O
that	O
the	O
association	O
between	O
Parkinsons	O
Disease	O
and	O
mutations	O
of	O
CYP2D6	B
is	O
most	O
likely	O
the	O
result	O
of	O
interactions	O
between	O
multiple	O
genetic	O
and	O
environmental	O
factors	O
.	O

However	O
,	O
CYP2D6	B
is	O
one	O
of	O
the	O
most	O
expressed	O
isoforms	O
in	O
dopaminergic	O
neurons	O
,	O
and	O
therefore	O
,	O
the	O
evidence	O
that	O
our	O
treatments	O
in	O
SH	O
-	O
SY5Y	O
cells	O
increased	O
7	O
-	O
hydroxycumarin	O
formation	O
clearly	O
indicated	O
that	O
the	O
induction	O
of	O
CYP	O
(	O
s	O
)	O
proteins	O
also	O
corresponded	O
to	O
an	O
increase	O
in	O
the	O
CYP	O
-	O
dependent	O
metabolism	O
.	O

The	O
results	O
demonstrate	O
that	O
cells	O
are	O
able	O
to	O
promote	O
the	O
CYP2D6	B
-	O
dependent	O
metabolism	O
of	O
the	O
compound	O
although	O
its	O
induction	O
does	O
not	O
lead	O
to	O
a	O
statistically	O
significant	O
increase	O
compared	O
to	O
control	O
.	O

This	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
dextromethorphan	O
is	O
only	O
metabolized	O
by	O
CYP2D6	B
,	O
unlike	O
7	O
-	O
ethoxycoumarin	O
,	O
and	O
its	O
low	O
concentration	O
in	O
our	O
cellular	O
preparations	O
,	O
even	O
in	O
the	O
case	O
of	O
induction	O
,	O
is	O
not	O
sufficient	O
to	O
increase	O
the	O
formation	O
of	O
dextrorphane	O
in	O
a	O
statistically	O
significant	O
manner	O
.	O

Our	O
study	O
showed	O
by	O
confocal	O
microscopy	O
analysis	O
that	O
CYP2D6	B
in	O
treated	O
cells	O
also	O
localized	O
at	O
mitochondria	O
,	O
and	O
at	O
a	O
minor	O
level	O
,	O
at	O
Endoplasmic	O
Reticulum	O
.	O

Targeting	O
this	O
organelle	O
is	O
a	O
key	O
feature	O
for	O
the	O
implications	O
of	O
CYP2D6	B
in	O
neurodegeneration	O
.	O

Some	O
polymorphisms	O
have	O
been	O
found	O
in	O
liver	O
mitochondria	O
,	O
and	O
,	O
in	O
other	O
in	O
vitro	O
studies	O
,	O
neurons	O
have	O
been	O
transduced	O
to	O
overexpress	O
a	O
mitochondrially	O
-	O
targeted	O
CYP2D6	B
.	O

This	O
experimental	O
evidence	O
may	O
represent	O
another	O
important	O
perspective	O
of	O
the	O
role	O
of	O
CYP2D6	B
in	O
detoxification	O
processes	O
,	O
since	O
this	O
isoform	O
is	O
proposed	O
to	O
be	O
neuroprotective	O
against	O
xenobiotics	O
that	O
target	O
the	O
mitochondria	O
,	O
such	O
as	O
the	O
MPP	O
^	O
+	O
.	O

However	O
,	O
the	O
expression	O
of	O
the	O
four	O
isoforms	O
in	O
general	O
can	O
vary	O
depending	O
on	O
the	O
brain	O
area	O
and	O
cellular	O
type	O
,	O
and	O
the	O
only	O
expression	O
of	O
CYP2D6	B
at	O
mitochondrial	O
level	O
highlights	O
the	O
importance	O
of	O
this	O
isoform	O
only	O
in	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Finally	O
,	O
our	O
results	O
in	O
cell	O
viability	O
suggest	O
that	O
the	O
induction	O
of	O
CYP2D6	B
and	O
2E1	O
might	O
have	O
a	O
protective	O
role	O
against	O
the	O
toxicity	O
promoted	O
by	O
MPP	O
^	O
+	O
.	O

Indeed	O
,	O
the	O
partial	O
neuroprotection	O
showed	O
by	O
BETA	O
-	O
NF	O
and	O
EtOH	O
treatments	O
agree	O
with	O
other	O
MTT	O
experiments	O
,	O
where	O
the	O
inhibition	O
of	O
CYP2D6	B
increased	O
the	O
toxic	O
effect	O
of	O
MPP	O
^	O
+	O
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Other	O
groups	O
have	O
shown	O
that	O
the	O
active	O
site	O
of	O
CYP2D6	B
is	O
large	O
enough	O
to	O
allow	O
MPP	O
^	O
+	O
to	O
enter	O
into	O
it	O
,	O
suggesting	O
that	O
the	O
metabolism	O
of	O
this	O
toxin	O
can	O
be	O
carried	O
out	O
by	O
this	O
isoform	O
.	O

Since	O
CYP2D6	B
and	O
MPP	O
^	O
+	O
target	O
mitochondria	O
,	O
we	O
expect	O
that	O
the	O
toxic	O
effect	O
and	O
the	O
protection	O
by	O
CYPs	O
observed	O
here	O
will	O
affect	O
mitochondrial	O
function	O
.	O

The	O
CYPs	O
activities	O
were	O
assayed	O
using	O
7	O
-	O
ethoxycoumarin	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
as	O
substrate	O
of	O
multiple	O
Cytochrome	B
P450	I
isoforms	O
or	O
dextromethorphan	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
as	O
CYP2D6	B
marker	O
substrate	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
in	O
SH	O
-	O
SY5Y	O
cells	O
,	O
CYP2D6	B
can	O
be	O
induced	O
by	O
EtOH	O
and	O
CYP2E1	B
by	O
BETA	O
-	O
NF	O
and	O
EtOH	O
.	O

We	O
also	O
propose	O
a	O
primary	O
role	O
of	O
CYP2D6	B
toward	O
the	O
metabolism	O
of	O
compounds	O
related	O
to	O
Parkinsons	O
Disease	O
due	O
its	O
presence	O
in	O
mitochondria	O
and	O
suggest	O
that	O
SH	O
-	O
SY5Y	O
cells	O
can	O
be	O
a	O
useful	O
in	O
vitro	O
experimental	O
method	O
to	O
clarify	O
the	O
overall	O
role	O
of	O
CYPs	O
at	O
neuronal	O
level	O
.	O

CYP2D6	B
metabolizes	O
about	O
20	O
%	O
of	O
clinically	O
relevant	O
drugs	O
,	O
and	O
its	O
characteristic	O
feature	O
is	O
a	O
possible	O
duplication	O
of	O
an	O
encoding	O
gene	O
,	O
which	O
has	O
an	O
impact	O
on	O
the	O
different	O
metabolism	O
of	O
drugs	O
among	O
populations	O
.	O

No	O
significant	O
changes	O
were	O
observed	O
for	O
CYP2D6	B
;	O
however	O
,	O
in	O
other	O
studied	O
members	O
of	O
the	O
CYP2	O
subfamily	O
(	O
2B6	O
and	O
2E1	O
)	O
,	O
we	O
observed	O
lower	O
expression	O
of	O
both	O
genes	O
in	O
HepaRG	O
cells	O
,	O
while	O
in	O
HepG2	O
cells	O
,	O
the	O
2B6	O
level	O
was	O
increased	O
.	O

456259	O
)	O
,	O
CYP2D6	B
*	O
1	O
(	O
Lot	O
No	O
.	O

Most	O
antidepressant	O
and	O
antipsychotic	O
drugs	O
have	O
moderately	O
long	O
half	O
-	O
lives	O
in	O
the	O
range	O
of	O
12	O
-	O
36	O
h	O
;	O
poor	O
(	O
with	O
either	O
inactive	O
or	O
low	O
-	O
activity	O
CYP2D6	B
)	O
;	O
or	O
ultrarapid	O
metabolizers	O
owing	O
to	O
genetic	O
polymorphisms	O
.	O

Thus	O
,	O
relatively	O
slow	O
recovery	O
is	O
anticipated	O
from	O
overdoses	O
if	O
the	O
patient	O
carries	O
the	O
low	O
-	O
activity	O
or	O
absent	O
CYP2D6	B
,	O
with	O
more	O
rapid	O
recovery	O
in	O
extensive	O
or	O
ultrarapid	O
metabolizers	O
.	O

Between	O
5	O
%	O
and	O
10	O
%	O
of	O
Europeans	O
and	O
approximately	O
1	O
%	O
of	O
Asians	O
are	O
poor	O
metabolizers	O
via	O
CYP2D6	B
.	O

However	O
,	O
PharmG	O
+	O
patients	O
treated	O
with	O
CYP2D6	B
substrates	O
that	O
were	O
carriers	O
of	O
CYP2D6	B
UMs	O
or	O
PMs	O
variants	O
showed	O
a	O
significantly	O
higher	O
improvement	O
in	O
global	O
,	O
psychic	O
and	O
other	O
UKU	O
side	O
effects	O
than	O
PharmG	O
patients	O
(	O
p	O
=	O
0	O
.	O
02	O
,	O
p	O
=	O
0	O
.	O
05	O
and	O
p	O
=	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O

Analyses	O
within	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
drugs	O
mainly	O
metabolised	O
by	O
the	O
enzyme	O
CYP2D6	B
(	O
risperidone	O
,	O
haloperidol	O
,	O
aripiprazole	O
,	O
pimozide	O
and	O
trifluoperazine	O
)	O
also	O
showed	O
no	O
differences	O
with	O
PharmG	O
+	O
and	O
PharmG	O
patients	O
showing	O
similar	O
variations	O
in	O
PANSS	O
scores	O
(	O
24	O
.	O
33	O
3	O
vs	O
26	O
.	O
47	O
2	O
)	O
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
difference	O
when	O
analysing	O
PANSS	O
score	O
improvement	O
between	O
PharmG	O
+	O
patients	O
(	O
26	O
.	O
6	O
3	O
.	O
5	O
)	O
and	O
PharmG	O
patients	O
(	O
28	O
.	O
63	O
3	O
.	O
7	O
)	O
treated	O
with	O
CYP2D6	B
substrates	O
.	O

The	O
PI	O
was	O
significantly	O
associated	O
to	O
improvements	O
in	O
total	O
(	O
6	O
.	O
92	O
improvement	O
in	O
PharmG	O
+	O
vs	O
1	O
.	O
27	O
in	O
PharmG	O
,	O
Wald	O
=	O
5	O
.	O
56	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
psychic	O
(	O
2	O
.	O
50	O
vs	O
0	O
.	O
53	O
improvement	O
,	O
Wald	O
=	O
3	O
.	O
96	O
,	O
p	O
=	O
0	O
.	O
05	O
)	O
and	O
other	O
UKU	O
side	O
effects	O
(	O
1	O
.	O
08	O
vs	O
0	O
.	O
3	O
,	O
Wald	O
=	O
6	O
.	O
19	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
in	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
CYP2D6	B
substrates	O
(	O
see	O
Table	O
.	O

The	O
subgroup	O
of	O
patients	O
treated	O
with	O
CYP2D6	B
substrates	O
(	O
risperidone	O
,	O
haloperidol	O
,	O
aripiprazole	O
,	O
pimozide	O
and	O
trifluoperazine	O
)	O
that	O
were	O
carriers	O
of	O
CYP2D6	B
UMs	O
or	O
PMs	O
variants	O
clearly	O
benefited	O
from	O
the	O
intervention	O
:	O
model	O
regression	O
analyses	O
showed	O
that	O
the	O
PI	O
resulted	O
in	O
a	O
significant	O
improvement	O
in	O
global	O
,	O
psychic	O
and	O
other	O
UKU	O
side	O
effects	O
(	O
p	O
=	O
0	O
.	O
02	O
,	O
p	O
=	O
0	O
.	O
05	O
and	O
p	O
=	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O

Nevertheless	O
,	O
we	O
performed	O
analyses	O
on	O
the	O
subgroups	O
of	O
patients	O
carrying	O
CYPs	O
functional	O
variants	O
(	O
either	O
UMs	O
or	O
PMs	O
)	O
,	O
and	O
investigated	O
the	O
two	O
largest	O
antipsychotic	O
groups	O
within	O
the	O
study	O
(	O
clozapine	O
and	O
CYP2D6	B
substrates	O
)	O
.	O

In	O
agreement	O
with	O
our	O
current	O
findings	O
in	O
male	O
mice	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
acute	O
Doxorubicin	O
cardiotoxicity	O
did	O
not	O
change	O
CYP2E1	B
expression	O
in	O
the	O
hearts	O
of	O
male	O
Sprague	O
Dawley	O
rats	O
.	O

However	O
,	O
Doxorubicin	O
induced	O
CYP2E1	B
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
in	O
H9c2	O
cardiomyoblasts	O
in	O
vitro	O
.	O

The	O
activity	O
of	O
7	O
-	O
methoxy	O
-	O
4	O
-	O
trifluoromethylcoumarin	O
dealkylation	O
is	O
the	O
diagnostic	O
marker	O
of	O
CYP2E1	B
.	O

The	O
activity	O
of	O
CYP2E1	B
was	O
determined	O
by	O
fluorescence	O
value	O
of	O
7	O
-	O
hydroxy	O
-	O
4	O
-	O
trifluoromethylcoumarin	O
conversed	O
from	O
7	O
-	O
methoxy	O
-	O
4	O
-	O
trifluoromethyl	O
-	O
coumarin	O
by	O
7	O
-	O
Methoxy	O
-	O
4	O
-	O
Trifluoromethylcoumarin	O
Dealkylation	O
.	O

Sort	O
=	O
Bait	O
protein	O
partners	O
were	O
identified	O
,	O
including	O
the	O
components	O
regulating	O
cytoskeleton	O
organization	O
(	O
BBIP1	O
and	O
ANKMY1	O
)	O
,	O
components	O
of	O
the	O
coagulation	O
cascade	O
of	O
human	O
blood	O
(	O
SERPINA1	O
,	O
SERPINA3	O
,	O
APOH	O
,	O
FGA	O
,	O
and	O
FN1	O
)	O
,	O
and	O
the	O
enzyme	O
involved	O
in	O
the	O
metabolism	O
of	O
xenobiotics	O
and	O
endogenous	O
bioregulators	O
(	O
CYP2E1	B
)	O
.	O

Surface	O
Plasmon	O
Resonance	O
validation	O
on	O
the	O
Biacore	O
3000	O
biosensor	O
confirmed	O
the	O
effectiveness	O
of	O
the	O
interaction	O
between	O
CYP2E1	B
(	O
the	O
enzyme	O
that	O
converts	O
prostaglandin	O
H2	O
to	O
12	O
-	O
HHT	O
/	O
thromboxane	O
A2	O
proantagonist	O
)	O
and	O
Https	O
:	O
/	O
/	O
Thebiogrid	O
.	O
org	O
/	O
112778	O
/	O
Summary	O
/	O
Homo	O
-	O
Sapiens	O
/	O
Tbxas1	O
.	O
Html	O
?	O

Importantly	O
,	O
the	O
TBXAS1CYP2E1	O
complex	O
formation	O
increases	O
fivefold	O
in	O
the	O
presence	O
of	O
isatin	O
(	O
indole	O
-	O
2	O
,	O
3	O
-	O
dione	O
,	O
a	O
low	O
-	O
molecular	O
nonpeptide	O
endogenous	O
bioregulator	O
,	O
a	O
product	O
of	O
CYP2E1	B
)	O
.	O

Since	O
CYP2E1	B
is	O
involved	O
in	O
the	O
metabolism	O
of	O
various	O
indole	O
derivatives	O
,	O
we	O
further	O
investigated	O
the	O
possible	O
influence	O
of	O
the	O
well	O
-	O
known	O
endogenous	O
bioregulator	O
isatin	O
(	O
indole	O
-	O
2	O
,	O
3	O
-	O
dione	O
)	O
on	O
the	O
interaction	O
of	O
CYP2E1	B
and	O
CYP11B2	B
with	O
Https	O
:	O
/	O
/	O
Thebiogrid	O
.	O
org	O
/	O
112778	O
/	O
Summary	O
/	O
Homo	O
-	O
Sapiens	O
/	O
Tbxas1	O
.	O
Html	O
?	O

Sort	O
=	O
Bait	O
CYP2E1	B
interaction	O
and	O
does	O
not	O
affect	O
the	O
Https	O
:	O
/	O
/	O
Thebiogrid	O
.	O
org	O
/	O
112778	O
/	O
Summary	O
/	O
Homo	O
-	O
Sapiens	O
/	O
Tbxas1	O
.	O
Html	O
?	O

The	O
presence	O
of	O
CYP2E1	B
,	O
which	O
belongs	O
to	O
the	O
cytochromes	O
P450	O
superfamily	O
,	O
in	O
the	O
list	O
of	O
fished	O
proteins	O
is	O
of	O
particular	O
interest	O
.	O

A	O
functional	O
relationship	O
between	O
CYP2E1	B
and	O
Https	O
:	O
/	O
/	O
Thebiogrid	O
.	O
org	O
/	O
112778	O
/	O
Summary	O
/	O
Homo	O
-	O
Sapiens	O
/	O
Tbxas1	O
.	O
Html	O
?	O

As	O
it	O
is	O
known	O
,	O
CYP2E1	B
is	O
characterized	O
by	O
broad	O
substrate	O
specificity	O
and	O
a	O
broad	O
tissue	O
localization	O
profile	O
,	O
including	O
the	O
liver	O
.	O

For	O
example	O
,	O
CYP2E1	B
can	O
oxidize	O
arachidonic	O
acid	O
(	O
via	O
-	O
1	O
-	O
hydroxylation	O
)	O
and	O
prostaglandin	O
H2	O
to	O
form	O
side	O
metabolites	O
,	O
which	O
,	O
in	O
turn	O
,	O
are	O
formed	O
in	O
the	O
prostaglandin	O
H2	O
to	O
thromboxane	O
A2	O
isomerization	O
reactions	O
.	O

Sort	O
=	O
Bait	O
,	O
synthesizing	O
thromboxane	O
A2	O
,	O
and	O
CYP2E1	B
could	O
serve	O
as	O
an	O
additional	O
mechanism	O
regulating	O
the	O
effectiveness	O
of	O
enzymatic	O
conversion	O
of	O
common	O
substrates	O
.	O

Sort	O
=	O
Bait	O
CYP2E1	B
complex	O
in	O
direct	O
Surface	O
Plasmon	O
Resonance	O
experiments	O
.	O

Thus	O
,	O
we	O
can	O
confidently	O
state	O
that	O
the	O
interaction	O
of	O
CYP2E1	B
and	O
CYP11B2	B
with	O
Https	O
:	O
/	O
/	O
Thebiogrid	O
.	O
org	O
/	O
112778	O
/	O
Summary	O
/	O
Homo	O
-	O
Sapiens	O
/	O
Tbxas1	O
.	O
Html	O
?	O

Sort	O
=	O
Bait	O
CYP2E1	B
complex	O
formation	O
were	O
(	O
6	O
.	O
9	O
0	O
.	O
3	O
)	O
10	O
^	O
-	O
7	O
M	O
and	O
(	O
4	O
.	O
3	O
0	O
.	O
4	O
)	O
10	O
^	O
-	O
7	O
M	O
,	O
respectively	O
.	O

Sort	O
=	O
Bait	O
CYP2E1	B
interactions	O
are	O
very	O
different	O
in	O
their	O
kinetic	O
parameters	O
.	O

Sort	O
=	O
Bait	O
CYP2E1	B
occur	O
about	O
an	O
order	O
of	O
magnitude	O
slower	O
compared	O
to	O
Https	O
:	O
/	O
/	O
Thebiogrid	O
.	O
org	O
/	O
112778	O
/	O
Summary	O
/	O
Homo	O
-	O
Sapiens	O
/	O
Tbxas1	O
.	O
Html	O
?	O

Since	O
CYP2E1	B
turned	O
out	O
to	O
be	O
one	O
of	O
the	O
proteins	O
that	O
interact	O
with	O
Https	O
:	O
/	O
/	O
Thebiogrid	O
.	O
org	O
/	O
112778	O
/	O
Summary	O
/	O
Homo	O
-	O
Sapiens	O
/	O
Tbxas1	O
.	O
Html	O
?	O

Sort	O
=	O
Bait	O
CYP2E1	B
complex	O
formation	O
.	O

Sort	O
=	O
Bait	O
and	O
CYP2E1	B
in	O
the	O
absence	O
and	O
presence	O
of	O
isatin	O
.	O

Sort	O
=	O
Bait	O
CYP2E1	B
complex	O
formation	O
,	O
but	O
it	O
has	O
no	O
effect	O
on	O
the	O
Https	O
:	O
/	O
/	O
Thebiogrid	O
.	O
org	O
/	O
112778	O
/	O
Summary	O
/	O
Homo	O
-	O
Sapiens	O
/	O
Tbxas1	O
.	O
Html	O
?	O

Sort	O
=	O
Bait	O
CYP2E1	B
in	O
the	O
presence	O
of	O
isatin	O
is	O
due	O
to	O
both	O
a	O
twofold	O
increase	O
in	O
k_on	O
values	O
and	O
a	O
2	O
.	O
5	O
-	O
fold	O
decrease	O
in	O
k_off	O
.	O

The	O
most	O
robust	O
evidence	O
supporting	O
this	O
hypothesis	O
is	O
found	O
in	O
short	O
-	O
term	O
oral	O
or	O
intraperitoneal	O
dose	O
mode	O
of	O
action	O
studies	O
in	O
which	O
the	O
lung	O
toxicity	O
of	O
styrene	O
and	O
a	O
previously	O
postulated	O
putative	O
lung	O
toxic	O
metabolite	O
,	O
styrene	O
oxide	O
(	O
a	O
primary	O
metabolite	O
of	O
CYP2E1	B
metabolism	O
;	O
)	O
,	O
was	O
completely	O
attenuated	O
in	O
CYP2F2	O
knockout	O
mice	O
and	O
in	O
mice	O
in	O
which	O
human	O
CYP2F1	O
was	O
inserted	O
as	O
a	O
transgene	O
in	O
the	O
knockout	O
mouse	O
strain	O
.	O

Despite	O
robust	O
mode	O
of	O
action	O
data	O
indicating	O
the	O
essential	O
role	O
of	O
styrene	O
CYP2F2	O
metabolism	O
in	O
mediating	O
the	O
lung	O
toxicity	O
of	O
styrene	O
,	O
these	O
data	O
do	O
not	O
fully	O
address	O
the	O
possibility	O
that	O
alternative	O
and	O
potentially	O
human	O
-	O
relevant	O
mode	O
(	O
s	O
)	O
of	O
action	O
outside	O
of	O
CYP2F2	O
metabolism	O
,	O
eg	O
,	O
styrene	O
oxide	O
formation	O
by	O
CYP2E1	B
,	O
might	O
be	O
contributing	O
to	O
styrene	O
-	O
induced	O
mouse	O
lung	O
tumors	O
.	O

As	O
CYP2F2	O
KO	O
mice	O
express	O
equal	O
amounts	O
of	O
CYP2E1	B
protein	O
in	O
WT	O
and	O
KO	O
mice	O
,	O
these	O
mice	O
strains	O
are	O
capable	O
of	O
generating	O
styrene	O
oxide	O
.	O

In	O
addition	O
,	O
styrene	O
oxide	O
lung	O
toxicity	O
was	O
completely	O
attenuated	O
in	O
CYP2F2	O
KO	O
mice	O
,	O
indicating	O
that	O
this	O
primary	O
metabolite	O
product	O
of	O
CYP2E1	B
metabolism	O
is	O
not	O
the	O
proximate	O
lung	O
toxic	O
metabolite	O
of	O
styrene	O
.	O

The	O
lack	O
of	O
a	O
role	O
for	O
CYP2E1	B
generated	O
styrene	O
oxide	O
in	O
lung	O
toxicity	O
is	O
consistent	O
with	O
the	O
observation	O
that	O
styrene	O
lung	O
toxicity	O
was	O
comparable	O
in	O
both	O
WT	O
and	O
CYP2E1	B
KO	O
mice	O
.	O

These	O
multiple	O
rodent	O
bioassays	O
support	O
a	O
conclusion	O
that	O
styrene	O
,	O
via	O
CYP2E1	B
-	O
mediated	O
styrene	O
oxide	O
formation	O
or	O
ring	O
-	O
oxidized	O
metabolite	O
(	O
s	O
)	O
from	O
CYP2F	O
metabolism	O
,	O
has	O
a	O
very	O
low	O
potential	O
for	O
inducing	O
cancer	O
in	O
any	O
tissue	O
other	O
than	O
mouse	O
lung	O
.	O

In	O
these	O
genetically	O
modified	O
mice	O
,	O
possible	O
styrene	O
metabolism	O
by	O
the	O
human	O
CYP2F	O
isoform	O
or	O
that	O
of	O
native	O
CYP2E1	B
in	O
the	O
CYP2F2	O
-	O
KO	O
mice	O
,	O
also	O
is	O
insufficient	O
to	O
initiate	O
any	O
pre	O
-	O
neoplastic	O
events	O
resulting	O
in	O
potential	O
cancer	O
outcomes	O
.	O

The	O
CYP2E1	B
enzyme	O
metabolizes	O
ethanol	O
,	O
tobacco	O
-	O
related	O
nitrosamines	O
,	O
as	O
well	O
as	O
other	O
xenobiotics	O
(	O
eg	O
,	O
acetaminophen	O
)	O
.	O

CYP2E1	B
is	O
also	O
induced	O
by	O
ethanol	O
,	O
increasing	O
alcohol	O
metabolism	O
in	O
cases	O
of	O
chronic	O
ethanol	O
consumption	O
.	O

CYP2E1	B
*	O
1D	O
has	O
been	O
associated	O
with	O
greater	O
CYP2E1	B
induction	O
by	O
ethanol	O
in	O
individuals	O
with	O
at	O
least	O
one	O
copy	O
of	O
the	O
allele	O
.	O

The	O
CYP2E1	B
*	O
5B	O
allele	O
,	O
also	O
referred	O
to	O
as	O
CYP2E1	B
*	O
c2	O
,	O
has	O
been	O
associated	O
with	O
increased	O
enzyme	O
activity	O
.	O

The	O
frequency	O
of	O
CYP2E1	B
*	O
1D	O
was	O
reported	O
to	O
be	O
9	O
.	O
3	O
%	O
in	O
the	O
FN	O
population	O
,	O
which	O
is	O
significantly	O
higher	O
than	O
that	O
seen	O
in	O
European	O
Canadians	O
(	O
2	O
.	O
1	O
%	O
)	O
.	O

Furthermore	O
,	O
FN	O
individuals	O
dependent	O
on	O
alcohol	O
(	O
as	O
defined	O
by	O
DSM	O
-	O
IV	O
)	O
had	O
a	O
higher	O
frequency	O
of	O
the	O
CYP2E1	B
*	O
1D	O
allele	O
,	O
compared	O
to	O
non	O
-	O
alcohol	O
dependent	O
FNs	O
.	O

CYP2E1	B
*	O
1D	O
genotype	O
was	O
also	O
associated	O
with	O
nicotine	O
dependence	O
in	O
FNs	O
,	O
however	O
further	O
studies	O
are	O
needed	O
to	O
elucidate	O
potential	O
mechanisms	O
responsible	O
for	O
this	O
relationship	O
.	O

The	O
MAF	O
of	O
the	O
CYP2E1	B
1295G	O
>	O
C	O
variant	O
was	O
determined	O
to	O
be	O
51	O
.	O
5	O
%	O
in	O
Huichols	O
,	O
an	O
Amerindian	O
population	O
of	O
Western	O
-	O
Central	O
Mexico	O
.	O

The	O
CYP2E1	B
1295G	O
>	O
C	O
variant	O
is	O
of	O
interest	O
when	O
considering	O
the	O
metabolism	O
of	O
ethanol	O
,	O
as	O
well	O
as	O
other	O
CYP2E1	B
substrates	O
and	O
further	O
studies	O
would	O
be	O
useful	O
to	O
establish	O
the	O
clinical	O
relevance	O
of	O
CYP2E1	B
variation	O
across	O
diverse	O
populations	O
.	O

It	O
has	O
been	O
reported	O
that	O
elevated	O
concentration	O
of	O
S	O
-	O
Adenosylmethionine	O
reduces	O
CYP2E1	B
^	O
and	O
CYP39A	O
^	O
,	O
but	O
markedly	O
induces	O
CYP4A	B
^	O
in	O
Glycine	O
N	O
-	O
Methyltransferase	O
Knockout	O
mice	O
.	O

reported	O
the	O
presence	O
of	O
the	O
following	O
CYPs	O
in	O
rat	O
skin	O
microsomes	O
:	O
CYP2B	O
,	O
CYP2C13	O
,	O
CYP2D1	O
,	O
CYP2D4	O
,	O
CYP2E1	B
,	O
CYP3A1	O
,	O
and	O
CYP3A2	O
,	O
their	O
levels	O
being	O
much	O
lower	O
than	O
in	O
the	O
liver	O
(	O
except	O
CYP2D4	O
,	O
which	O
was	O
not	O
observed	O
in	O
the	O
liver	O
)	O
.	O

This	O
CYP	O
turned	O
out	O
to	O
be	O
an	O
arachidonic	O
acid	O
8	O
,	O
9	O
-	O
and	O
11	O
,	O
12	O
-	O
epoxygenase	O
present	O
exclusively	O
in	O
sebocytes	O
(	O
Keeney	O
et	O
al	O
.	O
.	O
The	O
temporal	O
development	O
of	O
CYPs	O
in	O
rat	O
keratinocyte	O
monolayer	O
cultures	O
(	O
serum	O
-	O
free	O
)	O
appears	O
to	O
provide	O
temporal	O
limitations	O
of	O
usefulness	O
for	O
predictions	O
of	O
metabolism	O
-	O
dependent	O
toxicities	O
:	O
CYPs	O
3A1	O
and	O
3A2	O
proteins	O
were	O
very	O
low	O
,	O
CYP2E1	B
below	O
detection	O
on	O
day	O
0	O
,	O
while	O
near	O
confluency	O
of	O
the	O
keratinocytes	O
between	O
days	O
10	O
and	O
14	O
,	O
their	O
levels	O
became	O
similar	O
to	O
those	O
in	O
native	O
skin	O
(	O
Zhu	O
et	O
al	O
.	O
.	O
CYP	O
reductase	O
(	O
NADPH	O
CYP	O
oxidoreductase	O
)	O
protein	O
(	O
required	O
for	O
CYP	O
activity	O
)	O
has	O
been	O
shown	O
to	O
be	O
present	O
in	O
the	O
rat	O
skin	O
,	O
predominantly	O
in	O
the	O
epidermis	O
(	O
Takahara	O
et	O
al	O
.	O
.	O
See	O
also	O
Table	O
.	O

)	O
,	O
increased	O
para	O
-	O
nitrophenol	O
hydroxylation	O
(	O
CYP2E1	B
-	O
selective	O
)	O
after	O
treatment	O
of	O
the	O
rat	O
skin	O
with	O
clotrimazole	O
(	O
Merk	O
et	O
al	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
(	O
CYP	O
1	O
-	O
selective	O
)	O
:	O
10	O
.	O
7	O
pmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
PROD	B
(	O
CYP2B	O
-	O
selective	O
)	O
:	O
1	O
.	O
43	O
pmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
para	O
-	O
nitrophenol	O
hydroxylase	O
(	O
CYP2E1	B
-	O
selective	O
)	O
:	O
1	O
.	O
81	O
nmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
erythromycin	O
N	O
-	O
demethylase	O
(	O
CYP	O
3A	O
-	O
selective	O
)	O
:	O
3	O
.	O
26	O
nmol	O
/	O
min	O
/	O
mg	O
protein	O
.	O

Since	O
basal	O
CYP2E1	B
expression	O
was	O
absent	O
in	O
these	O
ORS	O
-	O
RHE	O
models	O
,	O
they	O
concluded	O
that	O
the	O
CYP	O
responsible	O
for	O
the	O
biotransformation	O
of	O
7	O
-	O
ethoxycoumarin	O
to	O
7	O
-	O
hydroxycoumarin	O
was	O
likely	O
to	O
be	O
CYP1B1	O
,	O
which	O
they	O
had	O
found	O
to	O
be	O
expressed	O
at	O
good	O
levels	O
.	O

CYP2E	O
subfamily	O
CYP2E1	B
transcripts	O
were	O
noted	O
in	O
human	O
keratinocytes	O
,	O
melanocytes	O
,	O
Langerhans	O
cells	O
and	O
fibroblasts	O
(	O
Baron	O
et	O
al	O
.	O

CYP2E1	B
mRNA	O
was	O
expressed	O
in	O
native	O
human	O
skin	O
,	O
both	O
,	O
in	O
the	O
epidermis	O
and	O
in	O
the	O
dermis	O
.	O

CYP2E1	B
-	O
typical	O
enzymatic	O
activity	O
in	O
the	O
human	O
skin	O
was	O
observed	O
toward	O
the	O
substrates	O
chlorzoxazone	O
and	O
toward	O
para	O
-	O
nitrophenol	O
in	O
microsomes	O
derived	O
from	O
the	O
total	O
human	O
skin	O
by	O
Rolsted	O
et	O
al	O
.	O

Some	O
examples	O
of	O
CYP2E1	B
substrates	O
:	O
ethanol	O
,	O
chlorzoxazone	O
,	O
benzene	O
,	O
17BETA	O
-	O
estradiol	O
,	O
estrone	O
,	O
retinoic	O
acid	O
,	O
fatty	O
acids	O
,	O
aflatoxin	O
B_1	O
,	O
nicotine	O
,	O
capsaicin	O
,	O
curcumin	O
,	O
short	O
-	O
chain	O
N	O
-	O
nitrosamines	O
(	O
Du	O
et	O
al	O
.	O

Effects	O
of	O
Flavonoids	O
in	O
Lysimachia	O
clethroides	O
Duby	O
on	O
the	O
Activities	O
of	O
Cytochrome	B
P450	I
CYP2E1	B
and	O
CYP3A4	B
in	O
Rat	O
Liver	O
Microsomes	O
.	O

Incubation	O
systems	O
were	O
established	O
to	O
investigate	O
the	O
effects	O
of	O
quercetin	O
,	O
kaempferol	O
,	O
isoquercitrin	O
and	O
astragalin	O
in	O
Lysimachia	O
clethroides	O
Duby	O
on	O
the	O
activities	O
of	O
CYP2E1	B
and	O
CYP3A4	B
in	O
rat	O
liver	O
microsomes	O
in	O
vitro	O
.	O

The	O
results	O
suggested	O
that	O
kaempferol	O
exhibited	O
a	O
weak	O
inhibition	O
of	O
CYP2E1	B
activity	O
with	O
an	O
IC50	O
of	O
60	O
.	O
26	O
2	O
.	O
54	O
M	O
,	O
while	O
quercetin	O
and	O
kaempferol	O
caused	O
a	O
moderate	O
inhibition	O
of	O
CYP3A4	B
activity	O
with	O
IC50	O
values	O
of	O
18	O
.	O
77	O
1	O
.	O
69	O
M	O
and	O
32	O
.	O
65	O
1	O
.	O
32	O
M	O
,	O
respectively	O
.	O

Isoquercitrin	O
and	O
astragalin	O
had	O
no	O
effects	O
on	O
the	O
activities	O
of	O
either	O
CYP2E1	B
or	O
CYP3A4	B
.	O

It	O
could	O
be	O
speculated	O
from	O
these	O
results	O
that	O
the	O
inhibitory	O
effects	O
of	O
quercetin	O
and	O
kaempferol	O
on	O
the	O
activities	O
of	O
CYP2E1	B
and	O
CYP3A4	B
could	O
be	O
the	O
mechanisms	O
underlying	O
the	O
hepatoprotective	O
effects	O
of	O
L	O
.	O
clethroides	O
.	O

It	O
has	O
been	O
shown	O
by	O
studies	O
in	O
the	O
literature	O
that	O
the	O
enzyme	O
CYP2E1	B
which	O
mediates	O
the	O
hepatocyte	O
damage	O
caused	O
by	O
a	O
variety	O
of	O
compounds	O
,	O
such	O
as	O
ethanol	O
and	O
CCl_4	O
,	O
is	O
considered	O
to	O
be	O
an	O
important	O
determinant	O
of	O
human	O
susceptibility	O
to	O
toxicity	O
and	O
carcinogenicity	O
caused	O
by	O
the	O
industrial	O
and	O
environmental	O
chemicals	O
.	O

CYP2E1	B
and	O
CYP3A4	B
are	O
not	O
only	O
the	O
metabolic	O
enzymes	O
directly	O
involved	O
in	O
hepatic	O
oxidative	O
damage	O
,	O
but	O
they	O
also	O
are	O
two	O
important	O
targets	O
of	O
the	O
oxidation	O
mechanism	O
of	O
acute	O
liver	O
injury	O
.	O

On	O
the	O
basis	O
of	O
previous	O
studies	O
,	O
the	O
impacts	O
of	O
quercetin	O
,	O
kaempferol	O
,	O
isoquercitrin	O
and	O
astragalin	O
on	O
the	O
activities	O
of	O
enzymes	O
CYP2E1	B
and	O
CYP3A4	B
in	O
rat	O
liver	O
microsomes	O
were	O
examined	O
,	O
aiming	O
to	O
investigate	O
the	O
correlation	O
between	O
the	O
hepatoprotective	O
effects	O
of	O
L	O
.	O
clethroides	O
and	O
the	O
antioxidant	O
activities	O
of	O
these	O
four	O
compounds	O
.	O

The	O
regressive	O
equations	O
obtained	O
by	O
the	O
Lineweaver	O
-	O
Burk	O
method	O
for	O
CYP2E1	B
and	O
CYP3A4	B
were	O
Y	O
=	O
835	O
.	O
9883X	O
+	O
9	O
.	O
1943	O
(	O
r	O
=	O
0	O
.	O
9864	O
)	O
and	O
Y	O
=	O
2388	O
.	O
0110X	O
+	O
14	O
.	O
1598	O
(	O
r	O
=	O
0	O
.	O
9961	O
)	O
respetively	O
.	O

The	O
effects	O
of	O
quercetin	O
,	O
kaempferol	O
,	O
isoquercitrin	O
and	O
astragalin	O
in	O
L	O
.	O
clethroides	O
and	O
clomethiazole	O
(	O
positive	O
control	O
)	O
on	O
CYP2E1	B
activity	O
are	O
shown	O
in	O
and	O
.	O

Clomethiazole	O
inhibited	O
the	O
production	O
of	O
4	O
-	O
nitrocatechol	O
with	O
an	O
IC_50	O
of	O
1	O
.	O
07	O
0	O
.	O
01	O
M	O
.	O
The	O
effects	O
of	O
quercetin	O
,	O
kaempferol	O
,	O
isoquercitrin	O
and	O
astragalin	O
on	O
CYP2E1	B
acivity	O
were	O
very	O
weak	O
and	O
their	O
IC_50	O
values	O
could	O
not	O
be	O
calculated	O
.	O

CYP2E1	B
and	O
CYP3A4	B
are	O
two	O
important	O
metabolic	O
enzymes	O
involved	O
in	O
liver	O
injury	O
.	O

Total	O
alkaloids	O
of	O
Rubus	O
alceaefolius	O
Poir	O
could	O
significantly	O
reduce	O
the	O
levels	O
of	O
GOT	O
and	O
GPT	O
,	O
protect	O
liver	O
cells	O
from	O
injury	O
,	O
and	O
inhibit	O
the	O
mRNA	O
expressions	O
of	O
CYP2E1	B
and	O
CYP3A1	O
in	O
liver	O
tissue	O
.	O

It	O
has	O
been	O
indicated	O
that	O
Gegen	O
powder	O
possesses	O
therapeutic	O
effects	O
on	O
acute	O
alcohol	O
-	O
induced	O
liver	O
injury	O
,	O
by	O
increasing	O
the	O
content	O
of	O
CYP450	O
and	O
reducing	O
the	O
activity	O
of	O
CYP2E1	B
.	O

Radix	O
Glycyrrhizae	O
could	O
protect	O
the	O
liver	O
injury	O
caused	O
by	O
Rhizoma	O
dioscorea	O
bulbifera	O
,	O
possibly	O
due	O
to	O
its	O
induction	O
of	O
activity	O
of	O
CYP2E1	B
and	O
CYP3A4	B
and	O
inhibition	O
of	O
the	O
mRNA	O
expression	O
.	O

Clomethiazole	O
and	O
ketoconazole	O
act	O
as	O
the	O
positive	O
inhibitors	O
for	O
CYP2E1	B
and	O
CYP3A4	B
can	O
significantly	O
inhibit	O
the	O
formation	O
of	O
metabolites	O
.	O

The	O
IC_50	O
values	O
of	O
clomethiazole	O
and	O
ketoconazole	O
were	O
1	O
.	O
07	O
0	O
.	O
01	O
M	O
and	O
0	O
.	O
25	O
0	O
.	O
01	O
M	O
,	O
respectively	O
,	O
which	O
are	O
consistent	O
with	O
literature	O
values	O
,	O
suggesting	O
that	O
the	O
incubation	O
systems	O
in	O
vitro	O
can	O
meet	O
the	O
activities	O
of	O
measurement	O
of	O
CYP2E1	B
and	O
CYP3A4	B
.	O

Thus	O
,	O
kaempferol	O
has	O
a	O
weakly	O
inhibitory	O
effect	O
on	O
CYP2E1	B
,	O
while	O
quercetin	O
and	O
kaempferol	O
have	O
moderate	O
inhibitory	O
effects	O
on	O
CYP3A4	B
.	O

The	O
results	O
of	O
this	O
study	O
showed	O
that	O
the	O
two	O
flavone	O
glycosides	O
(	O
isoquercitrin	O
and	O
astragalin	O
)	O
had	O
no	O
effect	O
on	O
the	O
activities	O
of	O
CYP2E1	B
and	O
CYP3A4	B
.	O

Cytochromes	O
P450	O
,	O
especially	O
CYP2E1	B
and	O
CYP3A4	B
,	O
are	O
responsible	O
for	O
metabolism	O
of	O
ethanol	O
,	O
CCl_4	O
and	O
other	O
solvents	O
in	O
the	O
body	O
.	O

In	O
the	O
model	O
of	O
alcohol	O
-	O
induced	O
liver	O
injury	O
,	O
the	O
expression	O
levels	O
of	O
CYP2E1	B
and	O
CYP3A4	B
were	O
enhanced	O
.	O

Researchers	O
have	O
used	O
CYP2E1	B
knockout	O
mice	O
to	O
evaluate	O
the	O
effect	O
of	O
CYP2E1	B
on	O
ethanol	O
-	O
induced	O
chronic	O
liver	O
injury	O
,	O
and	O
the	O
results	O
showed	O
that	O
the	O
fatty	O
liver	O
production	O
and	O
ethanol	O
-	O
induced	O
oxidative	O
stress	O
of	O
wild	O
-	O
type	O
mice	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
CYP2E1	B
knockout	O
mice	O
,	O
showing	O
that	O
CYP2E1	B
is	O
involved	O
in	O
the	O
oxidative	O
stress	O
of	O
the	O
body	O
,	O
increasing	O
the	O
severity	O
of	O
liver	O
damage	O
.	O

As	O
a	O
typical	O
poison	O
,	O
CC1_4	O
is	O
activated	O
by	O
CYP2E1	B
and	O
metabolized	O
to	O
a	O
series	O
of	O
highly	O
reactive	O
free	O
radicals	O
.	O

The	O
occurrence	O
of	O
liver	O
injury	O
can	O
be	O
reduced	O
or	O
even	O
suppressed	O
by	O
minimizing	O
the	O
activities	O
of	O
CYP2E1	B
and	O
CYP3A4	B
,	O
making	O
the	O
discovery	O
of	O
more	O
compounds	O
with	O
anti	O
-	O
oxidative	O
stress	O
from	O
natural	O
products	O
of	O
important	O
significance	O
.	O

The	O
in	O
vitro	O
incubation	O
system	O
of	O
CYP2E1	B
contained	O
liver	O
microsomes	O
,	O
MgCl_2	O
(	O
5	O
mM	O
)	O
,	O
4	O
-	O
nitrophenol	O
(	O
probe	O
substrate	O
)	O
and	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
in	O
a	O
final	O
volume	O
of	O
200	O
L	O
.	O
The	O
mixture	O
was	O
pre	O
-	O
incubated	O
5	O
min	O
at	O
37	O
C	O
thermostatic	O
constant	O
incubator	O
,	O
the	O
reaction	O
was	O
initiated	O
by	O
adding	O
NADPH	O
(	O
1	O
mM	O
)	O
.	O

To	O
evaluate	O
whether	O
quercetin	O
,	O
kaempferol	O
,	O
isoquercitrin	O
and	O
astragalin	O
affect	O
the	O
activity	O
of	O
CYP2E1	B
,	O
the	O
studies	O
were	O
carried	O
out	O
in	O
three	O
groups	O
.	O

The	O
effects	O
of	O
flavonoids	O
in	O
L	O
.	O
clethroides	O
on	O
CYP3A4	B
activity	O
were	O
basically	O
the	O
same	O
as	O
CYP2E1	B
.	O

The	O
positive	O
control	O
was	O
ketoconazole	O
,	O
and	O
Groups	O
2	O
and	O
3	O
experiments	O
were	O
performed	O
at	O
concentrations	O
of	O
0	O
.	O
02	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
2	O
,	O
1	O
and	O
5	O
M	O
.	O
In	O
vitro	O
rat	O
liver	O
microsomes	O
incubation	O
assay	O
methods	O
were	O
adopted	O
for	O
determining	O
the	O
effects	O
of	O
quercetin	O
,	O
kaempferol	O
,	O
isoquercitrin	O
and	O
astragalin	O
in	O
L	O
.	O
clethroides	O
on	O
the	O
activities	O
of	O
CYP2E1	B
and	O
CYP3A4	B
.	O

In	O
conclusion	O
,	O
kaempferol	O
has	O
a	O
weakly	O
inhibitory	O
effect	O
on	O
CYP2E1	B
,	O
while	O
quercetin	O
and	O
kaempferol	O
had	O
moderate	O
inhibitory	O
effects	O
on	O
CYP3A4	B
activity	O
.	O

Based	O
on	O
these	O
results	O
,	O
it	O
can	O
be	O
speculated	O
that	O
the	O
active	O
hepatoprotective	O
ingredients	O
of	O
L	O
.	O
clethroides	O
include	O
quercetin	O
and	O
kaempferol	O
,	O
which	O
confer	O
the	O
inhibitory	O
effects	O
on	O
the	O
activities	O
of	O
CYP2E1	B
and	O
CYP3A4	B
.	O

The	O
reduction	O
of	O
CYP2E1	B
and	O
CYP3A4	B
activities	O
can	O
mitigate	O
the	O
biotransformation	O
of	O
CC1_4	O
and	O
prevent	O
the	O
production	O
of	O
liver	O
damaging	O
substances	O
to	O
exert	O
a	O
liver	O
protective	O
role	O
.	O

Both	O
BETA	O
-	O
NF	O
and	O
EtOH	O
increased	O
CYP2E1	B
mRNA	O
(	O
4	O
-	O
and	O
1	O
.	O
4	O
-	O
fold	O
,	O
respectively	O
)	O
and	O
protein	O
levels	O
(	O
64	O
%	O
both	O
)	O
.	O

Another	O
important	O
isoform	O
in	O
the	O
Central	O
Nervous	O
System	O
is	O
CYP2E1	B
,	O
which	O
can	O
metabolize	O
l	O
-	O
deprenyl	O
in	O
C57BL	O
mice	O
but	O
not	O
in	O
monkeys	O
,	O
either	O
in	O
the	O
liver	O
or	O
brain	O
.	O

In	O
the	O
brain	O
of	O
Parkinsons	O
Disease	O
patients	O
,	O
the	O
CYP2E1	B
gene	O
seems	O
to	O
be	O
less	O
methylated	O
compared	O
to	O
healthy	O
brains	O
,	O
leading	O
to	O
a	O
higher	O
expression	O
of	O
this	O
isoform	O
.	O

CYP2E1	B
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
Parkinsons	O
Disease	O
due	O
to	O
its	O
capability	O
to	O
be	O
induced	O
,	O
its	O
ability	O
to	O
metabolize	O
several	O
xenobiotics	O
that	O
are	O
able	O
to	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
and	O
the	O
high	O
level	O
of	O
ROS	O
production	O
during	O
its	O
metabolic	O
reactions	O
.	O

Moreover	O
,	O
CYP2E1	B
also	O
present	O
polymorphisms	O
,	O
where	O
the	O
5	O
flanking	O
region	O
seems	O
to	O
be	O
important	O
for	O
the	O
metabolism	O
of	O
drugs	O
.	O

EtOH	O
is	O
the	O
most	O
studied	O
compound	O
for	O
CYP2E1	B
induction	O
in	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
experiments	O
.	O

Moreover	O
,	O
CYP2E1	B
promoted	O
an	O
increase	O
of	O
4	O
-	O
fold	O
changes	O
after	O
BETA	O
-	O
NF	O
treatment	O
while	O
EtOH	O
only	O
showed	O
a	O
nonsignificant	O
1	O
.	O
4	O
-	O
fold	O
change	O
(	O
b	O
)	O
.	O

Moreover	O
,	O
CYP2E1	B
showed	O
to	O
be	O
inducible	O
by	O
both	O
BETA	O
-	O
NF	O
and	O
EtOH	O
by	O
about	O
1	O
.	O
7	O
-	O
fold	O
(	O
b	O
)	O
.	O

The	O
analysis	O
of	O
the	O
CYP2E1	B
fluorescence	O
revealed	O
that	O
this	O
isoform	O
was	O
localized	O
with	O
Endoplasmic	O
Reticulum	O
and	O
not	O
with	O
mitochondria	O
.	O

BETA	O
-	O
NF	O
is	O
known	O
to	O
induce	O
Cytochrome	B
P450	I
isoforms	O
belonging	O
to	O
the	O
family	O
1A	O
and	O
1B	O
,	O
while	O
EtOH	O
induces	O
the	O
expression	O
of	O
CYP2E1	B
isoform	O
.	O

Moreover	O
,	O
CYP2E1	B
mRNA	O
levels	O
were	O
statistically	O
increased	O
by	O
BETA	O
-	O
NF	O
and	O
not	O
by	O
EtOH	O
.	O

However	O
,	O
both	O
treatments	O
were	O
able	O
to	O
increase	O
the	O
CYP2E1	B
proteins	O
as	O
observed	O
by	O
Western	O
Blot	O
analysis	O
in	O
undifferentiated	O
cells	O
,	O
while	O
only	O
EtOH	O
promoted	O
this	O
expression	O
in	O
the	O
differentiated	O
phenotype	O
.	O

Conversely	O
,	O
the	O
treatment	O
with	O
EtOH	O
did	O
not	O
show	O
a	O
significant	O
increase	O
of	O
the	O
CYP2E1	B
mRNA	O
levels	O
,	O
while	O
in	O
Western	O
Blot	O
analysis	O
we	O
observed	O
a	O
statistical	O
increase	O
of	O
protein	O
levels	O
.	O

These	O
results	O
are	O
justified	O
by	O
the	O
evidence	O
that	O
EtOH	O
promotes	O
CYP2E1	B
protein	O
stabilization	O
,	O
rather	O
than	O
regulation	O
via	O
receptor	O
activation	O
.	O

CYP2E1	B
induction	O
was	O
also	O
observed	O
in	O
vivo	O
,	O
where	O
rats	O
treated	O
with	O
EtOH	O
and	O
nicotine	O
had	O
increased	O
brain	O
levels	O
of	O
this	O
isoform	O
.	O

It	O
is	O
also	O
important	O
to	O
underline	O
the	O
contrasting	O
results	O
in	O
the	O
literature	O
on	O
the	O
role	O
of	O
CYP2E1	B
in	O
the	O
brain	O
.	O

However	O
,	O
in	O
another	O
study	O
by	O
the	O
same	O
group	O
,	O
the	O
knockout	O
mice	O
of	O
CYP2E1	B
^	O
/	O
were	O
shown	O
to	O
have	O
a	O
lower	O
degeneration	O
of	O
dopaminergic	O
neurons	O
after	O
acute	O
administration	O
of	O
this	O
toxin	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
study	O
of	O
six	O
Parkinsons	O
Disease	O
patients	O
showed	O
a	O
lower	O
DNA	O
methylation	O
at	O
the	O
promoter	O
region	O
of	O
CYP2E1	B
gene	O
in	O
both	O
cortex	O
and	O
putamen	O
,	O
and	O
an	O
increase	O
of	O
mRNA	O
levels	O
in	O
cortex	O
,	O
suggesting	O
that	O
epigenetic	O
variations	O
of	O
this	O
isoform	O
may	O
contribute	O
to	O
Parkinsons	O
Disease	O
susceptibility	O
,	O
but	O
they	O
did	O
not	O
study	O
the	O
correlation	O
between	O
mRNA	O
levels	O
and	O
proteins	O
or	O
enzymatic	O
activity	O
.	O

In	O
contrast	O
,	O
CYP2E1	B
appeared	O
to	O
partially	O
localize	O
in	O
the	O
Endoplasmic	O
Reticulum	O
,	O
as	O
it	O
has	O
been	O
reported	O
in	O
other	O
cell	O
types	O
and	O
tissues	O
.	O

Moreover	O
,	O
other	O
groups	O
have	O
indicated	O
the	O
possibility	O
that	O
CYP2E1	B
,	O
and	O
other	O
isoforms	O
,	O
may	O
target	O
the	O
mitochondria	O
in	O
other	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
.	O

However	O
,	O
the	O
intracellular	O
location	O
of	O
CYP2E1	B
is	O
still	O
a	O
subject	O
of	O
debate	O
.	O

On	O
the	O
other	O
hand	O
,	O
CYP2E1	B
has	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
the	O
intracellular	O
accumulation	O
of	O
this	O
toxin	O
rather	O
than	O
in	O
the	O
metabolism	O
itself	O
.	O

456217	O
)	O
,	O
CYP2E1	B
(	O
Lot	O
No	O
.	O

Employing	O
mice	O
with	O
genetic	O
ablation	O
of	O
CHIP	O
and	O
gp78	O
/	O
AMFR	O
E3	O
ubiquitin	O
-	O
ligases	O
that	O
stabilize	O
hepatic	O
CYP2E1	B
,	O
we	O
document	O
why	O
this	O
stabilization	O
not	O
always	O
leads	O
to	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
:	O
It	O
requires	O
concomitantly	O
enhanced	O
hepatic	O
lipogenesis	O
.	O
Image	O
1	O
The	O
ubiquitous	O
hemoproteins	O
cytochromes	O
P450	O
(	O
P450s	O
or	O
CYPs	O
;	O
MW	O
50	O
kDa	O
)	O
are	O
enzymes	O
engaged	O
both	O
in	O
synthetic	O
and	O
degradative	O
functions	O
critically	O
important	O
to	O
the	O
cellular	O
integrity	O
,	O
physiology	O
and	O
defense	O
,	O
.	O

Accordingly	O
,	O
the	O
dominant	O
human	O
liver	O
/	O
intestinal	O
CYP3A4	O
and	O
human	O
liver	O
CYP2E1	B
are	O
found	O
to	O
be	O
prototypic	O
ERAD	O
-	O
C	O
substrates	O
.	O

CYP3A4	O
,	O
accounting	O
for	O
30	O
%	O
of	O
the	O
hepatic	O
P450	O
content	O
,	O
is	O
engaged	O
in	O
the	O
metabolism	O
of	O
>	O
50	O
%	O
of	O
clinically	O
relevant	O
drugs	O
and	O
other	O
xenobiotics	O
,	O
whereas	O
CYP2E1	B
biotransforms	O
clinically	O
relevant	O
drugs	O
(	O
acetaminophen	O
,	O
halothane	O
)	O
,	O
EtOH	O
,	O
and	O
other	O
xenobiotics	O
,	O
carcinogens	O
(	O
nitrosamines	O
)	O
,	O
endogenous	O
acetone	O
and	O
fatty	O
acids	O
(	O
arachidonic	O
acid	O
)	O
to	O
toxic	O
/	O
reactive	O
intermediates	O
,	O
.	O

Hepatic	O
CYP2E1	B
similarly	O
exhibits	O
a	O
high	O
propensity	O
for	O
ROS	O
generation	O
and	O
is	O
labile	O
in	O
the	O
absence	O
of	O
relevant	O
substrates	O
and	O
/	O
or	O
inducers	O
that	O
stabilize	O
the	O
protein	O
,	O
.	O

Systematic	O
dissection	O
of	O
the	O
hepatic	O
CYP3A	O
and	O
CYP2E1	B
ERAD	O
-	O
C	O
process	O
employing	O
various	O
in	O
vivo	O
and	O
in	O
vitro	O
reconstituted	O
eukaryotic	O
systems	O
has	O
revealed	O
that	O
it	O
involves	O
initial	O
post	O
-	O
translational	O
phosphorylation	O
by	O
cytosolic	O
protein	O
kinases	O
A	O
and	O
C	O
of	O
P450	O
Ser	O
/	O
Thr	O
residues	O
,	O
.	O

In	O
vitro	O
functional	O
reconstitution	O
studies	O
,	O
of	O
E1	O
/	O
E2	O
/	O
E3	O
-	O
mediated	O
CYP3A4	O
and	O
CYP2E1	B
ubiquitination	O
have	O
identified	O
UbcH5a	O
/	O
Hsc70	O
/	O
Hsp40	O
/	O
CHIP	O
and	O
UBC7	O
/	O
AMFR	O
/	O
gp78	O
complexes	O
as	O
two	O
relevant	O
E2	O
/	O
E3	O
systems	O
in	O
CYP3A4	O
and	O
CYP2E1	B
ubiquitination	O
:	O
(	O
i	O
)	O
CHIP	O
(	O
carboxy	O
-	O
terminus	O
of	O
Hsc70	O
-	O
interacting	O
protein	O
)	O
,	O
a	O
cytoplasmic	O
Hsc70	O
-	O
cochaperone	O
,	O
functions	O
with	O
its	O
cognate	O
UbcH5a	O
E2	O
and	O
Hsc70	O
/	O
Hsp40	O
co	O
-	O
chaperones	O
in	O
substrate	O
ubiquitination	O
,	O
.	O

The	O
individual	O
roles	O
of	O
CHIP	O
and	O
gp78	O
in	O
CYP3A	O
and	O
CYP2E1	B
ubiquitination	O
and	O
Endoplasmic	O
Reticulum	O
-	O
Associated	O
Degradation	O
were	O
verified	O
upon	O
lentiviral	O
shRNA	O
interference	O
analyses	O
targeted	O
individually	O
against	O
each	O
of	O
these	O
E3s	O
in	O
cultured	O
rat	O
hepatocytes	O
,	O
.	O

For	O
instance	O
,	O
reported	O
that	O
curcumin	O
and	O
its	O
derivatives	O
inhibit	O
the	O
activity	O
of	O
CYP3A4	B
and	O
other	O
drug	O
-	O
metabolizing	O
enzymes	O
such	O
as	O
:	O
glutathione	O
-	O
S	O
-	O
transferase	O
and	O
UDP	O
-	O
glucuronosyltransferase	O
.	O

These	O
authors	O
reported	O
that	O
inhibition	O
by	O
curcumin	O
,	O
alone	O
or	O
in	O
combination	O
with	O
piperine	O
,	O
of	O
CYP3A4	B
could	O
be	O
harmful	O
,	O
especially	O
during	O
prolonged	O
usage	O
.	O

Similarly	O
,	O
the	O
-	O
flavonols	O
kaempferol	O
,	O
quercetin	O
,	O
and	O
galangin	O
were	O
reported	O
to	O
inhibit	O
CYP3A4	B
-	O
mediated	O
metabolism	O
of	O
xenobiotics	O
in	O
vitro	O
(	O
;	O
.	O

Furthermore	O
,	O
inhibitory	O
effects	O
of	O
catechins	O
on	O
CYP3A4	B
were	O
reported	O
in	O
some	O
studies	O
,	O
although	O
no	O
specific	O
mechanisms	O
of	O
action	O
were	O
reported	O
in	O
these	O
studies	O
.	O

The	O
CYP3A4	B
inactivation	O
potency	O
(	O
k_inact	O
/	O
K_i	O
ratio	O
)	O
of	O
fargesin	O
(	O
2	O
.	O
17	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
was	O
comparable	O
with	O
those	O
reported	O
for	O
some	O
phytochemicals	O
identified	O
as	O
mechanism	O
-	O
based	O
inhibitors	O
of	O
CYP3A4	B
including	O
aschantin	O
(	O
4	O
.	O
92	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
bergamottin	O
(	O
2	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
and	O
rutaecarpine	O
(	O
3	O
.	O
59	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
but	O
much	O
lower	O
than	O
those	O
reported	O
for	O
podophyllotoxin	O
(	O
13	O
.	O
63	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
phyllanthin	O
(	O
131	O
.	O
88	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
and	O
hypophyllanthin	O
(	O
83	O
.	O
21	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
in	O
human	O
liver	O
microsomes	O
.	O

The	O
k_inact	O
/	O
K_i	O
ratio	O
of	O
fargesin	O
against	O
CYP3A4	B
was	O
comparable	O
to	O
those	O
of	O
therapeutic	O
drugs	O
known	O
as	O
mechanism	O
-	O
based	O
CYP3A4	B
inhibitors	O
such	O
as	O
clarithromycin	O
(	O
1	O
-	O
13	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
erythromycin	O
(	O
3	O
-	O
9	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
amiodarone	O
(	O
4	O
.	O
5	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
,	O
and	O
fluoxetine	O
(	O
3	O
.	O
2	O
min	O
^	O
1	O
nM	O
^	O
1	O
)	O
in	O
human	O
liver	O
microsomes	O
.	O

Potential	O
Role	O
of	O
Patients	O
CYP3A	B
-	O
Status	O
in	O
Clozapine	O
Pharmacokinetics	O
.	O

The	O
functional	O
CYP3A5	B
*	O
1	O
allele	O
seemed	O
to	O
influence	O
clozapine	O
concentrations	O
in	O
those	O
patients	O
who	O
expressed	O
CYP3A4	B
at	O
low	O
levels	O
.	O

The	O
dose	O
requirement	O
for	O
the	O
therapeutic	O
concentration	O
of	O
clozapine	O
was	O
substantially	O
lower	O
in	O
low	O
CYP3A4	B
expresser	O
patients	O
than	O
in	O
normal	O
/	O
high	O
expressers	O
(	O
2	O
.	O
180	O
.	O
64	O
vs	O
4	O
.	O
981	O
.	O
40	O
mg	O
/	O
kg	O
,	O
P	O
<	O
.	O
0001	O
)	O
.	O

Furthermore	O
,	O
significantly	O
higher	O
plasma	O
concentration	O
ratios	O
of	O
norclozapine	O
/	O
clozapine	O
and	O
clozapine	O
N	O
-	O
oxide	O
/	O
clozapine	O
were	O
observed	O
in	O
the	O
patients	O
displaying	O
normal	O
/	O
high	O
CYP3A4	B
expression	O
than	O
in	O
the	O
low	O
expressers	O
.	O

Prospective	O
assaying	O
of	O
CYP3A	B
-	O
status	O
(	O
CYP3A4	B
expression	O
,	O
CYP3A5	B
genotype	O
)	O
may	O
better	O
identify	O
the	O
patients	O
with	O
higher	O
risk	O
of	O
inefficiency	O
or	O
adverse	O
reactions	O
and	O
may	O
facilitate	O
the	O
improvement	O
of	O
personalized	O
clozapine	O
therapy	O
;	O
however	O
,	O
further	O
clinical	O
studies	O
are	O
required	O
to	O
prove	O
the	O
benefit	O
of	O
CYP3A	B
testing	O
for	O
patients	O
under	O
clozapine	O
therapy	O
.	O

For	O
the	O
optimal	O
plasma	O
concentrations	O
(	O
200	O
-	O
600	O
ng	O
/	O
mL	O
)	O
,	O
CYP3A	B
-	O
status	O
guided	O
clozapine	O
dosing	O
was	O
proposed	O
(	O
4	O
.	O
98	O
mg	O
/	O
kg	O
for	O
the	O
normal	O
/	O
high	O
CYP3A4	B
expressers	O
and	O
CYP3A5	B
*	O
1	O
carriers	O
,	O
whereas	O
2	O
.	O
18	O
mg	O
/	O
kg	O
for	O
low	O
CYP3A4	B
expressers	O
)	O
.	O

Personalized	O
medication	O
taking	O
patients	O
CYP3A	B
status	O
into	O
account	O
may	O
facilitate	O
the	O
improvement	O
of	O
individual	O
clozapine	O
therapy	O
,	O
leading	O
to	O
the	O
dosage	O
optimization	O
for	O
a	O
more	O
effective	O
therapy	O
.	O

CYP3A4	B
seems	O
to	O
catalyze	O
N	O
-	O
oxidation	O
of	O
clozapine	O
,	O
whereas	O
the	O
formation	O
of	O
norclozapine	O
appears	O
to	O
be	O
more	O
complex	O
.	O

In	O
vitro	O
studies	O
have	O
demonstrated	O
that	O
at	O
high	O
clozapine	O
concentrations	O
,	O
CYP3A4	B
plays	O
a	O
primary	O
role	O
in	O
N	O
-	O
demethylation	O
can	O
modify	O
CYP	O
activities	O
,	O
resulting	O
in	O
transient	O
poor	O
(	O
or	O
extensive	O
)	O
metabolism	O
.	O

The	O
dose	O
and	O
patients	O
CYP3A4	B
expression	O
were	O
identified	O
as	O
significant	O
parameters	O
for	O
clozapine	O
concentration	O
(	O
P	O
<	O
.	O
0001	O
)	O
.	O

Model	O
parameters	O
k_0	O
and	O
k_1	O
were	O
estimated	O
for	O
low	O
and	O
normal	O
/	O
high	O
CYP3A4	B
expressers	O
individually	O
.	O

The	O
role	O
of	O
CYP3A4	B
in	O
the	O
metabolism	O
of	O
clozapine	O
at	O
therapeutic	O
or	O
higher	O
concentrations	O
has	O
been	O
demonstrated	O
;	O
however	O
,	O
the	O
contribution	O
of	O
the	O
highly	O
polymorphic	O
CYP3A5	B
must	O
be	O
clarified	O
.	O

In	O
the	O
present	O
study	O
,	O
10	O
subjects	O
carried	O
the	O
functional	O
CYP3A5	B
*	O
1	O
allele	O
,	O
whereas	O
most	O
of	O
the	O
patients	O
were	O
CYP3A5	B
nonexpressers	O
(	O
CYP3A5	B
*	O
3	O
/	O
*	O
3	O
)	O
and	O
were	O
therefore	O
expected	O
to	O
lack	O
the	O
functional	O
CYP3A5	B
enzyme	O
.	O

Of	O
92	O
patients	O
,	O
18	O
carried	O
CYP3A4	B
*	O
22	O
or	O
CYP3A4	B
*	O
1B	O
alleles	O
,	O
resulting	O
in	O
reduced	O
or	O
increased	O
expression	O
of	O
CYP3A4	B
,	O
respectively	O
;	O
however	O
,	O
these	O
alleles	O
cannot	O
explain	O
the	O
inter	O
-	O
individual	O
differences	O
in	O
CYP3A4	B
mRNA	O
levels	O
.	O

For	O
the	O
categorization	O
of	O
the	O
patients	O
regarding	O
CYP3A4	B
expression	O
,	O
more	O
useful	O
information	O
can	O
be	O
obtained	O
from	O
CYP3A4	B
mRNA	O
levels	O
than	O
from	O
CYP3A4	B
genotyping	O
.	O

CYP3A4	B
expression	O
assays	O
revealed	O
that	O
about	O
two	O
-	O
thirds	O
of	O
the	O
patients	O
expressed	O
CYP3A4	B
at	O
normal	O
level	O
,	O
approximately	O
30	O
%	O
was	O
low	O
CYP3A4	B
expressers	O
,	O
and	O
3	O
patients	O
displayed	O
high	O
CYP3A4	B
expression	O
.	O

One	O
of	O
the	O
high	O
CYP3A4	B
expressers	O
carried	O
CYP3A5	B
*	O
1	O
,	O
anticipating	O
rapid	O
metabolism	O
of	O
CYP3A	B
substrates	O
.	O

Strong	O
association	O
was	O
found	O
between	O
the	O
patients	O
CYP3A4	B
expression	O
and	O
normalized	O
clozapine	O
serum	O
levels	O
.	O

In	O
CYP3A5	B
nonexpressers	O
,	O
the	O
normalized	O
concentrations	O
were	O
significantly	O
higher	O
in	O
those	O
displaying	O
low	O
CYP3A4	B
mRNA	O
levels	O
than	O
in	O
normal	O
or	O
high	O
CYP3A4	B
expressers	O
(	O
185	O
.	O
5356	O
.	O
53	O
vs	O
78	O
.	O
0529	O
.	O
57	O
or	O
66	O
.	O
520	O
.	O
25	O
(	O
ng	O
/	O
mL	O
)	O
/	O
(	O
mg	O
/	O
kg	O
)	O
,	O
P	O
<	O
.	O
0001	O
)	O
.	O

The	O
patients	O
CYP3A5	B
genotype	O
was	O
significantly	O
associated	O
with	O
clozapine	O
concentrations	O
in	O
those	O
patients	O
who	O
expressed	O
CYP3A4	B
at	O
low	O
levels	O
(	O
P	O
<	O
.	O
0001	O
)	O
.	O

Further	O
confirmation	O
of	O
the	O
role	O
of	O
CYP3A5	B
is	O
needed	O
because	O
of	O
the	O
relatively	O
small	O
number	O
of	O
CYP3A5	B
expressers	O
.	O

The	O
patients	O
were	O
divided	O
into	O
4	O
groups	O
according	O
to	O
the	O
CYP3A5	B
genotype	O
(	O
CYP3A5	B
expressers	O
,	O
nonexpressers	O
)	O
and	O
CYP3A4	B
expression	O
(	O
low	O
,	O
normal	O
,	O
and	O
high	O
)	O
.	O

Significantly	O
higher	O
(	O
about	O
2	O
-	O
fold	O
)	O
clozapine	O
concentration	O
was	O
observed	O
in	O
CYP3A5	B
nonexpresser	O
patients	O
displaying	O
low	O
CYP3A4	B
expression	O
than	O
in	O
all	O
the	O
others	O
.	O

However	O
,	O
modelling	O
of	O
the	O
association	O
between	O
CYP3A4	B
expression	O
and	O
clozapine	O
concentrations	O
identified	O
only	O
2	O
groups	O
.	O

The	O
first	O
group	O
consisted	O
of	O
the	O
CYP3A5	B
nonexpressers	O
with	O
low	O
CYP3A4	B
mRNA	O
levels	O
,	O
whereas	O
the	O
remaining	O
3	O
combinations	O
(	O
normal	O
and	O
high	O
CYP3A4	B
expressers	O
with	O
CYP3A5	B
*	O
3	O
/	O
*	O
3	O
genotype	O
,	O
and	O
patients	O
with	O
CYP3A5	B
*	O
1	O
/	O
*	O
3	O
genotype	O
)	O
were	O
grouped	O
,	O
since	O
the	O
separate	O
models	O
for	O
these	O
combinations	O
did	O
not	O
result	O
in	O
significantly	O
different	O
parameters	O
.	O

The	O
models	O
were	O
able	O
to	O
predict	O
the	O
normalized	O
clozapine	O
concentrations	O
with	O
the	O
standard	O
deviations	O
of	O
15	O
.	O
68	O
and	O
6	O
.	O
65	O
ng	O
/	O
mL	O
for	O
the	O
low	O
CYP3A4	B
expressers	O
with	O
CYP3A5	B
*	O
3	O
/	O
*	O
3	O
genotype	O
and	O
the	O
rest	O
of	O
the	O
patients	O
,	O
respectively	O
.	O

The	O
2	O
models	O
for	O
prediction	O
of	O
clozapine	O
concentration	O
in	O
the	O
patients	O
expressing	O
CYP3A4	B
at	O
low	O
or	O
normal	O
/	O
high	O
levels	O
had	O
comparable	O
prediction	O
quality	O
and	O
were	O
found	O
to	O
be	O
applicable	O
for	O
prediction	O
of	O
optimal	O
dosing	O
.	O

The	O
models	O
proposed	O
significantly	O
lower	O
daily	O
dose	O
for	O
the	O
patients	O
expressing	O
CYP3A4	B
at	O
a	O
low	O
level	O
than	O
for	O
those	O
with	O
normal	O
/	O
high	O
CYP3A4	B
mRNA	O
levels	O
or	O
with	O
CYP3A5	B
*	O
1	O
/	O
*	O
3	O
genotype	O
(	O
the	O
dose	O
range	O
of	O
51	O
.	O
04	O
-	O
258	O
.	O
33	O
vs	O
227	O
.	O
39	O
-	O
586	O
.	O
38	O
mg	O
/	O
d	O
;	O
P	O
<	O
.	O
0001	O
)	O
,	O
whereas	O
the	O
actual	O
dosage	O
applied	O
for	O
low	O
and	O
normal	O
/	O
high	O
CYP3A4	B
expresser	O
patients	O
or	O
CYP3A5	B
expressers	O
was	O
identical	O
(	O
245	O
.	O
37158	O
.	O
88	O
vs	O
208	O
.	O
98120	O
.	O
69	O
mg	O
/	O
d	O
;	O
P	O
=	O
.	O
4166	O
)	O
.	O

Underdosing	O
occurred	O
more	O
frequently	O
,	O
primarily	O
in	O
the	O
patients	O
expressing	O
CYP3A4	B
at	O
a	O
normal	O
/	O
high	O
level	O
or	O
in	O
CYP3A5	B
expressers	O
.	O

Moreover	O
,	O
the	O
routine	O
dosing	O
regimen	O
appears	O
to	O
be	O
appropriate	O
for	O
the	O
patients	O
with	O
low	O
CYP3A4	B
mRNA	O
levels	O
rather	O
than	O
for	O
normal	O
/	O
high	O
expressers	O
.	O

Seven	O
of	O
the	O
24	O
low	O
expresser	O
patients	O
were	O
overdosed	O
,	O
whereas	O
the	O
clozapine	O
therapy	O
of	O
17	O
patients	O
(	O
71	O
%	O
)	O
in	O
the	O
low	O
CYP3A4	B
expresser	O
group	O
resulted	O
in	O
therapeutic	O
concentrations	O
of	O
clozapine	O
.	O

The	O
mathematical	O
model	O
displayed	O
clozapine	O
dosing	O
to	O
be	O
optimal	O
for	O
40	O
patients	O
in	O
the	O
normal	O
/	O
high	O
CYP3A4	B
expresser	O
and	O
CYP3A5	B
expresser	O
groups	O
(	O
n	O
=	O
68	O
)	O
,	O
whereas	O
41	O
%	O
were	O
underdosed	O
.	O

The	O
low	O
CYP3A4	B
expresser	O
patients	O
required	O
a	O
significantly	O
lower	O
(	O
50	O
%	O
)	O
dose	O
of	O
clozapine	O
for	O
the	O
optimal	O
serum	O
level	O
than	O
normal	O
/	O
high	O
CYP3A4	B
expressers	O
(	O
2	O
.	O
180	O
.	O
64	O
mg	O
/	O
kg	O
vs	O
4	O
.	O
981	O
.	O
40	O
mg	O
/	O
kg	O
;	O
P	O
<	O
.	O
0001	O
)	O
.	O

Several	O
CYPs	O
are	O
assumed	O
to	O
be	O
responsible	O
for	O
the	O
formation	O
of	O
norclozapine	O
,	O
while	O
CYP3A4	B
is	O
likely	O
to	O
catalyze	O
the	O
clozapine	O
N	O
-	O
oxidation	O
.	O

Strong	O
association	O
was	O
observed	O
between	O
the	O
metabolite	O
/	O
clozapine	O
ratios	O
and	O
CYP3A4	B
mRNA	O
levels	O
.	O

The	O
patients	O
who	O
expressed	O
CYP3A4	B
at	O
a	O
low	O
level	O
displayed	O
significantly	O
lower	O
norclozapine	O
/	O
clozapine	O
ratios	O
than	O
the	O
CYP3A4	B
normal	O
/	O
high	O
expressers	O
or	O
those	O
who	O
carry	O
CYP3A5	B
*	O
1	O
(	O
0	O
.	O
55210	O
.	O
1535	O
vs	O
0	O
.	O
76550	O
.	O
2088	O
;	O
P	O
<	O
.	O
0001	O
)	O
.	O

Furthermore	O
,	O
significantly	O
lower	O
clozapine	O
N	O
-	O
oxide	O
/	O
clozapine	O
ratios	O
were	O
observed	O
in	O
the	O
patients	O
displaying	O
low	O
CYP3A4	B
expression	O
than	O
in	O
CYP3A4	B
normal	O
/	O
high	O
expressers	O
(	O
0	O
.	O
22790	O
.	O
0887	O
vs	O
0	O
.	O
56590	O
.	O
1960	O
,	O
P	O
<	O
.	O
0001	O
)	O
.	O

The	O
strong	O
association	O
between	O
the	O
patients	O
CYP3A	B
status	O
and	O
the	O
serum	O
clozapine	O
concentrations	O
or	O
the	O
metabolite	O
/	O
clozapine	O
ratios	O
demonstrated	O
the	O
potential	O
role	O
of	O
CYP3A	B
enzymes	O
in	O
clozapine	O
clearance	O
.	O

The	O
following	O
indirect	O
evidences	O
can	O
predict	O
the	O
potential	O
role	O
of	O
CYP3A4	B
:	O
(	O
1	O
)	O
clozapine	O
N	O
-	O
demethylation	O
to	O
norclozapine	O
significantly	O
correlated	O
with	O
CYP3A4	B
-	O
selective	O
midazolam	O
clearance	O
;	O
(	O
2	O
)	O
concomitant	O
treatment	O
with	O
CYP3A4	B
inducers	O
,	O
such	O
as	O
carbamazepine	O
,	O
rifampicin	O
,	O
or	O
phenytoin	O
,	O
was	O
observed	O
to	O
substantially	O
reduce	O
clozapine	O
concentrations	O
;	O
and	O
(	O
3	O
)	O
initiation	O
of	O
the	O
CYP3A4	B
inhibitor	O
erythromycin	O
therapy	O
increased	O
clozapine	O
levels	O
and	O
evoked	O
toxic	O
symptoms	O
.	O

Therefore	O
,	O
the	O
relative	O
CYP	O
activities	O
predicted	O
the	O
potential	O
role	O
of	O
CYP3A4	B
/	O
5	O
in	O
clozapine	O
clearance	O
,	O
which	O
was	O
confirmed	O
by	O
the	O
2	O
-	O
fold	O
higher	O
normalized	O
clozapine	O
concentrations	O
and	O
by	O
the	O
halved	O
dose	O
-	O
requirement	O
in	O
low	O
CYP3A4	B
expressers	O
.	O

Valproate	O
has	O
been	O
proved	O
to	O
transcriptionally	O
induce	O
CYP3A4	B
expression	O
;	O
consequently	O
,	O
the	O
patients	O
CYP3A4	B
mRNA	O
levels	O
captured	O
the	O
influence	O
of	O
valproate	O
treatment	O
.	O

Additionally	O
,	O
the	O
normal	O
/	O
high	O
CYP3A4	B
activity	O
was	O
associated	O
with	O
increased	O
metabolite	O
formation	O
,	O
that	O
is	O
,	O
the	O
concentrations	O
of	O
norclozapine	O
and	O
clozapine	O
N	O
-	O
oxide	O
were	O
close	O
to	O
or	O
even	O
exceeded	O
clozapine	O
concentrations	O
.	O

For	O
achieving	O
the	O
therapeutic	O
concentration	O
,	O
twice	O
as	O
high	O
a	O
dose	O
was	O
necessary	O
for	O
the	O
normal	O
/	O
high	O
CYP3A4	B
expressers	O
and	O
CYP3A5	B
*	O
1	O
carriers	O
than	O
for	O
low	O
CYP3A4	B
expressers	O
.	O

Tailored	O
medication	O
controlled	O
by	O
patients	O
CYP3A4	B
expression	O
and	O
CYP3A5	B
genotype	O
may	O
facilitate	O
the	O
improvement	O
of	O
the	O
individual	O
clozapine	O
therapy	O
,	O
leading	O
to	O
the	O
dosage	O
optimization	O
for	O
a	O
more	O
effective	O
therapy	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
the	O
design	O
and	O
evaluation	O
of	O
bio	O
-	O
compatible	O
nanocarriers	O
trapping	O
a	O
natural	O
CYP3A4	B
-	O
inhibiting	O
compound	O
.	O

Our	O
aim	O
in	O
using	O
nanocarriers	O
was	O
to	O
target	O
the	O
natural	O
CYP3A4	B
-	O
inhibiting	O
agent	O
to	O
hepatic	O
Cytochrome	B
P450	I
3a4	I
and	O
leave	O
drug	O
-	O
metabolizing	O
enzymes	O
in	O
other	O
organs	O
undisturbed	O
.	O

In	O
parallel	O
,	O
these	O
nanocarriers	O
,	O
loaded	O
with	O
bergamottin	O
,	O
a	O
natural	O
CYP3A4	B
-	O
inhibiting	O
agent	O
,	O
-	O
were	O
tested	O
for	O
their	O
ability	O
to	O
interact	O
with	O
hepatocytes	O
in	O
vitro	O
,	O
modulate	O
Cytochrome	B
P450	I
3a4	I
activity	O
and	O
increase	O
the	O
antitumor	O
efficacy	O
of	O
docetaxel	O
.	O

Half	O
-	O
maximal	O
inhibitory	O
concentration	O
(	O
IC_50	O
)	O
was	O
determined	O
on	O
CYP3A4	B
-	O
expressing	O
HepaRG	O
cells	O
,	O
after	O
incubation	O
of	O
the	O
fluorogenic	O
substrate	O
DBOMF	O
,	O
specific	O
for	O
Cytochrome	B
P450	I
3a4	I
.	O

Even	O
though	O
PLGA	O
-	O
Ga	O
reach	O
the	O
hepatocytes	O
very	O
rapidly	O
,	O
Bergamottin	O
is	O
a	O
suicide	O
inhibitor	O
of	O
CYP3A4	B
:	O
its	O
inhibition	O
lasts	O
until	O
the	O
neosynthesis	O
of	O
Cytochrome	B
P450	I
3a4	I
proteins	O
,	O
so	O
for	O
at	O
least	O
24	O
hours	O
.	O

This	O
search	O
provided	O
further	O
details	O
on	O
other	O
sildenafil	O
-	O
related	O
compounds	O
:	O
primary	O
metabolite	O
(	O
N	O
-	O
desmethylsildenafil	O
)	O
,	O
drug	O
-	O
drug	O
interactions	O
with	O
CYP3A4	B
inhibitors	O
(	O
eg	O
ketoconazole	O
,	O
itraconazole	O
,	O
ritonavir	O
and	O
indinavir	O
)	O
and	O
other	O
PDE5	O
inhibitors	O
(	O
vardenafil	O
)	O
.	O

The	O
main	O
Gr	O
-	O
drug	O
interaction	O
mechanism	O
is	O
inactivation	O
of	O
the	O
enzyme	O
CYP3A4	B
by	O
furanocoumarins	O
.	O

CYP3A4	B
enzyme	O
participates	O
in	O
the	O
inactivation	O
of	O
various	O
drugs	O
;	O
it	O
is	O
located	O
in	O
the	O
intestinal	O
epithelium	O
and	O
the	O
liver	O
.	O

The	O
interacting	O
drugs	O
are	O
generally	O
characterized	O
by	O
the	O
oral	O
intake	O
,	O
low	O
to	O
intermediate	O
bioavailability	O
,	O
and	O
inactivation	O
by	O
the	O
CYP3A4	B
enzyme	O
.	O

Patients	O
with	O
higher	O
levels	O
of	O
CYP3A4	B
determined	O
in	O
intestinal	O
biopsies	O
may	O
require	O
higher	O
doses	O
of	O
corresponding	O
drugs	O
,	O
the	O
size	O
of	O
the	O
Gr	O
effect	O
being	O
generally	O
higher	O
in	O
such	O
patients	O
.	O

Artemether	O
is	O
an	O
effective	O
medication	O
against	O
malaria	O
;	O
however	O
,	O
relapses	O
may	O
occur	O
presumably	O
as	O
a	O
result	O
of	O
the	O
drug	O
metabolism	O
by	O
CYP3A4	B
.	O

Here	O
,	O
we	O
investigated	O
the	O
efficiencies	O
of	O
human	O
hepatic	O
microsomes	O
and	O
human	O
recombinant	O
CYP3A4	B
expressed	O
with	O
its	O
reductase	O
,	O
NADPH	O
:	O
CYP	O
oxidoreductase	O
(	O
POR	O
)	O
,	O
NADH	O
:	O
cytochrome	B
b	I
5	I
reductase	O
and	O
/	O
or	O
cytochrome	B
b	I
5	I
in	O
Supersomes	O
to	O
oxidize	O
this	O
drug	O
.	O

Using	O
HPLC	O
analysis	O
we	O
detected	O
up	O
to	O
five	O
ellipticine	O
metabolites	O
,	O
which	O
were	O
formed	O
by	O
human	O
hepatic	O
microsomes	O
and	O
human	O
CYP3A4	B
in	O
the	O
presence	O
of	O
NADPH	O
or	O
NADH	O
.	O

Human	O
CYP3A4	B
in	O
Supersomes	O
generated	O
only	O
three	O
metabolic	O
products	O
,	O
9	O
-	O
hydroxy	O
-	O
,	O
12	O
-	O
hydroxy	O
-	O
,	O
and	O
13	O
-	O
hydroxyellipticine	O
.	O

Using	O
the	O
32P	O
-	O
postlabeling	O
method	O
two	O
ellipticine	O
-	O
derived	O
DNA	O
adducts	O
were	O
generated	O
by	O
microsomes	O
and	O
the	O
CYP3A4	B
-	O
Supersome	O
system	O
,	O
both	O
in	O
the	O
presence	O
of	O
NADPH	O
and	O
NADH	O
.	O

In	O
the	O
presence	O
of	O
NADPH	O
or	O
NADH	O
,	O
cytochrome	B
b	I
5	I
stimulated	O
the	O
CYP3A4	B
-	O
mediated	O
oxidation	O
of	O
ellipticine	O
,	O
but	O
the	O
stimulation	O
effect	O
differed	O
for	O
individual	O
ellipticine	O
metabolites	O
.	O

The	O
results	O
demonstrate	O
that	O
cytochrome	B
b	I
5	I
plays	O
a	O
dual	O
role	O
in	O
the	O
CYP3A4	B
-	O
catalyzed	O
oxidation	O
of	O
ellipticine	O
:	O
(	O
1	O
)	O
cytochrome	B
b	I
5	I
mediates	O
CYP3A4	B
catalytic	O
activities	O
by	O
donating	O
the	O
first	O
and	O
second	O
electron	O
to	O
this	O
enzyme	O
in	O
its	O
catalytic	O
cycle	O
,	O
indicating	O
that	O
NADH	O
:	O
cytochrome	B
b	I
5	I
reductase	O
can	O
substitute	O
NADPH	O
-	O
dependent	O
POR	O
in	O
this	O
enzymatic	O
reaction	O
and	O
(	O
2	O
)	O
cytochrome	B
b	I
5	I
can	O
act	O
as	O
an	O
allosteric	O
modifier	O
of	O
the	O
CYP3A4	B
oxygenase	O
.	O

Of	O
the	O
CYP	O
enzymes	O
investigated	O
,	O
human	O
CYP3A4	B
is	O
the	O
most	O
active	O
enzyme	O
oxidizing	O
ellipticine	O
to	O
12	O
-	O
hydroxy	O
-	O
and	O
13	O
-	O
hydroxyellipticine	O
,	O
reactive	O
metabolites	O
that	O
dissociate	O
to	O
ellipticine	O
-	O
12	O
-	O
ylium	O
and	O
ellipticine	O
-	O
13	O
-	O
ylium	O
and	O
bind	O
to	O
DNA	O
(	O
see	O
Fig	O
)	O
[	O
,	O
.	O

The	O
CYP3A4	B
isoform	O
also	O
forms	O
other	O
ellipticine	O
metabolites	O
,	O
including	O
9	O
-	O
hydroxyellipticine	O
,	O
which	O
is	O
a	O
detoxification	O
product	O
,	O
as	O
well	O
as	O
7	O
-	O
hydroxyellipticine	O
and	O
ellipticine	O
N	O
^	O
2	O
-	O
oxide	O
as	O
minor	O
metabolites	O
[	O
,	O
.	O

CYP	O
enzymes	O
,	O
including	O
CYP3A4	B
,	O
are	O
components	O
of	O
the	O
monooxygenase	O
system	O
located	O
in	O
the	O
membrane	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
microsomes	O
)	O
.	O

Cytochrome	O
b	O
_5	O
has	O
been	O
reported	O
to	O
stimulate	O
the	O
oxidation	O
of	O
a	O
variety	O
of	O
CYP3A4	B
substrates	O
,	O
including	O
ellipticine	O
.	O

Interestingly	O
,	O
in	O
the	O
case	O
of	O
ellipticine	O
,	O
cytochrome	B
b	I
_5	I
,	O
when	O
reconstituted	O
with	O
CYP3A4	B
and	O
POR	O
,	O
alters	O
the	O
ratio	O
of	O
ellipticine	O
metabolites	O
formed	O
by	O
this	O
CYP	O
.	O

Hence	O
,	O
cytochrome	B
b	I
_5	I
seems	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
CYP3A4	B
-	O
mediated	O
DNA	O
-	O
damage	O
caused	O
by	O
these	O
ellipticine	O
metabolites	O
[	O
,	O
.	O

CYP3A4	B
-	O
mediated	O
oxidation	O
of	O
ellipticine	O
was	O
significantly	O
changed	O
only	O
by	O
holo	O
-	O
cytochrome	B
b	I
_5	I
containing	O
heme	O
,	O
while	O
neither	O
apo	O
-	O
cytochrome	B
b	I
_5	I
without	O
heme	O
or	O
Mn	O
-	O
cytochrome	B
b	I
_5	I
had	O
such	O
an	O
effect	O
.	O

Results	O
found	O
by	O
Guengerich	O
and	O
his	O
coworkers	O
demonstrated	O
that	O
cytochrome	B
b	I
_5	I
added	O
to	O
recombinant	O
CYP3A4	B
reconstituted	O
with	O
POR	O
enhanced	O
CYP3A4	B
marker	O
activity	O
,	O
testosterone	O
6	O
-	O
BETA	O
-	O
hydroxylation	O
.	O

They	O
also	O
showed	O
that	O
this	O
heme	O
protein	O
with	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
and	O
NADH	O
might	O
even	O
substitute	O
the	O
POR	O
/	O
NADPH	O
system	O
in	O
the	O
CYP3A4	B
catalysis	O
of	O
this	O
marker	O
reaction	O
.	O

Here	O
,	O
we	O
investigated	O
in	O
detail	O
,	O
whether	O
the	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
/	O
cytochrome	B
b	I
_5	I
/	O
NADH	O
system	O
can	O
also	O
be	O
the	O
sole	O
electron	O
donor	O
in	O
the	O
CYP3A4	B
-	O
catalyzed	O
oxidation	O
of	O
ellipticine	O
,	O
Another	O
aim	O
of	O
this	O
work	O
was	O
to	O
shed	O
more	O
light	O
on	O
the	O
further	O
functions	O
of	O
cytochrome	B
b	I
_5	I
in	O
this	O
CYP3A4	B
-	O
mediated	O
reaction	O
.	O

Three	O
enzymatic	O
systems	O
were	O
utilized	O
for	O
such	O
a	O
study	O
:	O
(	O
i	O
)	O
human	O
hepatic	O
microsomes	O
,	O
(	O
ii	O
)	O
microsomes	O
of	O
baculovirus	O
-	O
infected	O
insect	O
cells	O
(	O
Supersomes	O
)	O
containing	O
over	O
-	O
expressed	O
amounts	O
of	O
human	O
recombinant	O
CYP3A4	B
and	O
POR	O
,	O
as	O
well	O
as	O
the	O
basal	O
levels	O
of	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
and	O
cytochrome	B
b	I
_5	I
,	O
and	O
(	O
iii	O
)	O
the	O
analogous	O
Supersomes	O
,	O
but	O
also	O
containing	O
over	O
-	O
expressed	O
cytochrome	B
b	I
_5	I
,	O
at	O
a	O
molar	O
ratio	O
of	O
CYP3A4	B
to	O
cytochrome	B
b	I
_5	I
of	O
1	O
:	O
5	O
.	O

Here	O
,	O
we	O
show	O
that	O
three	O
of	O
these	O
metabolites	O
are	O
also	O
formed	O
in	O
human	O
hepatic	O
microsomes	O
in	O
the	O
presence	O
of	O
NADH	O
instead	O
of	O
NADPH	O
were	O
found	O
when	O
NADPH	O
or	O
NADH	O
was	O
omitted	O
from	O
the	O
incubation	O
mixtures	O
containing	O
human	O
hepatic	O
microsomes	O
and	O
(	O
iii	O
)	O
]	O
for	O
our	O
experiments	O
,	O
we	O
first	O
tested	O
whether	O
they	O
are	O
functionally	O
active	O
by	O
testing	O
the	O
CYP3A4	B
marker	O
activity	O
,	O
testosterone	O
6	O
-	O
BETA	O
-	O
hydroxylation	O
.	O

Our	O
results	O
showed	O
that	O
the	O
Supersomal	O
CYP3A4	B
systems	O
are	O
capable	O
of	O
catalyzing	O
this	O
marker	O
reaction	O
,	O
both	O
in	O
the	O
presence	O
of	O
NADPH	O
and	O
NADH	O
,	O
and	O
cytochrome	B
b	I
_5	I
stimulated	O
this	O
reaction	O
enormously	O
where	O
cytochrome	B
b	I
_5	I
was	O
over	O
-	O
expressed	O
with	O
CYP3A4	B
and	O
POR	O
at	O
a	O
molar	O
ratio	O
of	O
CYP3A4	B
:	O
cytochrome	B
b	I
_5	I
of	O
1	O
:	O
5	O
already	O
in	O
the	O
cells	O
from	O
which	O
CYP3A4	B
-	O
Supersomes	O
(	O
microsomes	O
)	O
were	O
isolated	O
.	O

This	O
finding	O
indicated	O
that	O
this	O
heme	O
protein	O
does	O
not	O
only	O
influence	O
the	O
transfer	O
of	O
electrons	O
during	O
the	O
second	O
reduction	O
of	O
CYP3A4	B
,	O
but	O
that	O
cytochrome	B
b	I
_5	I
can	O
also	O
induce	O
changes	O
in	O
the	O
conformation	O
of	O
the	O
CYP3A4	B
protein	O
,	O
leading	O
to	O
an	O
altered	O
profile	O
of	O
ellipticine	O
metabolites	O
.	O

Indeed	O
,	O
our	O
previous	O
studies	O
have	O
indicated	O
a	O
high	O
specificity	O
of	O
interaction	O
of	O
CYP3A4	B
with	O
holo	O
-	O
cytochrome	B
b	I
_5	I
containing	O
heme	O
,	O
which	O
is	O
necessary	O
not	O
only	O
for	O
electron	O
transfer	O
but	O
also	O
for	O
the	O
natural	O
conformation	O
of	O
the	O
cytochrome	B
b	I
_5	I
and	O
CYP3A4	B
proteins	O
.	O

One	O
reason	O
might	O
be	O
that	O
the	O
co	O
-	O
expression	O
of	O
the	O
CYP3A4	B
and	O
cytochrome	B
b	I
_5	I
proteins	O
from	O
their	O
cDNA	O
into	O
the	O
membrane	O
of	O
endoplasmic	O
reticulum	O
may	O
produce	O
protein	O
molecules	O
in	O
conformation	O
states	O
that	O
are	O
different	O
from	O
those	O
generated	O
after	O
the	O
reconstitution	O
of	O
cytochrome	B
b	I
_5	I
with	O
CYP3A4	B
in	O
Supersomes	O
,	O
thus	O
leading	O
to	O
different	O
enzymatic	O
activity	O
of	O
the	O
monooxygenase	O
system	O
.	O

In	O
the	O
presence	O
of	O
NADH	O
,	O
cytochrome	B
b	I
_5	I
over	O
-	O
expressed	O
in	O
CYP3A4	B
-	O
Supersomes	O
also	O
enhanced	O
ellipticine	O
oxidation	O
to	O
individual	O
metabolites	O
,	O
but	O
to	O
different	O
degrees	O
;	O
9	O
-	O
hydroxyelliptice	O
by	O
11	O
-	O
fold	O
,	O
12	O
-	O
hydroxyellipticine	O
by	O
1	O
.	O
3	O
-	O
fold	O
,	O
and	O
13	O
-	O
hydroxyellipticine	O
by	O
6	O
.	O
5	O
-	O
fold	O
,	O
which	O
led	O
to	O
the	O
formation	O
of	O
an	O
altered	O
pattern	O
of	O
ellipticine	O
metabolites	O
compared	O
to	O
basal	O
levels	O
without	O
over	O
-	O
expressed	O
cytochrome	B
b	I
_5	I
(	O
Fig	O
.	O

This	O
finding	O
demonstrated	O
that	O
cytochrome	B
b	I
_5	I
influences	O
the	O
CYP3A4	B
catalytic	O
activity	O
in	O
at	O
least	O
two	O
ways	O
.	O

First	O
,	O
this	O
heme	O
protein	O
can	O
mediate	O
CYP3A4	B
enzyme	O
activity	O
even	O
in	O
the	O
absence	O
of	O
the	O
NADPH	O
/	O
POR	O
system	O
,	O
by	O
donating	O
both	O
the	O
first	O
and	O
second	O
electron	O
from	O
NADH	O
to	O
CY3A4	O
in	O
the	O
catalytic	O
cycle	O
.	O

This	O
again	O
indicates	O
that	O
the	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
as	O
an	O
NADH	O
-	O
dependent	O
reductase	O
can	O
substitute	O
POR	O
in	O
this	O
enzymatic	O
reaction	O
and	O
that	O
the	O
NADH	O
/	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
/	O
cytochrome	B
b	I
_5	I
system	O
might	O
act	O
as	O
an	O
exclusive	O
donor	O
of	O
electrons	O
for	O
this	O
CYP3A4	B
-	O
mediated	O
ellipticine	O
oxidation	O
independent	O
of	O
NADPH	O
and	O
POR	O
.	O

Second	O
,	O
cytochrome	B
b	I
_5	I
can	O
also	O
induce	O
changes	O
in	O
the	O
conformation	O
of	O
the	O
CYP3A4	B
protein	O
,	O
resulting	O
in	O
changes	O
in	O
profile	O
of	O
ellipticine	O
metabolite	O
formation	O
.	O

In	O
further	O
experiments	O
,	O
DNA	O
adduct	O
formation	O
was	O
analyzed	O
in	O
incubations	O
with	O
ellipticine	O
and	O
human	O
hepatic	O
microsomes	O
or	O
human	O
CYP3A4	B
in	O
Supersomes	O
in	O
the	O
presence	O
of	O
DNA	O
.	O

Two	O
DNA	O
adducts	O
were	O
detected	O
by	O
the	O
^	O
32P	O
-	O
postlabeling	O
method	O
derived	O
from	O
ellipticine	O
activated	O
with	O
human	O
hepatic	O
microsomes	O
or	O
CYP3A4	B
-	O
Supersomes	O
,	O
both	O
in	O
the	O
presence	O
of	O
NADPH	O
and	O
NADH	O
was	O
previously	O
shown	O
to	O
be	O
generated	O
by	O
the	O
reaction	O
of	O
guanine	O
in	O
DNA	O
with	O
ellipticine	O
-	O
13	O
-	O
ylium	O
which	O
is	O
formed	O
by	O
the	O
decomposition	O
of	O
13	O
-	O
hydroxyellipticine	O
was	O
previously	O
shown	O
to	O
be	O
generated	O
by	O
reaction	O
of	O
guanine	O
in	O
DNA	O
with	O
ellipticine	O
-	O
12	O
-	O
ylium	O
formed	O
from	O
12	O
-	O
hydroxyellipticine	O
and	O
tumor	O
tissues	O
in	O
vivo	O
.	O

The	O
levels	O
of	O
ellipticine	O
-	O
derived	O
adduct	O
1	O
(	O
formed	O
predominantly	O
by	O
CYP3A4	B
)	O
generated	O
in	O
human	O
microsomes	O
were	O
2	O
.	O
8	O
-	O
fold	O
lower	O
with	O
NADH	O
than	O
with	O
NADPH	O
as	O
the	O
cofactor	O
,	O
which	O
is	O
in	O
agreement	O
with	O
a	O
2	O
.	O
6	O
-	O
fold	O
lower	O
efficiency	O
of	O
ellipticine	O
oxidation	O
to	O
13	O
-	O
hydroxyellipticine	O
by	O
human	O
microsomes	O
in	O
the	O
presence	O
of	O
NADH	O
,	O
indicating	O
that	O
adduct	O
2	O
might	O
be	O
also	O
formed	O
by	O
autooxidation	O
as	O
reported	O
previously	O
[	O
,	O
.	O

With	O
human	O
recombinant	O
CYP3A4	B
expressed	O
in	O
Supersomes	O
the	O
adducts	O
formed	O
were	O
the	O
same	O
as	O
those	O
generated	O
by	O
human	O
hepatic	O
microsomes	O
,	O
both	O
in	O
the	O
presence	O
of	O
NADPH	O
and	O
NADH	O
.	O

When	O
NADPH	O
or	O
NADH	O
was	O
omitted	O
from	O
the	O
incubation	O
mixtures	O
containing	O
CYP3A4	B
-	O
Supersomes	O
,	O
only	O
low	O
amounts	O
of	O
adduct	O
spot	O
2	O
were	O
detected	O
(	O
Fig	O
.	O

In	O
accordance	O
with	O
an	O
increase	O
in	O
ellipticine	O
oxidation	O
catalyzed	O
by	O
CYP3A4	B
-	O
Supersomes	O
with	O
over	O
-	O
expressed	O
cytochrome	B
b	I
_5	I
,	O
shown	O
in	O
Fig	O
,	O
the	O
presence	O
of	O
this	O
heme	O
protein	O
in	O
the	O
CYP3A4	B
system	O
led	O
to	O
higher	O
levels	O
of	O
ellipticine	O
-	O
derived	O
DNA	O
adducts	O
,	O
both	O
in	O
the	O
presence	O
of	O
NADPH	O
and	O
NADH	O
(	O
Fig	O
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
advance	O
our	O
knowledge	O
regarding	O
the	O
role	O
of	O
cytochrome	B
b	I
_5	I
in	O
the	O
reaction	O
cycle	O
of	O
CYP3A4	B
catalyzing	O
the	O
oxidation	O
of	O
the	O
anticancer	O
drug	O
ellipticine	O
.	O

We	O
found	O
that	O
oxidation	O
of	O
ellipticine	O
by	O
human	O
CYP3A4	B
in	O
the	O
natural	O
microsomal	O
system	O
of	O
human	O
liver	O
or	O
in	O
Supersomes	O
,	O
where	O
the	O
reductases	O
POR	O
and	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
and	O
cytochrome	B
b	I
_5	I
are	O
expressed	O
,	O
is	O
enhanced	O
by	O
cytochrome	B
b	I
_5	I
.	O

These	O
findings	O
demonstrated	O
that	O
cytochrome	B
b	I
_5	I
is	O
included	O
in	O
the	O
reduction	O
of	O
CYP3A4	B
catalyzed	O
both	O
by	O
the	O
NADPH	O
/	O
POR	O
system	O
and	O
a	O
system	O
consisting	O
exclusively	O
of	O
NADH	O
,	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
and	O
cytochrome	B
b	I
_5	I
,	O
and	O
thus	O
also	O
without	O
any	O
participation	O
of	O
NADPH	O
and	O
POR	O
.	O

Here	O
,	O
we	O
showed	O
that	O
if	O
NADPH	O
is	O
substituted	O
by	O
NADH	O
,	O
ellipticine	O
oxidation	O
is	O
catalyzed	O
by	O
experimental	O
CYP3A4	B
enzymatic	O
systems	O
.	O

Such	O
NADH	O
-	O
mediated	O
activity	O
of	O
the	O
employed	O
CYP3A4	B
systems	O
was	O
proven	O
by	O
the	O
formation	O
of	O
oxidized	O
ellipticine	O
metabolites	O
as	O
well	O
as	O
by	O
the	O
generation	O
of	O
ellipticine	O
-	O
derived	O
DNA	O
adducts	O
,	O
which	O
were	O
the	O
same	O
as	O
in	O
the	O
system	O
where	O
NADPH	O
was	O
used	O
as	O
electron	O
donor	O
.	O

The	O
results	O
of	O
our	O
present	O
study	O
as	O
well	O
as	O
those	O
reported	O
previously	O
indicated	O
that	O
cytochrome	B
b	I
_5	O
can	O
play	O
a	O
dual	O
role	O
in	O
the	O
CYP3A4	B
-	O
mediated	O
oxidation	O
of	O
ellipticine	O
.	O

Specifically	O
,	O
as	O
shown	O
here	O
,	O
(	O
i	O
)	O
it	O
acts	O
as	O
a	O
sole	O
electron	O
donor	O
to	O
CYP3A4	B
during	O
its	O
reaction	O
cycle	O
and	O
(	O
ii	O
)	O
it	O
can	O
also	O
act	O
as	O
an	O
allosteric	O
modifier	O
of	O
CYP3A4	B
oxygenase	O
.	O

The	O
finding	O
that	O
cytochrome	B
b	I
_5	O
with	O
its	O
reductase	O
,	O
NADH	O
:	O
cytochrome	B
b	I
_5	O
reductase	O
,	O
functions	O
as	O
an	O
exclusive	O
donor	O
for	O
both	O
electrons	O
in	O
the	O
first	O
and	O
second	O
reduction	O
steps	O
of	O
the	O
CYP3A4	B
-	O
catalyzed	O
oxidation	O
of	O
ellipticine	O
opens	O
the	O
door	O
for	O
further	O
research	O
.	O

CYP3A4	B
-	O
Supersomes	O
,	O
microsomes	O
isolated	O
from	O
insect	O
cells	O
transfected	O
with	O
a	O
baculovirus	O
construct	O
containing	O
cDNA	O
of	O
human	O
CYP3A4	B
and	O
POR	O
that	O
are	O
,	O
therefore	O
,	O
over	O
-	O
expressed	O
in	O
these	O
microsomes	O
,	O
were	O
purchased	O
from	O
the	O
Gentest	O
Corp	O
.	O

We	O
also	O
utilized	O
CYP3A4	B
-	O
Supersomes	O
which	O
also	O
contained	O
over	O
-	O
expressed	O
cytochrome	B
b	I
_5	O
,	O
in	O
a	O
molar	O
ratio	O
of	O
CYP3A4	B
to	O
cytochrome	B
b	I
_5	O
of	O
1	O
-	O
5	O
(	O
Gentest	O
Corp	O
.	O
,	O
Woburn	O
,	O
MI	O
,	O
USA	O
)	O
.	O

Incubation	O
mixtures	O
used	O
to	O
study	O
the	O
ellipticine	O
metabolism	O
by	O
human	O
hepatic	O
microsomes	O
or	O
Supersomes	O
contained	O
in	O
a	O
final	O
volume	O
of	O
0	O
.	O
5	O
cm	O
^	O
3	O
100	O
mmol	O
dm	O
^	O
3	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
mmol	O
dm	O
^	O
3	O
NADPH	O
or	O
NADH	O
,	O
0	O
.	O
025	O
mmol	O
dm	O
^	O
3	O
ellipticine	O
(	O
dissolved	O
in	O
0	O
.	O
005	O
cm	O
^	O
3	O
dimethyl	O
sulfoxide	O
,	O
DMSO	O
)	O
and	O
0	O
.	O
5	O
mg	O
protein	O
of	O
human	O
hepatic	O
microsomes	O
or	O
100	O
nmol	O
dm	O
^	O
3	O
human	O
recombinant	O
CYP3A4	B
in	O
Supersomes	O
either	O
with	O
or	O
without	O
cytochrome	B
b	I
_5	O
.	O

The	O
incubation	O
mixtures	O
for	O
measuring	O
the	O
testosterone	O
metabolism	O
contained	O
in	O
a	O
final	O
volume	O
of	O
0	O
.	O
5	O
cm	O
^	O
3	O
:	O
100	O
mmol	O
dm	O
^	O
3	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
50	O
mol	O
dm	O
^	O
3	O
testosterone	O
(	O
0	O
.	O
0025	O
cm	O
^	O
3	O
of	O
stock	O
methanol	O
solution	O
per	O
incubation	O
)	O
,	O
1	O
mmol	O
dm	O
^	O
3	O
NADPH	O
or	O
NADH	O
,	O
and	O
100	O
nmol	O
dm	O
^	O
3	O
human	O
recombinant	O
CYP3A4	B
in	O
Supersomes	O
either	O
with	O
or	O
without	O
cytochrome	B
b	I
_5	O
.	O

Negative	O
control	O
reactions	O
lacked	O
either	O
CYP3A4	B
-	O
Supersomes	O
systems	O
,	O
cofactors	O
or	O
testosterone	O
.	O

Incubation	O
mixtures	O
used	O
to	O
assess	O
DNA	O
adduct	O
formation	O
by	O
ellipticine	O
contained	O
0	O
.	O
5	O
mg	O
protein	O
of	O
human	O
hepatic	O
microsomes	O
or	O
100	O
nmol	O
dm	O
^	O
3	O
human	O
recombinant	O
CYP3A4	B
in	O
Supersomes	O
either	O
with	O
or	O
without	O
cytochrome	B
b	I
_5	O
,	O
0	O
.	O
1	O
mmol	O
dm	O
^	O
3	O
ellipticine	O
(	O
dissolved	O
in	O
0	O
.	O
0075	O
cm	O
^	O
3	O
methanol	O
)	O
,	O
and	O
0	O
.	O
5	O
mg	O
of	O
calf	O
thymus	O
DNA	O
in	O
a	O
final	O
volume	O
of	O
0	O
.	O
75	O
cm	O
^	O
3	O
as	O
described	O
previously	O
[	O
,	O
.	O

Control	O
incubations	O
were	O
carried	O
out	O
either	O
without	O
human	O
hepatic	O
microsomes	O
or	O
CYP3A4	B
in	O
Supersomes	O
without	O
NADPH	O
(	O
or	O
NADH	O
)	O
,	O
without	O
DNA	O
,	O
or	O
without	O
ellipticine	O
.	O

Assessment	O
of	O
the	O
inhibitory	O
effect	O
of	O
clarithromycin	O
on	O
CYP3A4	B
in	O
three	O
TC	O
-	O
HepG2	O
cells	O
indicated	O
that	O
there	O
was	O
a	O
concentration	O
-	O
dependent	O
inhibitory	O
effect	O
on	O
metabolic	O
activity	O
.	O

Specifically	O
,	O
increasing	O
concentrations	O
of	O
the	O
inhibitors	O
(	O
0	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
40	O
,	O
or	O
100	O
M	O
)	O
were	O
added	O
10	O
,	O
20	O
,	O
or	O
30	O
min	O
prior	O
to	O
the	O
addition	O
of	O
the	O
luminescent	O
CYP3A4	B
substrate	O
,	O
and	O
the	O
luminescence	O
levels	O
in	O
culture	O
media	O
were	O
used	O
to	O
determine	O
metabolite	O
levels	O
.	O

Further	O
,	O
because	O
the	O
CYP3A4	B
activity	O
level	O
in	O
TC	O
-	O
HepG2	O
cells	O
was	O
higher	O
than	O
that	O
in	O
human	O
hepatocytes	O
,	O
the	O
rate	O
of	O
metabolic	O
reduction	O
by	O
the	O
inhibitors	O
may	O
be	O
detected	O
with	O
high	O
sensitivity	O
.	O

Both	O
aflatoxin	O
B1	O
and	O
sterigmatocystin	O
convert	O
to	O
active	O
metabolites	O
via	O
CYP3A4	B
and	O
exert	O
hepatotoxicity	O
through	O
DNA	O
damage	O
[	O
,	O
.	O

The	O
aflatoxin	O
B1	O
forms	O
DNA	O
adduct	O
as	O
a	O
result	O
of	O
metabolic	O
activation	O
induced	O
mainly	O
by	O
CYP3A4	B
.	O

Similar	O
findings	O
have	O
been	O
demonstrated	O
for	O
milk	O
thistle	O
,	O
where	O
in	O
vitro	O
CYP3A4	B
inhibition	O
by	O
its	O
constituents	O
silymarin	O
and	O
silibinin	O
produced	O
IC_50	O
values	O
ranging	O
from	O
27	O
to	O
60	O
mol	O
/	O
L	O
.	O

examined	O
whether	O
the	O
concentration	O
of	O
the	O
supposed	O
bioactive	O
constituents	O
could	O
be	O
correlated	O
with	O
CYP3A4	B
enzyme	O
inhibition	O
,	O
but	O
with	O
no	O
significant	O
findings	O
.	O

For	O
example	O
,	O
different	O
probe	O
substrates	O
could	O
result	O
in	O
different	O
observations	O
in	O
CYP3A4	B
activities	O
due	O
to	O
different	O
substrate	O
binding	O
sites	O
.	O

The	O
activity	O
of	O
7	O
-	O
benzyloxy	O
-	O
4trifluoromethylcoumarin	O
dealkylation	O
is	O
the	O
diagnostic	O
marker	O
of	O
CYP3A4	B
.	O

The	O
activity	O
of	O
CYP3A4	B
was	O
determined	O
by	O
fluorescence	O
value	O
of	O
7	O
-	O
Hydroxy	O
-	O
4	O
-	O
Trifluoromethylcoumarin	O
conversed	O
from	O
7	O
-	O
benzyloxy	O
-	O
4	O
-	O
trifluoromethyl	O
-	O
coumarin	O
by	O
7	O
-	O
Benzyloxy	O
-	O
4trifluoromethylcoumarin	O
Dealkylation	O
.	O

Functional	O
assessment	O
of	O
CYP3A4	B
allelic	O
variants	O
on	O
lidocaine	O
metabolism	O
in	O
vitro	O
.	O

So	O
far	O
,	O
there	O
are	O
few	O
reports	O
about	O
the	O
functional	O
characterization	O
of	O
CYP3A4	B
variants	O
in	O
terms	O
of	O
specific	O
substrates	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
systematically	O
investigate	O
the	O
genetic	O
polymorphisms	O
of	O
23	O
CYP3A4	B
alleles	O
and	O
evaluate	O
their	O
catalytic	O
activities	O
on	O
the	O
metabolism	O
of	O
lidocaine	O
in	O
vitro	O
.	O

The	O
wild	O
-	O
type	O
and	O
22	O
CYP3A4	B
variants	O
were	O
expressed	O
in	O
Spodoptera	O
frugiperda	O
21	O
insect	O
cells	O
.	O

Then	O
the	O
insect	O
microsomes	O
were	O
incubated	O
with	O
the	O
CYP3A4	B
-	O
specific	O
substrate	O
lidocaine	O
.	O

Of	O
the	O
23	O
CYP3A4	B
allelic	O
variants	O
tested	O
,	O
2	O
variants	O
(	O
CYP3A4	B
*	O
17	O
and	O
CYP3A4	B
*	O
30	O
)	O
had	O
no	O
detectable	O
enzyme	O
activity	O
;	O
and	O
5	O
variants	O
(	O
CYP3A4	B
*	O
2	O
,	O
CYP3A4	B
*	O
5	O
,	O
CYP3A4	B
*	O
9	O
,	O
CYP3A4	B
*	O
16	O
and	O
CYP3A4	B
*	O
24	O
)	O
showed	O
significantly	O
decreased	O
intrinsic	O
clearance	O
values	O
compared	O
with	O
wild	O
-	O
type	O
CYP3A4	B
*	O
1	O
.	O

As	O
the	O
first	O
study	O
of	O
all	O
these	O
CYP3A4	B
alleles	O
for	O
lidocaine	O
metabolism	O
,	O
our	O
results	O
in	O
vitro	O
assessment	O
may	O
provide	O
novel	O
insights	O
into	O
the	O
allele	O
-	O
specific	O
and	O
substrate	O
-	O
specific	O
activity	O
of	O
CYP3A4	B
and	O
may	O
also	O
offer	O
a	O
reference	O
to	O
the	O
personalized	O
treatment	O
of	O
lidocaine	O
in	O
a	O
clinical	O
setting	O
.	O

It	O
is	O
well	O
known	O
that	O
CYP3A4	B
enzyme	O
plays	O
a	O
major	O
role	O
in	O
the	O
oxidative	O
metabolism	O
of	O
~	O
30	O
%	O
-	O
40	O
%	O
of	O
clinically	O
used	O
drugs	O
,	O
such	O
as	O
certain	O
antibiotics	O
(	O
erythromycin	O
)	O
,	O
antiarrhythmics	O
(	O
quinidine	O
)	O
,	O
antidepressants	O
(	O
sertraline	O
)	O
,	O
Cardiovascular	O
drugs	O
(	O
verapamil	O
)	O
as	O
well	O
as	O
some	O
endogenous	O
steroids	O
(	O
testosterone	O
and	O
estradiol	O
)	O
.	O
,	O
The	O
expression	O
of	O
CYP3A4	B
varies	O
40	O
-	O
fold	O
in	O
individual	O
human	O
livers	O
,	O
which	O
indicates	O
that	O
CYP3A4	B
is	O
one	O
of	O
the	O
highly	O
polymorphic	O
enzymes	O
.	O

Recently	O
,	O
increasing	O
evidence	O
has	O
shown	O
that	O
genetic	O
polymorphisms	O
of	O
CYP3A4	B
significantly	O
contribute	O
to	O
the	O
wide	O
inter	O
-	O
individual	O
variability	O
of	O
enzyme	O
activity	O
.	O

The	O
enormous	O
variation	O
observed	O
in	O
drug	O
metabolism	O
may	O
result	O
in	O
undesirable	O
adverse	O
side	O
effects	O
or	O
therapeutic	O
failure	O
,	O
thus	O
more	O
attention	O
should	O
be	O
paid	O
to	O
genetic	O
polymorphism	O
of	O
CYP3A4	B
.	O

To	O
date	O
,	O
46	O
different	O
types	O
of	O
CYP3A4	B
allelic	O
variants	O
have	O
been	O
identified	O
in	O
the	O
Human	O
CYP	O
Allele	O
Nomenclature	O
Committee	O
website	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
cypalleles	O
.	O
ki	O
.	O
se	O
/	O
cyp3a4	O
.	O
htm	O
)	O
.	O

In	O
our	O
previous	O
study	O
,	O
Hu	O
et	O
al	O
sequenced	O
the	O
promoter	O
regions	O
and	O
13	O
exon	O
junctions	O
of	O
CYP3A4	B
in	O
DNA	O
from	O
1	O
,	O
114	O
healthy	O
subjects	O
from	O
the	O
southern	O
region	O
of	O
China	O
.	O

Five	O
previously	O
reported	O
alleles	O
(	O
CYP3A4	B
*	O
1G	O
,	O
*	O
4	O
,	O
*	O
5	O
,	O
*	O
18B	O
and	O
*	O
23	O
)	O
were	O
detected	O
.	O

In	O
addition	O
,	O
a	O
total	O
of	O
7	O
novel	O
exonic	O
variants	O
were	O
also	O
detected	O
and	O
further	O
named	O
as	O
new	O
alleles	O
CYP3A4	B
*	O
28	O
-	O
*	O
34	O
by	O
the	O
Human	O
CYP	O
Allele	O
Nomenclature	O
Committee	O
.	O

In	O
this	O
study	O
,	O
lidocaine	O
,	O
as	O
a	O
CYP3A4	B
-	O
specific	O
substrate	O
,	O
was	O
used	O
to	O
assess	O
the	O
catalytic	O
activities	O
of	O
wild	O
-	O
type	O
CYP3A4	B
*	O
1	O
and	O
22	O
CYP3A4	B
alleles	O
found	O
in	O
the	O
Chinese	O
Han	O
population	O
(	O
15	O
alleles	O
were	O
previously	O
reported	O
,	O
and	O
7	O
novel	O
alleles	O
with	O
coding	O
regions	O
were	O
newly	O
found	O
)	O
.	O

The	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
fragments	O
for	O
each	O
CYP3A4	B
variants	O
were	O
constructed	O
by	O
the	O
overlap	O
extension	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
method	O
using	O
the	O
primers	O
that	O
are	O
listed	O
in	O
,	O
and	O
then	O
isolated	O
ORF	O
fragments	O
by	O
PCR	O
amplification	O
using	O
the	O
forward	O
primer	O
3A4	O
-	O
SALF	O
(	O
5	O
-	O
ACCAGTCGACATGG	O
CTCTCATCCCAGAC	O
-	O
3	O
,	O
introducing	O
1	O
Sal	O
site	O
)	O
and	O
the	O
reverse	O
primer	O
3A4	O
-	O
SR	O
(	O
5	O
-	O
CCAAACTAGTTCAGGCT	O
CCACTTACGGT	O
-	O
3	O
,	O
introducing	O
1	O
Spe	O
site	O
)	O
.	O

These	O
full	O
-	O
length	O
PCR	O
products	O
for	O
each	O
of	O
the	O
CYP3A4	B
variants	O
were	O
digested	O
and	O
ligated	O
to	O
the	O
pFastBac	O
-	O
OR	O
receptor	O
vector	O
to	O
produce	O
the	O
ultimate	O
dual	O
-	O
expression	O
vector	O
pFastBac	O
-	O
OR	O
-	O
CYP3A4	B
.	O

CYP3A4	B
expression	O
levels	O
were	O
determined	O
by	O
measured	O
difference	O
spectra	O
.	O

The	O
incubation	O
mixture	O
included	O
5	O
pmol	O
wild	O
-	O
type	O
CYP3A4	B
*	O
1	O
or	O
other	O
CYP3A4	B
mutants	O
,	O
5	O
pmol	O
purified	O
cytochrome	B
b5	I
,	O
lidocaine	O
and	O
100	O
mmol	O
/	O
L	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
.	O

The	O
addition	O
of	O
b5	O
was	O
to	O
deliver	O
electrons	O
and	O
support	O
CYP3A4	B
enzymatic	O
activities	O
.	O

To	O
obtain	O
comprehensive	O
data	O
on	O
the	O
enzymatic	O
properties	O
for	O
catalysis	O
of	O
MEGX	O
by	O
all	O
reported	O
CYP3A4	B
variants	O
in	O
Chinese	O
population	O
,	O
the	O
wild	O
-	O
type	O
CYP3A4	B
*	O
1	O
and	O
22	O
allelic	O
variants	O
of	O
CYP3A4	B
were	O
assessed	O
in	O
our	O
study	O
.	O

The	O
ratio	O
of	O
V_max	O
/	O
K_m	O
represents	O
the	O
intrinsic	O
clearance	O
(	O
C_Lint	O
)	O
,	O
which	O
can	O
evaluate	O
the	O
enzymatic	O
activity	O
of	O
each	O
CYP3A4	B
allelic	O
variant	O
as	O
an	O
evaluation	O
criteria	O
.	O

Michaelis	O
-	O
Menten	O
plots	O
of	O
lidocaine	O
for	O
the	O
tested	O
23	O
CYP3A4	B
enzymes	O
are	O
shown	O
in	O
,	O
and	O
the	O
corresponding	O
kinetic	O
parameters	O
are	O
summarized	O
in	O
.	O

For	O
the	O
Michaelis	O
-	O
Menten	O
kinetic	O
analysis	O
,	O
the	O
kinetic	O
parameters	O
of	O
CYP3A4	B
*	O
17	O
and	O
CYP3A4	B
*	O
30	O
could	O
not	O
be	O
determined	O
as	O
no	O
concentration	O
of	O
MEGX	O
was	O
detected	O
,	O
which	O
indicated	O
that	O
CYP3A4	B
*	O
17	O
and	O
CYP3A4	B
*	O
30	O
showed	O
extremely	O
low	O
activity	O
or	O
no	O
activity	O
.	O

Except	O
for	O
CYP3A4	B
*	O
17	O
and	O
CYP3A4	B
*	O
30	O
,	O
almost	O
all	O
allelic	O
variants	O
in	O
showed	O
significant	O
alteration	O
in	O
V_max	O
values	O
compared	O
with	O
the	O
wild	O
-	O
type	O
CYP3A4	B
*	O
1	O
:	O
Only	O
4	O
variants	O
CYP3A4	B
*	O
4	O
,	O
CYP3A4	B
*	O
9	O
,	O
CYP3A4	B
*	O
29	O
,	O
and	O
CYP3A4	B
*	O
31	O
exhibited	O
no	O
statistical	O
difference	O
;	O
6	O
variants	O
(	O
CYP3A4	B
*	O
2	O
,	O
CYP3A4	B
*	O
5	O
,	O
CYP3A4	B
*	O
16	O
,	O
CYP3A4	B
*	O
24	O
,	O
CYP3A4	B
*	O
28	O
,	O
and	O
CYP3A4	B
*	O
33	O
)	O
showed	O
mild	O
decrease	O
;	O
and	O
the	O
remaining	O
10	O
variants	O
displayed	O
significantly	O
increased	O
V_max	O
values	O
.	O

Meanwhile	O
,	O
most	O
variants	O
showed	O
obvious	O
changes	O
on	O
K_m	O
values	O
:	O
6	O
variants	O
(	O
CYP3A4	B
*	O
2	O
,	O
CYP3A4	B
*	O
3	O
,	O
CYP3A4	B
*	O
5	O
,	O
CYP3A4	B
*	O
9	O
,	O
CYP3A4	B
*	O
16	O
,	O
and	O
CYP3A4	B
*	O
34	O
)	O
exhibited	O
increased	O
K_m	O
values	O
with	O
~	O
1	O
.	O
13	O
-	O
2	O
.	O
34	O
-	O
fold	O
compared	O
with	O
CYP3A4	B
*	O
1	O
and	O
7	O
variants	O
(	O
CYP3A4	B
*	O
23	O
,	O
CYP3A4	B
*	O
24	O
,	O
CYP3A4	B
*	O
28	O
,	O
CYP3A4	B
*	O
29	O
,	O
CYP3A4	B
*	O
31	O
,	O
CYP3A4	B
*	O
32	O
,	O
and	O
CYP3A4	B
*	O
33	O
)	O
decreased	O
to	O
15	O
.	O
01	O
%	O
-	O
69	O
.	O
57	O
%	O
.	O

As	O
a	O
result	O
,	O
according	O
to	O
intrinsic	O
clearance	O
(	O
V_max	O
/	O
K_m	O
)	O
values	O
of	O
MEGX	O
compared	O
with	O
the	O
wild	O
type	O
,	O
CYP3A4	B
alleles	O
could	O
be	O
classified	O
into	O
3	O
categories	O
:	O
ten	O
variants	O
(	O
CYP3A4	B
*	O
11	O
,	O
*	O
14	O
,	O
*	O
15	O
,	O
*	O
18	O
,	O
*	O
19	O
,	O
*	O
23	O
,	O
*	O
29	O
,	O
*	O
31	O
,	O
*	O
32	O
,	O
and	O
*	O
34	O
)	O
exhibited	O
significantly	O
increased	O
intrinsic	O
clearance	O
values	O
(	O
123	O
.	O
27	O
%	O
-	O
213	O
.	O
61	O
%	O
relative	O
clearance	O
)	O
;	O
5	O
variants	O
(	O
CYP3A4	B
*	O
2	O
,	O
*	O
5	O
,	O
*	O
9	O
,	O
*	O
16	O
,	O
and	O
*	O
24	O
)	O
showed	O
lower	O
intrinsic	O
clearance	O
values	O
than	O
CYP3A4	B
*	O
1	O
(	O
27	O
.	O
93	O
%	O
-	O
67	O
.	O
93	O
%	O
relative	O
clearance	O
)	O
.	O

Another	O
5	O
variants	O
(	O
CYP3A4	B
*	O
3	O
,	O
*	O
4	O
,	O
*	O
10	O
,	O
*	O
28	O
,	O
and	O
*	O
33	O
)	O
were	O
without	O
statistical	O
significance	O
.	O

In	O
addition	O
,	O
to	O
investigate	O
the	O
enzymatic	O
abilities	O
of	O
23	O
CYP3A4	B
variants	O
between	O
different	O
substrate	O
,	O
lidocaine	O
and	O
1	O
typical	O
probing	O
substrate	O
for	O
the	O
CYP3A4	B
enzyme	O
were	O
used	O
in	O
the	O
in	O
vitro	O
functional	O
analysis	O
.	O

As	O
shown	O
in	O
,	O
variants	O
,	O
CYP3A4	B
*	O
17	O
and	O
CYP3A4	B
*	O
30	O
,	O
exhibited	O
extremely	O
low	O
enzymatic	O
activity	O
or	O
null	O
function	O
for	O
both	O
substrates	O
.	O

And	O
9	O
variants	O
(	O
CYP3A4	B
*	O
4	O
,	O
CYP3A4	B
*	O
5	O
,	O
CYP3A4	B
*	O
11	O
,	O
CYP3A4	B
*	O
15	O
,	O
CYP3A4	B
*	O
16	O
,	O
CYP3A4	B
*	O
17	O
,	O
CYP3A4	B
*	O
24	O
,	O
CYP3A4	B
*	O
30	O
,	O
and	O
CYP3A4	B
*	O
31	O
)	O
showed	O
similar	O
changed	O
trend	O
of	O
enzymatic	O
activities	O
compared	O
with	O
CYP3A4	B
*	O
1	O
toward	O
lidocaine	O
and	O
testosterone	O
.	O

Whereas	O
,	O
the	O
remaining	O
CYP3A4	B
variants	O
,	O
especially	O
CYP3A4	B
*	O
2	O
,	O
CYP3A4	B
*	O
14	O
,	O
CYP3A4	B
*	O
23	O
,	O
CYP3A4	B
*	O
29	O
,	O
CYP3A4	B
*	O
32	O
,	O
and	O
CYP3A4	B
*	O
34	O
,	O
displayed	O
obvious	O
different	O
relative	O
clearance	O
between	O
2	O
substrates	O
.	O

CYP3A4	B
exhibits	O
remarkable	O
individual	O
variation	O
in	O
expression	O
levels	O
,	O
which	O
may	O
be	O
caused	O
by	O
genetic	O
,	O
environmental	O
,	O
pathological	O
,	O
hormonal	O
,	O
and	O
dietary	O
factors	O
.	O

Increasing	O
evidence	O
suggests	O
that	O
genetic	O
polymorphism	O
is	O
a	O
primary	O
source	O
of	O
inter	O
-	O
individual	O
difference	O
in	O
drug	O
metabolism	O
.	O
,	O
Genetic	O
polymorphism	O
of	O
CYP3A4	B
can	O
greatly	O
influence	O
the	O
rate	O
of	O
elimination	O
of	O
lidocaine	O
,	O
thereby	O
may	O
result	O
in	O
adverse	O
effects	O
or	O
therapeutic	O
failures	O
.	O

Therefore	O
,	O
it	O
is	O
of	O
great	O
significance	O
to	O
functionally	O
characterize	O
the	O
enzymatic	O
activity	O
of	O
CYP3A4	B
variants	O
in	O
the	O
metabolism	O
of	O
lidocaine	O
in	O
vitro	O
.	O

To	O
better	O
understand	O
the	O
effects	O
of	O
CYP3A4	B
variants	O
on	O
the	O
metabolism	O
of	O
lidocaine	O
in	O
vitro	O
,	O
we	O
analyzed	O
the	O
wild	O
-	O
type	O
CYP3A4	B
*	O
1	O
and	O
22	O
CYP3A4	B
variants	O
found	O
in	O
Chinese	O
Han	O
population	O
in	O
detail	O
,	O
of	O
which	O
7	O
(	O
CYP3A4	B
*	O
28	O
-	O
*	O
34	O
)	O
were	O
new	O
alleles	O
and	O
another	O
15	O
alleles	O
(	O
CYP3A4	B
*	O
2	O
,	O
*	O
3	O
,	O
*	O
4	O
,	O
*	O
5	O
,	O
*	O
9	O
,	O
*	O
10	O
,	O
*	O
11	O
,	O
*	O
14	O
,	O
*	O
15	O
,	O
*	O
16	O
,	O
*	O
17	O
,	O
*	O
18	O
,	O
*	O
19	O
,	O
*	O
23	O
,	O
and	O
*	O
24	O
)	O
had	O
previously	O
been	O
reported	O
.	O

The	O
enzymatic	O
activity	O
of	O
CYP3A4	B
*	O
1	O
was	O
used	O
as	O
a	O
control	O
group	O
.	O

As	O
a	O
novel	O
allelic	O
variant	O
,	O
the	O
CYP3A4	B
*	O
30	O
(	O
R130STOP	O
)	O
,	O
which	O
contains	O
the	O
premature	O
stop	O
codon	O
,	O
produces	O
a	O
nonfunctional	O
protein	O
with	O
a	O
shorter	O
peptide	O
.	O

As	O
a	O
consequence	O
,	O
the	O
kinetic	O
parameters	O
of	O
CYP3A4	B
*	O
30	O
could	O
not	O
be	O
detected	O
and	O
it	O
showed	O
no	O
catalytic	O
activity	O
on	O
lidocaine	O
metabolism	O
.	O

Similar	O
to	O
CYP3A4	B
*	O
30	O
,	O
CYP3A4	B
*	O
17	O
exhibited	O
extremely	O
low	O
enzymatic	O
activity	O
toward	O
lidocaine	O
.	O

According	O
to	O
previous	O
reports	O
,	O
CYP3A4	B
*	O
17	O
produced	O
an	O
amino	O
acid	O
substitution	O
:	O
F189S	O
in	O
exon	O
7	O
,	O
and	O
it	O
exhibited	O
decreased	O
catalytic	O
activity	O
compared	O
with	O
the	O
wild	O
type	O
for	O
both	O
testosterone	O
and	O
chlorpyrifos	O
.	O
,	O
Aside	O
from	O
CYP3A4	B
*	O
17	O
and	O
CYP3A4	B
*	O
30	O
,	O
we	O
found	O
that	O
most	O
of	O
CYP3A4	B
variants	O
exhibited	O
higher	O
enzymatic	O
activity	O
than	O
wild	O
type	O
,	O
whereas	O
only	O
5	O
alleles	O
(	O
CYP3A4	B
*	O
2	O
,	O
*	O
5	O
,	O
*	O
9	O
,	O
*	O
16	O
,	O
and	O
*	O
24	O
)	O
showed	O
a	O
significantly	O
decreased	O
relative	O
clearance	O
compared	O
with	O
CYP3A4	B
*	O
1	O
(	O
27	O
.	O
93	O
%	O
-	O
67	O
.	O
93	O
%	O
)	O
.	O

Therefore	O
,	O
patients	O
carrying	O
the	O
CYP3A4	B
*	O
2	O
,	O
*	O
5	O
,	O
*	O
9	O
,	O
*	O
16	O
,	O
*	O
17	O
,	O
*	O
24	O
,	O
or	O
*	O
30	O
should	O
pay	O
more	O
attention	O
to	O
the	O
dose	O
of	O
lidocaine	O
,	O
in	O
order	O
to	O
avoid	O
lidocaine	O
-	O
induced	O
toxicity	O
or	O
delayed	O
emergence	O
from	O
anesthesia	O
.	O

Four	O
(	O
CYP3A4	B
*	O
29	O
,	O
*	O
31	O
,	O
*	O
32	O
,	O
and	O
*	O
34	O
)	O
of	O
novel	O
alleles	O
exhibited	O
significantly	O
increased	O
intrinsic	O
clearance	O
value	O
for	O
lidocaine	O
from	O
141	O
.	O
84	O
%	O
to	O
197	O
.	O
87	O
%	O
of	O
wild	O
-	O
type	O
CYP3A4	B
*	O
1	O
.	O

CYP3A4	B
*	O
28	O
showed	O
both	O
lower	O
V_max	O
and	O
K_m	O
values	O
so	O
that	O
the	O
intrinsic	O
clearance	O
showed	O
no	O
significant	O
difference	O
to	O
that	O
of	O
the	O
CYP3A4	B
*	O
1	O
.	O

Hu	O
et	O
al	O
found	O
that	O
CYP3A4	B
*	O
28	O
(	O
L22V	O
)	O
,	O
CYP3A4	B
*	O
31	O
(	O
H324Q	O
)	O
and	O
CYP3A4	B
*	O
32	O
(	O
I335T	O
)	O
can	O
damage	O
protein	O
function	O
.	O

However	O
,	O
as	O
for	O
our	O
result	O
that	O
these	O
alleles	O
exhibited	O
higher	O
catalytic	O
activity	O
than	O
wild	O
type	O
in	O
our	O
study	O
,	O
it	O
may	O
be	O
interpreted	O
that	O
His324	O
and	O
Ile335	O
are	O
not	O
involved	O
in	O
the	O
active	O
site	O
for	O
drug	O
-	O
substrate	O
binding	O
according	O
to	O
previously	O
reported	O
crystal	O
structures	O
of	O
the	O
CYP3A4	B
enzyme	O
.	O

CYP3A4	B
*	O
18	O
,	O
contains	O
a	O
nucleotide	O
substitution	O
of	O
T	O
>	O
C	O
at	O
position	O
878	O
of	O
the	O
cDNA	O
of	O
CYP3A4	B
and	O
results	O
in	O
an	O
amino	O
acid	O
change	O
of	O
Leu	O
to	O
Pro	O
at	O
codon	O
293	O
,	O
is	O
commonly	O
detected	O
in	O
Asians	O
.	O

According	O
to	O
previous	O
study	O
,	O
CYP3A4	B
*	O
18	O
exhibited	O
increased	O
turnover	O
numbers	O
for	O
testosterone	O
and	O
chlorpyrifos	O
in	O
vitro	O
.	O

Similarly	O
,	O
in	O
our	O
study	O
,	O
CYP3A4	B
*	O
18	O
,	O
with	O
a	O
distinctly	O
increased	O
V_max	O
,	O
showed	O
significantly	O
increased	O
relative	O
clearance	O
compared	O
with	O
CYP3A4	B
*	O
1	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
previous	O
study	O
of	O
testosterone	O
and	O
chlorpyrifos	O
,	O
2	O
typical	O
probing	O
substrates	O
for	O
CYP3A4	B
,	O
thus	O
indicating	O
that	O
our	O
CYP	O
expression	O
and	O
in	O
vitro	O
metabolism	O
system	O
were	O
suitable	O
for	O
analyzing	O
the	O
catalytic	O
activities	O
of	O
the	O
CYP3A4	B
allelic	O
variants	O
.	O

In	O
addition	O
,	O
CYP3A4	B
*	O
23	O
was	O
reported	O
by	O
Hu	O
et	O
al	O
for	O
the	O
first	O
time	O
in	O
the	O
Chinese	O
population	O
.	O

In	O
our	O
work	O
,	O
CYP3A4	B
*	O
23	O
exhibited	O
significantly	O
increased	O
intrinsic	O
clearance	O
value	O
(	O
206	O
.	O
96	O
%	O
of	O
CYP3A4	B
*	O
1	O
)	O
owing	O
to	O
marked	O
increase	O
in	O
V_max	O
and	O
huge	O
decrease	O
in	O
K_m	O
.	O

To	O
better	O
understand	O
the	O
enzymatic	O
characteristics	O
of	O
these	O
CYP3A4	B
allelic	O
isoforms	O
,	O
testosterone	O
,	O
as	O
a	O
probe	O
substrate	O
of	O
CYP3A4	B
,	O
was	O
also	O
used	O
to	O
detect	O
the	O
catalytic	O
activities	O
of	O
these	O
23	O
CYP3A4	B
variants	O
.	O

Then	O
we	O
compared	O
lidocaine	O
with	O
testosterone	O
,	O
although	O
some	O
CYP3A4	B
variants	O
exhibited	O
similar	O
pattern	O
for	O
the	O
metabolic	O
activity	O
toward	O
testosterone	O
,	O
most	O
of	O
the	O
variants	O
,	O
especially	O
like	O
CYP3A4	B
*	O
2	O
,	O
CYP3A4	B
*	O
29	O
,	O
CYP3A4	B
*	O
32	O
,	O
CYP3A4	B
*	O
33	O
,	O
and	O
CYP3A4	B
*	O
34	O
showed	O
different	O
relative	O
activities	O
for	O
the	O
probe	O
drug	O
.	O

These	O
results	O
suggested	O
that	O
CYP3A4	B
also	O
had	O
substrate	O
-	O
specific	O
alterations	O
in	O
metabolic	O
activity	O
and	O
we	O
infer	O
that	O
amino	O
acid	O
substitution	O
in	O
these	O
sites	O
might	O
have	O
different	O
impacts	O
for	O
different	O
substrate	O
of	O
CYP3A4	B
.	O

Moreover	O
,	O
genetic	O
polymorphism	O
and	O
substrate	O
-	O
specificity	O
of	O
CYP3A4	B
need	O
further	O
study	O
on	O
daily	O
used	O
drugs	O
in	O
order	O
to	O
help	O
in	O
personalized	O
medicine	O
for	O
patients	O
in	O
a	O
safe	O
and	O
reduced	O
toxicity	O
reaction	O
.	O

In	O
summary	O
,	O
this	O
study	O
provides	O
functional	O
assessment	O
of	O
23	O
CYP3A4	B
variants	O
on	O
lidocaine	O
metabolism	O
in	O
vitro	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
first	O
study	O
of	O
all	O
these	O
alleles	O
on	O
lidocaine	O
metabolism	O
,	O
the	O
research	O
may	O
help	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
polymorphism	O
of	O
CYP3A4	B
;	O
on	O
the	O
other	O
hand	O
,	O
this	O
study	O
could	O
help	O
clinical	O
assessment	O
of	O
the	O
lidocaine	O
metabolism	O
and	O
aid	O
the	O
application	O
of	O
this	O
knowledge	O
in	O
clinical	O
practice	O
.	O

However	O
,	O
further	O
studies	O
are	O
required	O
to	O
examine	O
a	O
wider	O
range	O
of	O
CYP3A4	B
substrates	O
,	O
including	O
clinically	O
used	O
drugs	O
.	O

Among	O
all	O
human	O
CYPs	O
,	O
CYP3A4	B
is	O
reported	O
to	O
be	O
involved	O
in	O
the	O
metabolism	O
of	O
50	O
%	O
of	O
all	O
pharmaceuticals	O
;	O
it	O
is	O
therefore	O
an	O
enzyme	O
of	O
general	O
interest	O
for	O
herb	O
-	O
drug	O
interactions	O
.	O

Several	O
herbs	O
and	O
natural	O
remedies	O
have	O
been	O
reported	O
to	O
induce	O
or	O
inhibit	O
CYP3A4	B
.	O

This	O
observation	O
was	O
further	O
supported	O
by	O
consistent	O
CYP3A4	B
expression	O
across	O
all	O
treatment	O
groups	O
.	O

Indeed	O
,	O
Berberine	O
has	O
been	O
shown	O
to	O
affect	O
the	O
metabolism	O
of	O
drugs	O
through	O
changes	O
in	O
CYP3A4	B
expression	O
.	O

The	O
effects	O
of	O
Berberine	O
on	O
CYP3A4	B
-	O
mediated	O
drug	O
metabolism	O
is	O
of	O
particular	O
interest	O
as	O
this	O
enzyme	O
degrades	O
several	O
widely	O
used	O
statin	O
drugs	O
(	O
eg	O
simvastatin	O
and	O
lovastatin	O
)	O
that	O
may	O
be	O
concomitantly	O
used	O
with	O
Berberine	O
to	O
treat	O
dyslipidemia	O
or	O
hypercholesterolemia	O
.	O

Two	O
livers	O
per	O
treatment	O
group	O
were	O
evaluated	O
for	O
CYP3A4	B
and	O
HMG	O
-	O
CoA	O
reductase	O
using	O
a	O
combination	O
of	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
and	O
western	O
blot	O
techniques	O
.	O

For	O
Enzyme	O
-	O
Linked	O
Immunosorbent	O
Assays	O
quantification	O
of	O
CYP3A4	B
and	O
HMG	O
-	O
CoA	O
reductase	O
were	O
performed	O
according	O
to	O
manufacturers	O
instructions	O
(	O
LifeSpan	O
BioSciences	O
LS	O
-	O
F22383	O
and	O
LifeSpan	O
BioSciences	O
LS	O
-	O
F15758	O
)	O
.	O

This	O
decrease	O
in	O
Demethylene	O
Berberine	O
Glucuronide	O
may	O
reflect	O
an	O
alteration	O
in	O
hepatic	O
function	O
such	O
as	O
changes	O
in	O
enzymes	O
responsible	O
for	O
berberine	O
metabolism	O
,	O
of	O
which	O
CYP3A4	B
is	O
a	O
significant	O
player	O
.	O

To	O
address	O
this	O
possibility	O
,	O
liver	O
samples	O
from	O
chronically	O
treated	O
animals	O
(	O
14	O
days	O
)	O
were	O
dissected	O
and	O
CYP3A4	B
was	O
quantified	O
by	O
Enzyme	O
-	O
Linked	O
Immunosorbent	O
Assays	O
and	O
western	O
blot	O
.	O

No	O
differences	O
in	O
CYP3A4	B
expression	O
were	O
observed	O
between	O
treatment	O
groups	O
.	O

Simvastatin	O
and	O
berberine	O
both	O
undergo	O
metabolism	O
in	O
the	O
liver	O
primarily	O
through	O
CYP3A4	B
.	O

While	O
transdermal	O
dihydroberberine	O
unequivocally	O
increased	O
berberine	O
levels	O
in	O
circulation	O
this	O
increase	O
had	O
no	O
effect	O
on	O
liver	O
or	O
kidney	O
function	O
nor	O
altered	O
the	O
expression	O
of	O
hepatic	O
enzymes	O
CYP3A4	B
and	O
HMG	O
-	O
CoA	O
reductase	O
.	O

The	O
CYP3A4	B
and	O
CYP3A5	B
enzymes	O
have	O
overlapping	O
substrate	O
specificity	O
and	O
together	O
,	O
they	O
control	O
the	O
clearance	O
of	O
approximately	O
50	O
%	O
of	O
all	O
drugs	O
eliminated	O
primarily	O
through	O
P450	O
-	O
mediated	O
biotransformation	O
.	O

CYP3A4	B
protein	O
is	O
present	O
in	O
almost	O
all	O
adults	O
,	O
whereas	O
CYP3A5	B
protein	O
expression	O
varies	O
across	O
different	O
ethnic	O
groups	O
;	O
polymorphisms	O
in	O
the	O
genes	O
encoding	O
these	O
proteins	O
are	O
shown	O
in	O
and	O
.	O

The	O
CYP3A5	B
enzyme	O
is	O
expressed	O
in	O
individuals	O
having	O
at	O
least	O
one	O
CYP3A5	B
*	O
1	O
allele	O
,	O
while	O
those	O
with	O
two	O
inactive	O
alleles	O
,	O
CYP3A5	B
*	O
3	O
,	O
*	O
6	O
,	O
or	O
*	O
7	O
,	O
encode	O
a	O
nonfunctional	O
protein	O
;	O
the	O
PM	O
phenotype	O
is	O
most	O
common	O
in	O
Europeans	O
and	O
less	O
so	O
in	O
Asians	O
and	O
African	O
Americans	O
.	O

The	O
CYP3A4	B
*	O
22	O
variant	O
is	O
also	O
associated	O
with	O
reduced	O
CYP3A4	B
protein	O
levels	O
and	O
enzyme	O
function	O
,	O
as	O
are	O
rare	O
deleterious	O
coding	O
variants	O
.	O

The	O
CYP3A4	B
*	O
1B	O
and	O
CYP3A4	B
*	O
1G	O
alleles	O
reportedly	O
affect	O
gene	O
transcription	O
but	O
functional	O
effects	O
are	O
unclear	O
,	O
as	O
the	O
data	O
are	O
mixed	O
and	O
interpretation	O
is	O
complicated	O
by	O
high	O
linkage	O
disequilibrium	O
with	O
CYP3A5	B
*	O
1	O
.	O

In	O
the	O
CSKT	O
population	O
,	O
resequencing	O
followed	O
by	O
subsequent	O
genotyping	O
identified	O
four	O
novel	O
CYP3A4	B
SNVs	O
-	O
three	O
intronic	O
and	O
one	O
in	O
the	O
5	O
UTR	O
region	O
.	O

The	O
known	O
CYP3A4	B
variants	O
,	O
*	O
1B	O
,	O
*	O
22	O
and	O
*	O
1G	O
were	O
found	O
at	O
frequencies	O
of	O
2	O
.	O
2	O
%	O
,	O
2	O
.	O
4	O
%	O
and	O
26	O
.	O
8	O
%	O
,	O
respectively	O
.	O

With	O
regard	O
to	O
CYP3A5	B
in	O
the	O
CSKT	O
population	O
,	O
CYP3A5	B
*	O
1	O
was	O
detected	O
at	O
a	O
frequency	O
of	O
7	O
.	O
5	O
%	O
,	O
CYP3A5	B
*	O
3	O
at	O
92	O
.	O
5	O
%	O
,	O
while	O
CYP3A5	B
*	O
6	O
and	O
*	O
7	O
were	O
not	O
detected	O
.	O

These	O
data	O
suggest	O
that	O
14	O
.	O
9	O
%	O
of	O
CSKT	O
individuals	O
express	O
CYP3A5	B
,	O
contributing	O
to	O
their	O
total	O
CYP3A	B
metabolic	O
activity	O
.	O

determined	O
the	O
MAFs	O
of	O
CYP3A4	B
variants	O
in	O
the	O
Tepehuano	O
and	O
Mestizo	O
populations	O
and	O
found	O
that	O
the	O
frequencies	O
were	O
not	O
significantly	O
different	O
between	O
these	O
two	O
group	O
.	O

The	O
MAFs	O
of	O
CYP3A4	B
*	O
1B	O
was	O
8	O
.	O
0	O
%	O
in	O
Tepehuanos	O
,	O
compared	O
to	O
8	O
.	O
8	O
%	O
in	O
Mestizos	O
and	O
CYP3A4	B
*	O
2	O
was	O
not	O
detected	O
in	O
the	O
Tepehuanos	O
but	O
was	O
found	O
at	O
a	O
low	O
frequency	O
of	O
0	O
.	O
5	O
%	O
in	O
Mestizos	O
.	O

CYP3A4	B
*	O
4	O
,	O
*	O
5	O
and	O
*	O
18	O
were	O
not	O
found	O
in	O
either	O
population	O
.	O

Although	O
the	O
variant	O
allele	O
frequencies	O
were	O
similar	O
between	O
Tepehuanos	O
and	O
Mestizos	O
for	O
CYP3A4	B
,	O
it	O
is	O
important	O
to	O
consider	O
that	O
these	O
populations	O
may	O
share	O
similar	O
allele	O
frequencies	O
in	O
other	O
P450	O
genes	O
.	O

found	O
that	O
the	O
CYP3A4	B
*	O
1B	O
MAF	O
was	O
4	O
.	O
8	O
%	O
in	O
an	O
Amerindian	O
population	O
including	O
the	O
Tarahumara	O
,	O
Tepehuano	O
,	O
Mexicanera	O
,	O
Huichol	O
,	O
Cora	O
,	O
Seri	O
,	O
Mayo	O
and	O
Guarijo	O
groups	O
.	O

The	O
CYP3A4	B
*	O
1B	O
allele	O
did	O
not	O
significantly	O
affect	O
the	O
parent	O
to	O
metabolite	O
ratio	O
of	O
dextromethorphan	O
to	O
3	O
-	O
methoxymorphinan	O
,	O
a	O
CYP3A4	B
mediated	O
pathway	O
.	O

About	O
15	O
%	O
of	O
the	O
CSKT	O
population	O
would	O
be	O
expected	O
to	O
express	O
CYP3A5	B
,	O
based	O
on	O
the	O
CYP3A5	B
*	O
1	O
allele	O
frequency	O
.	O

In	O
the	O
same	O
way	O
,	O
PAH	O
such	O
BaP	O
,	O
and	O
their	O
dihydrodiol	O
metabolites	O
,	O
were	O
able	O
to	O
activate	O
PXR	O
and	O
enhance	O
CYP3A4	B
expression	O
in	O
human	O
cell	O
lines	O
(	O
HepG2	O
and	O
HEK	O
-	O
293	O
cells	O
)	O
.	O

Glycine	O
N	O
-	O
methyltransferase	O
inhibits	O
aristolochic	O
acid	O
nephropathy	O
by	O
increasing	O
CYP3A44	O
and	O
decreasing	O
NQO1	O
expression	O
in	O
female	O
mouse	O
hepatocytes	O
.	O

Mechanism	O
-	O
wise	O
,	O
AAI	O
enhanced	O
Glycine	O
N	O
-	O
Methyltransferase	O
nuclear	O
translocation	O
,	O
resulting	O
in	O
Glycine	O
N	O
-	O
Methyltransferase	O
interaction	O
with	O
the	O
promoter	O
region	O
of	O
the	O
genes	O
encoding	O
Nuclear	O
Factor	O
-	O
E2	O
-	O
Related	O
Factor	O
2	O
and	O
CAR	O
/	O
PXR	O
,	O
the	O
transcription	O
factors	O
for	O
NQO1	O
and	O
CYP3A44	O
/	O
3A41	O
,	O
respectively	O
.	O

Unlike	O
the	O
preference	O
for	O
Nrf2	O
/	O
NQO1	O
transcriptions	O
at	O
lower	O
levels	O
of	O
Glycine	O
N	O
-	O
Methyltransferase	O
,	O
overexpression	O
of	O
Glycine	O
N	O
-	O
Methyltransferase	O
preferred	O
CAR	O
/	O
PXR	O
/	O
CYP3A44	O
/	O
3A41	O
transcriptions	O
and	O
alleviated	O
kidney	O
injury	O
upon	O
AAI	O
treatment	O
.	O

In	O
summary	O
,	O
hepatic	O
Glycine	O
N	O
-	O
Methyltransferase	O
protected	O
mice	O
from	O
AAI	O
nephropathy	O
by	O
enhancing	O
CAR	O
/	O
PXR	O
/	O
CYP3A44	O
/	O
3A41	O
transcriptions	O
and	O
reducing	O
Nrf2	O
/	O
NQO1	O
transcriptions	O
.	O

In	O
our	O
Gnmt	O
genetically	O
-	O
modified	O
mouse	O
models	O
,	O
we	O
were	O
able	O
to	O
induce	O
Aristolochic	O
Acids	O
nephropathy	O
in	O
a	O
C57BL	O
/	O
6	O
background	O
which	O
was	O
similar	O
to	O
the	O
human	O
histopathology	O
^	O
,	O
and	O
demostrated	O
that	O
Glycine	O
N	O
-	O
Methyltransferase	O
protected	O
mice	O
from	O
AAI	O
-	O
induced	O
kidney	O
injury	O
by	O
increasing	O
CAR	O
/	O
PXR	O
and	O
CYP3A44	O
/	O
3A41	O
transcriptions	O
and	O
decreasing	O
NRF2	O
/	O
NQO1	O
transcriptions	O
in	O
female	O
mouse	O
hepatocytes	O
.	O

These	O
results	O
may	O
explain	O
the	O
sex	O
difference	O
in	O
AAI	O
tolerance	O
and	O
suggest	O
that	O
Glycine	O
N	O
-	O
Methyltransferase	O
reduced	O
AAI	O
nephrotoxicity	O
by	O
regulating	O
female	O
-	O
specific	O
CYP3A44	O
and	O
CYP3A41	O
.	O

Also	O
,	O
compared	O
to	O
Wild	O
-	O
Type	O
control	O
female	O
mice	O
,	O
CYP3A44	O
and	O
CYP3A41	O
expressions	O
were	O
significantly	O
decreased	O
in	O
Glycine	O
N	O
-	O
Methyltransferase	O
Knockout	O
control	O
female	O
mice	O
(	O
Fig	O
.	O

The	O
CYP3A44	O
and	O
CYP3A41	O
expression	O
levels	O
increased	O
in	O
low	O
-	O
dose	O
AAI	O
-	O
treated	O
Wild	O
-	O
Type	O
female	O
mice	O
(	O
Fig	O
.	O

These	O
results	O
further	O
support	O
that	O
Glycine	O
N	O
-	O
Methyltransferase	O
protects	O
female	O
mice	O
from	O
AAI	O
-	O
induced	O
renal	O
damage	O
via	O
increasing	O
CYP3A44	O
/	O
41	O
expression	O
.	O

In	O
all	O
mice	O
after	O
AAV	O
-	O
GNMT	O
gene	O
therapy	O
,	O
Glycine	O
N	O
-	O
Methyltransferase	O
was	O
expressed	O
in	O
the	O
liver	O
but	O
not	O
in	O
the	O
kidneys	O
to	O
reduce	O
the	O
NQO1	O
mRNA	O
level	O
and	O
increase	O
CYP3A44	O
and	O
CYP3A41	O
mRNA	O
levels	O
in	O
the	O
corn	O
oil	O
-	O
treated	O
(	O
vehicle	O
control	O
)	O
mice	O
.	O

After	O
AAI	O
exposure	O
,	O
the	O
NQO1	O
was	O
upregulated	O
and	O
CYP3A44	O
and	O
3A41	O
were	O
downregulated	O
in	O
AAV	O
-	O
GNMT	O
-	O
treated	O
female	O
Knockout	O
mice	O
.	O

However	O
,	O
the	O
CYP3A44	O
and	O
CYP3A41	O
mRNA	O
levels	O
in	O
AAV	O
-	O
GNMT	O
-	O
treated	O
female	O
Knockout	O
mice	O
remained	O
higher	O
than	O
that	O
in	O
AAV	O
-	O
eGFP	O
-	O
treated	O
female	O
Knockout	O
mice	O
after	O
AAI	O
exposure	O
(	O
Fig	O
.	O

In	O
summary	O
,	O
Glycine	O
N	O
-	O
Methyltransferase	O
serves	O
as	O
a	O
protector	O
to	O
prevent	O
kidney	O
injury	O
from	O
AAI	O
toxicity	O
by	O
upregulating	O
CYP3A44	O
and	O
CYP3A41	O
in	O
mouse	O
liver	O
.	O

The	O
Chromatin	O
Immunoprecipitation	O
data	O
indicated	O
that	O
GNMT	O
-	O
CAR	O
and	O
GNMT	O
-	O
PXR	O
were	O
higher	O
at	O
low	O
AAI	O
concentration	O
than	O
at	O
higher	O
concentration	O
,	O
resulting	O
in	O
increases	O
in	O
CYP3A44	O
/	O
3A41	O
mRNA	O
levels	O
and	O
minor	O
kidney	O
injuries	O
,	O
upregulated	O
NQO1	O
mRNA	O
levels	O
and	O
damaged	O
kidney	O
severely	O
(	O
Fig	O
.	O

In	O
this	O
study	O
,	O
we	O
revealed	O
that	O
AAI	O
promotes	O
Glycine	O
N	O
-	O
Methyltransferase	O
nuclear	O
translocation	O
and	O
nuclear	O
Glycine	O
N	O
-	O
Methyltransferase	O
can	O
bind	O
to	O
the	O
promoter	O
regions	O
of	O
NRF2	O
and	O
CAR	O
/	O
PXR	O
and	O
enhance	O
subsequent	O
NQO1	O
and	O
CYP3A44	O
/	O
3A41	O
transcriptions	O
,	O
respectively	O
.	O

In	O
Wild	O
-	O
Type	O
female	O
mice	O
,	O
AAI	O
exposure	O
increased	O
GNMT	O
-	O
Nrf2	O
,	O
resulting	O
in	O
the	O
elevated	O
NOQ1	O
transcription	O
,	O
and	O
decreased	O
GNMT	O
-	O
CAR	O
and	O
GNMT	O
-	O
PXR	O
,	O
resulting	O
in	O
a	O
reduction	O
of	O
CYP3A44	O
/	O
CYP3A41	O
transcripts	O
.	O

Our	O
findings	O
suggest	O
that	O
CYP3A44	O
/	O
3A41	O
regulated	O
by	O
Glycine	O
N	O
-	O
Methyltransferase	O
is	O
highly	O
related	O
to	O
reduced	O
AAI	O
nephropathy	O
in	O
mice	O
,	O
although	O
the	O
catalytic	O
activities	O
of	O
mouse	O
CYP3A44	O
/	O
CYP3A41	O
towards	O
AAI	O
have	O
never	O
been	O
reported	O
.	O

Human	O
CYP3A4	B
is	O
the	O
homologue	O
of	O
mouse	O
CYP3A44	O
/	O
CYP3A41	O
,	O
a	O
protein	O
mainly	O
expressed	O
in	O
the	O
liver	O
and	O
small	O
intestine	O
and	O
responsible	O
for	O
the	O
metabolism	O
of	O
many	O
drugs	O
.	O

Women	O
have	O
higher	O
CYP3A4	B
activity	O
than	O
men	O
^	O
,	O
;	O
thus	O
,	O
many	O
drugs	O
metabolized	O
by	O
CYP3A4	B
clear	O
faster	O
in	O
women	O
than	O
men	O
^	O
,	O
.	O

Glycine	O
N	O
-	O
Methyltransferase	O
protects	O
mice	O
from	O
AAI	O
-	O
induced	O
kidney	O
injury	O
by	O
increasing	O
CAR	O
/	O
PXR	O
/	O
CYP3A44	O
/	O
3A41	O
transcription	O
and	O
decreasing	O
Nrf2	O
/	O
NQO1	O
transcription	O
in	O
female	O
hepatocytes	O
.	O

In	O
terms	O
of	O
Rheumatoid	O
Arthritis	O
,	O
hepatic	O
CYP1A	O
,	O
CYP3A	B
,	O
and	O
CYP2B	O
subfamily	O
enzymes	O
was	O
found	O
to	O
decrease	O
during	O
the	O
development	O
of	O
arthritis	O
and	O
was	O
accompanied	O
by	O
a	O
increase	O
in	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
-	O
ALPHA	O
)	O
and	O
interleukin	O
-	O
1BETA	O
(	O
IL	O
-	O
1BETA	O
)	O
.	O

The	O
metabolism	O
of	O
liquiritigenin	O
and	O
glycyrrhetinic	O
acid	O
were	O
mediated	O
by	O
CYP1A	O
and	O
CYP3A	B
,	O
respectively	O
,	O
and	O
glycyrrhetinic	O
acid	O
could	O
be	O
formed	O
from	O
hydrolysis	O
of	O
glycyrrhizin	O
in	O
intestinal	O
flora	O
according	O
to	O
this	O
summary	O
,	O
while	O
the	O
effect	O
of	O
CYPs	O
on	O
the	O
compounds	O
in	O
Zushima	O
was	O
not	O
reported	O
.	O

Alternatively	O
,	O
some	O
crystal	O
P450	O
structures	O
present	O
a	O
protein	O
that	O
exhibits	O
several	O
molecules	O
of	O
tightly	O
bound	O
ligands	O
,	O
as	O
,	O
for	O
instance	O
,	O
the	O
case	O
of	O
human	O
CYP3A4	B
with	O
a	O
metyrapone	O
molecule	O
bound	O
within	O
the	O
catalytic	O
cavity	O
and	O
a	O
progesterone	O
molecule	O
bound	O
at	O
its	O
surface	O
.	O

have	O
demonstrated	O
that	O
the	O
drug	O
-	O
drug	O
interaction	O
existing	O
between	O
atorvatstatin	O
,	O
which	O
is	O
a	O
cholesterol	O
-	O
lowering	O
drug	O
,	O
and	O
dronedarone	O
,	O
an	O
antiarrythmic	O
drug	O
,	O
on	O
CYP3A4	B
was	O
indeed	O
taking	O
place	O
by	O
a	O
crosstalk	O
between	O
a	O
site	O
on	O
the	O
surface	O
of	O
the	O
enzyme	O
,	O
at	O
which	O
progesterone	O
is	O
seen	O
bound	O
in	O
the	O
crystal	O
structure	O
,	O
and	O
the	O
buried	O
active	O
site	O
.	O

In	O
the	O
same	O
regard	O
,	O
Otyepka	O
and	O
his	O
collaborators	O
used	O
a	O
synergy	O
of	O
MOLE	O
,	O
the	O
standard	O
structure	O
-	O
based	O
approach	O
for	O
identifying	O
access	O
channel	O
,	O
and	O
a	O
bias	O
-	O
exchange	O
molecular	O
metadynamics	O
(	O
BE	O
-	O
META	O
)	O
to	O
study	O
in	O
silico	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
ligand	O
passage	O
through	O
the	O
flexible	O
channels	O
of	O
CYP3A4	B
embedded	O
in	O
a	O
1	O
,	O
2	O
-	O
dioleoyl	O
-	O
sn	O
-	O
glycero	O
-	O
3	O
-	O
phosphocholine	O
membrane	O
environment	O
.	O

A	O
CYP3A4	B
channel	O
,	O
namely	O
2af	O
,	O
seems	O
to	O
not	O
permit	O
exiting	O
through	O
it	O
due	O
to	O
a	O
very	O
high	O
free	O
energy	O
at	O
its	O
mouth	O
for	O
the	O
passage	O
of	O
the	O
product	O
.	O

These	O
results	O
provide	O
new	O
insights	O
into	O
the	O
mechanism	O
of	O
ligand	O
release	O
from	O
CYP3A4	B
.	O

However	O
,	O
the	O
movements	O
of	O
the	O
different	O
elements	O
forming	O
the	O
F	O
/	O
G	O
region	O
are	O
not	O
always	O
easy	O
to	O
identify	O
or	O
to	O
simulate	O
in	O
molecular	O
dynamics	O
,	O
since	O
,	O
for	O
instance	O
,	O
four	O
of	O
the	O
24	O
crystal	O
structures	O
of	O
CYP3A4	B
available	O
in	O
the	O
Protein	O
Data	O
Bank	O
have	O
missing	O
residues	O
in	O
the	O
F	O
and	O
F	O
helices	O
.	O

It	O
has	O
been	O
shown	O
that	O
one	O
of	O
them	O
,	O
channel	O
4	O
,	O
couldbe	O
predominantly	O
a	O
metabolite	O
egress	O
channel	O
in	O
CYP3A4	B
.	O

In	O
a	O
recent	O
study	O
,	O
Petitjean	O
and	O
his	O
collaborators	O
have	O
analyzed	O
24	O
crystal	O
structures	O
of	O
human	O
CYP3A4	B
with	O
their	O
newly	O
developed	O
algorithm	O
Computing	O
Cavities	O
,	O
Channels	O
,	O
Pores	O
And	O
Pockets	O
(	O
Computing	O
Cavities	O
,	O
Channels	O
,	O
Pores	O
and	O
Pockets	O
)	O
that	O
finds	O
out	O
the	O
different	O
ways	O
used	O
by	O
a	O
cylinder	O
to	O
escape	O
the	O
catalytic	O
cavity	O
.	O

They	O
choose	O
CYP3A4	B
because	O
its	O
numerous	O
crystal	O
structures	O
are	O
showing	O
an	O
impressive	O
flexibility	O
of	O
some	O
parts	O
of	O
the	O
protein	O
,	O
suggesting	O
that	O
the	O
ligand	O
access	O
and	O
the	O
exit	O
routes	O
might	O
differ	O
from	O
a	O
P450	O
structure	O
to	O
the	O
next	O
,	O
and	O
that	O
these	O
differences	O
might	O
be	O
correlated	O
to	O
ligand	O
physicochemical	O
properties	O
.	O

By	O
doing	O
so	O
,	O
they	O
have	O
classified	O
the	O
24	O
crystal	O
structures	O
in	O
three	O
groups	O
of	O
different	O
conformations	O
,	O
on	O
closed	O
,	O
named	O
C	O
,	O
in	O
which	O
a	O
substrate	O
-	O
free	O
CYP3A4	B
structure	O
is	O
found	O
,	O
and	O
two	O
open	O
conformations	O
,	O
named	O
O1	O
and	O
O2	O
.	O

They	O
have	O
also	O
identified	O
a	O
series	O
of	O
crucial	O
physicochemical	O
properties	O
for	O
a	O
molecule	O
to	O
be	O
a	O
CYP3A4	B
ligand	O
,	O
namely	O
its	O
hydrophobicity	O
(	O
LogP	O
)	O
,	O
the	O
flatness	O
of	O
the	O
cylinder	O
that	O
describes	O
it	O
,	O
its	O
ability	O
to	O
-	O
interactions	O
,	O
as	O
measured	O
by	O
the	O
Hckel	O
-	O
energy	O
,	O
and	O
the	O
number	O
of	O
ligand	O
molecules	O
that	O
can	O
bind	O
simultaneously	O
to	O
CYP3A4	B
.	O

In	O
this	O
interesting	O
in	O
silico	O
study	O
,	O
they	O
have	O
highlighted	O
the	O
key	O
role	O
of	O
two	O
amino	O
acid	O
residues	O
,	O
Leu212	O
and	O
Phe213	O
,	O
in	O
triggering	O
and	O
controlling	O
the	O
shift	O
between	O
the	O
three	O
different	O
conformations	O
of	O
CYP3A4	B
.	O

Phe213	O
has	O
been	O
also	O
identified	O
independently	O
as	O
a	O
critical	O
residue	O
in	O
allosteric	O
regulations	O
that	O
were	O
observed	O
with	O
CYP3A4	B
when	O
two	O
substrates	O
,	O
carbamazepine	O
and	O
progesterone	O
,	O
were	O
mixed	O
.	O

By	O
molecular	O
dynamic	O
simulations	O
of	O
human	O
CYP3A4	B
,	O
it	O
was	O
predicted	O
that	O
the	O
monooxygenation	O
products	O
of	O
temazepam	O
,	O
which	O
is	O
a	O
benzodiazepine	O
hypnotic	O
,	O
and	O
testosterone	O
are	O
each	O
using	O
a	O
different	O
channel	O
for	O
exiting	O
the	O
catalytic	O
cavity	O
once	O
produced	O
.	O

Two	O
phenylalanine	O
residues	O
were	O
prominent	O
in	O
that	O
control	O
in	O
CYP3A4	B
,	O
Phe215	O
,	O
and	O
Phe220	O
.	O

In	O
a	O
recent	O
study	O
of	O
the	O
binding	O
of	O
metconazole	O
,	O
an	O
enantiomeric	O
P450	O
inhibitor	O
,	O
to	O
CYP3A4	B
,	O
it	O
was	O
shown	O
that	O
two	O
aromatic	O
residues	O
were	O
involved	O
in	O
the	O
differential	O
binding	O
of	O
the	O
RS	O
and	O
SR	O
enantiomers	O
within	O
the	O
catalytic	O
cavity	O
.	O

This	O
again	O
suggests	O
that	O
the	O
different	O
positioning	O
of	O
each	O
enantiomer	O
within	O
CYP3A4	B
active	O
site	O
could	O
result	O
from	O
each	O
eniantomer	O
using	O
different	O
access	O
channels	O
.	O

A	O
molecular	O
dynamics	O
study	O
of	O
CYP3A4	B
embedded	O
in	O
bilayer	O
environments	O
presenting	O
increased	O
levels	O
of	O
cholesterol	O
(	O
from	O
0	O
%	O
up	O
to	O
50	O
%	O
)	O
shows	O
that	O
,	O
as	O
cholesterol	O
amounts	O
increase	O
,	O
the	O
immersion	O
an	O
inclination	O
of	O
the	O
CYP3A4	B
catalytic	O
domain	O
change	O
relatively	O
to	O
the	O
membrane	O
.	O

moreover	O
,	O
the	O
pattern	O
of	O
CYP3A4	B
accessible	O
channels	O
is	O
altered	O
.	O

)	O
,	O
increased	O
erythromycin	O
demethylase	O
(	O
CYP3A	B
-	O
selective	O
)	O
after	O
irradiation	O
with	O
UVB	O
(	O
Goerz	O
et	O
al	O
.	O
.	O
Experiments	O
with	O
submerged	O
cultures	O
of	O
skin	O
cells	O
from	O
newborn	O
rats	O
showed	O
that	O
six	O
-	O
to	O
sevenfold	O
increases	O
in	O
Aryl	O
Hydrocarbon	O
Hydroxylase	O
and	O
in	O
CYP	O
protein	O
after	O
in	O
vitro	O
exposure	O
to	O
benz	O
[	O
a	O
]	O
anthracene	O
.	O

reported	O
that	O
they	O
did	O
not	O
find	O
CYP1	O
,	O
CYP2B6	B
or	O
CYP3A	B
proteins	O
In	O
the	O
reconstructed	O
human	O
skin	O
models	O
EpiDerm	O
,	O
EpiSkin	O
^	O
and	O
SkinEthik	O
^	O
RHE	O
.	O

noticed	O
in	O
human	O
skin	O
microsomes	O
very	O
low	O
CYP3A	B
activities	O
(	O
just	O
exceeding	O
the	O
LOD	O
)	O
using	O
7	O
-	O
benzyloxyquinoline	O
as	O
selective	O
CYP3A	B
substrate	O
and	O
using	O
the	O
luminescent	O
Luc	O
-	O
BE	O
CYP3A	B
-	O
assay	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
,	O
7	O
-	O
Methoxyresorufin	O
-	O
O	O
-	O
Demethylase	O
and	O
PROD	B
<	O
0	O
.	O
2	O
pmolminmg	O
protein	O
)	O
,	O
while	O
very	O
low	O
CYP3A	B
activities	O
were	O
detected	O
(	O
Gtz	O
et	O
al	O
.	O
.	O
These	O
activities	O
and	O
lack	O
of	O
observed	O
activities	O
,	O
respectively	O
,	O
were	O
similar	O
as	O
the	O
results	O
obtained	O
by	O
the	O
same	O
authors	O
in	O
human	O
skin	O
(	O
presented	O
above	O
under	O
Human	O
skin	O
)	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
in	O
SkinEthik	O
^	O
RHE	O
:	O
2	O
.	O
8	O
,	O
in	O
Episkin	O
^	O
:	O
9	O
.	O
1	O
,	O
in	O
Episkin	O
^	O
FTM	O
:	O
2	O
.	O
6	O
,	O
compared	O
with	O
human	O
skin	O
:	O
3	O
.	O
0	O
;	O
7	O
-	O
benzoxy	O
4	O
-	O
trifluoromethylcoumarin	O
O	O
-	O
deethylase	O
activities	O
(	O
CYP3A5	B
/	O
3A7	O
-	O
selective	O
)	O
in	O
SkinEthik	O
^	O
RHE	O
:	O
13	O
.	O
3	O
,	O
in	O
Episkin	O
^	O
:	O
3	O
.	O
6	O
,	O
in	O
Episkin	O
^	O
FTM	O
:	O
3	O
.	O
3	O
,	O
compared	O
with	O
human	O
skin	O
:	O
3	O
.	O
8	O
;	O
7	O
-	O
methoxy	O
-	O
4	O
-	O
trifluoromethylcoumarin	O
O	O
-	O
dealkylase	O
activity	O
was	O
close	O
to	O
the	O
Limit	O
Of	O
Quantitation	O
of	O
0	O
.	O
5	O
in	O
all	O
three	O
skin	O
models	O
and	O
in	O
human	O
skin	O
.	O

CYP3A4	B
and	O
CYP3A5	B
Baron	O
et	O
al	O
.	O

showed	O
that	O
CYP3A5	B
,	O
but	O
not	O
CYP3A4	B
mRNA	O
was	O
constitutively	O
present	O
in	O
proliferating	O
human	O
skin	O
keratinocytes	O
in	O
culture	O
,	O
while	O
the	O
expression	O
of	O
CYP3A4	B
mRNA	O
was	O
induced	O
by	O
treatment	O
with	O
dexamethasone	O
.	O

Cyp3A4	O
mRNA	O
was	O
very	O
variably	O
expressed	O
in	O
various	O
skin	O
systems	O
,	O
whereby	O
it	O
was	O
not	O
clear	O
whether	O
CYP3A4	B
was	O
distinguished	O
from	O
CYP3A5	B
.	O

The	O
authors	O
report	O
that	O
CYP3A4	B
was	O
expressed	O
in	O
native	O
human	O
skin	O
,	O
both	O
in	O
the	O
epidermis	O
(	O
moderate	O
expression	O
in	O
the	O
epidermis	O
of	O
all	O
three	O
donors	O
investigated	O
)	O
and	O
in	O
the	O
dermis	O
(	O
weak	O
expression	O
in	O
the	O
dermis	O
from	O
one	O
out	O
of	O
the	O
three	O
donors	O
)	O
.	O

showed	O
that	O
CYP3A	B
protein	O
was	O
present	O
in	O
human	O
skin	O
.	O

observed	O
that	O
in	O
human	O
skin	O
testosterone	O
was	O
transformed	O
to	O
6	O
-	O
BETA	O
-	O
hydroxytestosterone	O
,	O
a	O
CYP3A	B
-	O
selective	O
activity	O
.	O

reported	O
that	O
native	O
human	O
skin	O
had	O
a	O
low	O
level	O
of	O
CYP3A4	B
protein	O
,	O
moderately	O
induced	O
after	O
24	O
h	O
by	O
2	O
mM	O
phenobarbital	O
,	O
which	O
,	O
however	O
,	O
was	O
not	O
accompanied	O
by	O
an	O
increase	O
in	O
CYP3A4	B
-	O
dependent	O
BROD	O
activity	O
by	O
phenobarbital	O
(	O
0	O
.	O
5	O
-	O
2	O
mM	O
for	O
24	O
,	O
48	O
and	O
72	O
h	O
)	O
nor	O
by	O
rifampicin	O
(	O
50	O
and	O
100	O
M	O
for	O
24	O
h	O
)	O
nor	O
by	O
dexamethasone	O
(	O
10	O
and	O
50	O
M	O
for	O
24	O
,	O
48	O
and	O
72	O
h	O
)	O
.	O

observed	O
in	O
proliferating	O
human	O
skin	O
keratinocytes	O
in	O
culture	O
constitutive	O
demethylation	O
of	O
the	O
CYP3A	B
-	O
selective	O
substrate	O
erythromycin	O
which	O
was	O
increased	O
by	O
treatment	O
with	O
dexamethasone	O
.	O

reported	O
that	O
the	O
hydroxylation	O
of	O
the	O
CYP3A	B
-	O
selective	O
substrate	O
cyclosporine	O
A	O
was	O
predominantly	O
occurring	O
in	O
human	O
dermis	O
-	O
derived	O
cultures	O
.	O

Some	O
examples	O
of	O
CYP3A	B
substrates	O
,	O
as	O
observed	O
in	O
skin	O
or	O
other	O
systems	O
:	O
17BETA	O
-	O
estadiol	O
,	O
ethinylestradiol	O
,	O
progesterone	O
,	O
levonorgestrel	O
,	O
testosterone	O
,	O
dehydroepiandrosterone	O
,	O
cortisol	O
,	O
dexamethasone	O
,	O
acetaminophen	O
,	O
benzphetamine	O
,	O
nifedipine	O
,	O
midazolam	O
,	O
aflatoxin	O
B_1	O
(	O
Oesch	O
-	O
Bartlomowicz	O
and	O
Oesch	O
.	O

Figure	O
shows	O
the	O
thermostability	O
results	O
for	O
the	O
CYP3A4	B
Wild	O
-	O
Type	O
and	O
variant	O
proteins	O
.	O

To	O
determine	O
the	O
effect	O
of	O
polymorphic	O
variation	O
on	O
CYP3A4	B
stability	O
,	O
the	O
effect	O
of	O
mutations	O
on	O
the	O
half	O
-	O
life	O
of	O
the	O
unstable	O
sub	O
-	O
population	O
and	O
the	O
effect	O
of	O
mutations	O
on	O
the	O
plateau	O
-	O
the	O
proportion	O
of	O
P450	O
making	O
up	O
the	O
stable	O
sub	O
-	O
population	O
-	O
were	O
considered	O
.	O

The	O
major	O
CYP3A4	B
peak	O
has	O
a	O
shoulder	O
corresponding	O
roughly	O
to	O
a	O
trimeric	O
or	O
tetrameric	O
protein	O
.	O

In	O
support	O
of	O
this	O
idea	O
,	O
previous	O
published	O
studies	O
examining	O
the	O
binding	O
kinetics	O
of	O
Carbon	O
Monoxide	O
to	O
CYP3A4	B
using	O
flash	O
photolysis	O
have	O
argued	O
that	O
there	O
are	O
two	O
kinetically	O
distinct	O
pools	O
of	O
P450	O
,	O
both	O
in	O
the	O
membrane	O
and	O
in	O
solution	O
^	O
,	O
.	O

Other	O
studies	O
have	O
also	O
observed	O
conformational	O
heterogeneity	O
for	O
CYP2B4	O
^	O
,	O
and	O
CYP3A4	B
proteins	O
^	O
using	O
hydrostatic	O
pressure	O
spectroscopy	O
.	O

In	O
another	O
study	O
it	O
was	O
shown	O
that	O
70	O
%	O
of	O
CYP3A4	B
in	O
solution	O
and	O
50	O
%	O
in	O
microsomes	O
was	O
susceptible	O
to	O
substrate	O
-	O
induced	O
spin	O
shifts	O
and	O
rapid	O
,	O
reversible	O
pressure	O
-	O
induced	O
P450	O
to	O
P420	O
conversions	O
^	O
.	O

In	O
solution	O
,	O
this	O
remaining	O
fraction	O
was	O
subject	O
to	O
slow	O
,	O
irreversible	O
inactivation	O
at	O
high	O
pressures	O
indicating	O
that	O
the	O
pressure	O
induced	O
P450	O
to	O
P420	O
conversion	O
of	O
CYP3A4	B
was	O
biphasic	O
consisting	O
of	O
a	O
fast	O
-	O
reversible	O
phase	O
and	O
a	O
slow	O
-	O
irreversible	O
phase	O
.	O

Similarly	O
to	O
CYP2B4	O
,	O
the	O
addition	O
of	O
detergents	O
known	O
to	O
break	O
up	O
oligomers	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
heterogeneity	O
of	O
CYP3A4	B
observed	O
in	O
solution	O
.	O

probed	O
the	O
geometry	O
of	O
CYP3A4	B
oligomers	O
in	O
microsomes	O
using	O
luminescence	O
energy	O
transfer	O
and	O
intermolecular	O
cross	O
-	O
linking	O
experiments	O
^	O
.	O

Their	O
results	O
suggest	O
that	O
the	O
most	O
likely	O
size	O
of	O
the	O
CYP3A4	B
oligomer	O
in	O
solution	O
and	O
in	O
the	O
membrane	O
is	O
a	O
trimer	O
(	O
or	O
multiples	O
of	O
this	O
)	O
,	O
involving	O
two	O
different	O
types	O
of	O
interaction	O
interfaces	O
between	O
subunits	O
,	O
one	O
of	O
which	O
is	O
similar	O
to	O
the	O
subunit	O
interface	O
observed	O
in	O
the	O
progesterone	O
-	O
bound	O
CYP3A4	B
crystal	O
structure	O
(	O
PDB	O
code	O
1W0F	O
)	O
^	O
.	O

The	O
estimated	O
molecular	O
weight	O
of	O
the	O
major	O
CYP3A4	B
oligomer	O
species	O
were	O
583	O
and	O
239	O
kDa	O
corresponded	O
most	O
closely	O
to	O
a	O
nonamer	O
and	O
a	O
tetramer	O
,	O
respectively	O
.	O

work	O
which	O
suggests	O
that	O
CYP3A4	B
oligomers	O
are	O
made	O
up	O
of	O
trimers	O
and	O
would	O
explain	O
the	O
1	O
:	O
2	O
conformer	O
distribution	O
observed	O
for	O
CYP3A4	B
,	O
where	O
3	O
of	O
the	O
monomeric	O
subunits	O
are	O
more	O
stable	O
than	O
the	O
other	O
6	O
.	O

A	O
previous	O
study	O
observed	O
at	O
least	O
three	O
major	O
CYP3A4	B
oligomers	O
in	O
solution	O
with	O
molecular	O
masses	O
of	O
215	O
,	O
290	O
,	O
and	O
450	O
kDa	O
using	O
continuous	O
molecular	O
weight	O
distribution	O
analysis	O
^	O
.	O

Mutations	O
in	O
close	O
proximity	O
to	O
the	O
haem	O
-	O
binding	O
region	O
,	O
such	O
as	O
L373F	O
(	O
haem	O
contact	O
)	O
and	O
M445T	O
(	O
predicted	O
to	O
be	O
destabilising	O
by	O
SDM	O
)	O
in	O
CYP3A4	B
,	O
destabilise	O
the	O
haem	O
significantly	O
in	O
both	O
conformers	O
,	O
increasing	O
the	O
proportion	O
of	O
protein	O
sensitive	O
to	O
rapid	O
heat	O
-	O
induced	O
conversion	O
to	O
P420	O
and	O
decreasing	O
the	O
half	O
-	O
life	O
of	O
this	O
conversion	O
.	O

While	O
this	O
residue	O
does	O
not	O
fall	O
within	O
a	O
substrate	O
recognition	O
site	O
,	O
it	O
is	O
solvent	O
accessible	O
and	O
is	O
predicted	O
to	O
form	O
part	O
of	O
the	O
CYP3A4	B
:	O
CPR	O
interface	O
so	O
any	O
destabilising	O
effects	O
in	O
this	O
region	O
may	O
also	O
alter	O
interactions	O
with	O
Cytochrome	B
P450	I
Reductase	O
.	O

CYP3A4	B
mutation	O
G56D	O
had	O
a	O
similar	O
effect	O
to	O
the	O
L373F	O
mutation	O
;	O
while	O
Gly	O
56	O
is	O
not	O
in	O
close	O
proximity	O
to	O
the	O
haem	O
-	O
binding	O
region	O
,	O
it	O
was	O
predicted	O
to	O
be	O
a	O
destabilising	O
mutation	O
by	O
Site	O
Directed	O
Mutator	O
and	O
falls	O
within	O
SRS1a	O
.	O

For	O
reasons	O
less	O
immediately	O
apparent	O
,	O
P218R	O
and	O
S222P	O
had	O
a	O
significant	O
effect	O
on	O
the	O
thermostability	O
of	O
CYP3A4	B
;	O
P218R	O
and	O
S222P	O
were	O
both	O
predicted	O
to	O
be	O
neutral	O
by	O
Site	O
Directed	O
Mutator	O
and	O
fall	O
within	O
the	O
flexible	O
F	O
-	O
G	O
loop	O
,	O
which	O
is	O
far	O
away	O
from	O
the	O
haem	O
-	O
binding	O
site	O
but	O
forms	O
part	O
of	O
substrate	O
recognition	O
site	O
(	O
2	O
,	O
3	O
)	O
at	O
the	O
proposed	O
interface	O
of	O
the	O
interacting	O
Cytochrome	B
P450	I
subunits	O
,	O
close	O
to	O
the	O
peripheral	O
effector	O
site	O
acts	O
as	O
a	O
lid	O
over	O
the	O
active	O
site	O
cavity	O
and	O
is	O
comprised	O
of	O
the	O
F	O
and	O
G	O
helix	O
connected	O
by	O
the	O
F	O
-	O
G	O
loop	O
.	O

Unlike	O
Pro	O
218	O
and	O
Ser	O
222	O
,	O
which	O
are	O
both	O
solvent	O
exposed	O
residues	O
with	O
side	O
chains	O
orientated	O
towards	O
the	O
bulk	O
solvent	O
,	O
Ile	O
223	O
is	O
buried	O
indicating	O
that	O
it	O
is	O
unlikely	O
to	O
interact	O
with	O
other	O
CYP3A4	B
molecules	O
directly	O
without	O
a	O
substantial	O
change	O
in	O
protein	O
conformation	O
.	O

A	O
recently	O
reported	O
crystal	O
structure	O
of	O
the	O
CYP3A4	B
I359L	O
variant	O
suggests	O
that	O
this	O
mutation	O
has	O
long	O
range	O
effects	O
-	O
transduced	O
along	O
the	O
I	O
-	O
helix	O
-	O
on	O
the	O
orientation	O
of	O
active	O
site	O
residues	O
,	O
altering	O
the	O
binding	O
mode	O
of	O
losartan	O
within	O
the	O
active	O
site	O
compared	O
to	O
the	O
wild	O
-	O
type	O
structure	O
^	O
.	O

Buried	O
Single	O
Nucleotide	O
Polymorphisms	O
in	O
close	O
proximity	O
to	O
the	O
haem	O
(	O
eg	O
CYP3A4	B
L373F	O
)	O
as	O
well	O
as	O
Single	O
Nucleotide	O
Polymorphisms	O
further	O
away	O
from	O
the	O
haem	O
-	O
binding	O
site	O
(	O
eg	O
CYP3A4	B
G56D	O
)	O
-	O
including	O
residues	O
in	O
solvent	O
accessible	O
,	O
variable	O
flexible	O
regions	O
predicted	O
to	O
be	O
neutral	O
(	O
eg	O
CYP3A4	B
,	O
S222P	O
and	O
P218R	O
)	O
-	O
had	O
significant	O
effects	O
on	O
thermostability	O
of	O
the	O
P450	O
form	O
.	O

For	O
example	O
,	O
bergamottin	O
is	O
reported	O
to	O
increase	O
the	O
blood	O
concentration	O
of	O
drugs	O
through	O
inhibition	O
of	O
hepatic	O
CYP3A	B
activity	O
,	O
thereby	O
enhancing	O
the	O
toxicity	O
of	O
drugs	O
such	O
as	O
atorvastatin	O
,	O
felodipine	O
,	O
and	O
verapamil	O
.	O

The	O
substrate	O
behavior	O
prediction	O
in	O
the	O
CYP3A4	B
indicated	O
that	O
only	O
1	O
and	O
2	O
could	O
be	O
substrates	O
,	O
because	O
these	O
molecules	O
meet	O
the	O
characteristics	O
of	O
the	O
pharmacophore	O
model	O
for	O
this	O
cytochrome	O
.	O

used	O
NMR	O
-	O
based	O
metabolomics	O
to	O
identify	O
a	O
metabolic	O
signature	O
associated	O
with	O
a	O
variation	O
in	O
induced	O
CYP3A4	B
activity	O
.	O

Ultraperformance	O
liquid	O
chromatography	O
combined	O
with	O
mass	O
spectrometry	O
was	O
performed	O
to	O
obtain	O
a	O
marker	O
for	O
CYP3A4	B
induction	O
:	O
the	O
ratio	O
of	O
3	O
-	O
hydroxyquinine	O
to	O
quinine	O
(	O
3OH	O
-	O
Q	O
/	O
Q	O
)	O
.	O

showed	O
that	O
the	O
plasma	O
concentrations	O
of	O
4b	O
-	O
hydroxycholesterol	O
increased	O
after	O
complete	O
induction	O
of	O
CYP3A4	B
/	O
5	O
by	O
carbamazepine	O
or	O
rifampicin	O
.	O

The	O
authors	O
suggested	O
that	O
4b	O
-	O
hydroxycholesterol	O
may	O
be	O
used	O
as	O
an	O
endogenous	O
marker	O
of	O
CYP3A	B
activity	O
.	O

Such	O
information	O
can	O
help	O
to	O
predict	O
CYP3A	B
activity	O
and	O
the	O
metabolism	O
level	O
of	O
CYP3A	B
-	O
mediated	O
drugs	O
prior	O
to	O
administration	O
.	O

One	O
example	O
of	O
the	O
modifying	O
influence	O
of	O
external	O
factors	O
is	O
the	O
effect	O
of	O
grapefruit	O
juice	O
components	O
on	O
the	O
expression	O
of	O
cytochrome	B
P	I
-	I
450	I
(	O
CYP3A4	B
)	O
and	O
,	O
accordingly	O
,	O
on	O
the	O
pharmacokinetics	O
of	O
CYP3A	B
-	O
mediated	O
drugs	O
.	O

The	O
Inhibitory	O
Effect	O
of	O
Flavonoid	O
Aglycones	O
on	O
the	O
Metabolic	O
Activity	O
of	O
CYP3A4	B
Enzyme	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
focus	O
on	O
possible	O
interactions	O
between	O
the	O
30	O
most	O
commonly	O
encountered	O
flavonoid	O
aglycones	O
on	O
the	O
metabolic	O
activity	O
of	O
CYP3A4	B
enzyme	O
.	O

6BETA	O
-	O
hydroxylation	O
of	O
testosterone	O
was	O
used	O
as	O
marker	O
reaction	O
of	O
CYP3A4	B
activity	O
.	O

Out	O
of	O
the	O
30	O
flavonoids	O
tested	O
,	O
7	O
significantly	O
inhibited	O
CYP3A4	B
,	O
most	O
prominent	O
being	O
acacetin	O
that	O
inhibited	O
95	O
%	O
of	O
enzyme	O
activity	O
at	O
1	O
M	O
concentration	O
.	O

These	O
results	O
alert	O
on	O
possible	O
flavonoid	O
-	O
drug	O
interactions	O
on	O
the	O
level	O
of	O
CYP3A4	B
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
inhibitory	O
effect	O
of	O
thirty	O
flavonoid	O
aglycones	O
,	O
most	O
commonly	O
found	O
in	O
herbal	O
drugs	O
and	O
propolis	O
,	O
on	O
the	O
most	O
important	O
drug	O
metabolizing	O
enzyme	O
CYP3A4	B
.	O

For	O
enzyme	O
activity	O
assessment	O
testosterone	O
6BETA	O
-	O
hydroxylation	O
was	O
used	O
as	O
it	O
represents	O
a	O
marker	O
reaction	O
of	O
CYP3A4	B
activity	O
.	O

To	O
test	O
the	O
CYP3A4	B
enzyme	O
inhibition	O
,	O
residual	O
activity	O
was	O
assessed	O
based	O
on	O
the	O
product	O
of	O
the	O
marker	O
reaction	O
generated	O
by	O
monitoring	O
incubations	O
with	O
addition	O
of	O
flavonoid	O
,	O
as	O
a	O
potential	O
inhibitor	O
,	O
versus	O
incubations	O
without	O
inhibitor	O
.	O

Negative	O
control	O
(	O
incubation	O
with	O
substrate	O
and	O
without	O
the	O
NADPH	O
generating	O
system	O
)	O
shows	O
no	O
product	O
generation	O
,	O
confirming	O
that	O
6BETA	O
-	O
hydroxytestosterone	O
is	O
product	O
of	O
generated	O
by	O
CYP3A4	B
enzyme	O
.	O

Troleandomycin	O
,	O
an	O
irreversible	O
inhibitor	O
of	O
CYP3A4	B
,	O
used	O
as	O
a	O
positive	O
control	O
in	O
25	O
M	O
concentration	O
caused	O
complete	O
inhibition	O
of	O
CYP3A4	B
,	O
while	O
0	O
.	O
15	O
M	O
ketoconazole	O
,	O
a	O
direct	O
reversible	O
inhibitor	O
of	O
CYP3A4	B
,	O
reduced	O
enzyme	O
activity	O
by	O
80	O
4	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Seven	O
flavonoids	O
have	O
been	O
shown	O
to	O
inhibit	O
CYP3A4	B
with	O
statistical	O
significance	O
p	O
<	O
0	O
.	O
05	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
on	O
CYP3A4	B
inhibition	O
.	O

Although	O
pharmacokinetic	O
of	O
pinocembrin	O
was	O
studied	O
,	O
no	O
CYP3A4	B
inhibition	O
was	O
reported	O
.	O

Residual	O
activity	O
of	O
CYP3A4	B
after	O
incubations	O
with	O
flavones	O
apigenin	O
,	O
chrysin	O
,	O
chrysin	O
dimethyl	O
ether	O
,	O
and	O
tangerine	O
was	O
24	O
%	O
,	O
17	O
%	O
,	O
61	O
%	O
,	O
and	O
42	O
%	O
.	O

Reversible	O
inhibition	O
of	O
CYP3A4	B
by	O
apigenin	O
was	O
reported	O
by	O
Li	O
et	O
al	O
.	O

However	O
,	O
based	O
on	O
our	O
study	O
metabolism	O
dependent	O
inhibition	O
of	O
CYP3A4	B
by	O
apigenin	O
,	O
here	O
reported	O
for	O
the	O
first	O
time	O
,	O
is	O
of	O
greater	O
importance	O
.	O

Neither	O
chrysin	O
,	O
nor	O
chrysin	O
dimethylether	O
were	O
reported	O
as	O
inhibitors	O
of	O
CYP3A4	B
previously	O
.	O

Although	O
the	O
effect	O
of	O
chrysin	O
on	O
1	O
-	O
hydroxilation	O
of	O
midazolam	O
(	O
another	O
marker	O
reaction	O
of	O
CYP3A4	B
enzyme	O
)	O
was	O
studied	O
,	O
inhibition	O
of	O
CYP3A4	B
activity	O
was	O
not	O
observed	O
.	O

However	O
,	O
in	O
our	O
study	O
in	O
which	O
residual	O
activity	O
of	O
CYP3A4	B
was	O
studied	O
on	O
testosterone	O
as	O
marker	O
substrate	O
,	O
an	O
inhibitory	O
effect	O
was	O
observed	O
.	O

who	O
reported	O
that	O
tangeretin	O
inhibited	O
CYP3A4	B
mediated	O
nifedipine	O
oxidation	O
in	O
human	O
liver	O
microsomes	O
in	O
an	O
uncompetitive	O
manner	O
with	O
inhibition	O
constant	O
of	O
72	O
M	O
.	O
Lastly	O
,	O
Takanaga	O
et	O
al	O
.	O

reported	O
no	O
influence	O
of	O
tangeretin	O
,	O
neither	O
activation	O
,	O
nor	O
inhibition	O
,	O
on	O
CYP3A4	B
activity	O
when	O
using	O
testosterone	O
as	O
marker	O
substrate	O
on	O
human	O
liver	O
microsomes	O
and	O
recombinant	O
CYP3A4	B
systems	O
.	O

Observed	O
difference	O
justifies	O
recommendations	O
of	O
medicinal	O
products	O
regulatory	O
agencies	O
to	O
use	O
at	O
least	O
two	O
marker	O
substrates	O
when	O
studding	O
CYP3A4	B
activity	O
.	O

did	O
not	O
observe	O
change	O
in	O
activity	O
of	O
CYP3A4	B
treated	O
with	O
isorhamnetin	O
on	O
hepatocyte	O
carcinoma	O
cell	O
line	O
HepG2	O
.	O

Interestingly	O
,	O
stimulation	O
of	O
enzyme	O
activity	O
of	O
CYP3A4	B
was	O
observed	O
with	O
tamarixetin	O
;	O
observed	O
residual	O
activity	O
was	O
195	O
%	O
.	O

have	O
shown	O
that	O
tamarixetin	O
has	O
no	O
influence	O
on	O
CYP3A4	B
induction	O
through	O
pregnane	O
X	O
receptor	O
,	O
constitutive	O
androstane	O
receptor	O
,	O
and	O
aryl	O
hydrocarbon	O
receptor	O
.	O

Our	O
observation	O
of	O
stimulation	O
of	O
CYP3A4	B
activity	O
by	O
tamarixetin	O
is	O
in	O
contrast	O
to	O
von	O
Moltke	O
et	O
al	O
.	O

Although	O
stimulation	O
in	O
vitro	O
(	O
not	O
mediated	O
by	O
increased	O
induction	O
of	O
enzyme	O
in	O
vivo	O
)	O
is	O
rarely	O
observed	O
,	O
it	O
has	O
been	O
reported	O
that	O
anticancer	O
drug	O
gefitinib	O
is	O
a	O
potent	O
stimulator	O
of	O
CYP3A4	B
.	O

Looking	O
at	O
the	O
structural	O
features	O
responsible	O
for	O
the	O
inhibitory	O
effect	O
,	O
it	O
can	O
be	O
observed	O
that	O
flavanones	O
and	O
flavones	O
hydroxylated	O
at	O
the	O
positions	O
5	O
and	O
7	O
of	O
the	O
A	O
ring	O
,	O
and	O
monosubstituted	O
at	O
the	O
position	O
4	O
of	O
the	O
B	O
ring	O
,	O
decrease	O
CYP3A4	B
enzyme	O
activity	O
regardless	O
of	O
group	O
present	O
(	O
methoxy	O
or	O
hydroxyl	O
)	O
eg	O
,	O
acacetin	O
and	O
apigenin	O
.	O

As	O
the	O
hydroxyl	O
group	O
at	O
the	O
B	O
ring	O
is	O
nonionizable	O
under	O
the	O
physiological	O
pH	O
,	O
hydrophobic	O
interactions	O
of	O
the	O
flavonoid	O
with	O
the	O
CYP3A4	B
are	O
probably	O
of	O
importance	O
.	O

However	O
,	O
in	O
that	O
instance	O
hydroxyl	O
group	O
should	O
not	O
be	O
methylated	O
,	O
and	O
susceptible	O
to	O
ionization	O
under	O
physiological	O
conditions	O
,	O
indicating	O
importance	O
of	O
ion	O
-	O
ion	O
interactions	O
between	O
flavanones	O
and	O
CYP3A4	B
enzyme	O
.	O

To	O
distinguish	O
if	O
the	O
observed	O
metabolism	O
dependent	O
inhibition	O
(	O
of	O
the	O
seven	O
confirmed	O
inhibitors	O
of	O
CYP3A4	B
in	O
this	O
study	O
)	O
was	O
a	O
result	O
of	O
time	O
dependent	O
inhibition	O
,	O
in	O
which	O
additional	O
time	O
is	O
needed	O
for	O
the	O
inhibitor	O
to	O
interact	O
with	O
enzyme	O
to	O
cause	O
the	O
inhibition	O
,	O
preincubations	O
were	O
conducted	O
without	O
presence	O
of	O
NADPH	O
coenzyme	O
.	O

In	O
this	O
way	O
,	O
no	O
reduction	O
of	O
CYP3A4	B
heme	O
iron	O
to	O
Fe	O
^	O
2	O
+	O
form	O
occurred	O
,	O
giving	O
sufficient	O
time	O
for	O
the	O
potential	O
inhibitor	O
to	O
interact	O
with	O
the	O
enzyme	O
.	O

Residual	O
CYP3A4	B
activity	O
was	O
57	O
10	O
%	O
(	O
p	O
=	O
0	O
.	O
047	O
)	O
,	O
34	O
10	O
%	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
and	O
45	O
3	O
%	O
(	O
p	O
=	O
0	O
.	O
019	O
)	O
,	O
respectively	O
.	O

However	O
,	O
no	O
statistical	O
difference	O
was	O
observed	O
in	O
residual	O
activity	O
of	O
CYP3A4	B
enzyme	O
for	O
apigenin	O
between	O
metabolism	O
and	O
time	O
dependent	O
inhibition	O
assays	O
,	O
indicating	O
that	O
apigenin	O
is	O
pure	O
reversible	O
inhibitor	O
of	O
CYP3A4	B
.	O

No	O
time	O
dependent	O
inhibition	O
was	O
observed	O
with	O
chrysin	O
dimethylether	O
,	O
isorhamnetin	O
,	O
pinocembrin	O
,	O
and	O
tangeretin	O
,	O
and	O
this	O
was	O
confirmed	O
in	O
direct	O
inhibition	O
assay	O
,	O
indicating	O
these	O
four	O
flavonoids	O
are	O
irreversible	O
inhibitors	O
of	O
CYP3A4	B
.	O

Direct	O
inhibition	O
assay	O
showed	O
inhibitory	O
effect	O
of	O
acacetin	O
,	O
apigenin	O
,	O
and	O
chrysin	O
on	O
CYP3A4	B
by	O
decreasing	O
residual	O
enzyme	O
activity	O
to	O
46	O
6	O
%	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
35	O
18	O
%	O
(	O
p	O
=	O
0	O
.	O
049	O
)	O
,	O
and	O
54	O
23	O
%	O
(	O
p	O
=	O
0	O
.	O
044	O
)	O
,	O
respectively	O
.	O

These	O
results	O
show	O
that	O
no	O
real	O
time	O
dependent	O
inhibition	O
is	O
present	O
,	O
and	O
observed	O
inhibition	O
of	O
CYP3A4	B
in	O
time	O
dependent	O
inhibition	O
assay	O
is	O
consequence	O
of	O
the	O
direct	O
inhibition	O
.	O

Time	O
dependent	O
inhibition	O
is	O
extremely	O
rare	O
for	O
human	O
cytochromes	O
P450	O
and	O
has	O
been	O
previously	O
reported	O
only	O
for	O
cilengitide	O
,	O
an	O
experimental	O
anticancer	O
drug	O
used	O
for	O
treatment	O
of	O
glioblastoma	O
,	O
and	O
CYP3A4	B
enzyme	O
in	O
which	O
inhibitor	O
was	O
in	O
extremely	O
high	O
millimolar	O
concentration	O
.	O

Moreover	O
,	O
data	O
published	O
is	O
not	O
always	O
confirmed	O
by	O
subsequent	O
studies	O
,	O
eg	O
,	O
tamarixetin	O
is	O
activator	O
of	O
CYP3A4	B
in	O
our	O
study	O
,	O
while	O
previously	O
it	O
has	O
been	O
reported	O
that	O
it	O
either	O
has	O
no	O
effect	O
or	O
it	O
inhibits	O
CYP3A4	B
.	O

For	O
the	O
first	O
time	O
we	O
have	O
reported	O
inhibition	O
of	O
CYP3A4	B
by	O
acacetin	O
,	O
pinocembrin	O
,	O
chrysin	O
,	O
and	O
chrysin	O
dimethylether	O
,	O
and	O
we	O
have	O
also	O
shown	O
that	O
pinocembrin	O
and	O
isorhamnetin	O
act	O
as	O
irreversible	O
inhibitors	O
of	O
CYP3A4	B
.	O

Sometimes	O
inhibitors	O
can	O
have	O
both	O
reversible	O
and	O
irreversible	O
effect	O
on	O
the	O
enzyme	O
as	O
it	O
has	O
been	O
shown	O
with	O
cilengitide	O
and	O
CYP3A4	B
.	O

For	O
the	O
evaluation	O
of	O
activity	O
of	O
CYP3A4	B
testosterone	O
was	O
used	O
as	O
marker	O
substrate	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

6BETA	O
-	O
Hydroxylation	O
of	O
testosterone	O
was	O
used	O
as	O
marker	O
reaction	O
to	O
monitor	O
activity	O
of	O
the	O
CYP3A4	B
enzyme	O
.	O

Incubation	O
mixture	O
contained	O
5	O
pmol	O
of	O
the	O
CYP3A4	B
enzyme	O
.	O

Out	O
of	O
30	O
flavonoids	O
screened	O
for	O
potential	O
CYP3A4	B
enzyme	O
inhibition	O
,	O
7	O
showed	O
statistically	O
significant	O
inhibition	O
.	O

These	O
results	O
bring	O
attention	O
to	O
possible	O
flavonoid	O
-	O
drug	O
interactions	O
on	O
the	O
level	O
of	O
CYP3A4	B
.	O

As	O
CYP3A4	B
is	O
the	O
most	O
significant	O
enzyme	O
for	O
the	O
metabolism	O
of	O
xenobiotics	O
including	O
drugs	O
,	O
further	O
in	O
vivo	O
studies	O
are	O
needed	O
to	O
assess	O
clinical	O
significance	O
of	O
the	O
observed	O
inhibitions	O
,	O
and	O
possible	O
drug	O
-	O
flavonoid	O
interactions	O
.	O

CYP3A4	B
,	O
a	O
major	O
enzyme	O
that	O
is	O
expressed	O
in	O
adult	O
liver	O
,	O
has	O
been	O
considered	O
to	O
be	O
an	O
important	O
factor	O
affecting	O
drug	O
absorption	O
.	O

The	O
effects	O
of	O
quercetin	O
,	O
kaempferol	O
,	O
isoquercitrin	O
and	O
astragalin	O
in	O
L	O
.	O
clethroides	O
and	O
ketoconazole	O
(	O
positive	O
control	O
)	O
on	O
CYP3A4	B
activity	O
are	O
shown	O
in	O
and	O
.	O

Ketoconazole	O
strongly	O
inhibited	O
the	O
production	O
of	O
6BETA	O
-	O
hydroxytestosterone	O
(	O
IC_50	O
=	O
0	O
.	O
25	O
0	O
.	O
01	O
M	O
)	O
,	O
but	O
the	O
effects	O
of	O
the	O
four	O
flavonoids	O
in	O
L	O
.	O
clethroides	O
on	O
CYP3A4	B
were	O
very	O
weak	O
and	O
their	O
IC_50	O
values	O
could	O
not	O
be	O
calculated	O
.	O

The	O
incubation	O
conditions	O
of	O
CYP3A4	B
were	O
basically	O
the	O
same	O
as	O
those	O
described	O
in	O
but	O
the	O
volume	O
of	O
incubation	O
mixture	O
was	O
500	O
L	O
and	O
the	O
reactions	O
were	O
terminated	O
by	O
adding	O
700	O
L	O
of	O
ice	O
-	O
cold	O
acetonitrile	O
containing	O
25	O
M	O
phenacetin	O
.	O

CYP3A4	B
showed	O
concentration	O
-	O
dependent	O
inhibition	O
by	O
ASP	O
,	O
GRT	O
,	O
and	O
FRE	O
at	O
25	O
,	O
50	O
,	O
and	O
100	O
g	O
/	O
mL	O
concentrations	O
.	O

ASP	O
,	O
GRT	O
,	O
and	O
FRE	O
time	O
-	O
dependently	O
inhibited	O
CYP3A4	B
activity	O
with	O
GRT	O
and	O
FRE	O
showing	O
a	O
more	O
potent	O
time	O
-	O
dependent	O
inhibition	O
,	O
comparable	O
to	O
erythromycin	O
.	O

Atorvastatin	O
used	O
to	O
treat	O
hypercholesterolemia	O
is	O
metabolized	O
by	O
CYP3A4	B
.	O

Most	O
drugs	O
and	O
xenobiotics	O
including	O
dietary	O
polyphenols	O
have	O
the	O
ability	O
to	O
bind	O
to	O
CYP3A4	B
as	O
substrates	O
.	O

Both	O
extracts	O
moderately	O
inhibited	O
CYP3A4	B
activity	O
(	O
31	O
.	O
33	O
4	O
.	O
69	O
g	O
/	O
mL	O
and	O
51	O
.	O
44	O
4	O
.	O
31	O
g	O
/	O
mL	O
,	O
respectively	O
)	O
(	O
b	O
)	O
,	O
while	O
ASP	O
displayed	O
weak	O
inhibition	O
of	O
CYP3A4	B
activity	O
(	O
69	O
.	O
57	O
4	O
.	O
03	O
g	O
/	O
mL	O
)	O
(	O
b	O
)	O
.	O

ASP	O
,	O
GRT	O
,	O
and	O
FRE	O
reduced	O
CYP3A4	B
activity	O
at	O
25	O
g	O
/	O
mL	O
(	O
62	O
.	O
9	O
%	O
,	O
36	O
.	O
9	O
%	O
and	O
61	O
.	O
4	O
%	O
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
50	O
g	O
/	O
mL	O
(	O
44	O
.	O
5	O
%	O
,	O
13	O
.	O
5	O
%	O
and	O
29	O
.	O
7	O
%	O
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
100	O
g	O
/	O
mL	O
(	O
28	O
.	O
1	O
%	O
,	O
1	O
.	O
7	O
%	O
and	O
9	O
.	O
2	O
%	O
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
(	O
c	O
)	O
.	O

PPAG	O
demonstrated	O
time	O
-	O
dependent	O
inhibition	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
only	O
CYP3A4	B
(	O
c	O
)	O
.	O

An	O
interesting	O
finding	O
,	O
however	O
,	O
is	O
the	O
time	O
-	O
dependent	O
inhibition	O
of	O
CYP3A4	B
activity	O
by	O
GRT	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
FRE	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
displaying	O
a	O
similar	O
effect	O
to	O
that	O
of	O
erythromycin	O
(	O
c	O
)	O
.	O

These	O
constituents	O
include	O
various	O
bioactive	O
compounds	O
that	O
can	O
either	O
activate	O
or	O
inhibit	O
CYP3A4	B
.	O

Echinacea	O
purpurea	O
,	O
a	O
known	O
plant	O
-	O
based	O
product	O
with	O
constituents	O
such	O
as	O
caffeic	O
acid	O
derivatives	O
,	O
amides	O
,	O
flavonoids	O
,	O
and	O
glycosides	O
,	O
displayed	O
weak	O
inhibitory	O
effects	O
of	O
CYP3A4	B
activity	O
with	O
IC_50	O
values	O
of	O
354	O
-	O
5394	O
g	O
/	O
mL	O
,	O
and	O
modestly	O
induced	O
hepatic	O
CYP3A4	B
activity	O
,	O
thereby	O
lowering	O
the	O
effective	O
concentration	O
of	O
drugs	O
,	O
such	O
as	O
midazolam	O
.	O

Of	O
these	O
,	O
CYP3A4	B
is	O
commonly	O
involved	O
in	O
herb	O
-	O
drug	O
interactions	O
as	O
it	O
metabolizes	O
about	O
50	O
%	O
of	O
clinically	O
-	O
prescribed	O
medications	O
.	O

for	O
rats	O
ingesting	O
rooibos	O
tea	O
for	O
two	O
weeks	O
suggested	O
a	O
possible	O
interaction	O
between	O
rooibos	O
tea	O
and	O
medicines	O
mediated	O
by	O
CYP3A	B
.	O

GRT	O
containing	O
higher	O
levels	O
of	O
polyphenols	O
,	O
in	O
particular	O
ASP	O
(	O
12	O
.	O
78	O
%	O
compared	O
to	O
0	O
.	O
36	O
%	O
)	O
,	O
demonstrated	O
a	O
more	O
potent	O
inhibition	O
of	O
CYP3A4	B
activity	O
than	O
FRE	O
with	O
IC_50	O
values	O
of	O
31	O
.	O
33	O
4	O
.	O
69	O
g	O
/	O
mL	O
and	O
51	O
.	O
44	O
4	O
.	O
31	O
g	O
/	O
mL	O
,	O
respectively	O
.	O

ASP	O
,	O
as	O
the	O
major	O
compound	O
,	O
moderately	O
inhibited	O
CYP3A4	B
activity	O
with	O
an	O
IC_50	O
value	O
of	O
69	O
.	O
57	O
4	O
.	O
03	O
g	O
/	O
mL	O
.	O

Luteolin	O
,	O
the	O
aglycone	O
of	O
rooibos	O
flavone	O
glucosides	O
,	O
orientin	O
and	O
isoorientin	O
,	O
and	O
quercetin	O
,	O
the	O
aglycone	O
of	O
rooibos	O
flavonol	O
glycosides	O
,	O
quercetin	O
-	O
3	O
-	O
O	O
-	O
robinobioside	O
,	O
rutin	O
,	O
hyperoside	O
,	O
and	O
isoquercitrin	O
,	O
have	O
previously	O
been	O
shown	O
to	O
inhibit	O
CYP3A4	B
.	O

Quercetin	O
is	O
a	O
more	O
effective	O
inhibitor	O
of	O
CYP3A4	B
than	O
its	O
3	O
-	O
O	O
-	O
rutinoside	O
,	O
rutin	O
.	O

The	O
inhibition	O
of	O
CYP3A4	B
was	O
also	O
demonstrated	O
to	O
be	O
both	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
.	O

Therefore	O
,	O
they	O
could	O
potentially	O
interfere	O
with	O
the	O
metabolism	O
and	O
alter	O
the	O
pharmacodynamics	O
of	O
drugs	O
,	O
such	O
as	O
atorvastatin	O
,	O
cyclosporine	O
,	O
felodopine	O
,	O
simvastatin	O
,	O
midazolam	O
,	O
erythromycin	O
,	O
and	O
doxorubicin	O
,	O
known	O
to	O
be	O
metabolized	O
by	O
CYP3A4	B
.	O

ASP	O
could	O
only	O
be	O
implicated	O
in	O
CYP3A4	B
inhibition	O
.	O

CYP3A4	B
is	O
a	O
well	O
-	O
known	O
oxidative	O
enzyme	O
that	O
is	O
mostly	O
involved	O
in	O
the	O
metabolism	O
of	O
xenobiotics	O
,	O
and	O
is	O
the	O
most	O
expressed	O
isoform	O
in	O
human	O
liver	O
.	O

CYP3A4	B
was	O
not	O
analyzed	O
because	O
it	O
was	O
included	O
in	O
the	O
study	O
during	O
the	O
Western	O
Blot	O
analysis	O
and	O
we	O
did	O
not	O
find	O
any	O
change	O
of	O
expression	O
with	O
the	O
treatments	O
.	O

We	O
also	O
observed	O
that	O
the	O
fluorescent	O
images	O
of	O
CYP3A4	B
did	O
not	O
report	O
a	O
preferential	O
localization	O
between	O
mitochondria	O
and	O
Endoplasmic	O
Reticulum	O
.	O

The	O
most	O
important	O
members	O
of	O
the	O
CYP	O
family	O
are	O
CYP3A	B
isoforms	O
,	O
especially	O
CYP3A4	B
which	O
is	O
responsible	O
for	O
~	O
30	O
%	O
of	O
the	O
total	O
hepatic	O
activity	O
of	O
CYP	O
.	O

The	O
problem	O
with	O
disturbances	O
of	O
CYP	O
reactions	O
caused	O
by	O
nanomaterials	O
is	O
a	O
new	O
topic	O
,	O
studied	O
most	O
recently	O
on	O
metallic	O
nanoparticles	O
(	O
gold	O
or	O
silver	O
)	O
and	O
using	O
the	O
CYP3A4	B
isoform	O
.	O

Single	O
-	O
walled	O
carbon	O
nanotubes	O
(	O
SWCNT	O
)	O
inhibited	O
the	O
activity	O
of	O
the	O
CYP3A4	B
enzyme	O
by	O
direct	O
interaction	O
between	O
SWCNT	O
and	O
the	O
enzyme	O
.	O

The	O
level	O
of	O
CYP3A4	O
was	O
decreased	O
in	O
all	O
nanostructure	O
groups	O
in	O
both	O
cell	O
lines	O
(	O
<	O
40	O
%	O
of	O
the	O
control	O
,	O
reaching	O
only	O
1	O
%	O
in	O
the	O
GO	O
group	O
in	O
HepaRG	O
cells	O
)	O
,	O
except	O
the	O
GN	O
group	O
in	O
HepaRG	O
cells	O
,	O
where	O
no	O
changes	O
occurred	O
.	O

It	O
was	O
previously	O
reported	O
that	O
SWCNT	O
inhibited	O
the	O
most	O
important	O
of	O
the	O
isoenzymes	O
,	O
CYP3A4	O
,	O
mostly	O
due	O
to	O
the	O
occurrence	O
of	O
-	O
stacking	O
interactions	O
between	O
the	O
nanotube	O
walls	O
and	O
aromatic	O
residues	O
of	O
the	O
enzyme	O
.	O

These	O
two	O
encoding	O
enzymes	O
were	O
highly	O
expressed	O
in	O
roots	O
than	O
stems	O
,	O
followed	O
by	O
CYP3A	B
family	O
members	O
(	O
6	O
.	O
1	O
%	O
)	O
and	O
CYP4	O
family	O
members	O
(	O
4	O
.	O
8	O
%	O
)	O
.	O

The	O
CYP3A	B
subfamily	O
of	O
enzymes	O
is	O
the	O
most	O
important	O
to	O
drug	O
metabolism	O
in	O
humans	O
because	O
these	O
enzymes	O
metabolize	O
the	O
majority	O
of	O
commercially	O
available	O
drugs	O
.	O

Surprisingly	O
,	O
sulfaphenazole	O
appeared	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
5hydroxylation	O
of	O
flucloxacillin	O
by	O
both	O
recombinant	O
CYP3A4	O
and	O
CYP3A7	O
.	O

There	O
are	O
large	O
interindividual	O
differences	O
in	O
plasma	O
concentrations	O
of	O
flucloxacillin	O
and	O
5hydroxymethyl	O
flucloxacillin	O
.	O
5Hydroxymethyl	O
flucloxacillin	O
is	O
much	O
more	O
toxic	O
to	O
biliary	O
epithelial	O
cells	O
than	O
flucloxacillin	O
.	O
A	O
previous	O
study	O
on	O
four	O
human	O
CYPs	O
showed	O
that	O
CYP3A4	O
exerted	O
the	O
highest	O
activity	O
of	O
flucloxacillin	O
hydroxylation	O
.	O

Another	O
study	O
showed	O
that	O
flucloxacillin	O
induces	O
CYP3A4	O
in	O
cell	O
lines	O
exposed	O
to	O
200	O
-	O
400	O
M	O
flucloxacillin	O
(	O
Huwyler	O
et	O
al	O
.	O
,	O
.	O

Furthermore	O
,	O
a	O
major	O
involvement	O
of	O
CYP3A4	O
in	O
drug	O
metabolism	O
complicates	O
prediction	O
of	O
pharmacokinetics	O
based	O
on	O
enzyme	O
kinetics	O
because	O
of	O
the	O
occurrence	O
of	O
atypical	O
enzyme	O
kinetics	O
,	O
such	O
as	O
substrate	O
activation	O
(	O
Houston	O
and	O
Kenworthy	O
,	O
;	O
Ekins	O
et	O
al	O
.	O
,	O
;	O
Atkins	O
,	O
;	O
Houston	O
and	O
Galetin	O
,	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
CYP3A4	O
by	O
drugs	O
appears	O
to	O
be	O
substratedependent	O
,	O
further	O
complicating	O
prediction	O
of	O
drug	O
-	O
drug	O
interactions	O
(	O
Stresser	O
et	O
al	O
.	O
,	O
.	O

456264	O
)	O
,	O
CYP3A4	O
(	O
Lot	O
No	O
.	O

456207	O
)	O
,	O
CYP3A5	B
(	O
Lot	O
No	O
.	O

456256	O
)	O
and	O
CYP3A7	O
(	O
Lot	O
No	O
.	O

At	O
100	O
M	O
flucloxacillin	O
,	O
CYP3A7	O
was	O
the	O
most	O
active	O
CYP	O
followed	O
by	O
CYP3A4	O
.	O

The	O
three	O
inhibitors	O
of	O
CYP3A	B
isoforms	O
,	O
KCZ	O
,	O
miconazole	O
and	O
troleandomycin	O
,	O
showed	O
a	O
relatively	O
modest	O
and	O
differential	O
inhibitory	O
effect	O
on	O
5HMFLX	O
formation	O
.	O

Even	O
at	O
the	O
highest	O
concentration	O
of	O
ketoconazole	O
,	O
which	O
inhibits	O
the	O
CYP3A	B
family	O
,	O
still	O
only	O
50	O
%	O
inhibition	O
was	O
observed	O
at	O
both	O
concentrations	O
of	O
flucloxacillin	O
.	O

The	O
other	O
CYP3A4	O
inhibitors	O
showed	O
only	O
20	O
to	O
40	O
%	O
inhibition	O
at	O
10	O
M	O
flucloxacillin	O
concentration	O
.	O

To	O
study	O
whether	O
sulfaphenazole	O
has	O
the	O
ability	O
to	O
inhibit	O
CYP3Amediated	O
hydroxylation	O
of	O
flucloxacillin	O
,	O
the	O
inhibitor	O
was	O
added	O
at	O
different	O
concentrations	O
to	O
incubations	O
of	O
CYP3A4	O
and	O
CYP3A7	O
,	O
with	O
flucloxacillin	O
and	O
testosterone	O
as	O
substrates	O
.	O

As	O
shown	O
in	O
Figure	O
A	O
,	O
B	O
,	O
sulfaphenazole	O
appeared	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
flucloxacillin	O
hydroxylation	O
by	O
recombinant	O
CYP3A4	O
and	O
CYP3A7	O
with	O
an	O
IC_50	O
of	O
4	O
.	O
1	O
0	O
.	O
4	O
M	O
and	O
6	O
.	O
1	O
0	O
.	O
5	O
M	O
respectively	O
.	O

At	O
these	O
sulfaphenazole	O
concentrations	O
,	O
no	O
inhibition	O
of	O
CYP3A4catalysed	O
6BETAhydroxylation	O
of	O
testosterone	O
was	O
observed	O
.	O

By	O
using	O
recombinant	O
CYPs	O
,	O
at	O
both	O
substrate	O
concentrations	O
used	O
,	O
CYP3A4	O
and	O
CYP3A7	O
appeared	O
to	O
be	O
the	O
most	O
active	O
enzymes	O
.	O

that	O
CYP3A4	O
is	O
likely	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
formation	O
of	O
5HMFLX	O
,	O
as	O
it	O
is	O
,	O
on	O
average	O
,	O
the	O
most	O
abundant	O
CYP	O
in	O
human	O
liver	O
(	O
mean	O
93	O
pmolmg	O
^	O
1	O
protein	O
)	O
(	O
Achour	O
et	O
al	O
.	O
,	O
.	O

CYP4A	B
is	O
one	O
of	O
the	O
-	O
hyroxylases	O
involved	O
in	O
metabolizing	O
Arachidonic	O
Acid	O
to	O
-	O
terminal	O
Hydroxyeicosatetraenoic	O
Acids	O
,	O
including	O
the	O
potent	O
vasoconstrictor	O
20	O
-	O
HETE	O
(	O
hydroxyeicosatetraenoic	O
acid	O
)	O
.	O

In	O
addition	O
to	O
regulating	O
EET	O
levels	O
,	O
Soluble	O
Epoxide	O
Hydrolase	O
expression	O
also	O
impacts	O
CYP	O
-	O
hydroxylase	O
pathway	O
;	O
as	O
reported	O
by	O
Yadav	O
et	O
al	O
.	O
,	O
CYP4A	B
level	O
was	O
increased	O
in	O
the	O
mesenteric	O
arteries	O
of	O
mice	O
with	O
endothelial	O
expression	O
of	O
Soluble	O
Epoxide	O
Hydrolase	O
(	O
Tie2	O
-	O
sEH	O
Tr	O
mice	O
)	O
.	O

The	O
final	O
concentrations	O
,	O
after	O
standardization	O
of	O
dose	O
(	O
0	O
.	O
01	O
,	O
0	O
.	O
1	O
,	O
1	O
,	O
&	O
10	O
M	O
)	O
response	O
for	O
the	O
various	O
drugs	O
used	O
in	O
this	O
study	O
were	O
10	O
M	O
for	O
rosiglitazone	O
(	O
PPARGAMMA	O
-	O
agonist	O
)	O
,	O
t	O
-	O
AUCB	O
(	O
trans	O
-	O
4	O
-	O
[	O
4	O
-	O
(	O
3	O
-	O
adamantan	O
-	O
1	O
-	O
yl	O
-	O
ureido	O
)	O
-	O
cyclohexyloxy	O
]	O
-	O
benzoic	O
acid	O
(	O
a	O
selective	O
sEH	O
-	O
inhibitor	O
,	O
University	O
of	O
California	O
,	O
Davis	O
)	O
,	O
and	O
1	O
M	O
DDMS	O
(	O
dibromo	O
-	O
dodecenyl	O
-	O
methylsulfimide	O
,	O
CYP4A	B
-	O
blocker	O
)	O
.	O

This	O
unexpected	O
finding	O
could	O
be	O
reconciled	O
with	O
our	O
functional	O
finding	O
of	O
decreased	O
Coronary	O
Reactive	O
Hyperemia	O
in	O
Tie2	O
-	O
sEH	O
Tr	O
mice	O
if	O
we	O
consider	O
another	O
important	O
finding	O
:	O
the	O
level	O
of	O
CYP4A	B
.	O

CYP4A	B
is	O
an	O
-	O
hyroxylase	O
involved	O
in	O
metabolizing	O
Arachidonic	O
Acid	O
to	O
the	O
potent	O
vasoconstrictor	O
20	O
-	O
HETE	O
.	O

has	O
recently	O
reported	O
that	O
CYP4A	B
level	O
was	O
increased	O
in	O
the	O
mesenteric	O
arteries	O
of	O
Tie2	O
-	O
sEH	O
Tr	O
mice	O
.	O

These	O
data	O
suggest	O
that	O
while	O
the	O
decrease	O
in	O
mid	O
-	O
chain	O
Hydroxyeicosatetraenoic	O
Acids	O
observed	O
in	O
the	O
heart	O
perfusates	O
of	O
Tie2	O
-	O
sEH	O
Tr	O
mice	O
should	O
have	O
enhanced	O
Coronary	O
Reactive	O
Hyperemia	O
,	O
the	O
reported	O
increased	O
expression	O
of	O
CYP4A	B
in	O
the	O
same	O
mice	O
may	O
have	O
overridden	O
the	O
effect	O
of	O
decreased	O
mid	O
-	O
chain	O
Hydroxyeicosatetraenoic	O
Acids	O
and	O
caused	O
a	O
net	O
effect	O
of	O
decreased	O
Coronary	O
Reactive	O
Hyperemia	O
.	O

As	O
mentioned	O
earlier	O
,	O
-	O
terminal	O
Hydroxyeicosatetraenoic	O
Acids	O
are	O
generated	O
from	O
Arachidonic	O
Acid	O
by	O
CYP	O
-	O
hydroxylases	O
,	O
primarily	O
CYP4A	B
and	O
CYP4F	O
subfamilies	O
,	O
with	O
20	O
-	O
HETE	O
being	O
the	O
primary	O
product	O
.	O

The	O
changes	O
in	O
the	O
renal	O
production	O
of	O
20	O
-	O
HETE	O
was	O
consistent	O
with	O
the	O
expression	O
level	O
of	O
CYP4A	B
protein	O
.	O

Upregulation	O
of	O
CYP4A	B
,	O
may	O
contribute	O
to	O
reduced	O
Coronary	O
Reactive	O
Hyperemia	O
in	O
Tie2	O
-	O
sEH	O
Tr	O
compared	O
to	O
Wild	O
Type	O
mice	O
.	O

One	O
such	O
mechanism	O
is	O
the	O
upregulation	O
of	O
CYP4A	B
reported	O
in	O
Tie2	O
-	O
sEH	O
Tr	O
mice	O
and	O
the	O
possible	O
increase	O
in	O
20	O
-	O
HETE	O
.	O

Interestingly	O
,	O
in	O
our	O
microarray	O
data	O
,	O
CYP4A	B
were	O
significantly	O
induced	O
up	O
to	O
4	O
-	O
to	O
6	O
-	O
fold	O
by	O
AAI	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
effect	O
of	O
acute	O
Doxorubicin	O
exposure	O
on	O
the	O
expression	O
of	O
Cytochrome	B
P450	I
genes	O
in	O
the	O
hearts	O
of	O
both	O
male	O
and	O
female	O
C57Bl	O
/	O
6	O
mice	O
.	O

Total	O
RNA	O
was	O
extracted	O
and	O
expression	O
of	O
natriuretic	O
peptides	O
,	O
inflammatory	O
and	O
apoptotic	O
markers	O
,	O
and	O
Cytochrome	B
P450	I
genes	O
was	O
measured	O
by	O
real	O
-	O
time	O
Time	O
-	O
Polymerase	O
Chain	O
Reaction	O
.	O

Acute	O
Doxorubicin	O
exposure	O
altered	O
the	O
gene	O
expression	O
of	O
multiple	O
Cytochrome	B
P450	I
genes	O
in	O
a	O
sex	O
-	O
dependent	O
manner	O
.	O

Acute	O
Doxorubicin	O
exposure	O
causes	O
sex	O
-	O
dependent	O
alteration	O
of	O
cardiac	O
Cytochrome	B
P450	I
gene	O
expression	O
.	O

Sex	O
-	O
divergent	O
expression	O
of	O
Cytochrome	B
P450	I
genes	O
has	O
been	O
well	O
studied	O
in	O
the	O
liver	O
;	O
however	O
,	O
a	O
few	O
studies	O
have	O
also	O
reported	O
sex	O
-	O
divergent	O
expression	O
of	O
Cytochrome	B
P450	I
genes	O
in	O
other	O
organs	O
.	O

Of	O
interest	O
,	O
a	O
recent	O
study	O
has	O
demonstrated	O
sex	O
-	O
dependent	O
expression	O
of	O
some	O
Cytochrome	B
P450	I
genes	O
in	O
the	O
rodent	O
heart	O
.	O

Nevertheless	O
,	O
the	O
sex	O
-	O
dependent	O
effect	O
of	O
Doxorubicin	O
on	O
Cytochrome	B
P450	I
gene	O
expression	O
is	O
still	O
not	O
known	O
.	O

We	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
DOX	O
-	O
induced	O
alteration	O
of	O
Cytochrome	B
P450	I
gene	O
expression	O
is	O
sex	O
-	O
dependent	O
which	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
sex	O
-	O
related	O
differences	O
of	O
DOX	O
-	O
induced	O
cardiotoxicity	O
.	O

Since	O
we	O
previously	O
reported	O
changes	O
of	O
certain	O
Cytochrome	B
P450	I
genes	O
by	O
acute	O
Doxorubicin	O
exposure	O
in	O
male	O
rats	O
,	O
the	O
mouse	O
orthologs	O
of	O
those	O
rat	O
Cytochrome	B
P450	I
genes	O
were	O
selected	O
for	O
the	O
current	O
study	O
.	O

To	O
correct	O
for	O
multiple	O
comparisons	O
,	O
a	O
false	O
discovery	O
rate	O
of	O
5	O
%	O
was	O
applied	O
for	O
p	O
values	O
of	O
Doxorubicin	O
effect	O
,	O
sex	O
effect	O
,	O
and	O
interaction	O
effect	O
on	O
Cytochrome	B
P450	I
gene	O
expressions	O
by	O
the	O
Two	O
-	O
stage	O
linear	O
step	O
-	O
up	O
procedure	O
of	O
Benjamini	O
,	O
Krieger	O
,	O
and	O
Yekutieli	O
.	O

In	O
addition	O
,	O
we	O
have	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
acute	O
Doxorubicin	O
exposure	O
alters	O
Cytochrome	B
P450	I
gene	O
expression	O
in	O
a	O
sex	O
-	O
dependent	O
manner	O
.	O

Structural	O
Characterization	O
and	O
Ligand	O
/	O
Inhibitor	O
Identification	O
Provide	O
Functional	O
Insights	O
into	O
the	O
Mycobacterium	O
tuberculosis	O
Cytochrome	B
P450	I
CYP126A1	O
.	O

Suicide	O
Inhibition	O
of	O
Cytochrome	B
P450	I
Enzymes	I
by	O
Cyclopropylamines	O
via	O
a	O
Ring	O
-	O
Opening	O
Mechanism	O
:	O
Proton	O
-	O
Coupled	O
Electron	O
Transfer	O
Makes	O
a	O
Difference	O
.	O

Glutathione	O
-	O
S	O
-	O
transferases	O
and	O
Cytochrome	B
P450	I
families	O
are	O
the	O
most	O
common	O
detoxification	O
genes	O
among	O
hymenoptera	O
and	O
we	O
examined	O
these	O
two	O
families	O
in	O
detail	O
.	O

Cytochrome	B
P450	I
superfamily	O
evolution	O
in	O
Formicidae	O
was	O
extensively	O
studied	O
.	O

Cytochrome	B
P450	I
genes	O
have	O
wide	O
range	O
of	O
substrates	O
and	O
single	O
amino	O
acid	O
substitution	O
can	O
drastically	O
change	O
substrate	O
specificity	O
.	O

Cytochrome	B
P450	I
genes	O
may	O
also	O
be	O
important	O
in	O
resistance	O
to	O
urban	O
pollutants	O
of	O
different	O
chemical	O
composition	O
(	O
polycyclic	O
hydrocarbons	O
,	O
plastics	O
,	O
and	O
petrochemicals	O
)	O
.	O

In	O
recent	O
times	O
,	O
studies	O
have	O
also	O
suggested	O
possible	O
interactions	O
between	O
dietary	O
polyphenols	O
and	O
Cytochrome	B
P450	I
3A4	O
,	O
which	O
could	O
lead	O
to	O
some	O
adverse	O
effects	O
.	O

Inhibitory	O
Effects	O
of	O
Dimethyllirioresinol	O
,	O
Epimagnolin	O
A	O
,	O
Eudesmin	O
,	O
Fargesin	O
,	O
and	O
Magnolin	O
on	O
Cytochrome	B
P450	I
Enzyme	O
Activities	O
in	O
Human	O
Liver	O
Microsomes	O
.	O

For	O
the	O
prediction	O
of	O
herb	O
-	O
drug	O
interaction	O
,	O
it	O
is	O
necessary	O
to	O
investigate	O
the	O
in	O
vitro	O
inhibitory	O
effects	O
of	O
herb	O
drugs	O
and	O
the	O
constituents	O
on	O
major	O
human	O
Cytochrome	B
P450	I
enzyme	I
activities	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
in	O
vitro	O
inhibition	O
potency	O
and	O
inhibition	O
mechanisms	O
of	O
dimethyllirioresinol	O
,	O
epimagnolin	O
A	O
,	O
eudesmin	O
,	O
fargesin	O
,	O
and	O
magnolin	O
on	O
8	O
major	O
human	O
Cytochrome	B
P450	I
(	O
CYPs	O
1A2	O
,	O
2A6	O
,	O
2B6	O
,	O
2C8	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
and	O
3A4	O
)	O
activities	O
in	O
pooled	O
human	O
liver	O
microsomes	O
were	O
evaluated	O
to	O
decide	O
the	O
performance	O
of	O
in	O
vivo	O
drug	O
interaction	O
studies	O
of	O
dimethyllirioresinol	O
,	O
epimagnolin	O
A	O
,	O
eudesmin	O
,	O
fargesin	O
,	O
and	O
magnolin	O
.	O

These	O
results	O
indicate	O
that	O
Cytochrome	B
P450	I
inhibitory	O
capacity	O
of	O
tetrahydrofurofuranoid	O
lignans	O
depends	O
on	O
the	O
presence	O
of	O
a	O
methylenedioxyphenyl	O
moiety	O
.	O

The	O
incubation	O
mixtures	O
were	O
prepared	O
in	O
total	O
volumes	O
of	O
100	O
L	O
as	O
follows	O
:	O
50	O
mM	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
.	O
0	O
mM	O
NADPH	O
,	O
10	O
mM	O
MgCl_2	O
,	O
pooled	O
human	O
liver	O
microsomes	O
(	O
0	O
.	O
2	O
mg	O
/	O
mL	O
)	O
,	O
various	O
concentrations	O
of	O
dimethyllirioresinol	O
,	O
epimagnolin	O
A	O
,	O
eudesmin	O
,	O
fargesin	O
,	O
or	O
magnolin	O
in	O
acetonitrile	O
(	O
final	O
concentrations	O
of	O
0	O
.	O
1	O
-	O
100	O
M	O
,	O
acetonitrile	O
0	O
.	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
)	O
,	O
and	O
a	O
cocktail	O
of	O
seven	O
Cytochrome	B
P450	I
probe	O
substrates	O
(	O
2	O
.	O
0	O
M	O
amodiaquine	O
,	O
5	O
M	O
bufuralol	O
,	O
2	O
.	O
5	O
M	O
coumarin	O
,	O
10	O
M	O
diclofenac	O
,	O
100	O
M	O
[	O
S	O
]	O
-	O
mephenytoin	O
,	O
2	O
.	O
5	O
M	O
midazolam	O
,	O
and	O
50	O
M	O
phenacetin	O
,	O
acetonitrile	O
0	O
.	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
)	O
.	O

Epimagnolin	O
A	O
,	O
eudesmin	O
,	O
and	O
magnolin	O
showed	O
no	O
reversible	O
or	O
time	O
-	O
dependent	O
inhibition	O
of	O
8	O
major	O
Cytochrome	B
P450	I
activities	O
at	O
100	O
M	O
in	O
human	O
liver	O
microsomes	O
.	O

Cytochrome	B
P450	I
1B1	O
inhibition	O
suppresses	O
tumorigenicity	O
of	O
prostate	O
cancer	O
via	O
caspase	O
-	O
1	O
activation	O
.	O

Cytochrome	B
P450	I
1B1	O
is	O
recognized	O
as	O
a	O
universal	O
tumor	O
biomarker	O
and	O
a	O
feasible	O
therapeutic	O
target	O
due	O
to	O
its	O
specific	O
overexpression	O
in	O
cancer	O
tissues	O
.	O

Despite	O
its	O
up	O
-	O
regulation	O
in	O
prostate	O
cancer	O
,	O
biological	O
significance	O
and	O
clinicopathological	O
features	O
of	O
Cytochrome	B
P450	I
1b1	O
are	O
still	O
elusive	O
.	O

Here	O
,	O
we	O
show	O
that	O
overexpression	O
or	O
hyperactivation	O
of	O
Cytochrome	B
P450	I
1b1	O
stimulated	O
proliferative	O
,	O
migratory	O
and	O
invasive	O
potential	O
of	O
non	O
-	O
tumorigenic	O
Prostate	O
Cancer	O
cells	O
.	O

Attenuation	O
of	O
Cytochrome	B
P450	I
1b1	O
with	O
its	O
specific	O
small	O
hairpin	O
RNAs	O
greatly	O
reduced	O
proliferation	O
through	O
apoptotic	O
cell	O
death	O
and	O
impaired	O
migration	O
and	O
invasion	O
in	O
Prostate	O
Cancer	O
cells	O
.	O

Intratumoral	O
injection	O
of	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
attenuated	O
growth	O
of	O
pre	O
-	O
existing	O
tumors	O
.	O

The	O
antitumor	O
effect	O
of	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
was	O
also	O
observed	O
in	O
prostate	O
tumor	O
xenograft	O
mouse	O
models	O
.	O

Among	O
the	O
genes	O
altered	O
by	O
Cytochrome	B
P450	I
1b1	O
knockdown	O
,	O
reduction	O
of	O
caspase	O
-	O
1	O
activity	O
attenuated	O
the	O
antitumor	O
effect	O
of	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
.	O

Indeed	O
,	O
Cytochrome	B
P450	I
1b1	O
regulates	O
Caspase	O
-	O
1	O
expression	O
or	O
activity	O
.	O

Finally	O
,	O
Cytochrome	B
P450	I
1b1	O
expression	O
was	O
increased	O
in	O
higher	O
grades	O
of	O
Prostate	O
Cancer	O
and	O
overall	O
survival	O
was	O
significantly	O
reduced	O
in	O
patients	O
with	O
high	O
levels	O
of	O
Cytochrome	B
P450	I
1b1	O
protein	O
.	O

Cytochrome	B
P450	I
1b1	O
expression	O
was	O
reversely	O
associated	O
with	O
Caspase	O
-	O
1	O
expression	O
in	O
clinical	O
tissue	O
samples	O
.	O

Together	O
,	O
our	O
results	O
demonstrate	O
that	O
Cytochrome	B
P450	I
1b1	O
regulates	O
Prostate	O
Cancer	O
tumorigenesis	O
by	O
inhibiting	O
Caspase	O
-	O
1	O
activation	O
.	O

Among	O
CYP1	O
family	O
members	O
,	O
Cytochrome	B
P450	I
1b1	O
is	O
the	O
only	O
member	O
of	O
the	O
CYP1B	O
subfamily	O
and	O
mainly	O
implicated	O
in	O
the	O
hydroxylation	O
of	O
estrogen	O
and	O
activation	O
of	O
environmental	O
carcinogens	O
.	O

Cytochrome	B
P450	I
1b1	O
protein	O
is	O
found	O
in	O
the	O
cancer	O
cells	O
of	O
various	O
cancerous	O
tissues	O
but	O
is	O
undetectable	O
or	O
minimally	O
expressed	O
in	O
the	O
adjacent	O
normal	O
cells	O
of	O
cancer	O
tissues	O
and	O
normal	O
tissues	O
.	O

Therefore	O
,	O
Cytochrome	B
P450	I
1b1	O
has	O
been	O
recognized	O
as	O
a	O
potential	O
tumor	O
biomarker	O
and	O
a	O
promising	O
target	O
for	O
anticancer	O
therapy	O
.	O

Tumor	O
-	O
specific	O
overexpression	O
of	O
Cytochrome	B
P450	I
1b1	O
indicates	O
its	O
role	O
as	O
a	O
regulator	O
of	O
tumor	O
progression	O
.	O

showed	O
that	O
Cytochrome	B
P450	I
1b1	O
knockdown	O
inhibits	O
endometrial	O
carcinogenesis	O
by	O
affecting	O
cellular	O
proliferation	O
,	O
cell	O
cycle	O
and	O
invasive	O
potential	O
through	O
the	O
regulation	O
of	O
cyclin	O
E1	O
,	O
Skp2	O
,	O
and	O
TRAIL	O
.	O

In	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
,	O
Cytochrome	B
P450	I
1b1	O
knockdown	O
reduced	O
the	O
migration	O
and	O
proliferation	O
of	O
premalignant	O
cells	O
and	O
CYP1B1	O
-	O
mediated	O
estrogen	O
metabolism	O
is	O
essential	O
for	O
cancer	O
development	O
.	O

We	O
reported	O
that	O
Cytochrome	B
P450	I
1b1	O
expression	O
is	O
regulated	O
by	O
miR	O
-	O
200c	O
and	O
high	O
Cytochrome	B
P450	I
1b1	O
levels	O
contribute	O
to	O
resistance	O
of	O
renal	O
cell	O
carcinoma	O
to	O
docetaxel	O
.	O

In	O
addition	O
,	O
Cytochrome	B
P450	I
1b1	O
reduction	O
altered	O
expression	O
of	O
CDC20	O
and	O
DAPK1	O
and	O
resulted	O
in	O
the	O
disturbance	O
of	O
cell	O
cycle	O
and	O
apoptosis	O
in	O
Renal	O
Cell	O
Carcinoma	O
.	O

Cytochrome	B
P450	I
1b1	O
expression	O
has	O
been	O
found	O
in	O
both	O
normal	O
prostate	O
tissues	O
and	O
prostate	O
tumors	O
including	O
normal	O
-	O
adjacent	O
tissues	O
,	O
with	O
markedly	O
higher	O
levels	O
in	O
Prostate	O
Cancer	O
compared	O
with	O
benign	O
tissues	O
[	O
,	O
.	O

CpG	O
methylation	O
of	O
the	O
promoter	O
/	O
enhancer	O
has	O
been	O
suggested	O
as	O
a	O
mechanism	O
controlling	O
cancer	O
-	O
specific	O
expression	O
of	O
Cytochrome	B
P450	I
1b1	O
.	O

Cytochrome	B
P450	I
1b1	O
metabolites	O
such	O
as	O
4	O
-	O
hydroxyestradiol	O
and	O
2	O
-	O
amino	O
-	O
1	O
-	O
methyl	O
-	O
6	O
-	O
phenylimidazo	O
[	O
4	O
,	O
5	O
-	O
b	O
]	O
pyridine	O
were	O
reported	O
to	O
induce	O
Prostate	O
Cancer	O
in	O
experimental	O
animal	O
models	O
[	O
,	O
.	O

Polymorphic	O
variants	O
of	O
Cytochrome	B
P450	I
1b1	O
altering	O
the	O
catabolism	O
of	O
estrogen	O
may	O
modify	O
prostate	O
cancer	O
risk	O
and	O
may	O
also	O
predict	O
response	O
to	O
chemotherapy	O
.	O

These	O
evidences	O
strongly	O
suggest	O
that	O
Cytochrome	B
P450	I
1b1	O
plays	O
a	O
potentially	O
crucial	O
role	O
in	O
prostate	O
tumor	O
development	O
and	O
progression	O
.	O

However	O
,	O
the	O
functional	O
impact	O
and	O
clinicopathological	O
significance	O
of	O
Cytochrome	B
P450	I
1b1	O
up	O
-	O
regulation	O
in	O
Prostate	O
Cancer	O
are	O
still	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
functional	O
role	O
of	O
Cytochrome	B
P450	I
1b1	O
in	O
the	O
transformation	O
and	O
tumorigenesis	O
of	O
Prostate	O
Cancer	O
.	O

We	O
also	O
assessed	O
the	O
feasibility	O
of	O
Cytochrome	B
P450	I
1b1	O
targeting	O
for	O
the	O
treatment	O
of	O
Prostate	O
Cancer	O
in	O
an	O
experimental	O
animal	O
model	O
.	O

The	O
molecular	O
target	O
of	O
Cytochrome	B
P450	I
1b1	O
action	O
and	O
clinical	O
relevance	O
of	O
its	O
overexpression	O
were	O
also	O
elucidated	O
.	O

Relative	O
expression	O
of	O
Cytochrome	B
P450	I
1b1	O
protein	O
and	O
mRNA	O
was	O
amplified	O
in	O
all	O
the	O
examined	O
cancer	O
cell	O
lines	O
compared	O
with	O
the	O
RWPE	O
-	O
1	O
cells	O
.	O

To	O
explore	O
the	O
functional	O
role	O
of	O
Cytochrome	B
P450	I
1b1	O
in	O
Prostate	O
Cancer	O
,	O
we	O
first	O
investigated	O
the	O
effect	O
of	O
its	O
up	O
-	O
regulation	O
in	O
prostate	O
epithelial	O
cells	O
using	O
RWPE	O
-	O
1	O
cell	O
lines	O
.	O

Exogenous	O
expression	O
of	O
Cytochrome	B
P450	I
1b1	O
significantly	O
enhanced	O
proliferation	O
and	O
colony	O
formation	O
and	O
also	O
stimulated	O
cell	O
motility	O
and	O
invasiveness	O
of	O
RWPE	O
-	O
1	O
cells	O
and	O
promoted	O
growth	O
,	O
motility	O
and	O
invasiveness	O
of	O
RWPE	O
-	O
1	O
cells	O
(	O
Figure	O
to	O
.	O

These	O
results	O
indicate	O
that	O
overexpression	O
and	O
activation	O
of	O
Cytochrome	B
P450	I
1b1	O
regulates	O
oncogenic	O
activity	O
in	O
prostate	O
cells	O
.	O

Since	O
Cytochrome	B
P450	I
1b1	O
is	O
up	O
-	O
regulated	O
in	O
Prostate	O
Cancer	O
cells	O
,	O
we	O
used	O
a	O
Cytochrome	B
P450	I
1b1	O
knockdown	O
approach	O
with	O
lentivirus	O
-	O
mediated	O
shRNA	O
targeting	O
Cytochrome	B
P450	I
1b1	O
to	O
explore	O
its	O
biological	O
significance	O
.	O

To	O
this	O
end	O
,	O
we	O
generated	O
Cytochrome	B
P450	I
1b1	O
deficient	O
PC	O
-	O
3	O
and	O
DU145	O
cells	O
.	O

Among	O
the	O
4	O
shRNA	O
candidates	O
,	O
the	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
#	O
4	O
construct	O
in	O
PC	O
-	O
3	O
cells	O
and	O
#	O
2	O
construct	O
in	O
DU145	O
cells	O
exhibited	O
the	O
best	O
efficiency	O
by	O
transient	O
transfection	O
and	O
were	O
used	O
for	O
establishing	O
stable	O
cell	O
lines	O
.	O

Subclones	O
were	O
produced	O
from	O
stably	O
transfected	O
Cytochrome	B
P450	I
1b1	O
shRNAs	O
and	O
the	O
resultant	O
knockdown	O
cell	O
lines	O
,	O
PC	O
-	O
3	O
/	O
CYP1B1	O
shRNA	O
#	O
4	O
-	O
2	O
and	O
#	O
4	O
-	O
3	O
,	O
and	O
DU145	O
/	O
CYP1B1	O
shRNA	O
#	O
2	O
-	O
12	O
and	O
#	O
2	O
-	O
23	O
,	O
were	O
selected	O
for	O
the	O
further	O
functional	O
studies	O
(	O
Figure	O
and	O
;	O
.	O

No	O
difference	O
in	O
cell	O
growth	O
and	O
morphology	O
was	O
observed	O
during	O
first	O
and	O
the	O
2	O
days	O
of	O
cell	O
growth	O
but	O
cell	O
proliferation	O
was	O
significantly	O
decreased	O
starting	O
3	O
days	O
after	O
seeding	O
of	O
both	O
Cytochrome	B
P450	I
1b1	O
knockdown	O
cell	O
lines	O
(	O
Figure	O
and	O
.	O

Clonogenic	O
assays	O
also	O
confirmed	O
the	O
impact	O
of	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
on	O
delayed	O
growth	O
of	O
cells	O
(	O
Figure	O
and	O
.	O

To	O
further	O
understand	O
the	O
growth	O
-	O
inhibitory	O
effect	O
of	O
Cytochrome	B
P450	I
1b1	O
reduction	O
,	O
we	O
assessed	O
apoptosis	O
and	O
cell	O
cycle	O
distribution	O
by	O
flow	O
cytometric	O
analysis	O
.	O

The	O
apoptotic	O
cell	O
fractions	O
were	O
significantly	O
increased	O
in	O
Cytochrome	B
P450	I
1b1	O
knockdown	O
cells	O
(	O
Figure	O
and	O
.	O

We	O
did	O
observe	O
that	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
results	O
in	O
lower	O
motility	O
and	O
invasiveness	O
of	O
Prostate	O
Cancer	O
cells	O
(	O
Figure	O
and	O
;	O
.	O

These	O
results	O
suggest	O
that	O
Cytochrome	B
P450	I
1b1	O
plays	O
a	O
role	O
as	O
an	O
oncogene	O
in	O
Prostate	O
Cancer	O
and	O
its	O
targeted	O
inhibition	O
could	O
suppress	O
tumorigenesis	O
.	O

To	O
validate	O
the	O
antitumor	O
effect	O
of	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
and	O
further	O
examine	O
its	O
use	O
as	O
therapeutic	O
target	O
for	O
prostate	O
cancer	O
,	O
in	O
vivo	O
models	O
were	O
utilized	O
.	O

In	O
one	O
model	O
,	O
Cytochrome	B
P450	I
1b1	O
or	O
control	O
shRNA	O
were	O
administered	O
intratumourally	O
after	O
allowing	O
inoculated	O
PC	O
-	O
3	O
cells	O
to	O
establish	O
into	O
tumors	O
.	O

As	O
shown	O
in	O
Figure	O
and	O
,	O
decreased	O
growth	O
was	O
observed	O
in	O
tumors	O
receiving	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
compared	O
to	O
those	O
treated	O
with	O
control	O
shRNA	O
.	O

The	O
average	O
tumor	O
size	O
after	O
5	O
weeks	O
of	O
control	O
shRNA	O
injection	O
was	O
595	O
.	O
7102	O
.	O
6	O
mm	O
^	O
3	O
compared	O
to	O
249	O
.	O
346	O
.	O
6	O
mm	O
^	O
3	O
in	O
tumors	O
treated	O
with	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
.	O

Administration	O
of	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
induced	O
low	O
cell	O
proliferation	O
in	O
tumors	O
compared	O
to	O
those	O
treated	O
with	O
control	O
shRNA	O
(	O
Figure	O
.	O

Reduction	O
of	O
Cytochrome	B
P450	I
1b1	O
protein	O
level	O
was	O
confirmed	O
in	O
tumors	O
injected	O
with	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
(	O
Figure	O
.	O

In	O
addition	O
,	O
PC	O
-	O
3	O
cells	O
stably	O
expressing	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
#	O
4	O
-	O
2	O
or	O
control	O
shRNA	O
were	O
subcutaneously	O
injected	O
into	O
the	O
flank	O
of	O
nude	O
mice	O
.	O

Decreased	O
prostate	O
tumor	O
growth	O
was	O
observed	O
in	O
tumors	O
expressing	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
#	O
4	O
-	O
2	O
compared	O
to	O
those	O
expressing	O
control	O
shRNA	O
(	O
Figure	O
.	O

The	O
average	O
tumor	O
size	O
after	O
5	O
weeks	O
was	O
792	O
.	O
5116	O
.	O
2	O
mm	O
^	O
3	O
in	O
PC	O
-	O
3	O
/	O
control	O
shRNA	O
cells	O
and	O
240	O
.	O
081	O
.	O
9	O
mm	O
^	O
3	O
in	O
tumors	O
stably	O
expressing	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
#	O
4	O
-	O
2	O
(	O
Figure	O
.	O

Tumor	O
cells	O
containing	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
displayed	O
a	O
significant	O
difference	O
in	O
the	O
number	O
of	O
Ki67	O
-	O
positive	O
cells	O
compared	O
to	O
cells	O
harboring	O
control	O
shRNA	O
(	O
Figure	O
.	O

The	O
level	O
of	O
Cytochrome	B
P450	I
1b1	O
protein	O
was	O
reduced	O
in	O
tumors	O
expressing	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
(	O
Figure	O
.	O

These	O
results	O
suggest	O
that	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
effectively	O
inhibits	O
growth	O
of	O
tumor	O
cells	O
in	O
vivo	O
and	O
could	O
be	O
a	O
therapeutic	O
target	O
for	O
Prostate	O
Cancer	O
.	O

To	O
delineate	O
the	O
mechanism	O
of	O
the	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
-	O
induced	O
antitumor	O
effect	O
,	O
we	O
looked	O
for	O
changes	O
in	O
gene	O
expression	O
in	O
PC	O
-	O
3	O
/	O
CYP1B1	O
shRNA	O
#	O
4	O
-	O
2	O
cells	O
using	O
the	O
Human	O
Apoptosis	O
RT	O
^	O
2	O
Profiler	O
PCR	O
Array	O
and	O
Human	O
CancerPathFinder	O
RT	O
^	O
2	O
Profiler	O
PCR	O
Array	O
.	O

Thus	O
,	O
we	O
hypothesize	O
Caspase	O
-	O
1	O
to	O
be	O
a	O
potential	O
target	O
of	O
CYP1B1	O
-	O
mediated	O
tumorigenic	O
activity	O
and	O
antitumor	O
effect	O
of	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
.	O

In	O
addition	O
to	O
PC	O
-	O
3	O
cells	O
,	O
Cytochrome	B
P450	I
1b1	O
knockdown	O
induces	O
Caspase	O
-	O
1	O
mRNA	O
and	O
protein	O
expression	O
in	O
DU145	O
cells	O
(	O
Figure	O
and	O
.	O

Consistent	O
with	O
upregulation	O
at	O
the	O
gene	O
level	O
,	O
Caspase	O
-	O
1	O
enzyme	O
activity	O
was	O
also	O
significantly	O
enhanced	O
in	O
both	O
Cytochrome	B
P450	I
1b1	O
knockdown	O
cells	O
(	O
Figure	O
.	O

To	O
determine	O
the	O
impact	O
of	O
Caspase	O
-	O
1	O
on	O
the	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
-	O
mediated	O
anti	O
-	O
tumor	O
effect	O
,	O
we	O
examined	O
the	O
rate	O
of	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

Treatment	O
with	O
Z	O
-	O
YVAD	O
-	O
fmk	O
,	O
a	O
specific	O
inhibitor	O
of	O
Caspase	O
-	O
1	O
,	O
accelerated	O
the	O
rates	O
of	O
proliferation	O
in	O
Cytochrome	B
P450	I
1b1	O
knockdown	O
cells	O
(	O
Figure	O
.	O

Next	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
Caspase	O
-	O
1	O
in	O
the	O
low	O
migration	O
and	O
invasiveness	O
caused	O
by	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
.	O

In	O
addition	O
to	O
the	O
genetic	O
approach	O
,	O
Caspase	O
-	O
1	O
activity	O
was	O
increased	O
by	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetramethoxystilbene	O
,	O
a	O
chemical	O
inhibitor	O
of	O
Cytochrome	B
P450	I
1b1	O
(	O
Figure	O
.	O

On	O
the	O
other	O
hand	O
,	O
Cytochrome	B
P450	I
1b1	O
overexpression	O
or	O
activation	O
by	O
7	O
,	O
12	O
-	O
Dimethylbenz	O
[	O
A	O
]	O
Anthracene	O
reduced	O
expression	O
and	O
activity	O
of	O
Caspase	O
-	O
1	O
in	O
RWPE	O
-	O
1	O
cells	O
(	O
Figure	O
and	O
.	O

As	O
shown	O
in	O
Figure	O
,	O
most	O
Cytochrome	B
P450	I
1b1	O
protein	O
was	O
expressed	O
in	O
the	O
glandular	O
epithelium	O
of	O
Prostate	O
Cancer	O
tissues	O
.	O

In	O
contrast	O
,	O
weak	O
or	O
no	O
epithelial	O
Cytochrome	B
P450	I
1b1	O
expression	O
was	O
found	O
in	O
benign	O
prostatic	O
hypertrophy	O
tissues	O
with	O
average	O
staining	O
scores	O
of	O
0	O
.	O
670	O
.	O
20	O
(	O
versus	O
2	O
.	O
170	O
.	O
22	O
in	O
cancer	O
tissues	O
)	O
was	O
observed	O
in	O
54	O
.	O
5	O
%	O
of	O
patients	O
with	O
low	O
Gleason	O
score	O
(	O
4	O
-	O
6	O
)	O
,	O
84	O
.	O
0	O
%	O
of	O
patients	O
with	O
Gleason	O
score	O
7	O
,	O
and	O
86	O
.	O
7	O
%	O
of	O
patients	O
with	O
higher	O
Gleason	O
score	O
(	O
8	O
-	O
10	O
)	O
with	O
biochemical	O
recurrence	O
in	O
the	O
patient	O
samples	O
(	O
Figure	O
.	O

Furthermore	O
,	O
overall	O
survival	O
was	O
significantly	O
reduced	O
in	O
patients	O
with	O
high	O
levels	O
of	O
Cytochrome	B
P450	I
1b1	O
protein	O
(	O
Figure	O
.	O

To	O
determine	O
whether	O
Cytochrome	B
P450	I
1b1	O
expression	O
is	O
correlated	O
with	O
Caspase	O
-	O
1	O
level	O
,	O
we	O
first	O
examined	O
the	O
level	O
of	O
Caspase	O
-	O
1	O
in	O
prostate	O
cancer	O
tissue	O
samples	O
.	O

Next	O
,	O
we	O
categorized	O
tissue	O
specimens	O
as	O
either	O
high	O
or	O
low	O
Cytochrome	B
P450	I
1b1	O
expression	O
groups	O
as	O
previously	O
determined	O
and	O
measured	O
Caspase	O
-	O
1	O
expression	O
.	O

As	O
shown	O
in	O
Figure	O
and	O
,	O
prostate	O
tumors	O
with	O
strong	O
Cytochrome	B
P450	I
1b1	O
expression	O
showed	O
low	O
Caspase	O
-	O
1	O
levels	O
.	O

On	O
the	O
contrary	O
,	O
Prostate	O
Cancer	O
samples	O
with	O
relatively	O
low	O
Cytochrome	B
P450	I
1b1	O
expression	O
had	O
a	O
significantly	O
higher	O
level	O
of	O
Caspase	O
-	O
1	O
expression	O
as	O
compared	O
to	O
those	O
with	O
high	O
Cytochrome	B
P450	I
1b1	O
expression	O
.	O

In	O
addition	O
,	O
increased	O
Caspase	O
-	O
1	O
expression	O
was	O
found	O
in	O
the	O
tumors	O
injected	O
with	O
or	O
stably	O
expressing	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
(	O
Figure	O
and	O
.	O

Since	O
Cytochrome	B
P450	I
1b1	O
is	O
implicated	O
as	O
an	O
important	O
factor	O
in	O
the	O
development	O
of	O
various	O
cancers	O
,	O
understanding	O
the	O
precise	O
mechanisms	O
of	O
CYP1B1	O
-	O
mediated	O
cancer	O
progression	O
is	O
required	O
in	O
the	O
development	O
of	O
new	O
strategies	O
for	O
cancer	O
treatment	O
.	O

Cytochrome	B
P450	I
1b1	O
provokes	O
an	O
oncogenic	O
phenotype	O
by	O
damaging	O
DNA	O
through	O
the	O
formation	O
of	O
8	O
-	O
hydroxy	O
-	O
2	O
-	O
deoxyguanosine	O
.	O

Recently	O
,	O
several	O
molecular	O
targets	O
of	O
Cytochrome	B
P450	I
1b1	O
have	O
been	O
found	O
and	O
indicate	O
the	O
participation	O
of	O
Cytochrome	B
P450	I
1b1	O
in	O
multiple	O
pathways	O
during	O
the	O
progression	O
of	O
various	O
types	O
of	O
cancer	O
[	O
,	O
.	O

2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
Tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
,	O
a	O
strong	O
Cytochrome	B
P450	I
1b1	O
activator	O
,	O
suppressed	O
activities	O
of	O
Caspase	O
-	O
1	O
and	O
CASP3	O
in	O
the	O
apoptotic	O
cell	O
death	O
of	O
hepatocytes	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
Caspase	O
-	O
1	O
is	O
significantly	O
up	O
-	O
regulated	O
by	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
and	O
is	O
a	O
newly	O
identified	O
target	O
molecule	O
of	O
CYP1B1	O
-	O
mediated	O
tumorigenesis	O
.	O

Given	O
that	O
Cytochrome	B
P450	I
1b1	O
knockdown	O
increases	O
Caspase	O
-	O
1	O
,	O
we	O
suggest	O
an	O
alternative	O
mechanism	O
for	O
Caspase	O
-	O
1	O
suppression	O
and	O
its	O
critical	O
role	O
in	O
CYP1B1	O
-	O
mediated	O
regulation	O
of	O
Prostate	O
Cancer	O
progression	O
.	O

According	O
to	O
Gregoraszczuk	O
et	O
al	O
.	O
,	O
17BETA	O
-	O
estradiol	O
(	O
E_2	O
)	O
increases	O
Cytochrome	B
P450	I
1b1	O
protein	O
expression	O
,	O
changing	O
the	O
local	O
metabolic	O
activation	O
pathway	O
to	O
increased	O
4	O
-	O
OHE_2	O
production	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
reduction	O
of	O
4	O
-	O
OHE_2	O
levels	O
by	O
Cytochrome	B
P450	I
1b1	O
suppression	O
may	O
lead	O
to	O
Caspase	O
-	O
1	O
activation	O
.	O

Cytochrome	B
P450	I
enzyme	I
promotes	O
reactive	O
oxygen	O
species	O
generation	O
which	O
occurs	O
during	O
the	O
metabolic	O
conversion	O
of	O
procarcinogens	O
to	O
their	O
ultimate	O
reactive	O
electrophilic	O
intermediates	O
.	O

However	O
,	O
interestingly	O
,	O
a	O
lack	O
of	O
Cytochrome	B
P450	I
1b1	O
expression	O
and	O
/	O
or	O
activity	O
leads	O
to	O
accumulation	O
of	O
Reactive	O
Oxygen	O
Species	O
and	O
increased	O
intracellular	O
oxidative	O
stress	O
in	O
retinal	O
endothelial	O
cells	O
,	O
perivascular	O
supporting	O
cells	O
,	O
and	O
trabecular	O
meshwork	O
cells	O
.	O

Therefore	O
,	O
it	O
is	O
plausible	O
that	O
Reactive	O
Oxygen	O
Species	O
produced	O
by	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
activates	O
Caspase	O
-	O
1	O
which	O
induces	O
antitumor	O
effects	O
in	O
Prostate	O
Cancer	O
cells	O
.	O

Due	O
to	O
a	O
contradictory	O
report	O
suggesting	O
that	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
reduces	O
Reactive	O
Oxygen	O
Species	O
production	O
in	O
vascular	O
smooth	O
muscle	O
cell	O
,	O
this	O
hypothesis	O
needs	O
further	O
clarification	O
.	O

Thus	O
,	O
it	O
would	O
be	O
of	O
interest	O
to	O
examine	O
the	O
expression	O
and	O
function	O
of	O
Cytochrome	B
P450	I
1b1	O
in	O
pancreatic	O
cancer	O
and	O
determine	O
its	O
relationship	O
with	O
Caspase	O
-	O
1	O
.	O

To	O
analyze	O
the	O
therapeutic	O
potential	O
of	O
lentivirus	O
-	O
delivered	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
,	O
we	O
performed	O
a	O
pre	O
-	O
clinical	O
study	O
.	O

The	O
recombinant	O
lentivirus	O
expressing	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
was	O
intratumorally	O
injected	O
into	O
established	O
tumors	O
or	O
tumor	O
cells	O
expressing	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
were	O
injected	O
into	O
nude	O
mice	O
.	O

These	O
results	O
demonstrate	O
that	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
by	O
lentivirus	O
-	O
mediated	O
shRNA	O
resulted	O
in	O
a	O
beneficial	O
effect	O
in	O
vivo	O
.	O

To	O
our	O
knowledge	O
,	O
our	O
study	O
is	O
the	O
first	O
report	O
determining	O
the	O
therapeutic	O
effect	O
of	O
lentivirus	O
expressing	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
.	O

Further	O
development	O
of	O
a	O
lentiviral	O
vector	O
expressing	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
may	O
result	O
in	O
a	O
protective	O
effect	O
in	O
vivo	O
against	O
Prostate	O
Cancer	O
.	O

Cytochrome	B
P450	I
1b1	O
is	O
overexpressed	O
in	O
a	O
variety	O
of	O
human	O
tumor	O
cells	O
including	O
prostate	O
cancer	O
[	O
,	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
high	O
levels	O
of	O
Cytochrome	B
P450	I
1b1	O
are	O
associated	O
with	O
parameters	O
such	O
as	O
Gleason	O
score	O
and	O
survival	O
rate	O
of	O
Prostate	O
Cancer	O
patients	O
.	O

Thus	O
,	O
Cytochrome	B
P450	I
1b1	O
could	O
be	O
a	O
potential	O
prognostic	O
and	O
diagnostic	O
marker	O
for	O
Prostate	O
Cancer	O
.	O

We	O
also	O
found	O
that	O
Cytochrome	B
P450	I
1b1	O
expression	O
is	O
inversely	O
associated	O
with	O
Caspase	O
-	O
1	O
levels	O
in	O
human	O
Prostate	O
Cancer	O
tissues	O
(	O
Figure	O
.	O

In	O
addition	O
,	O
it	O
will	O
be	O
of	O
interest	O
to	O
perform	O
studies	O
on	O
the	O
association	O
of	O
Cytochrome	B
P450	I
1b1	O
expression	O
and	O
its	O
polymorphic	O
variants	O
with	O
Caspase	O
-	O
1	O
expression	O
in	O
Prostate	O
Cancer	O
patients	O
.	O

In	O
summary	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
Cytochrome	B
P450	I
1b1	O
induces	O
tumorigenecity	O
of	O
Prostate	O
Cancer	O
cells	O
by	O
modulating	O
Caspase	O
-	O
1	O
expression	O
.	O

We	O
also	O
presented	O
data	O
indicating	O
the	O
feasibility	O
of	O
using	O
in	O
vivo	O
lentivirus	O
-	O
delivered	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
to	O
reduce	O
the	O
tumor	O
burden	O
in	O
animals	O
.	O

This	O
result	O
supports	O
the	O
idea	O
that	O
attenuation	O
of	O
Cytochrome	B
P450	I
1b1	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
Prostate	O
Cancer	O
.	O

Finally	O
,	O
we	O
show	O
the	O
clinical	O
relevance	O
and	O
inverse	O
correlation	O
between	O
Cytochrome	B
P450	I
1b1	O
and	O
Caspase	O
-	O
1	O
in	O
human	O
tissue	O
specimens	O
.	O

Immunoblotting	O
was	O
carried	O
out	O
according	O
to	O
standard	O
protocols	O
with	O
antibodies	O
against	O
TNFRSF9	O
(	O
Sigma	O
)	O
,	O
Lymphotoxin	O
Alpha	O
(	O
GeneTex	O
,	O
San	O
Antonio	O
,	O
TX	O
)	O
,	O
Cytochrome	B
P450	I
1b1	O
,	O
CD27	O
,	O
Interleukin	O
8	O
,	O
Thrombospondin	O
1	O
(	O
Abcam	O
,	O
Cambridge	O
,	O
MA	O
)	O
,	O
Spleen	O
Tyrosine	O
Kinase	O
,	O
Fbj	O
Murine	O
Osteosarcoma	O
Viral	O
Oncogene	O
Homolog	O
,	O
Myelocytomatosis	O
Viral	O
Oncogene	O
Homolog	O
,	O
NFKBIA	O
,	O
CASPASE	O
-	O
1	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Danvers	O
,	O
MA	O
)	O
.	O

Ectopic	O
expression	O
of	O
Cytochrome	B
P450	I
1b1	O
plasmid	O
(	O
OriGene	O
Techologies	O
,	O
Rockville	O
,	O
MD	O
)	O
in	O
RWPE	O
-	O
1	O
cells	O
and	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
(	O
Origene	O
)	O
in	O
PC	O
-	O
3	O
and	O
DU145	O
cells	O
along	O
with	O
their	O
controls	O
were	O
achieved	O
using	O
lentivirus	O
as	O
per	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

For	O
intratumoral	O
injection	O
of	O
lentivirus	O
-	O
mediated	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
,	O
five	O
week	O
old	O
male	O
mice	O
(	O
Charles	O
River	O
,	O
Burlington	O
,	O
MA	O
)	O
were	O
injected	O
subcutaneously	O
into	O
the	O
dorsal	O
flank	O
area	O
with	O
200	O
l	O
of	O
RPMI	O
1640	O
medium	O
containing	O
PC	O
-	O
3	O
cells	O
(	O
510	O
^	O
6	O
cells	O
)	O
.	O

Once	O
tumors	O
reached	O
a	O
volume	O
of	O
30	O
-	O
40	O
mm	O
^	O
3	O
,	O
the	O
tumors	O
were	O
injected	O
every	O
3	O
days	O
with	O
50	O
l	O
(	O
410	O
^	O
7	O
cells	O
)	O
of	O
viral	O
particles	O
containing	O
Cytochrome	B
P450	I
1b1	O
or	O
control	O
shRNA	O
.	O

For	O
the	O
subcutaneous	O
xenograft	O
mouse	O
model	O
,	O
PC	O
-	O
3	O
cells	O
(	O
510	O
^	O
6	O
cells	O
)	O
stably	O
transfected	O
with	O
either	O
Cytochrome	B
P450	I
1b1	O
shRNA	O
#	O
4	O
-	O
2	O
or	O
control	O
shRNA	O
suspended	O
in	O
100	O
l	O
RPMI	O
1640	O
medium	O
were	O
subcutaneously	O
injected	O
into	O
the	O
right	O
backside	O
flank	O
of	O
five	O
week	O
old	O
male	O
nude	O
mice	O
.	O

To	O
investigate	O
the	O
expression	O
of	O
genes	O
regulated	O
by	O
Cytochrome	B
P450	I
1b1	O
inhibition	O
,	O
the	O
RT	O
^	O
2	O
Profiler	O
PCR	O
Array	O
Human	O
Apoptosis	O
and	O
Human	O
Cancer	O
PathwayFinder	O
(	O
SABiosciences	O
,	O
Frederick	O
,	O
MD	O
)	O
were	O
used	O
as	O
per	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Chi	O
-	O
square	O
test	O
was	O
used	O
for	O
analyzing	O
the	O
correlation	O
between	O
clinicopathologic	O
parameters	O
and	O
Cytochrome	B
P450	I
1b1	O
protein	O
expression	O
.	O

Nanocarriers	O
were	O
evaluated	O
in	O
vitro	O
for	O
their	O
Cytochrome	B
P450	I
3a4	I
inhibition	O
capacity	O
and	O
in	O
vivo	O
for	O
their	O
biodistribution	O
,	O
and	O
finally	O
injected	O
24	O
hours	O
prior	O
to	O
the	O
drug	O
docetaxel	O
,	O
for	O
their	O
ability	O
to	O
improve	O
the	O
efficiency	O
of	O
the	O
drug	O
docetaxel	O
.	O

Nanoparticles	O
of	O
poly	O
(	O
lactic	O
-	O
co	O
-	O
glycolic	O
)	O
acid	O
(	O
PLGA	O
)	O
with	O
a	O
hydrodynamic	O
diameter	O
of	O
63	O
nm	O
,	O
functionalized	O
with	O
galactosamine	O
,	O
showed	O
efficient	O
in	O
vitro	O
Cytochrome	B
P450	I
3a4	I
inhibition	O
and	O
the	O
highest	O
accumulation	O
in	O
hepatocytes	O
.	O

HepaRG	O
cells	O
were	O
cultivated	O
to	O
induce	O
Cytochrome	B
P450	I
3a4	I
.	O

In	O
vitro	O
IC_50	O
values	O
of	O
Cytochrome	B
P450	I
3a4	I
by	O
Bergamottin	O
in	O
different	O
nanocarriers	O
were	O
measured	O
on	O
the	O
HepaRG	O
cell	O
line	O
,	O
,	O
using	O
a	O
fluorogenic	O
substrate	O
:	O
DBOMF	O
.	O

Different	O
nanocarriers	O
were	O
designed	O
to	O
encapsulate	O
the	O
hydrophobic	O
Bergamottin	O
,	O
inhibitor	O
of	O
Cytochrome	B
P450	I
3a4	I
,	O
to	O
make	O
it	O
injectable	O
and	O
to	O
deliver	O
it	O
to	O
hepatocytes	O
.	O

Indeed	O
,	O
as	O
a	O
polysaccharide	O
,	O
HA	O
is	O
reported	O
to	O
confer	O
stealth	O
properties	O
to	O
the	O
nanoparticles	O
they	O
functionalize	O
.	O
,	O
To	O
test	O
the	O
Cytochrome	B
P450	I
3a4	I
inhibition	O
of	O
the	O
Bergamottin	O
in	O
the	O
nanocarriers	O
,	O
their	O
IC_50	O
was	O
evaluated	O
on	O
the	O
hepatocyte	O
cell	O
line	O
,	O
HepaRG	O
,	O
induced	O
to	O
express	O
active	O
Cytochrome	B
P450	I
3a4	I
.	O

The	O
24	O
-	O
hour	O
time	O
lapse	O
is	O
more	O
ethical	O
regarding	O
volumes	O
injected	O
to	O
mice	O
and	O
allows	O
Bergamottin	O
to	O
exit	O
from	O
PLGA	O
nanoparticles	O
and	O
to	O
bind	O
to	O
Cytochrome	B
P450	I
3a4	I
.	O

Our	O
strategy	O
is	O
to	O
inhibit	O
Cytochrome	B
P450	I
3a4	I
activity	O
in	O
hepatocytes	O
,	O
decrease	O
docetaxels	O
metabolism	O
in	O
the	O
liver	O
and	O
increase	O
its	O
concentration	O
in	O
the	O
tumor	O
.	O

Inhibiting	O
Cytochrome	B
P450	I
3a4	I
in	O
particular	O
,	O
by	O
which	O
docetaxel	O
is	O
metabolized	O
,	O
would	O
allow	O
increasing	O
the	O
concentration	O
of	O
docetaxel	O
in	O
HCCs	O
and	O
avoid	O
resistance	O
mechanisms	O
.	O

We	O
showed	O
an	O
effective	O
targeting	O
and	O
Cytochrome	B
P450	I
3a4	I
inhibition	O
following	O
intravenous	O
injection	O
of	O
PLGA	O
-	O
Ga	O
Bergamottin	O
nanoparticles	O
.	O

Cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
are	O
a	O
superfamily	O
of	O
important	O
biocatalysts	O
that	O
perform	O
an	O
extraordinary	O
breadth	O
of	O
biochemical	O
reactions	O
,	O
and	O
have	O
been	O
widely	O
applied	O
to	O
oxidation	O
of	O
complex	O
organic	O
substrates	O
and	O
biosynthesis	O
of	O
chemical	O
building	O
block	O
molecules	O
.	O

Preliminary	O
in	O
vitro	O
screening	O
for	O
potential	O
off	O
-	O
target	O
activity	O
of	O
S2218	O
included	O
tests	O
for	O
Cytochrome	B
P450	I
inhibition	O
,	O
a	O
receptor	O
lead	O
profiling	O
panel	O
(	O
consisting	O
of	O
68	O
receptor	O
binding	O
assays	O
for	O
GPCRs	O
,	O
ion	O
channels	O
,	O
nuclear	O
receptors	O
,	O
transporters	O
)	O
,	O
and	O
a	O
hERG	O
inhibition	O
assay	O
.	O

The	O
tests	O
for	O
Cytochrome	B
P450	I
inhibition	O
were	O
performed	O
using	O
recombinant	O
human	O
enzymes	O
expressed	O
in	O
insect	O
Sf9	O
cells	O
using	O
spectrofluorimetric	O
substrates	O
.	O

None	O
of	O
the	O
five	O
Cytochrome	B
P450	I
isoforms	O
tested	O
(	O
CYPs	O
1A2	O
,	O
2C19	O
,	O
2C9	O
,	O
2D6	O
and	O
3A4	O
)	O
were	O
inhibited	O
by	O
>	O
7	O
%	O
in	O
the	O
presence	O
of	O
10	O
M	O
S2218	O
in	O
the	O
spectrofluorimetric	O
assay	O
.	O

(	O
2016	O
)	O
Role	O
of	O
Cytochrome	B
P450	I
2C8	O
in	O
Drug	O
Metabolism	O
and	O
Interactions	O
.	O

(	O
2017	O
)	O
Cytochrome	B
P450	I
eicosanoids	O
in	O
cerebrovascular	O
function	O
and	O
disease	O
.	O

(	O
2015	O
)	O
Cytochrome	B
P450	I
1	O
family	O
and	O
cancers	O
.	O

(	O
2016	O
)	O
Recent	O
Structural	O
Insights	O
into	O
Cytochrome	B
P450	I
Function	O
.	O

(	O
2017	O
)	O
Cytochrome	O
P450derived	O
eicosanoids	O
and	O
heart	O
function	O
.	O

Gene	O
expression	O
levels	O
of	O
all	O
four	O
CYPs	O
and	O
POR	O
,	O
as	O
well	O
as	O
the	O
Cytochrome	B
P450	I
activities	O
,	O
were	O
higher	O
in	O
TC	O
-	O
HepG2	O
clones	O
than	O
in	O
parental	O
HepG2	O
cells	O
.	O

Additionally	O
,	O
the	O
activity	O
levels	O
of	O
all	O
CYPs	O
were	O
reduced	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
by	O
specific	O
Cytochrome	B
P450	I
inhibitors	O
.	O

Furthermore	O
,	O
preincubation	O
of	O
TC	O
-	O
HepG2	O
cells	O
with	O
Cytochrome	B
P450	I
inhibitors	O
known	O
as	O
time	O
-	O
dependent	O
inhibitors	O
prior	O
to	O
the	O
addition	O
of	O
CYP	O
-	O
specific	O
substrates	O
determined	O
that	O
Cytochrome	B
P450	I
inhibition	O
was	O
enhanced	O
in	O
the	O
Time	O
-	O
Dependent	O
Inhibitors	O
group	O
than	O
in	O
the	O
non	O
-	O
TDI	O
group	O
.	O

Finally	O
,	O
the	O
assessment	O
of	O
the	O
metabolic	O
activity	O
of	O
four	O
CYPs	O
indicated	O
that	O
all	O
three	O
clones	O
were	O
more	O
active	O
than	O
the	O
original	O
HepG2	O
cells	O
and	O
that	O
the	O
Cytochrome	B
P450	I
activity	O
was	O
either	O
comparable	O
or	O
higher	O
than	O
those	O
in	O
primary	O
human	O
hepatocytes	O
.	O

Consequently	O
,	O
although	O
the	O
gene	O
expression	O
increased	O
,	O
Cytochrome	B
P450	I
activity	O
was	O
barely	O
detectable	O
.	O

Briefly	O
,	O
Cytochrome	B
P450	I
inhibitors	O
were	O
added	O
to	O
the	O
culture	O
media	O
at	O
the	O
same	O
time	O
as	O
the	O
metabolic	O
substrate	O
to	O
test	O
direct	O
inhibition	O
or	O
1	O
hour	O
prior	O
to	O
the	O
addition	O
of	O
the	O
metabolic	O
substrate	O
to	O
test	O
time	O
-	O
dependent	O
inhibition	O
.	O

In	O
addition	O
,	O
for	O
all	O
compounds	O
,	O
K_i	O
,	O
app	O
,	O
indicating	O
Cytochrome	B
P450	I
reactivation	O
,	O
was	O
lower	O
in	O
TC	O
-	O
HepG2	O
cells	O
than	O
in	O
human	O
hepatocytes	O
.	O

Moreover	O
,	O
transgene	O
expression	O
was	O
maintained	O
over	O
the	O
long	O
-	O
term	O
culture	O
conditions	O
,	O
and	O
Cytochrome	B
P450	I
activities	O
derived	O
from	O
the	O
transgenes	O
were	O
either	O
comparable	O
or	O
higher	O
than	O
those	O
detected	O
in	O
human	O
hepatocytes	O
.	O

When	O
no	O
genes	O
were	O
introduced	O
,	O
HepG2	O
cells	O
exhibited	O
low	O
expression	O
of	O
POR	O
and	O
Cytochrome	B
P450	I
.	O

These	O
results	O
suggest	O
that	O
the	O
introduction	O
of	O
other	O
factors	O
,	O
in	O
addition	O
to	O
POR	O
as	O
a	O
coenzyme	O
,	O
is	O
required	O
to	O
create	O
substitutable	O
hepatic	O
cells	O
from	O
human	O
non	O
-	O
hepatic	O
cells	O
for	O
testing	O
Cytochrome	B
P450	I
metabolism	O
.	O

One	O
major	O
reason	O
for	O
the	O
dropout	O
of	O
candidate	O
compounds	O
during	O
development	O
the	O
removal	O
of	O
novel	O
drugs	O
from	O
the	O
market	O
after	O
launch	O
is	O
drug	O
-	O
drug	O
interactions	O
caused	O
by	O
Cytochrome	B
P450	I
inhibition	O
.	O

To	O
avoid	O
Drug	O
-	O
Drug	O
Interactions	O
,	O
pharmaceutical	O
companies	O
implement	O
Cytochrome	B
P450	I
inhibition	O
studies	O
starting	O
with	O
the	O
initial	O
drug	O
discovery	O
stage	O
.	O

Cytochrome	B
P450	I
inhibition	O
patterns	O
are	O
categorized	O
as	O
either	O
Direct	O
Inhibition	O
or	O
Time	O
-	O
Dependent	O
Inhibitors	O
.	O

All	O
four	O
Cytochrome	B
P450	I
molecular	O
species	O
could	O
replicate	O
the	O
Time	O
-	O
Dependent	O
Inhibitors	O
reported	O
by	O
previous	O
studies	O
using	O
human	O
hepatocytes	O
.	O

By	O
observing	O
the	O
enzyme	O
kinetics	O
of	O
Cytochrome	B
P450	I
metabolite	O
production	O
,	O
reversible	O
inhibitors	O
can	O
be	O
further	O
classified	O
into	O
subgroups	O
:	O
competitive	O
,	O
noncompetitive	O
,	O
or	O
uncompetitive	O
inhibitors	O
(	O
Zhang	O
and	O
Wong	O
.	O

In	O
the	O
interpretation	O
of	O
both	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
inhibitory	O
potential	O
and	O
characteristics	O
of	O
R	O
.	O
rosea	O
on	O
Cytochrome	B
P450	I
enzyme	I
activity	O
,	O
the	O
potential	O
differences	O
in	O
biochemical	O
activity	O
of	O
multiple	O
unknown	O
constituents	O
must	O
also	O
be	O
taken	O
into	O
consideration	O
.	O

Further	O
studies	O
should	O
evaluate	O
possible	O
Cytochrome	B
P450	I
enzyme	I
effects	O
of	O
other	O
commercially	O
available	O
R	O
.	O
rosea	O
products	O
and	O
in	O
more	O
detail	O
attempt	O
to	O
identify	O
which	O
of	O
the	O
R	O
.	O
rosea	O
constituents	O
that	O
are	O
responsible	O
for	O
these	O
effects	O
.	O

The	O
descriptive	O
models	O
for	O
predicting	O
the	O
activities	O
of	O
these	O
Cytochrome	B
P450	I
Enzymes	I
in	O
Human	O
Liver	O
Microsomes	O
were	O
developed	O
solely	O
on	O
the	O
basis	O
of	O
the	O
measured	O
activities	O
of	O
a	O
smaller	O
number	O
of	O
more	O
readily	O
assayed	O
Cytochrome	B
P450	I
Enzymes	I
.	O

As	O
the	O
principal	O
class	O
of	O
hepatic	O
drug	O
metabolizing	O
enzymes	O
,	O
Cytochrome	B
P450	I
Enzymes	I
play	O
a	O
critically	O
important	O
role	O
in	O
the	O
biosynthesis	O
and	O
degradation	O
of	O
endogenous	O
compounds	O
and	O
the	O
metabolism	O
of	O
drugs	O
and	O
environmental	O
procarcinogens	O
.	O

Interindividual	O
variation	O
in	O
drug	O
metabolism	O
,	O
which	O
encompasses	O
genetic	O
polymorphisms	O
of	O
Cytochrome	B
P450	I
Enzymes	I
,	O
smoking	O
,	O
drinking	O
,	O
age	O
,	O
and	O
gender	O
,	O
has	O
a	O
substantial	O
impact	O
on	O
individual	O
drug	O
safety	O
and	O
efficacy	O
,	O
raising	O
a	O
challenge	O
to	O
guide	O
individualized	O
medicine	O
.	O

A	O
multitude	O
of	O
different	O
Cytochrome	B
P450	I
Enzymes	I
share	O
similar	O
physical	O
and	O
molecular	O
characteristics	O
,	O
are	O
colocalized	O
on	O
the	O
cytoplasmic	O
side	O
of	O
the	O
endoplasmic	O
reticulum	O
,	O
and	O
coordinately	O
carry	O
out	O
the	O
biosynthesis	O
and	O
degradation	O
of	O
endogenous	O
steroids	O
,	O
lipids	O
,	O
and	O
vitamins	O
as	O
well	O
as	O
many	O
exogenous	O
substances	O
.	O

Our	O
previous	O
studies	O
also	O
have	O
shown	O
that	O
a	O
high	O
degree	O
of	O
correlation	O
existed	O
at	O
the	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
Cytochrome	B
P450	I
Enzymes	I
.	O

These	O
correlations	O
among	O
Cytochrome	B
P450	I
Enzymes	I
at	O
the	O
protein	O
,	O
mRNA	O
,	O
and	O
activity	O
levels	O
suggest	O
that	O
descriptive	O
models	O
based	O
on	O
multiple	O
linear	O
regression	O
might	O
be	O
developed	O
to	O
predict	O
the	O
activities	O
of	O
some	O
Cytochrome	B
P450	I
Enzymes	I
solely	O
on	O
the	O
basis	O
of	O
measured	O
activities	O
of	O
a	O
smaller	O
number	O
of	O
more	O
readily	O
assayed	O
CYP	O
enzymes	O
.	O

Recently	O
,	O
to	O
predict	O
the	O
in	O
vivo	O
clearance	O
for	O
Cytochrome	B
P450	I
Enzymes	I
more	O
accurately	O
,	O
we	O
introduced	O
correction	O
coefficients	O
into	O
the	O
Vitro	O
-	O
In	O
Vivo	O
Extrapolation	O
method	O
based	O
on	O
the	O
study	O
of	O
Halifax	O
and	O
Houston	O
,	O
who	O
developed	O
the	O
conventional	O
bias	O
corrected	O
in	O
vitro	O
-	O
in	O
vivo	O
extrapolation	O
(	O
CBC	O
-	O
IVIVE	O
)	O
method	O
.	O

Combining	O
descriptive	O
models	O
and	O
CBC	O
-	O
IVIVE	O
might	O
allow	O
us	O
to	O
accurately	O
predict	O
total	O
CYP	O
-	O
mediated	O
drug	O
clearance	O
in	O
vivo	O
based	O
on	O
the	O
measured	O
activities	O
of	O
a	O
few	O
Cytochrome	B
P450	I
Enzymes	I
using	O
a	O
small	O
quantity	O
of	O
liver	O
tissue	O
.	O

Herein	O
,	O
we	O
obtained	O
105	O
liver	O
tissue	O
samples	O
derived	O
from	O
123	O
liver	O
samples	O
taken	O
from	O
normal	O
tissue	O
adjacent	O
to	O
surgical	O
biopsies	O
,	O
which	O
allowed	O
us	O
to	O
measure	O
the	O
activities	O
of	O
ten	O
Cytochrome	B
P450	I
Enzymes	I
in	O
each	O
sample	O
and	O
provided	O
the	O
foundation	O
for	O
the	O
development	O
of	O
descriptive	O
models	O
that	O
could	O
be	O
used	O
to	O
estimate	O
the	O
activities	O
of	O
six	O
Cytochrome	B
P450	I
Enzymes	I
by	O
actually	O
measuring	O
four	O
CYP	O
activities	O
.	O

To	O
strengthen	O
the	O
clinical	O
values	O
,	O
the	O
CL_H	O
of	O
probe	O
drugs	O
for	O
six	O
Cytochrome	B
P450	I
Enzymes	I
were	O
extrapolated	O
using	O
CBC	O
-	O
IVIVE	O
method	O
,	O
and	O
the	O
extrapolation	O
accuracy	O
was	O
evaluated	O
.	O

)	O
,	O
as	O
follows	O
:	O
First	O
,	O
each	O
kinetic	O
parameter	O
(	O
V_max	O
,	O
K_m	O
,	O
and	O
CL_int	O
)	O
of	O
the	O
ten	O
Cytochrome	B
P450	I
Enzymes	I
was	O
treated	O
as	O
a	O
dataset	O
,	O
which	O
then	O
generated	O
three	O
datasets	O
.	O

For	O
each	O
training	O
set	O
,	O
the	O
data	O
of	O
one	O
CYP	O
were	O
set	O
as	O
the	O
dependent	O
variable	O
and	O
the	O
datasets	O
of	O
the	O
other	O
Cytochrome	B
P450	I
Enzymes	I
were	O
set	O
as	O
independent	O
variables	O
,	O
from	O
which	O
a	O
multiple	O
linear	O
regression	O
model	O
was	O
developed	O
by	O
a	O
stepwise	O
method	O
(	O
criteria	O
:	O
probability	O
of	O
F	O
to	O
enter	O
was	O
0	O
.	O
05	O
,	O
probability	O
of	O
F	O
to	O
remove	O
was	O
0	O
.	O
10	O
)	O
.	O

The	O
correction	O
coefficient	O
,	O
the	O
plasma	O
unbound	O
fraction	O
(	O
f_u	O
,	O
p	O
)	O
,	O
and	O
blood	O
-	O
to	O
-	O
plasma	O
concentration	O
ratio	O
(	O
R_B	O
)	O
of	O
each	O
probe	O
drug	O
for	O
six	O
Cytochrome	B
P450	I
Enzymes	I
were	O
obtained	O
from	O
literature	O
.	O

In	O
order	O
to	O
predict	O
activities	O
of	O
several	O
Cytochrome	B
P450	I
Enzymes	I
based	O
on	O
known	O
CYP	O
activities	O
,	O
the	O
principle	O
that	O
the	O
numbers	O
of	O
Cytochrome	B
P450	I
Enzymes	I
were	O
known	O
as	O
little	O
as	O
possible	O
was	O
upheld	O
to	O
analyze	O
all	O
multiple	O
linear	O
regression	O
equations	O
carefully	O
.	O

Of	O
note	O
,	O
prediction	O
of	O
some	O
CYP	O
-	O
mediated	O
metabolic	O
activities	O
in	O
vitro	O
did	O
not	O
require	O
knowledge	O
of	O
all	O
four	O
Cytochrome	B
P450	I
Enzymes	I
activities	O
;	O
some	O
activities	O
could	O
be	O
predicted	O
on	O
just	O
one	O
or	O
two	O
known	O
CYP	O
activities	O
.	O

For	O
K_m	O
,	O
although	O
some	O
descriptive	O
models	O
of	O
Cytochrome	B
P450	I
Enzymes	I
could	O
not	O
be	O
developed	O
,	O
the	O
K_m	O
values	O
of	O
most	O
Cytochrome	B
P450	I
Enzymes	I
could	O
be	O
calculated	O
as	O
their	O
respective	O
V_max	O
divided	O
by	O
corresponding	O
CL_int	O
.	O

In	O
short	O
,	O
the	O
prediction	O
for	O
six	O
Cytochrome	B
P450	I
Enzymes	I
needed	O
1	O
-	O
3	O
measured	O
CYP	O
values	O
.	O

The	O
ranges	O
of	O
predicted	O
CL_int	O
for	O
all	O
Cytochrome	B
P450	I
Enzymes	I
were	O
smaller	O
than	O
the	O
measured	O
data	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
drug	O
clearance	O
values	O
for	O
six	O
Cytochrome	B
P450	I
Enzymes	I
in	O
vivo	O
and	O
in	O
vivo	O
based	O
on	O
measured	O
activities	O
of	O
four	O
Cytochrome	B
P450	I
Enzymes	I
in	O
Human	O
Liver	O
Microsomes	O
.	O

There	O
is	O
no	O
published	O
correlation	O
between	O
structures	O
of	O
Cytochrome	B
P450	I
Enzymes	I
from	O
different	O
chromosomes	O
,	O
although	O
haplotypes	O
exist	O
for	O
some	O
Cytochrome	B
P450	I
Enzymes	I
on	O
the	O
same	O
chromosome	O
.	O

As	O
a	O
consequence	O
of	O
this	O
,	O
predictive	O
models	O
for	O
K_m	O
of	O
some	O
Cytochrome	B
P450	I
Enzymes	I
could	O
not	O
be	O
developed	O
.	O

Although	O
these	O
descriptive	O
models	O
could	O
use	O
data	O
on	O
some	O
Cytochrome	B
P450	I
Enzymes	I
to	O
predict	O
activities	O
of	O
others	O
,	O
there	O
are	O
limitations	O
.	O

Although	O
the	O
models	O
were	O
established	O
using	O
the	O
data	O
on	O
ten	O
Cytochrome	B
P450	I
Enzymes	I
from	O
105	O
normal	O
liver	O
tissue	O
samples	O
from	O
a	O
Chinese	O
Han	O
population	O
,	O
the	O
models	O
should	O
be	O
further	O
improved	O
and	O
validated	O
in	O
larger	O
samples	O
and	O
in	O
different	O
ethnic	O
groups	O
.	O

To	O
be	O
helpful	O
for	O
drug	O
development	O
,	O
we	O
combined	O
the	O
descriptive	O
models	O
and	O
the	O
CBC	O
-	O
IVIVE	O
further	O
to	O
extrapolate	O
the	O
CL_H	O
of	O
probe	O
drugs	O
for	O
six	O
Cytochrome	B
P450	I
Enzymes	I
.	O

first	O
reported	O
3	O
,	O
4	O
,	O
5	O
,	O
4	O
-	O
TMS	O
as	O
a	O
novel	O
selective	O
and	O
strong	O
inhibitor	O
of	O
human	O
Cytochrome	B
P450	I
1	O
(	O
CYP1B1	O
)	O
.	O

This	O
property	O
of	O
Pentamethoxystilbene	O
could	O
have	O
diversified	O
its	O
role	O
in	O
various	O
cancers	O
,	O
because	O
Cytochrome	B
P450	I
(	O
P450	O
)	O
1B1	O
was	O
expressed	O
in	O
various	O
human	O
tissues	O
,	O
including	O
prostate	O
,	O
ovary	O
,	O
uterus	O
and	O
mammary	O
gland	O
.	O

A	O
drug	O
should	O
not	O
be	O
rapidly	O
metabolized	O
by	O
Cytochrome	B
P450	I
Enzymes	I
if	O
it	O
is	O
to	O
maintain	O
an	O
effective	O
concentration	O
.	O

In	O
addition	O
,	O
it	O
should	O
not	O
inhibit	O
drug	O
-	O
metabolizing	O
Cytochrome	B
P450	I
Enzymes	I
,	O
because	O
such	O
an	O
effect	O
could	O
elevate	O
the	O
concentration	O
of	O
a	O
co	O
-	O
administered	O
drug	O
and	O
potentially	O
lead	O
to	O
drug	O
overdose	O
-	O
an	O
effect	O
known	O
as	O
a	O
drug	O
-	O
drug	O
interaction	O
(	O
Murray	O
,	O
.	O

In	O
drug	O
development	O
,	O
in	O
vitro	O
assays	O
are	O
routinely	O
used	O
to	O
assess	O
interactions	O
between	O
drug	O
candidates	O
and	O
Cytochrome	B
P450	I
Enzymes	I
.	O

However	O
,	O
there	O
is	O
a	O
need	O
for	O
in	O
silico	O
models	O
that	O
assess	O
potential	O
interactions	O
with	O
Cytochrome	B
P450	I
Enzymes	I
in	O
the	O
early	O
stages	O
of	O
drug	O
development	O
.	O

For	O
all	O
Cytochrome	B
P450	I
Enzymes	I
,	O
we	O
classified	O
inhibitors	O
and	O
non	O
-	O
inhibitors	O
as	O
positives	O
and	O
negatives	O
,	O
respectively	O
.	O

This	O
interaction	O
could	O
lead	O
to	O
the	O
reduced	O
metabolism	O
of	O
coadministered	O
drugs	O
which	O
are	O
Cytochrome	B
P450	I
substrates	O
,	O
leading	O
to	O
potential	O
risks	O
of	O
toxicity	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
potential	O
Cytochrome	B
P450	I
inhibitory	O
effects	O
of	O
herbal	O
medicines	O
including	O
grape	O
fruit	O
juice	O
,	O
garlic	O
,	O
ginseng	O
(	O
Ginseng	O
species	O
.	O

Based	O
on	O
these	O
data	O
,	O
clinical	O
use	O
of	O
A	O
.	O
Lancea	O
as	O
crude	O
extract	O
should	O
be	O
safe	O
with	O
respect	O
to	O
its	O
low	O
propensity	O
to	O
interfere	O
with	O
major	O
hepatic	O
Cytochrome	B
P450	I
metabolism	O
when	O
given	O
together	O
with	O
other	O
drugs	O
particularly	O
as	O
an	O
adjunctive	O
therapy	O
with	O
conventional	O
chemotherapeutic	O
drugs	O
.	O

Cytochrome	B
P450	I
,	O
a	O
family	O
of	O
heme	O
-	O
containing	O
monooxygenases	O
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
hydroxylation	O
of	O
vitamin	O
D	O
.	O

net	O
/	O
2142	O
/	O
90774	O
)	O
,	O
which	O
undoubtedly	O
may	O
be	O
functionally	O
significant	O
,	O
since	O
Cytochrome	B
P450	I
Reductase	O
is	O
a	O
known	O
protein	O
partner	O
of	O
the	O
microsomal	O
cytochromes	O
P450	O
.	O

Mice	O
were	O
infected	O
with	O
three	O
different	O
doses	O
of	O
Methicillin	O
-	O
Resistant	O
Staphylococcus	O
Aureus	O
and	O
the	O
changes	O
in	O
Cytochrome	B
P450	I
expression	O
,	O
cytokines	O
,	O
and	O
oxidative	O
stress	O
markers	O
were	O
evaluated	O
.	O

The	O
increased	O
inflammation	O
and	O
oxidative	O
stress	O
further	O
induced	O
a	O
significant	O
decrease	O
in	O
the	O
mRNA	O
levels	O
and	O
activities	O
of	O
Cytochrome	B
P450	I
1A2	O
,	O
2D22	O
,	O
2E1	O
,	O
and	O
3A1	O
in	O
MRSA	O
-	O
infected	O
mice	O
within	O
the	O
first	O
day	O
of	O
infection	O
.	O

In	O
this	O
study	O
,	O
to	O
assist	O
in	O
unnecessary	O
treatment	O
failure	O
or	O
poisoning	O
,	O
we	O
examined	O
the	O
changes	O
in	O
Cytochrome	B
P450	I
expression	O
in	O
mice	O
infected	O
with	O
Methicillin	O
-	O
Resistant	O
Staphylococcus	O
Aureus	O
and	O
assessed	O
whether	O
the	O
underlying	O
mechanism	O
was	O
related	O
to	O
the	O
associated	O
changes	O
in	O
cytokines	O
and	O
oxidative	O
stress	O
.	O

The	O
expression	O
levels	O
of	O
the	O
following	O
target	O
genes	O
were	O
analyzed	O
:	O
Cytochrome	B
P450	I
1A2	O
,	O
2D22	O
,	O
2E1	O
,	O
and	O
3A11	O
.	O

The	O
activities	O
of	O
the	O
Cytochrome	B
P450	I
1A2	O
,	O
2D22	O
,	O
2E1	O
,	O
and	O
3A11	O
enzymes	O
were	O
assessed	O
as	O
previously	O
described	O
,	O
with	O
slight	O
modifications	O
.	O
,	O
All	O
microsomal	O
incubations	O
were	O
conducted	O
for	O
60	O
min	O
at	O
37C	O
in	O
a	O
final	O
volume	O
of	O
500	O
L	O
containing	O
pooled	O
microsomes	O
(	O
1	O
mg	O
/	O
mL	O
protein	O
)	O
and	O
an	O
NADPH	O
-	O
regenerating	O
system	O
.	O

The	O
relevant	O
enzyme	O
activities	O
were	O
evaluated	O
based	O
on	O
the	O
reduction	O
in	O
concentrations	O
of	O
the	O
four	O
probe	O
substrates	O
:	O
phenacetin	O
,	O
dextromethorphan	O
,	O
chlorzoxazole	O
,	O
and	O
testosterone	O
for	O
Cytochrome	B
P450	I
1A2	O
,	O
2D22	O
,	O
2E1	O
,	O
and	O
3A11	O
,	O
respectively	O
.	O

For	O
Cytochrome	B
P450	I
1A2	O
and	O
3A11	O
mRNA	O
,	O
a	O
significant	O
decrease	O
was	O
observed	O
in	O
all	O
groups	O
on	O
day	O
1	O
.	O

The	O
mRNA	O
level	O
of	O
CYP	O
1A2	O
in	O
the	O
L	O
and	O
H	O
groups	O
was	O
significantly	O
decreased	O
on	O
days	O
3	O
and	O
7	O
,	O
but	O
increased	O
on	O
day	O
7	O
in	O
group	O
M	O
.	O
The	O
mRNA	O
level	O
of	O
Cytochrome	B
P450	I
3A11	O
was	O
decreased	O
significantly	O
on	O
day	O
3	O
and	O
remained	O
low	O
in	O
group	O
L	O
on	O
day	O
7	O
,	O
but	O
was	O
significantly	O
induced	O
in	O
groups	O
M	O
and	O
H	O
.	O
The	O
mRNA	O
level	O
of	O
Cytochrome	B
P450	I
2D22	O
was	O
significantly	O
suppressed	O
by	O
Methicillin	O
-	O
Resistant	O
Staphylococcus	O
Aureus	O
in	O
the	O
M	O
and	O
H	O
groups	O
on	O
day	O
1	O
,	O
but	O
was	O
increased	O
in	O
the	O
M	O
group	O
on	O
day	O
7	O
.	O

The	O
mRNA	O
level	O
of	O
Cytochrome	B
P450	I
2E1	O
was	O
significantly	O
reduced	O
by	O
Methicillin	O
-	O
Resistant	O
Staphylococcus	O
Aureus	O
in	O
the	O
M	O
and	O
H	O
groups	O
on	O
day	O
1	O
,	O
increased	O
in	O
the	O
L	O
and	O
M	O
groups	O
,	O
but	O
reduced	O
in	O
the	O
H	O
group	O
on	O
day	O
3	O
,	O
and	O
then	O
significantly	O
increased	O
in	O
the	O
M	O
and	O
H	O
groups	O
on	O
day	O
7	O
.	O

The	O
activities	O
of	O
Cytochrome	B
P450	I
1A2	O
and	O
Cytochrome	B
P450	I
3A11	O
decreased	O
significantly	O
in	O
the	O
infection	O
groups	O
on	O
day	O
1	O
.	O

The	O
activity	O
of	O
Cytochrome	B
P450	I
1A2	O
was	O
consistently	O
suppressed	O
on	O
days	O
3	O
and	O
7	O
,	O
but	O
recovered	O
to	O
normal	O
levels	O
in	O
the	O
M	O
and	O
L	O
groups	O
on	O
day	O
3	O
.	O

The	O
activity	O
of	O
Cytochrome	B
P450	I
3A11	O
was	O
continuously	O
suppressed	O
from	O
day	O
3	O
.	O

Cytochrome	B
P450	I
2D22	O
activity	O
was	O
decreased	O
in	O
the	O
M	O
and	O
H	O
groups	O
on	O
day	O
3	O
.	O

The	O
activity	O
of	O
Cytochrome	B
P450	I
2E1	O
was	O
decreased	O
significantly	O
in	O
the	O
M	O
and	O
H	O
groups	O
for	O
7	O
days	O
.	O

CYP450s	O
are	O
the	O
main	O
enzymes	O
responsible	O
for	O
drug	O
metabolism	O
in	O
the	O
liver	O
;	O
their	O
expression	O
is	O
regulated	O
by	O
various	O
factors	O
,	O
including	O
infection	O
,	O
disease	O
,	O
age	O
,	O
food	O
,	O
and	O
stress	O
.	O
-	O
Inflammation	O
and	O
oxidative	O
stress	O
are	O
the	O
main	O
causes	O
for	O
the	O
changes	O
of	O
Cytochrome	B
P450	I
caused	O
by	O
infection	O
and	O
other	O
diseases	O
.	O

In	O
addition	O
to	O
the	O
inflammation	O
caused	O
by	O
Escherichia	O
coli	O
,	O
lipopolysaccharide	O
is	O
also	O
a	O
major	O
cause	O
of	O
Cytochrome	B
P450	I
enzyme	I
inhibition	O
.	O

The	O
inhibitory	O
effect	O
of	O
Cytochrome	B
P450	I
1A2	O
and	O
3A11	O
was	O
detected	O
from	O
3	O
days	O
after	O
infection	O
and	O
resumed	O
on	O
the	O
seventh	O
day	O
,	O
whereas	O
the	O
inhibi	O
tion	O
effect	O
of	O
Cytochrome	B
P450	I
2D22	O
and	O
2E1	O
lasted	O
until	O
7	O
days	O
after	O
infection	O
.	O

The	O
Cytochrome	B
P450	I
enzyme	I
,	O
a	O
key	O
determinant	O
of	O
drug	O
-	O
drug	O
interactions	O
,	O
forms	O
the	O
basis	O
of	O
clinically	O
personalized	O
drug	O
monitoring	O
.	O

This	O
is	O
mainly	O
manifested	O
by	O
increased	O
inflammatory	O
factors	O
,	O
decreased	O
antioxidant	O
enzymes	O
,	O
and	O
increased	O
oxidative	O
metabolites	O
,	O
which	O
are	O
accompanied	O
by	O
liver	O
Cytochrome	B
P450	I
enzyme	I
expression	O
and	O
a	O
rapid	O
decrease	O
in	O
activity	O
.	O

Gene	O
Duplication	O
Leads	O
to	O
Altered	O
Membrane	O
Topology	O
of	O
a	O
Cytochrome	B
P450	I
Enzyme	O
in	O
Seed	O
Plants	O
.	O

Fungal	O
Cytochrome	O
P450s	O
and	O
the	O
P450	O
Complement	O
of	O
Fusarium	O
graminearum	O
.	O

Cytochrome	O
P450s	O
,	O
heme	O
-	O
containing	O
monooxygenases	O
,	O
play	O
important	O
roles	O
in	O
a	O
wide	O
variety	O
of	O
metabolic	O
processes	O
important	O
for	O
development	O
as	O
well	O
as	O
biotic	O
/	O
trophic	O
interactions	O
in	O
most	O
living	O
organisms	O
.	O

Various	O
fungal	O
Cytochrome	O
P450s	O
are	O
involved	O
in	O
not	O
only	O
ergosterol	O
synthesis	O
and	O
virulence	O
but	O
also	O
in	O
the	O
production	O
of	O
a	O
wide	O
array	O
of	O
secondary	O
metabolites	O
,	O
which	O
exert	O
toxic	O
effects	O
on	O
humans	O
and	O
other	O
animals	O
.	O

Although	O
few	O
studies	O
have	O
investigated	O
the	O
functions	O
of	O
fungal	O
Cytochrome	O
P450s	O
,	O
a	O
recent	O
systematic	O
functional	O
analysis	O
of	O
CYP	O
genes	O
in	O
the	O
plant	O
pathogen	O
Fusarium	O
graminearum	O
identified	O
several	O
novel	O
Cytochrome	O
P450s	O
specifically	O
involved	O
in	O
virulence	O
,	O
asexual	O
and	O
sexual	O
development	O
,	O
and	O
degradation	O
of	O
xenobiotics	O
.	O

This	O
review	O
provides	O
fundamental	O
information	O
on	O
fungal	O
Cytochrome	O
P450s	O
and	O
a	O
new	O
platform	O
for	O
further	O
metabolomic	O
and	O
biochemical	O
studies	O
of	O
Cytochrome	O
P450s	O
in	O
toxigenic	O
fungi	O
.	O

Cytochrome	O
P450s	O
,	O
which	O
are	O
heme	O
-	O
containing	O
proteins	O
,	O
represent	O
one	O
of	O
the	O
largest	O
protein	O
families	O
;	O
they	O
are	O
present	O
in	O
all	O
biological	O
kingdoms	O
.	O

Cytochrome	O
P450s	O
commonly	O
act	O
as	O
terminal	O
monooxygenases	O
in	O
a	O
range	O
of	O
biochemical	O
reactions	O
including	O
hydroxylation	O
,	O
dealkylation	O
,	O
epoxidation	O
,	O
deamination	O
,	O
desulfuration	O
,	O
dehalogenation	O
,	O
sulfoxidation	O
,	O
and	O
N	O
-	O
oxide	O
reduction	O
,	O
by	O
catalyzing	O
the	O
transfer	O
of	O
molecular	O
oxygen	O
to	O
various	O
cellular	O
substrates	O
.	O

This	O
diversity	O
of	O
catalytic	O
capabilities	O
and	O
the	O
ability	O
to	O
manipulate	O
them	O
means	O
that	O
Cytochrome	O
P450s	O
have	O
been	O
under	O
the	O
spotlight	O
for	O
biotechnological	O
applications	O
,	O
such	O
as	O
biosynthesis	O
of	O
useful	O
chemical	O
compounds	O
.	O

The	O
function	O
of	O
human	O
Cytochrome	O
P450s	O
has	O
been	O
extensively	O
studied	O
since	O
1960	O
,	O
particularly	O
with	O
respect	O
to	O
xenobiotic	O
and	O
drug	O
metabolism	O
.	O

Insect	O
genomes	O
contain	O
various	O
numbers	O
of	O
Cytochrome	O
P450s	O
,	O
for	O
example	O
,	O
76	O
-	O
91	O
in	O
Drosophila	O
species	O
(	O
fruit	O
flies	O
)	O
,	O
87	O
in	O
Bombyx	O
mori	O
(	O
silkworm	O
)	O
,	O
and	O
46	O
in	O
Apis	O
mellifera	O
(	O
honey	O
bee	O
)	O
.	O

In	O
insects	O
,	O
Cytochrome	O
P450s	O
are	O
involved	O
in	O
the	O
production	O
of	O
defence	O
toxins	O
and	O
pheromones	O
.	O

Plant	O
Cytochrome	O
P450s	O
are	O
mainly	O
involved	O
in	O
biosynthesis	O
of	O
protective	O
toxins	O
and	O
repellent	O
molecules	O
,	O
as	O
well	O
as	O
various	O
signalling	O
molecules	O
.	O

Whereas	O
yeast	O
-	O
like	O
fungi	O
possess	O
relatively	O
few	O
Cytochrome	O
P450s	O
(	O
three	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
six	O
in	O
Cryptococcus	O
neoformans	O
,	O
and	O
10	O
in	O
Candida	O
albicans	O
)	O
,	O
filamentous	O
fungi	O
tend	O
to	O
possess	O
more	O
CYP	O
genes	O
.	O

Plant	O
pathogenic	O
fungi	O
tend	O
to	O
possess	O
larger	O
numbers	O
of	O
CYP	O
genes	O
;	O
for	O
example	O
,	O
Magnaporthe	O
oryzae	O
and	O
Cryphonectria	O
parasitica	O
harbor	O
107	O
and	O
121	O
Cytochrome	O
P450s	O
,	O
respectively	O
.	O

Fungal	O
Cytochrome	O
P450s	O
are	O
involved	O
in	O
diverse	O
biological	O
processes	O
,	O
including	O
production	O
of	O
primary	O
and	O
secondary	O
metabolites	O
and	O
denitrification	O
.	O

However	O
,	O
compared	O
to	O
plants	O
and	O
animals	O
,	O
few	O
fungal	O
Cytochrome	O
P450s	O
have	O
been	O
functionally	O
characterized	O
.	O

Investigation	O
of	O
fungal	O
Cytochrome	O
P450s	O
will	O
improve	O
our	O
understanding	O
of	O
fungal	O
biology	O
and	O
metabolism	O
,	O
and	O
may	O
offer	O
opportunities	O
to	O
exploit	O
their	O
catalytic	O
functions	O
.	O

In	O
this	O
review	O
,	O
we	O
provide	O
an	O
overview	O
of	O
the	O
fungal	O
metabolic	O
systems	O
in	O
which	O
Cytochrome	O
P450s	O
play	O
roles	O
,	O
such	O
as	O
primary	O
and	O
secondary	O
metabolism	O
,	O
degradation	O
of	O
xenobiotics	O
,	O
and	O
other	O
fungal	O
traits	O
.	O

We	O
also	O
present	O
a	O
phenome	O
-	O
based	O
functional	O
analysis	O
of	O
whole	O
CYP	O
genes	O
in	O
the	O
plant	O
pathogenic	O
fungus	O
Fusarium	O
graminearum	O
,	O
which	O
illuminates	O
the	O
functional	O
diversity	O
and	O
potential	O
applications	O
of	O
fungal	O
Cytochrome	O
P450s	O
.	O

In	O
particular	O
,	O
filamentous	O
fungi	O
have	O
an	O
outstanding	O
ability	O
to	O
degrade	O
a	O
variety	O
of	O
toxic	O
substances	O
(	O
eg	O
,	O
environmental	O
pollutants	O
,	O
xenobiotics	O
,	O
and	O
plant	O
-	O
derived	O
toxins	O
)	O
,	O
and	O
some	O
filamentous	O
fungi	O
are	O
well	O
known	O
for	O
production	O
of	O
characteristic	O
toxins	O
via	O
Cytochrome	O
P450s	O
.	O

CYP	O
nomenclature	O
is	O
mainly	O
based	O
on	O
amino	O
acid	O
sequence	O
identity	O
;	O
40	O
%	O
identity	O
or	O
greater	O
places	O
Cytochrome	O
P450s	O
in	O
the	O
same	O
family	O
and	O
greater	O
than	O
55	O
%	O
identity	O
places	O
Cytochrome	O
P450s	O
in	O
the	O
same	O
subfamily	O
.	O

As	O
mentioned	O
above	O
,	O
Cytochrome	O
P450s	O
are	O
key	O
enzymes	O
in	O
many	O
fungal	O
processes	O
,	O
and	O
classifiable	O
into	O
multigene	O
families	O
,	O
CYP51	O
-	O
CYP69	O
,	O
CYP501	O
-	O
CYP699	O
,	O
and	O
CYP5001	O
-	O
CYP6999	O
.	O

CYP51	O
,	O
CYP56	O
,	O
CYP61	O
,	O
and	O
many	O
other	O
known	O
fungal	O
Cytochrome	O
P450s	O
are	O
involved	O
in	O
biosynthesis	O
of	O
primary	O
and	O
secondary	O
metabolites	O
,	O
as	O
well	O
as	O
detoxification	O
/	O
degradation	O
of	O
xenobiotics	O
.	O

Many	O
studies	O
have	O
predicted	O
the	O
functions	O
of	O
Cytochrome	O
P450s	O
of	O
individual	O
fungi	O
using	O
bioinformatics	O
tools	O
.	O

Fungal	O
Cytochrome	O
P450s	O
are	O
grouped	O
in	O
15	O
clades	O
based	O
on	O
their	O
phylogenetic	O
relationships	O
.	O

Recently	O
,	O
14	O
,	O
896	O
Cytochrome	O
P450s	O
were	O
identified	O
from	O
157	O
fungal	O
and	O
oomycete	O
species	O
.	O

However	O
,	O
the	O
precise	O
biological	O
functions	O
of	O
most	O
fungal	O
Cytochrome	O
P450s	O
remain	O
undefined	O
.	O

For	O
example	O
,	O
the	O
Cytochrome	O
P450s	O
And	O
The	O
P450	O
Complement	O
of	O
the	O
white	O
rot	O
fungus	O
Phanerochaete	O
chrysosporium	O
comprises	O
~	O
150	O
Cytochrome	O
P450s	O
,	O
mostly	O
arranged	O
in	O
gene	O
clusters	O
.	O

In	O
this	O
fungus	O
,	O
except	O
for	O
the	O
structurally	O
and	O
functionally	O
conserved	O
fungal	O
CYP	O
families	O
,	O
CYP51	O
,	O
CYP61	O
,	O
and	O
CYP53	O
,	O
the	O
roles	O
of	O
the	O
other	O
Cytochrome	O
P450s	O
are	O
still	O
largely	O
unknown	O
and	O
await	O
functional	O
characterization	O
.	O

Many	O
fungal	O
Cytochrome	O
P450s	O
are	O
known	O
to	O
be	O
involved	O
in	O
mycotoxin	O
biosynthesis	O
.	O

Among	O
the	O
26	O
genes	O
located	O
in	O
the	O
aflatoxin	O
biosynthetic	O
gene	O
cluster	O
,	O
aflG	O
,	O
aflQ	O
,	O
aflU	O
,	O
and	O
aflV	O
encode	O
Cytochrome	O
P450s	O
.	O

In	O
addition	O
to	O
polyketide	O
synthases	O
and	O
non	O
-	O
ribosomal	O
peptide	O
synthases	O
,	O
several	O
key	O
genes	O
required	O
for	O
biosynthesis	O
of	O
Ochratoxin	O
A	O
including	O
putative	O
Cytochrome	O
P450s	O
were	O
identified	O
in	O
a	O
few	O
Aspergillus	O
species	O
.	O

Among	O
xenobiotic	O
-	O
metabolizing	O
enzymes	O
,	O
Cytochrome	O
P450s	O
are	O
the	O
most	O
abundant	O
and	O
versatile	O
.	O

Studies	O
of	O
mammalian	O
xenobiotic	O
-	O
metabolizing	O
Cytochrome	O
P450s	O
have	O
led	O
to	O
the	O
discovery	O
and	O
characterization	O
of	O
the	O
xenobiotic	O
metabolism	O
pathways	O
.	O

In	O
humans	O
,	O
drug	O
-	O
metabolizing	O
Cytochrome	O
P450s	O
mostly	O
presenting	O
in	O
the	O
liver	O
are	O
responsible	O
for	O
oxidative	O
metabolism	O
of	O
xenobiotics	O
.	O

Many	O
insect	O
Cytochrome	O
P450s	O
also	O
play	O
roles	O
in	O
detoxification	O
of	O
xenobiotics	O
.	O

Insect	O
Cytochrome	O
P450s	O
are	O
inducible	O
in	O
response	O
to	O
botanical	O
insecticides	O
and	O
/	O
or	O
plant	O
secondary	O
metabolites	O
.	O

Also	O
,	O
some	O
plant	O
Cytochrome	O
P450s	O
involved	O
in	O
the	O
detoxification	O
of	O
xenobiotics	O
such	O
as	O
herbicides	O
.	O

One	O
of	O
the	O
best	O
-	O
characterized	O
fungal	O
Cytochrome	O
P450s	O
is	O
a	O
pisatin	O
demethylase	O
(	O
PDA	O
,	O
CYP57A1	O
)	O
,	O
which	O
was	O
first	O
identified	O
in	O
N	O
.	O
haematococca	O
.	O

One	O
particularly	O
well	O
-	O
studied	O
fungal	O
Cytochrome	O
P450s	O
is	O
CYP51	O
,	O
which	O
mediates	O
primary	O
metabolism	O
of	O
ergosterol	O
biosynthesis	O
.	O

Significant	O
regulation	O
of	O
Cytochrome	O
P450s	O
has	O
been	O
observed	O
during	O
host	O
-	O
pathogen	O
interactions	O
via	O
gene	O
/	O
transcriptome	O
profiling	O
analyses	O
of	O
several	O
fungi	O
,	O
eg	O
,	O
F	O
.	O
graminearum	O
,	O
Curvularia	O
lunata	O
,	O
and	O
Heterobasidion	O
annosum	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
yet	O
known	O
.	O

Several	O
fungal	O
Cytochrome	O
P450s	O
have	O
been	O
known	O
to	O
play	O
critical	O
roles	O
in	O
primary	O
and	O
secondary	O
metabolism	O
and	O
degradation	O
of	O
xenobiotics	O
.	O

Besides	O
,	O
some	O
Cytochrome	O
P450s	O
in	O
pathogenic	O
fungi	O
has	O
emerged	O
as	O
important	O
enzymes	O
in	O
virulence	O
.	O

However	O
,	O
the	O
involvement	O
of	O
Cytochrome	O
P450s	O
in	O
fungal	O
development	O
and	O
other	O
functions	O
,	O
such	O
as	O
virulence	O
or	O
xenobiotic	O
detoxification	O
,	O
has	O
rarely	O
been	O
elucidated	O
,	O
and	O
there	O
has	O
been	O
no	O
systematic	O
approach	O
to	O
the	O
investigation	O
of	O
Cytochrome	O
P450s	O
in	O
filamentous	O
fungi	O
,	O
including	O
plant	O
pathogens	O
.	O

To	O
date	O
,	O
only	O
nine	O
F	O
.	O
graminearum	O
Cytochrome	O
P450s	O
have	O
been	O
functionally	O
characterized	O
.	O

Four	O
Cytochrome	O
P450s	O
(	O
TRI1	O
,	O
TRI4	O
,	O
TRI13	O
,	O
and	O
TRI11	O
)	O
are	O
involved	O
in	O
trichothecene	O
biosynthesis	O
,	O
and	O
Fg08079	O
and	O
CLM2	O
are	O
required	O
for	O
the	O
biosynthesis	O
of	O
butenolide	O
and	O
culmorin	O
,	O
respectively	O
.	O

To	O
systematically	O
characterize	O
the	O
Cytochrome	O
P450s	O
And	O
The	O
P450	O
Complement	O
of	O
F	O
.	O
graminearum	O
,	O
CYP	O
gene	O
knockout	O
mutants	O
were	O
generated	O
,	O
and	O
a	O
comprehensive	O
phenome	O
of	O
102	O
CYP	O
mutant	O
library	O
of	O
F	O
.	O
graminearum	O
was	O
tested	O
in	O
38	O
traits	O
.	O

Four	O
Cytochrome	O
P450s	O
,	O
Tri1	O
,	O
Tri4	O
,	O
Tri11	O
,	O
and	O
Tri13	O
,	O
are	O
involved	O
in	O
biosynthesis	O
of	O
trichothecenes	O
.	O

Among	O
the	O
four	O
Cytochrome	O
P450s	O
in	O
the	O
trichothecene	O
biosynthetic	O
gene	O
cluster	O
,	O
Tri13	O
,	O
3	O
-	O
acetyltrichothecene	O
C	O
-	O
4	O
hydroxylase	O
,	O
is	O
responsible	O
for	O
hydroxylation	O
of	O
trichothecenes	O
at	O
C	O
-	O
4	O
;	O
the	O
gene	O
is	O
therefore	O
a	O
determinant	O
of	O
the	O
DON	O
-	O
and	O
NIV	O
-	O
producing	O
chemotypes	O
in	O
F	O
.	O
graminearum	O
.	O

Likewise	O
,	O
some	O
putative	O
xenobiotic	O
-	O
metabolizing	O
Cytochrome	O
P450s	O
in	O
F	O
.	O
graminearum	O
have	O
been	O
characterized	O
based	O
on	O
genetic	O
evidence	O
.	O

Our	O
previous	O
study	O
on	O
the	O
systematic	O
functional	O
characterization	O
of	O
CYP	O
genes	O
in	O
F	O
.	O
graminearum	O
revealed	O
that	O
many	O
novel	O
Cytochrome	O
P450s	O
are	O
closely	O
involved	O
in	O
fungal	O
developmental	O
processes	O
including	O
virulence	O
.	O

Using	O
this	O
phenotypic	O
dataset	O
,	O
we	O
could	O
gain	O
insight	O
into	O
the	O
cryptic	O
functions	O
of	O
Cytochrome	O
P450s	O
in	O
fungi	O
.	O

In	O
infection	O
assays	O
with	O
flowering	O
wheat	O
heads	O
,	O
deletion	O
mutants	O
of	O
five	O
Cytochrome	O
P450s	O
,	O
Fg03700	O
(	O
CYP620B1	O
)	O
,	O
Fg02111	O
(	O
CYP636A1	O
)	O
,	O
Fg00012	O
(	O
CYP630A1	O
)	O
,	O
Fg10451	O
(	O
CYP53A8	O
)	O
,	O
and	O
Fg12737	O
(	O
CYP537A2	O
)	O
,	O
showed	O
reduced	O
virulence	O
compared	O
to	O
the	O
wild	O
type	O
(	O
d	O
)	O
.	O

We	O
suspect	O
that	O
these	O
Cytochrome	O
P450s	O
,	O
which	O
displayed	O
reduced	O
virulence	O
when	O
deleted	O
,	O
are	O
involved	O
in	O
degradation	O
of	O
plant	O
-	O
derived	O
metabolites	O
or	O
plant	O
tissues	O
for	O
successful	O
infection	O
.	O

Recently	O
,	O
comparative	O
in	O
planta	O
transcriptome	O
analyses	O
revealed	O
that	O
more	O
than	O
40	O
Cytochrome	O
P450s	O
may	O
be	O
involved	O
in	O
host	O
-	O
pathogen	O
interactions	O
of	O
F	O
.	O
graminearum	O
.	O

Fungal	O
Cytochrome	O
P450s	O
play	O
essential	O
roles	O
for	O
survival	O
,	O
and	O
several	O
azole	O
fungicides	O
that	O
are	O
mainly	O
targeted	O
at	O
the	O
Cytochrome	O
P450s	O
have	O
been	O
commercially	O
used	O
for	O
control	O
of	O
animal	O
and	O
plant	O
pathogenic	O
fungi	O
.	O

Decades	O
of	O
studies	O
on	O
fungal	O
genetics	O
and	O
biochemistry	O
have	O
established	O
the	O
involvement	O
of	O
Cytochrome	O
P450s	O
in	O
many	O
bioconversion	O
processes	O
related	O
to	O
degradation	O
of	O
foreign	O
compounds	O
and	O
biosynthesis	O
of	O
secondary	O
metabolites	O
in	O
fungi	O
.	O

However	O
,	O
scant	O
information	O
is	O
available	O
on	O
Cytochrome	O
P450s	O
and	O
their	O
involvement	O
in	O
fungal	O
developmental	O
processes	O
,	O
including	O
virulence	O
,	O
due	O
to	O
the	O
lack	O
of	O
CYP	O
mutants	O
defective	O
in	O
those	O
phenotypes	O
and	O
available	O
up	O
-	O
to	O
-	O
date	O
molecular	O
techniques	O
.	O

Using	O
data	O
from	O
a	O
systematic	O
functional	O
genomic	O
study	O
of	O
F	O
.	O
graminearum	O
,	O
we	O
identified	O
some	O
clues	O
to	O
the	O
novel	O
functions	O
of	O
Cytochrome	O
P450s	O
in	O
toxigenic	O
fungi	O
.	O

Further	O
studies	O
should	O
focus	O
on	O
the	O
identification	O
of	O
the	O
substrate	O
specificity	O
of	O
Cytochrome	O
P450s	O
using	O
metabolomic	O
and	O
/	O
or	O
biochemical	O
approaches	O
.	O

These	O
multidisciplinary	O
studies	O
on	O
Cytochrome	O
P450s	O
will	O
provide	O
fundamental	O
information	O
on	O
fungal	O
-	O
specific	O
Cytochrome	O
P450s	O
compared	O
to	O
those	O
of	O
other	O
organisms	O
and	O
new	O
insights	O
into	O
fungal	O
biology	O
and	O
virulence	O
.	O

Inhibition	O
of	O
Cytochrome	B
P450	I
Activities	O
by	O
Extracts	O
of	O
Hyptis	O
verticillata	O
Jacq	O
.	O

Ligand	O
Access	O
Channels	O
in	O
Cytochrome	B
P450	I
Enzymes	I
:	O
A	O
Review	O
.	O

Cytochrome	B
P450	I
(	O
P450	O
)	O
have	O
been	O
found	O
in	O
most	O
of	O
organisms	O
where	O
they	O
were	O
looked	O
for	O
,	O
with	O
some	O
noticeable	O
exceptions	O
,	O
such	O
as	O
E	O
.	O
coli	O
.	O

Previously	O
we	O
carried	O
out	O
in	O
silico	O
studies	O
to	O
explore	O
the	O
effect	O
of	O
Single	O
Nucleotide	O
Polymorphisms	O
on	O
Cytochrome	B
P450	I
function	O
,	O
using	O
in	O
silico	O
calculations	O
to	O
predict	O
the	O
effect	O
of	O
mutations	O
on	O
protein	O
stability	O
.	O

Variant	O
alleles	O
include	O
deletions	O
,	O
insertions	O
,	O
copy	O
number	O
variants	O
and	O
single	O
nucleotide	O
polymorphisms	O
,	O
both	O
in	O
the	O
coding	O
and	O
non	O
-	O
coding	O
regions	O
of	O
the	O
genes	O
,	O
which	O
can	O
alter	O
Cytochrome	B
P450	I
expression	O
levels	O
as	O
well	O
as	O
protein	O
function	O
^	O
.	O

There	O
are	O
now	O
around	O
800	O
published	O
Cytochrome	B
P450	I
X	O
-	O
ray	O
crystal	O
structures	O
,	O
including	O
well	O
over	O
100	O
human	O
Cytochrome	B
P450	I
structures	O
crystallised	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
range	O
of	O
ligands	O
.	O

While	O
CYP450s	O
have	O
traditionally	O
been	O
regarded	O
as	O
monomers	O
,	O
there	O
is	O
increasing	O
evidence	O
that	O
cross	O
-	O
talk	O
occurs	O
between	O
multiple	O
Cytochrome	B
P450	I
isoforms	O
within	O
the	O
membrane	O
via	O
homo	O
-	O
and	O
hetero	O
-	O
oligomerisation	O
^	O
,	O
.	O

Atypical	O
kinetic	O
profiles	O
are	O
commonly	O
observed	O
for	O
drug	O
metabolising	O
Cytochrome	B
P450	I
isoforms	O
^	O
,	O
and	O
crystal	O
structures	O
have	O
confirmed	O
that	O
multiple	O
ligands	O
can	O
bind	O
within	O
the	O
large	O
flexible	O
active	O
sites	O
of	O
these	O
enzymes	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
combined	O
in	O
silico	O
protein	O
stability	O
calculation	O
with	O
structure	O
-	O
function	O
relationships	O
to	O
predict	O
the	O
phenotypic	O
effect	O
of	O
Single	O
Nucleotide	O
Polymorphisms	O
in	O
the	O
major	O
drug	O
metabolising	O
Cytochrome	B
P450	I
isoforms	O
^	O
.	O

Cytochrome	B
P450	I
function	O
is	O
affected	O
in	O
vivo	O
by	O
a	O
range	O
of	O
factors	O
,	O
including	O
interaction	O
with	O
the	O
membrane	O
,	O
redox	O
partners	O
and	O
other	O
Cytochrome	B
P450	I
molecules	O
,	O
as	O
well	O
as	O
the	O
diverse	O
range	O
of	O
substrates	O
that	O
could	O
be	O
affected	O
by	O
Single	O
Nucleotide	O
Polymorphisms	O
in	O
a	O
substrate	O
specific	O
manner	O
.	O

Despite	O
this	O
,	O
in	O
our	O
previous	O
study	O
we	O
found	O
that	O
Single	O
Nucleotide	O
Polymorphisms	O
predicted	O
to	O
alter	O
protein	O
stability	O
or	O
located	O
in	O
regions	O
important	O
for	O
catalytic	O
function	O
are	O
more	O
likely	O
to	O
have	O
effects	O
on	O
Cytochrome	B
P450	I
function	O
,	O
based	O
on	O
available	O
in	O
vitro	O
activity	O
data	O
^	O
.	O

The	O
reduced	O
ferrous	O
form	O
of	O
the	O
haem	O
ion	O
binds	O
Carbon	O
Monoxide	O
,	O
yielding	O
an	O
absorption	O
peak	O
at	O
450	O
nm	O
,	O
provided	O
the	O
haem	O
group	O
is	O
correctly	O
incorporated	O
into	O
the	O
Cytochrome	B
P450	I
,	O
providing	O
a	O
measure	O
of	O
the	O
active	O
protein	O
in	O
the	O
sample	O
(	O
although	O
technically	O
the	O
enzyme	O
is	O
rendered	O
inactive	O
on	O
coordination	O
to	O
CO	O
)	O
.	O

When	O
the	O
Cytochrome	B
P450	I
protein	O
samples	O
were	O
incubated	O
at	O
an	O
elevated	O
temperature	O
,	O
the	O
peak	O
at	O
450	O
nm	O
shifted	O
to	O
420	O
nm	O
indicating	O
the	O
thermal	O
conversion	O
of	O
active	O
P450	O
into	O
inactive	O
P420	O
(	O
Fig	O
.	O

However	O
,	O
studies	O
where	O
the	O
M445T	O
variant	O
was	O
expressed	O
in	O
E	O
.	O
coli	O
,	O
quantified	O
using	O
Carbon	O
Monoxide	O
spectral	O
binding	O
assays	O
and	O
reconstituted	O
with	O
Cytochrome	B
P450	I
Reductase	O
and	O
lipids	O
,	O
reported	O
no	O
significant	O
difference	O
in	O
turnover	O
numbers	O
for	O
testosterone	O
^	O
,	O
or	O
chlorpyrifos	O
at	O
the	O
single	O
substrate	O
concentrations	O
tested	O
^	O
.	O

The	O
presence	O
of	O
lipids	O
and	O
Cytochrome	B
P450	I
Reductase	O
in	O
their	O
reconstituted	O
reaction	O
mixture	O
may	O
have	O
a	O
stabilising	O
effect	O
on	O
the	O
protein	O
.	O

The	O
F	O
-	O
G	O
loop	O
has	O
also	O
been	O
implemented	O
in	O
the	O
dimerization	O
of	O
several	O
mammalian	O
Cytochrome	B
P450	I
isoforms	O
,	O
both	O
in	O
solution	O
and	O
membranes	O
^	O
,	O
,	O
,	O
.	O

This	O
mutation	O
is	O
situated	O
on	O
the	O
surface	O
of	O
the	O
protein	O
,	O
outside	O
the	O
cluster	O
of	O
charged	O
residues	O
responsible	O
for	O
Cytochrome	B
P450	I
Reductase	O
binding	O
,	O
but	O
it	O
has	O
been	O
proposed	O
that	O
it	O
could	O
affect	O
interactions	O
with	O
CPR	O
^	O
.	O

SDMs	O
low	O
sensitivity	O
is	O
expected	O
since	O
effects	O
on	O
haem	O
binding	O
and	O
quaternary	O
structure	O
are	O
not	O
accounted	O
for	O
by	O
SDM	O
:	O
of	O
the	O
5	O
false	O
negatives	O
,	O
as	O
predicted	O
by	O
Site	O
Directed	O
Mutator	O
,	O
one	O
(	O
L373F	O
)	O
is	O
a	O
haem	O
contact	O
and	O
two	O
may	O
alter	O
oligomer	O
formation	O
(	O
P218R	O
,	O
S222P	O
)	O
;	O
the	O
other	O
two	O
variants	O
were	O
either	O
incorrectly	O
predicted	O
by	O
Site	O
Directed	O
Mutator	O
or	O
have	O
long	O
range	O
effects	O
on	O
oligomer	O
formation	O
,	O
Cytochrome	B
P450	I
conformation	O
or	O
haem	O
binding	O
,	O
without	O
significantly	O
disrupting	O
the	O
stability	O
of	O
the	O
protein	O
fold	O
.	O

There	O
is	O
a	O
growing	O
body	O
of	O
evidence	O
indicating	O
that	O
homo	O
-	O
and	O
hetero	O
-	O
oligomer	O
formation	O
plays	O
a	O
key	O
role	O
in	O
Cytochrome	B
P450	I
regulation	O
in	O
membranes	O
^	O
,	O
,	O
,	O
.	O

Cytochrome	B
P450	I
protein	O
samples	O
were	O
diluted	O
in	O
storage	O
buffer	O
to	O
a	O
concentration	O
of	O
1	O
mg	O
/	O
ml	O
and	O
divided	O
into	O
two	O
cuvettes	O
(	O
one	O
reference	O
and	O
one	O
sample	O
cuvette	O
)	O
.	O

20	O
l	O
of	O
Cytochrome	B
P450	I
protein	O
sample	O
in	O
storage	O
buffer	O
(	O
~	O
2	O
mg	O
/	O
ml	O
total	O
protein	O
concentration	O
)	O
was	O
injected	O
onto	O
the	O
column	O
.	O

Functional	O
annotations	O
were	O
carried	O
out	O
as	O
described	O
in	O
and	O
using	O
the	O
same	O
parameters	O
as	O
in	O
:	O
putative	O
Carbohydrate	O
-	O
Active	O
enZYmes	O
(	O
CAZYmes	O
)	O
,	O
peroxidases	O
,	O
cytochromes	O
P450	O
(	O
P450s	O
)	O
,	O
cellular	O
transporters	O
,	O
and	O
genes	O
associated	O
with	O
secondary	O
metabolism	O
,	O
were	O
identified	O
using	O
dbCAN	O
,	O
fPoxDB	O
,	O
The	O
Cytochrome	B
P450	I
Homepage	O
,	O
Transporter	O
Classification	O
Database	O
,	O
and	O
antiSMASH	O
v	O
.	O
4	O
.	O
0	O
.	O
0	O
,	O
respectively	O
.	O

Spring	O
against	O
Cytochrome	B
P450	I
and	O
Uridine	O
5	O
-	O
Diphosphoglucuronosyltransferase	O
Isoforms	O
on	O
Human	O
Liver	O
Microsomes	O
.	O

Regarding	O
Cytochrome	B
P450	I
2D6	O
,	O
the	O
primary	O
characteristic	O
of	O
their	O
substrates	O
is	O
the	O
presence	O
of	O
basic	O
nitrogen	O
atom	O
placed	O
5	O
or	O
7	O
from	O
the	O
site	O
of	O
oxidation	O
.	O

Additionally	O
,	O
an	O
important	O
metabolic	O
property	O
to	O
consider	O
is	O
the	O
capability	O
of	O
these	O
compounds	O
to	O
inhibit	O
the	O
Cytochrome	B
P450	I
isoforms	O
,	O
which	O
is	O
an	O
adverse	O
effect	O
.	O

Detoxification	O
of	O
insecticides	O
in	O
mosquitoes	O
include	O
three	O
major	O
gene	O
families	O
:	O
Cytochrome	O
P450s	O
,	O
esterases	O
,	O
and	O
glutathion	O
S	O
-	O
transferases	O
.	O

They	O
encoded	O
an	O
alcohol	O
dehydrogenase	O
(	O
AAEL012457	O
)	O
,	O
an	O
amine	O
oxidase	O
(	O
AAEL009044	O
)	O
,	O
Carboxy	O
/	O
choline	O
esterase	O
(	O
AAEL002385	O
)	O
,	O
19	O
Cytochrome	B
P450	I
,	O
and	O
a	O
glucosyl	O
/	O
glucuronosyl	O
transferase	O
(	O
AAEL003099	O
)	O
.	O

Nineteen	O
Cytochrome	B
P450	I
included	O
,	O
CYP6CB1	O
(	O
AAEL009018	O
)	O
,	O
CYP9M10	O
(	O
AAEL009125	O
)	O
,	O
and	O
P450s	O
of	O
the	O
CYP9J	O
subfamily	O
such	O
as	O
CYP9J10	O
(	O
AAEL006798	O
)	O
and	O
CYP9J28	O
(	O
AAEL014617	O
)	O
,	O
from	O
which	O
several	O
members	O
were	O
shown	O
to	O
contribute	O
to	O
deltamethrin	O
metabolism	O
.	O

Starting	O
at	O
24	O
hours	O
,	O
treatment	O
with	O
B	O
[	O
a	O
]	O
P	O
significantly	O
increases	O
the	O
fold	O
change	O
of	O
all	O
three	O
Cytochrome	B
P450	I
genes	O
,	O
and	O
their	O
expression	O
appears	O
to	O
be	O
the	O
greatest	O
following	O
48	O
hours	O
of	O
B	O
[	O
a	O
]	O
P	O
treatment	O
.	O

The	O
24	O
-	O
hour	O
delay	O
after	O
B	O
[	O
a	O
]	O
P	O
exposure	O
was	O
chosen	O
because	O
it	O
corresponds	O
to	O
the	O
beginning	O
of	O
the	O
induction	O
of	O
Cytochrome	B
P450	I
genes	O
.	O

Treatment	O
of	O
Normal	O
Human	O
Keratinocytes	O
following	O
either	O
the	O
SSL	O
/	O
B	O
[	O
a	O
]	O
P	O
or	O
B	O
[	O
a	O
]	O
P	O
/	O
SSL	O
protocols	O
led	O
to	O
a	O
reduced	O
induction	O
of	O
Cytochrome	B
P450	I
genes	O
than	O
exposure	O
to	O
pure	O
B	O
[	O
a	O
]	O
P	O
.	O
SSL	O
was	O
also	O
found	O
to	O
lead	O
to	O
a	O
decrease	O
in	O
the	O
yield	O
of	O
adducts	O
produced	O
in	O
DNA	O
upon	O
exposure	O
to	O
B	O
[	O
a	O
]	O
P	O
.	O
At	O
72	O
hours	O
,	O
the	O
difference	O
lost	O
statistical	O
significance	O
.	O

It	O
should	O
be	O
stressed	O
that	O
this	O
stimulation	O
of	O
the	O
expression	O
of	O
Cytochrome	B
P450	I
genes	O
remains	O
modest	O
compared	O
to	O
the	O
almost	O
two	O
orders	O
of	O
magnitude	O
larger	O
expression	O
following	O
B	O
[	O
a	O
]	O
P	O
treatment	O
.	O

We	O
did	O
not	O
observe	O
the	O
same	O
modest	O
stimulation	O
of	O
Cytochrome	B
P450	I
expression	O
by	O
Simulated	O
Sunlight	O
in	O
the	O
combination	O
with	O
exposure	O
to	O
B	O
[	O
a	O
]	O
P	O
either	O
before	O
or	O
after	O
irradiation	O
.	O

We	O
made	O
the	O
same	O
observations	O
of	O
a	O
decreased	O
expression	O
of	O
Cytochrome	B
P450	I
genes	O
and	O
formation	O
of	O
BPDE	O
-	O
N	O
^	O
2	O
-	O
dGuo	O
in	O
this	O
model	O
as	O
in	O
skin	O
.	O

Yet	O
,	O
as	O
observed	O
by	O
others	O
^	O
,	O
,	O
,	O
,	O
,	O
,	O
Simulated	O
Sunlight	O
alone	O
lead	O
to	O
a	O
small	O
over	O
expression	O
of	O
Cytochrome	B
P450	I
genes	O
.	O

However	O
,	O
the	O
latter	O
process	O
does	O
not	O
explain	O
the	O
massive	O
reduction	O
in	O
expression	O
of	O
Cytochrome	B
P450	I
genes	O
.	O

First	O
,	O
the	O
reduced	O
expression	O
of	O
Cytochrome	B
P450	I
genes	O
could	O
be	O
explained	O
by	O
the	O
well	O
-	O
documented	O
temporary	O
arrest	O
in	O
RNA	O
synthesis	O
in	O
transcribed	O
genes	O
that	O
takes	O
place	O
following	O
Ultraviolet	O
irradiation	O
^	O
-	O
.	O

Cytochrome	B
P450	I
(	O
CYP	O
)	O
can	O
catalyze	O
reactions	O
of	O
oxidation	O
,	O
reduction	O
,	O
or	O
the	O
oxidative	O
breakdown	O
of	O
xenobiotics	O
(	O
Lamb	O
et	O
al	O
.	O

Cytochrome	B
P450	I
is	O
a	O
particularly	O
well	O
-	O
investigated	O
example	O
^	O
,	O
.	O

Cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
are	O
mainly	O
responsible	O
for	O
the	O
metabolism	O
of	O
drugs	O
and	O
other	O
compounds	O
including	O
phytochemicals	O
in	O
the	O
liver	O
,	O
kidney	O
and	O
intestines	O
.	O

BETA	O
-	O
Naphtoflavone	O
and	O
Ethanol	O
Induce	O
Cytochrome	B
P450	I
and	O
Protect	O
towards	O
MPP	O
+	O
Toxicity	O
in	O
Human	O
Neuroblastoma	O
SH	O
-	O
SY5Y	O
Cells	O
.	O

Cytochrome	B
P450	I
isozymes	O
vary	O
their	O
expression	O
depending	O
on	O
the	O
brain	O
area	O
,	O
the	O
cell	O
type	O
,	O
and	O
the	O
presence	O
of	O
drugs	O
.	O

We	O
have	O
studied	O
the	O
inducibility	O
of	O
Cytochrome	B
P450	I
isozymes	O
in	O
human	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
,	O
treated	O
with	O
BETA	O
-	O
naphtoflavone	O
(	O
BETA	O
-	O
NF	O
)	O
or	O
ethanol	O
(	O
EtOH	O
)	O
as	O
inducers	O
,	O
by	O
qRT	O
-	O
PCR	O
,	O
Western	O
blot	O
,	O
and	O
metabolic	O
activity	O
assays	O
.	O

These	O
data	O
indicate	O
that	O
Cytochrome	B
P450	I
is	O
inducible	O
in	O
SH	O
-	O
SY5Y	O
cells	O
and	O
underline	O
this	O
in	O
vitro	O
system	O
for	O
studying	O
the	O
role	O
of	O
CYPs	O
in	O
neurodegeneration	O
.	O

Cytochrome	B
P450	I
is	O
a	O
superfamily	O
of	O
isozymes	O
involved	O
in	O
the	O
metabolism	O
of	O
xenobiotics	O
in	O
liver	O
and	O
other	O
extra	O
-	O
hepatic	O
tissues	O
.	O

In	O
the	O
brain	O
,	O
Cytochrome	B
P450	I
concentration	O
is	O
approximately	O
0	O
.	O
5	O
-	O
2	O
%	O
of	O
that	O
in	O
liver	O
microsomes	O
.	O

Therefore	O
,	O
other	O
groups	O
have	O
used	O
this	O
cell	O
line	O
for	O
the	O
study	O
of	O
many	O
features	O
linked	O
to	O
this	O
neurodegenerative	O
disease	O
including	O
the	O
induction	O
and	O
protective	O
role	O
of	O
Cytochrome	B
P450	I
against	O
toxic	O
compounds	O
related	O
to	O
Parkinsons	O
Disease	O
.	O

BETA	O
-	O
NF	O
is	O
the	O
agonist	O
of	O
the	O
well	O
-	O
known	O
Aryl	O
Hydrocarbon	O
Receptors	O
,	O
which	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
some	O
Cytochrome	B
P450	I
isoforms	O
.	O

Here	O
,	O
we	O
introduce	O
a	O
new	O
study	O
where	O
BETA	O
-	O
NF	O
and	O
EtOH	O
have	O
been	O
used	O
to	O
investigate	O
the	O
induction	O
of	O
Cytochrome	B
P450	I
isozymes	O
in	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
and	O
their	O
intracellular	O
localization	O
.	O

Differentiated	O
cells	O
presented	O
a	O
significant	O
increase	O
of	O
Cytochrome	B
P450	I
2D6	O
protein	O
levels	O
after	O
treatment	O
with	O
either	O
BETA	O
-	O
NF	O
or	O
EtOH	O
of	O
1	O
.	O
5	O
-	O
and	O
1	O
.	O
4	O
-	O
fold	O
increase	O
,	O
respectively	O
.	O

On	O
the	O
contrary	O
,	O
the	O
treatment	O
with	O
BETA	O
-	O
NF	O
did	O
not	O
promote	O
the	O
increase	O
in	O
the	O
expression	O
of	O
Cytochrome	B
P450	I
2E1	O
,	O
while	O
EtOH	O
significantly	O
increased	O
it	O
.	O

7	O
-	O
Ethoxycoumarin	O
is	O
metabolized	O
by	O
many	O
Cytochrome	B
P450	I
isoforms	O
involved	O
in	O
xenobiotic	O
metabolism	O
.	O

It	O
must	O
be	O
underlined	O
that	O
due	O
to	O
low	O
fluorescent	O
intensity	O
in	O
control	O
conditions	O
,	O
the	O
colocalization	O
plugin	O
was	O
not	O
able	O
to	O
correlate	O
the	O
Cytochrome	B
P450	I
channel	O
with	O
either	O
mitochondria	O
or	O
Endoplasmic	O
Reticulum	O
.	O

Our	O
results	O
are	O
in	O
agreement	O
with	O
Imran	O
et	O
al	O
.	O
,	O
who	O
showed	O
that	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlordibenzo	O
-	O
p	O
-	O
dioxin	O
,	O
one	O
of	O
the	O
most	O
potent	O
inducers	O
of	O
CYP1	O
family	O
via	O
Aryl	O
Hydrocarbon	O
Receptors	O
,	O
is	O
able	O
to	O
increase	O
the	O
mRNA	O
levels	O
of	O
these	O
Cytochrome	B
P450	I
isoforms	O
only	O
at	O
10	O
nM	O
in	O
SH	O
-	O
SY5Y	O
cells	O
,	O
while	O
2	O
.	O
5	O
and	O
5	O
nM	O
did	O
not	O
have	O
this	O
effect	O
.	O

Furthermore	O
,	O
the	O
Western	O
Blot	O
experiments	O
performed	O
in	O
differentiated	O
cells	O
provide	O
a	O
more	O
realistic	O
view	O
of	O
the	O
Central	O
Nervous	O
System	O
,	O
taken	O
into	O
account	O
the	O
different	O
expression	O
patterns	O
of	O
Cytochrome	B
P450	I
isoforms	O
in	O
brain	O
cells	O
/	O
areas	O
.	O

In	O
order	O
to	O
study	O
the	O
metabolic	O
capability	O
of	O
SH	O
-	O
SY5Y	O
cells	O
after	O
the	O
induction	O
of	O
Cytochrome	B
P450	I
isoforms	O
,	O
we	O
used	O
7	O
-	O
ethoxycoumarin	O
as	O
substrate	O
for	O
a	O
broad	O
number	O
of	O
Cytochrome	B
P450	I
isozymes	O
.	O

The	O
localization	O
of	O
Cytochrome	B
P450	I
in	O
mitochondria	O
can	O
contribute	O
to	O
the	O
bioactivation	O
/	O
detoxification	O
processes	O
of	O
neurotoxins	O
.	O

Therefore	O
,	O
other	O
Cytochrome	B
P450	I
isoforms	O
can	O
have	O
an	O
important	O
role	O
in	O
xenobiotic	O
metabolism	O
in	O
other	O
brain	O
regions	O
,	O
and	O
at	O
the	O
same	O
time	O
,	O
they	O
do	O
not	O
have	O
to	O
necessarily	O
be	O
associate	O
with	O
positive	O
effects	O
.	O

This	O
toxin	O
can	O
be	O
metabolized	O
by	O
the	O
Cytochrome	B
P450	I
system	O
as	O
already	O
reported	O
.	O

Since	O
Cytochrome	B
P450	I
is	O
not	O
able	O
to	O
metabolize	O
this	O
compound	O
,	O
we	O
confirmed	O
that	O
the	O
effects	O
observed	O
were	O
not	O
produced	O
by	O
the	O
inducers	O
itself	O
,	O
but	O
by	O
the	O
promotion	O
of	O
the	O
Cytochrome	B
P450	I
system	O
.	O

The	O
enzyme	O
activities	O
were	O
expressed	O
as	O
pmol	O
metabolite	O
per	O
mg	O
of	O
protein	O
in	O
24	O
h	O
.	O
A	O
staining	O
approach	O
to	O
evaluate	O
the	O
Cytochrome	B
P450	I
location	O
in	O
SH	O
-	O
SY5Y	O
was	O
carried	O
out	O
by	O
confocal	O
imaging	O
.	O

Cytochrome	B
P450	I
,	O
a	O
superfamily	O
of	O
monooxygenase	O
,	O
plays	O
critical	O
roles	O
in	O
biosynthesis	O
of	O
plant	O
secondary	O
metabolites	O
such	O
as	O
triterpenes	O
,	O
alkaloids	O
,	O
and	O
sterols	O
.	O

Influence	O
of	O
mentioned	O
extracts	O
and	O
their	O
key	O
constituents	O
on	O
warfarin	O
pharmacodynamic	O
and	O
kinetic	O
actions	O
and	O
Cytochrome	B
P450	I
Enzymes	I
activity	O
were	O
evaluated	O
.	O

Furthermore	O
,	O
potential	O
involvement	O
in	O
Cytochrome	B
P450	I
Enzymes	O
inhibition	O
was	O
also	O
investigated	O
in	O
vitro	O
on	O
isolated	O
primary	O
rat	O
hepatocytes	O
.	O

In	O
addition	O
,	O
the	O
potential	O
inhibition	O
of	O
selected	O
Cytochrome	B
P450	I
Enzymes	O
enzymes	O
that	O
are	O
responsible	O
for	O
warfarin	O
metabolism	O
is	O
investigated	O
with	O
the	O
herbal	O
drugs	O
in	O
vitro	O
on	O
rat	O
isolated	O
primary	O
hepatocytes	O
.	O

After	O
16	O
h	O
of	O
incubation	O
,	O
each	O
well	O
of	O
cultured	O
rat	O
hepatocytes	O
were	O
treated	O
with	O
25	O
l	O
of	O
warfarin	O
,	O
guava	O
leaves	O
extract	O
,	O
quercetin	O
,	O
pomegranate	O
peel	O
extract	O
,	O
ellagic	O
acid	O
,	O
a	O
combination	O
of	O
warfarin	O
with	O
each	O
test	O
compound	O
in	O
addition	O
to	O
the	O
control	O
Cytochrome	B
P450	I
Enzymes	O
inhibitors	O
namely	O
;	O
ketoconazole	O
,	O
sulfamethoxazole	O
or	O
trimethoprim	O
.	O

Noteworthy	O
,	O
the	O
evaluation	O
of	O
CYP450	O
enzymes	O
,	O
namely	O
,	O
CYP2C9	O
,	O
2C8	O
,	O
3A4	O
was	O
based	O
on	O
cell	O
-	O
based	O
investigations	O
and	O
sufficient	O
inhibition	O
of	O
corresponding	O
well	O
-	O
known	O
Cytochrome	B
P450	I
Enzymes	O
control	O
inhibitors	O
including	O
,	O
sulfamethoxazole	O
,	O
trimethoprim	O
and	O
ketoconazole	O
confirms	O
that	O
in	O
vitro	O
investigation	O
of	O
mentioned	O
Cytochrome	B
P450	I
Enzymes	O
isoforms	O
on	O
rat	O
hepatocyte	O
is	O
possible	O
,	O
as	O
raised	O
in	O
the	O
literature	O
[	O
,	O
.	O

In	O
regard	O
to	O
results	O
presented	O
for	O
ellagic	O
acid	O
,	O
and	O
since	O
it	O
is	O
known	O
to	O
exert	O
inhibition	O
on	O
CYP2C9	O
,	O
its	O
effect	O
may	O
be	O
due	O
to	O
a	O
decrease	O
in	O
hepatic	O
first	O
-	O
pass	O
metabolism	O
of	O
warfarin	O
due	O
to	O
its	O
ability	O
to	O
inhibit	O
such	O
Cytochrome	B
P450	I
Enzymes	O
isoform	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
guava	O
leaves	O
extract	O
and	O
quercetin	O
to	O
inhibit	O
some	O
of	O
hepatic	O
Cytochrome	B
P450	I
Enzymes	O
isoforms	O
associated	O
with	O
warfarin	O
metabolism	O
such	O
as	O
CYP2C9	O
,	O
2C8	O
and	O
3A4	O
may	O
be	O
responsible	O
for	O
increasing	O
warfarin	O
plasma	O
concentration	O
[	O
,	O
.	O

In	O
vitro	O
warfarin	O
-	O
herb	O
interactions	O
and	O
their	O
effects	O
on	O
hepatic	O
Cytochrome	B
P450	I
Enzymes	O
isoforms	O
showed	O
that	O
CYP2C9	O
,	O
2C8	O
and	O
3A4	O
activities	O
in	O
primary	O
isolated	O
and	O
cultured	O
rat	O
hepatocytes	O
were	O
not	O
affected	O
by	O
warfarin	O
.	O

Since	O
Cytochrome	B
P450	I
Enzymes	O
isoforms	O
other	O
than	O
2C9	O
,	O
2C8	O
and	O
3A4	O
are	O
involved	O
in	O
warfarin	O
metabolism	O
,	O
further	O
study	O
with	O
more	O
focus	O
on	O
pomegranate	O
peel	O
and	O
its	O
constituents	O
is	O
therefore	O
suggested	O
.	O

To	O
achieve	O
this	O
,	O
the	O
hit	O
compounds	O
evaluated	O
for	O
either	O
substrate	O
or	O
inhibitors	O
of	O
Cytochrome	B
P450	I
Enzymes	O
along	O
with	O
Cytochrome	B
P450	I
Enzymes	O
of	O
Human	O
Liver	O
Microsomes	O
.	O

These	O
metabolism	O
properties	O
were	O
explored	O
in	O
silico	O
and	O
summarized	O
by	O
predicting	O
the	O
metabolic	O
sites	O
as	O
well	O
as	O
metabolites	O
,	O
and	O
type	O
of	O
Cytochrome	B
P450	I
Enzymes	O
involved	O
enzymes	O
,	O
which	O
catalyzes	O
xenobiotics	O
/	O
drugs	O
in	O
phase	O
II	O
metabolism	O
and	O
transform	O
the	O
small	O
molecules	O
to	O
water	O
-	O
soluble	O
form	O
,	O
which	O
may	O
lead	O
to	O
the	O
easy	O
elimination	O
of	O
xenobiotics	O
.	O

Cytochrome	O
P450s	O
,	O
which	O
comprise	O
one	O
of	O
the	O
largest	O
and	O
oldest	O
gene	O
superfamilies	O
,	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
biosynthesis	O
of	O
secondary	O
metabolites	O
such	O
as	O
flavonoids	O
.	O

In	O
this	O
study	O
,	O
78	O
unigene	O
Differentially	O
Expressed	O
Genes	O
were	O
annotated	O
as	O
Cytochrome	O
P450s	O
.	O

Cytochrome	O
P450s	O
are	O
known	O
to	O
play	O
central	O
roles	O
in	O
the	O
evolution	O
of	O
metabolic	O
complexity	O
and	O
in	O
the	O
production	O
of	O
secondary	O
metabolites	O
,	O
including	O
flavonoid	O
metabolites	O
.	O

Two	O
Cytochrome	O
P450s	O
(	O
CfCYP93B	O
and	O
CfCYP706C	O
)	O
isolated	O
from	O
Coleus	O
forskohlii	O
are	O
involved	O
in	O
the	O
biosynthesis	O
of	O
flavonoids	O
and	O
CYP93B	O
isolated	O
from	O
hybrid	O
Gerbera	O
encodes	O
flavone	O
synthase	O
II	O
,	O
which	O
catalyzes	O
flavanones	O
into	O
flavones	O
.	O

The	O
expression	O
of	O
Cytochrome	O
P450s	O
also	O
has	O
a	O
significant	O
effect	O
on	O
the	O
content	O
of	O
flavonoids	O
in	O
plants	O
.	O

Several	O
enzymes	O
including	O
those	O
belonging	O
to	O
the	O
Cytochrome	B
P450	I
family	O
play	O
crucial	O
roles	O
in	O
the	O
generation	O
of	O
either	O
a	O
stable	O
plaque	O
or	O
progression	O
to	O
an	O
unstable	O
plaque	O
with	O
poor	O
prognosis	O
for	O
atherosclerosis	O
outcome	O
(	O
Silvestre	O
-	O
Roig	O
et	O
al	O
.	O
,	O
;	O
Song	O
et	O
al	O
.	O
,	O
;	O
Stefanadis	O
et	O
al	O
.	O
,	O
.	O

Cholesterol	O
also	O
acts	O
as	O
a	O
substrate	O
for	O
various	O
enzyme	O
activities	O
including	O
those	O
belonging	O
to	O
the	O
Cytochrome	B
P450	I
family	O
(	O
Pikuleva	O
,	O
;	O
Rogers	O
et	O
al	O
.	O
,	O
.	O

The	O
Cytochrome	B
P450	I
system	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
various	O
CVDs	O
including	O
atherosclerosis	O
and	O
aneurysms	O
(	O
Song	O
et	O
al	O
.	O
,	O
;	O
Thirunavukkarasu	O
et	O
al	O
.	O
,	O
.	O

The	O
cholesterol	O
metabolizing	O
ability	O
of	O
Cytochrome	B
P450	I
family	O
members	O
varies	O
depending	O
on	O
the	O
physiological	O
requirements	O
of	O
different	O
organs	O
and	O
in	O
vivo	O
cholesterol	O
levels	O
.	O

The	O
importance	O
of	O
Cytochrome	B
P450	I
in	O
mycobacteria	O
is	O
known	O
.	O

Iron	O
is	O
necessary	O
for	O
mycobacterial	O
Cytochrome	B
P450	I
(	O
Ouellet	O
et	O
al	O
.	O
,	O
)	O
activity	O
and	O
iron	O
has	O
been	O
recognized	O
as	O
a	O
crucial	O
element	O
for	O
the	O
survival	O
of	O
intracellular	O
mycobacteria	O
(	O
Ratledge	O
,	O
;	O
Janagama	O
et	O
al	O
.	O
,	O
;	O
Lamont	O
et	O
al	O
.	O
,	O
.	O

Thus	O
,	O
the	O
importance	O
of	O
Cytochrome	B
P450	I
from	O
the	O
pathogen	O
perspective	O
has	O
been	O
explored	O
albeit	O
not	O
in	O
depth	O
.	O

From	O
the	O
host	O
perspective	O
,	O
a	O
transcriptomic	O
analysis	O
of	O
Tuberculosis	O
granulomas	O
has	O
revealed	O
a	O
characteristic	O
downregulation	O
of	O
several	O
Cytochrome	B
P450	I
genes	O
in	O
cells	O
within	O
these	O
granulomas	O
(	O
Eisenreich	O
et	O
al	O
.	O
,	O
.	O

Cytochrome	B
P450	I
monooxygenases	O
are	O
involved	O
in	O
biosynthesis	O
of	O
oxysterols	O
(	O
Pikuleva	O
,	O
)	O
,	O
however	O
the	O
dynamics	O
between	O
the	O
expression	O
of	O
Cytochrome	B
P450	I
genes	O
in	O
granuloma	O
formation	O
and	O
cholesterol	O
metabolism	O
has	O
not	O
been	O
assessed	O
in	O
Mycobacterium	O
Tuberculosis	O
infection	O
.	O

Apart	O
from	O
their	O
direct	O
role	O
in	O
modulating	O
host	O
cholesterol	O
metabolism	O
,	O
members	O
of	O
the	O
Cytochrome	B
P450	I
family	O
such	O
as	O
Cyp4501b1	O
(	O
Cyp1b1	O
)	O
are	O
involved	O
in	O
the	O
metabolism	O
of	O
sex	O
steroidal	O
hormones	O
with	O
the	O
resultant	O
metabolites	O
produced	O
being	O
implicated	O
to	O
play	O
a	O
role	O
in	O
the	O
gender	O
differences	O
noticed	O
to	O
the	O
susceptibility	O
to	O
cardiac	O
and	O
renal	O
diseases	O
(	O
Jennings	O
et	O
al	O
.	O
,	O
;	O
Pingili	O
et	O
al	O
.	O
,	O
;	O
Song	O
et	O
al	O
.	O
,	O
;	O
Thirunavukkarasu	O
et	O
al	O
.	O
,	O
.	O

Therefore	O
,	O
extrapolating	O
from	O
the	O
evidence	O
for	O
Cyp1b1	O
in	O
gender	O
specific	O
pathogeneis	O
of	O
CVDs	O
,	O
it	O
would	O
be	O
worthwhile	O
to	O
explore	O
further	O
the	O
role	O
of	O
Cytochrome	B
P450	I
family	O
members	O
in	O
mycobacterial	O
infections	O
due	O
to	O
a	O
necessity	O
for	O
a	O
sex	O
-	O
tailored	O
therapeutic	O
approach	O
in	O
view	O
of	O
the	O
gender	O
related	O
susceptibility	O
to	O
disease	O
.	O

Kistamicin	O
contains	O
three	O
crosslinks	O
,	O
including	O
an	O
unusual	O
15	O
-	O
membered	O
A	O
-	O
O	O
-	O
B	O
ring	O
,	O
despite	O
the	O
presence	O
of	O
only	O
two	O
Cytochrome	B
P450	I
Oxy	O
enzymes	O
thought	O
to	O
catalyse	O
formation	O
of	O
such	O
crosslinks	O
within	O
the	O
biosynthetic	O
gene	O
cluster	O
.	O

The	O
most	O
abundant	O
in	O
the	O
plasma	O
is	O
sorafenib	O
N	O
-	O
oxide	O
(	O
M2	O
)	O
,	O
which	O
is	O
produced	O
by	O
Cytochrome	B
P450	I
3a4	I
and	O
exhibits	O
an	O
in	O
vitro	O
potency	O
similar	O
to	O
the	O
parental	O
drug	O
.	O

Given	O
the	O
key	O
role	O
of	O
Cytochrome	B
P450	I
3a4	I
and	O
Udp	O
Glucuronosyltransferase	O
1a9	O
in	O
sorafenib	O
metabolism	O
,	O
inducers	O
or	O
inhibitors	O
of	O
these	O
enzymes	O
,	O
such	O
as	O
some	O
foods	O
and	O
co	O
-	O
administered	O
drugs	O
(	O
eg	O
,	O
carbamazepine	O
,	O
dexamethasone	O
,	O
phenobarbital	O
,	O
phenytoin	O
,	O
rifampin	O
,	O
rifabutin	O
,	O
St	O
.	O

The	O
liver	O
metabolism	O
of	O
regorafenib	O
,	O
even	O
if	O
less	O
well	O
-	O
characterized	O
,	O
is	O
comparable	O
with	O
that	O
of	O
sorafenib	O
and	O
occurs	O
through	O
an	O
oxidative	O
process	O
mediated	O
by	O
Cytochrome	B
P450	I
3a4	O
and	O
glucuronidation	O
mediated	O
by	O
Udp	O
Glucuronosyltransferase	O
1a9	O
.	O

A	O
descriptive	O
study	O
assessed	O
Cytochrome	B
P450	I
3a4	O
and	O
Udp	O
Glucuronosyltransferase	O
1a9	O
genetic	O
variability	O
by	O
sequencing	O
the	O
germline	O
DNA	O
of	O
three	O
patients	O
with	O
metastatic	O
colorectal	O
cancer	O
experiencing	O
severe	O
toxic	O
hepatitis	O
after	O
sorafenib	O
treatment	O
and	O
reported	O
that	O
two	O
patients	O
were	O
heterozygous	O
for	O
the	O
UGT1A9	O
*	O
22	O
(	O
rs3832043	O
)	O
polymorphism	O
.	O

This	O
drug	O
undergoes	O
hepatic	O
metabolism	O
by	O
Cytochrome	B
P450	I
3a4	O
and	O
,	O
to	O
a	O
minor	O
extent	O
,	O
by	O
CYP2C9	O
.	O

Lenvatinib	O
is	O
metabolized	O
in	O
liver	O
microsomes	O
mostly	O
through	O
Cytochrome	B
P450	I
3a4	O
(	O
>	O
80	O
%	O
)	O
and	O
,	O
to	O
a	O
minor	O
extent	O
,	O
by	O
aldehyde	O
oxidase	O
and	O
acts	O
as	O
a	O
substrate	O
for	O
Atp	O
-	O
Binding	O
Cassette	O
transporters	O
,	O
encoded	O
by	O
the	O
ABCB1	O
and	O
ABCG2	O
genes	O
,	O
such	O
as	O
BCRP	O
and	O
P	O
-	O
glycoprotein	O
.	O

Overexpression	O
of	O
a	O
Novel	O
Cytochrome	B
P450	I
Promotes	O
Flavonoid	O
Biosynthesis	O
and	O
Osmotic	O
Stress	O
Tolerance	O
in	O
Transgenic	O
Arabidopsis	O
.	O

However	O
,	O
the	O
explicit	O
regulation	O
mechanism	O
of	O
Cytochrome	O
P450s	O
related	O
to	O
flavonoid	O
biosynthesis	O
largely	O
remains	O
elusive	O
.	O

The	O
result	O
of	O
the	O
qRT	O
-	O
PCR	O
assays	O
indicated	O
that	O
the	O
expression	O
level	O
of	O
most	O
of	O
the	O
flavonoid	O
pathway	O
genes	O
,	O
including	O
PAL	O
(	O
Phenylalanine	O
ammonia	O
lyase	O
)	O
,	O
Chalcone	O
Isomerase	O
(	O
Chalcone	O
isomerase	O
)	O
,	O
CYP82G1	O
(	O
Cytochrome	B
P450	I
monooxygenase	O
)	O
,	O
F3H	O
(	O
flavonoid	O
3	O
-	O
hydroxylase	O
)	O
,	O
and	O
FLS	O
(	O
Flavonol	O
synthase	O
)	O
were	O
more	O
abundantly	O
up	O
-	O
regulated	O
in	O
the	O
ARB3	O
-	O
CtCYP82G24	O
overexpression	O
line	O
than	O
that	O
of	O
wild	O
-	O
type	O
plant	O
.	O

The	O
heme	O
-	O
containing	O
Cytochrome	B
P450	I
enzymes	I
activate	O
molecular	O
oxygen	O
utilizing	O
NADPH	O
as	O
an	O
electron	O
donor	O
.	O

Cytochrome	B
P450	I
enzymes	I
involved	O
in	O
steroidogenesis	O
can	O
be	O
divided	O
into	O
two	O
groups	O
based	O
on	O
their	O
intracellular	O
location	O
and	O
mode	O
of	O
electron	O
transfer	O
.	O

Cytochrome	B
P450	I
type	O
I	O
enzymes	O
are	O
located	O
within	O
the	O
inner	O
mitochondrial	O
membrane	O
and	O
are	O
dependent	O
on	O
ferredoxin	O
and	O
ferredoxin	O
reductase	O
for	O
the	O
delivery	O
of	O
their	O
electrons	O
from	O
NADPH	O
.	O

Ferredoxin	O
reductase	O
is	O
a	O
flavoprotein	O
that	O
oxidizes	O
NADPH	O
and	O
transfers	O
electrons	O
to	O
ferredoxin	O
,	O
a	O
small	O
iron	O
-	O
sulfur	O
protein	O
,	O
which	O
acts	O
as	O
a	O
mobile	O
electron	O
carrier	O
,	O
delivering	O
the	O
electrons	O
to	O
the	O
Cytochrome	B
P450	I
.	O

In	O
addition	O
to	O
the	O
steroidogenic	O
Cytochrome	B
P450	I
enzymes	I
described	O
in	O
Section	O
,	O
hepatic	O
xenobiotic	O
-	O
metabolizing	O
members	O
of	O
the	O
Cytochrome	O
P450	O
superfamily	O
are	O
able	O
to	O
modify	O
steroid	O
hormones	O
and	O
generate	O
a	O
plethora	O
of	O
minor	O
steroid	O
metabolites	O
.	O

Cytochrome	B
P450	I
enzymes	I
have	O
potential	O
uses	O
in	O
the	O
synthesis	O
and	O
discovery	O
of	O
drugs	O
,	O
as	O
well	O
as	O
drug	O
development	O
.	O

Cytochrome	B
P450	I
enzymes	I
metabolize	O
thousands	O
of	O
endogenous	O
and	O
exogenous	O
chemicals	O
.	O

Cytochrome	B
P450	I
enzymes	I
are	O
bound	O
to	O
membranes	O
within	O
a	O
cell	O
and	O
contain	O
a	O
heme	O
pigment	O
that	O
absorbs	O
light	O
at	O
a	O
wavelength	O
of	O
450	O
nm	O
when	O
exposed	O
to	O
carbon	O
monoxide	O
.	O

Cytochrome	B
P450	I
enzymes	I
play	O
a	O
role	O
in	O
the	O
synthesis	O
of	O
many	O
molecules	O
including	O
steroid	O
hormones	O
,	O
certain	O
Fatty	O
Acids	O
(	O
cholesterol	O
and	O
other	O
fatty	O
acids	O
)	O
,	O
and	O
acids	O
used	O
to	O
digest	O
Fatty	O
Acids	O
(	O
bile	O
acids	O
)	O
.	O

In	O
24	O
h	O
,	O
Doxorubicin	O
exposure	O
caused	O
male	O
-	O
specific	O
induction	O
of	O
Cyp1b1	O
and	O
female	O
-	O
specific	O
induction	O
of	O
Cyp2c29	O
and	O
Cyp2e1	B
.	O

Similar	O
to	O
Cyp2c29	O
,	O
acute	O
DOX	O
-	O
induced	O
cardiotoxicity	O
induced	O
the	O
gene	O
expression	O
of	O
Cyp2e1	B
only	O
in	O
the	O
hearts	O
of	O
female	O
mice	O
24	O
h	O
following	O
Doxorubicin	O
administration	O
.	O

Despite	O
the	O
well	O
-	O
documented	O
role	O
of	O
hepatic	O
Cyp2e1	B
in	O
mediating	O
alcohol	O
-	O
induced	O
hepatotoxicity	O
,	O
the	O
role	O
of	O
cardiac	O
Cyp2e1	B
is	O
not	O
well	O
studied	O
.	O

Pharmacological	O
inhibition	O
and	O
genetic	O
knock	O
down	O
of	O
Cyp2e1	B
have	O
been	O
shown	O
to	O
confer	O
cardioprotection	O
in	O
a	O
DOX	O
-	O
induced	O
dilated	O
cardiomyopathy	O
mouse	O
model	O
by	O
inhibiting	O
oxidative	O
stress	O
and	O
apoptosis	O
.	O

Nevertheless	O
,	O
Cyp2e1	B
metabolizes	O
arachidonic	O
acid	O
to	O
19	O
-	O
hydroxyeicosatetraenoic	O
acid	O
which	O
has	O
cardioprotective	O
properties	O
.	O

Therefore	O
,	O
further	O
research	O
is	O
needed	O
to	O
confirm	O
whether	O
cardiac	O
Cyp2e1	B
is	O
protective	O
or	O
detrimental	O
to	O
the	O
heart	O
.	O

As	O
illustrated	O
in	O
Fig	O
,	O
significant	O
male	O
-	O
specific	O
induction	O
of	O
Cyp1b1	O
and	O
female	O
-	O
specific	O
induction	O
of	O
Cyp2c29	O
and	O
Cyp2e1	B
may	O
play	O
important	O
roles	O
in	O
mediating	O
sex	O
-	O
related	O
differences	O
of	O
DOX	O
-	O
induced	O
cardiotoxicity	O
.	O

One	O
day	O
following	O
Doxorubicin	O
injection	O
,	O
a	O
greater	O
than	O
80	O
%	O
reduction	O
in	O
the	O
expression	O
of	O
Cyp1a1	B
in	O
the	O
heart	O
was	O
observed	O
in	O
both	O
male	O
and	O
female	O
mice	O
(	O
p	O
value	O
=	O
0	O
.	O
05	O
in	O
males	O
)	O
.	O

Cyp1a1	B
gene	O
expression	O
returned	O
to	O
a	O
control	O
value	O
in	O
females	O
,	O
but	O
not	O
in	O
males	O
,	O
6	O
days	O
post	O
-	O
DOX	O
,	O
demonstrating	O
a	O
significant	O
sex	O
effect	O
was	O
observed	O
6	O
days	O
after	O
Doxorubicin	O
injection	O
.	O

In	O
the	O
current	O
study	O
,	O
acute	O
Doxorubicin	O
exposure	O
caused	O
a	O
marked	O
inhibition	O
of	O
Cyp1a1	B
gene	O
expression	O
in	O
the	O
hearts	O
of	O
male	O
and	O
female	O
mice	O
1	O
day	O
after	O
Doxorubicin	O
injection	O
.	O

Similarly	O
,	O
a	O
single	O
10	O
mg	O
/	O
kg	O
Doxorubicin	O
injection	O
caused	O
significant	O
induction	O
of	O
Cyp1a1	B
in	O
the	O
hearts	O
of	O
8	O
-	O
week	O
-	O
old	O
male	O
C57Bl	O
/	O
6	O
mice	O
.	O

In	O
order	O
to	O
confirm	O
our	O
current	O
finding	O
,	O
we	O
used	O
three	O
different	O
sets	O
of	O
Cyp1a1	B
primers	O
selected	O
from	O
three	O
different	O
studies	O
(	O
Additional	O
file	O
.	O

The	O
three	O
different	O
experiments	O
resulted	O
in	O
the	O
same	O
finding	O
,	O
confirming	O
the	O
inhibition	O
of	O
Cyp1a1	B
gene	O
expression	O
in	O
this	O
study	O
.	O

DOX	O
-	O
mediated	O
inhibition	O
of	O
Cyp1a1	B
may	O
be	O
attributed	O
to	O
DOX	O
-	O
induced	O
inflammation	O
,	O
since	O
inflammation	O
has	O
been	O
shown	O
to	O
downregulate	O
Cyp1a1	B
in	O
the	O
hearts	O
of	O
male	O
C57Bl	O
/	O
6	O
mice	O
.	O

However	O
,	O
this	O
notion	O
cannot	O
explain	O
the	O
inhibition	O
of	O
Cyp1a1	B
in	O
the	O
hearts	O
of	O
female	O
mice	O
,	O
since	O
they	O
had	O
minimal	O
inflammation	O
.	O

Of	O
interest	O
,	O
the	O
gene	O
expression	O
of	O
Cyp1a1	B
returned	O
to	O
a	O
control	O
value	O
6	O
days	O
after	O
Doxorubicin	O
administration	O
in	O
female	O
,	O
but	O
not	O
in	O
male	O
mice	O
,	O
indicating	O
the	O
recovery	O
of	O
the	O
female	O
hearts	O
from	O
the	O
early	O
DOX	O
-	O
induced	O
injury	O
.	O

The	O
expression	O
of	O
additional	O
CYPs	O
(	O
Cyp1a1	B
,	O
Cyp1b1	O
,	O
Cyp2e1	O
)	O
was	O
observed	O
in	O
the	O
skin	O
of	O
C57BL	O
/	O
6J	O
mice	O
by	O
Flowers	O
et	O
al	O
.	O
.	O
In	O
the	O
mouse	O
skin	O
the	O
expression	O
of	O
several	O
Cyp	O
genes	O
was	O
demonstrated	O
on	O
the	O
RNA	O
level	O
.	O

Determination	O
of	O
(	O
CD	O
-	O
1	O
)	O
mouse	O
cutaneous	O
RNA	O
levels	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
showed	O
transcripts	O
arising	O
from	O
Cyp4f13	O
and	O
4f16	O
(	O
most	O
abundant	O
)	O
,	O
Cyp4f18	O
and	O
4f39	O
(	O
intermediate	O
)	O
,	O
Cyp4f14	O
,	O
4f17	O
,	O
and	O
4f37	O
(	O
low	O
)	O
,	O
and	O
from	O
Cyp4f15	O
and	O
Cyp4f40	O
(	O
highly	O
variable	O
or	O
too	O
low	O
to	O
measure	O
in	O
some	O
animals	O
)	O
(	O
Du	O
et	O
al	O
.	O
.	O
In	O
addition	O
,	O
the	O
expression	O
of	O
the	O
Cyp1a1	B
,	O
Cyp1b1	O
,	O
Cyp2e1	O
genes	O
was	O
observed	O
in	O
(	O
C57BL	O
/	O
6J	O
)	O
mouse	O
skin	O
(	O
Flowers	O
et	O
al	O
.	O
.	O
Interestingly	O
,	O
recent	O
studies	O
by	O
Borland	O
et	O
al	O
.	O

Cyp1a1	B
,	O
Cyp1b1	O
and	O
Cyp3a11	O
,	O
but	O
not	O
Ahr	O
expression	O
in	O
the	O
skin	O
also	O
were	O
enhanced	O
by	O
7	O
,	O
12	O
-	O
Dimethylbenz	O
[	O
A	O
]	O
Anthracene	O
.	O

Acute	O
exposure	O
to	O
Doxorubicin	O
significantly	O
increased	O
Cyp4a10	O
mRNA	O
levels	O
in	O
hearts	O
of	O
both	O
male	O
and	O
female	O
mice	O
(	O
twofold	O
and	O
sixfold	O
induction	O
,	O
respectively	O
)	O
1	O
day	O
after	O
Doxorubicin	O
administration	O
.	O

This	O
was	O
reversed	O
in	O
both	O
sexes	O
6	O
days	O
after	O
treatment	O
with	O
a	O
significant	O
effect	O
of	O
sex	O
on	O
Cyp4a10	O
expression	O
.	O

Several	O
studies	O
have	O
investigated	O
the	O
sexual	O
divergence	O
of	O
Cyp4a10	O
expression	O
in	O
the	O
kidney	O
and	O
liver	O
of	O
different	O
strains	O
of	O
mice	O
.	O

In	O
one	O
study	O
,	O
there	O
was	O
no	O
sex	O
-	O
dependent	O
difference	O
in	O
the	O
expression	O
of	O
Cyp4a10	O
in	O
the	O
kidney	O
of	O
C57Bl	O
/	O
6	O
mice	O
.	O

In	O
another	O
study	O
,	O
Cyp4a10	O
was	O
expressed	O
at	O
a	O
higher	O
level	O
in	O
the	O
liver	O
and	O
kidney	O
of	O
female	O
than	O
in	O
male	O
C57Bl	O
/	O
6	O
mice	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
information	O
about	O
sex	O
-	O
related	O
differences	O
in	O
Cyp4a10	O
expression	O
in	O
the	O
mouse	O
heart	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
found	O
that	O
the	O
expression	O
of	O
Cyp4a10	O
was	O
significantly	O
lower	O
in	O
the	O
hearts	O
of	O
control	O
female	O
than	O
in	O
control	O
male	O
mice	O
in	O
the	O
24	O
-	O
h	O
cohort	O
,	O
suggesting	O
organ	O
-	O
specific	O
sexual	O
divergence	O
in	O
Cyp4a10	O
expression	O
.	O

Although	O
the	O
expression	O
of	O
Cyp4a10	O
in	O
the	O
hearts	O
of	O
female	O
mice	O
was	O
60	O
%	O
of	O
its	O
expression	O
in	O
male	O
mice	O
in	O
the	O
6	O
-	O
day	O
cohort	O
,	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Lower	O
expression	O
of	O
cardiac	O
Cyp4a10	O
may	O
contribute	O
to	O
the	O
overall	O
protection	O
of	O
females	O
against	O
heart	O
disease	O
as	O
Cyp4a10	O
has	O
been	O
shown	O
to	O
metabolize	O
arachidonic	O
acid	O
to	O
the	O
cardiotoxic	O
metabolite	O
20	O
-	O
hydroxyeicosatetraenoic	O
acid	O
.	O

Despite	O
a	O
lower	O
constitutive	O
expression	O
of	O
Cyp4a10	O
in	O
the	O
female	O
hearts	O
,	O
acute	O
DOX	O
-	O
induced	O
cardiotoxicity	O
caused	O
a	O
marked	O
induction	O
of	O
Cyp4a10	O
in	O
the	O
hearts	O
of	O
both	O
male	O
and	O
female	O
mice	O
,	O
suggesting	O
that	O
this	O
enzyme	O
may	O
not	O
play	O
an	O
important	O
role	O
in	O
the	O
sexual	O
dimorphism	O
of	O
DOX	O
-	O
induced	O
cardiotoxicity	O
.	O

These	O
data	O
provide	O
important	O
insights	O
into	O
the	O
structural	O
properties	O
and	O
the	O
molecular	O
selectivity	O
of	O
this	O
M	O
.	O
tuberculosis	O
P450	B
enzyme	I
,	O
highlighting	O
its	O
capacity	O
to	O
bind	O
large	O
compounds	O
,	O
and	O
the	O
ability	O
of	O
molecules	O
with	O
nitroaromatic	O
groups	O
to	O
moonlight	O
as	O
substrates	O
through	O
inducing	O
formation	O
of	O
high	O
spin	O
heme	O
iron	O
in	O
CYP126A1	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
structural	O
data	O
for	O
the	O
widely	O
conserved	O
M	O
.	O
tuberculosis	O
CYP126A1	O
P450	B
enzyme	I
and	O
provides	O
important	O
insights	O
into	O
CYP126A1	O
molecular	O
selectivity	O
and	O
structural	O
adaptation	O
to	O
the	O
binding	O
of	O
large	O
compounds	O
.	O

Future	O
work	O
will	O
be	O
directed	O
at	O
the	O
identification	O
of	O
the	O
natural	O
substrate	O
(	O
s	O
)	O
for	O
this	O
widely	O
conserved	O
P450	B
enzyme	I
.	O

The	O
action	O
of	O
vitamin	O
D	O
and	O
its	O
active	O
metabolite	O
(	O
calcitriol	O
)	O
in	O
the	O
modulation	O
of	O
immune	O
function	O
was	O
documented	O
more	O
than	O
3	O
decades	O
ago	O
.	O
-	O
Vitamin	O
D	O
and	O
CYP27B1	O
(	O
a	O
mitochondrial	O
P450	B
enzyme	I
that	O
converts	O
25	O
[	O
OH	O
]	O
D	O
to	O
1	O
,	O
25	O
[	O
OH	O
]	O
D	O
)	O
play	O
crucial	O
roles	O
in	O
both	O
adaptive	O
and	O
innate	O
immunity	O
.	O

This	O
investigation	O
suggests	O
a	O
modification	O
of	O
the	O
membrane	O
topology	O
of	O
this	O
protein	O
,	O
unprecedented	O
for	O
a	O
plant	O
P450	B
enzyme	I
.	O

Cross	O
-	O
membrane	O
electron	O
transfer	O
has	O
been	O
suggested	O
to	O
occur	O
with	O
a	O
mammalian	O
P450	B
enzyme	I
.	O

Gene	O
sequence	O
changes	O
(	O
single	O
nucleotide	O
variation	O
and	O
structural	O
variation	O
referred	O
to	O
collectively	O
as	O
alleles	O
)	O
that	O
lead	O
to	O
altered	O
P450	B
enzyme	I
activity	O
can	O
be	O
classified	O
into	O
four	O
phenotypic	O
groups	O
:	O
poor	O
metabolizer	O
(	O
PM	O
)	O
,	O
intermediate	O
metabolizer	O
(	O
IM	O
)	O
,	O
extensive	O
metabolizer	O
(	O
EM	O
)	O
and	O
ultra	O
-	O
rapid	O
metabolizer	O
(	O
UM	O
)	O
.	O

For	O
instance	O
,	O
Arabidopsis	O
thaliana	O
CYP74A	O
,	O
which	O
is	O
an	O
untypical	O
P450	B
enzyme	I
that	O
does	O
require	O
molecular	O
dioxygen	O
,	O
is	O
specific	O
of	O
a	O
single	O
substrate	O
yielding	O
an	O
allene	O
oxide	O
.	O

The	O
most	O
used	O
algorithms	O
,	O
the	O
CAVER	O
-	O
MOLE	O
series	O
that	O
was	O
developed	O
by	O
Michal	O
Otyepka	O
and	O
his	O
collaborators	O
,	O
use	O
a	O
fixed	O
-	O
size	O
sphere	O
of	O
specified	O
diameter	O
placed	O
close	O
to	O
the	O
heme	O
iron	O
ion	O
in	O
the	O
distal	O
cavity	O
of	O
the	O
P450	B
enzyme	I
to	O
identify	O
all	O
of	O
the	O
direct	O
paths	O
connecting	O
the	O
buried	O
active	O
site	O
to	O
the	O
protein	O
surface	O
by	O
rolling	O
it	O
out	O
of	O
the	O
active	O
site	O
.	O

In	O
numerous	O
experiments	O
,	O
multiple	O
molecules	O
of	O
ligands	O
have	O
been	O
observed	O
to	O
bind	O
simultaneously	O
to	O
P450	B
enzyme	I
.	O

In	O
the	O
crystal	O
structure	O
of	O
CYP102	O
,	O
also	O
known	O
as	O
P450	O
BM3	O
,	O
a	O
fatty	O
acid	O
hydroxylase	O
P450	B
enzyme	I
that	O
is	O
isolated	O
from	O
Bacillus	O
megaterium	O
,	O
the	O
active	O
site	O
cavity	O
is	O
accessible	O
through	O
a	O
clearly	O
visible	O
long	O
channel	O
that	O
links	O
the	O
heme	O
iron	O
distal	O
environment	O
to	O
the	O
bulk	O
solvent	O
.	O

In	O
this	O
historical	O
study	O
,	O
a	O
P450	B
enzyme	I
was	O
shown	O
for	O
the	O
first	O
time	O
to	O
exhibit	O
some	O
flexibility	O
,	O
coincidental	O
with	O
the	O
opening	O
at	O
the	O
protein	O
surface	O
of	O
an	O
access	O
channel	O
to	O
its	O
buried	O
active	O
site	O
.	O

To	O
our	O
knowledge	O
,	O
no	O
plant	O
P450	B
enzyme	I
has	O
been	O
analyzed	O
for	O
CAVER	O
channels	O
.	O

The	O
composition	O
of	O
the	O
membrane	O
may	O
also	O
affect	O
the	O
P450	O
functioning	O
;	O
and	O
the	O
orientation	O
of	O
the	O
catalytic	O
domain	O
of	O
the	O
P450	B
enzyme	I
relative	O
to	O
the	O
membrane	O
was	O
shown	O
to	O
change	O
depending	O
on	O
the	O
charge	O
of	O
the	O
bilayer	O
phospholipids	O
in	O
molecular	O
dynamics	O
simulations	O
.	O

Such	O
a	O
study	O
would	O
lead	O
to	O
a	O
better	O
knowledge	O
of	O
what	O
combination	O
of	O
amino	O
acid	O
residues	O
in	O
a	O
P450	B
enzyme	I
distinguishes	O
a	O
ligand	O
(	O
a	O
bound	O
molecule	O
that	O
not	O
reaches	O
easily	O
the	O
productive	O
step	O
of	O
the	O
catalytic	O
cycle	O
)	O
from	O
a	O
substrate	O
(	O
a	O
bound	O
molecule	O
that	O
reaches	O
the	O
productive	O
step	O
)	O
.	O

P450	O
Oxidoreductase	O
contains	O
a	O
flavin	O
adenine	O
dinucleotide	O
and	O
a	O
flavin	O
mononucleotide	O
allowing	O
the	O
enzyme	O
to	O
oxidize	O
NADPH	O
and	O
reduce	O
the	O
Cytochrome	B
P450	B
enzyme	I
in	O
a	O
stepwise	O
manner	O
.	O

CYP1A	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
health	O
in	O
the	O
body	O
.	O
Image	O
1	O
The	O
cytochrome	B
P450	B
enzyme	I
is	O
one	O
of	O
the	O
most	O
abundant	O
and	O
diverse	O
superfamilies	O
,	O
which	O
contains	O
hemoprotein	O
.	O

The	O
levels	O
and	O
ratio	O
of	O
the	O
novel	O
constituents	O
varied	O
depending	O
on	O
the	O
P450	B
enzyme	I
,	O
with	O
CYP712K1	O
favoring	O
formation	O
of	O
6	O
and	O
CYP712K2	O
favoring	O
formation	O
of	O
5	O
.	O

In	O
many	O
bacterial	O
P450s	O
,	O
the	O
substrate	O
-	O
induced	O
High	O
Spin	O
shift	O
is	O
associated	O
with	O
a	O
substantial	O
increase	O
in	O
the	O
P450	O
heme	O
iron	O
Fe	O
^	O
III	O
/	O
Fe	O
^	O
II	O
reduction	O
potential	O
(	O
eg	O
from	O
368	O
to	O
239	O
mV	O
(	O
versus	O
normal	O
hydrogen	O
electrode	O
)	O
for	O
the	O
Bacillus	O
megaterium	O
CYP102A1	O
(	O
P450	O
BM3	O
)	O
heme	O
domain	O
on	O
binding	O
arachidonic	O
acid	O
and	O
from	O
approximately	O
300	O
to	O
170	O
mV	O
for	O
the	O
Pseudomonas	O
putida	O
P450cam	B
on	O
binding	O
d	O
-	O
camphor	O
)	O
(	O
,	O
.	O

This	O
computational	O
method	O
,	O
as	O
well	O
as	O
the	O
steered	O
molecular	O
dynamics	O
approach	O
,	O
identified	O
several	O
main	O
access	O
/	O
exit	O
channels	O
in	O
the	O
crystal	O
structure	O
of	O
P450cam	B
.	O

P450cam	B
was	O
considered	O
for	O
a	O
long	O
time	O
to	O
not	O
show	O
structural	O
flexibility	O
,	O
since	O
the	O
first	O
crystal	O
structures	O
of	O
the	O
substrate	O
-	O
free	O
and	O
substrate	O
-	O
bound	O
forms	O
of	O
P450cam	B
were	O
similarly	O
exhibiting	O
a	O
compact	O
conformation	O
.	O

But	O
,	O
some	O
fifteen	O
years	O
later	O
,	O
Goodin	O
and	O
his	O
collaborators	O
showed	O
that	O
P450cam	B
can	O
visit	O
an	O
open	O
conformation	O
in	O
the	O
absence	O
of	O
substrate	O
when	O
the	O
concentration	O
in	O
potassium	O
ion	O
in	O
the	O
crystallization	O
medium	O
is	O
considerably	O
lowered	O
.	O

The	O
opening	O
of	O
the	O
P450cam	B
structure	O
is	O
due	O
to	O
a	O
concerted	O
backward	O
movement	O
of	O
the	O
F	O
-	O
and	O
G	O
-	O
helices	O
and	O
an	O
uprising	O
of	O
the	O
F	O
/	O
G	O
loop	O
,	O
together	O
with	O
a	O
higher	O
degree	O
of	O
flexibility	O
of	O
the	O
B	O
/	O
C	O
loop	O
.	O

This	O
opening	O
of	O
P450cam	B
structure	O
unveils	O
an	O
access	O
channel	O
linking	O
the	O
protein	O
surface	O
,	O
in	O
the	O
vicinity	O
of	O
the	O
F	O
/	O
G	O
loop	O
,	O
to	O
the	O
catalytic	O
cavity	O
.	O

Finally	O
,	O
P450cam	B
was	O
shown	O
to	O
adopt	O
up	O
to	O
three	O
different	O
conformations	O
,	O
named	O
C	O
,	O
I	O
,	O
and	O
O	O
,	O
each	O
being	O
adapted	O
to	O
the	O
substrate	O
size	O
.	O

The	O
C	O
-	O
conformation	O
is	O
the	O
one	O
of	O
the	O
camphor	O
complex	O
and	O
with	O
substrate	O
-	O
free	O
P450cam	B
at	O
high	O
potassium	O
ion	O
concentration	O
.	O

The	O
O	O
-	O
conformation	O
is	O
the	O
one	O
observed	O
with	O
substrate	O
-	O
free	O
P450cam	B
at	O
low	O
potassium	O
ion	O
concentration	O
.	O

When	O
added	O
after	O
Oxygen	O
-	O
Glucose	O
Deprivation	O
,	O
CSP	O
-	O
1103	O
prevented	O
the	O
apoptosis	O
cascade	O
by	O
reducing	O
cytochrome	B
c	I
release	O
and	O
caspase	O
-	O
3	O
activation	O
and	O
the	O
secondary	O
necrosis	O
.	O

In	O
fact	O
,	O
signs	O
of	O
apoptosis	O
exist	O
,	O
including	O
cytochrome	B
c	I
release	O
,	O
activation	O
of	O
caspases	O
-	O
3	O
and	O
-	O
9	O
,	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
dUTP	O
nick	O
end	O
labeling	O
positivity	O
,	O
thus	O
making	O
this	O
cascade	O
a	O
potential	O
target	O
for	O
neuroprotection	O
.	O

Neuronal	O
cells	O
display	O
TUNEL	O
-	O
positivity	O
and	O
release	O
of	O
cytochrome	B
c	I
in	O
the	O
cytosol	O
within	O
6	O
h	O
after	O
the	O
Oxygen	O
-	O
Glucose	O
Deprivation	O
,	O
in	O
the	O
absence	O
of	O
lactate	O
dehydrogenase	O
release	O
.	O

As	O
a	O
further	O
marker	O
of	O
apoptosis	O
,	O
we	O
investigated	O
the	O
levels	O
of	O
cytochrome	B
c	I
released	O
from	O
mitochondria	O
after	O
Oxygen	O
-	O
Glucose	O
Deprivation	O
exposure	O
.	O

The	O
neuroprotection	O
elicited	O
by	O
CSP	O
-	O
1103	O
,	O
added	O
in	O
the	O
post	O
Oxygen	O
-	O
Glucose	O
Deprivation	O
period	O
,	O
comprised	O
the	O
inhibition	O
of	O
the	O
cytochrome	B
c	I
-	O
and	O
caspase	O
-	O
3	O
dependent	O
apoptotic	O
cascade	O
,	O
as	O
well	O
as	O
inhibition	O
of	O
necrosis	O
and	O
the	O
p38	O
and	O
NF	O
-	O
B	O
signaling	O
pathways	O
.	O

CSP	O
-	O
1103	O
reduced	O
the	O
activation	O
of	O
caspase	O
-	O
3	O
as	O
well	O
as	O
the	O
cytoplasmic	O
release	O
of	O
cytochrome	B
c	I
from	O
mitochondria	O
,	O
which	O
are	O
early	O
markers	O
of	O
apoptotic	O
pathway	O
activation	O
.	O

The	O
neuronal	O
apoptosis	O
was	O
evaluated	O
by	O
measuring	O
the	O
level	O
of	O
cytochrome	B
c	I
and	O
cleaved	O
-	O
caspase	O
-	O
3	O
(	O
immunocytochemistry	O
and	O
WB	O
)	O
at	O
the	O
indicated	O
times	O
.	O

The	O
protein	O
lysates	O
(	O
20	O
g	O
/	O
sample	O
)	O
were	O
processed	O
for	O
Western	O
Blot	O
analysis	O
using	O
the	O
following	O
primary	O
antibodies	O
;	O
polyclonal	O
anti	O
-	O
caspase	O
-	O
3	O
antibody	O
(	O
1	O
:	O
500	O
,	O
#	O
9662	O
Cell	O
Signaling	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
,	O
monoclonal	O
anti	O
-	O
cytochrome	B
c	I
antibody	O
(	O
1	O
:	O
300	O
,	O
sc13156	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Dallas	O
,	O
TX	O
,	O
USA	O
)	O
,	O
polyclonal	O
anti	O
-	O
p38	O
Mitogen	O
-	O
Activated	O
Protein	O
Kinase	O
(	O
1	O
:	O
500	O
,	O
#	O
9212	O
Cell	O
Signaling	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
,	O
monoclonal	O
anti	O
-	O
phospho	O
-	O
p38	O
Mitogen	O
-	O
Activated	O
Protein	O
Kinase	O
(	O
Thr180	O
/	O
Tyr182	O
)	O
antibody	O
(	O
1	O
:	O
500	O
,	O
#	O
4511	O
Cell	O
Signaling	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
,	O
and	O
polyclonal	O
anti	O
-	O
actin	O
antibody	O
(	O
1	O
:	O
1000	O
,	O
#	O
A5060	O
Sigma	O
Aldrich	O
,	O
St	O
.	O

All	O
terminal	O
oxidases	O
,	O
either	O
directly	O
or	O
via	O
soluble	O
cytochrome	B
c	I
,	O
accept	O
electrons	O
from	O
quinones	O
(	O
UQs	O
)	O
,	O
which	O
are	O
the	O
most	O
important	O
compounds	O
in	O
the	O
membrane	O
of	O
most	O
prokaryotes	O
,	O
working	O
as	O
lipophilic	O
electron	O
and	O
proton	O
shuttles	O
.	O

The	O
quantity	O
of	O
the	O
enzyme	O
was	O
also	O
assessed	O
by	O
measuring	O
cytochrome	B
c	I
oxidase	O
activity	O
in	O
solubilized	O
membranes	O
,	O
which	O
is	O
independent	O
of	O
the	O
cellular	O
electron	O
transport	O
chain	O
.	O

^	O
With	O
similar	O
background	O
concentrations	O
in	O
control	O
samples	O
,	O
the	O
concentrations	O
of	O
superoxide	O
anion	O
were	O
1	O
.	O
3	O
and	O
0	O
.	O
4	O
nmol	O
cytochrome	B
c	I
reduced	O
/	O
mg	O
in	O
the	O
animals	O
treated	O
with	O
the	O
tertiary	O
mixture	O
or	O
TCDD	O
alone	O
,	O
respectively	O
.	O

A	O
diheme	O
cytochrome	O
c_4	O
,	O
Cyc1	O
,	O
has	O
been	O
proposed	O
to	O
be	O
a	O
periplasmic	O
electron	O
shuttle	O
in	O
the	O
iron	O
-	O
oxidizing	O
bacterium	O
M	O
.	O
ferrooxydans	O
.	O

The	O
effects	O
of	O
pHK	O
-	O
PAS	O
were	O
correlated	O
with	O
dissociation	O
of	O
endogenous	O
full	O
-	O
length	O
Hexokinase	O
Ii	O
from	O
mitochondria	O
and	O
release	O
of	O
cytochrome	B
c	I
.	O
Of	O
significance	O
,	O
pHK	O
-	O
PAS	O
treatment	O
of	O
noncancerous	O
HEK293	O
cells	O
resulted	O
in	O
substantially	O
lower	O
cytotoxicity	O
.	O

Moreover	O
,	O
high	O
levels	O
of	O
mitochondria	O
-	O
bound	O
Hexokinase	O
Ii	O
protect	O
cancer	O
cells	O
against	O
death	O
by	O
maintaining	O
the	O
integrity	O
of	O
the	O
Outer	O
Mitochondrial	O
Membrane	O
and	O
inhibiting	O
release	O
of	O
key	O
apoptogenic	O
molecules	O
,	O
such	O
as	O
cytochrome	B
c	I
,	O
from	O
the	O
intermembrane	O
space	O
(	O
,	O
.	O

Mouse	O
monoclonal	O
human	O
Hexokinase	O
Ii	O
,	O
VDAC1	O
,	O
cytochrome	B
c	I
,	O
and	O
BETA	O
-	O
actin	O
Abs	O
,	O
as	O
well	O
as	O
horseradish	O
peroxidase	O
-	O
conjugated	O
mouse	O
IgG	O
Ab	O
,	O
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Dallas	O
,	O
TX	O
,	O
USA	O
)	O
.	O

Oxygen	O
Consumption	O
Rate	O
was	O
measured	O
for	O
20	O
min	O
to	O
establish	O
a	O
baseline	O
rate	O
,	O
followed	O
by	O
sequential	O
addition	O
of	O
1	O
.	O
0	O
M	O
FCCP	O
,	O
an	O
uncoupling	O
agent	O
that	O
induces	O
maximal	O
oxygen	O
consumption	O
by	O
cytochrome	B
c	I
oxidase	O
(	O
complex	O
IV	O
)	O
,	O
and	O
a	O
mixture	O
of	O
1	O
.	O
0	O
M	O
rotenone	O
and	O
1	O
.	O
0	O
M	O
antimycin	O
A	O
,	O
which	O
inhibit	O
complexes	O
I	O
and	O
III	O
,	O
respectively	O
,	O
and	O
effectively	O
shut	O
down	O
mitochondrial	O
respiration	O
.	O

Samples	O
(	O
2	O
g	O
/	O
lane	O
)	O
were	O
electrophoresed	O
on	O
a	O
10	O
-	O
12	O
%	O
SDS	O
polyacrylamide	O
gel	O
,	O
transferred	O
to	O
a	O
nitrocellulose	O
membrane	O
,	O
and	O
incubated	O
overnight	O
with	O
mouse	O
anti	O
-	O
human	O
Hexokinase	O
Ii	O
,	O
VDAC1	O
,	O
or	O
cytochrome	B
c	I
(	O
1	O
:	O
1000	O
)	O
Abs	O
or	O
anti	O
-	O
BETA	O
-	O
actin	O
Ab	O
(	O
1	O
:	O
2000	O
)	O
,	O
followed	O
by	O
incubation	O
for	O
3	O
h	O
with	O
horseradish	O
peroxidase	O
-	O
conjugated	O
mouse	O
IgG	O
Ab	O
(	O
1	O
:	O
10	O
,	O
000	O
)	O
.	O

Depletion	O
of	O
_m	O
by	O
FCCP	O
results	O
in	O
uninhibited	O
electron	O
flow	O
through	O
the	O
mitochondrial	O
respiratory	O
chain	O
,	O
which	O
leads	O
to	O
maximal	O
oxygen	O
consumption	O
by	O
cytochrome	B
c	I
oxidase	O
(	O
complex	O
IV	O
)	O
.	O

HeLa	O
cells	O
were	O
treated	O
with	O
50	O
M	O
pHK	O
-	O
PAS	O
for	O
24	O
-	O
72	O
h	O
,	O
and	O
immunoblotting	O
was	O
used	O
to	O
determine	O
the	O
amount	O
of	O
endogenous	O
Hexokinase	O
Ii	O
,	O
Voltage	O
-	O
Dependent	O
Anion	O
Channel	O
,	O
and	O
cytochrome	B
c	I
in	O
mitochondria	O
-	O
enriched	O
and	O
cytosolic	O
fractions	O
at	O
different	O
time	O
points	O
.	O

Similarly	O
,	O
cytochrome	B
c	I
levels	O
in	O
the	O
cytosolic	O
fraction	O
increased	O
with	O
pHK	O
-	O
PAS	O
incubation	O
time	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
pHK	O
-	O
PAS	O
specifically	O
displaces	O
Hexokinase	O
Ii	O
from	O
mitochondria	O
in	O
cancer	O
cells	O
without	O
affecting	O
localization	O
of	O
Voltage	O
-	O
Dependent	O
Anion	O
Channel	O
to	O
the	O
Outer	O
Mitochondrial	O
Membrane	O
,	O
and	O
this	O
disruption	O
of	O
the	O
HKII	O
-	O
VDAC	O
complex	O
triggers	O
release	O
of	O
cytochrome	B
c	I
to	O
the	O
cytosol	O
and	O
apoptosis	O
.	O

However	O
,	O
unlike	O
in	O
HeLa	O
cells	O
,	O
the	O
competitive	O
dissociation	O
of	O
Hexokinase	O
Ii	O
from	O
mitochondria	O
in	O
HEK293	O
cells	O
was	O
not	O
accompanied	O
by	O
a	O
significant	O
release	O
of	O
cytochrome	B
c	I
to	O
the	O
cytosol	O
.	O

Disruption	O
of	O
the	O
VDAC	O
-	O
HKII	O
interaction	O
leads	O
to	O
_m	O
depolarization	O
,	O
inhibition	O
of	O
mitochondrial	O
respiration	O
and	O
glycolysis	O
,	O
depletion	O
of	O
intracellular	O
ATP	O
levels	O
,	O
release	O
of	O
cytochrome	B
c	I
and	O
,	O
finally	O
,	O
apoptosis	O
.	O

Moreover	O
,	O
unlike	O
either	O
the	O
Voltage	O
-	O
Dependent	O
Anion	O
Channel	O
or	O
Bax	O
channels	O
,	O
the	O
VDAC	O
-	O
Bax	O
pore	O
is	O
large	O
enough	O
to	O
allow	O
passage	O
of	O
cytochrome	B
c	I
to	O
the	O
cytosol	O
.	O

Dissociation	O
of	O
Hexokinase	O
Ii	O
from	O
mitochondria	O
in	O
noncancerous	O
cells	O
,	O
therefore	O
,	O
does	O
not	O
lead	O
to	O
apoptosis	O
,	O
as	O
illustrated	O
by	O
the	O
lack	O
of	O
cytochrome	B
c	I
release	O
in	O
HEK293	O
cells	O
.	O

Disruption	O
of	O
the	O
HKII	O
-	O
VDAC	O
interaction	O
in	O
cancer	O
cells	O
results	O
in	O
_m	O
depolarization	O
,	O
inhibition	O
of	O
mitochondrial	O
respiration	O
and	O
glycolysis	O
,	O
depletion	O
of	O
intracellular	O
ATP	O
levels	O
,	O
release	O
of	O
cytochrome	B
c	I
,	O
and	O
,	O
finally	O
,	O
apoptosis	O
.	O

ROCK	O
activation	O
phosphorylated	O
Rac1b	O
at	O
Ser71	O
and	O
increased	O
ROS	O
levels	O
by	O
facilitating	O
the	O
interaction	O
between	O
Rac1b	O
and	O
cytochrome	B
c	I
.	O
Conversely	O
,	O
ROCK	O
inactivation	O
with	O
Y27632	O
abolished	O
their	O
interaction	O
,	O
concomitant	O
with	O
ROS	O
reduction	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
ROCK	O
could	O
regulate	O
ROS	O
generation	O
by	O
modulating	O
the	O
interaction	O
between	O
Rac1b	O
and	O
cytochrome	B
c	I
.	O
The	O
present	O
screening	O
strategy	O
consisted	O
of	O
two	O
different	O
methods	O
to	O
evaluate	O
the	O
capacity	O
of	O
restoration	O
in	O
senescent	O
HGPS	O
fibroblasts	O
:	O
(	O
i	O
)	O
reducing	O
ROS	O
levels	O
and	O
(	O
ii	O
)	O
increasing	O
cell	O
numbers	O
.	O

A	O
recent	O
study	O
shows	O
that	O
Rac1	O
regulates	O
mitochondrial	O
ROS	O
generation	O
via	O
its	O
interaction	O
with	O
cytochrome	B
c	I
(	O
OsbornHeaford	O
et	O
al	O
.	O
,	O
.	O

As	O
we	O
had	O
observed	O
that	O
mitochondrial	O
ROS	O
levels	O
were	O
reduced	O
upon	O
Y27632	O
treatment	O
,	O
we	O
hypothesized	O
that	O
(	O
i	O
)	O
Rac1b	O
would	O
interact	O
with	O
cytochrome	B
c	I
,	O
and	O
(	O
ii	O
)	O
ROCK	O
would	O
regulate	O
ROS	O
levels	O
by	O
modulating	O
the	O
interaction	O
between	O
Rac1b	O
and	O
cytochrome	B
c	I
.	O
We	O
found	O
that	O
Rac1b	O
interacted	O
with	O
cytochrome	B
c	I
and	O
that	O
its	O
interaction	O
was	O
increased	O
by	O
RhoA	O
/	O
ROCK	O
activation	O
but	O
was	O
decreased	O
by	O
cotreatment	O
with	O
Y27632	O
.	O

The	O
increased	O
association	O
of	O
Rac1b	O
with	O
cytochrome	B
c	I
was	O
expected	O
to	O
increase	O
ROS	O
levels	O
.	O

These	O
results	O
imply	O
that	O
ROCK	O
regulates	O
mitochondrial	O
function	O
through	O
modulating	O
the	O
interaction	O
between	O
Rac1b	O
and	O
cytochrome	B
c	I
.	O
To	O
further	O
verify	O
whether	O
the	O
ROCK	O
-	O
Rac1b	O
-	O
cytochrome	B
c	I
axis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
ROS	O
levels	O
,	O
we	O
examined	O
whether	O
Y27632	O
treatment	O
could	O
decrease	O
ROS	O
generation	O
in	O
Rac1bdeficient	O
cells	O
.	O

This	O
result	O
implies	O
that	O
the	O
ROSreducing	O
effect	O
of	O
Y27632	O
is	O
achieved	O
by	O
regulating	O
the	O
ROCK	O
-	O
Rac1b	O
-	O
cytochrome	B
c	I
axis	O
.	O

The	O
heme	O
group	O
of	O
cytochrome	B
c	I
accepts	O
electrons	O
from	O
complex	O
III	O
and	O
transfers	O
them	O
to	O
complex	O
IV	O
(	O
cytochrome	B
c	I
oxidase	O
;	O
COX	O
;	O
Zorov	O
et	O
al	O
.	O
,	O
.	O

Thus	O
,	O
we	O
examined	O
whether	O
COX	O
activity	O
is	O
regulated	O
by	O
the	O
ROCK	O
-	O
Rac1b	O
-	O
cytochrome	B
c	I
axis	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
amelioration	O
of	O
misshapen	O
nuclei	O
by	O
Y27632	O
may	O
be	O
achieved	O
by	O
regulating	O
ROCK	O
-	O
Rac1b	O
-	O
cytochrome	B
c	I
axis	O
.	O

A	O
previous	O
study	O
has	O
shown	O
that	O
p66Shc	O
triggers	O
mitochondrial	O
ROS	O
generation	O
by	O
oxidizing	O
cytochrome	B
c	I
(	O
Giorgio	O
et	O
al	O
.	O
,	O
.	O

Similarly	O
,	O
Rac1	O
produces	O
mitochondrial	O
ROS	O
through	O
directly	O
intercepting	O
electrons	O
from	O
cytochrome	B
c	I
as	O
does	O
p66Shc	O
(	O
OsbornHeaford	O
et	O
al	O
.	O
,	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
uncovered	O
a	O
novel	O
mechanism	O
in	O
which	O
ROCK	O
regulates	O
mitochondrial	O
ROS	O
generation	O
by	O
modulating	O
the	O
interaction	O
between	O
Rac1b	O
and	O
cytochrome	B
c	I
.	O
RhoA	O
/	O
ROCK	O
activation	O
induced	O
the	O
phosphorylation	O
of	O
Rac1b	O
at	O
Ser	O
71	O
and	O
facilitated	O
the	O
interaction	O
between	O
Rac1b	O
and	O
cytochrome	B
c	I
.	O
This	O
interaction	O
could	O
induce	O
the	O
partial	O
reduction	O
in	O
oxygen	O
by	O
intercepting	O
electrons	O
from	O
cytochrome	B
c	I
in	O
a	O
similar	O
manner	O
as	O
p66Shc	O
and	O
Rac1	O
.	O

On	O
the	O
contrary	O
,	O
ROCK	O
inactivation	O
with	O
Y27632	O
hampered	O
the	O
interaction	O
between	O
Rac1b	O
and	O
cytochrome	B
c	I
.	O
Taken	O
together	O
,	O
the	O
results	O
from	O
our	O
study	O
reveal	O
the	O
novel	O
roles	O
of	O
ROCK	O
as	O
a	O
binding	O
partner	O
for	O
Rac1b	O
and	O
a	O
regulator	O
of	O
mitochondrial	O
ROS	O
generation	O
.	O

Specific	O
expression	O
and	O
function	O
of	O
the	O
A	O
-	O
type	O
cytochrome	B
c	I
oxidase	O
under	O
starvation	O
conditions	O
in	O
Pseudomonas	O
aeruginosa	O
.	O

Pseudomonas	O
aeruginosa	O
has	O
one	O
A	O
-	O
type	O
(	O
caa3	O
)	O
and	O
multiple	O
C	O
-	O
type	O
(	O
cbb3	O
)	O
cytochrome	B
c	I
oxidases	O
as	O
well	O
as	O
two	O
quinol	O
oxidases	O
for	O
aerobic	O
respiration	O
.	O

The	O
bacterial	O
A	O
-	O
type	O
(	O
aa_3	O
-	O
type	O
)	O
cytochrome	B
c	I
oxidase	O
is	O
a	O
member	O
of	O
the	O
heme	O
-	O
copper	O
oxidase	O
superfamily	O
and	O
is	O
closely	O
related	O
to	O
the	O
mitochondrial	O
terminal	O
oxidase	O
.	O

Electrons	O
are	O
transferred	O
from	O
cytochrome	B
c	I
to	O
the	O
catalytic	O
center	O
via	O
Cu_A	O
and	O
a	O
low	O
spin	O
heme	O
a	O
,	O
which	O
are	O
located	O
in	O
subunits	O
II	O
and	O
I	O
,	O
respectively	O
.	O

The	O
opportunistic	O
human	O
pathogen	O
Pseudomonas	O
aeruginosa	O
was	O
reported	O
to	O
have	O
at	O
least	O
five	O
terminal	O
oxidases	O
for	O
aerobic	O
respiration	O
,	O
including	O
one	O
A	O
-	O
type	O
and	O
two	O
C	O
-	O
type	O
(	O
cbb_3	O
-	O
1	O
and	O
cbb_3	O
-	O
2	O
)	O
cytochrome	B
c	I
oxidases	O
,	O
as	O
well	O
as	O
A	O
-	O
type	O
quinol	O
oxidase	O
(	O
bo_3	O
)	O
and	O
cyanide	O
insensitive	O
oxidase	O
(	O
CIO	O
)	O
,	O
which	O
is	O
a	O
non	O
-	O
heme	O
-	O
copper	O
quinol	O
oxidase	O
.	O

In	O
the	O
cox	O
gene	O
cluster	O
(	O
PA0105	O
-	O
0108	O
)	O
,	O
coxB	O
(	O
PA0105	O
)	O
,	O
coxA	O
(	O
PA0106	O
)	O
,	O
and	O
coxC	O
(	O
coIII	O
)	O
(	O
PA0108	O
)	O
encode	O
subunits	O
II	O
,	O
I	O
,	O
and	O
III	O
of	O
the	O
A	O
-	O
type	O
cytochrome	B
c	I
oxidase	O
,	O
respectively	O
.	O

The	O
product	O
of	O
the	O
cox	O
genes	O
was	O
reported	O
to	O
be	O
the	O
aa_3	O
cytochrome	B
c	I
oxidase	O
in	O
previous	O
reports	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
found	O
that	O
a	O
quadruple	O
mutant	O
strain	O
designated	O
as	O
QXAa	O
,	O
which	O
was	O
deficient	O
in	O
the	O
four	O
terminal	O
oxidase	O
gene	O
clusters	O
encoding	O
two	O
C	O
-	O
type	O
cytochrome	B
c	I
oxidases	O
and	O
two	O
quinol	O
oxidases	O
,	O
was	O
unable	O
to	O
grow	O
under	O
aerobic	O
conditions	O
,	O
thereby	O
suggesting	O
that	O
the	O
cox	O
genes	O
were	O
tightly	O
repressed	O
or	O
the	O
gene	O
product	O
was	O
not	O
functional	O
in	O
the	O
mutant	O
.	O

The	O
cytochrome	B
c	I
oxidase	O
activity	O
was	O
not	O
detected	O
by	O
the	O
Nadi	O
assay	O
by	O
the	O
overexpression	O
of	O
the	O
cox	O
genes	O
in	O
the	O
anaerobically	O
grown	O
cells	O
of	O
strain	O
PTO5	O
.	O

No	O
activity	O
was	O
also	O
observed	O
when	O
the	O
cox	O
genes	O
were	O
overexpressed	O
in	O
the	O
aerobically	O
grown	O
cells	O
of	O
QXCi	O
,	O
which	O
is	O
deficient	O
in	O
the	O
cytochrome	B
c	I
oxidase	O
genes	O
but	O
can	O
grow	O
aerobically	O
by	O
using	O
the	O
CIO	O
quinol	O
oxidase	O
.	O

These	O
results	O
indicate	O
that	O
the	O
poor	O
growth	O
of	O
QXAaS2	O
was	O
not	O
due	O
to	O
the	O
low	O
cytochrome	B
c	I
oxidase	O
activity	O
.	O

Thus	O
,	O
the	O
utilization	O
of	O
A	O
-	O
type	O
cytochrome	B
c	I
oxidases	O
only	O
under	O
starvation	O
conditions	O
might	O
be	O
a	O
common	O
feature	O
of	O
several	O
proteobacteria	O
.	O

To	O
complete	O
the	O
oxidation	O
pathway	O
of	O
the	O
SOR	O
reaction	O
products	O
,	O
we	O
searched	O
in	O
the	O
A	O
.	O
copahuensis	O
genome	O
for	O
putative	O
sulfite	O
:	O
acceptor	O
oxidoreductase	O
(	O
SAOR	O
)	O
enzymes	O
using	O
the	O
reported	O
sequence	O
of	O
the	O
molybdopterin	O
binding	O
subunit	O
A	O
of	O
the	O
sulfite	O
:	O
cytochrome	B
c	I
oxidoreductase	O
from	O
Starkeya	O
novella	O
DSM	O
506	O
(	O
acc	O
number	O
AAF64400	O
,	O
encoded	O
by	O
sorA	O
gene	O
)	O
.	O

Loss	O
of	O
Parkinson	O
'	O
s	O
disease	O
-	O
associated	O
protein	O
CHCHD2	O
affects	O
mitochondrial	O
crista	O
structure	O
and	O
destabilizes	O
cytochrome	B
c	I
.	O
Mutations	O
in	O
CHCHD2	O
have	O
been	O
identified	O
in	O
some	O
Parkinson	O
'	O
s	O
disease	O
cases	O
.	O

CHCHD2	O
binds	O
to	O
cytochrome	B
c	I
along	O
with	O
a	O
member	O
of	O
the	O
Bax	O
inhibitor	O
-	O
1	O
superfamily	O
,	O
MICS1	O
,	O
and	O
modulated	O
cell	O
death	O
signalling	O
,	O
suggesting	O
that	O
CHCHD2	O
dynamically	O
regulates	O
the	O
functions	O
of	O
cytochrome	B
c	I
in	O
both	O
oxidative	O
phosphorylation	O
and	O
cell	O
death	O
in	O
response	O
to	O
mitochondrial	O
stress	O
.	O

Here	O
the	O
authors	O
investigate	O
the	O
physiological	O
and	O
pathological	O
roles	O
of	O
CHCHD2	O
in	O
Drosophila	O
and	O
mammalian	O
cells	O
,	O
and	O
find	O
that	O
it	O
regulates	O
mitochondrial	O
respiration	O
through	O
stabilizing	O
cytochrome	B
c	I
.	O
Mutations	O
in	O
the	O
CHCHD2	O
gene	O
cause	O
an	O
autosomal	O
dominant	O
form	O
of	O
late	O
-	O
onset	O
Parkinson	O
'	O
s	O
Disease	O
.	O

A	O
study	O
of	O
yeast	O
CHCHD2	O
ortholog	O
Mic17	O
indicated	O
that	O
the	O
loss	O
of	O
Mic17	O
decreased	O
oxygen	O
consumption	O
and	O
altered	O
activities	O
in	O
respiratory	O
complexes	O
III	O
(	O
ubiquinol	O
-	O
cytochrome	B
c	I
[	O
Cyt	O
c	O
]	O
reductase	O
)	O
and	O
IV	O
(	O
Cyt	O
c	O
oxidase	O
)	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
whereas	O
an	O
oxidative	O
phosphorylation	O
computational	O
expression	O
screen	O
using	O
mouse	O
and	O
human	O
microarray	O
data	O
revealed	O
that	O
CHCHD2	O
is	O
required	O
for	O
the	O
Oxidative	O
Phosphorylation	O
function	O
in	O
mammalian	O
cells	O
.	O

For	O
the	O
measurement	O
of	O
the	O
complex	O
III	O
activity	O
,	O
cytochrome	B
c	I
reductase	O
assay	O
buffer	O
(	O
50	O
mM	O
potassium	O
phosphate	O
buffer	O
pH	O
7	O
.	O
5	O
,	O
1	O
mM	O
n	O
-	O
dodecyl	O
BETA	O
-	O
D	O
-	O
maltoside	O
[	O
DDM	O
]	O
,	O
1	O
mM	O
KCN	O
,	O
2	O
M	O
rotenone	O
,	O
250	O
M	O
EDTA	O
,	O
and	O
1	O
mg	O
ml	O
^	O
1	O
BSA	O
,	O
50	O
M	O
oxidized	O
cytochrome	B
c	I
)	O
with	O
or	O
without	O
25	O
M	O
antimycin	O
A	O
was	O
divided	O
into	O
100	O
l	O
aliquots	O
in	O
a	O
microplate	O
and	O
left	O
at	O
RT	O
for	O
5	O
min	O
.	O

The	O
cytochrome	B
c	I
reductase	O
activity	O
was	O
monitored	O
by	O
adding	O
200	O
M	O
decylubiquinol	O
,	O
and	O
0	O
.	O
075	O
g	O
of	O
mitochondrial	O
samples	O
to	O
the	O
reaction	O
mix	O
and	O
following	O
an	O
increase	O
in	O
absorbance	O
at	O
550	O
nm	O
.	O

For	O
the	O
measurement	O
of	O
the	O
complex	O
IV	O
activity	O
,	O
cytochrome	B
c	I
oxidase	O
buffer	O
(	O
25	O
mM	O
potassium	O
phosphate	O
pH7	O
.	O
0	O
,	O
0	O
.	O
45	O
mM	O
DDM	O
and	O
100	O
M	O
reduced	O
cytochrome	B
c	I
)	O
with	O
or	O
without	O
2	O
mM	O
KCN	O
was	O
divided	O
into	O
100	O
l	O
aliquots	O
in	O
a	O
microplate	O
.	O

The	O
cytochrome	B
c	I
oxidase	O
activity	O
was	O
monitored	O
by	O
adding	O
0	O
.	O
1	O
g	O
of	O
mitochondrial	O
samples	O
to	O
the	O
reaction	O
mix	O
and	O
following	O
a	O
decrease	O
in	O
absorbance	O
at	O
550	O
nm	O
.	O

Loss	O
of	O
Parkinson	O
'	O
s	O
disease	O
-	O
associated	O
protein	O
CHCHD2	O
affects	O
mitochondrial	O
crista	O
structure	O
and	O
destabilizes	O
cytochrome	B
c	I
.	O
Nat	O
.	O

We	O
hypothesized	O
that	O
these	O
extracellular	O
non	O
-	O
cytochrome	B
c	I
proteins	O
(	O
ENCP	O
)	O
could	O
contribute	O
to	O
EET	O
,	O
especially	O
with	O
the	O
facilitation	O
of	O
electron	O
mediators	O
.	O

The	O
extracellular	O
non	O
-	O
cytochrome	B
c	I
proteins	O
(	O
ENCP	O
)	O
may	O
be	O
generated	O
by	O
secretion	O
or	O
lysis	O
of	O
biofilm	O
cells	O
and	O
play	O
important	O
roles	O
in	O
redox	O
processes	O
,	O
cell	O
protection	O
and	O
other	O
functions	O
.	O

Physiological	O
and	O
molecular	O
tests	O
in	O
this	O
and	O
our	O
previous	O
study	O
demonstrated	O
that	O
the	O
ccmA	O
-	O
mutant	O
of	O
S	O
.	O
decolorationis	O
S12	O
was	O
deficient	O
in	O
cytochrome	B
c	I
generation	O
and	O
anaerobic	O
growth	O
(	O
Supplementary	O
Figure	O
)	O
.	O

To	O
allow	O
planktonic	O
and	O
biofilm	O
cell	O
growth	O
of	O
MT	O
-	O
S12	O
and	O
WT	O
-	O
S12	O
strains	O
,	O
MFCs	O
were	O
operated	O
aerobically	O
for	O
the	O
first	O
24	O
h	O
after	O
inoculation	O
which	O
showed	O
similar	O
growth	O
of	O
the	O
two	O
strains	O
generating	O
capacity	O
of	O
planktonic	O
MT	O
-	O
S12	O
and	O
WT	O
-	O
S12	O
were	O
comparable	O
,	O
indicating	O
that	O
cytochrome	B
c	I
had	O
no	O
significant	O
effects	O
on	O
the	O
aerobic	O
growth	O
and	O
flavin	O
secretion	O
of	O
S	O
.	O
decolorationis	O
S12	O
.	O

It	O
is	O
likely	O
that	O
the	O
anaerobic	O
microenvironment	O
within	O
the	O
biofilm	O
prevented	O
the	O
growth	O
of	O
MT	O
-	O
S12	O
biofilm	O
cells	O
as	O
cytochrome	B
c	I
are	O
needed	O
in	O
Shewanella	O
anaerobic	O
growth	O
.	O

Electricity	O
generation	O
by	O
WT	O
-	O
S12	O
started	O
within	O
3	O
h	O
upon	O
switch	O
and	O
increased	O
to	O
the	O
maximal	O
value	O
of	O
56	O
.	O
4	O
A	O
within	O
33	O
h	O
and	O
abiotic	O
controls	O
(	O
Supplementary	O
Figure	O
)	O
showed	O
no	O
obvious	O
electricity	O
generation	O
,	O
indicating	O
that	O
cytochrome	B
c	I
-	O
deficient	O
MT	O
-	O
S12	O
lost	O
the	O
electrode	O
respiration	O
capacity	O
.	O

This	O
is	O
predictable	O
as	O
cytochrome	B
c	I
has	O
been	O
demonstrated	O
to	O
be	O
essential	O
in	O
EET	O
capacity	O
of	O
Shewanella	O
and	O
other	O
reported	O
microbes	O
capable	O
of	O
electrode	O
respiration	O
(	O
;	O
.	O

During	O
previous	O
preliminary	O
genome	O
analysis	O
of	O
M	O
.	O
roseus	O
,	O
three	O
putative	O
terminal	O
oxidoreductases	O
were	O
revealed	O
:	O
two	O
heme	O
-	O
copper	O
cytochrome	B
c	I
oxidases	O
and	O
a	O
quinol	O
oxidase	O
of	O
the	O
bd	O
-	O
type	O
.	O

Included	O
among	O
those	O
proteins	O
were	O
(	O
i	O
)	O
the	O
catalytic	O
subunit	O
CoxI	O
and	O
the	O
subunit	O
CoxII	O
of	O
the	O
cc	O
(	O
o	O
/	O
b	O
)	O
o_3	O
cytochrome	O
oxidase	O
,	O
(	O
ii	O
)	O
its	O
redox	O
partner	O
class	O
I	O
soluble	O
cytochrome	O
c_551	O
/	O
c_552	O
(	O
MROS_0033	O
)	O
,	O
two	O
subunits	O
of	O
the	O
alternative	O
complex	O
III	O
,	O
ActC	O
and	O
fused	O
ActDE	O
,	O
encoded	O
in	O
the	O
same	O
cluster	O
with	O
the	O
cc	O
(	O
o	O
/	O
b	O
)	O
o_3	O
oxidase	O
by	O
MROS_0043	O
and	O
MROS_0042	O
,	O
respectively	O
,	O
and	O
(	O
iv	O
)	O
the	O
metal	O
ion	O
-	O
binding	O
subunit	O
of	O
copper	O
-	O
transporting	O
ATPase	O
,	O
MROS_1511	O
,	O
proposed	O
to	O
participate	O
in	O
the	O
biogenesis	O
of	O
heme	O
-	O
copper	O
oxidases	O
in	O
M	O
.	O
roseus	O
.	O

Upregulation	O
at	O
aerobic	O
versus	O
fermentative	O
growth	O
was	O
statistically	O
significant	O
for	O
the	O
following	O
proteins	O
:	O
(	O
i	O
)	O
the	O
catalytic	O
subunit	O
of	O
the	O
Alternative	O
Complex	O
Iii	O
complex	O
,	O
ActB	O
(	O
encoded	O
by	O
MROS_0044	O
)	O
,	O
(	O
ii	O
)	O
the	O
NADH	O
-	O
dehydrogenase	O
subunit	O
,	O
NuoG	O
(	O
encoded	O
by	O
MROS_2032	O
)	O
,	O
essential	O
to	O
provide	O
the	O
catalytic	O
site	O
for	O
NADH	O
oxidation	O
in	O
respiratory	O
complex	O
I	O
,	O
the	O
SCO1	O
/	O
SenC	O
domain	O
protein	O
encoded	O
by	O
MROS_0039	O
,	O
which	O
is	O
located	O
in	O
the	O
same	O
cluster	O
(	O
MROS_0034	O
-	O
0039	O
)	O
as	O
the	O
cc	O
(	O
o	O
/	O
b	O
)	O
o_3	O
oxidase	O
genes	O
and	O
could	O
determine	O
the	O
post	O
-	O
translational	O
step	O
in	O
the	O
accumulation	O
of	O
heme	O
-	O
copper	O
oxidase	O
subunits	O
,	O
CoxI	O
and	O
CoxII	O
,	O
(	O
iv	O
)	O
the	O
cytochrome	B
c	I
biogenesis	O
protein	O
F	O
,	O
encoded	O
by	O
MROS_0623	O
(	O
CcmF	O
)	O
.	O

Approximately	O
90	O
%	O
of	O
cellular	O
ATP	O
is	O
generated	O
in	O
mitochondria	O
through	O
the	O
OXPHOS	O
pathway	O
,	O
and	O
CYC1	O
(	O
also	O
referred	O
to	O
cytochrome	O
c1	O
)	O
is	O
a	O
hemecontaining	O
subunit	O
of	O
complex	O
III	O
.	O

AbbreviationsCYC1cytochrome	O
c1DCISductal	O
carcinoma	O
in	O
situ	O
ERestrogen	O
receptorGOgene	O
ontologyHER2human	O
epidermal	O
growth	O
factor	O
receptor	O
2LIlabeling	O
indexOXPHOSoxidative	O
phosphorylationPRprogesterone	O
receptorRPL13Aribosomal	O
protein	O
L13AsiCTRLnegative	O
control	O
siRNA	O
.	O

SR48692	O
induced	O
massive	O
apoptosis	O
,	O
which	O
was	O
related	O
to	O
mitochondrial	O
cytochrome	B
c	I
release	O
and	O
Membrane	O
Potential	O
loss	O
.	O

Cells	O
were	O
stained	O
with	O
anti	O
-	O
cytochrome	B
c	I
antibodies	O
.	O

Increased	O
Mitochondrial	O
Outer	O
Membrane	O
Permeabilisation	O
results	O
in	O
the	O
release	O
of	O
proteins	O
,	O
including	O
cytochrome	B
c	I
,	O
thus	O
initiating	O
a	O
caspase	O
cascade	O
and	O
subsequent	O
cell	O
death	O
(	O
;	O
.	O

Our	O
data	O
showed	O
that	O
SR48692	O
treatment	O
induced	O
cytochrome	B
c	I
release	O
and	O
decline	O
of	O
m	O
.	O
Meanwhile	O
,	O
NTSR1	O
knockdown	O
also	O
induced	O
significant	O
decline	O
of	O
m	O
.	O
These	O
data	O
indicated	O
that	O
NTSR1	O
inhibition	O
-	O
induced	O
apoptosis	O
was	O
tightly	O
related	O
to	O
mitochondrial	O
activities	O
.	O

The	O
key	O
process	O
of	O
mitochondria	O
-	O
mediated	O
apoptosis	O
is	O
the	O
collapse	O
of	O
mitochondrial	O
membrane	O
potential	O
,	O
which	O
is	O
followed	O
by	O
the	O
translocation	O
of	O
cytochrome	B
c	I
from	O
the	O
mitochondria	O
into	O
the	O
cytosol	O
.	O

The	O
release	O
of	O
cytochrome	B
c	I
from	O
the	O
mitochondria	O
to	O
the	O
cytosol	O
is	O
one	O
of	O
the	O
early	O
events	O
that	O
subsequently	O
lead	O
to	O
apoptosis	O
by	O
activation	O
of	O
caspases	O
,	O
including	O
caspase	O
-	O
3	O
.	O

The	O
release	O
of	O
cytochrome	B
c	I
into	O
cytosol	O
leads	O
to	O
activation	O
of	O
procaspase	O
-	O
9	O
in	O
the	O
apoptosome	O
and	O
then	O
causes	O
the	O
cleavage	O
of	O
caspase	O
-	O
3	O
.	O

The	O
mitochondrial	O
pathway	O
of	O
cell	O
death	O
is	O
mediated	O
by	O
Bcl	O
-	O
2	O
family	O
proteins	O
which	O
disrupt	O
the	O
mitochondria	O
membrane	O
potential	O
and	O
result	O
in	O
release	O
of	O
apoptogenic	O
factors	O
such	O
as	O
cytochrome	B
c	I
,	O
Smac	O
/	O
Diablo	O
,	O
and	O
AIF	O
,	O
into	O
the	O
cytosol	O
.	O

In	O
this	O
content	O
,	O
we	O
examined	O
the	O
cytochrome	B
c	I
levels	O
in	O
cytosol	O
fractions	O
of	O
cells	O
treated	O
with	O
Se	O
-	O
PPC	O
at	O
doses	O
of	O
4	O
,	O
8	O
,	O
and	O
16	O
g	O
/	O
mL	O
.	O

The	O
result	O
of	O
western	O
blot	O
showed	O
that	O
the	O
cytosolic	O
cytochrome	B
c	I
protein	O
expression	O
increased	O
markedly	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
in	O
Se	O
-	O
PPC	O
-	O
treated	O
cells	O
(	O
B	O
)	O
.	O

Since	O
release	O
of	O
cytochrome	B
c	I
into	O
the	O
cytosol	O
is	O
usually	O
preceded	O
or	O
accompanied	O
by	O
a	O
loss	O
or	O
disruption	O
of	O
mitochondrial	O
membrane	O
potential	O
and	O
this	O
collapse	O
is	O
an	O
essential	O
step	O
occurring	O
in	O
cells	O
undergoing	O
apoptosis	O
.	O

All	O
of	O
these	O
stimuli	O
result	O
in	O
opening	O
of	O
the	O
mitochondrial	O
permeability	O
transition	O
pore	O
,	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
,	O
and	O
release	O
of	O
cytochrome	B
c	I
to	O
activate	O
apoptosome	O
containing	O
Apaf	O
-	O
1	O
,	O
caspase	O
-	O
9	O
,	O
and	O
caspase	O
-	O
3	O
.	O

These	O
apoptotic	O
mitochondrial	O
events	O
are	O
regulated	O
by	O
members	O
of	O
B	O
cell	O
lymphoma	O
2	O
(	O
Bcl	O
-	O
2	O
)	O
family	O
proteins	O
,	O
in	O
which	O
Bax	O
and	O
Bak	O
trigger	O
cytochrome	B
c	I
release	O
and	O
apoptosis	O
,	O
whereas	O
Bcl2	O
,	O
Bcl	O
-	O
xL	O
and	O
Bcl	O
-	O
w	O
,	O
inhibit	O
apoptosis	O
.	O

Alpha	O
-	O
mangostin	O
-	O
induced	O
Reactive	O
Oxygen	O
Species	O
generation	O
has	O
also	O
been	O
observed	O
to	O
trigger	O
mitochondria	O
-	O
mediated	O
apoptotic	O
cell	O
death	O
,	O
including	O
increased	O
cytochrome	B
c	I
release	O
and	O
activation	O
of	O
caspase	O
-	O
9	O
/	O
caspase	O
-	O
3	O
cascade	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
breast	O
cancer	O
cells	O
.	O

They	O
reported	O
two	O
potential	O
enzymes	O
,	O
cytochrome	B
c	I
reductase	O
(	O
Cgr1	O
)	O
and	O
FAD	O
-	O
binding	O
fumarate	O
reductase	O
(	O
Cgr2	O
)	O
,	O
based	O
on	O
the	O
structural	O
and	O
sequence	O
homology	O
analysis	O
for	O
the	O
reduction	O
of	O
digoxin	O
.	O

^	O
,	O
In	O
the	O
model	O
of	O
TNF	O
/	O
galactosamine	O
(	O
TNF	O
/	O
GalN	O
)	O
-	O
induced	O
hepatocyte	O
apoptosis	O
,	O
the	O
sustained	O
C	O
-	O
Jun	O
N	O
-	O
Terminal	O
Kinase	O
activation	O
is	O
critical	O
in	O
modulating	O
the	O
Bcl	O
family	O
members	O
,	O
which	O
are	O
the	O
gatekeepers	O
of	O
mitochondrial	O
outer	O
membrane	O
permeabilization	O
leading	O
to	O
the	O
release	O
of	O
cytochrome	B
c	I
and	O
other	O
apoptogenic	O
proteins	O
.	O

Complex	O
IV	O
activity	O
was	O
determined	O
by	O
following	O
the	O
oxidation	O
of	O
reduced	O
cytochrome	B
c	I
to	O
decreased	O
absorbance	O
at	O
550	O
nm	O
.	O

^	O
Because	O
Pteridine	O
Reductase	O
-	O
1	O
enzymes	O
use	O
H_2B	O
as	O
a	O
substrate	O
and	O
also	O
require	O
NADPH	O
for	O
the	O
reaction	O
,	O
the	O
reduction	O
of	O
H_2B	O
to	O
H_4B	O
by	O
Pteridine	O
Reductase	O
-	O
1	O
is	O
nonenzymatically	O
linked	O
with	O
the	O
reduction	O
of	O
cytochrome	B
c	I
in	O
this	O
assay	O
,	O
which	O
is	O
detected	O
at	O
550	O
nm	O
.	O

The	O
final	O
reaction	O
mixture	O
contained	O
the	O
test	O
compound	O
in	O
a	O
range	O
of	O
concentrations	O
and	O
TbPTR1	O
/	O
LmPTR1	O
(	O
6	O
.	O
0	O
nM	O
/	O
12	O
.	O
0	O
nM	O
)	O
,	O
H_2B	O
(	O
0	O
.	O
3	O
M	O
/	O
3	O
.	O
0	O
M	O
)	O
,	O
cytochrome	B
c	I
(	O
100	O
M	O
/	O
100	O
M	O
)	O
,	O
and	O
NADPH	O
(	O
500	O
M	O
/	O
500	O
M	O
)	O
.	O

Compound	O
screening	O
was	O
performed	O
by	O
addition	O
of	O
the	O
compound	O
to	O
assay	O
plates	O
(	O
in	O
100	O
%	O
DMSO	O
)	O
,	O
followed	O
by	O
addition	O
of	O
45	O
L	O
reaction	O
mix	O
(	O
enzyme	O
,	O
H_2B	O
,	O
and	O
cytochrome	B
c	I
in	O
20	O
mM	O
sodium	O
citrate	O
buffer	O
)	O
.	O

Ubiquinol	O
cytochrome	B
c	I
oxidoreductase	O
(	O
bc1	O
complex	O
)	O
serves	O
as	O
an	O
important	O
electron	O
junction	O
in	O
many	O
respiratory	O
systems	O
.	O

It	O
funnels	O
electrons	O
coming	O
from	O
NADH	O
and	O
ubiquinol	O
to	O
cytochrome	B
c	I
,	O
but	O
it	O
is	O
also	O
capable	O
of	O
producing	O
significant	O
amounts	O
of	O
the	O
free	O
radical	O
superoxide	O
.	O

Ubiquinol	O
cytochrome	B
c	I
oxidoreductase	O
(	O
bc_1	O
complex	O
)	O
is	O
an	O
essential	O
enzyme	O
for	O
all	O
mammalian	O
cells	O
.	O

Quinones	O
are	O
lipophilic	O
,	O
mobile	O
electron	O
carrier	O
analogs	O
to	O
the	O
hydrophilic	O
NADH	O
molecule	O
and	O
cytochrome	B
c	I
hemeprotein	O
.	O

The	O
complex	O
catalyzes	O
the	O
exergonic	O
two	O
-	O
electron	O
oxidation	O
of	O
quinol	O
to	O
the	O
one	O
-	O
electron	O
reduction	O
of	O
cytochrome	B
c	I
while	O
transferring	O
two	O
charge	O
-	O
equivalents	O
across	O
biological	O
membranes	O
.	O

The	O
net	O
biochemical	O
reaction	O
is	O
the	O
oxidation	O
of	O
a	O
quinol	O
molecule	O
,	O
reduction	O
of	O
two	O
cytochrome	B
c	I
hemeproteins	O
,	O
release	O
of	O
four	O
chemical	O
protons	O
on	O
the	O
opposite	O
side	O
of	O
charge	O
transfer	O
,	O
and	O
consumption	O
of	O
two	O
matrix	O
protons	O
.	O

The	O
first	O
electron	O
is	O
passed	O
down	O
the	O
high	O
potential	O
chain	O
to	O
reduce	O
cytochrome	B
c	I
at	O
this	O
outer	O
surface	O
.	O

Another	O
turnover	O
(	O
ie	O
,	O
a	O
second	O
quinol	O
oxidation	O
at	O
the	O
Q_p	O
site	O
)	O
generates	O
a	O
second	O
reduced	O
cytochrome	B
c	I
molecule	O
and	O
a	O
fully	O
reduced	O
quinol	O
at	O
the	O
Q_n	O
site	O
(	O
matrix	O
side	O
)	O
.	O

In	O
total	O
,	O
two	O
quinol	O
molecules	O
are	O
oxidized	O
to	O
form	O
two	O
reduced	O
cytochrome	B
c	I
molecules	O
and	O
regenerate	O
a	O
quinol	O
molecule	O
at	O
the	O
Q_n	O
site	O
.	O

Briefly	O
,	O
electrons	O
are	O
added	O
to	O
the	O
complex	O
via	O
ubiquinol	O
(	O
QH_2	O
)	O
oxidation	O
in	O
a	O
two	O
-	O
electron	O
step	O
at	O
the	O
Q_p	O
site	O
and	O
removed	O
via	O
Q	O
reduction	O
at	O
the	O
Q_n	O
site	O
and	O
cytochrome	B
c	I
reduction	O
at	O
the	O
cytochrome	O
c_1	O
site	O
.	O

For	O
simplicity	O
,	O
we	O
lump	O
QH_2	O
oxidation	O
at	O
the	O
Q_p	O
site	O
with	O
cytochrome	B
c	I
reduction	O
at	O
the	O
c_1	O
site	O
,	O
so	O
electrons	O
enter	O
the	O
bc_1	O
complex	O
one	O
at	O
a	O
time	O
at	O
the	O
Q_p	O
site	O
.	O

We	O
assume	O
the	O
Rieske	O
Iron	O
Sulfur	O
Protein	O
and	O
cytochrome	O
c_1	O
redox	O
kinetics	O
are	O
not	O
rate	O
limiting	O
under	O
normal	O
turnover	O
conditions	O
.	O

With	O
a	O
steady	O
-	O
state	O
solution	O
for	O
the	O
electronic	O
states	O
known	O
,	O
the	O
steady	O
-	O
state	O
turnover	O
rates	O
for	O
cytochrome	B
c	I
reduction	O
,	O
superoxide	O
production	O
,	O
QH_2	O
oxidation	O
,	O
and	O
Q	O
reduction	O
can	O
be	O
computed	O
using	O
Eqs	O
.	O

The	O
superoxide	O
data	O
consist	O
of	O
rich	O
data	O
sets	O
that	O
report	O
the	O
rate	O
of	O
superoxide	O
production	O
as	O
a	O
function	O
of	O
membrane	O
potential	O
and	O
the	O
effect	O
of	O
antimycin	O
A	O
on	O
both	O
cytochrome	B
c	I
reduction	O
and	O
superoxide	O
production	O
.	O

In	O
many	O
experiments	O
used	O
to	O
parameterize	O
the	O
model	O
,	O
the	O
Q	O
analogs	O
exhibited	O
a	O
nonenzymatic	O
reaction	O
with	O
cytochrome	B
c	I
that	O
is	O
strongly	O
pH	O
dependent	O
(	O
,	O
.	O

In	O
most	O
articles	O
,	O
the	O
authors	O
indicated	O
that	O
this	O
oxidation	O
rate	O
was	O
subtracted	O
from	O
the	O
measured	O
rate	O
of	O
cytochrome	B
c	I
reduction	O
.	O

These	O
results	O
show	O
that	O
the	O
model	O
is	O
capable	O
of	O
recapitulating	O
the	O
observed	O
cytochrome	B
c	I
reduction	O
kinetics	O
under	O
a	O
wide	O
variety	O
of	O
experimental	O
conditions	O
.	O

Sensitivity	O
analysis	O
identifies	O
the	O
top	O
-	O
10	O
ranked	O
parameters	O
that	O
are	O
associated	O
with	O
the	O
internal	O
energy	O
states	O
of	O
the	O
enzyme	O
,	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
the	O
catalytic	O
cycle	O
,	O
the	O
antimycin	O
A	O
-	O
inhibition	O
factors	O
,	O
four	O
quinone	O
and	O
cytochrome	B
c	I
binding	O
constants	O
,	O
and	O
parameters	O
related	O
to	O
the	O
experimental	O
design	O
for	O
two	O
data	O
sets	O
.	O

In	O
addition	O
,	O
the	O
values	O
given	O
in	O
are	O
averages	O
of	O
the	O
nonzero	O
local	O
sensitivity	O
coefficients	O
computed	O
from	O
model	O
outputs	O
(	O
cytochrome	B
c	I
reduction	O
and	O
superoxide	O
production	O
rates	O
)	O
coinciding	O
with	O
the	O
data	O
using	O
Eqs	O
.	O

The	O
model	O
reproduces	O
the	O
cytochrome	B
c	I
reduction	O
and	O
corresponding	O
superoxide	O
production	O
rates	O
for	O
various	O
pharmacological	O
manipulations	O
.	O

Under	O
the	O
control	O
conditions	O
,	O
the	O
phospholipid	O
vesicles	O
reconstituted	O
with	O
bc_1	O
complex	O
exhibited	O
moderate	O
cytochrome	B
c	I
reduction	O
rates	O
with	O
elevated	O
superoxide	O
production	O
rates	O
.	O

With	O
the	O
addition	O
of	O
FCCP	O
,	O
both	O
the	O
membrane	O
potential	O
and	O
pH	O
gradient	O
are	O
abolished	O
,	O
and	O
the	O
rate	O
of	O
cytochrome	B
c	I
reduction	O
significantly	O
increases	O
whereas	O
the	O
rate	O
of	O
superoxide	O
production	O
dramatically	O
falls	O
to	O
the	O
minimum	O
level	O
.	O

When	O
nigericin	O
is	O
present	O
,	O
the	O
pH	O
gradient	O
is	O
converted	O
to	O
a	O
membrane	O
potential	O
that	O
leads	O
to	O
more	O
superoxide	O
production	O
with	O
a	O
negligible	O
effect	O
on	O
cytochrome	B
c	I
reduction	O
relative	O
to	O
the	O
control	O
.	O

This	O
leads	O
to	O
a	O
significant	O
stimulation	O
of	O
cytochrome	B
c	I
reduction	O
,	O
and	O
the	O
superoxide	O
production	O
rate	O
collapses	O
to	O
values	O
similar	O
to	O
the	O
FCCP	O
condition	O
.	O

The	O
cytochrome	B
c	I
reduction	O
rate	O
falls	O
to	O
levels	O
about	O
twice	O
that	O
of	O
the	O
superoxide	O
production	O
.	O

This	O
is	O
due	O
to	O
the	O
bypass	O
reaction	O
whereby	O
the	O
first	O
electron	O
from	O
QH_2	O
reduces	O
cytochrome	B
c	I
,	O
the	O
second	O
electron	O
reduces	O
oxygen	O
to	O
produce	O
superoxide	O
(	O
as	O
shown	O
in	O
)	O
,	O
and	O
then	O
the	O
superoxide	O
reduces	O
cytochrome	B
c	I
.	O
In	O
addition	O
,	O
the	O
model	O
recapitulates	O
the	O
exponential	O
dependency	O
on	O
membrane	O
potential	O
for	O
superoxide	O
production	O
rather	O
well	O
.	O

These	O
net	O
rates	O
are	O
determined	O
by	O
several	O
conditions	O
:	O
1	O
)	O
increased	O
levels	O
of	O
reduced	O
cytochrome	B
c	I
;	O
2	O
)	O
the	O
Q	O
and	O
QH_2	O
dissociation	O
constants	O
at	O
the	O
Q_p	O
site	O
;	O
3	O
)	O
superoxide	O
scavenging	O
by	O
Q	O
;	O
and	O
4	O
)	O
antimycin	O
A	O
-	O
dependent	O
effects	O
of	O
the	O
rate	O
constants	O
at	O
the	O
Q_p	O
site	O
,	O
as	O
discussed	O
in	O
the	O
paragraph	O
above	O
.	O

For	O
condition	O
1	O
,	O
we	O
found	O
peak	O
superoxide	O
production	O
rates	O
near	O
a	O
30	O
%	O
oxidized	O
Q	O
pool	O
when	O
cytochrome	B
c	I
was	O
only	O
5	O
%	O
or	O
20	O
%	O
reduced	O
.	O

But	O
it	O
is	O
unlikely	O
that	O
these	O
levels	O
of	O
reduced	O
cytochrome	B
c	I
are	O
produced	O
in	O
either	O
study	O
.	O

In	O
the	O
presence	O
of	O
antimycin	O
A	O
,	O
cytochrome	B
c	I
oxidase	O
keeps	O
cytochrome	B
c	I
completely	O
oxidized	O
.	O

The	O
ability	O
of	O
antimycin	O
A	O
to	O
stimulate	O
cytochrome	B
c	I
reduction	O
by	O
the	O
bc_1	O
complex	O
is	O
compelling	O
evidence	O
for	O
cross	O
-	O
monomer	O
electron	O
equilibration	O
.	O

However	O
,	O
when	O
only	O
a	O
single	O
antimycin	O
A	O
molecule	O
is	O
bound	O
to	O
the	O
dimer	O
,	O
cytochrome	B
c	I
reduction	O
is	O
stimulated	O
.	O

But	O
when	O
a	O
single	O
antimycin	O
A	O
molecule	O
is	O
bound	O
to	O
the	O
dimer	O
at	O
one	O
of	O
the	O
Q_n	O
sites	O
,	O
both	O
Q_p	O
sites	O
become	O
operational	O
and	O
the	O
rate	O
of	O
cytochrome	B
c	I
reduction	O
is	O
increased	O
by	O
a	O
factor	O
of	O
2	O
.	O

This	O
leads	O
to	O
an	O
overall	O
increase	O
in	O
the	O
maximal	O
rate	O
of	O
cytochrome	B
c	I
reduction	O
by	O
a	O
factor	O
of	O
1	O
.	O
15	O
in	O
the	O
heterogeneously	O
inhibited	O
population	O
of	O
bc_1	O
complexes	O
.	O

For	O
the	O
Q_n	O
site	O
,	O
Wikstrm	O
derives	O
values	O
for	O
the	O
both	O
QH_2	O
and	O
Q	O
binding	O
constants	O
with	O
QH_2	O
binding	O
100	O
-	O
fold	O
tighter	O
than	O
Q	O
.	O
Using	O
these	O
results	O
,	O
we	O
can	O
derive	O
a	O
See	O
,	O
Right	O
Column	O
Panels	O
of	O
values	O
that	O
leads	O
to	O
tenable	O
cytochrome	B
c	I
reduction	O
and	O
superoxide	O
production	O
rates	O
shown	O
in	O
.	O

The	O
bell	O
-	O
shaped	O
relationship	O
between	O
the	O
cytochrome	B
c	I
reduction	O
rate	O
and	O
Q	O
-	O
pool	O
redox	O
state	O
and	O
the	O
exponential	O
dependency	O
of	O
superoxide	O
production	O
rate	O
on	O
membrane	O
potential	O
is	O
similar	O
to	O
our	O
prior	O
simulations	O
.	O

This	O
phenomenon	O
is	O
characterized	O
by	O
the	O
possibility	O
of	O
two	O
free	O
radical	O
production	O
rates	O
at	O
a	O
given	O
rate	O
of	O
cytochrome	B
c	I
reduction	O
.	O

Some	O
other	O
notable	O
differences	O
between	O
our	O
previous	O
simulations	O
and	O
the	O
current	O
ones	O
are	O
the	O
overall	O
shapes	O
of	O
the	O
cytochrome	B
c	I
reduction	O
and	O
superoxide	O
production	O
rates	O
as	O
a	O
function	O
of	O
membrane	O
potential	O
and	O
Q	O
-	O
pool	O
redox	O
state	O
,	O
maximum	O
rates	O
of	O
superoxide	O
production	O
,	O
and	O
the	O
enzyme	O
distribution	O
surfaces	O
.	O

For	O
cytochrome	B
c	I
reduction	O
,	O
the	O
maximum	O
rate	O
occurs	O
when	O
the	O
Q	O
pool	O
is	O
90	O
%	O
reduced	O
and	O
the	O
membrane	O
potential	O
is	O
low	O
.	O

But	O
as	O
the	O
membrane	O
potential	O
increases	O
,	O
the	O
maximum	O
rate	O
of	O
cytochrome	B
c	I
reduction	O
occurs	O
when	O
the	O
Q	O
-	O
pool	O
redox	O
state	O
is	O
closer	O
to	O
65	O
%	O
reduced	O
.	O

During	O
cytochrome	B
c	I
reduction	O
,	O
the	O
one	O
-	O
,	O
two	O
-	O
,	O
and	O
three	O
-	O
electron	O
reduced	O
states	O
are	O
the	O
most	O
significant	O
states	O
(	O
see	O
and	O
.	O

The	O
bell	O
-	O
shaped	O
relationship	O
between	O
cytochrome	B
c	I
reduction	O
and	O
the	O
Q	O
-	O
pool	O
redox	O
state	O
makes	O
either	O
possibility	O
feasible	O
(	O
see	O
.	O

They	O
both	O
report	O
the	O
rate	O
of	O
oxygen	O
consumption	O
(	O
stoichiometrically	O
linked	O
to	O
cytochrome	B
c	I
reduction	O
)	O
,	O
membrane	O
potential	O
,	O
pH	O
,	O
and	O
redox	O
state	O
of	O
the	O
cytochrome	B
c	I
pool	O
.	O

shows	O
model	O
simulations	O
using	O
these	O
data	O
sets	O
as	O
fixed	O
inputs	O
for	O
the	O
model	O
(	O
cytochrome	B
c	I
redox	O
state	O
,	O
membrane	O
potential	O
,	O
and	O
pH	O
)	O
while	O
solving	O
for	O
the	O
Q	O
-	O
pool	O
redox	O
state	O
as	O
a	O
variable	O
for	O
each	O
value	O
of	O
the	O
bc_1	O
content	O
to	O
match	O
the	O
reported	O
oxygen	O
consumption	O
rates	O
(	O
proportional	O
to	O
the	O
turnover	O
of	O
the	O
bc_1	O
complex	O
)	O
.	O

The	O
reductase	O
domain	O
of	O
NOS	O
catalyses	O
the	O
reduction	O
of	O
cytochrome	B
c	I
and	O
other	O
redoxactive	O
dyes	O
[	O
345	O
]	O
.	O

The	O
cytochrome	B
c	I
oxidase	O
(	O
CcoNOQP	O
)	O
is	O
of	O
the	O
cbb_3	O
type	O
,	O
often	O
found	O
in	O
microaerophiles	O
,	O
and	O
has	O
a	O
very	O
high	O
oxygen	O
affinity	O
(	O
K	O
_d	O
40	O
nM	O
)	O
that	O
may	O
allow	O
growth	O
at	O
lower	O
oxygen	O
levels	O
than	O
the	O
alternative	O
bdlike	O
(	O
CioAB	O
or	O
CydAB	O
)	O
quinol	O
oxidase	O
(	O
K	O
_d	O
8	O
M	O
;	O
Jackson	O
et	O
al	O
.	O
,	O
.	O

What	O
is	O
clear	O
is	O
that	O
C	O
.	O
jejuni	O
is	O
not	O
deficient	O
in	O
oxidative	O
stress	O
defence	O
enzymes	O
(	O
reviewed	O
by	O
Flint	O
et	O
al	O
.	O
,	O
)	O
with	O
most	O
strains	O
possessing	O
catalase	O
,	O
superoxide	O
dismutase	O
,	O
three	O
cytoplasmic	O
peroxiredoxins	O
(	O
AhpC	O
,	O
Tpx	O
and	O
Bcp	O
)	O
,	O
two	O
cytoplasmic	O
methionine	O
sulphoxide	O
reductases	O
,	O
two	O
periplasmic	O
cytochrome	B
c	I
peroxidases	O
,	O
a	O
desulforuberythrin	O
and	O
several	O
hemerythrins	O
(	O
Parkhill	O
et	O
al	O
.	O
,	O
;	O
Flint	O
et	O
al	O
.	O
,	O
.	O

At	O
least	O
three	O
soluble	O
periplasmic	O
cytochromes	O
c	O
have	O
been	O
shown	O
to	O
have	O
a	O
role	O
in	O
the	O
transfer	O
of	O
electrons	O
between	O
the	O
cytochrome	O
bc_1	O
complex	O
and	O
the	O
cbb_3type	O
cytochrome	B
c	I
oxidase	O
(	O
Liu	O
and	O
Kelly	O
,	O
)	O
;	O
these	O
are	O
CccA	O
(	O
Cj1153	O
)	O
,	O
CccB	O
(	O
Cj1020	O
)	O
and	O
CccC	O
(	O
Cj0037	O
)	O
.	O

In	O
contrast	O
,	O
cj0037c	O
(	O
cccC	O
)	O
was	O
strongly	O
downregulated	O
(	O
greater	O
than	O
fivefold	O
)	O
and	O
the	O
CccC	O
protein	O
was	O
correspondingly	O
23	O
.	O
5fold	O
more	O
abundant	O
at	O
150	O
%	O
versus	O
40	O
%	O
aerobiosis	O
(	O
Supporting	O
Information	O
Table	O
S2	O
)	O
,	O
suggesting	O
a	O
specific	O
oxygenlinked	O
role	O
,	O
perhaps	O
as	O
the	O
preferred	O
electron	O
donor	O
to	O
the	O
cytochrome	B
c	I
oxidase	O
(	O
Liu	O
and	O
Kelly	O
,	O
.	O

The	O
ccoP	O
gene	O
of	O
the	O
cbb_3type	O
cytochrome	B
c	I
oxidase	O
(	O
CcoNOQP	O
)	O
was	O
the	O
only	O
gene	O
of	O
this	O
complex	O
that	O
showed	O
an	O
expression	O
change	O
during	O
the	O
transition	O
to	O
low	O
oxygen	O
(	O
Supporting	O
Information	O
Table	O
S1	O
)	O
,	O
but	O
CcoP	O
and	O
CcoO	O
were	O
only	O
slightly	O
(	O
1	O
.	O
6	O
and	O
1	O
.	O
9fold	O
respectively	O
)	O
more	O
abundant	O
at	O
40	O
%	O
aerobiosis	O
(	O
Supporting	O
Information	O
Table	O
S2	O
)	O
.	O

Measurements	O
of	O
cytochrome	B
c	I
oxidase	O
activity	O
confirmed	O
there	O
was	O
no	O
significant	O
difference	O
in	O
cells	O
grown	O
at	O
the	O
high	O
and	O
low	O
aerobiosis	O
conditions	O
(	O
Supporting	O
Information	O
Fig	O
S3F	O
)	O
.	O

Apart	O
from	O
FrdABC	O
,	O
these	O
enzymes	O
all	O
have	O
integral	O
cytochrome	B
c	I
electron	O
transferring	O
or	O
catalytic	O
subunits	O
.	O

Interestingly	O
,	O
three	O
enzymes	O
of	O
haem	O
biosynthesis	O
,	O
HemA	O
,	O
HemL	O
and	O
HemN	O
,	O
and	O
the	O
cytochrome	B
c	I
synthase	O
CcsBA	O
(	O
Cj1013	O
;	O
Liu	O
and	O
Kelly	O
,	O
)	O
were	O
2	O
.	O
1fold	O
,	O
1	O
.	O
8fold	O
,	O
fourfold	O
and	O
1	O
.	O
8fold	O
higher	O
at	O
40	O
%	O
aerobiosis	O
respectively	O
(	O
Supporting	O
Information	O
Table	O
S2	O
)	O
,	O
in	O
keeping	O
with	O
an	O
extra	O
demand	O
for	O
cytochrome	B
c	I
biogenesis	O
under	O
these	O
conditions	O
.	O

Campylobacter	O
jejuni	O
encodes	O
two	O
periplasmic	O
dihaem	O
cytochrome	B
c	I
peroxidases	O
(	O
Cj0358	O
and	O
Cj0020	O
in	O
NCTC11168	O
)	O
.	O

Finally	O
,	O
unlike	O
the	O
cytoplasmic	O
peroxidatic	O
enzymes	O
discussed	O
above	O
,	O
the	O
regulatory	O
behaviour	O
of	O
the	O
two	O
periplasmic	O
cytochrome	B
c	I
peroxidases	O
(	O
CCPs	O
)	O
in	O
C	O
.	O
jejuni	O
is	O
clearly	O
distinct	O
,	O
with	O
cj0358	O
gene	O
expression	O
and	O
Cj0358	O
protein	O
abundance	O
being	O
increased	O
at	O
low	O
aerobiosis	O
but	O
cj0020c	O
unchanged	O
.	O

manifest	O
activation	O
of	O
antioxidant	O
enzymes	O
:	O
catalases	O
,	O
cytochrome	B
c	I
peroxidase	O
,	O
thioredoxin	O
,	O
and	O
superoxide	O
dismutases	O
,	O
and	O
a	O
metabolic	O
shift	O
to	O
the	O
pentose	O
phosphate	O
pathway	O
,	O
characterized	O
by	O
increased	O
NADPH	O
production	O
in	O
the	O
cytoplasm	O
,	O
as	O
an	O
electron	O
source	O
for	O
the	O
glutathione	O
peroxidase	O
system	O
,	O
which	O
points	O
to	O
restoration	O
of	O
the	O
cellular	O
redox	O
homeostasis	O
.	O

After	O
blocking	O
with	O
5	O
%	O
non	O
-	O
fat	O
dry	O
milk	O
in	O
TBS	O
with	O
Tween	O
-	O
20	O
buffer	O
,	O
blots	O
were	O
incubated	O
with	O
primary	O
monoclonal	O
antibodies	O
at	O
4C	O
overnight	O
:	O
Rabbit	O
anti	O
-	O
ALPHA	O
-	O
SYN	O
(	O
ab138501	O
;	O
1	O
:	O
500	O
;	O
Abcam	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
,	O
rabbit	O
anti	O
-	O
P	O
-	O
Ser129	O
ALPHA	O
-	O
SYN	O
(	O
ab51253	O
;	O
1	O
:	O
500	O
;	O
Abcam	O
)	O
,	O
rabbit	O
anti	O
-	O
Bcl	O
-	O
2	O
(	O
ab32124	O
;	O
1	O
:	O
1	O
,	O
000	O
;	O
Abcam	O
)	O
,	O
rabbit	O
anti	O
-	O
Bax	O
(	O
ab32503	O
;	O
1	O
:	O
1	O
,	O
000	O
;	O
Abcam	O
)	O
,	O
rabbit	O
anti	O
-	O
Cyt	O
-	O
c	O
(	O
ab133504	O
;	O
1	O
:	O
1	O
,	O
000	O
;	O
Abcam	O
)	O
,	O
anti	O
-	O
GAPDH	O
(	O
A01622	O
-	O
40	O
;	O
1	O
:	O
3	O
,	O
000	O
;	O
GenScript	O
,	O
Nanjing	O
,	O
China	O
)	O
and	O
anti	O
-	O
cytochrome	B
c	I
oxidase	O
(	O
COX	O
IV	O
;	O
1	O
:	O
1	O
,	O
000	O
,	O
sc	O
-	O
376731	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
,	O
Dallas	O
,	O
TX	O
,	O
USA	O
)	O
,	O
then	O
incubated	O
with	O
goat	O
horseradish	O
peroxidase	O
-	O
conjugated	O
corresponding	O
secondary	O
antibodies	O
(	O
ab6721	O
and	O
ab6789	O
;	O
1	O
:	O
3	O
,	O
000	O
;	O
Abcam	O
)	O
at	O
room	O
temperature	O
for	O
1	O
h	O
.	O
Proteins	O
were	O
detected	O
using	O
an	O
enhanced	O
chemiluminescence	O
plus	O
kit	O
(	O
Pierce	O
;	O
Thermo	O
Fisher	O
Scientific	O
,	O
Inc	O
.	O
)	O

Despite	O
its	O
beneficial	O
role	O
in	O
preventing	O
oxidative	O
stress	O
,	O
H_2S	O
can	O
become	O
toxic	O
to	O
both	O
mitochondria	O
and	O
bacterial	O
cells	O
,	O
primarily	O
because	O
it	O
blocks	O
aerobic	O
respiration	O
through	O
inhibition	O
of	O
the	O
cytochrome	B
c	I
oxidase	O
^	O
-	O
.	O

Given	O
that	O
H_2S	O
competes	O
with	O
O_2	O
for	O
cytochrome	B
c	I
oxidase	O
binding	O
,	O
we	O
decided	O
to	O
investigate	O
the	O
role	O
of	O
Blh	O
as	O
a	O
sulfide	O
oxidation	O
enzyme	O
,	O
particularly	O
when	O
O_2	O
becomes	O
limited	O
to	O
the	O
cells	O
.	O

It	O
also	O
induced	O
mitochondrial	O
apoptosis	O
by	O
increasing	O
the	O
expression	O
of	O
Bax	O
,	O
caspase	O
-	O
9	O
,	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
and	O
mitochondrial	O
membrane	O
potential	O
loss	O
and	O
leaks	O
of	O
cytochrome	B
c	I
(	O
Cyt	O
C	O
)	O
from	O
mitochondria	O
in	O
MCF	O
-	O
7	O
cells	O
and	O
decreasing	O
the	O
expression	O
of	O
mitochondrial	O
Bcl	O
-	O
2	O
.	O

The	O
cytoplasm	O
around	O
the	O
vacuoles	O
was	O
immunopositive	O
for	O
cytochrome	B
c	I
,	O
tom	O
20	O
,	O
and	O
SOD	O
-	O
1	O
,	O
suggesting	O
that	O
these	O
vacuoles	O
might	O
occur	O
within	O
mitochondria	O
.	O

Immunohistochemistry	O
was	O
performed	O
using	O
the	O
following	O
primary	O
antibodies	O
:	O
anti	O
-	O
slow	O
myosin	O
(	O
clone	O
NOQ7	O
.	O
5	O
.	O
4D	O
;	O
1	O
:	O
4	O
,	O
000	O
;	O
Sigma	O
-	O
Aldrich	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
anti	O
-	O
canine	O
fast	O
myosin	O
(	O
rabbit	O
polyclonal	O
;	O
1	O
:	O
100	O
;	O
Sigma	O
-	O
Aldrich	O
)	O
,	O
anti	O
-	O
nestin	O
(	O
rabbit	O
polyclonal	O
;	O
1	O
:	O
20	O
;	O
Immuno	O
-	O
Biological	O
Laboratories	O
,	O
Fujioka	O
,	O
Japan	O
)	O
,	O
anti	O
-	O
myogenin	O
(	O
clone	O
F5D	O
;	O
1	O
:	O
50	O
;	O
Dako	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
anti	O
-	O
cytochrome	B
c	I
(	O
clone	O
A	O
-	O
8	O
;	O
1	O
:	O
200	O
;	O
Santa	O
Cruz	O
,	O
Dallas	O
,	O
TX	O
,	O
U	O
.	O
S	O
.	O
A	O
.	O

The	O
cytoplasm	O
around	O
the	O
vacuoles	O
was	O
immunopositive	O
for	O
cytochrome	B
c	I
,	O
tom	O
20	O
(	O
b	O
)	O
and	O
SOD	O
-	O
1	O
(	O
c	O
)	O
.	O

Immunohistochemistry	O
for	O
cytochrome	B
c	I
(	O
a	O
)	O
,	O
tom	O
20	O
(	O
b	O
)	O
and	O
SOD	O
-	O
1	O
(	O
c	O
)	O
.	O

In	O
the	O
present	O
Shiba	O
case	O
,	O
the	O
cytoplasm	O
around	O
the	O
vacuoles	O
was	O
immunopositive	O
for	O
mitochondrial	O
markers	O
such	O
as	O
cytochrome	B
c	I
,	O
tom	O
20	O
,	O
and	O
SOD	O
-	O
1	O
.	O

Inducing	O
cell	O
death	O
in	O
vitro	O
in	O
cancer	O
cells	O
by	O
targeted	O
delivery	O
of	O
cytochrome	B
c	I
via	O
a	O
transferrin	O
conjugate	O
.	O

To	O
actively	O
target	O
lung	O
cancer	O
cells	O
,	O
we	O
have	O
developed	O
a	O
conjugate	O
of	O
the	O
apoptosis	O
inducing	O
protein	O
cytochrome	B
c	I
with	O
transferrin	O
because	O
the	O
transferrin	O
receptor	O
is	O
overexpressed	O
by	O
many	O
rapidly	O
dividing	O
cancer	O
cells	O
.	O

Confocal	O
results	O
demonstrated	O
the	O
cellular	O
uptake	O
of	O
the	O
cytochrome	B
c	I
-	O
transferrin	O
conjugate	O
by	O
transferrin	O
receptor	O
overexpressing	O
A549	O
lung	O
cancer	O
cells	O
.	O

This	O
is	O
the	O
case	O
for	O
the	O
alternative	O
complex	O
III	O
,	O
a	O
quinol	O
:	O
cytochrome	B
c	I
/	O
HiPIP	O
oxidoreductase	O
.	O

The	O
oxidation	O
of	O
quinol	O
with	O
subsequent	O
reduction	O
of	O
cytochrome	B
c	I
seemed	O
until	O
1999	O
to	O
evade	O
the	O
paradigm	O
of	O
diversified	O
respiratory	O
chains	O
in	O
prokaryotes	O
.	O

This	O
notion	O
changed	O
with	O
the	O
identification	O
of	O
alternative	O
complex	O
III	O
,	O
a	O
quinol	O
:	O
cytochrome	B
c	I
/	O
high	O
potential	O
iron	O
-	O
sulfur	O
protein	O
oxidoreductase	O
that	O
was	O
identified	O
in	O
Rhodothermus	O
marinus	O
^	O
.	O

In	O
addition	O
to	O
reducing	O
periplasmatic	O
proteins	O
,	O
such	O
as	O
HiPIP	O
^	O
and	O
soluble	O
cytochrome	B
c	I
^	O
,	O
Alternative	O
Complex	O
Iii	O
can	O
directly	O
transfer	O
electrons	O
from	O
quinol	O
to	O
the	O
caa_3	O
terminal	O
oxidase	O
without	O
the	O
intervention	O
of	O
any	O
soluble	O
electron	O
carrier	O
^	O
.	O

ActA	O
is	O
a	O
pentaheme	O
cytochrome	B
c	I
,	O
anchored	O
to	O
the	O
membrane	O
by	O
an	O
N	O
-	O
terminal	O
Transmembrane	O
Helices	O
(	O
Supplementary	O
Fig	O
.	O

ActE	O
is	O
a	O
monoheme	O
cytochrome	B
c	I
,	O
located	O
on	O
the	O
top	O
of	O
ActA	O
.	O

ACIII	O
is	O
a	O
quinol	O
:	O
cytochrome	B
c	I
/	O
HiPIP	O
oxidoreductase	O
.	O

Our	O
study	O
provides	O
insights	O
into	O
the	O
catalytic	O
mechanism	O
of	O
a	O
type	O
of	O
quinol	O
:	O
cytochrome	B
c	I
/	O
HiPIP	O
oxidoreductase	O
.	O

Cyanide	O
is	O
a	O
powerful	O
toxic	O
chemical	O
that	O
shows	O
high	O
affinity	O
for	O
iron	O
and	O
other	O
metals	O
,	O
blocking	O
the	O
function	O
of	O
different	O
metalloproteins	O
like	O
the	O
cytochrome	B
c	I
oxidase	O
involved	O
in	O
the	O
cellular	O
respiratory	O
process	O
(	O
Solomonson	O
;	O
Jnemann	O
;	O
Gupta	O
,	O
Balomajumder	O
and	O
Agarwal	O
;	O
Luque	O
-	O
Almagro	O
,	O
Moreno	O
-	O
Vivin	O
and	O
Roldn	O
.	O

At	O
the	O
beginning	O
of	O
growth	O
,	O
the	O
upregulation	O
of	O
genes	O
involved	O
in	O
oxidative	O
phosphorylation	O
(	O
ctaG	O
,	O
SO3058	O
,	O
coxA	O
)	O
indicates	O
an	O
increase	O
in	O
electron	O
-	O
transporting	O
activity	O
and	O
the	O
hydrolysis	O
of	O
ATP	O
(	O
SO3885	O
)	O
,	O
along	O
with	O
the	O
downregulation	O
of	O
subunits	O
for	O
the	O
synthesis	O
of	O
a	O
cytochrome	B
c	I
-	O
oxidase	O
(	O
ccoQ	O
)	O
,	O
an	O
ATPase	O
(	O
atpC	O
)	O
,	O
a	O
periplasmic	O
monoheme	O
cytochrome	B
C	I
(	O
scyA	O
)	O
,	O
and	O
a	O
succinate	O
dehydrogenase	O
(	O
sdhB	O
)	O
responsible	O
for	O
the	O
reduction	O
of	O
ubiquinone	O
to	O
ubiquinol	O
.	O

Towards	O
the	O
end	O
of	O
exponential	O
growth	O
,	O
the	O
upregulation	O
of	O
coxA	O
is	O
maintained	O
,	O
accompanied	O
by	O
the	O
downregulation	O
of	O
two	O
subunits	O
for	O
the	O
cbb3	O
-	O
type	O
cytochrome	B
c	I
-	O
oxidase	O
(	O
ccoQ	O
,	O
ccoP	O
)	O
,	O
one	O
subunit	O
of	O
the	O
cytochrome	O
bd	O
complex	O
(	O
cydA	O
)	O
,	O
and	O
three	O
components	O
of	O
the	O
cytochrome	B
c	I
maturation	O
(	O
Ccm	O
)	O
system	O
(	O
ccmC	O
,	O
ccmD	O
,	O
ccmE	O
)	O
,	O
responsible	O
for	O
the	O
catalytic	O
activity	O
of	O
cytochromes	O
.	O

The	O
cytochrome	B
c	I
(	O
cyt	O
c	O
)	O
subunit	O
,	O
which	O
possesses	O
three	O
hemes	O
(	O
heme	O
1	O
,	O
heme	O
2	O
,	O
and	O
heme	O
3	O
,	O
from	O
the	O
N	O
-	O
terminal	O
sequence	O
)	O
,	O
is	O
known	O
to	O
enable	O
DET	O
;	O
however	O
,	O
details	O
of	O
the	O
electron	O
transfer	O
pathway	O
remain	O
unknown	O
.	O

We	O
assessed	O
species	O
diversity	O
among	O
the	O
populations	O
by	O
analyzing	O
the	O
nucleotide	O
sequence	O
in	O
a	O
670bp	O
region	O
of	O
the	O
mitochondrial	O
cytochrome	B
c	I
oxidase	O
I	O
(	O
COI	O
)	O
,	O
a	O
region	O
that	O
has	O
proven	O
effective	O
in	O
species	O
identification	O
within	O
North	O
American	O
Hyalella	O
(	O
Major	O
,	O
Soucek	O
,	O
Giordano	O
,	O
Wetzel	O
,	O
&	O
SotoAdames	O
,	O
;	O
Wellborn	O
&	O
Broughton	O
,	O
;	O
Witt	O
et	O
al	O
.	O
,	O
.	O

The	O
SH1	O
-	O
SH3	O
extracts	O
protected	O
SH	O
-	O
SY5Y	O
cells	O
from	O
6	O
-	O
hydroxydopamine	O
(	O
6	O
-	O
OHDA	O
)	O
-	O
induced	O
apoptosis	O
as	O
illustrated	O
by	O
cell	O
cycle	O
distribution	O
,	O
cytochrome	B
c	I
release	O
,	O
activation	O
of	O
caspase	O
-	O
8	O
,	O
-	O
9	O
,	O
and	O
-	O
3	O
,	O
and	O
DNA	O
fragmentation	O
analyses	O
.	O

In	O
order	O
to	O
further	O
examine	O
the	O
protective	O
effects	O
of	O
SH1	O
-	O
SH3	O
on	O
6	O
-	O
OHDA	O
-	O
induced	O
apoptosis	O
in	O
SH	O
-	O
SY5Y	O
cells	O
,	O
the	O
cell	O
cycle	O
distribution	O
,	O
cytochrome	B
c	I
release	O
,	O
activation	O
of	O
caspase	O
-	O
8	O
,	O
-	O
9	O
,	O
and	O
-	O
3	O
,	O
and	O
DNA	O
fragmentation	O
were	O
performed	O
by	O
flow	O
cytometry	O
.	O

Here	O
,	O
an	O
immunodetection	O
of	O
cytochrome	B
c	I
by	O
flow	O
cytometry	O
was	O
applied	O
to	O
quantify	O
release	O
of	O
cytochrome	B
c	I
in	O
cells	O
.	O

When	O
cells	O
were	O
treated	O
with	O
75	O
M	O
6	O
-	O
OHDA	O
,	O
the	O
population	O
of	O
high	O
fluorescent	O
cells	O
decreased	O
from	O
96	O
.	O
80	O
%	O
0	O
.	O
22	O
%	O
(	O
control	O
)	O
to	O
43	O
.	O
47	O
%	O
0	O
.	O
53	O
%	O
,	O
indicating	O
cytochrome	B
c	I
underwent	O
release	O
from	O
mitochondria	O
.	O

In	O
addition	O
,	O
SH3	O
was	O
more	O
effective	O
at	O
preventing	O
6	O
-	O
OHDA	O
-	O
induced	O
cytochrome	B
c	I
release	O
in	O
cells	O
than	O
SH1	O
and	O
SH2	O
.	O

The	O
intrinsic	O
pathway	O
occurs	O
following	O
loss	O
of	O
mitochondrial	O
transmembrane	O
potential	O
,	O
resulting	O
in	O
the	O
release	O
of	O
cytochrome	B
c	I
into	O
the	O
cytoplasm	O
.	O

In	O
summary	O
,	O
all	O
of	O
the	O
treated	O
fucoidan	O
extracts	O
SH1	O
-	O
SH3	O
protected	O
SH	O
-	O
SY5Y	O
cells	O
from	O
6	O
-	O
OHDA	O
-	O
induced	O
apoptosis	O
as	O
illustrated	O
by	O
the	O
cell	O
cycle	O
distribution	O
,	O
cytochrome	B
c	I
release	O
,	O
activation	O
of	O
caspase	O
-	O
8	O
,	O
-	O
9	O
,	O
and	O
-	O
3	O
,	O
and	O
DNA	O
fragmentation	O
analyses	O
.	O

Next	O
the	O
cells	O
were	O
washed	O
with	O
2	O
mL	O
1	O
permeabilization	O
buffer	O
twice	O
,	O
and	O
the	O
cells	O
were	O
resuspended	O
with	O
100	O
L	O
1	O
permeabilization	O
buffer	O
,	O
followed	O
by	O
addition	O
of	O
10	O
L	O
FITC	O
(	O
fluorescein	O
isothiocyanate	O
)	O
-	O
labelled	O
anti	O
-	O
cytochrome	B
c	I
antibody	O
(	O
Thermo	O
Fisher	O
Scientific	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
,	O
and	O
incubation	O
at	O
room	O
temperature	O
for	O
60	O
min	O
in	O
the	O
dark	O
.	O

Fucoidan	O
extracts	O
SH1	O
-	O
SH3	O
protected	O
SH	O
-	O
SY5Y	O
cells	O
from	O
6	O
-	O
OHDA	O
-	O
induced	O
apoptosis	O
as	O
illustrated	O
by	O
the	O
cell	O
cycle	O
distribution	O
,	O
cytochrome	B
c	I
release	O
,	O
activation	O
of	O
caspase	O
-	O
8	O
,	O
-	O
9	O
,	O
and	O
-	O
3	O
,	O
and	O
DNA	O
fragmentation	O
analyses	O
.	O

As	O
standards	O
was	O
used	O
a	O
mixture	O
containing	O
aldolase	O
(	O
Mm	O
158	O
kDa	O
)	O
,	O
ferritin	O
(	O
Mm	O
440	O
kDa	O
)	O
,	O
conalbumin	O
(	O
Mm	O
75	O
kDa	O
)	O
,	O
carbonic	O
anhydrase	O
(	O
Mm	O
29	O
kDa	O
)	O
and	O
cytochrome	B
c	I
(	O
Mm	O
12	O
.	O
4	O
kDa	O
)	O
,	O
and	O
dextran	O
blue	O
(	O
Mm	O
2000	O
kDa	O
)	O
as	O
void	O
volume	O
marker	O
.	O

^	O
These	O
electrons	O
are	O
transferred	O
to	O
cytochromes	O
c	O
and	O
are	O
finally	O
transferred	O
to	O
oxygen	O
by	O
cytochrome	B
c	I
oxidase	O
.	O

Finally	O
,	O
the	O
activation	O
of	O
t	O
-	O
Bid	O
causes	O
the	O
interaction	O
with	O
BAX	O
(	O
1FI6	O
)	O
y	O
/	O
o	O
BAK	O
(	O
2IMT	O
)	O
which	O
stimulates	O
the	O
release	O
of	O
cytochrome	B
c	I
.	O
In	O
this	O
point	O
,	O
the	O
target	O
molecules	O
2	O
-	O
4	O
interact	O
with	O
BAX	O
in	O
order	O
to	O
strengthen	O
the	O
release	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
shown	O
that	O
some	O
of	O
the	O
stress	O
signals	O
mediated	O
and	O
regulated	O
by	O
BCL2	O
family	O
proteins	O
result	O
in	O
mitochondria	O
releasing	O
cytochrome	B
c	I
.	O
This	O
is	O
,	O
indeed	O
,	O
the	O
first	O
step	O
in	O
the	O
intrinsic	O
pathway	O
of	O
apoptosis	O
.	O

Sodium	O
alginate	O
,	O
bovine	O
serum	O
albumin	O
,	O
and	O
cytochrome	B
c	I
represented	O
extracellular	O
polysaccharides	O
,	O
proteins	O
,	O
and	O
electrochemically	O
active	O
components	O
,	O
respectively	O
.	O

Relative	O
to	O
the	O
anaerobic	O
inorganic	O
control	O
,	O
Pb	O
release	O
increased	O
by	O
156	O
,	O
202	O
,	O
and	O
198	O
g	O
/	O
L	O
when	O
sEPS	O
was	O
present	O
on	O
the	O
cathode	O
side	O
at	O
200	O
mg	O
/	O
L	O
(	O
100	O
mg	O
/	O
L	O
alginate	O
+	O
100	O
mg	O
/	O
L	O
BSA	O
)	O
,	O
400	O
mg	O
/	O
L	O
(	O
200	O
mg	O
/	O
L	O
alginate	O
+	O
200	O
mg	O
/	O
L	O
BSA	O
)	O
,	O
and	O
200	O
mg	O
/	O
L	O
with	O
123	O
.	O
84	O
mg	O
/	O
L	O
cytochrome	B
c	I
,	O
respectively	O
,	O
under	O
anaerobic	O
conditions	O
.	O

In	O
the	O
absence	O
of	O
bacterial	O
cells	O
and	O
cytochrome	B
c	I
(	O
Cyto	O
.	O

c	O
on	O
the	O
cathode	O
,	O
three	O
-	O
way	O
Analysis	O
Of	O
Variance	O
of	O
theoretically	O
oxidized	O
lead	O
on	O
Dissolved	O
Oxygen	O
,	O
cytochrome	B
c	I
,	O
and	O
cells	O
showed	O
that	O
(	O
1	O
)	O
the	O
interaction	O
between	O
Dissolved	O
Oxygen	O
and	O
cytochrome	B
c	I
was	O
significant	O
and	O
(	O
2	O
)	O
the	O
interaction	O
between	O
Dissolved	O
Oxygen	O
and	O
cells	O
was	O
also	O
significant	O
.	O

Except	O
for	O
Dissolved	O
Oxygen	O
,	O
the	O
main	O
effects	O
of	O
the	O
two	O
other	O
factors	O
were	O
not	O
significant	O
,	O
suggesting	O
that	O
in	O
the	O
presence	O
of	O
cytochrome	B
c	I
,	O
availability	O
of	O
oxygen	O
to	O
the	O
cathode	O
is	O
crucial	O
.	O

The	O
same	O
Analysis	O
Of	O
Variance	O
with	O
aqueous	O
lead	O
concentrations	O
as	O
the	O
response	O
showed	O
that	O
the	O
interaction	O
between	O
Dissolved	O
Oxygen	O
and	O
cytochrome	B
c	I
was	O
significant	O
(	O
F_1	O
,	O
13	O
=	O
4	O
.	O
78	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
;	O
the	O
main	O
effects	O
of	O
Dissolved	O
Oxygen	O
and	O
cytochrome	B
c	I
were	O
also	O
significant	O
.	O

In	O
addition	O
,	O
a	O
hematite	O
-	O
hematite	O
galvanic	O
test	O
showed	O
that	O
cytochrome	B
c	I
,	O
without	O
oxygen	O
,	O
cannot	O
ennoble	O
iron	O
oxide	O
.	O

The	O
UV	O
-	O
vis	O
absorption	O
spectra	O
show	O
peaks	O
near	O
520	O
and	O
550	O
nm	O
emerging	O
after	O
the	O
reaction	O
of	O
cytochrome	B
c	I
on	O
the	O
cathode	O
(	O
B	O
)	O
,	O
implying	O
the	O
reduction	O
of	O
cytochrome	B
c	I
.	O

^	O
This	O
evidence	O
leads	O
to	O
the	O
conclusions	O
that	O
during	O
these	O
corrosion	O
tests	O
(	O
1	O
)	O
cytochrome	B
c	I
can	O
be	O
oxidized	O
by	O
Dissolved	O
Oxygen	O
and	O
(	O
2	O
)	O
cytochrome	B
c	I
may	O
have	O
mediated	O
electron	O
transfer	O
from	O
a	O
more	O
reduced	O
cathode	O
to	O
Dissolved	O
Oxygen	O
and	O
thus	O
facilitated	O
the	O
oxidation	O
of	O
the	O
cathode	O
by	O
Dissolved	O
Oxygen	O
.	O

Moreover	O
,	O
the	O
SEC	O
ICP	O
-	O
MS	O
chromatograms	O
(	O
A	O
)	O
indicate	O
that	O
cytochrome	B
c	I
dramatically	O
alters	O
the	O
apparent	O
molecular	O
weight	O
distribution	O
of	O
lead	O
.	O

Although	O
present	O
at	O
a	O
low	O
level	O
,	O
cytochrome	B
c	I
may	O
be	O
better	O
able	O
to	O
complex	O
with	O
lead	O
compared	O
to	O
alginate	O
,	O
perhaps	O
due	O
to	O
its	O
relatively	O
small	O
size	O
(	O
12	O
000	O
Daltons	O
)	O
.	O

Thus	O
,	O
it	O
is	O
reasonable	O
to	O
assume	O
that	O
cytochrome	B
c	I
may	O
have	O
also	O
complexed	O
ferrous	O
ions	O
,	O
assisting	O
the	O
cathode	O
to	O
revert	O
to	O
the	O
oxidized	O
condition	O
.	O

c	O
on	O
the	O
anode	O
,	O
a	O
three	O
-	O
way	O
Analysis	O
Of	O
Variance	O
of	O
theoretically	O
oxidized	O
lead	O
on	O
Dissolved	O
Oxygen	O
,	O
cytochrome	B
c	I
,	O
and	O
cells	O
showed	O
that	O
all	O
the	O
interactions	O
were	O
not	O
significant	O
and	O
only	O
the	O
main	O
effect	O
of	O
Dissolved	O
Oxygen	O
was	O
significant	O
.	O

In	O
contrast	O
,	O
Analysis	O
Of	O
Variance	O
with	O
measured	O
lead	O
concentrations	O
as	O
the	O
response	O
showed	O
that	O
the	O
interaction	O
between	O
cytochrome	B
c	I
and	O
cells	O
was	O
significant	O
and	O
the	O
main	O
effects	O
of	O
cytochrome	B
c	I
(	O
F_1	O
,	O
13	O
=	O
42	O
.	O
23	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
cells	O
(	O
F_1	O
,	O
13	O
=	O
12	O
.	O
99	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
were	O
also	O
significant	O
.	O

When	O
the	O
cathode	O
was	O
under	O
anaerobic	O
condition	O
,	O
the	O
corrosion	O
current	O
in	O
the	O
presence	O
of	O
cytochrome	B
c	I
generally	O
fell	O
in	O
the	O
low	O
range	O
,	O
below	O
3	O
A	O
,	O
as	O
evident	O
from	O
(	O
sEPS	O
on	O
Pb	O
,	O
C	O
&	O
D	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
(	O
1	O
)	O
galvanic	O
current	O
cannot	O
reveal	O
the	O
effect	O
of	O
cytochrome	B
c	I
and	O
its	O
interaction	O
with	O
DO	O
/	O
cells	O
on	O
the	O
anode	O
and	O
(	O
2	O
)	O
when	O
cytochrome	B
c	I
is	O
in	O
contact	O
with	O
lead	O
,	O
it	O
encourages	O
non	O
-	O
galvanic	O
corrosion	O
.	O

The	O
lead	O
-	O
lead	O
galvanic	O
test	O
with	O
cytochrome	B
c	I
supports	O
the	O
idea	O
that	O
cytochrome	B
c	I
can	O
accept	O
electrons	O
from	O
lead	O
.	O

Although	O
an	O
environmental	O
biofilm	O
actively	O
conducting	O
dissimilatory	O
metal	O
oxide	O
reduction	O
usually	O
contains	O
a	O
fraction	O
of	O
oxidized	O
cytochrome	B
c	I
,	O
^	O
microorganisms	O
involved	O
in	O
a	O
corrosion	O
reaction	O
may	O
directly	O
oxidize	O
metal	O
surfaces	O
with	O
the	O
assistance	O
of	O
oxidized	O
cytochrome	B
c	I
.	O

^	O
,	O
,	O
,	O
,	O
,	O
Together	O
with	O
its	O
lead	O
-	O
binding	O
ability	O
(	O
A	O
)	O
,	O
the	O
current	O
work	O
suggests	O
that	O
electrochemically	O
active	O
proteins	O
,	O
such	O
as	O
cytochrome	B
c	I
,	O
may	O
result	O
in	O
localized	O
non	O
-	O
galvanic	O
corrosion	O
of	O
lead	O
.	O

This	O
direct	O
electron	O
transfer	O
might	O
have	O
relied	O
on	O
either	O
cytoplasmic	O
membrane	O
-	O
associated	O
or	O
extracellular	O
cytochrome	B
c	I
.	O

Sodium	O
alginate	O
and	O
bovine	O
serum	O
albumin	O
were	O
employed	O
as	O
models	O
for	O
polysaccharides	O
and	O
proteins	O
in	O
Extracellular	O
Polymeric	O
Substances	O
,	O
respectively	O
;	O
cytochrome	B
c	I
was	O
used	O
to	O
represent	O
electrochemically	O
active	O
small	O
-	O
sized	O
proteins	O
in	O
Extracellular	O
Polymeric	O
Substances	O
.	O

Within	O
each	O
group	O
,	O
three	O
different	O
sEPS	O
conditions	O
were	O
examined	O
:	O
100	O
mg	O
/	O
L	O
alginate	O
+	O
100	O
mg	O
/	O
L	O
Bovine	O
Serum	O
Albumin	O
(	O
labeled	O
sEPS1	O
)	O
;	O
200	O
mg	O
/	O
L	O
alginate	O
+	O
200	O
mg	O
/	O
L	O
Bovine	O
Serum	O
Albumin	O
(	O
labeled	O
sEPS2	O
)	O
;	O
and	O
100	O
mg	O
/	O
L	O
alginate	O
+	O
100	O
mg	O
/	O
L	O
Bovine	O
Serum	O
Albumin	O
+	O
123	O
.	O
84	O
mg	O
/	O
L	O
cytochrome	B
c	I
(	O
C7752	O
,	O
Sigma	O
-	O
Aldrich	O
)	O
(	O
labeled	O
Cyto	O
.	O

The	O
concentration	O
of	O
cytochrome	B
c	I
was	O
determined	O
according	O
to	O
a	O
previous	O
study	O
on	O
Geobacter	O
species	O
.	O

In	O
the	O
presence	O
of	O
cytochrome	B
c	I
and	O
cells	O
,	O
three	O
-	O
way	O
Analysis	O
Of	O
Variance	O
was	O
applied	O
to	O
examine	O
the	O
main	O
effects	O
of	O
Dissolved	O
Oxygen	O
(	O
anaerobic	O
and	O
aerobic	O
)	O
,	O
cytochrome	B
c	I
(	O
sEPS1	O
and	O
Cyto	O
.	O

Flakes	O
of	O
cytochrome	B
c	I
were	O
dissolved	O
in	O
the	O
base	O
electrolyte	O
when	O
needed	O
.	O

The	O
experiment	O
was	O
run	O
following	O
these	O
steps	O
:	O
de	O
-	O
aeration	O
,	O
equilibrium	O
current	O
(	O
ie	O
,	O
zero	O
current	O
)	O
collection	O
for	O
3	O
h	O
,	O
disconnection	O
,	O
injection	O
of	O
a	O
specified	O
amount	O
of	O
sEPS	O
/	O
cytochrome	B
c	I
stock	O
solution	O
to	O
the	O
control	O
side	O
(	O
connected	O
to	O
the	O
COM	O
port	O
)	O
,	O
de	O
-	O
aeration	O
of	O
the	O
control	O
side	O
,	O
and	O
current	O
collection	O
for	O
another	O
3	O
h	O
.	O
A	O
half	O
level	O
of	O
cytochrome	B
c	I
was	O
used	O
(	O
61	O
.	O
92	O
mg	O
/	O
L	O
)	O
.	O

Although	O
the	O
cytochrome	B
c	I
oxidase	O
subunit	O
1	O
(	O
COI	O
)	O
is	O
a	O
marker	O
of	O
choice	O
for	O
single	O
animal	O
specimen	O
DNA	O
barcoding	O
(	O
see	O
BOLD	O
,	O
)	O
,	O
its	O
interest	O
has	O
been	O
disputed	O
for	O
DNA	O
metabarcoding	O
studies	O
.	O

For	O
example	O
,	O
the	O
subunits	O
of	O
cytochrome	B
c	I
reductase	O
(	O
QcrCAB	O
;	O
MSMEG_4261	O
-	O
4263	O
)	O
and	O
aa_3	O
cytochrome	B
c	I
oxidase	O
(	O
CtaC	O
;	O
MSMEG_4268	O
)	O
,	O
as	O
well	O
as	O
the	O
subunits	O
of	O
H	O
^	O
+	O
-	O
ATPases	O
(	O
eg	O
,	O
alfa	O
,	O
beta	O
,	O
H	O
,	O
F	O
,	O
and	O
A	O
;	O
MSMEG_4938	O
,	O
MSMEG_4936	O
,	O
MSMEG_4939	O
,	O
MSMEG_4940	O
,	O
MSMEG_4942	O
,	O
respectively	O
)	O
are	O
enriched	O
in	O
the	O
PM	O
-	O
CW	O
proteome	O
.	O

Moreover	O
,	O
it	O
also	O
induced	O
cytochrome	B
c	I
release	O
from	O
the	O
mitochondria	O
to	O
the	O
cytoplasm	O
and	O
metacaspase	O
activation	O
.	O

Moreover	O
,	O
a	O
loss	O
of	O
cytochrome	B
c	I
synthesis	O
(	O
or	O
depletion	O
of	O
its	O
levels	O
within	O
the	O
cells	O
)	O
also	O
results	O
in	O
apoptosis	O
.	O

To	O
analyze	O
cytosolic	O
and	O
mitochondrial	O
cytochrome	B
c	I
levels	O
,	O
the	O
obtained	O
supernatant	O
was	O
centrifuged	O
at	O
50	O
,	O
000	O
rpm	O
for	O
45	O
min	O
.	O

The	O
released	O
cytoplasmic	O
cytochrome	B
c	I
was	O
measured	O
in	O
the	O
supernatant	O
.	O

After	O
treatment	O
with	O
500	O
mg	O
/	O
mL	O
ascorbic	O
acid	O
for	O
5	O
min	O
,	O
the	O
cytochrome	B
c	I
content	O
in	O
the	O
cytoplasmic	O
or	O
mitochondrial	O
samples	O
was	O
determined	O
by	O
spectrophotometric	O
analysis	O
at	O
550	O
nm	O
.	O

Here	O
,	O
the	O
translocation	O
of	O
cytochrome	B
c	I
from	O
the	O
mitochondria	O
and	O
metacaspase	O
activity	O
were	O
examined	O
.	O

Compared	O
to	O
the	O
control	O
cells	O
,	O
the	O
relative	O
levels	O
of	O
cytosolic	O
cytochrome	B
c	I
were	O
observed	O
to	O
have	O
increased	O
while	O
mitochondrial	O
cytochrome	B
c	I
contents	O
were	O
simultaneously	O
observed	O
to	O
have	O
decreased	O
upon	O
coumarin	O
treatment	O
,	O
thereby	O
revealing	O
that	O
coumarin	O
triggered	O
the	O
release	O
of	O
cytochrome	B
c	I
from	O
the	O
mitochondria	O
to	O
the	O
cytosol	O
.	O

Mitochondria	O
also	O
play	O
an	O
important	O
role	O
in	O
yeast	O
apoptosis	O
since	O
this	O
organelle	O
is	O
the	O
major	O
site	O
for	O
ROS	O
production	O
and	O
contains	O
many	O
proapoptotic	O
factors	O
such	O
as	O
cytochrome	B
c	I
,	O
Aif1p	O
,	O
and	O
Nuc1p	O
(	O
Pereira	O
et	O
al	O
.	O
,	O
.	O

To	O
study	O
the	O
pattern	O
of	O
cell	O
death	O
,	O
the	O
features	O
of	O
yeast	O
apoptosis	O
were	O
determined	O
,	O
including	O
PS	O
externalization	O
,	O
DNA	O
fragmentation	O
,	O
cytochrome	B
c	I
release	O
,	O
and	O
metacaspase	O
activation	O
(	O
Carmona	O
-	O
Gutierrez	O
et	O
al	O
.	O
,	O
.	O

The	O
results	O
showed	O
that	O
coumarin	O
treatment	O
led	O
to	O
PS	O
exposure	O
on	O
the	O
outer	O
leaflet	O
,	O
DNA	O
fragmentation	O
and	O
nuclear	O
condensation	O
,	O
cytochrome	B
c	I
release	O
from	O
the	O
mitochondria	O
to	O
the	O
cytosol	O
,	O
and	O
metacaspase	O
activation	O
,	O
suggesting	O
that	O
coumarin	O
induced	O
apoptosis	O
in	O
C	O
.	O
albicans	O
.	O

During	O
apoptosis	O
,	O
oxidative	O
stress	O
induces	O
the	O
mitochondrial	O
permeability	O
transition	O
pore	O
(	O
PTP	O
)	O
to	O
open	O
,	O
which	O
then	O
triggers	O
the	O
mitochondrial	O
outer	O
membrane	O
permeabilization	O
(	O
MOMP	O
)	O
that	O
is	O
involved	O
in	O
the	O
release	O
of	O
cytochrome	B
c	I
and	O
other	O
proapoptotic	O
factors	O
,	O
leading	O
to	O
subsequent	O
metacaspase	O
activation	O
(	O
Simon	O
et	O
al	O
.	O
,	O
.	O

Under	O
oxidative	O
stress	O
,	O
this	O
Ca	O
^	O
2	O
+	O
signal	O
can	O
lead	O
to	O
PTP	O
opening	O
and	O
release	O
of	O
cytochrome	B
c	I
and	O
other	O
proapoptotic	O
factors	O
,	O
which	O
ultimately	O
results	O
in	O
the	O
formation	O
of	O
apoptotic	O
bodies	O
and	O
cell	O
death	O
.	O

LY	O
,	O
CW	O
,	O
and	O
YY	O
participated	O
in	O
measuring	O
ROS	O
,	O
Ca	O
^	O
2	O
+	O
levels	O
,	O
cytochrome	B
c	I
contents	O
,	O
and	O
metacasapse	O
activity	O
.	O

Comparative	O
genomic	O
studies	O
of	O
the	O
bacterial	O
MFS	O
-	O
type	O
copper	O
importer	O
CcoA	O
,	O
required	O
for	O
cbb3	O
-	O
type	O
cytochrome	B
c	I
oxidase	O
(	O
cbb3	O
-	O
Cox	O
)	O
biogenesis	O
,	O
revealed	O
a	O
widespread	O
CcoA	O
-	O
like	O
transporters	O
family	O
,	O
containing	O
the	O
conserved	O
CcoA	O
Cu	O
-	O
binding	O
MxxxM	O
and	O
HxxxM	O
motifs	O
.	O

Earlier	O
genetic	O
and	O
biochemical	O
studies	O
unequivocally	O
established	O
that	O
CcoA	O
imports	O
Cu	O
destined	O
to	O
the	O
catalytic	O
site	O
(	O
Cu_B	O
center	O
)	O
of	O
the	O
cbb_3	O
-	O
type	O
cytochrome	B
c	I
oxidases	O
(	O
cbb_3	O
-	O
Cox	O
)	O
,	O
where	O
O_2	O
is	O
reduced	O
to	O
H_2O	O
during	O
aerobic	O
respiration	O
^	O
-	O
.	O

The	O
third	O
neighborhood	O
N3	O
(	O
green	O
triangles	O
in	O
Fig	O
)	O
contained	O
genes	O
encoding	O
a	O
BamE	O
-	O
like	O
outer	O
membrane	O
protein	O
assembly	O
factor	O
(	O
PF04355	O
)	O
,	O
a	O
putative	O
ubiquinol	O
-	O
cytochrome	B
c	I
oxidoreductase	O
(	O
cytochrome	O
bc_1	O
complex	O
)	O
chaperone	O
(	O
PF03981	O
)	O
,	O
a	O
putative	O
thiamine	O
-	O
monophosphate	O
kinase	O
(	O
PF00586	O
-	O
PF02769	O
)	O
and	O
/	O
or	O
a	O
putative	O
6	O
,	O
7	O
-	O
dimethyl	O
-	O
8	O
-	O
ribityllumazine	O
synthase	O
(	O
ribH	O
involved	O
in	O
riboflavin	O
biosynthesis	O
,	O
PF00885	O
)	O
.	O

The	O
Riboflavin	O
Biosynthesis	O
Pathway	O
protein	O
RibH	O
,	O
BamE	O
-	O
like	O
outer	O
membrane	O
protein	O
assembly	O
factor	O
,	O
and	O
ubiquinol	O
-	O
cytochrome	B
c	I
oxidoreductase	O
chaperone	O
from	O
N3	O
were	O
enriched	O
at	O
the	O
family	O
,	O
but	O
not	O
at	O
the	O
order	O
level	O
(	O
SI	O
Table	O
.	O

Notably	O
,	O
some	O
Called	O
Rfnt	O
genes	O
located	O
in	O
neighborhood	O
N3	O
were	O
found	O
to	O
be	O
associated	O
with	O
a	O
gene	O
encoding	O
a	O
putative	O
chaperone	O
of	O
ubiquinol	O
-	O
cytochrome	B
c	I
oxidoreductase	O
.	O

To	O
200	O
L	O
of	O
diluted	O
cell	O
lysate	O
in	O
0	O
.	O
3	O
mol	O
L	O
^	O
1	O
potassium	O
phosphate	O
buffer	O
at	O
pH	O
7	O
.	O
7	O
containing	O
40	O
mol	O
L	O
^	O
1	O
cytochrome	B
c	I
,	O
100	O
mol	O
L	O
^	O
1	O
NADPH	O
was	O
added	O
to	O
initiate	O
the	O
reduction	O
of	O
cytochrome	B
c	I
and	O
the	O
reaction	O
was	O
followed	O
at	O
550	O
nm	O
and	O
23C	O
.	O

The	O
reaction	O
rate	O
was	O
calculated	O
using	O
an	O
extinction	O
coefficient	O
of	O
e_550	O
nm	O
of	O
21	O
mmol	O
L	O
^	O
1	O
cm	O
^	O
1	O
for	O
reduced	O
cytochrome	B
c	I
.	O
POR	O
activity	O
was	O
converted	O
to	O
POR	O
content	O
based	O
on	O
the	O
assumption	O
that	O
3000	O
nmol	O
of	O
cytochrome	B
c	I
is	O
reduced	O
/	O
min	O
per	O
nmol	O
POR	O
at	O
23C	O
.	O
,	O
All	O
incubations	O
were	O
carried	O
out	O
in	O
96well	O
PCR	O
plates	O
in	O
50	O
L	O
total	O
volume	O
at	O
37C	O
,	O
as	O
previously	O
described	O
.	O

This	O
enhancement	O
was	O
ultra	O
-	O
structurally	O
verified	O
via	O
observation	O
of	O
trapped	O
mitochondria	O
within	O
LC3	O
-	O
labeled	O
membranes	O
,	O
upregulation	O
of	O
LC3	O
protein	O
levels	O
,	O
colocalization	O
of	O
LC3	O
and	O
cytochrome	B
c	I
,	O
and	O
reduced	O
expression	O
of	O
mitochondrial	O
proteins	O
.	O

The	O
following	O
primary	O
antibodies	O
were	O
used	O
:	O
Rabbit	O
anti	O
-	O
LC3B	O
antibody	O
(	O
PM063	O
)	O
from	O
MBL	O
,	O
Nagoya	O
,	O
Japan	O
;	O
rabbit	O
anti	O
-	O
PINK1	O
(	O
BC100	O
-	O
494	O
)	O
,	O
rabbit	O
anti	O
-	O
Parkin	O
(	O
NB100	O
-	O
91921	O
)	O
,	O
and	O
mouse	O
anti	O
-	O
p62	O
(	O
H00008878	O
-	O
M01	O
)	O
antibodies	O
from	O
Novus	O
Biologicals	O
(	O
Briarwood	O
Avenue	O
,	O
Building	O
IV	O
Centennial	O
,	O
CO	O
,	O
USA	O
)	O
;	O
goat	O
anti	O
-	O
pan	O
-	O
cathepsin	O
(	O
sc	O
-	O
6499	O
)	O
,	O
mouse	O
anti	O
-	O
Parkin	O
(	O
sc	O
-	O
32282	O
)	O
,	O
mouse	O
anti	O
-	O
Actin	O
(	O
sc	O
-	O
47778	O
)	O
,	O
and	O
mouse	O
anti	O
-	O
cytochrome	B
c	I
(	O
7H8	O
)	O
:	O
(	O
sc	O
-	O
13560	O
)	O
antibodies	O
from	O
Santa	O
Cruz	O
Biologicals	O
(	O
Dallas	O
,	O
TX	O
,	O
USA	O
)	O
;	O
rabbit	O
anti	O
-	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
and	O
rabbit	O
anti	O
-	O
iNOS	O
(	O
ab15323	O
)	O
antibodies	O
from	O
Abcam	O
Biologicals	O
(	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
;	O
rabbit	O
anti	O
-	O
TFEB	O
(	O
MBS9125929	O
)	O
from	O
MyBioSource	O
Biologicals	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
;	O
and	O
rabbit	O
anti	O
-	O
Cytochrome	B
c	I
oxidase	O
(	O
COX	O
)	O
IV	O
(	O
3E11	O
)	O
from	O
cell	O
signaling	O
Biologicals	O
(	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
.	O

For	O
double	O
labeling	O
of	O
LC3	O
with	O
either	O
cytochrome	B
c	I
(	O
a	O
mitochondrial	O
marker	O
)	O
or	O
p62	O
,	O
we	O
used	O
a	O
simultaneous	O
application	O
of	O
two	O
primary	O
antibodies	O
followed	O
by	O
Alexa	O
Fluor	O
594	O
and	O
488	O
-	O
conjugated	O
secondary	O
antibodies	O
.	O

Proteins	O
were	O
detected	O
with	O
the	O
specific	O
primary	O
antibodies	O
for	O
LC3	O
,	O
cytochrome	B
c	I
,	O
Parkin	O
,	O
TFEB	O
,	O
COX	O
IV	O
,	O
and	O
iNOS	O
,	O
and	O
then	O
with	O
specific	O
peroxidase	O
-	O
labeled	O
secondary	O
antibodies	O
as	O
previously	O
reported	O
.	O

Double	O
-	O
labeling	O
with	O
IF	O
LC3	O
and	O
cytochrome	B
c	I
revealed	O
enhanced	O
co	O
-	O
localization	O
in	O
ETR	O
SCs	O
(	O
A	O
)	O
,	O
indicating	O
the	O
formation	O
of	O
mitophagosomes	O
as	O
reported	O
in	O
past	O
studies	O
.	O

Western	O
blot	O
and	O
analysis	O
(	O
B	O
,	O
C	O
)	O
showed	O
a	O
significant	O
reduction	O
of	O
cytochrome	B
c	I
(	O
15	O
kDa	O
)	O
,	O
indicating	O
mitochondrial	O
damage	O
within	O
Mversus	O
Additional	O
Western	O
blot	O
analysis	O
showed	O
that	O
the	O
expression	O
level	O
of	O
COX	O
IV	O
(	O
17	O
kDa	O
)	O
(	O
inner	O
mitochondrial	O
membrane	O
protein	O
)	O
was	O
also	O
reduced	O
in	O
testes	O
of	O
ETRs	O
(	O
D	O
,	O
E	O
)	O
.	O

Enhanced	O
autophagic	O
clearance	O
of	O
damaged	O
mitochondria	O
within	O
MVs	O
of	O
ETR	O
SCs	O
in	O
the	O
current	O
study	O
is	O
evidenced	O
by	O
engulfment	O
of	O
these	O
mitochondria	O
by	O
LC3	O
-	O
II	O
-	O
decorated	O
autophagosomal	O
membranes	O
,	O
enhanced	O
co	O
-	O
localization	O
of	O
LC3	O
with	O
cytochrome	B
c	I
and	O
p62	O
,	O
and	O
reduced	O
cytochrome	B
c	I
protein	O
levels	O
.	O

By	O
checking	O
available	O
publications	O
,	O
we	O
have	O
found	O
the	O
following	O
enzymes	O
that	O
have	O
been	O
reported	O
as	O
ETC	O
components	O
under	O
anaerobic	O
conditions	O
:	O
FADH_2	O
-	O
NAD	O
oxidoreductase	O
Rnf	O
;	O
membrane	O
-	O
bound	O
hydrogenases	O
Ech	O
and	O
Mbh	O
;	O
methyltransferase	O
Mtr	O
;	O
NADH	O
dehydrogenases	O
Nuo	O
,	O
Ndh	O
,	O
and	O
Hox	O
;	O
cytochrome	B
c	I
reductase	O
Pet	O
and	O
TorC	O
;	O
cytochrome	O
bd	O
oxidase	O
Cyd	O
;	O
sulfate	O
reductase	O
Apr	O
;	O
nitrite	O
reductase	O
NrfA	O
;	O
nitrate	O
reductases	O
Nar	O
and	O
NapA	O
;	O
fumarate	O
reductase	O
Sdh	O
;	O
and	O
cytochrome	O
o	O
oxidase	O
Cyo	O
(	O
;	O
.	O

Second	O
,	O
the	O
abundance	O
of	O
cytochrome	B
c	I
reductase	O
(	O
Pet	O
and	O
torC	O
)	O
and	O
sulfate	O
reductase	O
Apr	O
was	O
less	O
than	O
1	O
in	O
all	O
samples	O
,	O
and	O
the	O
species	O
whose	O
genomes	O
encoded	O
it	O
were	O
not	O
detected	O
in	O
this	O
study	O
.	O

We	O
therefore	O
speculated	O
that	O
the	O
species	O
whose	O
genomes	O
encoded	O
cytochrome	B
c	I
reductase	O
and	O
Apr	O
could	O
not	O
be	O
present	O
in	O
the	O
ruminal	O
microbiome	O
.	O

The	O
OxLDL	O
mediated	O
ROS	O
generated	O
triggers	O
the	O
cytochrome	B
c	I
mediated	O
apoptosis	O
cascade	O
leading	O
to	O
cellular	O
death	O
and	O
debris	O
accumulation	O
(	O
Leiva	O
et	O
al	O
.	O
,	O
.	O

The	O
Surface	O
-	O
Enhanced	O
Raman	O
Scattering	O
spectra	O
of	O
hen	O
egg	O
white	O
lysozyme	O
,	O
avidin	O
,	O
cytochrome	B
c	I
,	O
hemoglobin	O
,	O
and	O
Bovine	O
Serum	O
Albumin	O
,	O
recorded	O
using	O
these	O
nanoparticles	O
,	O
are	O
similar	O
to	O
the	O
Raman	O
ones	O
recorded	O
in	O
solution	O
or	O
in	O
solid	O
samples	O
.	O

Here	O
,	O
we	O
report	O
a	O
quantum	O
biological	O
electron	O
tunnelling	O
junction	O
and	O
its	O
application	O
in	O
real	O
-	O
time	O
optical	O
detection	O
of	O
Quantum	O
Biological	O
Electron	O
Tunnelling	O
and	O
the	O
dynamics	O
of	O
Electron	O
Transfer	O
in	O
mitochondrial	O
cytochrome	B
c	I
during	O
cell	O
life	O
and	O
death	O
process	O
.	O

Using	O
Quantum	O
Biological	O
Electron	O
Tunnelling	O
spectroscopy	O
,	O
we	O
optically	O
capture	O
real	O
-	O
time	O
Electron	O
Transfer	O
in	O
cytochrome	B
c	I
redox	O
dynamics	O
during	O
cellular	O
apoptosis	O
and	O
necrosis	O
in	O
living	O
cells	O
.	O

Here	O
,	O
the	O
authors	O
demonstrate	O
real	O
-	O
time	O
optical	O
detection	O
of	O
quantum	O
biological	O
electron	O
tunnelling	O
between	O
nanoparticles	O
and	O
cytochrome	B
c	I
inside	O
living	O
cells	O
.	O

Here	O
,	O
we	O
report	O
the	O
first	O
observation	O
of	O
Quantum	O
Biological	O
Electron	O
Tunnelling	O
in	O
living	O
enzyme	O
cytochrome	B
c	I
(	O
Cyt	O
c	O
)	O
,	O
which	O
plays	O
key	O
functions	O
in	O
many	O
metabolic	O
processes	O
as	O
well	O
as	O
life	O
and	O
death	O
decisions	O
,	O
such	O
as	O
respiration	O
^	O
,	O
,	O
apoptosis	O
activation	O
^	O
,	O
the	O
regulation	O
of	O
many	O
diseases	O
,	O
such	O
as	O
diabetes	O
^	O
and	O
neurodegenerative	O
disorders	O
^	O
.	O

Consequently	O
,	O
some	O
of	O
these	O
proteins	O
,	O
namely	O
,	O
cytochrome	B
c	I
(	O
Cyt	O
c	O
)	O
and	O
hemoglobin	O
,	O
were	O
also	O
tested	O
for	O
peroxide	O
inactivation	O
and	O
were	O
found	O
to	O
behave	O
in	O
a	O
similar	O
manner	O
as	O
Horseradish	O
Peroxidase	O
(	O
A	O
,	O
B	O
)	O
.	O

Cyanide	O
was	O
also	O
used	O
to	O
inhibit	O
cytochrome	B
c	I
oxidase	O
,	O
preventing	O
the	O
transport	O
of	O
electrons	O
from	O
cytochrome	B
c	I
to	O
oxygen	O
.	O

This	O
complex	O
has	O
two	O
unique	O
characteristics	O
:	O
(	O
i	O
)	O
it	O
lacks	O
an	O
extracellular	O
cytochrome	B
c	I
,	O
and	O
(	O
ii	O
)	O
the	O
periplasmic	O
decaheme	O
cytochrome	B
c	I
undergoes	O
proteolytic	O
cleavage	O
to	O
produce	O
a	O
functional	O
electron	O
transfer	O
protein	O
.	O

Using	O
Rhodopseudomonas	O
palustris	O
TIE	O
-	O
1	O
as	O
a	O
model	O
,	O
we	O
show	O
that	O
a	O
single	O
periplasmic	O
decaheme	O
cytochrome	B
c	I
,	O
PioA	O
,	O
and	O
an	O
outer	O
membrane	O
porin	O
,	O
PioB	O
,	O
form	O
a	O
complex	O
allowing	O
extracellular	O
electron	O
uptake	O
across	O
the	O
outer	O
membrane	O
from	O
both	O
soluble	O
iron	O
and	O
poised	O
electrodes	O
.	O

The	O
Shewanella	O
complex	O
is	O
comprised	O
of	O
a	O
porin	O
(	O
MtrB	O
)	O
and	O
two	O
decaheme	O
cytochrome	B
c	I
proteins	O
(	O
MtrA	O
and	O
MtrC	O
from	O
periplasmic	O
and	O
extracellular	O
sides	O
,	O
respectively	O
)	O
as	O
an	O
electron	O
conduit	O
.	O

Deletion	O
of	O
the	O
extracellular	O
decaheme	O
cytochrome	B
c	I
component	O
of	O
the	O
conduit	O
(	O
MtrC	O
and	O
its	O
paralogues	O
,	O
OmcA	O
and	O
MtrF	O
)	O
abrogates	O
Shewanellas	O
ability	O
to	O
reduce	O
Fe	O
(	O
III	O
)	O
or	O
transfer	O
electrons	O
to	O
electrodes	O
.	O

The	O
operon	O
encodes	O
PioA	O
,	O
a	O
decaheme	O
cytochrome	B
c	I
(	O
cyt	O
c	O
)	O
,	O
PioB	O
,	O
an	O
outer	O
membrane	O
porin	O
,	O
and	O
PioC	O
,	O
a	O
high	O
-	O
potential	O
iron	O
-	O
sulfur	O
protein	O
.	O

Therefore	O
,	O
the	O
PioAB	O
complex	O
is	O
distinct	O
from	O
other	O
porin	O
-	O
cytochrome	B
c	I
systems	O
found	O
in	O
nonphototrophic	O
bacteria	O
.	O

For	O
correct	O
localization	O
of	O
the	O
protein	O
in	O
E	O
.	O
colis	O
periplasm	O
,	O
we	O
replaced	O
the	O
PioA	O
signal	O
peptide	O
with	O
a	O
validated	O
signal	O
peptide	O
of	O
the	O
cytochrome	O
c_4	O
gene	O
.	O

Bacterial	O
respiration	O
takes	O
place	O
via	O
respiratory	O
chain	O
mechanism	O
consisting	O
of	O
(	O
i	O
)	O
NADH	O
-	O
quinone	O
oxidoreductase	O
,	O
(	O
ii	O
)	O
succinate	O
dehydrogenase	O
,	O
(	O
iii	O
)	O
cytochrome	B
c	I
oxidoreductase	O
and	O
(	O
iv	O
)	O
cytochrome	B
c	I
oxidase	O
.	O

Various	O
peroxidases	O
use	O
FAD	O
-	O
linked	O
oxidase	O
,	O
cytochrome	B
c	I
oxidase	O
and	O
H_2O_2	O
generated	O
by	O
them	O
for	O
dynamic	O
participation	O
in	O
LDCs	O
degradation	O
.	O

A	O
mutant	O
strain	O
of	O
Methanosarcina	O
mazei	O
lacking	O
the	O
gene	O
MM_0633	O
encoding	O
for	O
the	O
multi	O
-	O
heme	O
cytochrome	B
c	I
family	O
protein	O
(	O
mutant	O
name	O
-	O
M	O
.	O
mazei	O
633	O
k	O
.	O
o	O
.	O
)	O

Part	O
of	O
the	O
RpoS	O
regulon	O
are	O
genes	O
for	O
the	O
cytochrome	B
c	I
oxidase	O
,	O
which	O
is	O
thought	O
to	O
be	O
most	O
likely	O
responsible	O
for	O
cell	O
growth	O
with	O
oxygen	O
,	O
but	O
genes	O
for	O
a	O
cytochrome	O
d	O
ubiquinol	O
oxidase	O
and	O
a	O
rubredoxin	O
-	O
oxygen	O
oxidoreductase	O
have	O
also	O
been	O
found	O
to	O
be	O
regulated	O
by	O
RpoS	O
and	O
encode	O
for	O
enzymes	O
that	O
may	O
play	O
a	O
role	O
in	O
oxygen	O
reduction	O
.	O

Usually	O
in	O
aerobic	O
bacteria	O
,	O
cytochrome	O
bc1	O
complex	O
and	O
cytochrome	B
c	I
oxidase	O
,	O
which	O
represent	O
complexes	O
III	O
and	O
IV	O
of	O
the	O
oxidative	O
phosphorylation	O
pathway	O
,	O
are	O
responsible	O
for	O
the	O
transportation	O
of	O
electrons	O
from	O
the	O
membrane	O
bound	O
quinon	O
pool	O
to	O
a	O
cytochrome	B
c	I
,	O
which	O
then	O
functions	O
as	O
electron	O
donor	O
for	O
the	O
reduction	O
of	O
oxygen	O
to	O
water	O
.	O

The	O
cytochrome	B
c	I
oxidase	O
was	O
formerly	O
suspected	O
to	O
be	O
the	O
enzyme	O
responsible	O
for	O
oxygen	O
reduction	O
in	O
G	O
.	O
sulfurreducens	O
.	O

These	O
authors	O
even	O
reported	O
that	O
cell	O
growth	O
with	O
oxygen	O
was	O
impossible	O
without	O
cytochrome	B
c	I
oxidase	O
(	O
W	O
.	O
Lin	O
,	O
unpublished	O
results	O
according	O
to	O
)	O
.	O

This	O
organism	O
contains	O
two	O
oxygen	O
reductases	O
,	O
a	O
c	O
-	O
type	O
oxidase	O
cc	O
(	O
b	O
/	O
o	O
)	O
c_3	O
cytochrome	O
oxidase	O
)	O
and	O
a	O
bd	O
-	O
type	O
quinol	O
oxidase	O
,	O
both	O
are	O
similar	O
to	O
the	O
cytochrome	B
c	I
oxidase	O
(	O
98	O
%	O
query	O
coverage	O
and	O
61	O
.	O
12	O
%	O
identity	O
)	O
and	O
the	O
cytochrome	O
bd	O
menaquinol	O
oxidase	O
(	O
99	O
%	O
query	O
coverage	O
and	O
57	O
.	O
47	O
%	O
identity	O
)	O
of	O
G	O
.	O
sulfurreducens	O
,	O
respectively	O
(	O
determined	O
by	O
BLASTP	O
)	O
.	O

Studies	O
on	O
lung	O
cancer	O
demonstrated	O
that	O
the	O
amount	O
of	O
oxygen	O
-	O
utilizing	O
hemoproteins	O
,	O
such	O
as	O
cytoglobin	O
,	O
cytochrome	B
c	I
,	O
cytochrome	O
P450	O
family	O
1	O
subfamily	O
B	O
member	O
1	O
and	O
prostaglandin	O
-	O
endoperoxide	O
synthase	O
2	O
(	O
COX2	O
)	O
are	O
higher	O
in	O
tumor	O
cells	O
as	O
compared	O
to	O
normal	O
cells	O
and	O
that	O
,	O
at	O
least	O
for	O
cytoglobin	O
and	O
cytochrome	B
c	I
,	O
their	O
levels	O
depend	O
on	O
the	O
rate	O
of	O
heme	O
synthesis	O
and	O
cellular	O
heme	O
content	O
.	O

S	O
.	O
oneidensis	O
MR	O
-	O
1	O
encodes	O
two	O
cytochrome	B
c	I
synthetases	O
(	O
CcmF	O
and	O
SirE	O
)	O
and	O
two	O
apocytochrome	O
c	O
chaperones	O
(	O
CcmI	O
and	O
SirG	O
)	O
.	O

SO_0265	O
was	O
identified	O
as	O
ccmI	O
,	O
and	O
was	O
initially	O
determined	O
to	O
have	O
a	O
nonessential	O
role	O
in	O
cytochrome	B
c	I
maturation	O
in	O
S	O
.	O
oneidensis	O
^	O
,	O
but	O
subsequently	O
found	O
to	O
have	O
a	O
role	O
in	O
maturation	O
of	O
canonical	O
heme	O
binding	O
motifs	O
and	O
to	O
be	O
required	O
for	O
maturation	O
of	O
the	O
nitrite	O
reductase	O
,	O
NrfA	O
^	O
.	O

SirEF	O
are	O
similar	O
to	O
the	O
NrfEF	O
cytochrome	B
c	I
synthetase	O
and	O
thiol	O
-	O
oxidoreductase	O
that	O
are	O
required	O
for	O
heme	O
ligation	O
to	O
the	O
CXXCK	O
site	O
in	O
NrfA	O
(	O
31	O
)	O
.	O

These	O
results	O
indicated	O
that	O
the	O
sulfite	O
reduction	O
deficiency	O
observed	O
in	O
the	O
cytochrome	B
c	I
maturation	O
mutants	O
was	O
due	O
to	O
decreased	O
protein	O
levels	O
,	O
most	O
likely	O
due	O
to	O
instability	O
and	O
degradation	O
of	O
the	O
unmatured	O
apoprotein	O
.	O

In	O
bacteria	O
,	O
System	O
I	O
(	O
Ccm	O
)	O
or	O
System	O
II	O
(	O
Ccs	O
)	O
is	O
required	O
for	O
holocytochrome	O
c	O
maturation	O
and	O
involves	O
an	O
apocytochrome	O
c	O
chaperone	O
and	O
a	O
cytochrome	B
c	I
synthetase	O
.	O

Recently	O
,	O
CcmI_So	O
(	O
SO_0265	O
)	O
was	O
identified	O
as	O
a	O
cytochrome	B
c	I
maturation	O
protein	O
required	O
for	O
maturation	O
of	O
the	O
nitrite	O
reductase	O
NrfA	O
^	O
,	O
and	O
that	O
we	O
predicted	O
functions	O
as	O
an	O
apocytochrome	O
c	O
chaperone	O
for	O
maturation	O
of	O
the	O
sulfite	O
reductase	O
SirA	O
.	O

The	O
lack	O
of	O
a	O
dedicated	O
cytochrome	B
c	I
synthetase	O
system	O
for	O
maturation	O
of	O
the	O
nitrite	O
reductase	O
in	O
S	O
.	O
oneidensis	O
,	O
suggests	O
that	O
CcmFHI	O
may	O
form	O
the	O
heme	O
lyase	O
complex	O
responsible	O
for	O
heme	O
attachment	O
to	O
the	O
CXXCK	O
site	O
.	O

SirEF	O
,	O
which	O
are	O
similar	O
to	O
cytochrome	B
c	I
synthetases	O
(	O
CcmF	O
)	O
and	O
thiol	O
oxidoreductases	O
(	O
CcmH	O
)	O
^	O
,	O
appear	O
to	O
be	O
essential	O
for	O
sulfite	O
reductase	O
activity	O
and	O
stability	O
.	O

Our	O
results	O
suggest	O
that	O
SirA	O
requires	O
a	O
dedicated	O
cytochrome	B
c	I
synthetase	O
for	O
its	O
maturation	O
,	O
but	O
unlike	O
other	O
c	O
-	O
type	O
cytochromes	O
studied	O
to	O
date	O
,	O
it	O
appears	O
to	O
require	O
two	O
apocytochrome	O
c	O
chaperones	O
for	O
this	O
process	O
.	O

Our	O
results	O
described	O
above	O
,	O
in	O
combination	O
with	O
previously	O
published	O
findings	O
,	O
indicate	O
an	O
unusual	O
cytochrome	B
c	I
maturation	O
system	O
in	O
S	O
.	O
oneidensis	O
.	O

These	O
findings	O
add	O
another	O
twist	O
to	O
the	O
already	O
complex	O
mechanism	O
of	O
cytochrome	B
c	I
maturation	O
in	O
bacteria	O
.	O

On	O
the	O
other	O
hand	O
,	O
Ferredoxin	O
did	O
not	O
stimulate	O
the	O
formation	O
of	O
O_2	O
^	O
measured	O
using	O
O_2	O
^	O
traps	O
such	O
as	O
epinephrine	O
or	O
cytochrome	B
c	I
.	O
This	O
suggests	O
that	O
the	O
formation	O
of	O
O_2	O
^	O
by	O
exogenous	O
Ferredoxin	O
is	O
very	O
slow	O
in	O
comparison	O
to	O
the	O
formation	O
of	O
O_2	O
^	O
by	O
thylakoid	O
-	O
bound	O
photoreductants	O
.	O

Formation	O
of	O
21	O
mol	O
O_2	O
^	O
(	O
mg	O
Chl	O
)	O
^	O
1	O
h	O
^	O
1	O
,	O
measured	O
as	O
an	O
SOD	O
-	O
dependent	O
cytochrome	B
c	I
reduction	O
,	O
was	O
observed	O
in	O
D1	O
/	O
D2	O
/	O
cytochrome	O
b559	O
complexes	O
illuminated	O
at	O
200	O
W	O
m	O
^	O
2	O
in	O
the	O
presence	O
of	O
an	O
artificial	O
electron	O
donor	O
.	O

It	O
has	O
been	O
shown	O
that	O
both	O
the	O
photoreduction	O
of	O
cytochrome	B
c	I
and	O
photooxidation	O
of	O
epinephrine	O
,	O
which	O
have	O
been	O
used	O
as	O
traps	O
for	O
O_2	O
^	O
,	O
were	O
inhibited	O
by	O
SOD	O
.	O

The	O
accumulation	O
of	O
H_2O_2	O
in	O
a	O
thylakoid	O
suspension	O
in	O
the	O
presence	O
of	O
cytochrome	B
c	I
,	O
that	O
reacts	O
with	O
O_2	O
^	O
in	O
aqueous	O
phase	O
(	O
Reaction	O
(	O
31	O
)	O
)	O
preventing	O
the	O
dismutation	O
of	O
O_2	O
^	O
,	O
was	O
attributed	O
to	O
the	O
formation	O
of	O
H_2O_2	O
within	O
the	O
thylakoid	O
membrane	O
via	O
Reaction	O
(	O
114	O
)	O
.	O

The	O
amount	O
of	O
detectable	O
O_2	O
^	O
,	O
measured	O
using	O
cytochrome	B
c	I
as	O
a	O
trap	O
of	O
O_2	O
^	O
,	O
was	O
found	O
to	O
be	O
about	O
25	O
%	O
of	O
the	O
amount	O
of	O
O_2	O
^	O
estimated	O
from	O
the	O
O_2	O
consumption	O
rate	O
.	O

Thylakoid	O
membranes	O
have	O
also	O
been	O
shown	O
to	O
accumulate	O
H_2O_2	O
in	O
the	O
presence	O
of	O
cytochrome	B
c	I
that	O
reacts	O
with	O
O_2	O
^	O
and	O
prevents	O
the	O
formation	O
of	O
H_2O_2	O
via	O
superoxide	O
dismutation	O
(	O
Reaction	O
(	O
31	O
)	O
)	O
.	O

These	O
results	O
contradict	O
with	O
the	O
results	O
of	O
Asada	O
et	O
al	O
.	O
,	O
where	O
cytochrome	B
c	I
completely	O
inhibited	O
H_2O_2	O
formation	O
by	O
thylakoids	O
.	O

However	O
,	O
in	O
a	O
later	O
work	O
of	O
Takahashi	O
and	O
Asada	O
,	O
the	O
formation	O
of	O
H_2O_2	O
in	O
the	O
presence	O
of	O
cytochrome	B
c	I
was	O
shown	O
.	O

In	O
fact	O
,	O
cytotoxic	O
effects	O
of	O
exogenous	O
Carbon	O
Monoxide	O
involve	O
cytochrome	B
c	I
oxidase	O
inhibition	O
and	O
defects	O
on	O
mitochondrial	O
metabolism	O
and	O
energy	O
production	O
.	O

Likewise	O
in	O
HEK293	O
cells	O
,	O
it	O
was	O
also	O
demonstrated	O
that	O
HO	O
-	O
1	O
overexpression	O
and	O
endogenous	O
Carbon	O
Monoxide	O
production	O
also	O
moderately	O
decreased	O
cellular	O
respiration	O
along	O
with	O
partial	O
inhibition	O
of	O
cytochrome	B
c	I
oxidase	O
.	O

In	O
fact	O
,	O
Carbon	O
Monoxide	O
binds	O
to	O
cytochrome	B
c	I
oxidase	O
and	O
slows	O
down	O
the	O
rate	O
of	O
electron	O
transport	O
,	O
leading	O
to	O
electrons	O
accumulation	O
,	O
in	O
particular	O
at	O
complex	O
III	O
.	O

Likewise	O
,	O
CO	O
-	O
mediated	O
inhibition	O
of	O
cytochrome	B
c	I
oxidase	O
can	O
be	O
partial	O
or	O
transitory	O
,	O
which	O
enables	O
low	O
levels	O
of	O
ROS	O
production	O
without	O
further	O
damaging	O
mitochondria	O
.	O

Low	O
concentrations	O
of	O
exogenous	O
Carbon	O
Monoxide	O
partially	O
inhibited	O
cytochrome	B
c	I
activity	O
,	O
generating	O
mitochondrial	O
ROS	O
,	O
which	O
in	O
turn	O
limited	O
LPS	O
-	O
induced	O
inflammation	O
by	O
promoting	O
p38	O
MAPK	O
phosphorylation	O
and	O
decreasing	O
TNF	O
-	O
ALPHA	O
levels	O
.	O

Subcellular	O
localization	O
of	O
Carbon	O
Monoxide	O
can	O
also	O
regulate	O
ROS	O
production	O
,	O
for	O
instance	O
Taill	O
and	O
colleagues	O
have	O
demonstrated	O
that	O
CORM	O
-	O
2	O
treatment	O
inhibited	O
the	O
activity	O
of	O
NAD	O
(	O
P	O
)	O
H	O
oxidase	O
cytochrome	O
b_558	O
,	O
which	O
decreases	O
plasmatic	O
membrane	O
ROS	O
production	O
,	O
while	O
there	O
is	O
an	O
increase	O
on	O
mitochondrial	O
ROS	O
generation	O
by	O
targeting	O
cytochrome	B
c	I
oxidase	O
.	O

Moreover	O
,	O
the	O
same	O
researchers	O
also	O
shown	O
that	O
under	O
hypoxia	O
,	O
HIF	O
-	O
1	O
modulates	O
the	O
expression	O
of	O
cytochrome	B
c	I
oxidase	O
subunit	O
4	O
,	O
by	O
decreasing	O
COX4	O
-	O
1	O
and	O
increasing	O
COX4	O
-	O
2	O
,	O
which	O
promotes	O
COX	O
activity	O
,	O
oxygen	O
consumption	O
and	O
ATP	O
production	O
.	O

Likewise	O
,	O
knockdown	O
expression	O
of	O
Transcription	O
Factor	O
Eb	O
also	O
decrease	O
expression	O
of	O
lysosomal	O
genes	O
(	O
Lamp1	O
,	O
cathepsin	O
B	O
and	O
TPP1	O
)	O
,	O
along	O
with	O
a	O
decrease	O
on	O
mitochondrial	O
DNA	O
,	O
mitochondrial	O
biogenesis	O
markers	O
(	O
PGC	O
-	O
1ALPHA	O
,	O
Nrf1	O
and	O
TFAM	O
)	O
and	O
mitochondrial	O
proteins	O
,	O
such	O
as	O
COX	O
II	O
,	O
COX	O
IV	O
and	O
cytochrome	B
c	I
.	O
In	O
summary	O
,	O
Transcription	O
Factor	O
Eb	O
emerges	O
as	O
a	O
key	O
regulator	O
of	O
CO	O
-	O
dependent	O
cytoprotection	O
in	O
hepatocytes	O
,	O
being	O
associated	O
with	O
modulation	O
of	O
Mitochondria	O
Via	O
Autophagy	O
and	O
mitochondrial	O
biogenesis	O
.	O

Overexpression	O
of	O
HO	O
-	O
1	O
or	O
its	O
up	O
-	O
regulation	O
by	O
treatment	O
with	O
cobalt	O
protoporphyrin	O
leaded	O
to	O
a	O
robust	O
increase	O
in	O
carnitine	O
,	O
citrate	O
,	O
deoxynucleotide	O
,	O
dicarboxylate	O
and	O
ADP	O
/	O
ATP	O
carriers	O
,	O
along	O
with	O
an	O
increase	O
on	O
cytochrome	B
c	I
oxidase	O
activity	O
,	O
suggesting	O
an	O
improvement	O
on	O
mitochondrial	O
metabolism	O
.	O

Carbon	O
Monoxide	O
protection	O
against	O
Membrane	O
Permeabilization	O
was	O
assessed	O
by	O
inhibition	O
of	O
mitochondrial	O
swelling	O
,	O
mitochondrial	O
depolarization	O
,	O
inner	O
membrane	O
permeabilization	O
and	O
cytochrome	B
c	I
release	O
,	O
as	O
well	O
as	O
by	O
modulation	O
of	O
cytochrome	B
c	I
oxidase	O
activity	O
.	O

In	O
addition	O
,	O
Carbon	O
Monoxide	O
transiently	O
decreased	O
specific	O
activity	O
of	O
cytochrome	B
c	I
oxidase	O
during	O
the	O
first	O
10	O
min	O
of	O
exposition	O
and	O
at	O
30	O
min	O
there	O
was	O
an	O
increase	O
of	O
its	O
activity	O
.	O

This	O
CO	O
-	O
induced	O
two	O
-	O
step	O
response	O
in	O
cytochrome	B
c	I
activity	O
was	O
also	O
observed	O
in	O
non	O
-	O
synaptic	O
mitochondria	O
isolated	O
from	O
rat	O
cortex	O
.	O

Carbon	O
Monoxide	O
pushed	O
the	O
glycolysis	O
/	O
oxidative	O
phosphorylation	O
balance	O
towards	O
Glycolysis	O
/	O
Oxidative	O
Phosphorylation	O
and	O
increased	O
specific	O
activity	O
of	O
cytochrome	B
c	I
oxidase	O
,	O
along	O
with	O
an	O
enhancement	O
of	O
mitochondrial	O
population	O
.	O

Therefore	O
,	O
one	O
may	O
speculate	O
that	O
Carbon	O
Monoxide	O
generates	O
small	O
amounts	O
of	O
ROS	O
by	O
partially	O
and	O
transitorily	O
inhibiting	O
cytochrome	B
c	I
oxidase	O
.	O

These	O
ROS	O
act	O
as	O
signaling	O
molecules	O
that	O
,	O
in	O
turn	O
,	O
improve	O
mitochondrial	O
metabolism	O
and	O
function	O
;	O
including	O
cytochrome	B
c	I
oxidase	O
activity	O
.	O

Nevertheless	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
this	O
dual	O
effect	O
of	O
Carbon	O
Monoxide	O
on	O
cytochrome	B
c	I
oxidase	O
activity	O
is	O
not	O
yet	O
clearly	O
disclosed	O
.	O

The	O
fact	O
that	O
Carbon	O
Monoxide	O
targets	O
mitochondria	O
,	O
in	O
particular	O
cytochrome	B
c	I
oxidase	O
,	O
originates	O
several	O
consequences	O
:	O
(	O
i	O
)	O
generation	O
of	O
ROS	O
for	O
downstream	O
signaling	O
,	O
(	O
ii	O
)	O
alterations	O
in	O
oxygen	O
consumption	O
implying	O
uncoupling	O
effects	O
and	O
/	O
or	O
improvement	O
of	O
mitochondrial	O
respiration	O
and	O
ATP	O
production	O
,	O
(	O
iii	O
)	O
regulation	O
of	O
mitochondrial	O
quality	O
control	O
,	O
including	O
mitochondrial	O
biogenesis	O
,	O
Mitochondria	O
Via	O
Autophagy	O
and	O
fusion	O
/	O
fission	O
.	O

Citrate	O
synthase	O
and	O
complex	O
I	O
-	O
IV	O
activities	O
were	O
determined	O
by	O
monitoring	O
appearance	O
or	O
disappearance	O
of	O
specific	O
substrates	O
at	O
specific	O
wavelengths	O
using	O
spectrophotometry	O
(	O
eg	O
,	O
oxidation	O
of	O
NADH	O
for	O
complex	O
I	O
activity	O
at	O
340	O
nm	O
in	O
the	O
presence	O
and	O
absence	O
of	O
rotenone	O
to	O
evaluate	O
complex	O
I	O
-	O
specific	O
activity	O
,	O
reduction	O
of	O
cytochrome	B
c	I
for	O
complex	O
III	O
activity	O
at	O
550	O
nm	O
)	O
.	O

Porcine	O
deltacoronavirus	O
induces	O
caspase	O
-	O
dependent	O
apoptosis	O
through	O
activation	O
of	O
the	O
cytochrome	B
c	I
-	O
mediated	O
intrinsic	O
mitochondrial	O
pathway	O
.	O

PDCoV	O
-	O
mediated	O
Mitochondrial	O
Outer	O
Membrane	O
Permeabilization	O
resulted	O
in	O
apoptogenic	O
cytochrome	B
c	I
release	O
into	O
the	O
cytoplasm	O
.	O

Mitochondrial	O
cytochrome	B
c	I
leakage	O
executed	O
apoptotic	O
cell	O
death	O
in	O
Porcine	O
Deltacoronavirus	O
infection	O
.	O

Experimental	O
data	O
indicated	O
that	O
Porcine	O
Deltacoronavirus	O
infection	O
led	O
to	O
Bax	O
-	O
mediated	O
mitochondrial	O
outer	O
membrane	O
permeabilization	O
,	O
resulting	O
in	O
specific	O
relocation	O
of	O
the	O
mitochondrial	O
cytochrome	B
c	I
(	O
cyt	O
c	O
)	O
into	O
the	O
cytoplasm	O
.	O

Antibodies	O
specific	O
for	O
cytochrome	B
c	I
(	O
cyt	O
c	O
)	O
,	O
apoptosis	O
-	O
inducing	O
factor	O
,	O
Bax	O
,	O
Sp1	O
,	O
and	O
BETA	O
-	O
actin	O
and	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
-	O
conjugated	O
secondary	O
antibodies	O
were	O
obtained	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
)	O
.	O

In	O
a	O
proof	O
-	O
of	O
-	O
concept	O
study	O
,	O
confocal	O
Raman	O
microscopy	O
with	O
excitation	O
resonant	O
to	O
the	O
heme	O
c	O
moiety	O
of	O
cytochrome	B
c	I
was	O
used	O
to	O
compare	O
the	O
cytochrome	B
c	I
content	O
and	O
activity	O
of	O
stressed	O
and	O
unstressed	O
Nitrosomonas	O
europaea	O
(	O
Nm	O
50	O
)	O
,	O
Nitrosomonas	O
eutropha	O
(	O
Nm	O
57	O
)	O
,	O
Nitrosospira	O
briensis	O
(	O
Nsp	O
10	O
)	O
,	O
and	O
Nitrosospira	O
species	O
(	O
Nsp	O
02	O
)	O
in	O
vivo	O
.	O

In	O
addition	O
,	O
cells	O
with	O
predominantly	O
ferrous	O
cytochrome	B
c	I
content	O
were	O
found	O
in	O
deprived	O
Nitrosomonas	O
eutropha	O
and	O
Nitrosospira	O
samples	O
,	O
which	O
may	O
be	O
indicative	O
of	O
ongoing	O
electron	O
storage	O
at	O
the	O
time	O
of	O
measurement	O
.	O

The	O
electron	O
transport	O
along	O
these	O
pathways	O
is	O
predominantly	O
performed	O
by	O
several	O
cytochrome	B
c	I
proteins	O
,	O
some	O
of	O
which	O
hold	O
more	O
than	O
one	O
heme	O
c	O
in	O
their	O
protic	O
matrix	O
.	O

For	O
a	O
scheme	O
of	O
the	O
electron	O
transport	O
and	O
the	O
ammonia	O
oxidation	O
pathways	O
for	O
N	O
.	O
europaea	O
,	O
including	O
the	O
associated	O
cytochrome	B
c	I
proteins	O
,	O
see	O
Sedlacek	O
et	O
al	O
.	O
.	O
A	O
comparative	O
quantitative	O
proteomic	O
study	O
of	O
growing	O
and	O
ammonia	O
-	O
starved	O
N	O
.	O
europaea	O
cells	O
by	O
Pellitteri	O
-	O
Hahn	O
et	O
al	O
.	O

found	O
that	O
energy	O
-	O
starved	O
cells	O
shifted	O
their	O
cellular	O
activity	O
from	O
biosynthesis	O
toward	O
cellular	O
survival	O
functions	O
,	O
reporting	O
a	O
significantly	O
increased	O
abundance	O
of	O
cytochrome	B
c	I
in	O
the	O
ammonia	O
-	O
starved	O
cells	O
as	O
compared	O
to	O
growing	O
cells	O
,	O
which	O
was	O
interpreted	O
as	O
a	O
cellular	O
strategy	O
for	O
a	O
rapid	O
growth	O
response	O
.	O

The	O
mRNA	O
levels	O
for	O
cytochrome	B
c	I
reported	O
by	O
Wei	O
et	O
al	O
.	O

While	O
the	O
crucial	O
enzymes	O
AMO	O
,	O
HAO	O
,	O
and	O
NOR	O
of	O
the	O
ammonia	O
oxidation	O
pathways	O
were	O
not	O
directly	O
accessible	O
with	O
Raman	O
microscopy	O
in	O
vivo	O
,	O
it	O
was	O
possible	O
to	O
target	O
the	O
cytochrome	B
c	I
responsible	O
for	O
the	O
required	O
electron	O
transport	O
along	O
these	O
pathways	O
with	O
resonance	O
Raman	O
micro	O
-	O
spectroscopy	O
,	O
a	O
technique	O
also	O
uniquely	O
positioned	O
to	O
determine	O
conformational	O
changes	O
of	O
cytochrome	B
c	I
and	O
its	O
redox	O
state	O
(	O
ferrous	O
versus	O
ferric	O
hemes	O
c	O
)	O
.	O

Hu	O
et	O
al	O
.	O
,	O
in	O
their	O
annotation	O
of	O
the	O
resonance	O
Raman	O
spectra	O
of	O
extracted	O
cytochrome	B
c	I
,	O
previously	O
reported	O
large	O
changes	O
in	O
both	O
the	O
resonant	O
excitation	O
wavelength	O
and	O
the	O
specifically	O
enhanced	O
molecular	O
vibrations	O
dependent	O
on	O
the	O
redox	O
state	O
of	O
the	O
protein	O
.	O

cm	O
^	O
1	O
,	O
which	O
at	O
532	O
nm	O
excitation	O
is	O
one	O
of	O
the	O
strongest	O
Raman	O
lines	O
in	O
ferrous	O
cytochrome	B
c	I
,	O
but	O
is	O
very	O
weak	O
if	O
the	O
protein	O
is	O
in	O
ferric	O
state	O
.	O

used	O
Raman	O
microscopy	O
with	O
cytochrome	B
-	I
c	I
-	O
resonant	O
excitation	O
at	O
532	O
nm	O
,	O
using	O
the	O
redox	O
state	O
of	O
cytochrome	B
c	I
as	O
a	O
crucial	O
indicator	O
for	O
cell	O
apoptosis	O
,	O
while	O
Kakita	O
et	O
al	O
.	O

monitored	O
photothermally	O
induced	O
mitochondrially	O
mediated	O
apoptosis	O
in	O
situ	O
based	O
on	O
the	O
Raman	O
spectrum	O
of	O
cytochrome	B
c	I
,	O
using	O
surface	O
-	O
enhanced	O
resonant	O
Raman	O
microscopy	O
with	O
gold	O
nanoparticles	O
and	O
785	O
nm	O
excitation	O
.	O

for	O
the	O
quantitative	O
detection	O
of	O
cytochrome	B
c	I
in	O
living	O
cells	O
,	O
and	O
Zhu	O
et	O
al	O
.	O

studied	O
the	O
influence	O
of	O
redox	O
state	O
on	O
cytochrome	B
c	I
release	O
in	O
apoptosis	O
using	O
Raman	O
microscopy	O
with	O
nickel	O
substrates	O
.	O

In	O
this	O
work	O
,	O
we	O
present	O
a	O
proof	O
of	O
concept	O
of	O
the	O
use	O
of	O
straightforward	O
confocal	O
Raman	O
microscopy	O
with	O
532	O
nm	O
excitation	O
,	O
resonant	O
to	O
the	O
Q	O
-	O
band	O
of	O
the	O
heme	O
c	O
moiety	O
in	O
cytochrome	B
c	I
,	O
to	O
non	O
-	O
invasively	O
and	O
in	O
vivo	O
analyze	O
the	O
response	O
of	O
four	O
species	O
of	O
AOB	O
,	O
Nitrosomonas	O
europaea	O
,	O
Nitrosomonas	O
eutropha	O
,	O
Nitrosospira	O
briensis	O
,	O
and	O
Nitrosospira	O
species	O
.	O

to	O
oxygen	O
deprivation	O
in	O
comparison	O
to	O
non	O
-	O
oxygen	O
-	O
deprived	O
cultures	O
based	O
on	O
1000	O
individual	O
cells	O
per	O
sampling	O
,	O
confirming	O
elevated	O
cytochrome	B
c	I
content	O
and	O
activity	O
following	O
oxygen	O
deprivation	O
in	O
a	O
purely	O
optical	O
measurement	O
with	O
low	O
impact	O
on	O
culture	O
volumes	O
.	O

A	O
frequency	O
-	O
doubled	O
continuous	O
-	O
wave	O
Nd	O
:	O
YAG	O
laser	O
at	O
531	O
.	O
9	O
nm	O
,	O
suitable	O
for	O
resonantly	O
enhancing	O
the	O
Q	O
-	O
band	O
of	O
the	O
heme	O
c	O
moiety	O
of	O
cytochrome	B
c	I
in	O
its	O
ferrous	O
(	O
Fe	O
^	O
2	O
+	O
)	O
state	O
,	O
was	O
used	O
for	O
excitation	O
.	O

The	O
Raman	O
lines	O
of	O
the	O
four	O
main	O
vibrations	O
of	O
resonantly	O
excited	O
cytochrome	B
c	I
,	O
_15	O
,	O
_22	O
,	O
_21	O
,	O
and	O
_19	O
at	O
750	O
,	O
1130	O
,	O
1314	O
,	O
and	O
1587	O
rel	O
.	O

This	O
fit	O
perfectly	O
with	O
the	O
results	O
of	O
Hu	O
et	O
al	O
.	O
,	O
who	O
analyzed	O
reconstituted	O
cytochrome	B
c	I
protein	O
in	O
potassium	O
phosphate	O
buffer	O
solution	O
,	O
identifying	O
the	O
lines	O
in	O
the	O
complete	O
resonance	O
Raman	O
spectra	O
of	O
ferrous	O
and	O
ferric	O
cytochrome	B
c	I
.	O
With	O
532	O
nm	O
excitation	O
,	O
they	O
found	O
the	O
Raman	O
line	O
of	O
the	O
_15	O
vibration	O
at	O
750	O
rel	O
.	O

cm	O
^	O
1	O
to	O
be	O
among	O
the	O
strongest	O
lines	O
in	O
the	O
spectrum	O
of	O
ferrous	O
cytochrome	B
c	I
,	O
but	O
among	O
the	O
weakest	O
lines	O
in	O
ferric	O
cytochrome	B
c	I
,	O
whereas	O
the	O
Raman	O
line	O
of	O
the	O
_19	O
vibration	O
at	O
1587	O
rel	O
.	O

cm	O
^	O
1	O
and	O
used	O
it	O
to	O
differentiate	O
between	O
healthy	O
and	O
apoptotic	O
and	O
pre	O
-	O
apoptotic	O
brain	O
cells	O
of	O
Mongolian	O
gerbils	O
,	O
associating	O
the	O
line	O
shift	O
with	O
cytochrome	B
c	I
deformation	O
due	O
to	O
the	O
protein	O
binding	O
to	O
membrane	O
elements	O
.	O

A	O
similar	O
observation	O
was	O
reported	O
earlier	O
by	O
Murgida	O
and	O
Hildebrandt	O
,	O
who	O
saw	O
a	O
10	O
cm	O
^	O
1	O
upshift	O
in	O
the	O
line	O
of	O
the	O
_19	O
vibration	O
in	O
ferrous	O
compared	O
to	O
ferric	O
cytochrome	B
c	I
adsorbed	O
to	O
a	O
surface	O
-	O
enhanced	O
Raman	O
active	O
substrate	O
.	O

cm	O
^	O
1	O
,	O
which	O
would	O
be	O
caused	O
by	O
such	O
a	O
shift	O
in	O
the	O
spectra	O
of	O
some	O
but	O
not	O
all	O
the	O
cytochrome	B
c	I
within	O
the	O
respective	O
cell	O
,	O
therefore	O
indicated	O
that	O
the	O
observed	O
differences	O
in	O
the	O
summarized	O
cytochrome	B
c	I
resonant	O
Raman	O
spectra	O
of	O
the	O
bacteria	O
were	O
indeed	O
primarily	O
due	O
to	O
the	O
redox	O
state	O
of	O
the	O
cytochrome	B
c	I
,	O
as	O
analyzed	O
by	O
Hu	O
et	O
al	O
.	O
,	O
and	O
thus	O
to	O
their	O
electron	O
transport	O
function	O
,	O
and	O
not	O
due	O
to	O
deformations	O
caused	O
by	O
other	O
stress	O
reactions	O
of	O
the	O
respective	O
cells	O
.	O

Therefore	O
,	O
the	O
relative	O
intensity	O
(	O
I_Raman	O
)	O
of	O
the	O
two	O
Raman	O
lines	O
(	O
relRI	O
)	O
could	O
be	O
used	O
as	O
a	O
functional	O
marker	O
for	O
the	O
summarized	O
redox	O
state	O
(	O
ferrous	O
versus	O
ferric	O
)	O
of	O
all	O
the	O
cytochrome	B
c	I
of	O
the	O
respective	O
bacterial	O
cell	O
,	O
and	O
thus	O
its	O
ongoing	O
electron	O
transport	O
activity	O
at	O
the	O
time	O
of	O
measurement	O
with	O
I_Raman	O
being	O
the	O
intensity	O
of	O
the	O
Raman	O
line	O
associated	O
with	O
the	O
respective	O
vibration	O
in	O
the	O
spectrum	O
of	O
that	O
individual	O
bacterial	O
cell	O
.	O

The	O
elevated	O
cytochrome	B
c	I
activity	O
of	O
oxygen	O
-	O
deprived	O
N	O
.	O
eutropha	O
and	O
Nitrosospira	O
fit	O
well	O
with	O
the	O
results	O
reported	O
by	O
Sedlacek	O
et	O
al	O
.	O

and	O
Pellitteri	O
-	O
Hahn	O
et	O
al	O
.	O
,	O
whose	O
works	O
indicated	O
a	O
significant	O
increase	O
in	O
the	O
cytochrome	B
c	I
content	O
of	O
stressed	O
cells	O
,	O
but	O
contradicted	O
Wei	O
et	O
al	O
.	O
,	O
who	O
reported	O
mRNA	O
levels	O
for	O
cytochrome	B
c	I
in	O
growing	O
cells	O
to	O
exceed	O
those	O
of	O
energy	O
-	O
starved	O
cells	O
by	O
a	O
factor	O
of	O
10	O
.	O

used	O
transcriptomics	O
on	O
stressed	O
N	O
.	O
europaea	O
to	O
elucidate	O
the	O
stress	O
response	O
to	O
either	O
ammonia	O
or	O
oxygen	O
limitation	O
,	O
reporting	O
that	O
the	O
transcripts	O
for	O
protein	O
-	O
encoding	O
genes	O
related	O
to	O
energy	O
production	O
and	O
conservation	O
,	O
including	O
for	O
the	O
proteins	O
AMO	O
,	O
HAO	O
,	O
and	O
NOR	O
,	O
were	O
increased	O
during	O
oxygen	O
-	O
deprived	O
growth	O
,	O
while	O
three	O
cytochrome	B
c	I
proteins	O
associated	O
with	O
the	O
ammonia	O
-	O
oxidizing	O
pathway	O
were	O
even	O
among	O
the	O
top	O
20	O
%	O
of	O
genes	O
transcribed	O
under	O
stress	O
conditions	O
.	O

Kozlowski	O
et	O
al	O
.	O
,	O
who	O
compared	O
the	O
metabolism	O
pathways	O
of	O
several	O
AOB	O
based	O
on	O
micro	O
-	O
respirometry	O
and	O
genome	O
analysis	O
,	O
confirmed	O
that	O
these	O
enzymes	O
and	O
cytochrome	B
c	I
proteins	O
are	O
encoded	O
in	O
multiple	O
copies	O
by	O
N	O
.	O
europaea	O
,	O
N	O
.	O
eutropha	O
,	O
and	O
Nitrosospira	O
,	O
including	O
the	O
associated	O
cytochrome	B
c	I
proteins	O
.	O

The	O
observed	O
differences	O
in	O
cytochrome	B
c	I
activity	O
of	O
Nitrosospira	O
briensis	O
and	O
Nitrosospira	O
species	O
(	O
Nsp	O
02	O
)	O
correlated	O
well	O
with	O
their	O
respective	O
oxygenation	O
histories	O
(	O
compare	O
.	O

Nitrosospira	O
briensis	O
has	O
been	O
reported	O
to	O
have	O
decreasing	O
AMO	O
mRNA	O
expression	O
during	O
starvation	O
,	O
but	O
to	O
rapidly	O
recover	O
after	O
starvation	O
periods	O
of	O
up	O
to	O
two	O
weeks	O
,	O
with	O
only	O
small	O
changes	O
in	O
the	O
soluble	O
proteins	O
,	O
including	O
cytochrome	B
c	I
,	O
between	O
growing	O
and	O
ammonium	O
-	O
starved	O
cells	O
.	O

However	O
,	O
the	O
relRI	O
trends	O
of	O
N	O
.	O
europaea	O
did	O
not	O
show	O
an	O
elevated	O
cytochrome	B
c	I
activity	O
indicative	O
of	O
a	O
noticeable	O
stress	O
response	O
in	O
its	O
cells	O
at	O
all	O
(	O
see	O
b	O
)	O
.	O

Interestingly	O
,	O
the	O
oxygen	O
-	O
deprived	O
N	O
.	O
eutropha	O
appeared	O
to	O
have	O
a	O
significantly	O
more	O
evenly	O
distributed	O
cytochrome	B
c	I
activity	O
,	O
with	O
its	O
relRI	O
ranging	O
from	O
1	O
.	O
7	O
to	O
1	O
.	O
9	O
,	O
than	O
non	O
-	O
deprived	O
N	O
.	O
eutropha	O
,	O
with	O
a	O
relRI	O
range	O
from	O
1	O
.	O
2	O
to	O
1	O
.	O
75	O
(	O
see	O
.	O

In	O
line	O
with	O
previous	O
evidence	O
,	O
the	O
level	O
of	O
cytosolic	O
cytochrome	B
-	I
c	I
was	O
already	O
detectable	O
2	O
h	O
after	O
Oxygen	O
-	O
Glucose	O
Deprivation	O
and	O
further	O
increased	O
at	O
6	O
h	O
.	O
CSP	O
-	O
1103	O
significantly	O
prevented	O
cytochrome	B
-	I
c	I
release	O
from	O
2	O
h	O
on	O
(	O
A	O
-	O
D	O
)	O
.	O

Selection	O
of	O
a	O
laser	O
excitation	O
wavelength	O
corresponding	O
to	O
the	O
electronic	O
absorption	O
maximum	O
of	O
a	O
particular	O
chemical	O
^	O
(	O
for	O
example	O
530	O
.	O
9	O
nm	O
will	O
excite	O
cytochromes	O
)	O
^	O
enhances	O
the	O
Raman	O
signal	O
of	O
particular	O
bands	O
by	O
a	O
factor	O
of	O
10	O
^	O
3	O
-	O
10	O
^	O
5	O
(	O
ref	O
.	O
.	O
This	O
has	O
been	O
used	O
to	O
extensively	O
study	O
haemoglobin	O
and	O
observe	O
cytochrome	B
-	I
c	I
release	O
from	O
mitochondria	O
during	O
apoptosis	O
.	O

The	O
protein	O
expression	O
levels	O
of	O
total	O
ALPHA	O
-	O
SYN	O
,	O
phosphorylated	O
Ser129	O
ALPHA	O
-	O
SYN	O
,	O
B	O
-	O
cell	O
lymphoma	O
2	O
(	O
Bcl	O
-	O
2	O
)	O
,	O
Bcl	O
-	O
2	O
-	O
associated	O
X	O
protein	O
and	O
cytochrome	B
-	I
c	I
(	O
Cyt	O
-	O
c	O
)	O
were	O
analyzed	O
by	O
western	O
blotting	O
.	O

They	O
reported	O
that	O
the	O
heme	O
-	O
copper	O
-	O
containing	O
cytochrome	B
-	I
c	I
oxidases	O
encoded	O
by	O
N	O
.	O
europaea	O
were	O
upregulated	O
during	O
oxygen	O
-	O
limited	O
growth	O
.	O

Incidentally	O
,	O
we	O
used	O
confocal	O
Raman	O
microscopy	O
with	O
cytochrome	B
-	I
c	I
-	O
resonant	O
excitation	O
at	O
532	O
nm	O
and	O
hierarchical	O
cluster	O
analysis	O
for	O
the	O
in	O
vivo	O
discrimination	O
and	O
identification	O
of	O
several	O
species	O
of	O
purple	O
non	O
-	O
sulfur	O
bacteria	O
and	O
AOB	O
in	O
planktonic	O
cultures	O
,	O
as	O
well	O
as	O
associated	O
in	O
microbial	O
wastewater	O
biofilms	O
.	O

Since	O
cytochrome	B
-	I
c	I
-	O
resonant	O
Raman	O
spectra	O
always	O
contain	O
a	O
fluorescent	O
background	O
originating	O
from	O
the	O
cytochrome	O
itself	O
,	O
the	O
Raman	O
spectra	O
were	O
baseline	O
corrected	O
using	O
the	O
IMM	O
algorithm	O
developed	O
by	O
Koch	O
et	O
al	O
.	O
,	O
which	O
combines	O
computational	O
efficiency	O
with	O
reliable	O
maintaining	O
of	O
line	O
shapes	O
and	O
relative	O
intensities	O
against	O
the	O
background	O
of	O
strong	O
fluorescence	O
often	O
found	O
in	O
Raman	O
spectra	O
recorded	O
in	O
vivo	O
.	O

We	O
searched	O
PubMed	O
,	O
EMBASE	O
,	O
Web	O
of	O
Science	O
,	O
the	O
Cochrane	O
Library	O
,	O
Chinese	O
Biomedical	O
Literature	O
Database	O
,	O
and	O
Wanfang	O
Database	O
(	O
between	O
January	O
1990	O
and	O
October	O
2016	O
)	O
using	O
the	O
following	O
search	O
terms	O
:	O
(	O
Ischemic	O
stroke	O
OR	O
IS	O
)	O
AND	O
(	O
cytochrome	B
p450	I
2E1	O
OR	O
cytochrome	B
p450	I
IIJ2	O
OR	O
CYP2J2	O
)	O
AND	O
(	O
SNP	O
OR	O
polymorphism	O
OR	O
allele	O
OR	O
variation	O
)	O
.	O

Heme	O
b	O
(	O
Fe	O
protoporphyrin	O
IX	O
)	O
is	O
the	O
most	O
versatile	O
heme	O
in	O
organisms	O
and	O
is	O
a	O
constituent	O
of	O
the	O
b	O
type	O
cytochromes	O
,	O
catalases	O
,	O
peroxidases	O
,	O
cytochrome	B
p450	I
,	O
globin	O
and	O
nitrate	O
reductase	O
(	O
;	O
.	O

Phenobarbital	O
is	O
known	O
to	O
induce	O
the	O
expression	O
of	O
cytochrome	B
p450	I
enzymes	O
in	O
the	O
liver	O
,	O
and	O
the	O
induction	O
of	O
these	O
enzymes	O
are	O
likely	O
to	O
speed	O
up	O
the	O
metabolism	O
of	O
not	O
only	O
Phenobarbital	O
,	O
but	O
also	O
estrogens	O
and	O
progestins	O
.	O

In	O
case	O
of	O
cytochrome	B
p450	I
and	O
cytochrome	B
p450	I
monooxygenase	O
multiple	O
isomers	O
were	O
reported	O
.	O

and	O
Kyoto	O
Encyclopedia	O
Gene	O
And	O
Genome	O
pathway	O
of	O
terpenoid	O
backbone	O
biosynthesis	O
,	O
the	O
tentative	O
biosynthesis	O
pathway	O
of	O
andrographolide	O
in	O
kalmegh	O
was	O
proposed	O
of	O
cytochrome	B
p450	I
related	O
to	O
specialized	O
terpene	O
metabolism	O
were	O
identified	O
(	O
suppl	O
Table	O
S7	O
)	O
.	O

The	O
cytochrome	B
p450	I
enzyme	O
converts	O
Ent	O
-	O
diterpenol	O
into	O
andrographolide	O
and	O
deoxy	O
-	O
didehydroandrographolide	O
secondary	O
metabolites	O
,	O
whereas	O
cytochrome	B
p450	I
GT	O
(	O
glycosyl	O
transferase	O
)	O
converts	O
Ent	O
-	O
diterpenol	O
into	O
neoandrographolide	O
(	O
Garg	O
et	O
al	O
.	O

In	O
functional	O
annotation	O
of	O
this	O
leaf	O
transcriptome	O
,	O
the	O
cytochrome	B
p450	I
GT	O
was	O
not	O
reported	O
may	O
be	O
because	O
of	O
its	O
higher	O
expression	O
was	O
reported	O
in	O
root	O
tissue	O
,	O
not	O
in	O
leaf	O
(	O
Garg	O
et	O
al	O
.	O
.	O
The	O
expression	O
of	O
deoxy	O
-	O
didehydroandrographolide	O
was	O
highest	O
in	O
stem	O
,	O
whereas	O
,	O
very	O
low	O
in	O
leaf	O
tissue	O
(	O
Garg	O
et	O
al	O
.	O
)	O

and	O
the	O
highest	O
andrographolide	O
was	O
detected	O
in	O
leaf	O
as	O
compared	O
to	O
other	O
panchang	O
(	O
Pandey	O
and	O
Mandal	O
;	O
Sharma	O
et	O
al	O
.	O
.	O
Therefore	O
,	O
some	O
other	O
isomers	O
of	O
cytochrome	B
p450	I
(	O
cytochrome	B
p450	I
98	O
,	O
cytochrome	B
p450	I
706	O
,	O
etc	O
.	O
)	O

^	O
With	O
the	O
same	O
TEQ	O
dose	O
used	O
in	O
this	O
study	O
(	O
100	O
ng	O
/	O
kg	O
/	O
day	O
)	O
,	O
a	O
limited	O
subset	O
of	O
genes	O
,	O
which	O
included	O
CAT	O
,	O
cytochrome	B
b5	I
(	O
CYPB5	O
)	O
,	O
and	O
COX	O
oxidative	O
stress	O
response	O
genes	O
,	O
was	O
activated	O
by	O
PeCDF	O
and	O
PCB	O
126	O
alone	O
,	O
but	O
not	O
TCDD	O
.	O

It	O
is	O
known	O
that	O
crARC	O
requires	O
a	O
cytochrome	B
b5	I
(	O
crCytb5	O
-	O
1	O
)	O
and	O
a	O
cytochrome	B
b5	I
reductase	O
(	O
crCytb5	O
-	O
R	O
)	O
that	O
form	O
an	O
electron	O
transport	O
chain	O
from	O
NADH	O
to	O
the	O
substrates	O
.	O

In	O
the	O
presence	O
of	O
NADH	O
,	O
each	O
human	O
Molybdenum	O
enzyme	O
exerts	O
reductase	O
activity	O
towards	O
NHCs	O
with	O
cytochrome	B
b_5	I
and	O
NADH	O
cytochrome	B
b_5	I
reductase	O
.	O

However	O
,	O
the	O
bacterial	O
ARCO	O
is	O
a	O
two	O
-	O
component	O
system	O
that	O
uses	O
ferredoxin	O
fused	O
to	O
the	O
C	O
-	O
termini	O
Mitochondrial	O
Amidoxime	O
Reducing	O
Component	O
enzyme	O
(	O
YcbX	O
)	O
instead	O
of	O
cytochrome	O
and	O
as	O
a	O
second	O
component	O
,	O
uses	O
flavin	O
reductase	O
(	O
CysJ	O
)	O
instead	O
of	O
NADH	O
cytochrome	B
b_5	I
reductase	O
.	O

We	O
found	O
that	O
Chlamydomonas	O
ARCO	O
is	O
the	O
Molybdenum	O
enzyme	O
crARC	O
,	O
the	O
cytochrome	B
b_5	I
-	O
1	O
(	O
crCytb5	O
-	O
1	O
)	O
and	O
one	O
NADH	O
cytochrome	B
b_5	I
reductase	O
(	O
crCytb5	O
-	O
R	O
)	O
,	O
similar	O
to	O
its	O
human	O
counterpart	O
and	O
different	O
from	O
the	O
two	O
components	O
in	O
a	O
prokaryotic	O
system	O
.	O

The	O
human	O
ARCO	O
apart	O
from	O
the	O
N	O
-	O
Hydroxylated	O
Compounds	O
and	O
N	O
-	O
Omega	O
-	O
Hydroxy	O
-	O
L	O
-	O
Arginine	O
reductions	O
is	O
also	O
able	O
to	O
catalyze	O
the	O
reduction	O
of	O
nitrite	O
to	O
NO	O
using	O
cytochrome	B
b_5	I
-	O
1	O
-	O
1	O
and	O
cytochrome	B
b_5	I
reductase	O
as	O
partners	O
,	O
however	O
,	O
only	O
under	O
anaerobic	O
conditions	O
.	O

However	O
,	O
N	O
-	O
Hydroxylated	O
Compounds	O
reductase	O
activity	O
in	O
humans	O
is	O
strictly	O
dependent	O
on	O
cytochrome	B
b_5	I
reductase	O
CYB5R3	O
and	O
mitochondrial	O
cytochrome	B
b_5	I
CYTB5	O
.	O

Endothelial	O
cytochrome	B
b5	I
reductase	O
3	O
was	O
further	O
reported	O
to	O
regulate	O
this	O
process	O
through	O
the	O
reduction	O
of	O
the	O
haem	O
iron	O
of	O
Hb	O
-	O
ALPHA	O
,	O
and	O
genetic	O
and	O
pharmacological	O
inhibition	O
of	O
cytochrome	B
b5	I
reductase	O
3	O
was	O
found	O
to	O
enhance	O
Nitric	O
Oxide	O
bioactivity	O
in	O
small	O
vessels	O
.	O

When	O
coupled	O
with	O
suitable	O
cellular	O
reducing	O
systems	O
,	O
such	O
as	O
ascorbate	O
or	O
cytochrome	B
b5	I
reductase	O
/	O
cytochrome	B
b5	I
/	O
NADH	O
,	O
Cygb	O
has	O
been	O
demonstrated	O
to	O
function	O
as	O
a	O
Nitric	O
Oxide	O
Dioxygenase	O
,	O
efficiently	O
regulating	O
the	O
rate	O
of	O
O_2	O
-	O
dependent	O
Nitric	O
Oxide	O
consumption	O
.	O

Both	O
ascorbate	O
and	O
cytochrome	B
b5	I
reductase	O
/	O
cytochrome	B
b5	I
/	O
NADH	O
serve	O
as	O
effective	O
reducing	O
systems	O
for	O
Cygb	O
,	O
with	O
the	O
latter	O
serving	O
as	O
the	O
major	O
reducing	O
system	O
in	O
Smooth	O
Muscle	O
Cells	O
.	O

We	O
observe	O
that	O
the	O
reduction	O
rate	O
of	O
Cygb	O
is	O
10	O
times	O
faster	O
than	O
that	O
of	O
other	O
globins	O
such	O
as	O
Myoglobin	O
or	O
Hb	O
-	O
ALPHA	O
when	O
reductase	O
systems	O
(	O
such	O
as	O
cytochrome	B
b5	I
reductase	O
/	O
cytochrome	B
b5	I
/	O
NADH	O
)	O
are	O
used	O
,	O
and	O
several	O
hundred	O
times	O
greater	O
when	O
ascorbate	O
is	O
the	O
reductant	O
.	O

Since	O
it	O
is	O
thought	O
that	O
cytochrome	B
b5	I
reductase	O
3	O
is	O
of	O
particular	O
importance	O
as	O
a	O
globin	O
reductase	O
,	O
experiments	O
were	O
performed	O
in	O
vascular	O
Smooth	O
Muscle	O
Cells	O
with	O
b5R	O
-	O
siRNA	O
treatment	O
to	O
knockdown	O
B5	O
Reductase	O
3	O
expression	O
.	O

Smooth	O
Muscle	O
Cells	O
were	O
transfected	O
with	O
Cygb	O
siRNA	O
or	O
cytochrome	B
b5	I
reductase	O
3	O
siRNA	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
using	O
Lipofectamine	O
RNAiMAX	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
.	O

The	O
following	O
antibodies	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
were	O
used	O
:	O
rabbit	O
polyclonal	O
anti	O
-	O
Cygb	O
(	O
sc	O
-	O
66855	O
;	O
diluted	O
1	O
:	O
200	O
)	O
,	O
anti	O
-	O
Mb	O
(	O
sc	O
-	O
25607	O
;	O
diluted	O
1	O
:	O
200	O
)	O
,	O
anti	O
-	O
Hb	O
-	O
ALPHA	O
(	O
sc	O
-	O
21005	O
;	O
diluted	O
1	O
:	O
200	O
)	O
,	O
cytochrome	B
b5	I
reductase	O
3	O
(	O
sc	O
-	O
398043	O
;	O
diluted	O
1	O
:	O
200	O
)	O
and	O
mouse	O
monoclonal	O
anti	O
-	O
actin	O
(	O
sc	O
-	O
47778	O
;	O
diluted	O
1	O
:	O
500	O
)	O
.	O

The	O
reduction	O
of	O
globins	O
by	O
a	O
reductant	O
or	O
a	O
reducing	O
system	O
(	O
cytochrome	B
b5	I
reductase	O
/	O
b5	O
/	O
NADH	O
)	O
was	O
performed	O
in	O
a	O
cuvette	O
under	O
anaerobic	O
conditions	O
.	O

Two	O
Clark	O
-	O
type	O
Nitric	O
Oxide	O
electrodes	O
(	O
NOCHM	O
-	O
4	O
,	O
WPI	O
,	O
Sarasota	O
,	O
FL	O
)	O
were	O
placed	O
in	O
the	O
chamber	O
through	O
two	O
ports	O
on	O
the	O
side	O
wall	O
of	O
the	O
chamber	O
for	O
measuring	O
the	O
rate	O
of	O
Nitric	O
Oxide	O
metabolism	O
by	O
isolated	O
normal	O
Smooth	O
Muscle	O
Cells	O
,	O
Cygb	O
knockdown	O
(	O
Cygb	O
siRNA	O
)	O
Smooth	O
Muscle	O
Cells	O
or	O
cytochrome	B
b5	I
reductase	O
3	O
knockdown	O
(	O
b5R	O
siRNA	O
)	O
Smooth	O
Muscle	O
Cells	O
.	O

Similarly	O
,	O
the	O
non	O
-	O
synonymous	O
polymorphism	O
T14798C	O
,	O
which	O
maps	O
to	O
cytochrome	B
b	I
gene	O
,	O
was	O
strongly	O
associated	O
with	O
differential	O
abundance	O
of	O
Dialister	O
in	O
the	O
vaginal	O
posterior	O
fornix	O
(	O
Evaldson	O
et	O
al	O
.	O
,	O
.	O

We	O
found	O
homologous	O
of	O
the	O
sox	O
genes	O
in	O
a	O
cluster	O
that	O
codes	O
for	O
putative	O
SoxA	O
(	O
quinol	O
oxidases	O
subunit	O
II	O
)	O
,	O
SoxB	O
(	O
cytochromes	O
aa	O
_3	O
subunit	O
)	O
and	O
SoxC	O
(	O
quinol	O
oxidase	O
cytochrome	B
b	I
subunit	O
)	O
proteins	O
,	O
all	O
with	O
very	O
high	O
similarity	O
to	O
SoxABC	O
proteins	O
of	O
Acidianus	O
,	O
Metallosphaera	O
,	O
and	O
Sulfolobus	O
species	O
.	O

As	O
mentioned	O
above	O
A	O
.	O
copahuensis	O
has	O
homologous	O
proteins	O
to	O
the	O
cbsAB	O
/	O
soxNL	O
cluster	O
encoding	O
a	O
cytochrome	B
b	I
(	O
SoxN	O
)	O
,	O
a	O
2Fe	O
-	O
2S	O
Rieske	O
protein	O
(	O
SoxL	O
)	O
and	O
an	O
analog	O
to	O
the	O
cytochromes	O
c	O
_1	O
(	O
CbsA	O
)	O
.	O

Additionally	O
,	O
the	O
DNP	O
sensitivity	O
-	O
enhanced	O
two	O
-	O
dimensional	O
13C	O
/	O
13C	O
chemical	O
shift	O
correlations	O
via	O
proton	O
driven	O
spin	O
diffusion	O
provided	O
distance	O
constraints	O
to	O
characterize	O
protein	O
-	O
lipid	O
interactions	O
and	O
revealed	O
the	O
transmembrane	O
topology	O
of	O
cytochrome	B
b5	I
.	O

Rabbit	O
cytochrome	B
b_5	I
,	O
a	O
16	O
.	O
7	O
kDa	O
protein	O
,	O
is	O
composed	O
of	O
three	O
structurally	O
distinct	O
domains	O
:	O
a	O
25	O
-	O
amino	O
acid	O
transmembrane	O
ALPHA	O
-	O
helix	O
domain	O
at	O
the	O
carboxyl	O
-	O
terminus	O
and	O
a	O
95	O
-	O
residue	O
heme	O
-	O
containing	O
electron	O
-	O
carrier	O
soluble	O
domain	O
at	O
the	O
amino	O
-	O
terminus	O
;	O
the	O
two	O
domains	O
are	O
connected	O
via	O
a	O
14	O
-	O
amino	O
acid	O
flexible	O
linker	O
domain	O
^	O
,	O
.	O

In	O
addition	O
to	O
the	O
aforementioned	O
drug	O
metabolisms	O
through	O
the	O
complex	O
formations	O
,	O
cytochrome	B
b_5	I
also	O
catalyzes	O
a	O
wide	O
variety	O
of	O
biosynthesis	O
including	O
testosterones	O
,	O
cholesterols	O
,	O
and	O
unsaturated	O
lipids	O
^	O
.	O

Solution	O
NMR	O
measurements	O
on	O
^	O
13C	O
-	O
labeled	O
cytochrome	B
b_5	I
embedded	O
in	O
q	O
=	O
0	O
.	O
25	O
DLPC	O
/	O
DHPC	O
isotropic	O
bicelles	O
confirmed	O
that	O
the	O
scrambling	O
of	O
isotope	O
^	O
13C	O
-	O
labels	O
did	O
not	O
occur	O
.	O

Furthermore	O
,	O
our	O
previous	O
studies	O
revealed	O
that	O
multidimensional	O
MAS	O
ssNMR	O
experiments	O
performed	O
on	O
uniformly	O
^	O
13C	O
-	O
labeled	O
cytochrome	B
b_5	I
reconstituted	O
in	O
DMPC	O
mutilamellar	O
vesicles	O
(	O
MLVs	O
)	O
gave	O
rise	O
to	O
spectra	O
with	O
low	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
at	O
310	O
K	O
^	O
.	O

This	O
surprisingly	O
poor	O
performance	O
of	O
dipolar	O
-	O
based	O
ssNMR	O
is	O
attributed	O
to	O
the	O
highly	O
dynamic	O
features	O
of	O
cytochrome	B
b_5	I
^	O
,	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
polarizing	O
efficiency	O
of	O
these	O
two	O
different	O
biradicals	O
,	O
one	O
-	O
dimensional	O
^	O
13C	O
CPMAS	O
NMR	O
spectra	O
^	O
of	O
selectively	O
^	O
13C	O
-	O
labeled	O
cytochrome	B
b_5	I
embedded	O
in	O
DMPC	O
MLVs	O
were	O
recorded	O
with	O
and	O
without	O
microwave	O
irradiation	O
,	O
as	O
shown	O
in	O
Fig	O
.	O

Sensitivity	O
-	O
enhanced	O
DNP	O
two	O
-	O
dimensional	O
(	O
2D	O
)	O
^	O
13C	O
-	O
^	O
13C	O
chemical	O
shift	O
correlation	O
experiments	O
under	O
MAS	O
conditions	O
were	O
performed	O
on	O
10	O
mM	O
AMUPol	O
-	O
containing	O
membrane	O
-	O
bound	O
selectively	O
^	O
13C	O
-	O
labeled	O
cytochrome	B
b_5	I
using	O
the	O
proton	O
driven	O
spin	O
diffusion	O
(	O
PDSD	O
)	O
pulse	O
sequence	O
^	O
,	O
.	O

As	O
reported	O
in	O
our	O
previous	O
studies	O
,	O
2D	O
^	O
13C	O
/	O
^	O
13C	O
PDSD	O
chemical	O
shift	O
correlation	O
experiments	O
on	O
uniformly	O
^	O
13C	O
^	O
15	O
,	O
N	O
-	O
labeled	O
cytochrome	B
b_5	I
at	O
cryogenic	O
temperatures	O
exhibited	O
inhomogeneous	O
broadening	O
of	O
resonances	O
mainly	O
due	O
to	O
the	O
presence	O
of	O
multiple	O
conformations	O
,	O
which	O
largely	O
gave	O
rise	O
to	O
unresolved	O
cross	O
peaks	O
in	O
the	O
all	O
^	O
13C	O
/	O
^	O
13C	O
PDSD	O
spectra	O
at	O
100	O
K	O
^	O
,	O
.	O

In	O
order	O
to	O
achieve	O
better	O
spectral	O
resolution	O
,	O
2D	O
DNP	O
NMR	O
was	O
performed	O
on	O
cytochrome	B
b_5	I
with	O
site	O
-	O
specific	O
^	O
13C	O
-	O
labeled	O
chemical	O
groups	O
in	O
selected	O
amino	O
acid	O
residues	O
,	O
as	O
shown	O
in	O
Fig	O
.	O

This	O
dilution	O
of	O
observed	O
correlations	O
in	O
2D	O
PDSD	O
experiments	O
allowed	O
us	O
to	O
acquire	O
well	O
-	O
resolved	O
cross	O
peaks	O
of	O
cytochrome	B
b_5	I
even	O
at	O
99	O
.	O
5	O
K	O
.	O
Furthermore	O
,	O
based	O
on	O
these	O
well	O
-	O
resolved	O
2D	O
^	O
13C	O
/	O
^	O
13C	O
chemical	O
shift	O
correlations	O
,	O
80	O
%	O
of	O
^	O
13C	O
chemical	O
shift	O
resonances	O
of	O
^	O
13C	O
-	O
labeled	O
sites	O
in	O
transmembrane	O
domain	O
can	O
be	O
assigned	O
,	O
as	O
shown	O
in	O
Fig	O
and	O
summarized	O
in	O
Table	O
.	O

To	O
address	O
these	O
goals	O
,	O
we	O
strategically	O
chose	O
specific	O
site	O
labeling	O
of	O
selective	O
amino	O
acids	O
,	O
including	O
[	O
1	O
-	O
^	O
13C	O
]	O
valine	O
,	O
[	O
2	O
-	O
^	O
13C	O
]	O
leucine	O
,	O
[	O
3	O
-	O
^	O
13C	O
]	O
alanine	O
,	O
and	O
tryptophan	O
(	O
indole	O
ring	O
-	O
2	O
-	O
^	O
13C	O
)	O
,	O
to	O
make	O
use	O
of	O
the	O
unique	O
patterns	O
in	O
the	O
amino	O
acid	O
sequence	O
of	O
cytochrome	B
b_5	I
.	O

In	O
cytochrome	B
b_5	I
,	O
the	O
unique	O
sets	O
of	O
amino	O
acids	O
,	O
Trp_113Val_114	O
,	O
Ala_120Leu_121	O
,	O
and	O
Val_123Ala_124Leu_125	O
,	O
are	O
only	O
found	O
in	O
the	O
transmembrane	O
region	O
.	O

In	O
this	O
study	O
,	O
the	O
high	O
sensitivity	O
of	O
DNP	O
spectroscopy	O
allows	O
us	O
to	O
observe	O
protein	O
-	O
lipid	O
intramolecular	O
interactions	O
between	O
cytochrome	B
b_5	I
and	O
lipids	O
.	O

In	O
addition	O
to	O
these	O
intramolecular	O
^	O
13C	O
correlations	O
of	O
cytochrome	B
b_5	I
significant	O
lipid	O
-	O
protein	O
intermolecular	O
interactions	O
were	O
observed	O
in	O
the	O
2D	O
^	O
13C	O
/	O
^	O
13C	O
PDSD	O
chemical	O
shift	O
correlation	O
spectrum	O
,	O
as	O
shown	O
in	O
Fig	O
.	O

Based	O
on	O
these	O
resonance	O
assignments	O
,	O
interatomic	O
interactions	O
between	O
amino	O
acid	O
residues	O
in	O
cytochrome	B
b_5	I
(	O
including	O
L99	O
,	O
W109	O
,	O
W110	O
,	O
W113	O
,	O
L121	O
,	O
L125	O
)	O
,	O
and	O
DMPC	O
lipid	O
bilayers	O
were	O
unequivocally	O
observed	O
.	O

On	O
the	O
other	O
hand	O
,	O
interaction	O
between	O
L99	O
and	O
the	O
lipid	O
bilayer	O
also	O
agrees	O
with	O
our	O
previous	O
results	O
obtained	O
by	O
high	O
-	O
resolution	O
MAS	O
NMR	O
and	O
solution	O
NMR	O
on	O
the	O
rabbit	O
cytochrome	B
b_5	I
embedded	O
in	O
dodecyl	O
-	O
phosphocholine	O
(	O
DPC	O
)	O
micelles	O
^	O
,	O
.	O

Our	O
experimental	O
results	O
suggest	O
that	O
the	O
transmembrane	O
topology	O
of	O
cytochrome	B
b_5	I
can	O
be	O
determined	O
using	O
the	O
aforementioned	O
protein	O
-	O
lipid	O
interactions	O
,	O
as	O
shown	O
in	O
Fig	O
.	O

The	O
distance	O
between	O
the	O
^	O
13C	O
labeled	O
positions	O
of	O
W113	O
and	O
L125	O
is	O
22	O
.	O
4	O
based	O
on	O
the	O
PDB	O
structure	O
of	O
cytochrome	B
b_5	I
^	O
.	O

This	O
topological	O
information	O
of	O
the	O
ALPHA	O
-	O
helix	O
domain	O
of	O
cytochrome	B
b_5	I
in	O
DMPC	O
lipid	O
bilayers	O
is	O
in	O
excellent	O
agreement	O
with	O
our	O
previous	O
ssNMR	O
studies	O
on	O
magnetically	O
-	O
aligned	O
bicelles	O
(	O
15	O
3	O
)	O
^	O
,	O
.	O

This	O
suggests	O
that	O
intermolecular	O
interactions	O
between	O
cytochrome	B
b_5	I
and	O
DMPC	O
lipid	O
bilayers	O
,	O
including	O
side	O
chain	O
-	O
lipid	O
interactions	O
,	O
can	O
be	O
retained	O
even	O
under	O
frozen	O
conditions	O
,	O
even	O
though	O
the	O
lipid	O
phases	O
vary	O
from	O
liquid	O
-	O
crystalline	O
phase	O
to	O
gel	O
phase	O
under	O
these	O
two	O
distinct	O
experimental	O
conditions	O
.	O

Purified	O
labeled	O
proteins	O
,	O
both	O
rabbit	O
cytochrome	B
b_5	I
and	O
cytochrome	O
2B4	O
,	O
were	O
first	O
assembled	O
into	O
a	O
complex	O
,	O
and	O
then	O
reconstituted	O
into	O
DMPC	O
lipid	O
bilayers	O
hydrated	O
with	O
AMUPol	O
solutions	O
containing	O
[	O
D_8	O
]	O
glycerol	O
/	O
D_2O	O
/	O
H_2O	O
(	O
60	O
:	O
30	O
:	O
10	O
volume	O
ratio	O
)	O
as	O
described	O
in	O
the	O
materials	O
and	O
methods	O
section	O
.	O

At	O
these	O
cryogenic	O
temperatures	O
,	O
cytochrome	B
b_5	I
maintains	O
its	O
topology	O
and	O
ALPHA	O
-	O
helical	O
structure	O
in	O
the	O
transmembrane	O
region	O
,	O
hence	O
the	O
functional	O
transmembrane	O
complex	O
of	O
cytochromes	O
can	O
be	O
retained	O
under	O
the	O
experimental	O
conditions	O
employed	O
in	O
this	O
study	O
.	O

According	O
to	O
these	O
studies	O
,	O
the	O
molecular	O
interactions	O
in	O
the	O
soluble	O
domains	O
of	O
cytochromes	O
exhibit	O
dynamic	O
encounter	O
complexes	O
mediated	O
by	O
both	O
hydrophobic	O
and	O
electrostatic	O
interactions	O
with	O
multiple	O
complex	O
formations	O
,	O
which	O
were	O
explained	O
through	O
the	O
mutagenesis	O
studies	O
and	O
line	O
-	O
broadening	O
of	O
unformly	O
-	O
^	O
15N	O
labeled	O
cytochrome	B
b_5	I
using	O
solution	O
NMR	O
spectroscopy	O
^	O
.	O

Interestingly	O
,	O
the	O
presence	O
of	O
highly	O
conserved	O
LxxxL	O
motif	O
between	O
L121	O
and	O
L125	O
was	O
observed	O
in	O
the	O
amino	O
acid	O
sequences	O
of	O
cytochrome	B
b_5	I
from	O
various	O
eukaryotes	O
,	O
as	O
shown	O
in	O
Fig	O
.	O

The	O
experimental	O
results	O
indicate	O
that	O
the	O
topology	O
of	O
cytochrome	O
b_5	O
in	O
the	O
DMPC	O
lipid	O
bilayers	O
suggest	O
that	O
amino	O
acid	O
residues	O
,	O
L121	O
and	O
L125	O
are	O
located	O
near	O
the	O
upper	O
chain	O
/	O
glycerol	O
region	O
,	O
which	O
has	O
an	O
unique	O
environment	O
for	O
membrane	O
-	O
associated	O
proteins	O
.	O

In	O
particular	O
,	O
the	O
remarkable	O
sensitivity	O
enhancement	O
of	O
NMR	O
signals	O
achieved	O
by	O
DNP	O
at	O
cryogenic	O
temperatures	O
can	O
potentially	O
provide	O
structural	O
information	O
of	O
in	O
-	O
vivo	O
membrane	O
protein	O
complexes	O
at	O
-	O
work	O
,	O
as	O
we	O
have	O
recently	O
demonstrated	O
for	O
cytochrome	O
b_5	O
in	O
in	O
-	O
cell	O
conditions	O
^	O
,	O
.	O

Here	O
,	O
we	O
used	O
the	O
mitochondrial	O
cytochrome	B
b	I
(	O
Cytb	O
)	O
and	O
12	O
nuclear	O
DNA	O
loci	O
to	O
investigate	O
phylogeographic	O
structures	O
of	O
the	O
sharpbelly	O
(	O
Hemiculter	O
leucisculus	O
)	O
in	O
rivers	O
in	O
southern	O
China	O
and	O
explored	O
how	O
the	O
geological	O
and	O
climatic	O
factors	O
have	O
shaped	O
the	O
genetic	O
diversity	O
and	O
evolutionary	O
history	O
of	O
this	O
species	O
.	O

The	O
partial	O
mitochondrial	O
cytochrome	B
b	I
gene	O
(	O
Cytb	O
)	O
was	O
amplified	O
for	O
all	O
individuals	O
using	O
the	O
universal	O
primers	O
L14724	O
and	O
H15915	O
.	O

We	O
also	O
evaluated	O
the	O
effectiveness	O
of	O
coenzymes	O
of	O
two	O
of	O
the	O
microsomal	O
reductases	O
,	O
NADPH	O
as	O
a	O
coenzyme	O
of	O
POR	O
,	O
and	O
NADH	O
as	O
a	O
coenzyme	O
of	O
NADH	O
:	O
cytochrome	B
b	I
5	I
reductase	O
,	O
to	O
mediate	O
ellipticine	O
oxidation	O
in	O
these	O
enzyme	O
systems	O
.	O

The	O
second	O
electron	O
needed	O
for	O
the	O
reduction	O
of	O
CYP	O
in	O
the	O
monooxygenase	O
reaction	O
cycle	O
may	O
also	O
be	O
provided	O
by	O
cytochrome	B
b	I
_5	I
in	O
the	O
presence	O
of	O
POR	O
or	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
,	O
but	O
cytochrome	B
b	I
_5	I
also	O
plays	O
additional	O
roles	O
in	O
the	O
monooxygenase	O
system	O
.	O

It	O
was	O
demonstrated	O
that	O
a	O
second	O
electron	O
donor	O
,	O
cytochrome	B
b	I
_5	I
,	O
could	O
also	O
modulate	O
(	O
stimulate	O
and	O
/	O
or	O
inhibit	O
)	O
the	O
activity	O
of	O
several	O
CYPs	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
amounts	O
of	O
the	O
detoxification	O
metabolites	O
(	O
7	O
-	O
hydroxyellipticine	O
and	O
9	O
-	O
hydroxyellipticine	O
)	O
were	O
not	O
changed	O
with	O
added	O
cytochrome	B
b	I
_5	I
,	O
whereas	O
oxidation	O
of	O
ellipticine	O
to	O
12	O
-	O
hydroxyellipticine	O
,	O
13	O
-	O
hydroxyellipticine	O
,	O
and	O
ellipticine	O
N	O
^	O
2	O
-	O
oxide	O
,	O
the	O
metabolites	O
responsible	O
for	O
the	O
formation	O
of	O
covalent	O
DNA	O
adducts	O
,	O
increased	O
considerably	O
.	O

In	O
addition	O
to	O
the	O
classical	O
reductase	O
POR	O
with	O
its	O
cofactor	O
NADPH	O
,	O
cytochrome	B
b	I
_5	I
plus	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
has	O
come	O
into	O
focus	O
,	O
and	O
,	O
therefore	O
,	O
its	O
role	O
in	O
ellipticine	O
oxidation	O
was	O
the	O
aim	O
of	O
this	O
study	O
.	O

NADPH	O
and	O
NADH	O
,	O
cofactors	O
of	O
the	O
two	O
microsomal	O
reductases	O
POR	O
and	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
,	O
respectively	O
,	O
were	O
utilized	O
as	O
electron	O
donors	O
for	O
CYP	O
-	O
mediated	O
ellipticine	O
oxidation	O
.	O

In	O
this	O
system	O
,	O
reconstitution	O
with	O
cytochrome	B
b	I
_5	I
only	O
increased	O
the	O
formation	O
of	O
12	O
-	O
hydroxy	O
-	O
and	O
13	O
-	O
hydroxyellipticine	O
but	O
not	O
that	O
of	O
9	O
-	O
hydroxyellipticine	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
function	O
of	O
cytochrome	B
b	I
_5	I
in	O
this	O
reaction	O
is	O
complex	O
.	O

Ellipticine	O
oxidation	O
does	O
not	O
only	O
occur	O
in	O
the	O
presence	O
of	O
the	O
coenzymes	O
of	O
POR	O
,	O
NADPH	O
,	O
but	O
also	O
in	O
the	O
presence	O
of	O
NADH	O
,	O
which	O
is	O
the	O
exclusive	O
coenzyme	O
of	O
another	O
microsomal	O
reductase	O
,	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
.	O

However	O
,	O
because	O
they	O
are	O
microsomes	O
(	O
particles	O
of	O
broken	O
endoplasmic	O
reticulum	O
)	O
,	O
other	O
enzymes	O
(	O
proteins	O
)	O
of	O
the	O
endoplasmic	O
reticulum	O
membrane	O
(	O
ie	O
NADH	O
:	O
cytochrome	B
b	I
_5	O
reductase	O
and	O
cytochrome	B
b	I
_5	O
)	O
are	O
also	O
expressed	O
at	O
basal	O
levels	O
in	O
these	O
Supersomes	O
(	O
Gentest	O
Corp	O
.	O
,	O
Woburn	O
,	O
MI	O
,	O
USA	O
)	O
.	O

However	O
,	O
reduction	O
of	O
CoM	O
-	O
S	O
-	O
S	O
-	O
CoB	O
is	O
catalyzed	O
by	O
a	O
membrane	O
-	O
bound	O
heterodisulfide	O
reductase	O
,	O
which	O
obtains	O
electrons	O
from	O
reduced	O
methanophenazine	O
(	O
MPhH_2	O
,	O
functionally	O
analogous	O
to	O
quinoles	O
)	O
via	O
its	O
cytochrome	B
b	I
subunit	O
,	O
which	O
is	O
coupled	O
to	O
the	O
generation	O
of	O
a	O
proton	O
motive	O
force	O
.	O

During	O
hydrogenotrophic	O
methanogenesis	O
,	O
a	O
membrane	O
-	O
bound	O
(	O
F_420	O
non	O
-	O
reducing	O
)	O
hydrogenase	O
(	O
Vho	O
)	O
oxidizes	O
H_2	O
and	O
transfers	O
electrons	O
via	O
cytochrome	B
b	I
to	O
oxidized	O
methanophenazine	O
,	O
again	O
generating	O
a	O
proton	O
motive	O
force	O
.	O

(	O
presence	O
of	O
CYP	O
and	O
cytochrome	O
b5	O
)	O
.	O

The	O
maximum	O
activity	O
of	O
7	O
-	O
ethoxyresorufin	O
-	O
o	O
-	O
deethylase	O
(	O
EROD	B
)	O
is	O
substantially	O
higher	O
(	O
1	O
.	O
2	O
-	O
3	O
.	O
0	O
-	O
fold	O
)	O
for	O
PeCDF	O
than	O
TCDD	O
with	O
the	O
same	O
TEQ	O
dose	O
.	O

observed	O
significant	O
,	O
nonadditive	O
interaction	O
for	O
EROD	B
activity	O
at	O
31	O
and	O
53	O
weeks	O
in	O
the	O
tertiary	O
mixture	O
exposed	O
samples	O
but	O
not	O
at	O
14	O
weeks	O
.	O

Both	O
activities	O
(	O
EROD	B
and	O
phenacetin	O
deethylase	O
)	O
were	O
not	O
markedly	O
changed	O
after	O
a	O
freezing	O
/	O
thawing	O
cycle	O
,	O
whereas	O
Kao	O
et	O
al	O
.	O

In	O
mice	O
,	O
berberine	O
(	O
300	O
mg	O
/	O
kg	O
)	O
increased	O
hepatic	O
Cyp1a2	B
mRNA	O
without	O
affecting	O
EROD	B
activity	O
.	O

B	O
(	O
a	O
)	O
P	O
(	O
2	O
M	O
,	O
24	O
h	O
)	O
stimulated	O
cellular	O
EROD	B
activity	O
by	O
2	O
-	O
fold	O
in	O
MCF	O
-	O
7	O
cells	O
,	O
but	O
not	O
in	O
MB	O
-	O
231	O
cells	O
.	O

In	O
MCF	O
-	O
7	O
and	O
MB	O
-	O
231	O
cells	O
,	O
the	O
24	O
-	O
h	O
exposure	O
to	O
0	O
.	O
2	O
-	O
20	O
M	O
berberine	O
,	O
palmatine	O
and	O
jatrorrhizine	O
did	O
not	O
significantly	O
affect	O
cellular	O
EROD	B
activity	O
.	O

Even	O
after	O
prolonging	O
the	O
exposure	O
time	O
to	O
48	O
h	O
,	O
10	O
M	O
berberine	O
did	O
not	O
increase	O
EROD	B
activity	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

The	O
bioavailability	O
and	O
metabolism	O
of	O
CsA	O
are	O
controlled	O
by	O
efflux	O
pumps	O
belonging	O
to	O
the	O
ABC	O
transporter	O
family	O
as	O
Pgp	O
and	O
members	O
of	O
the	O
cytochrome	B
P	I
-	I
450	I
isoenzyme	O
,	O
and	O
CsA	O
can	O
thus	O
be	O
involved	O
in	O
the	O
activity	O
of	O
efflux	O
pumps	O
.	O

The	O
aqueous	O
extract	O
of	O
A	O
.	O
paniculata	O
significantly	O
increased	O
the	O
pentoxyresorufin	O
O	O
-	O
dealkylase	O
activity	O
,	O
suggesting	O
that	O
A	O
.	O
paniculata	O
constituents	O
might	O
affect	O
hepatic	O
cytochrome	B
P	I
-	I
450	I
enzyme	O
.	O

PMS	O
was	O
reported	O
to	O
be	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
human	O
cytochrome	B
P	I
-	I
450	I
(	O
CYP1B1	O
)	O
.	O

Various	O
molecules	O
such	O
as	O
heme	O
,	O
fatty	O
acid	O
2	O
-	O
hydroxylase	O
,	O
cytochrome	B
P	I
-	I
450	I
enzymes	O
,	O
insulin	O
receptor	O
,	O
epidermal	O
growth	O
factor	O
receptor	O
,	O
Erbb2	O
,	O
and	O
membrane	O
progestin	O
receptor	O
ALPHA	O
(	O
mPRALPHA	O
,	O
PAQR7	O
)	O
can	O
interact	O
and	O
associate	O
with	O
Pgrmc1	O
.	O

Similarly	O
,	O
the	O
blue	O
light	O
induced	O
the	O
expression	O
of	O
putative	O
LDA	O
enzymes	O
including	O
aryl	O
-	O
alcohol	O
dehydrogenase	O
(	O
XLOC_008717	O
)	O
,	O
pyranose	O
2	O
-	O
oxidase	O
(	O
XLOC_009983	O
)	O
,	O
and	O
monooxygenase	O
(	O
XLOC_003435	O
)	O
and	O
the	O
red	O
light	O
influenced	O
the	O
expression	O
of	O
cytochrome	B
P	I
-	I
450	I
(	O
XLOC_007791	O
,	O
XLOC_00671	O
,	O
XLOC_006683	O
,	O
XLOC_001969	O
,	O
and	O
XLOC_007717	O
)	O
.	O

Cytochrome	B
c	I
is	O
a	O
component	O
of	O
the	O
ETC	O
.	O

Cytochrome	B
c	I
is	O
fused	O
with	O
subunit	O
II	O
in	O
these	O
enzymes	O
.	O

Cytochrome	B
c	I
oxidase	O
activity	O
was	O
visualized	O
using	O
the	O
Nadi	O
assay	O
according	O
to	O
the	O
method	O
described	O
previously	O
.	O

Electricity	O
Generation	O
by	O
Shewanella	O
decolorationis	O
S12	O
without	O
Cytochrome	B
c	I
.	O
Bacterial	O
extracellular	O
electron	O
transfer	O
(	O
EET	O
)	O
plays	O
a	O
key	O
role	O
in	O
various	O
natural	O
and	O
engineering	O
processes	O
.	O

Cytochrome	B
c	I
is	O
essential	O
for	O
the	O
anaerobic	O
growth	O
of	O
Shewanella	O
species	O
.	O

Cytochrome	O
c1	O
in	O
ductal	O
carcinoma	O
in	O
situ	O
of	O
breast	O
associated	O
with	O
proliferation	O
and	O
comedo	O
necrosis	O
.	O

Cytochrome	O
c1	O
(	O
CYC1	O
)	O
is	O
a	O
subunit	O
of	O
complex	O
III	O
in	O
the	O
mitochondrial	O
oxidative	O
phosphorylation	O
that	O
is	O
involved	O
in	O
energy	O
production	O
.	O

Cytochrome	B
c	I
release	O
was	O
detected	O
by	O
using	O
immunofluorescence	O
.	O

Cytochrome	B
c	I
then	O
forms	O
an	O
apoptosome	O
containing	O
apoptosis	O
activating	O
factor	O
1	O
and	O
caspase	O
-	O
9	O
,	O
which	O
then	O
activates	O
the	O
downstream	O
apoptotic	O
signals	O
.	O

Analysis	O
of	O
a	O
Functional	O
Dimer	O
Model	O
of	O
Ubiquinol	O
Cytochrome	B
c	I
Oxidoreductase	O
.	O

Cytochrome	B
c	I
and	O
transferrin	O
were	O
cross	O
-	O
linked	O
with	O
a	O
redox	O
sensitive	O
disulfide	O
bond	O
for	O
the	O
intra	O
-	O
cellular	O
release	O
of	O
the	O
protein	O
upon	O
endocytosis	O
by	O
the	O
transferrin	O
receptor	O
.	O

Cytochrome	B
c	I
(	O
Cyt	O
c	O
)	O
is	O
one	O
such	O
protein	O
that	O
has	O
attracted	O
the	O
attention	O
of	O
research	O
groups	O
due	O
to	O
its	O
potential	O
to	O
be	O
developed	O
into	O
a	O
potent	O
and	O
selective	O
anticancer	O
drug	O
.	O

Mutagenesis	O
Study	O
of	O
the	O
Cytochrome	B
c	I
Subunit	O
Responsible	O
for	O
the	O
Direct	O
Electron	O
Transfer	O
-	O
Type	O
Catalytic	O
Activity	O
of	O
FAD	O
-	O
Dependent	O
Glucose	O
Dehydrogenase	O
.	O

Cytochrome	B
c	I
release	O
from	O
mitochondria	O
to	O
cytosol	O
is	O
a	O
hallmark	O
of	O
apoptosis	O
and	O
is	O
often	O
utilized	O
to	O
characterize	O
the	O
mitochondria	O
-	O
dependent	O
apoptotic	O
pathway	O
.	O

Cytochrome	B
c	I
forms	O
a	O
complex	O
with	O
the	O
cytoplasmic	O
protein	O
Apaf	O
-	O
1	O
and	O
pro	O
-	O
caspase	O
-	O
9	O
that	O
is	O
termed	O
the	O
apoptosome	O
that	O
results	O
in	O
activation	O
of	O
caspase	O
-	O
3	O
,	O
leading	O
to	O
systematic	O
disassembly	O
of	O
the	O
cell	O
.	O

Cytochrome	B
c	I
,	O
mobile	O
in	O
Extracellular	O
Polymeric	O
Substances	O
or	O
associated	O
with	O
cytoplasmic	O
membranes	O
,	O
is	O
widely	O
reported	O
as	O
the	O
reducing	O
/	O
oxidizing	O
equivalent	O
during	O
microorganism	O
-	O
metal	O
oxide	O
redox	O
reactions	O
^	O
,	O
and	O
was	O
chosen	O
here	O
as	O
a	O
model	O
molecule	O
.	O

Cytochrome	B
c	I
oxidases	O
,	O
both	O
aa3	O
-	O
and	O
cbb3	O
-	O
type	O
,	O
were	O
widespread	O
in	O
all	O
three	O
lake	O
environments	O
and	O
frequently	O
co	O
-	O
occurred	O
within	O
MAGs	O
.	O

Cytochrome	B
c	I
levels	O
were	O
examined	O
as	O
described	O
previously	O
with	O
minor	O
modification	O
(	O
Choi	O
and	O
Lee	O
,	O
;	O
Yun	O
and	O
Lee	O
,	O
.	O

Cytochrome	B
c	I
release	O
from	O
the	O
mitochondria	O
to	O
the	O
cytoplasm	O
is	O
a	O
crucial	O
event	O
,	O
which	O
activates	O
metacaspase	O
,	O
thereby	O
inducing	O
apoptosis	O
(	O
Wu	O
et	O
al	O
.	O
,	O
.	O

Cytochrome	B
c	I
showed	O
a	O
significant	O
response	O
to	O
Bombyx	O
Mori	O
Nucleopolyhedrovirus	O
infection	O
in	O
our	O
previous	O
transcriptome	O
study	O
.	O

Apart	O
from	O
this	O
QC	O
also	O
reported	O
as	O
an	O
inhibitor	O
of	O
cytochrome	B
P450	I
enzyme	I
which	O
is	O
the	O
main	O
enzyme	O
of	O
Mycophenolic	O
Acid	O
metabolism	O
(	O
;	O
.	O

In	O
addition	O
,	O
the	O
blood	O
circulation	O
time	O
of	O
Mycophenolic	O
Acid	O
also	O
increased	O
by	O
QC	O
through	O
inhibition	O
of	O
Mycophenolic	O
Acid	O
metabolism	O
mediated	O
by	O
cytochrome	B
P450	I
enzyme	I
as	O
discussed	O
blow	O
in	O
pharmacokinetic	O
analysis	O
.	O

For	O
the	O
evaluation	O
of	O
the	O
inhibitory	O
effects	O
of	O
dimethyllirioresinol	O
,	O
epimagnolin	O
A	O
,	O
eudesmin	O
,	O
fargesin	O
,	O
and	O
magnolin	O
on	O
CYP2B6	B
-	O
catalyzed	O
bupropion	O
hydroxylation	O
,	O
each	O
incubation	O
mixture	O
in	O
a	O
total	O
volume	O
of	O
100	O
L	O
contained	O
50	O
mM	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
10	O
mM	O
MgCl_2	O
,	O
pooled	O
human	O
liver	O
microsomes	O
(	O
0	O
.	O
2	O
mg	O
/	O
mL	O
)	O
,	O
50	O
M	O
bupropion	O
,	O
and	O
various	O
concentrations	O
of	O
dimethyllirioresinol	O
,	O
epimagnolin	O
A	O
,	O
eudesmin	O
,	O
fargesin	O
,	O
or	O
magnolin	O
in	O
acetonitrile	O
(	O
0	O
.	O
1	O
-	O
100	O
M	O
)	O
,	O
according	O
to	O
our	O
previous	O
report	O
.	O

Efavirenz	O
is	O
metabolized	O
through	O
CYP2B6	B
.	O

The	O
prevalence	O
of	O
poor	O
phenotypes	O
of	O
CYP2B6	B
has	O
been	O
reported	O
to	O
be	O
as	O
high	O
as	O
20	O
.	O
56	O
%	O
in	O
a	O
study	O
performed	O
in	O
similar	O
population	O
.	O

They	O
were	O
created	O
by	O
crossbreeding	O
a	O
previously	O
created	O
transgenic	O
strain	O
containing	O
CYP2A13	O
/	O
CYP2B6	B
/	O
CYP2F1	O
with	O
the	O
CYP2F2	O
KO	O
mice	O
.	O

The	O
CYP2B6	B
enzyme	O
metabolizes	O
bupropion	O
,	O
cyclophosphamide	O
,	O
efavirenz	O
,	O
ketamine	O
,	O
methadone	O
,	O
as	O
well	O
as	O
other	O
drugs	O
.	O

CYP2B6	B
*	O
4	O
(	O
K262R	O
)	O
variation	O
confers	O
increased	O
enzyme	O
activity	O
,	O
while	O
CYP2B6	B
*	O
6	O
is	O
a	O
haplotype	O
that	O
includes	O
both	O
K262R	O
and	O
Q172H	O
and	O
confers	O
reduced	O
function	O
;	O
it	O
is	O
common	O
among	O
different	O
ethnic	O
groups	O
.	O

For	O
example	O
,	O
in	O
the	O
Yupik	O
AN	O
population	O
,	O
the	O
reported	O
CYP2B6	B
*	O
6	O
,	O
was	O
51	O
.	O
7	O
%	O
.	O

Unlike	O
CYP2A6	O
,	O
CYP2B6	B
genotype	O
was	O
not	O
found	O
to	O
be	O
associated	O
with	O
nicotine	O
metabolism	O
in	O
this	O
population	O
.	O

Previous	O
studies	O
found	O
weak	O
linkage	O
disequilibrium	O
between	O
the	O
CYP2A6	O
and	O
CYP2B6	B
genes	O
(	O
localized	O
together	O
on	O
chromosome	O
19	O
)	O
,	O
however	O
,	O
Binnington	O
et	O
al	O
.	O

The	O
authors	O
proposed	O
that	O
the	O
unique	O
linkage	O
disequilibrium	O
observed	O
between	O
the	O
reference	O
CYP2A6	O
*	O
1B	O
allele	O
and	O
the	O
low	O
activity	O
CYP2B6	B
*	O
6	O
allele	O
may	O
be	O
responsible	O
for	O
the	O
higher	O
nicotine	O
metabolism	O
in	O
Yupik	O
individuals	O
with	O
CYP2B6	B
*	O
6	O
genotype	O
.	O

One	O
of	O
the	O
structural	O
determinants	O
of	O
substrate	O
specificity	O
for	O
cyclophosphamide	O
,	O
which	O
is	O
an	O
antitumor	O
prodrug	O
,	O
has	O
been	O
recently	O
identified	O
in	O
CYP2B6	B
and	O
CYP2B11	O
enzymes	O
.	O

CYP2B11	O
presents	O
a	O
K_M	O
for	O
cyclophosphamide	O
50	O
-	O
fold	O
lower	O
than	O
that	O
of	O
CYP2B6	B
.	O

The	O
CYP2B6	B
sequence	O
was	O
sliced	O
into	O
15	O
contiguous	O
sequence	O
modules	O
and	O
each	O
of	O
them	O
was	O
used	O
to	O
replace	O
its	O
counterpart	O
into	O
the	O
CYP2B11	O
backbone	O
,	O
generating	O
15	O
individual	O
chimeras	O
.	O

One	O
of	O
the	O
15	O
chimeras	O
,	O
namely	O
,	O
chimera	O
G	O
,	O
was	O
found	O
to	O
be	O
exhibit	O
an	O
affinity	O
for	O
cyclophosphamide	O
that	O
was	O
similar	O
to	O
that	O
of	O
CYP2B6	B
though	O
its	O
sequence	O
is	O
that	O
of	O
CYP2B11	O
with	O
a	O
minor	O
change	O
of	O
six	O
residues	O
into	O
those	O
of	O
the	O
CYP2B6	B
sequence	O
.	O

When	O
positioned	O
on	O
the	O
crystal	O
structure	O
of	O
CYP2B6	B
,	O
these	O
changes	O
are	O
found	O
to	O
be	O
located	O
on	O
the	O
F	O
/	O
G	O
region	O
,	O
inside	O
the	O
F	O
/	O
G	O
region	O
.	O

The	O
entrance	O
of	O
channel	O
2f	O
,	O
one	O
of	O
the	O
several	O
access	O
channels	O
viewed	O
in	O
CYP2B6	B
,	O
is	O
lined	O
by	O
the	O
F	O
/	O
G	O
elements	O
.	O

When	O
these	O
fifteen	O
CYP2B6	B
/	O
2B11	O
chimeras	O
were	O
assayed	O
with	O
a	O
marker	O
CYP2B	O
substrate	O
,	O
namely	O
7	O
-	O
ethoxy	O
-	O
4	O
-	O
trifluorometyl	O
-	O
coumarin	O
,	O
they	O
all	O
exhibit	O
a	O
similar	O
affinity	O
for	O
this	O
fluorogenic	O
substrate	O
.	O

reported	O
that	O
in	O
adult	O
human	O
skin	O
the	O
CYP2B6	B
RNA	O
,	O
but	O
not	O
CYP2A6	O
and	O
3A4	O
mRNAs	O
decreased	O
with	O
increasing	O
age	O
.	O

No	O
CYP2A6	O
and	O
3A4	O
mRNA	O
was	O
seen	O
in	O
the	O
human	O
keratinocyte	O
cell	O
line	O
HCaT	O
,	O
while	O
CYP2B6	B
mRNA	O
levels	O
were	O
about	O
the	O
same	O
as	O
in	O
skin	O
(	O
Janmohamed	O
et	O
al	O
.	O
.	O
Rea	O
et	O
al	O
.	O

observed	O
similar	O
levels	O
of	O
the	O
mRNAs	O
of	O
CYP2B6	B
/	O
7	O
,	O
CYP	O
2E1	O
,	O
CYP	O
reductase	O
and	O
the	O
aryl	O
hydrocarbon	O
receptor	O
nuclear	O
translocator	O
,	O
while	O
that	O
of	O
CY1A1	O
,	O
1B1	O
and	O
aryl	O
hydrocarbon	O
receptor	O
RNA	O
levels	O
were	O
higher	O
in	O
the	O
SVpgC2a	O
cells	O
.	O

reported	O
the	O
finding	O
of	O
CYP2B6	B
mRNA	O
in	O
human	O
skin	O
,	O
Baron	O
et	O
al	O
.	O

did	O
neither	O
detect	O
CYP2B6	B
mRNA	O
in	O
human	O
skin	O
nor	O
in	O
primary	O
human	O
keratinocytes	O
nor	O
in	O
fibroblasts	O
nor	O
in	O
Langerhans	O
cells	O
.	O

did	O
not	O
detect	O
CYP2B6	B
mRNA	O
in	O
the	O
three	O
-	O
dimensional	O
reconstructed	O
human	O
skin	O
models	O
EpiDerm	O
^	O
and	O
StrataTest	O
^	O
.	O

that	O
CYP2B6	B
mRNA	O
levels	O
ranged	O
in	O
skin	O
biopsies	O
from	O
27	O
individuals	O
from	O
the	O
highest	O
values	O
measured	O
for	O
10	O
CYPs	O
down	O
to	O
undetected	O
.	O

reported	O
that	O
in	O
the	O
human	O
epidermis	O
CYP2B6	B
protein	O
was	O
detected	O
and	O
was	O
localized	O
in	O
the	O
suprabasal	O
cell	O
layers	O
.	O

Most	O
but	O
not	O
all	O
studies	O
report	O
failure	O
of	O
finding	O
CYP2B6	B
-	O
dependent	O
enzymatic	O
activities	O
in	O
human	O
skin	O
or	O
human	O
skin	O
-	O
derived	O
preparations	O
.	O

Attempts	O
to	O
induce	O
PROD	O
activities	O
in	O
the	O
human	O
reconstructed	O
skin	O
model	O
EpiDerm	O
^	O
using	O
quite	O
a	O
number	O
of	O
CYP2B6	B
inducers	O
(	O
phenobarbital	O
,	O
rifampicin	O
,	O
6	O
-	O
(	O
4	O
-	O
chlorophenyl	O
)	O
imidazo	O
[	O
2	O
,	O
1	O
-	O
b	O
]	O
[	O
1	O
,	O
3	O
]	O
thiazole	O
-	O
5	O
-	O
carbaldehyde	O
-	O
O	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorobenzyl	O
)	O
oxime	O
(	O
CITCO	O
)	O
as	O
well	O
as	O
cyclophosphamide	O
)	O
also	O
failed	O
(	O
Gtz	O
et	O
al	O
.	O
.	O
In	O
contrast	O
to	O
these	O
negative	O
findings	O
Baron	O
et	O
al	O
.	O

As	O
found	O
in	O
skin	O
-	O
derived	O
preparations	O
or	O
in	O
other	O
systems	O
CYP2B6	B
is	O
active	O
toward	O
:	O
several	O
physiological	O
substrates	O
(	O
including	O
17BETA	O
-	O
estradiol	O
,	O
estrone	O
,	O
testosterone	O
,	O
retinoic	O
acid	O
)	O
,	O
xenobiotic	O
compounds	O
(	O
including	O
coumarin	O
,	O
nicotine	O
,	O
cyclophosphamide	O
,	O
ochratoxin	O
A	O
)	O
(	O
Ekins	O
and	O
Wrighton	O
;	O
Oesch	O
-	O
Bartlomowicz	O
and	O
Oesch	O
.	O

CYP2B6	B
,	O
1A1	O
,	O
and	O
3A4	O
,	O
have	O
not	O
been	O
directly	O
related	O
to	O
Parkinsons	O
Disease	O
,	O
but	O
they	O
also	O
have	O
an	O
important	O
role	O
in	O
the	O
central	O
nervous	O
system	O
as	O
they	O
can	O
be	O
regulated	O
by	O
several	O
xenobiotics	O
in	O
both	O
the	O
liver	O
and	O
the	O
brain	O
.	O

In	O
the	O
liver	O
,	O
CYP2B6	B
is	O
involved	O
in	O
the	O
metabolism	O
of	O
therapeutic	O
drugs	O
and	O
other	O
exogenous	O
and	O
endogenous	O
compounds	O
.	O

Additionally	O
,	O
CYP2B6	B
has	O
been	O
found	O
in	O
the	O
frontal	O
cortex	O
of	O
human	O
brain	O
and	O
other	O
brain	O
areas	O
of	O
African	O
Green	O
monkeys	O
.	O

CNS	O
-	O
acting	O
drugs	O
,	O
such	O
as	O
bupropion	O
or	O
selegiline	O
,	O
can	O
be	O
therefore	O
be	O
metabolized	O
by	O
CYP2B6	B
.	O

456254	O
)	O
,	O
CYP2B6	B
(	O
Lot	O
No	O
.	O

Nicotine	O
oxidation	O
by	O
genetic	O
variants	O
of	O
CYP2B6	B
and	O
in	O
human	O
brain	O
microsomes	O
.	O

CYP2B6	B
is	O
a	O
minor	O
contributor	O
to	O
hepatic	O
nicotine	O
metabolism	O
,	O
but	O
the	O
enzyme	O
has	O
been	O
proposed	O
as	O
relevant	O
to	O
nicotinerelated	O
behaviors	O
because	O
of	O
reported	O
CYP2B6	B
mRNA	O
expression	O
in	O
human	O
brain	O
tissue	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
CYP2B6	B
variants	O
would	O
be	O
associated	O
with	O
altered	O
nicotine	O
oxidation	O
,	O
and	O
that	O
nicotine	O
metabolism	O
by	O
CYP2B6	B
would	O
be	O
detected	O
in	O
human	O
brain	O
microsomes	O
.	O

We	O
generated	O
recombinant	O
enzymes	O
in	O
insect	O
cells	O
corresponding	O
to	O
nine	O
common	O
CYP2B6	B
haplotypes	O
and	O
demonstrate	O
genetically	O
determined	O
differences	O
in	O
nicotine	O
oxidation	O
to	O
nicotine	O
iminium	O
ion	O
and	O
nornicotine	O
for	O
both	O
(	O
S	O
)	O
and	O
(	O
R	O
)	O
nicotine	O
.	O

Notably	O
,	O
the	O
CYP2B6	B
.	O
6	O
and	O
CYP2B6	B
.	O
9	O
variants	O
demonstrated	O
lower	O
intrinsic	O
clearance	O
relative	O
to	O
the	O
reference	O
enzyme	O
,	O
CYP2B6	B
.	O
1	O
.	O

Furthermore	O
,	O
metabolism	O
of	O
common	O
CYP2B6	B
probe	O
substrates	O
,	O
methadone	O
and	O
ketamine	O
,	O
is	O
not	O
detected	O
in	O
the	O
presence	O
of	O
brain	O
microsomes	O
.	O

We	O
conclude	O
that	O
CYP2B6	B
metabolizes	O
nicotine	O
stereoselectively	O
and	O
common	O
CYP2B6	B
variants	O
differ	O
in	O
nicotine	O
metabolism	O
activity	O
,	O
but	O
did	O
not	O
find	O
evidence	O
of	O
CYP2B6	B
activity	O
in	O
human	O
brain	O
.	O

CYP2B6	B
is	O
a	O
minor	O
contributor	O
to	O
hepatic	O
nicotine	O
metabolism	O
with	O
a	O
K	O
_m	O
approximately	O
10fold	O
higher	O
than	O
that	O
of	O
CYP2A6	O
.	O

Genetic	O
variation	O
in	O
the	O
CYP2B6	B
locus	O
has	O
a	O
small	O
but	O
clinically	O
insignificant	O
influence	O
on	O
in	O
vivo	O
nicotine	O
clearance	O
in	O
most	O
subjects	O
,	O
,	O
but	O
may	O
be	O
important	O
in	O
CYP2A6	O
slow	O
metabolizers	O
.	O

CYP2B6	B
has	O
also	O
been	O
reported	O
to	O
be	O
expressed	O
in	O
human	O
brain	O
tissue	O
,	O
unlike	O
CYP2A6	O
,	O
and	O
it	O
has	O
therefore	O
been	O
proposed	O
that	O
genetic	O
variation	O
affecting	O
the	O
CYP2B6	B
enzyme	O
might	O
play	O
a	O
significant	O
role	O
in	O
nicotinerelated	O
phenotypes	O
.	O

CYP2B6	B
is	O
highly	O
polymorphic	O
,	O
and	O
common	O
haplotypes	O
,	O
especially	O
CYP2B6	B
*	O
6	O
and	O
*	O
9	O
,	O
containing	O
516G	O
>	O
T	O
(	O
Q172H	O
,	O
minor	O
allele	O
frequency	O
26	O
%	O
in	O
European	O
Americans	O
,	O
37	O
%	O
in	O
African	O
Americans	O
(	O
http	O
:	O
/	O
/	O
eversusgs	O
.	O
washington	O
.	O
edu	O
/	O
EVS	O
/	O
)	O
)	O
are	O
associated	O
with	O
clinically	O
significantly	O
altered	O
pharmacokinetics	O
for	O
different	O
substrates	O
,	O
relative	O
to	O
the	O
reference	O
allele	O
.	O
,	O
Because	O
the	O
effects	O
of	O
CYP2B6	B
polymorphisms	O
on	O
CYP2B6	B
activity	O
is	O
substratespecific	O
,	O
activities	O
of	O
different	O
CYP2B6	B
isoforms	O
cannot	O
be	O
assumed	O
for	O
untested	O
substrates	O
,	O
such	O
as	O
nicotine	O
.	O

Therefore	O
,	O
we	O
have	O
expressed	O
polymorphic	O
CYP2B6	B
enzymes	O
and	O
measured	O
their	O
nicotine	O
metabolism	O
activity	O
in	O
vitro	O
.	O

CYP2B6	B
variants	O
,	O
reference	O
allele	O
P450	O
oxidoreductase	O
(	O
POR	O
)	O
,	O
and	O
reference	O
allele	O
cytochrome	O
b	O
_5	O
vectors	O
were	O
previously	O
generated	O
,	O
and	O
recombinant	O
proteins	O
previously	O
expressed	O
in	O
insect	O
cells	O
,	O
as	O
described	O
.	O
,	O
Haplotype	O
selection	O
was	O
based	O
on	O
the	O
known	O
clinical	O
significance	O
and	O
frequency	O
of	O
the	O
polymorphism	O
,	O
and	O
a	O
desire	O
to	O
inform	O
the	O
mechanistic	O
basis	O
for	O
the	O
influence	O
of	O
these	O
polymorphisms	O
on	O
metabolism	O
.	O

There	O
is	O
growing	O
evidence	O
that	O
the	O
influence	O
of	O
CYP2B6	B
polymorphisms	O
varies	O
between	O
substrates	O
,	O
and	O
may	O
vary	O
between	O
enantiomers	O
of	O
those	O
substrates	O
.	O

Results	O
were	O
expressed	O
as	O
fmol	O
min	O
^	O
1	O
mg	O
^	O
1	O
of	O
total	O
brain	O
protein	O
,	O
as	O
CYP2B6	B
protein	O
was	O
not	O
detectable	O
.	O

Incubations	O
with	O
recombinant	O
CYP2B6	B
/	O
POR	O
/	O
b5	O
proceeded	O
for	O
10	O
minutes	O
and	O
incubations	O
with	O
human	O
brain	O
microsomes	O
proceeded	O
for	O
1	O
hour	O
,	O
unless	O
otherwise	O
noted	O
,	O
following	O
a	O
2minute	O
preincubation	O
and	O
initiation	O
with	O
25	O
,	O
50	O
,	O
100	O
,	O
250	O
,	O
500	O
,	O
1000	O
,	O
1	O
,	O
500	O
,	O
or	O
2	O
,	O
000	O
mol	O
L	O
^	O
1	O
Snicotine	O
or	O
Rnicotine	O
(	O
Toronto	O
Research	O
Chemicals	O
,	O
Toronto	O
,	O
Canada	O
)	O
in	O
the	O
presence	O
of	O
1	O
mmol	O
L	O
^	O
1	O
NADPH	O
(	O
SigmaAldrich	O
,	O
St	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
retention	O
times	O
for	O
nicotine	O
iminium	O
and	O
nornicotine	O
(	O
a	O
minor	O
CYP2B6	B
nicotine	O
metabolite	O
)	O
were	O
2	O
.	O
5	O
and	O
3	O
.	O
7	O
minutes	O
,	O
respectively	O
;	O
for	O
cis	O
and	O
trans	O
nicotineNoxide	O
,	O
they	O
were	O
4	O
.	O
7	O
and	O
5	O
.	O
2	O
minutes	O
,	O
respectively	O
.	O

Nine	O
recombinant	O
versions	O
of	O
the	O
CYP2B6	B
enzymes	O
,	O
representing	O
common	O
CYP2B6	B
haplotypes	O
,	O
were	O
expressed	O
to	O
assess	O
their	O
relative	O
nicotine	O
metabolism	O
activities	O
.	O

In	O
order	O
to	O
determine	O
if	O
effects	O
on	O
CYP2B6	B
nicotine	O
metabolism	O
activity	O
were	O
also	O
enantiomerspecific	O
,	O
incubations	O
with	O
four	O
CYP2B6	B
haplotypes	O
were	O
repeated	O
with	O
(	O
R	O
)	O
nicotinenicotine	O
and	O
(	O
S	O
)	O
nicotine	O
,	O
but	O
differences	O
between	O
CYP2B6	B
variants	O
appear	O
consistent	O
,	O
that	O
is	O
,	O
the	O
activity	O
of	O
CYP2B6	B
.	O
6	O
,	O
was	O
again	O
lower	O
than	O
the	O
reference	O
allele	O
enzyme	O
for	O
nicotine	O
iminum	O
(	O
Cl_int	O
=	O
0	O
.	O
8	O
vs	O
1	O
.	O
8	O
L	O
^	O
1	O
min	O
^	O
1	O
nmol	O
^	O
1	O
)	O
and	O
nornicotine	O
(	O
Cl_int	O
=	O
0	O
.	O
1	O
vs	O
0	O
.	O
2	O
L	O
^	O
1	O
min	O
^	O
1	O
nmol	O
^	O
1	O
)	O
.	O

Interestingly	O
,	O
the	O
regioselectivity	O
of	O
the	O
enzyme	O
,	O
that	O
is	O
,	O
the	O
metabolite	O
ratio	O
of	O
nicotine	O
iminium	O
ion	O
vs	O
nornicotine	O
,	O
was	O
relatively	O
consistent	O
among	O
different	O
CYP2B6	B
variants	O
,	O
but	O
differed	O
between	O
(	O
S	O
)	O
and	O
(	O
R	O
)	O
nicotine	O
(	O
Tables	O
and	O
.	O

On	O
further	O
characterizing	O
one	O
brain	O
,	O
we	O
found	O
the	O
NADPHindependent	O
nicotineiminium	O
formation	O
did	O
not	O
follow	O
MichaelisMenten	O
kinetics	O
and	O
ketamine	O
(	O
80	O
mol	O
L	O
^	O
1	O
)	O
,	O
the	O
approximate	O
K	O
_m	O
for	O
CYP2B6	B
for	O
each	O
substrate	O
.	O
,	O
Neither	O
2ethylidene1	O
,	O
5dimethyl3	O
,	O
3diphenylpyrrolidine	O
(	O
EDDP	O
)	O
nor	O
norketamine	O
were	O
detected	O
,	O
respectively	O
.	O

Importantly	O
,	O
common	O
functional	O
polymorphisms	O
in	O
CYP2B6	B
alter	O
enzyme	O
activity	O
in	O
a	O
substratedependent	O
manner	O
,	O
,	O
and	O
thus	O
it	O
is	O
important	O
to	O
evaluate	O
these	O
enzyme	O
variants	O
for	O
any	O
CYP2B6	B
substrate	O
.	O

The	O
differences	O
we	O
report	O
,	O
both	O
for	O
(	O
S	O
)	O
nicotine	O
and	O
(	O
R	O
)	O
nicotine	O
,	O
confirm	O
the	O
expectation	O
of	O
altered	O
activities	O
for	O
common	O
variants	O
including	O
CYP2B6	B
.	O
6	O
and	O
CYP2B6	B
.	O
9	O
,	O
relative	O
to	O
the	O
reference	O
allele	O
enzyme	O
,	O
CYP2B6	B
.	O
1	O
.	O

Of	O
particular	O
interest	O
are	O
the	O
differences	O
in	O
activity	O
related	O
to	O
the	O
two	O
amino	O
acid	O
changes	O
,	O
Q172H	O
and	O
K262R	O
,	O
which	O
individually	O
define	O
the	O
CYP2B6	B
*	O
9	O
and	O
CYP2B6	B
*	O
4	O
variants	O
respectively	O
,	O
and	O
together	O
define	O
the	O
very	O
common	O
CYP2B6	B
*	O
6	O
haplotype	O
.	O

For	O
most	O
substrates	O
,	O
activity	O
of	O
the	O
CYP2B6	B
.	O
9	O
variant	O
is	O
exceptionally	O
low	O
,	O
activity	O
of	O
the	O
CYP2B6	B
.	O
4	O
variant	O
is	O
similar	O
or	O
greater	O
than	O
that	O
of	O
the	O
reference	O
allele	O
,	O
while	O
the	O
activity	O
of	O
CYP2B6	B
.	O
6	O
lies	O
between	O
CYP2B6	B
.	O
4	O
and	O
CYP2B6	B
.	O
9	O
,	O
depending	O
on	O
substrate	O
.	O
,	O
This	O
demonstrates	O
that	O
the	O
K262R	O
amino	O
acid	O
change	O
can	O
partially	O
compensate	O
for	O
the	O
Q172H	O
lossoffunction	O
,	O
depending	O
on	O
substrate	O
,	O
and	O
we	O
find	O
this	O
to	O
be	O
the	O
case	O
for	O
nicotine	O
as	O
well	O
.	O

CYP2B6	B
*	O
6	O
is	O
the	O
most	O
commonly	O
studied	O
variant	O
haplotype	O
because	O
of	O
its	O
high	O
population	O
frequency	O
and	O
has	O
been	O
associated	O
with	O
low	O
activity	O
in	O
vivo	O
.	O
,	O
However	O
,	O
it	O
is	O
also	O
important	O
to	O
note	O
that	O
part	O
of	O
this	O
loss	O
of	O
activity	O
may	O
be	O
due	O
to	O
differences	O
in	O
mRNA	O
or	O
protein	O
expression	O
or	O
splicing	O
,	O
and	O
not	O
strictly	O
related	O
to	O
catalytic	O
activity	O
.	O
,	O
CYP2B6	B
*	O
6	O
(	O
and	O
CYP2B6	B
*	O
9	O
)	O
have	O
also	O
been	O
reportedly	O
associated	O
with	O
more	O
rapid	O
in	O
vivo	O
nicotine	O
metabolism	O
.	O

Although	O
H19	O
does	O
not	O
seem	O
to	O
play	O
a	O
role	O
in	O
bile	O
acid	O
synthesis	O
,	O
its	O
direct	O
repressor	O
,	O
SHP	O
,	O
represses	O
CYP7A1	O
and	O
CYP8B1	O
after	O
activation	O
by	O
FXR	O
.	O

The	O
genes	O
that	O
are	O
overexpressed	O
in	O
Theca	O
cells	O
(	O
cluster	O
4	O
)	O
are	O
particularly	O
involved	O
in	O
cholesterol	O
import	O
(	O
SCARB1	O
,	O
STARD5	O
)	O
,	O
bile	O
acid	O
metabolism	O
(	O
CH25H	O
)	O
,	O
HDL	O
-	O
mediated	O
lipid	O
transport	O
(	O
APOA1	O
,	O
PLTP	O
,	O
SCARB1	O
)	O
,	O
lipid	O
degradation	O
(	O
LPL	O
,	O
PLIN5	O
)	O
,	O
and	O
steroidogenesis	O
(	O
CYP27A	O
,	O
CYP7B1	O
,	O
TM7SF2	O
)	O
.	O

According	O
to	O
the	O
Karu	O
model	O
,	O
red	O
(	O
~	O
630	O
nm	O
)	O
photons	O
are	O
absorbed	O
in	O
cytochrome	B
C	I
oxidase	O
,	O
a	O
key	O
enzyme	O
in	O
the	O
electron	O
transport	O
chain	O
embedded	O
within	O
the	O
membrane	O
of	O
mitochondria	O
.	O

Further	O
investigation	O
on	O
intracellular	O
mechanisms	O
indicated	O
that	O
cytochrome	B
C	I
was	O
released	O
from	O
mitochondria	O
into	O
cytosol	O
in	O
A549	O
cells	O
after	O
Se	O
-	O
PPC	O
treatment	O
.	O

This	O
assay	O
was	O
performed	O
according	O
to	O
cytochrome	B
C	I
releasing	O
apoptosis	O
assay	O
kits	O
(	O
Biovision	O
,	O
San	O
Francisco	O
,	O
CA	O
,	O
USA	O
)	O
instructions	O
.	O

Then	O
western	O
blot	O
proceeded	O
with	O
cytochrome	B
C	I
antibody	O
(	O
Biovision	O
,	O
San	O
Francisco	O
,	O
CA	O
,	O
USA	O
)	O
.	O

We	O
found	O
that	O
ALPHA	O
-	O
mangostin	O
effectively	O
inhibited	O
cell	O
viability	O
,	O
resulted	O
in	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
,	O
release	O
of	O
cytochrome	B
C	I
,	O
increase	O
of	O
Bax	O
,	O
decrease	O
of	O
Bcl	O
-	O
2	O
,	O
and	O
activation	O
of	O
caspase	O
-	O
9	O
/	O
caspase	O
-	O
3	O
cascade	O
in	O
cervical	O
cancer	O
cells	O
.	O

To	O
further	O
demonstrate	O
ALPHA	O
-	O
mangostin	O
-	O
induced	O
apoptotic	O
cell	O
death	O
in	O
cervical	O
cancer	O
cells	O
,	O
mitochondrial	O
membrane	O
potential	O
,	O
expression	O
of	O
apoptosis	O
activator	O
,	O
Bax	O
,	O
and	O
anti	O
-	O
apoptotic	O
protein	O
,	O
Bcl	O
-	O
2	O
,	O
and	O
release	O
of	O
cytochrome	B
C	I
were	O
tested	O
.	O

A	O
simultaneous	O
increase	O
of	O
pro	O
-	O
apoptotic	O
proteins	O
,	O
including	O
Bax	O
and	O
cytochrome	B
C	I
,	O
and	O
a	O
decrease	O
in	O
anti	O
-	O
apoptotic	O
protein	O
,	O
Bcl	O
-	O
2	O
,	O
were	O
also	O
observed	O
upon	O
treatment	O
of	O
increased	O
concentrations	O
of	O
ALPHA	O
-	O
mangostin	O
in	O
both	O
HeLa	O
and	O
SiHa	O
cells	O
(	O
Figure	O
and	O
.	O

In	O
summary	O
,	O
results	O
of	O
these	O
experiments	O
demonstrate	O
that	O
ALPHA	O
-	O
mangostin	O
enhances	O
Reactive	O
Oxygen	O
Species	O
amounts	O
to	O
activate	O
the	O
ASK	O
/	O
p38	O
signaling	O
pathway	O
and	O
damage	O
the	O
integrity	O
of	O
mitochondria	O
,	O
including	O
loss	O
of	O
Membrane	O
Potential	O
,	O
increase	O
of	O
Bax	O
and	O
cytochrome	B
C	I
release	O
,	O
and	O
decrease	O
of	O
Bcl	O
-	O
2	O
,	O
leading	O
to	O
activation	O
of	O
caspase	O
-	O
9	O
/	O
caspase	O
-	O
3	O
cascade	O
,	O
and	O
induction	O
of	O
apoptosis	O
in	O
cervical	O
cancer	O
cells	O
(	O
Figure	O
.	O

Results	O
of	O
the	O
present	O
study	O
have	O
shown	O
that	O
ALPHA	O
-	O
mangostin	O
induces	O
generation	O
of	O
Reactive	O
Oxygen	O
Species	O
to	O
activate	O
the	O
ASK	O
/	O
p38	O
signaling	O
pathway	O
and	O
rupture	O
mitochondria	O
,	O
followed	O
by	O
loss	O
of	O
Membrane	O
Potential	O
,	O
increase	O
of	O
Bax	O
and	O
cytochrome	B
C	I
release	O
,	O
decrease	O
of	O
Bcl	O
-	O
2	O
,	O
leading	O
to	O
triggering	O
caspase	O
-	O
9	O
/	O
caspase	O
-	O
3	O
cascade	O
and	O
inducing	O
apoptosis	O
in	O
cervical	O
cancer	O
cells	O
.	O

The	O
antibodies	O
against	O
phosphory	O
-	O
ERK	O
,	O
phosphory	O
-	O
p38	O
,	O
phosphory	O
-	O
JNK	O
,	O
ERK	O
,	O
p38	O
,	O
JNK	O
,	O
phosphory	O
-	O
MKK3	O
/	O
6	O
,	O
MKK3	O
/	O
6	O
,	O
Bcl	O
-	O
2	O
,	O
Bax	O
,	O
cytochrome	B
C	I
,	O
COX4	O
,	O
ALPHA	O
-	O
tubulin	O
,	O
BETA	O
-	O
actin	O
,	O
siRNA	O
-	O
ERK	O
,	O
siRNA	O
-	O
JNK	O
and	O
siRNA	O
-	O
p38	O
,	O
siRNA	O
-	O
ASK1	O
,	O
siRNA	O
-	O
MKK3	O
/	O
6	O
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Dallas	O
,	O
Texas	O
)	O
.	O

After	O
blocking	O
,	O
the	O
membrane	O
was	O
hybridized	O
with	O
the	O
antibodies	O
against	O
cleaved	O
-	O
caspase	O
-	O
3	O
(	O
1	O
:	O
1000	O
)	O
,	O
cleaved	O
-	O
caspase	O
-	O
9	O
(	O
1	O
:	O
1000	O
)	O
,	O
cleaved	O
-	O
PARP	O
(	O
1	O
:	O
1000	O
)	O
,	O
phosphory	O
-	O
ERK	O
(	O
1	O
:	O
1000	O
)	O
,	O
phosphory	O
-	O
p38	O
(	O
1	O
:	O
1000	O
)	O
,	O
phosphory	O
-	O
JNK	O
(	O
1	O
:	O
1000	O
)	O
,	O
ERK	O
(	O
1	O
:	O
2000	O
)	O
,	O
p38	O
(	O
1	O
:	O
1000	O
)	O
,	O
JNK	O
(	O
1	O
:	O
1000	O
)	O
,	O
phosphory	O
-	O
ASK1	O
(	O
1	O
:	O
1000	O
)	O
,	O
Apoptosis	O
Signal	O
-	O
Regulating	O
Kinase	O
1	O
(	O
1	O
:	O
1000	O
)	O
,	O
phosphory	O
-	O
MKK3	O
/	O
6	O
(	O
1	O
:	O
1000	O
)	O
,	O
MKK3	O
/	O
6	O
(	O
1	O
:	O
1000	O
)	O
,	O
Bcl	O
-	O
2	O
(	O
1	O
:	O
1000	O
)	O
,	O
Bax	O
(	O
1	O
:	O
1000	O
)	O
,	O
cytochrome	B
C	I
(	O
1	O
:	O
500	O
)	O
,	O
COX4	O
(	O
1	O
:	O
1000	O
)	O
,	O
ALPHA	O
-	O
tubulin	O
(	O
1	O
:	O
2000	O
)	O
and	O
BETA	O
-	O
actin	O
(	O
1	O
:	O
2000	O
)	O
.	O

Reduced	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
and	O
horse	O
cytochrome	B
C	I
were	O
obtained	O
from	O
Solarbio	O
Science	O
and	O
Technology	O
co	O
.	O
.	O
Methanol	O
and	O
acetonitrile	O
were	O
HPLC	O
grade	O
and	O
were	O
purchased	O
from	O
Siyou	O
Chemical	O
Reagent	O
Co	O
.	O
.	O
As	O
reported	O
recently	O
,	O
105	O
liver	O
samples	O
were	O
selected	O
from	O
123	O
liver	O
samples	O
obtained	O
from	O
patients	O
undergoing	O
liver	O
surgery	O
during	O
2012	O
and	O
2014	O
at	O
the	O
First	O
Affiliated	O
Hospital	O
of	O
Zhengzhou	O
University	O
,	O
the	O
Peoples	O
Hospital	O
of	O
Henan	O
Province	O
,	O
and	O
the	O
Tumors	O
Hospital	O
of	O
Henan	O
Province	O
.	O

Since	O
H_2S	O
blocks	O
aerobic	O
respiration	O
by	O
competing	O
with	O
O_2	O
for	O
cytochrome	B
C	I
oxidase	O
binding	O
,	O
Blh	O
helps	O
to	O
maintain	O
a	O
high	O
O_2	O
flux	O
,	O
especially	O
when	O
O_2	O
becomes	O
a	O
limiting	O
factor	O
to	O
the	O
cells	O
.	O

The	O
mitochondrial	O
stress	O
causes	O
both	O
the	O
release	O
of	O
cytochrome	B
C	I
,	O
the	O
conversion	O
of	O
the	O
procaspase	O
9	O
in	O
caspase	O
9	O
,	O
and	O
finally	O
the	O
activation	O
of	O
caspases	O
3	O
and	O
7	O
.	O

We	O
found	O
that	O
mitochondrial	O
release	O
of	O
cytochrome	B
C	I
into	O
the	O
cytoplasm	O
also	O
increased	O
,	O
indicating	O
that	O
apoptosis	O
had	O
been	O
activated	O
.	O

It	O
then	O
causes	O
mitochondrial	O
outer	O
membrane	O
permeabilization	O
,	O
releasing	O
cytochrome	B
C	I
and	O
inducing	O
apoptosis	O
.	O
,	O
In	O
this	O
study	O
,	O
after	O
transfection	O
of	O
B16	O
cells	O
with	O
pcDNA3	O
.	O
1UTB	O
,	O
cytochrome	B
C	I
was	O
released	O
from	O
mitochondria	O
;	O
downregulated	O
BCL2	O
and	O
upregulated	O
BAX	O
levels	O
were	O
related	O
to	O
melanoma	O
cell	O
apoptosis	O
,	O
presenting	O
further	O
evidence	O
that	O
the	O
p53	O
pathway	O
is	O
activated	O
when	O
UTB	O
is	O
overexpressed	O
in	O
B16	O
cells	O
.	O

Numerous	O
oxidative	O
metabolic	O
functions	O
were	O
identified	O
in	O
these	O
bins	O
,	O
including	O
oxygen	O
respiration	O
,	O
thiosulfate	O
oxidation	O
through	O
the	O
Sox	O
pathway	O
and	O
metal	O
oxidation	O
via	O
multiheme	O
cytochrome	B
C	I
.	O
A	O
strong	O
metabolic	O
potential	O
for	O
degradation	O
of	O
various	O
organic	O
compounds	O
,	O
including	O
urea	O
,	O
hydrocarbons	O
and	O
aromatic	O
compounds	O
was	O
also	O
identified	O
.	O

Apoptosis	O
rate	O
,	O
cytochrome	B
C	I
and	O
cleaved	O
caspase3	O
increased	O
,	O
and	O
cell	O
viability	O
decreased	O
following	O
bubble	O
contact	O
for	O
10	O
,	O
20	O
or	O
30	O
minutes	O
,	O
but	O
not	O
for	O
1	O
or	O
5	O
minutes	O
.	O

Cell	O
viability	O
,	O
apoptosis	O
rate	O
and	O
expressions	O
of	O
cytochrome	B
C	I
and	O
cleaved	O
caspase3	O
were	O
determined	O
prior	O
to	O
the	O
experiment	O
for	O
assessing	O
endothelial	O
function	O
at	O
12	O
hours	O
following	O
bubble	O
contact	O
.	O

Although	O
neonatal	O
survival	O
is	O
associated	O
with	O
CYP1A2	O
in	O
Cyp1a2	B
knockout	O
mice	O
,	O
the	O
relationship	O
between	O
retinol	O
and	O
reproductive	O
diseases	O
remains	O
unclear	O
.	O

For	O
example	O
,	O
as	O
early	O
as	O
in	O
1995	O
,	O
Gonzalez	O
and	O
colleagues	O
reported	O
that	O
neonatal	O
deaths	O
were	O
observed	O
in	O
the	O
Cyp1a2	B
global	O
Knockout	O
mouse	O
model	O
,	O
possibly	O
due	O
to	O
respiratory	O
distress	O
caused	O
by	O
Cyp1a2	B
deficiency	O
.	O

Cyp1a2	B
Knockout	O
mice	O
liver	O
cDNA	O
microarray	O
analysis	O
showed	O
that	O
Cyp1a2	B
deficiency	O
affected	O
insulin	O
function	O
,	O
lipogenesis	O
,	O
fatty	O
acid	O
biosynthesis	O
and	O
cholesterol	O
biosynthesis	O
.	O

48	O
h	O
after	O
application	O
of	O
7	O
,	O
12	O
-	O
Dimethylbenz	O
[	O
A	O
]	O
Anthracene	O
,	O
skin	O
expression	O
of	O
Pxr	O
and	O
Cyp1a1	O
mRNAs	O
were	O
markedly	O
increased	O
,	O
Cyp1b1	O
and	O
Cyp3a11	O
only	O
moderately	O
and	O
Ahr	O
not	O
at	O
all	O
.	O

Expression	O
of	O
Cyp1b1	O
and	O
Cyp1a1	O
mRNAs	O
peaked	O
at	O
4	O
h	O
,	O
expression	O
of	O
Cyp3a11	O
mRNA	O
peaked	O
at	O
24	O
h	O
(	O
upregulation	O
of	O
Pregnane	O
X	O
Receptor	O
in	O
the	O
DMBA	O
-	O
treated	O
skin	O
was	O
confirmed	O
at	O
the	O
protein	O
level	O
)	O
.	O

We	O
observed	O
a	O
significant	O
increase	O
in	O
the	O
expression	O
of	O
Cyp3a11	O
in	O
female	O
SPF	O
mice	O
compared	O
to	O
the	O
male	O
group	O
.	O

However	O
,	O
the	O
sex	O
differences	O
were	O
erased	O
in	O
GF	O
mice	O
,	O
and	O
the	O
expression	O
of	O
Cyp3a11	O
was	O
about	O
the	O
same	O
in	O
both	O
sexes	O
.	O

The	O
Cyp3a11	O
mRNA	O
was	O
significantly	O
increased	O
(	O
21	O
times	O
)	O
in	O
female	O
SPF	O
mice	O
compared	O
to	O
their	O
male	O
counterparts	O
.	O

The	O
expression	O
of	O
Cyp3a13	O
was	O
slightly	O
increased	O
in	O
the	O
females	O
of	O
both	O
the	O
group	O
SPF	O
and	O
GF	O
mice	O
.	O

A	O
higher	O
expression	O
of	O
Cyp3a11	O
in	O
female	O
mice	O
than	O
males	O
was	O
reported	O
earlier	O
(	O
;	O
.	O

Sort	O
=	O
Bait	O
immobilized	O
on	O
the	O
optical	O
chip	O
and	O
identified	O
another	O
potential	O
protein	O
partner	O
(	O
CYP11B2	B
)	O
.	O

Sort	O
=	O
Bait	O
CYP11B2	B
interaction	O
.	O

It	O
was	O
shown	O
that	O
all	O
protein	O
analytes	O
,	O
except	O
for	O
CYP11B2	B
,	O
did	O
not	O
bind	O
to	O
Https	O
:	O
/	O
/	O
Thebiogrid	O
.	O
org	O
/	O
112778	O
/	O
Summary	O
/	O
Homo	O
-	O
Sapiens	O
/	O
Tbxas1	O
.	O
Html	O
?	O

Sort	O
=	O
Bait	O
CYP11B2	B
and	O
Https	O
:	O
/	O
/	O
Thebiogrid	O
.	O
org	O
/	O
112778	O
/	O
Summary	O
/	O
Homo	O
-	O
Sapiens	O
/	O
Tbxas1	O
.	O
Html	O
?	O

Sort	O
=	O
Bait	O
CYP11B2	B
.	O

Sort	O
=	O
Bait	O
CYP11B2	B
complex	O
formation	O
was	O
a	O
new	O
and	O
unexpected	O
result	O
,	O
since	O
CYP11B2	B
was	O
not	O
identified	O
as	O
a	O
protein	O
partner	O
of	O
Https	O
:	O
/	O
/	O
Thebiogrid	O
.	O
org	O
/	O
112778	O
/	O
Summary	O
/	O
Homo	O
-	O
Sapiens	O
/	O
Tbxas1	O
.	O
Html	O
?	O

These	O
data	O
are	O
quite	O
comparable	O
,	O
they	O
are	O
not	O
due	O
to	O
the	O
false	O
-	O
negative	O
results	O
of	O
molecular	O
fishing	O
,	O
and	O
can	O
be	O
explained	O
in	O
terms	O
of	O
the	O
tissue	O
-	O
specific	O
CYP11B2	B
expression	O
profile	O
(	O
preferential	O
expression	O
in	O
the	O
adrenal	O
tissue	O
)	O
,	O
which	O
appears	O
from	O
the	O
information	O
in	O
the	O
open	O
Internet	O
resources	O
Proteinatlas	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
proteinatlas	O
.	O
org	O
)	O
and	O
Genecards	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
genecards	O
.	O
org	O
)	O
and	O
publications	O
[	O
38	O
]	O
.	O

Sort	O
=	O
Bait	O
and	O
CYP11B2	B
.	O

CYP11A1	B
converts	O
cholesterol	O
to	O
pregnenolone	O
,	O
followed	O
by	O
the	O
HSD3B2	O
-	O
catalyzed	O
conversion	O
of	O
pregnenolone	O
to	O
the	O
^	O
4	O
steroid	O
,	O
progesterone	O
.	O

Pregnenolone	O
,	O
produced	O
from	O
the	O
CYP11A1	B
catalyzed	O
side	O
-	O
chain	O
cleavage	O
of	O
cholesterol	O
,	O
is	O
converted	O
to	O
17ALPHA	O
-	O
hydroxyprogesterone	O
(	O
17OHP	O
)	O
,	O
the	O
universal	O
precursor	O
of	O
cortisol	O
production	O
,	O
by	O
HSD3B2	O
and	O
CYP17A1	O
17ALPHA	O
-	O
hydroxylase	O
activity	O
.	O

Examples	O
for	O
such	O
reactions	O
from	O
steroid	O
biosynthesis	O
are	O
the	O
side	O
-	O
chain	O
cleavage	O
of	O
cholesterol	O
catalyzed	O
by	O
CYP11A1	B
and	O
the	O
17	B
,	I
20	I
-	I
lyase	I
activity	O
of	O
CYP17A1	O
producing	O
C_19	O
steroids	O
from	O
C_21	O
substrates	O
(	O
Section	O
2	O
.	O
5	O
.	O
3	O
)	O
.	O

Anti	O
-	O
P450	O
autoantibodies	O
(	O
anti	O
-	O
liver	O
kidney	O
microsomal	O
Type	O
I	O
)	O
targeting	O
CYP2D6	O
are	O
also	O
detected	O
in	O
chronic	O
autoimmune	O
hepatitis	O
and	O
hepatitis	O
C	O
viral	O
infections	O
,	O
anti	O
-	O
CYP11A1	B
in	O
type	O
II	O
autoimmune	O
hepatic	O
polyendocrine	O
syndrome	O
,	O
and	O
anti	O
-	O
CYP17	B
and	O
anti	O
-	O
CYP21	O
in	O
Addison	O
'	O
s	O
disease	O
,	O
.	O

This	O
is	O
performed	O
by	O
CYP11A1	B
in	O
mammals	O
and	O
CYP90B1	O
in	O
plants	O
.	O

The	O
first	O
reaction	O
is	O
the	O
conversion	O
of	O
cholesterol	O
to	O
pregnenolone	O
by	O
the	O
cholesterol	O
side	O
-	O
chain	O
cleavage	O
enzyme	O
CYP11A1	B
.	O

In	O
vertebrates	O
,	O
the	O
conversion	O
of	O
cholesterol	O
to	O
pregnenolone	O
is	O
mediated	O
by	O
CYP11A1	B
homologues	O
.	O

CYP11A1	B
perform	O
a	O
triple	O
reaction	O
,	O
including	O
Adrenodoxin	O
reductase	O
,	O
Adrenodoxine	O
,	O
and	O
side	O
-	O
chain	O
cleavage	O
.	O

CYP11A1	B
performs	O
the	O
22R	O
-	O
C	O
hydroxylation	O
of	O
cholesterol	O
,	O
followed	O
by	O
20R	O
-	O
C	O
hydroxylation	O
(	O
B	O
)	O
.	O

CYP11A1	B
displays	O
a	O
cavity	O
,	O
called	O
a	O
sterol	O
-	O
binding	O
pocket	O
,	O
which	O
interacts	O
with	O
the	O
3BETA	O
-	O
hydroxyl	O
group	O
of	O
cholesterol	O
.	O

A	O
major	O
difference	O
between	O
CYP11A1	B
and	O
CYP90B1	O
is	O
the	O
stereo	O
specificity	O
.	O

Finally	O
,	O
CYP11B1	B
,	O
located	O
in	O
the	O
mitochondria	O
of	O
the	O
zona	O
fasciculata	O
cells	O
,	O
facilitates	O
the	O
final	O
step	O
in	O
glucocorticoid	O
biosynthesis	O
by	O
catalyzing	O
the	O
conversion	O
of	O
11	O
-	O
deoxycortisol	O
to	O
cortisol	O
.	O

Therefore	O
,	O
we	O
monitored	O
the	O
mRNA	O
and	O
protein	O
expression	O
of	O
CYPs	O
(	O
CYP	B
1A1	I
and	O
2A6	O
)	O
in	O
U1	O
cells	O
after	O
four	O
days	O
of	O
Cell	O
Culture	O
Supernatant	O
exposure	O
.	O

We	O
particularly	O
examined	O
the	O
expressions	O
of	O
CYP	B
1A1	I
and	O
2A6	O
,	O
because	O
these	O
CYPs	O
are	O
significantly	O
expressed	O
in	O
U1	O
cells	O
,	O
and	O
they	O
are	O
induced	O
by	O
various	O
xenobiotics	O
including	O
tobacco	O
constituents	O
and	O
environmental	O
contaminants	O
via	O
an	O
oxidative	O
stress	O
pathway	O
.	O

Further	O
,	O
the	O
commonly	O
used	O
housekeeping	O
genes	O
of	O
cells	O
,	O
actin	O
,	O
and	O
Glyceraldehyde	O
3	O
-	O
Phosphate	O
Dehydrogenase	O
,	O
were	O
detected	O
only	O
in	O
Caski	O
cells	O
but	O
not	O
in	O
their	O
Eversus	O
Finally	O
,	O
the	O
Extracellular	O
Vesicles	O
demonstrated	O
acetylcholine	O
esterase	O
activity	O
(	O
C	O
)	O
,	O
suggesting	O
the	O
isolation	O
of	O
functional	O
Eversus	O
To	O
determine	O
whether	O
oxidative	O
stress	O
plays	O
a	O
potential	O
role	O
in	O
Caski	O
cell	O
-	O
induced	O
effects	O
on	O
U1	O
cells	O
,	O
we	O
measured	O
important	O
oxidative	O
stress	O
-	O
inducing	O
CYP	O
enzymes	O
,	O
common	O
antioxidant	O
enzymes	O
(	O
AOE	O
)	O
,	O
and	O
Human	O
Papillomavirus	O
proteins	O
in	O
Caski	O
-	O
derived	O
Eversus	O
Our	O
Western	O
blot	O
images	O
showed	O
the	O
expression	O
of	O
CYP	O
enzymes	O
(	O
CYP	B
1A1	I
,	O
1B1	O
,	O
and	O
2A6	O
)	O
,	O
AOE	O
(	O
SOD1	O
)	O
,	O
and	O
Human	O
Papillomavirus	O
16	O
oncoprotein	O
E6	O
in	O
CCS	O
-	O
derived	O
Extracellular	O
Vesicles	O
(	O
A	O
;	O
.	O

Treatment	O
of	O
resveratrol	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
0001	O
,	O
n	O
=	O
3	O
)	O
,	O
ellipticine	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
0001	O
,	O
n	O
=	O
3	O
)	O
,	O
or	O
tryptamine	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
0001	O
,	O
n	O
=	O
3	O
)	O
significantly	O
reduced	O
the	O
viral	O
load	O
in	O
CCS	O
-	O
EVs	O
exposed	O
U1	O
cells	O
,	O
suggesting	O
the	O
role	O
of	O
CYP	B
1A1	I
and	O
2A6	O
,	O
and	O
oxidative	O
stress	O
on	O
viral	O
load	O
increase	O
in	O
U1	O
cells	O
(	O
A	O
,	O
B	O
)	O
.	O

Chinese	O
woodchucks	O
with	O
different	O
susceptibility	O
to	O
WHV	O
infection	O
differ	O
in	O
their	O
genetic	O
background	O
exemplified	O
by	O
cytochrome	B
B	I
and	O
MHC	O
-	O
DRB	O
molecules	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
susceptibility	O
to	O
WHV	O
infection	O
of	O
M	O
.	O
himalayana	O
from	O
different	O
areas	O
and	O
their	O
association	O
with	O
the	O
animal	O
genetic	O
background	O
exemplified	O
by	O
cytochrome	B
B	I
and	O
MHC	O
-	O
DRB	O
molecules	O
.	O

The	O
sequences	O
of	O
cytochrome	B
B	I
gene	O
and	O
MHC	O
-	O
DRB	O
molecules	O
were	O
obtained	O
and	O
sorted	O
with	O
Clustalx	O
software	O
.	O

All	O
of	O
the	O
animals	O
belong	O
to	O
the	O
same	O
subspecies	O
M	O
.	O
himalayana	O
robusta	O
identified	O
by	O
cytochrome	B
B	I
gene	O
sequences	O
.	O

Based	O
on	O
their	O
nucleotide	O
variation	O
pattern	O
,	O
8	O
alleles	O
of	O
cytochrome	B
B	I
gene	O
were	O
identified	O
,	O
and	O
7	O
MHC	O
-	O
DRB	O
alleles	O
were	O
identified	O
.	O

Allele	O
A	O
of	O
cytochrome	B
B	I
and	O
Allele	O
Mamo	O
-	O
DRB1	O
*	O
02	O
of	O
MHC	O
-	O
DRB	O
was	O
found	O
to	O
be	O
frequent	O
in	O
animals	O
from	O
TR	O
and	O
TD	O
areas	O
,	O
while	O
Allele	O
H	O
of	O
cytochrome	B
B	I
and	O
Allele	O
Mamo	O
-	O
DRB1	O
*	O
07	O
of	O
MHC	O
-	O
DRB	O
was	O
predominant	O
in	O
animals	O
from	O
GD	O
and	O
WL	O
areas	O
.	O

The	O
genetic	O
background	O
exemplified	O
by	O
cytochrome	B
B	I
and	O
MHC	O
-	O
DRB	O
differed	O
in	O
Chinese	O
woodchucks	O
with	O
different	O
susceptibility	O
to	O
WHV	O
infection	O
.	O

Therefore	O
,	O
partial	O
or	O
complete	O
sequences	O
of	O
the	O
mitochondrial	O
genome	O
,	O
in	O
particular	O
the	O
sequences	O
of	O
the	O
mitochondrial	O
cytochrome	B
B	I
,	O
have	O
been	O
used	O
extensively	O
in	O
studies	O
on	O
population	O
genetics	O
,	O
phylogeny	O
and	O
phylogeography	O
in	O
Rodentia	O
.	O

We	O
aimed	O
to	O
determine	O
the	O
association	O
between	O
WHV	O
infection	O
and	O
the	O
genetic	O
background	O
of	O
M	O
himalayana	O
exemplified	O
by	O
cytochrome	B
B	I
and	O
MHC	O
-	O
DRB	O
molecules	O
.	O

The	O
PCR	O
Primers	O
cytB	O
-	O
1	O
/	O
2	O
were	O
designed	O
according	O
to	O
the	O
cytochrome	B
B	I
sequence	O
of	O
M	O
.	O
Himalayan	O
(	O
AY143928	O
)	O
.	O

The	O
PCR	O
fragments	O
of	O
cytochrome	B
B	I
were	O
purified	O
and	O
subjected	O
to	O
direct	O
sequencing	O
from	O
both	O
orientations	O
using	O
primers	O
cytB	O
-	O
1	O
and	O
cytB	O
-	O
2	O
.	O

Whole	O
blood	O
was	O
collected	O
before	O
WHV	O
inoculation	O
,	O
and	O
cytochrome	B
B	I
gene	O
fragments	O
were	O
amplified	O
using	O
total	O
DNA	O
and	O
the	O
primer	O
cytB	O
-	O
1	O
and	O
cytB	O
-	O
2	O
.	O

The	O
PCR	O
products	O
were	O
directly	O
sequenced	O
,	O
and	O
cytochrome	B
B	I
sequences	O
from	O
37	O
Chinese	O
woodchucks	O
were	O
obtained	O
,	O
11	O
from	O
TR	O
area	O
,	O
8	O
from	O
TD	O
area	O
,	O
9	O
from	O
GD	O
area	O
,	O
and	O
9	O
from	O
WL	O
area	O
.	O

Notably	O
,	O
only	O
partial	O
sequence	O
of	O
cytochrome	B
B	I
gene	O
(	O
nt	O
64	O
-	O
1080	O
)	O
was	O
included	O
for	O
the	O
analysis	O
,	O
since	O
the	O
direct	O
sequencing	O
only	O
generated	O
reliable	O
data	O
for	O
the	O
middle	O
part	O
of	O
PCR	O
fragments	O
.	O

Based	O
on	O
the	O
pattern	O
of	O
the	O
substitutions	O
,	O
all	O
of	O
the	O
sequences	O
were	O
assigned	O
to	O
8	O
alleles	O
,	O
named	O
A	O
,	O
B	O
,	O
C	O
,	O
D	O
,	O
E	O
,	O
F	O
,	O
G	O
,	O
and	O
H	O
.	O
Chinese	O
woodchucks	O
mainly	O
belong	O
to	O
5	O
species	O
,	O
M	O
.	O
himalayana	O
,	O
M	O
.	O
sibirica	O
,	O
M	O
.	O
caudata	O
,	O
M	O
.	O
baibacina	O
,	O
and	O
M	O
.	O
bobak	O
,	O
therefore	O
the	O
cytochrome	B
B	I
sequences	O
of	O
the	O
5	O
Chinese	O
woodchuck	O
species	O
were	O
downloaded	O
from	O
GenBank	O
,	O
at	O
least	O
two	O
sequences	O
for	O
each	O
species	O
.	O

The	O
phylogenetic	O
tree	O
of	O
cytochrome	B
B	I
sequences	O
was	O
conducted	O
using	O
the	O
14	O
downloaded	O
sequences	O
and	O
the	O
8	O
alleles	O
,	O
and	O
indicated	O
that	O
all	O
of	O
the	O
animals	O
from	O
the	O
4	O
areas	O
belonged	O
to	O
the	O
same	O
species	O
M	O
.	O
himalayana	O
from	O
M	O
.	O
himalayana	O
robusta	O
was	O
published	O
by	O
Steppen	O
et	O
al	O
.	O
,	O
and	O
the	O
animals	O
were	O
collected	O
from	O
Yushu	O
,	O
Qinghai	O
,	O
China	O
.	O

Since	O
the	O
mitochondrial	O
DNA	O
haplotype	O
frequencies	O
were	O
considered	O
to	O
be	O
primarily	O
controlled	O
by	O
migration	O
and	O
genetic	O
drift	O
,	O
and	O
that	O
most	O
intraspecies	O
variation	O
is	O
selectively	O
neutral	O
,	O
we	O
compared	O
the	O
frequencies	O
of	O
the	O
8	O
cytochrome	B
B	I
alleles	O
in	O
the	O
animals	O
from	O
the	O
four	O
areas	O
have	O
allele	O
A	O
(	O
37	O
.	O
84	O
%	O
,	O
14	O
/	O
37	O
)	O
or	O
H	O
(	O
35	O
.	O
14	O
%	O
,	O
13	O
/	O
37	O
)	O
,	O
indicating	O
these	O
two	O
alleles	O
were	O
the	O
predominant	O
alleles	O
in	O
the	O
animals	O
from	O
TR	O
,	O
TD	O
,	O
GD	O
,	O
and	O
WL	O
areas	O
of	O
Qinghai	O
province	O
and	O
11	O
.	O
76	O
%	O
(	O
2	O
/	O
17	O
)	O
(	O
P	O
=	O
0	O
.	O
1089	O
)	O
,	O
respectively	O
,	O
while	O
those	O
of	O
allele	O
H	O
were	O
5	O
.	O
00	O
%	O
(	O
1	O
/	O
20	O
)	O
and	O
70	O
.	O
59	O
%	O
(	O
12	O
/	O
17	O
)	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
respectively	O
(	O
Table	O
.	O

These	O
results	O
indicated	O
allele	O
A	O
and	O
H	O
of	O
mitochondrial	O
cytochrome	B
B	I
gene	O
may	O
be	O
predominant	O
in	O
animals	O
with	O
the	O
high	O
or	O
low	O
replicative	O
pattern	O
of	O
WHV	O
infection	O
,	O
respectively	O
.	O

All	O
of	O
the	O
animals	O
belong	O
to	O
the	O
same	O
subspecies	O
M	O
.	O
himalayana	O
robusta	O
identified	O
by	O
the	O
analysis	O
of	O
mitochondrial	O
cytochrome	B
B	I
sequences	O
.	O

Based	O
on	O
the	O
profiles	O
of	O
the	O
nucleotide	O
substitutions	O
,	O
eight	O
different	O
alleles	O
of	O
mitochondrial	O
cytochrome	B
B	I
gene	O
were	O
identified	O
in	O
the	O
animals	O
used	O
in	O
this	O
study	O
.	O

Two	O
full	O
-	O
length	O
microsomal	O
P450s	O
,	O
namely	O
CYP19	B
aromatase	O
and	O
yeast	O
CYP51	O
,	O
have	O
also	O
been	O
crystallized	O
and	O
their	O
structure	O
shows	O
clearly	O
the	O
position	O
of	O
the	O
N	O
-	O
terminal	O
membrane	O
anchor	O
relative	O
to	O
the	O
rest	O
of	O
the	O
protein	O
.	O

The	O
methylated	O
isoflavone	O
,	O
biochanin	O
A	O
inhibits	O
aromatase	O
activity	O
when	O
a	O
significant	O
reduction	O
in	O
CYP19	B
mRNA	O
abundance	O
was	O
found	O
in	O
estrogen	O
receptor	O
-	O
negative	O
breast	O
cancer	O
cells	O
.	O

The	O
resulting	O
A4	O
(	O
and	O
testosterone	O
)	O
enters	O
the	O
granulosa	O
cells	O
where	O
the	O
expression	O
of	O
CYP19A1	O
(	O
aromatase	O
)	O
results	O
in	O
estrogen	O
biosynthesis	O
.	O

While	O
A4	O
can	O
be	O
metabolized	O
to	O
testosterone	O
by	O
AKR1C3	O
in	O
the	O
theca	O
cells	O
,	O
the	O
majority	O
diffuses	O
to	O
the	O
granulosa	O
cells	O
where	O
the	O
high	O
expression	O
levels	O
of	O
CYP19A1	O
results	O
in	O
the	O
production	O
of	O
estrone	O
.	O

Testosterone	O
diffusing	O
from	O
the	O
theca	O
cells	O
also	O
serves	O
as	O
the	O
substrate	O
for	O
CYP19A1	O
,	O
directly	O
contributing	O
to	O
17BETA	O
-	O
estradiol	O
production	O
.	O

Some	O
CYPs	O
metabolize	O
only	O
one	O
(	O
or	O
very	O
few	O
)	O
substrates	O
,	O
such	O
as	O
CYP19	B
(	O
aromatase	O
)	O
,	O
while	O
others	O
may	O
metabolize	O
multiple	O
substrates	O
.	O

The	O
X	O
-	O
ray	O
structures	O
and	O
data	O
of	O
protein	O
targets	O
were	O
obtained	O
from	O
the	O
protein	O
data	O
bank	O
(	O
www	O
.	O
rcsb	O
.	O
org	O
)	O
:	O
CYP17A1	O
(	O
17a	O
-	O
hydroxylase	O
/	O
C17	O
,	O
20	O
-	O
lyase	O
,	O
Protein	O
Data	O
Bank	O
ID	O
:	O
6CIZ	O
,	O
6CHI	O
,	O
6CIR	O
,	O
5UYS	O
,	O
4NKZ	O
,	O
4NKX	O
,	O
4NKV	O
,	O
4NKW	O
,	O
and	O
3RUK	O
)	O
and	O
CYP19A1	O
(	O
aromatase	O
,	O
Protein	O
Data	O
Bank	O
ID	O
:	O
3S7S	O
)	O
.	O

Estrogen	O
deficiency	O
in	O
men	O
with	O
mutations	O
in	O
the	O
gene	O
codifying	O
for	O
aromatase	O
(	O
CYP19A1	O
,	O
the	O
enzyme	O
converting	O
testosterone	O
in	O
estrogen	O
)	O
show	O
impaired	O
glucose	O
and	O
lipid	O
liver	O
metabolism	O
(	O
,	O
.	O

Hollenberg	O
and	O
his	O
coworkers	O
have	O
identified	O
several	O
putative	O
access	O
channels	O
in	O
CYP2B1	B
enzyme	O
using	O
CAVER	O
.	O

However	O
,	O
this	O
variant	O
was	O
catalyzing	O
the	O
O	O
-	O
deethylation	O
of	O
the	O
coumarin	O
substrate	O
at	O
a	O
rate	O
that	O
was	O
five	O
-	O
fold	O
lower	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
CYP2B1	B
.	O

The	O
differential	O
modification	O
of	O
the	O
dynamics	O
of	O
the	O
multiple	O
access	O
channels	O
in	O
CYP2B1	B
by	O
blocking	O
one	O
of	O
them	O
had	O
resulted	O
in	O
a	O
differential	O
impact	O
on	O
substrate	O
specificity	O
by	O
filling	O
the	O
empty	O
space	O
in	O
the	O
protein	O
periphery	O
.	O

Thus	O
,	O
CYP2B1	B
and	O
CYP2C11	O
,	O
in	O
cultured	O
rat	O
hepatocytes	O
treated	O
with	O
Autophagic	O
-	O
Lysosomal	O
Degradation	O
inhibitors	O
[	O
3	O
-	O
methyladenine	O
(	O
3MA	O
)	O
/	O
NH_4Cl	O
]	O
or	O
heterologously	O
expressed	O
in	O
a	O
vacuolar	O
(	O
lysosomal	O
)	O
degradation	O
-	O
deficient	O
S	O
.	O
cerevisiae	O
strain	O
,	O
are	O
stabilized	O
relative	O
to	O
those	O
expressed	O
in	O
wild	O
-	O
type	O
or	O
proteasomal	O
-	O
subunit	O
defective	O
strains	O
,	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
,	O
PROD	B
,	O
para	O
-	O
nitrophenol	O
hydroxylase	O
,	O
and	O
erythromycin	O
N	O
-	O
demethylase	O
activities	O
,	O
Das	O
et	O
al	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
4	O
.	O
62	O
0	O
.	O
54	O
,	O
PROD	B
below	O
detection	O
(	O
LOQ	O
1	O
.	O
87	O
pmol	O
)	O
,	O
tolbutamide	O
4	O
-	O
hydroxylation	O
1	O
.	O
66	O
0	O
.	O
49	O
,	O
bufuralol	O
1	O
-	O
hydroxylation	O
0	O
.	O
26	O
0	O
.	O
03	O
,	O
chlorzoxazone	O
6	O
-	O
hydroxylation	O
below	O
detection	O
(	O
LOQ	O
12	O
.	O
8	O
pmol	O
)	O
,	O
midazolam	O
1	O
-	O
hydroxylation	O
2	O
.	O
32	O
0	O
.	O
21	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
,	O
7	O
-	O
methoxyresorufin	O
-	O
O	O
-	O
demethylase	O
,	O
PROD	B
or	O
O	O
-	O
dealkylase	O
activities	O
for	O
7	O
-	O
methoxy	O
-	O
4	O
-	O
trifluoromethylcoumarin	O
(	O
broad	O
-	O
spectrum	O
CYP12	O
)	O
substrate	O
were	O
not	O
detected	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
and	O
PROD	B
activities	O
were	O
present	O
and	O
were	O
increased	O
by	O
treatment	O
with	O
the	O
CYP	O
inducers	O
3	O
-	O
methylcholanthrene	O
,	O
BETA	O
-	O
naphthoflavone	O
and	O
phenobarbital	O
and	O
decreased	O
by	O
the	O
presence	O
of	O
the	O
CYP	O
inhibitors	O
ALPHA	O
-	O
naphthoflavone	O
and	O
metyrapone	O
(	O
Gelardi	O
et	O
al	O
.	O
.	O
A	O
comparative	O
study	O
by	O
Gtz	O
et	O
al	O
.	O

PROD	B
activity	O
(	O
CYP2B	O
-	O
selective	O
)	O
was	O
not	O
increased	O
by	O
rifampicin	O
,	O
CITCO	O
(	O
6	O
-	O
(	O
4	O
-	O
chlorophenyl	O
)	O
imidazo	O
-	O
[	O
2	O
,	O
1	O
-	O
b	O
]	O
[	O
1	O
,	O
3	O
]	O
thiazole	O
-	O
5	O
-	O
carbaldehyde	O
-	O
O	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorobenzyl	O
)	O
oxime	O
)	O
or	O
cyclophosphamide	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
,	O
PROD	B
and	O
BROD	B
activities	O
were	O
below	O
the	O
Limit	O
Of	O
Detection	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
,	O
PROD	B
and	O
7	O
-	O
benzoxyresorufin	O
O	O
-	O
debenzylase	O
activities	O
were	O
observed	O
already	O
early	O
on	O
in	O
a	O
reconstructed	O
epidermis	O
model	O
generated	O
from	O
human	O
hair	O
follicles	O
of	O
the	O
outer	O
root	O
sheath	O
(	O
Pham	O
et	O
al	O
.	O
.	O
7	O
-	O
Ethoxycoumarin	O
-	O
O	O
-	O
Dealkylase	O
activity	O
was	O
seen	O
in	O
EpiSkin	O
^	O
and	O
was	O
increased	O
at	O
low	O
concentrations	O
of	O
the	O
CYP	O
inducers	O
and	O
inhibitors	O
econazole	O
and	O
clotrimazole	O
,	O
and	O
was	O
inhibited	O
in	O
presence	O
of	O
their	O
high	O
concentrations	O
(	O
Cotovio	O
et	O
al	O
.	O
.	O
Harris	O
et	O
al	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
0	O
.	O
001	O
nmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
for	O
PROD	B
0	O
.	O
0025	O
nmol	O
/	O
min	O
/	O
mg	O
protein	O
and	O
for	O
BROD	B
0	O
.	O
002	O
nmol	O
/	O
min	O
/	O
mg	O
protein	O
(	O
Jckh	O
et	O
al	O
.	O
.	O
In	O
EpiDerm	O
^	O
microsomes	O
no	O
Et	O
Al	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
,	O
7	O
-	O
Methoxyresorufin	O
-	O
O	O
-	O
Demethylase	O
,	O
PROD	B
or	O
7	O
-	O
methoxy	O
-	O
4	O
-	O
trifluoromethylcoumarin	O
O	O
-	O
dealkylase	O
activities	O
were	O
detected	O
(	O
LOD	O
for	O
Et	O
Al	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
and	O
PROD	B
activities	O
were	O
increased	O
by	O
treatment	O
with	O
3	O
-	O
methylcholanthrene	O
,	O
while	O
PROD	B
and	O
7	O
-	O
methoxy	O
-	O
4	O
-	O
trifluoromethylcoumarin	O
O	O
-	O
dealkylase	O
activities	O
remained	O
undetected	O
even	O
after	O
treatment	O
with	O
CITCO	O
(	O
6	O
-	O
(	O
4	O
-	O
chlorophenyl	O
)	O
imidazo	O
[	O
2	O
,	O
1	O
-	O
b	O
]	O
[	O
1	O
,	O
3	O
]	O
thiazole	O
-	O
5	O
-	O
carbaldehyde	O
-	O
O	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorobenzyl	O
)	O
oxime	O
)	O
or	O
rifampicin	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
,	O
PROD	B
or	O
BROD	B
activities	O
(	O
LOD	O
1	O
,	O
4	O
and	O
1	O
pmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
respectively	O
)	O
.	O

Paliperidone	O
is	O
not	O
metabolized	O
by	O
CYP	B
2D6	I
cytochrome	O
system	O
.	O

Replicated	O
associations	O
for	O
variants	O
in	O
CYP4X1	O
,	O
CYP24A1	O
,	O
and	O
CYP26B1	B
with	O
disease	O
-	O
free	O
survival	O
of	O
all	O
patients	O
or	O
patients	O
stratified	O
to	O
subgroups	O
according	O
to	O
therapy	O
type	O
have	O
not	O
passed	O
a	O
false	O
discovery	O
rate	O
test	O
.	O

The	O
rs62150087	O
in	O
CYP26B1	B
significantly	O
associated	O
with	O
Disease	O
-	O
Free	O
Survival	O
in	O
a	O
group	O
of	O
cytotoxic	O
therapy	O
-	O
treated	O
patients	O
(	O
p	O
=	O
0	O
.	O
016	O
,	O
HR	O
=	O
0	O
.	O
54	O
,	O
CI	O
=	O
0	O
.	O
33	O
-	O
0	O
.	O
89	O
)	O
,	O
but	O
not	O
in	O
unselected	O
patients	O
(	O
p	O
=	O
0	O
.	O
122	O
)	O
.	O

Variant	O
rs62150087	O
in	O
CYP26B1	B
was	O
significantly	O
associated	O
with	O
Disease	O
-	O
Free	O
Survival	O
in	O
the	O
HER2	O
-	O
enriched	O
group	O
of	O
the	O
patients	O
regardless	O
of	O
the	O
therapy	O
(	O
all	O
patients	O
or	O
patients	O
who	O
received	O
cytotoxic	O
therapy	O
)	O
.	O

The	O
variant	O
rs62150087	O
(	O
500	O
bp	O
downstream	O
of	O
CYP26B1	B
)	O
was	O
associated	O
with	O
Disease	O
-	O
Free	O
Survival	O
in	O
our	O
sets	O
of	O
patients	O
.	O

A	O
genome	O
-	O
wide	O
association	O
study	O
on	O
the	O
Chinese	O
population	O
identified	O
CYP26B1	B
as	O
a	O
candidate	O
gene	O
for	O
esophageal	O
squamous	O
cell	O
carcinoma	O
risk	O
.	O

According	O
to	O
the	O
authors	O
,	O
a	O
variant	O
rs138478634	O
in	O
CYP26B1	B
influences	O
the	O
risk	O
through	O
catabolism	O
of	O
an	O
anticancer	O
nutrient	O
all	O
-	O
trans	O
retinoic	O
acid	O
.	O

Considering	O
the	O
ability	O
of	O
CYP26B1	B
to	O
metabolize	O
retinoic	O
acid	O
,	O
there	O
is	O
support	O
for	O
the	O
observed	O
effect	O
of	O
rs62150087	O
on	O
worse	O
patient	O
survival	O
.	O

Both	O
the	O
Cytochrome	B
B	I
SYBR	O
and	O
probe	O
Polymerase	O
Chain	O
Reaction	O
protocols	O
showed	O
as	O
high	O
sensitivity	O
and	O
specificity	O
as	O
their	O
conventional	O
counterpart	O
,	O
except	O
missing	O
one	O
P	O
.	O
malariae	O
sample	O
.	O

For	O
use	O
in	O
clinical	O
diagnosis	O
and	O
epidemiological	O
studies	O
the	O
highly	O
sensitive	O
and	O
user	O
-	O
friendly	O
Cytochrome	B
B	I
SYBR	O
q	O
-	O
PCR	O
method	O
is	O
a	O
relevant	O
tool	O
.	O

Subsequently	O
,	O
mitochondrial	O
targets	O
,	O
such	O
as	O
Cytochrome	B
B	I
,	O
emerged	O
since	O
the	O
genome	O
is	O
conserved	O
and	O
exists	O
in	O
about	O
20	O
-	O
160	O
copies	O
depending	O
on	O
the	O
development	O
stage	O
[	O
,	O
.	O

A	O
genus	O
-	O
specific	O
Cytochrome	B
B	I
conventional	O
Polymerase	O
Chain	O
Reaction	O
has	O
proved	O
to	O
be	O
highly	O
sensitive	O
and	O
specific	O
in	O
field	O
studies	O
[	O
,	O
.	O

The	O
clinical	O
patient	O
material	O
,	O
used	O
to	O
assess	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
designed	O
Cytochrome	B
B	I
SYBR	O
/	O
TaqMan	O
real	O
-	O
time	O
assays	O
,	O
was	O
a	O
defined	O
collection	O
of	O
33	O
confirmed	O
positive	O
(	O
18	O
P	O
.	O
falciparum	O
,	O
eight	O
P	O
.	O
vivax	O
,	O
three	O
P	O
.	O
ovale	O
,	O
two	O
P	O
.	O
malariae	O
,	O
and	O
two	O
P	O
.	O
falciparum	O
+	O
P	O
.	O
malariae	O
)	O
,	O
and	O
80	O
confirmed	O
negative	O
samples	O
,	O
from	O
113	O
fever	O
patients	O
with	O
potential	O
malaria	O
collected	O
between	O
2006	O
and	O
2013	O
at	O
Haukeland	O
University	O
Hospital	O
,	O
Bergen	O
,	O
Norway	O
.	O

The	O
consensus	O
on	O
which	O
samples	O
were	O
positive	O
or	O
negative	O
was	O
based	O
on	O
results	O
from	O
previously	O
performed	O
analyses	O
by	O
routine	O
microscopy	O
,	O
the	O
Polymerase	O
Chain	O
Reaction	O
reference	O
method	O
described	O
by	O
Singh	O
et	O
al	O
.	O
,	O
a	O
genus	O
-	O
specific	O
Cytochrome	B
B	I
Polymerase	O
Chain	O
Reaction	O
,	O
a	O
species	O
-	O
specific	O
18S	O
Polymerase	O
Chain	O
Reaction	O
(	O
all	O
conventional	O
)	O
,	O
and	O
sequencing	O
.	O

The	O
samples	O
were	O
confirmed	O
positive	O
by	O
the	O
same	O
genus	O
-	O
specific	O
Cytochrome	B
B	I
,	O
and	O
species	O
-	O
specific	O
18S	O
conventional	O
Polymerase	O
Chain	O
Reaction	O
assays	O
(	O
or	O
sequencing	O
)	O
as	O
the	O
Norwegian	O
cohort	O
.	O

To	O
serve	O
as	O
a	O
standard	O
curve	O
for	O
q	O
-	O
PCR	O
,	O
a	O
custom	O
designed	O
EcoRI	O
linearized	O
q	O
-	O
PCR	O
template	O
,	O
with	O
a	O
pUCminusMCS	O
vector	O
backbone	O
and	O
this	O
studys	O
Cytochrome	B
B	I
amplification	O
target	O
(	O
220	O
bp	O
)	O
as	O
insert	O
(	O
OriGene	O
Technologies	O
,	O
Rockville	O
,	O
MD	O
,	O
USA	O
)	O
,	O
was	O
applied	O
in	O
a	O
10	O
-	O
fold	O
dilution	O
series	O
,	O
range	O
2	O
.	O
7	O
x	O
10	O
^	O
8	O
-	O
2	O
.	O
7	O
copies	O
of	O
target	O
DNA	O
/	O
reaction	O
(	O
rxn	O
)	O
,	O
run	O
in	O
duplicates	O
.	O

A	O
conventional	O
single	O
-	O
step	O
genus	O
-	O
specific	O
Cytochrome	B
B	I
Polymerase	O
Chain	O
Reaction	O
was	O
converted	O
to	O
one	O
SYBR	O
and	O
one	O
TaqMan	O
real	O
-	O
time	O
Polymerase	O
Chain	O
Reaction	O
protocol	O
using	O
the	O
same	O
primers	O
.	O

For	O
the	O
Cytochrome	B
B	I
SYBR	O
/	O
TaqMan	O
real	O
-	O
time	O
Polymerase	O
Chain	O
Reaction	O
protocols	O
designed	O
and	O
optimized	O
in	O
this	O
study	O
the	O
following	O
primers	O
were	O
applied	O
:	O
PgMt19	O
F3	O
forward	O
(	O
5	O
-	O
tcg	O
ctt	O
cta	O
acg	O
gtg	O
aac	O
)	O
and	O
PgMt19	O
B3	O
reverse	O
(	O
5	O
-	O
aat	O
tga	O
tag	O
tat	O
cag	O
cta	O
tcc	O
ata	O
g	O
)	O
,	O
previously	O
published	O
for	O
a	O
loop	O
-	O
mediated	O
isothermal	O
amplification	O
method	O
.	O

To	O
investigate	O
the	O
quality	O
of	O
the	O
stored	O
DNA	O
,	O
samples	O
of	O
extremely	O
low	O
parasitaemia	O
were	O
reanalysed	O
with	O
the	O
Cytochrome	B
B	I
conventional	O
Polymerase	O
Chain	O
Reaction	O
(	O
primers	O
PgMt19	O
F3	O
&	O
B3	O
)	O
,	O
run	O
in	O
triplicates	O
,	O
as	O
previously	O
described	O
by	O
Haanshuus	O
et	O
al	O
.	O
,	O
but	O
with	O
a	O
primer	O
concentration	O
of	O
1	O
M	O
(	O
incorrect	O
concentration	O
given	O
in	O
the	O
publication	O
)	O
.	O

To	O
ensure	O
that	O
real	O
-	O
time	O
Polymerase	O
Chain	O
Reaction	O
products	O
showed	O
the	O
same	O
high	O
quality	O
sequences	O
for	O
species	O
identification	O
as	O
for	O
the	O
Cytochrome	B
B	I
conventional	O
Polymerase	O
Chain	O
Reaction	O
,	O
all	O
positive	O
products	O
amplified	O
by	O
the	O
Cytochrome	B
B	I
SYBR	O
real	O
-	O
time	O
Polymerase	O
Chain	O
Reaction	O
from	O
the	O
Norwegian	O
material	O
,	O
were	O
sequenced	O
in	O
one	O
direction	O
applying	O
primer	O
PgMt19	O
F3	O
as	O
previously	O
described	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
designed	O
and	O
optimized	O
genus	O
-	O
specific	O
Cytochrome	B
B	I
SYBR	O
and	O
TaqMan	O
Polymerase	O
Chain	O
Reaction	O
protocols	O
were	O
assessed	O
applying	O
the	O
Norwegian	O
clinical	O
material	O
.	O

Among	O
the	O
five	O
included	O
assays	O
the	O
Var	O
Gene	O
Acidic	O
Terminal	O
Sequence	O
TaqMan	O
Polymerase	O
Chain	O
Reaction	O
method	O
showed	O
a	O
high	O
sensitivity	O
,	O
and	O
was	O
therefore	O
chosen	O
for	O
further	O
assessment	O
together	O
with	O
the	O
designed	O
Cytochrome	B
B	I
SYBR	O
/	O
TaqMan	O
Polymerase	O
Chain	O
Reaction	O
protocols	O
,	O
applying	O
P	O
.	O
falciparum	O
positive	O
Tanzanian	O
field	O
material	O
.	O

Furthermore	O
,	O
the	O
sensitivity	O
of	O
applying	O
whole	O
blood	O
versus	O
that	O
of	O
using	O
filter	O
paper	O
as	O
field	O
material	O
was	O
compared	O
,	O
and	O
the	O
difference	O
in	O
C_t	O
trends	O
for	O
the	O
Cytochrome	B
B	I
SYBR	O
real	O
-	O
time	O
Polymerase	O
Chain	O
Reaction	O
results	O
are	O
shown	O
in	O
.	O

Among	O
the	O
field	O
samples	O
extracted	O
from	O
whole	O
blood	O
,	O
previously	O
obtained	O
research	O
microscopy	O
and	O
Rapid	O
Diagnostic	O
Tests	O
results	O
were	O
correlated	O
with	O
positive	O
C_t	O
values	O
of	O
the	O
Cytochrome	B
B	I
SYBR	O
Polymerase	O
Chain	O
Reaction	O
as	O
presented	O
in	O
.	O

Therefore	O
,	O
the	O
quality	O
of	O
the	O
stored	O
DNA	O
was	O
tested	O
by	O
reanalysing	O
,	O
with	O
the	O
Cytochrome	B
B	I
conventional	O
Polymerase	O
Chain	O
Reaction	O
,	O
all	O
samples	O
which	O
were	O
negative	O
or	O
had	O
a	O
C_t	O
value	O
above	O
30	O
by	O
the	O
Cytochrome	B
B	I
SYBR	O
real	O
-	O
time	O
method	O
.	O

The	O
designed	O
Cytochrome	B
B	I
SYBR	O
Polymerase	O
Chain	O
Reaction	O
assay	O
showed	O
better	O
results	O
than	O
using	O
TaqMan	O
probe	O
(	O
Tables	O
and	O
and	O
and	O
.	O

To	O
present	O
an	O
alternative	O
and	O
relevant	O
application	O
of	O
q	O
-	O
PCR	O
data	O
in	O
epidemiological	O
studies	O
,	O
the	O
association	O
between	O
low	O
-	O
level	O
parasitaemia	O
identified	O
by	O
the	O
Cytochrome	B
B	I
SYBR	O
q	O
-	O
PCR	O
results	O
and	O
clinical	O
and	O
demographic	O
factors	O
(	O
among	O
the	O
74	O
field	O
samples	O
extracted	O
from	O
whole	O
blood	O
)	O
,	O
were	O
evaluated	O
applying	O
cross	O
tabulation	O
and	O
multiple	O
logistic	O
regression	O
analysis	O
.	O

When	O
applying	O
2	O
l	O
template	O
,	O
1000	O
copies	O
of	O
the	O
Cytochrome	B
B	I
target	O
/	O
rxn	O
,	O
corresponds	O
to	O
3	O
-	O
25	O
P	O
.	O
falciparum	O
p	O
/	O
l	O
depending	O
on	O
the	O
parasite	O
stage	O
.	O

The	O
genus	O
-	O
specific	O
Cytochrome	B
B	I
conventional	O
Polymerase	O
Chain	O
Reaction	O
,	O
has	O
previously	O
been	O
applied	O
in	O
studies	O
from	O
Tanzania	O
and	O
India	O
,	O
where	O
the	O
Polymerase	O
Chain	O
Reaction	O
detected	O
as	O
much	O
as	O
72	O
%	O
(	O
55	O
/	O
76	O
,	O
N	O
=	O
304	O
)	O
and	O
71	O
%	O
(	O
162	O
/	O
228	O
,	O
N	O
=	O
1168	O
)	O
submicroscopic	O
malaria	O
respectively	O
[	O
,	O
.	O

)	O
,	O
the	O
Cytochrome	B
B	I
SYBR	O
(	O
Xu	O
et	O
al	O
.	O

)	O
,	O
and	O
this	O
studys	O
Cytochrome	B
B	I
SYBR	O
Polymerase	O
Chain	O
Reaction	O
.	O

The	O
Cytochrome	B
B	I
SYBR	O
assay	O
from	O
Xu	O
et	O
al	O
.	O

)	O
,	O
and	O
the	O
Cytochrome	B
B	I
SYBR	O
(	O
Xu	O
et	O
al	O
.	O

Due	O
to	O
potentially	O
reduced	O
quality	O
of	O
the	O
stored	O
DNA	O
,	O
and	O
low	O
reproducibility	O
for	O
samples	O
with	O
extremely	O
low	O
parasitaemia	O
,	O
the	O
field	O
material	O
(	O
N	O
=	O
111	O
)	O
was	O
also	O
used	O
for	O
sensitivity	O
assessment	O
of	O
the	O
the	O
designed	O
Cytochrome	B
B	I
SYBR	O
/	O
TaqMan	O
and	O
the	O
Var	O
Gene	O
Acidic	O
Terminal	O
Sequence	O
TaqMan	O
Polymerase	O
Chain	O
Reaction	O
methods	O
.	O

also	O
showed	O
that	O
the	O
Var	O
Gene	O
Acidic	O
Terminal	O
Sequence	O
assay	O
detected	O
five	O
more	O
positive	O
samples	O
than	O
the	O
Cytochrome	B
B	I
SYBR	O
method	O
.	O

With	O
regards	O
to	O
the	O
two	O
different	O
amplification	O
targets	O
Cytochrome	B
B	I
versus	O
Var	O
Gene	O
Acidic	O
Terminal	O
Sequence	O
,	O
Cytochrome	B
B	I
Polymerase	O
Chain	O
Reaction	O
assays	O
should	O
in	O
theory	O
be	O
twice	O
as	O
sensitive	O
as	O
Var	O
Gene	O
Acidic	O
Terminal	O
Sequence	O
Polymerase	O
Chain	O
Reaction	O
in	O
detecting	O
gametocytes	O
,	O
while	O
Var	O
Gene	O
Acidic	O
Terminal	O
Sequence	O
targets	O
should	O
be	O
about	O
three	O
times	O
as	O
sensitive	O
as	O
Cytochrome	B
B	I
in	O
detecting	O
ring	O
stage	O
parasites	O
.	O

The	O
quality	O
of	O
the	O
stored	O
DNA	O
in	O
this	O
study	O
was	O
tested	O
by	O
reanalyzing	O
the	O
samples	O
with	O
the	O
Cytochrome	B
B	I
conventional	O
Polymerase	O
Chain	O
Reaction	O
used	O
in	O
the	O
first	O
analyses	O
of	O
the	O
Tanzanian	O
field	O
material	O
.	O

The	O
highly	O
sensitive	O
,	O
specific	O
,	O
and	O
user	O
-	O
friendly	O
Cytochrome	B
B	I
SYBR	O
q	O
-	O
PCR	O
developed	O
in	O
this	O
study	O
can	O
be	O
useful	O
in	O
both	O
epidemiological	O
and	O
clinical	O
malaria	O
studies	O
.	O

The	O
possible	O
generation	O
of	O
O_2	O
^	O
by	O
quinones	O
at	O
Q_A	O
and	O
Q_B	O
pockets	O
is	O
illustrated	O
in	O
A	O
.	O
In	O
untreated	O
chloroplasts	O
,	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
is	O
found	O
in	O
high	O
potential	O
,	O
intermediate	O
potential	O
and	O
low	O
potential	O
forms	O
.	O

The	O
E_m	O
values	O
of	O
the	O
three	O
forms	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
are	O
(	O
see	O
review	O
)	O
:	O
High	O
Potential	O
form	O
:	O
350	O
-	O
450	O
mV	O
;	O
IP	O
form	O
:	O
150	O
-	O
260	O
mV	O
;	O
LP	O
form	O
:	O
50	O
-	O
110	O
mV	O
.	O

In	O
isolated	O
thylakoid	O
membranes	O
,	O
85	O
%	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
was	O
in	O
the	O
High	O
Potential	O
form	O
.	O

This	O
idea	O
is	O
supported	O
by	O
the	O
finding	O
that	O
PQH_2	O
can	O
reduce	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
in	O
both	O
intact	O
chloroplasts	O
and	O
in	O
PSII	O
Reaction	O
Centers	O
preparates	O
.	O

The	O
photoreduction	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
was	O
found	O
in	O
isolated	O
thylakoids	O
and	O
was	O
inhibited	O
by	O
DCMU	O
.	O

In	O
Triton	O
X	O
-	O
100	O
-	O
solubilized	O
PSII	O
particles	O
,	O
which	O
mostly	O
have	O
the	O
Low	O
Potential	O
form	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
,	O
short	O
-	O
chain	O
PQs	O
stimulated	O
both	O
photoreduction	O
and	O
dark	O
oxidation	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
.	O

The	O
involvement	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
in	O
electron	O
transfer	O
reactions	O
of	O
PSII	O
indicates	O
that	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
is	O
a	O
redox	O
active	O
component	O
that	O
can	O
potentially	O
reduce	O
O_2	O
.	O

It	O
has	O
been	O
shown	O
that	O
fast	O
,	O
dark	O
reoxidation	O
of	O
the	O
PQ	O
pool	O
in	O
thylakoid	O
membranes	O
is	O
not	O
caused	O
by	O
direct	O
oxidation	O
of	O
PQH_2	O
by	O
O_2	O
,	O
and	O
it	O
was	O
suggested	O
that	O
the	O
Low	O
Potential	O
form	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
can	O
transfer	O
an	O
electron	O
to	O
O_2	O
and	O
thereby	O
act	O
as	O
a	O
PQH_2	O
:	O
O_2	O
oxidoreductase	O
.	O

In	O
isolated	O
PSII	O
membranes	O
,	O
O_2	O
has	O
been	O
shown	O
to	O
compete	O
with	O
prenylquinones	O
for	O
oxidation	O
of	O
the	O
Low	O
Potential	O
form	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
,	O
suggesting	O
that	O
Low	O
Potential	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
can	O
form	O
O_2	O
^	O
.	O

This	O
finding	O
was	O
interpreted	O
to	O
indicate	O
that	O
these	O
quinones	O
reduce	O
Low	O
Potential	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
,	O
which	O
then	O
undergoes	O
spontaneous	O
autoxidation	O
,	O
resulting	O
in	O
O_2	O
^	O
formation	O
.	O

However	O
,	O
the	O
reduction	O
in	O
O_2	O
by	O
Low	O
Potential	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
is	O
thermodynamically	O
unfavorable	O
,	O
taking	O
into	O
account	O
that	O
the	O
redox	O
potential	O
of	O
the	O
Low	O
Potential	O
form	O
is	O
usually	O
within	O
20	O
-	O
110	O
mV	O
in	O
untreated	O
membranes	O
,	O
although	O
sometimes	O
an	O
Low	O
Potential	O
form	O
with	O
a	O
negative	O
potential	O
is	O
observed	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
Bombyx	O
mori	O
Cytochrome	B
C	I
in	O
resistance	O
to	O
Bombyx	O
Mori	O
Nucleopolyhedrovirus	O
infection	O
.	O

However	O
,	O
the	O
role	O
of	O
Cytochrome	B
C	I
is	O
not	O
clear	O
in	O
insect	O
cell	O
apoptosis	O
.	O

It	O
has	O
been	O
reported	O
that	O
Cytochrome	B
C	I
is	O
not	O
involved	O
in	O
apoptosis	O
in	O
Drosophila	O
by	O
the	O
release	O
from	O
mitochondria	O
.	O

In	O
another	O
study	O
,	O
mitochondria	O
were	O
involved	O
in	O
host	O
defenses	O
against	O
environmental	O
pressure	O
by	O
releasing	O
Cytochrome	B
C	I
into	O
the	O
cytoplasm	O
to	O
activate	O
apoptosis	O
in	O
the	O
Spodoptera	O
litura	O
and	O
Spodoptera	O
frugiperda	O
(	O
Sf9	O
)	O
cell	O
line	O
.	O

It	O
has	O
been	O
reported	O
widely	O
that	O
Cytochrome	B
C	I
showed	O
a	O
significant	O
response	O
to	O
viral	O
infection	O
.	O

Liu	O
et	O
al	O
.	O
,	O
reported	O
that	O
Cytochrome	B
C	I
activates	O
the	O
apoptotic	O
signaling	O
pathway	O
to	O
defend	O
against	O
Anagrapha	O
falcifera	O
Multiple	O
Nuclear	O
Polyhedrosis	O
Virus	O
infection	O
in	O
Lepidopteran	O
Spodoptera	O
litura	O
cells	O
.	O

Carthy	O
et	O
al	O
.	O
,	O
found	O
that	O
Cytochrome	B
C	I
released	O
from	O
mitochondria	O
may	O
be	O
involved	O
in	O
activating	O
caspase	O
after	O
coxsackievirus	O
B3	O
infection	O
,	O
and	O
this	O
contributes	O
to	O
the	O
loss	O
of	O
host	O
cell	O
viability	O
and	O
progeny	O
virus	O
release	O
.	O

Machida	O
et	O
al	O
.	O
,	O
reported	O
that	O
inhibition	O
of	O
Cytochrome	B
C	I
release	O
resulted	O
in	O
suppression	O
of	O
Fas	O
-	O
mediated	O
cell	O
death	O
,	O
which	O
could	O
cause	O
hepatitis	O
C	O
virus	O
persistent	O
infection	O
in	O
transgenic	O
mice	O
.	O

In	O
our	O
previous	O
transcriptome	O
study	O
,	O
Cytochrome	B
C	I
showed	O
a	O
significant	O
response	O
in	O
resistant	O
strain	O
BC9	O
following	O
Bombyx	O
Mori	O
Nucleopolyhedrovirus	O
infection	O
,	O
and	O
it	O
might	O
be	O
involved	O
in	O
regulating	O
the	O
mitochondrial	O
apoptosis	O
pathway	O
to	O
defend	O
against	O
Bombyx	O
Mori	O
Nucleopolyhedrovirus	O
infection	O
,	O
but	O
that	O
still	O
needs	O
further	O
study	O
.	O

Therefore	O
,	O
the	O
high	O
conservation	O
of	O
Cytochrome	B
C	I
amino	O
acids	O
among	O
different	O
species	O
shows	O
that	O
Bombyx	O
Mori	O
Cytc	O
may	O
play	O
a	O
vital	O
role	O
in	O
the	O
apoptosis	O
pathway	O
in	O
the	O
silkworm	O
.	O

The	O
CDS	O
sequence	O
of	O
Bombyx	O
Mori	O
Cytc	O
and	O
those	O
in	O
other	O
species	O
were	O
derived	O
from	O
NCBI	O
,	O
which	O
were	O
used	O
to	O
analyze	O
the	O
evolutionary	O
relationships	O
of	O
Cytochrome	B
C	I
among	O
different	O
species	O
.	O

The	O
homologous	O
gene	O
sequences	O
of	O
Bombyx	O
Mori	O
Cytc	O
in	O
M	O
.	O
musculus	O
and	O
Arabidopsis	O
shared	O
a	O
low	O
sequence	O
identity	O
with	O
Bombyx	O
Mori	O
Cytc	O
,	O
indicating	O
that	O
Cytochrome	B
C	I
gene	O
in	O
the	O
earlier	O
species	O
might	O
have	O
diverged	O
before	O
the	O
appearance	O
of	O
these	O
orders	O
during	O
evolution	O
.	O

The	O
lack	O
of	O
CYP17A1	O
expression	O
in	O
the	O
zona	O
glomerulosa	O
together	O
with	O
the	O
abundant	O
expression	O
of	O
HSD3B2	O
ensures	O
that	O
all	O
steroid	O
intermediates	O
are	O
directed	O
towards	O
aldosterone	O
biosynthesis	O
.	O

The	O
CYP17A1	O
-	O
catalyzed	O
17ALPHA	O
-	O
hydroxylation	O
of	O
pregnenolone	O
yields	O
17ALPHA	O
-	O
hydroxypregnenolone	O
,	O
which	O
serves	O
as	O
the	O
preferred	O
substrate	O
for	O
the	O
17	B
,	I
20	I
-	I
lyase	I
activity	O
of	O
CYP17A1	O
,	O
producing	O
C_19	O
steroids	O
from	O
C_21	O
precursors	O
[	O
,	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
17	B
,	I
20	I
-	I
lyase	I
activity	O
of	O
CYP17A1	O
is	O
dependent	O
on	O
augmentation	O
by	O
cytochrome	O
b_5	O
(	O
CYB5A	O
)	O
in	O
addition	O
to	O
electron	O
transfer	O
from	O
P450	O
Oxidoreductase	O
.	O

Like	O
in	O
the	O
zona	O
reticularis	O
,	O
the	O
Leydig	O
cells	O
of	O
the	O
testes	O
follow	O
the	O
^	O
5	O
pathway	O
due	O
to	O
the	O
co	O
-	O
expression	O
of	O
CYP17A1	O
and	O
CYB5A	O
.	O

Allopregnanolone	O
can	O
then	O
be	O
converted	O
to	O
17ALPHA	O
-	O
hydroxyallopregnanolone	O
,	O
which	O
serves	O
as	O
an	O
excellent	O
substrate	O
for	O
the	O
17	B
,	I
20	I
-	I
lyase	I
activity	O
of	O
CYP17A1	O
,	O
yielding	O
androsterone	O
.	O

The	O
20alpha	O
/	O
Beta	O
-	O
Reduction	O
Of	O
Tetrahydrocortisol	O
and	O
Tetrahydrocortisone	O
can	O
also	O
be	O
subject	O
to	O
an	O
elusive	O
side	O
-	O
chain	O
cleavage	O
reaction	O
not	O
catalyzed	O
by	O
CYP17A1	O
,	O
producing	O
C_19	O
metabolites	O
of	O
glucocorticoid	O
origin	O
.	O

The	O
cytochromes	O
P450	O
17A1	O
/	O
19A1	O
(	O
CYP17A1	O
/	O
CYP17A1	O
)	O
have	O
a	O
strong	O
correlation	O
with	O
cell	O
apoptosis	O
,	O
because	O
most	O
of	O
them	O
have	O
an	O
Abiraterone	O
-	O
specific	O
active	O
site	O
.	O

As	O
can	O
be	O
seen	O
in	O
,	O
the	O
CYP17A1	O
proteins	O
(	O
except	O
3S7S	O
)	O
have	O
stronger	O
binding	O
abilities	O
than	O
the	O
reference	O
drug	O
Abiraterone	O
acetate	O
(	O
8	O
.	O
91	O
kcal	O
/	O
mol	O
)	O
.	O

A	O
similar	O
analysis	O
suggests	O
that	O
12n	O
could	O
interact	O
strongly	O
with	O
CYP17A1	O
family	O
proteins	O
(	O
6CIZ	O
)	O
.	O

The	O
most	O
active	O
compound	O
,	O
12n	O
,	O
fitted	O
the	O
active	O
sites	O
of	O
CYP17A1	O
(	O
6CIZ	O
)	O
well	O
.	O

Interestingly	O
,	O
enzymes	O
with	O
20BETA	O
-	O
HSD	O
and	O
17	B
,	I
20	I
-	I
lyase	I
activity	O
have	O
been	O
recently	O
identified	O
in	O
a	O
microbial	O
inhabitant	O
of	O
the	O
urinary	O
tract	O
.	O

In	O
mammalian	O
retina	O
,	O
cholesterol	O
excess	O
is	O
mainly	O
metabolized	O
to	O
oxysterols	O
by	O
cytochromes	O
P450	O
27A1	O
and	O
46A1	O
(	O
CYP46A1	B
)	O
or	O
removed	O
on	O
lipoprotein	O
particles	O
containing	O
apolipoprotein	O
E	O
.	O
In	O
contrast	O
,	O
esterification	O
by	O
sterol	O
-	O
O	O
-	O
acyltransferase	O
1	O
plays	O
only	O
a	O
minor	O
role	O
in	O
this	O
process	O
.	O

Output	O
includes	O
metabolism	O
to	O
oxysterols	O
by	O
the	O
cytochrome	O
P450	O
enzymes	O
Cytochromes	O
P450	O
27a1	O
and	O
CYP46A1	B
,	O
the	O
photoreceptor	O
phagocytosis	O
,	O
and	O
efflux	O
to	O
lipoprotein	O
particles	O
,	O
which	O
circulate	O
in	O
the	O
intraretinal	O
space	O
.	O

The	O
second	O
were	O
the	O
genes	O
related	O
to	O
inflammation	O
(	O
Ccl2	O
,	O
Cox2	O
,	O
Il	O
-	O
6	O
,	O
and	O
TnfALPHA	O
)	O
,	O
whose	O
expression	O
is	O
controlled	O
by	O
NF	O
-	O
B	O
,	O
which	O
in	O
turn	O
is	O
negatively	O
regulated	O
by	O
liver	O
X	O
receptors	O
(	O
LXRs	O
,	O
transcription	O
factors	O
)	O
when	O
they	O
are	O
activated	O
by	O
oxysterols	O
produced	O
by	O
Cytochromes	O
P450	O
27a1	O
and	O
CYP46A1	B
.	O

Nevertheless	O
,	O
collectively	O
,	O
the	O
data	O
obtained	O
suggested	O
that	O
cholesterol	O
transport	O
mediated	O
by	O
the	O
major	O
retinal	O
apolipoproteins	O
did	O
not	O
seem	O
to	O
be	O
significantly	O
affected	O
by	O
simultaneous	O
absence	O
of	O
Cytochromes	O
P450	O
27a1	O
,	O
CYP46A1	B
,	O
and	O
SOAT1	O
.	O

Only	O
three	O
enzymes	O
(	O
CYP27A1	O
,	O
CYP46A1	B
,	O
and	O
SOAT1	O
)	O
metabolize	O
intracellular	O
(	O
unesterified	O
)	O
cholesterol	O
in	O
the	O
retina	O
with	O
retinal	O
cholesterol	O
content	O
being	O
almost	O
doubled	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
mice	O
and	O
normal	O
in	O
Soat1	O
^	O
/	O
mice	O
.	O

Similarly	O
,	O
by	O
generating	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
,	O
we	O
expected	O
an	O
additive	O
genotype	O
effect	O
due	O
to	O
simultaneous	O
blockage	O
of	O
the	O
two	O
major	O
pathways	O
of	O
retinal	O
cholesterol	O
output	O
-	O
cholesterol	O
removal	O
via	O
metabolism	O
(	O
CYP27A1	O
and	O
CYP46A1	B
)	O
and	O
Lipoprotein	O
Particles	O
containing	O
Apolipoprotein	O
E	O
which	O
accepts	O
cholesterol	O
effluxed	O
from	O
cells	O
.	O

Accordingly	O
,	O
retinal	O
cholesterol	O
levels	O
are	O
unchanged	O
in	O
Soat1	O
/	O
mice	O
but	O
are	O
increased	O
in	O
Cyp27a1	O
/	O
Cyp46a1	B
/	O
and	O
Apoe	O
/	O
mice	O
.	O

Herein	O
,	O
we	O
characterized	O
Cyp27a1	O
/	O
Cyp46a1	B
/	O
Soat1	O
/	O
and	O
Cyp27a1	O
/	O
Cyp46a1	B
/	O
Apoe	O
/	O
mice	O
.	O

Conversely	O
,	O
in	O
Cyp27a1	O
/	O
Cyp46a1	B
/	O
Apoe	O
/	O
mice	O
,	O
retinal	O
cholesterol	O
levels	O
were	O
increased	O
while	O
anatomical	O
structure	O
and	O
vasculature	O
were	O
unaffected	O
with	O
only	O
male	O
mice	O
showing	O
a	O
decrease	O
in	O
electroretinographic	O
responses	O
.	O

Sterol	O
profiling	O
,	O
qRT	O
-	O
PCR	O
,	O
proteomics	O
,	O
and	O
transmission	O
electron	O
microscopy	O
mapped	O
potential	O
compensatory	O
mechanisms	O
in	O
the	O
Cyp27a1	O
/	O
Cyp46a1	B
/	O
Soat1	O
/	O
and	O
Cyp27a1	O
/	O
Cyp46a1	B
/	O
Apoe	O
/	O
retina	O
.	O

In	O
addition	O
,	O
there	O
was	O
altered	O
abundance	O
of	O
proteins	O
in	O
Cyp27a1	O
/	O
Cyp46a1	B
/	O
Soat1	O
/	O
mice	O
that	O
can	O
affect	O
photoreceptor	O
function	O
,	O
survival	O
,	O
and	O
retinal	O
energy	O
homeostasis	O
(	O
glucose	O
and	O
fatty	O
acid	O
metabolism	O
)	O
.	O

To	O
ascertain	O
retinal	O
significance	O
of	O
cholesterol	O
removal	O
by	O
metabolism	O
and	O
Lipoprotein	O
Particles	O
,	O
we	O
previously	O
comprehensively	O
characterized	O
the	O
retina	O
of	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
mice	O
and	O
mice	O
lacking	O
Apolipoprotein	O
E	O
,	O
a	O
major	O
apolipoprotein	O
in	O
the	O
retina	O
.	O

In	O
addition	O
,	O
there	O
were	O
focal	O
accumulations	O
of	O
free	O
(	O
unesterified	O
)	O
cholesterol	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
retina	O
,	O
impairments	O
in	O
the	O
retinal	O
function	O
(	O
as	O
assessed	O
by	O
electroretinographic	O
recordings	O
,	O
ERG	O
)	O
,	O
and	O
pathologic	O
changes	O
in	O
retinal	O
blood	O
vessels	O
.	O

We	O
also	O
generated	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
and	O
established	O
that	O
retinal	O
cholesterol	O
esterification	O
is	O
mediated	O
by	O
SOAT1	O
.	O

The	O
purpose	O
of	O
the	O
present	O
work	O
was	O
to	O
gain	O
insight	O
into	O
the	O
interplay	O
between	O
retinal	O
pathways	O
of	O
cholesterol	O
output	O
by	O
finishing	O
ophthalmic	O
characterizations	O
of	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
and	O
generating	O
as	O
well	O
as	O
characterizing	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
.	O

In	O
addition	O
,	O
we	O
mapped	O
retinal	O
proteins	O
and	O
processes	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
-	O
mice	O
that	O
could	O
be	O
linked	O
to	O
retinal	O
cholesterol	O
-	O
related	O
pathways	O
and	O
be	O
important	O
for	O
retinal	O
structure	O
,	O
function	O
,	O
and	O
metabolism	O
.	O

Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
mice	O
were	O
generated	O
previously	O
in	O
this	O
laboratory	O
and	O
were	O
on	O
a	O
mixed	O
strain	O
background	O
(	O
C57BL	O
/	O
6J	O
;	O
129S6	O
/	O
SvEv	O
)	O
.	O

Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
mice	O
were	O
crossed	O
with	O
Soat1	O
^	O
/	O
or	O
Apoe	O
^	O
/	O
mice	O
to	O
generate	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
,	O
respectively	O
.	O

Briefly	O
,	O
three	O
biological	O
replicates	O
per	O
genotype	O
(	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
or	O
C57BL	O
/	O
6J	O
,	O
6	O
-	O
8	O
month	O
old	O
male	O
mice	O
)	O
,	O
each	O
containing	O
two	O
retinas	O
from	O
two	O
different	O
mice	O
,	O
were	O
frozen	O
,	O
cryo	O
-	O
pulverized	O
,	O
and	O
lysed	O
with	O
3	O
%	O
SDS	O
.	O

We	O
examined	O
6	O
-	O
and	O
12	O
-	O
month	O
old	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
by	O
using	O
SD	O
-	O
OCT	O
,	O
Fluorescein	O
Angiography	O
,	O
and	O
ERG	O
.	O

In	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
of	O
both	O
sexes	O
,	O
dark	O
-	O
adapted	O
(	O
scotopic	O
)	O
ERGs	O
were	O
decreased	O
at	O
6	O
months	O
,	O
and	O
this	O
decrease	O
was	O
more	O
pronounced	O
at	O
12	O
months	O
(	O
A	O
)	O
.	O

In	O
addition	O
,	O
male	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
had	O
a	O
decrease	O
in	O
the	O
b	O
-	O
wave	O
of	O
light	O
-	O
adapted	O
(	O
photopic	O
)	O
ERGs	O
,	O
also	O
with	O
a	O
progression	O
at	O
1	O
year	O
.	O

In	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
,	O
the	O
ERGs	O
of	O
female	O
animals	O
were	O
essentially	O
unaffected	O
,	O
and	O
only	O
male	O
mice	O
had	O
statistically	O
significant	O
reductions	O
in	O
both	O
scotopic	O
and	O
photopic	O
ERGs	O
at	O
12	O
months	O
(	O
C	O
)	O
.	O

Three	O
retinal	O
sterols	O
(	O
cholesterol	O
,	O
lathosterol	O
,	O
and	O
desmosterol	O
)	O
as	O
well	O
as	O
serum	O
cholesterol	O
were	O
quantified	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
,	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
,	O
and	O
Soat1	O
^	O
/	O
mice	O
and	O
compared	O
with	O
those	O
in	O
other	O
knockout	O
lines	O
determined	O
by	O
us	O
previously	O
.	O

In	O
both	O
serum	O
and	O
retina	O
,	O
the	O
levels	O
of	O
total	O
cholesterol	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
were	O
more	O
similar	O
to	O
those	O
in	O
Soat1	O
^	O
/	O
and	O
Apoe	O
^	O
/	O
mice	O
,	O
respectively	O
,	O
than	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
mice	O
(	O
A	O
,	O
B	O
,	O
.	O

Yet	O
serum	O
cholesterol	O
did	O
not	O
seem	O
to	O
be	O
an	O
important	O
contributor	O
to	O
retinal	O
cholesterol	O
as	O
the	O
sex	O
differences	O
in	O
the	O
levels	O
of	O
this	O
sterol	O
in	O
Apoe	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
were	O
not	O
translated	O
into	O
similar	O
sex	O
differences	O
in	O
the	O
levels	O
of	O
total	O
retinal	O
cholesterol	O
.	O

In	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
,	O
retinal	O
lathosterol	O
but	O
not	O
desmosterol	O
content	O
was	O
decreased	O
as	O
compared	O
to	O
those	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
and	O
Soat1	O
^	O
/	O
mice	O
(	O
C	O
,	O
D	O
,	O
.	O

This	O
compensatory	O
decrease	O
is	O
consistent	O
with	O
the	O
known	O
sensitivity	O
of	O
cholesterol	O
biosynthesis	O
to	O
changes	O
in	O
intracellular	O
levels	O
of	O
unesterified	O
cholesterol	O
and	O
can	O
be	O
a	O
reason	O
for	O
why	O
total	O
retinal	O
cholesterol	O
was	O
normal	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
.	O

Similarly	O
,	O
a	O
decrease	O
in	O
retinal	O
cholesterol	O
biosynthesis	O
was	O
observed	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
,	O
whose	O
levels	O
of	O
both	O
retinal	O
lathosterol	O
and	O
desmosterol	O
were	O
approximately	O
the	O
mean	O
between	O
the	O
sterol	O
levels	O
in	O
Apoe	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
mice	O
and	O
mirrored	O
the	O
total	O
cholesterol	O
levels	O
in	O
the	O
retina	O
of	O
the	O
three	O
genotypes	O
.	O

Two	O
groups	O
of	O
retinal	O
genes	O
were	O
quantified	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
and	O
compared	O
with	O
that	O
in	O
wild	O
type	O
C57BL	O
/	O
6J	O
animals	O
.	O

However	O
,	O
these	O
changes	O
were	O
mostly	O
sex	O
-	O
specific	O
and	O
therefore	O
likely	O
did	O
not	O
contribute	O
to	O
retinal	O
cholesterol	O
levels	O
that	O
were	O
similar	O
in	O
female	O
and	O
male	O
animals	O
of	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
genotypes	O
.	O

Only	O
Apoa1	O
and	O
Apoa2	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
as	O
well	O
as	O
Apob	O
and	O
Apoj	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
showed	O
expression	O
changes	O
that	O
are	O
common	O
for	O
both	O
sexes	O
.	O

This	O
was	O
conducted	O
on	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
versus	O
Wild	O
Type	O
male	O
mice	O
to	O
gain	O
insight	O
into	O
whether	O
there	O
are	O
additional	O
mechanisms	O
that	O
contribute	O
to	O
the	O
normalization	O
of	O
retinal	O
cholesterol	O
levels	O
besides	O
a	O
decrease	O
in	O
cholesterol	O
biosynthesis	O
.	O

The	O
label	O
-	O
free	O
analysis	O
was	O
used	O
,	O
which	O
confirmed	O
unaltered	O
retinal	O
expression	O
of	O
APOA4	O
and	O
Apolipoprotein	O
E	O
suggested	O
by	O
the	O
mRNA	O
measurements	O
but	O
did	O
not	O
show	O
altered	O
abundance	O
of	O
APOA1	O
,	O
APOA2	O
,	O
and	O
APOJ	O
,	O
whose	O
gene	O
expression	O
was	O
affected	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
versus	O
Wild	O
Type	O
retina	O
of	O
male	O
mice	O
.	O

Out	O
of	O
these	O
proteins	O
,	O
the	O
abundance	O
of	O
41	O
proteins	O
was	O
increased	O
and	O
that	O
of	O
3	O
proteins	O
was	O
decreased	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
versus	O
Wild	O
Type	O
retina	O
.	O

Protein	O
grouping	O
based	O
on	O
function	O
suggested	O
that	O
at	O
least	O
6	O
biological	O
processes	O
could	O
be	O
affected	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
:	O
(	O
1	O
)	O
cytoskeletal	O
dynamics	O
and	O
vesicle	O
formation	O
(	O
11	O
proteins	O
,	O
)	O
;	O
(	O
2	O
)	O
energy	O
homeostasis	O
(	O
9	O
proteins	O
,	O
)	O
;	O
(	O
3	O
)	O
genetic	O
information	O
transfer	O
(	O
DNA	O
/	O
RNA	O
processing	O
,	O
transcription	O
,	O
regulation	O
of	O
transcription	O
and	O
translation	O
,	O
9	O
proteins	O
)	O
;	O
(	O
4	O
)	O
inflammation	O
(	O
7	O
proteins	O
)	O
;	O
(	O
5	O
)	O
synaptic	O
function	O
(	O
4	O
proteins	O
)	O
;	O
and	O
(	O
6	O
)	O
ubiquitination	O
(	O
3	O
proteins	O
)	O
.	O

This	O
approach	O
revealed	O
several	O
differences	O
between	O
Wild	O
Type	O
,	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
,	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
.	O

First	O
,	O
undigested	O
material	O
was	O
observed	O
in	O
some	O
of	O
the	O
Retinal	O
Pigment	O
Epithelium	O
cells	O
of	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
but	O
not	O
Wild	O
Type	O
or	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
(	O
A	O
-	O
C	O
)	O
,	O
probably	O
a	O
reflection	O
of	O
impaired	O
phagocytosis	O
at	O
the	O
phagolysosomal	O
stage	O
.	O

Second	O
,	O
chromatin	O
condensation	O
was	O
more	O
abundant	O
in	O
the	O
photoreceptor	O
nuclei	O
of	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
than	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
and	O
was	O
essentially	O
absent	O
in	O
Wild	O
Type	O
mice	O
(	O
D	O
-	O
F	O
)	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
increased	O
photoreceptor	O
apoptosis	O
documented	O
previously	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
.	O

Third	O
,	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
had	O
increased	O
,	O
as	O
compared	O
to	O
Wild	O
Type	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
,	O
with	O
the	O
presence	O
of	O
multivesicular	O
bodies	O
at	O
both	O
apical	O
and	O
basal	O
sides	O
of	O
the	O
Retinal	O
Pigment	O
Epithelium	O
(	O
A	O
-	O
H	O
,	O
O	O
-	O
Q	O
)	O
in	O
agreement	O
with	O
the	O
change	O
in	O
vesicular	O
traffic	O
suggested	O
by	O
the	O
proteomics	O
analysis	O
.	O

Similarly	O
,	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
had	O
more	O
frequent	O
extracellular	O
vesicles	O
in	O
the	O
outer	O
nuclear	O
layer	O
(	O
I	O
-	O
M	O
,	O
R	O
-	O
T	O
)	O
,	O
and	O
extensive	O
budding	O
of	O
the	O
caveoli	O
-	O
like	O
structures	O
in	O
the	O
blood	O
vessel	O
pericytes	O
and	O
endothelium	O
of	O
the	O
ganglion	O
cell	O
layer	O
.	O

Thus	O
,	O
intracellular	O
and	O
extracellular	O
vesicular	O
traffic	O
seemed	O
to	O
be	O
increased	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
relative	O
to	O
Wild	O
Type	O
or	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
and	O
directed	O
toward	O
both	O
choriocapillaries	O
and	O
inner	O
retina	O
blood	O
vessels	O
.	O

Hence	O
by	O
generating	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
,	O
we	O
expected	O
that	O
their	O
retinal	O
cholesterol	O
will	O
still	O
be	O
increased	O
as	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
mice	O
but	O
be	O
unesterified	O
as	O
in	O
Soat1	O
^	O
/	O
mice	O
(	O
B	O
)	O
.	O

Yet	O
,	O
the	O
retinal	O
cholesterol	O
levels	O
were	O
normal	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
(	O
B	O
)	O
,	O
thus	O
suggesting	O
that	O
there	O
are	O
compensatory	O
responses	O
in	O
the	O
retina	O
,	O
which	O
lowered	O
the	O
sterol	O
levels	O
.	O

However	O
,	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
retina	O
had	O
lower	O
,	O
not	O
higher	O
,	O
total	O
cholesterol	O
levels	O
than	O
the	O
Apoe	O
^	O
/	O
retina	O
(	O
B	O
)	O
,	O
also	O
an	O
indication	O
of	O
the	O
compensatory	O
responses	O
.	O

The	O
levels	O
of	O
lathosterol	O
were	O
decreased	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
as	O
compared	O
to	O
Soat1	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
retina	O
,	O
and	O
both	O
sterols	O
were	O
decreased	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
retina	O
as	O
compared	O
to	O
the	O
Apoe	O
^	O
/	O
retina	O
(	O
C	O
,	O
D	O
)	O
.	O

These	O
decreases	O
suggested	O
that	O
the	O
retinal	O
cholesterol	O
biosynthesis	O
is	O
decreased	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
,	O
and	O
represents	O
a	O
compensatory	O
response	O
to	O
the	O
triple	O
gene	O
ablations	O
.	O

Next	O
,	O
we	O
assessed	O
the	O
apolipoprotein	O
-	O
mediated	O
retinal	O
cholesterol	O
traffic	O
by	O
measuring	O
the	O
mRNA	O
for	O
different	O
apolipoproteins	O
and	O
conducting	O
retinal	O
proteomics	O
on	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
versus	O
Wild	O
Type	O
mice	O
(	O
;	O
.	O

Rather	O
,	O
retinal	O
proteomics	O
pointed	O
to	O
enhanced	O
vesicle	O
formation	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
versus	O
Wild	O
Type	O
retina	O
as	O
an	O
expression	O
of	O
7	O
proteins	O
from	O
the	O
endosomal	O
,	O
secretory	O
,	O
and	O
protrusion	O
formation	O
pathways	O
(	O
CHGA	O
,	O
HDAC6	O
,	O
PAFAH1B	O
,	O
SEPT6	O
,	O
SRP19	O
,	O
TAGLN2	O
,	O
and	O
TAGLN3	O
,	O
)	O
was	O
increased	O
in	O
the	O
former	O
.	O

Here	O
,	O
we	O
describe	O
a	O
novel	O
in	O
vivo	O
system	O
using	O
genetically	O
modified	O
rats	O
deficient	O
in	O
the	O
Cyp27b1	B
or	O
Vdr	O
genes	O
.	O

Although	O
Cyp27b1	B
-	O
knockout	O
,	O
Vdr	O
-	O
KO	O
,	O
and	O
Vdr	O
(	O
R270L	O
)	O
rats	O
each	O
showed	O
rickets	O
symptoms	O
,	O
including	O
abnormal	O
bone	O
formation	O
,	O
they	O
were	O
significantly	O
different	O
from	O
each	O
other	O
.	O

Administration	O
of	O
25	O
(	O
OH	O
)	O
D3	O
reversed	O
rickets	O
symptoms	O
in	O
Cyp27b1	B
-	O
KO	O
and	O
Vdr	O
(	O
R270L	O
)	O
rats	O
.	O

Interestingly	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
synthesized	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
,	O
probably	O
by	O
Cyp27a1	O
.	O

To	O
confirm	O
the	O
direct	O
action	O
of	O
25	O
(	O
OH	O
)	O
D_3	O
in	O
vivo	O
,	O
we	O
previously	O
examined	O
its	O
effect	O
on	O
osteogenesis	O
in	O
Cyp27b1	B
knockout	O
mice	O
.	O

Surprisingly	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
was	O
detected	O
at	O
normal	O
levels	O
in	O
Cyp27b1	B
-	O
KO	O
mice	O
administered	O
25	O
(	O
OH	O
)	O
D_3	O
at	O
150	O
gkg	O
^	O
1day	O
^	O
1	O
.	O

Plasma	O
calcium	O
levels	O
,	O
bone	O
mineral	O
densities	O
,	O
and	O
sexual	O
reproduction	O
in	O
Cyp27b1	B
-	O
KO	O
mice	O
were	O
all	O
normalized	O
by	O
25	O
(	O
OH	O
)	O
D_3	O
administration	O
,	O
while	O
plasma	O
25	O
(	O
OH	O
)	O
D_3	O
levels	O
were	O
enhanced	O
several	O
-	O
fold	O
relative	O
to	O
the	O
normal	O
level	O
^	O
.	O

Based	O
on	O
the	O
activity	O
of	O
1ALPHA	O
-	O
hydroxylation	O
toward	O
25	O
(	O
OH	O
)	O
D_3	O
in	O
liver	O
mitochondrial	O
fractions	O
prepared	O
from	O
Cyp27b1	B
-	O
KO	O
mice	O
,	O
we	O
assumed	O
that	O
Cyp27a1	O
converted	O
25	O
(	O
OH	O
)	O
D_3	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
^	O
.	O

Thus	O
,	O
we	O
generated	O
a	O
Cyp27b1	B
-	O
deficient	O
rat	O
model	O
to	O
clarify	O
the	O
detailed	O
metabolism	O
of	O
25	O
(	O
OH	O
)	O
D_3	O
.	O

In	O
the	O
current	O
study	O
,	O
Cyp27b1	B
-	O
KO	O
rats	O
were	O
produced	O
by	O
genome	O
editing	O
using	O
the	O
CRISPR	O
/	O
Cas9	O
system	O
^	O
-	O
.	O

As	O
mentioned	O
above	O
,	O
it	O
was	O
difficult	O
to	O
verify	O
the	O
direct	O
effect	O
of	O
25	O
(	O
OH	O
)	O
D_3	O
in	O
Cyp27b1	B
-	O
KO	O
mice	O
due	O
to	O
the	O
Cyp27b1	B
-	O
independent	O
production	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
,	O
and	O
it	O
was	O
reasonable	O
to	O
assume	O
that	O
a	O
similar	O
phenomenon	O
would	O
occur	O
in	O
rats	O
.	O

Five	O
offspring	O
were	O
obtained	O
from	O
125	O
embryos	O
microinjected	O
for	O
Cyp27b1	B
-	O
KO	O
,	O
4	O
of	O
which	O
had	O
mutations	O
at	O
target	O
sites	O
.	O

Among	O
the	O
4	O
pups	O
with	O
target	O
mutations	O
,	O
1	O
was	O
found	O
to	O
have	O
a	O
25	O
amino	O
acid	O
deletion	O
containing	O
the	O
cysteine	O
residue	O
,	O
which	O
is	O
the	O
fifth	O
ligand	O
of	O
heme	O
iron	O
and	O
the	O
active	O
center	O
of	O
Cyp27b1	B
.	O

We	O
also	O
confirmed	O
that	O
no	O
off	O
-	O
target	O
site	O
events	O
occurred	O
in	O
potential	O
Off	O
Target	O
Sites	O
searched	O
by	O
the	O
CRISPR	O
Direct	O
tool	O
(	O
http	O
:	O
/	O
/	O
crispr	O
.	O
dbcls	O
.	O
jp	O
/	O
)	O
among	O
all	O
Genetically	O
Modified	O
rat	O
strains	O
except	O
for	O
Cyp27b1	B
-	O
OTS8	O
.	O

We	O
could	O
not	O
examine	O
the	O
Off	O
-	O
Target	O
Site	O
event	O
in	O
Cyp27b1	B
-	O
OTS8	O
because	O
it	O
was	O
impossible	O
to	O
amplify	O
this	O
region	O
(	O
see	O
Supplementary	O
Tables	O
and	O
.	O

The	O
appearance	O
of	O
WT	O
,	O
mutant	O
Vdr	O
(	O
R270L	O
)	O
and	O
Vdr	O
-	O
KO	O
rats	O
fed	O
an	O
F	O
-	O
2	O
diet	O
and	O
Cyp27b1	B
-	O
KO	O
rats	O
fed	O
a	O
CE	O
-	O
2	O
diet	O
at	O
15	O
weeks	O
after	O
birth	O
are	O
detailed	O
in	O
Fig	O
.	O

Whereas	O
Cyp27b1	B
-	O
KO	O
rats	O
were	O
much	O
smaller	O
than	O
WT	O
rats	O
,	O
Vdr	O
(	O
R270L	O
)	O
and	O
Vdr	O
-	O
KO	O
rats	O
were	O
somewhat	O
smaller	O
than	O
WT	O
rats	O
.	O

Heterozygotes	O
of	O
Cyp27b1	B
-	O
KO	O
,	O
Vdr	O
(	O
R270L	O
)	O
,	O
and	O
Vdr	O
-	O
KO	O
rats	O
showed	O
phenotypes	O
similar	O
to	O
those	O
of	O
WT	O
rats	O
at	O
15	O
weeks	O
.	O

Growth	O
curves	O
of	O
mutant	O
Vdr	O
(	O
R270L	O
)	O
and	O
Vdr	O
-	O
KO	O
rats	O
fed	O
the	O
F	O
-	O
2	O
diet	O
and	O
Cyp27b1	B
-	O
KO	O
rats	O
fed	O
the	O
CE	O
-	O
2	O
diet	O
are	O
shown	O
in	O
Fig	O
.	O

Growth	O
was	O
significantly	O
inhibited	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
but	O
was	O
only	O
slightly	O
inhibited	O
in	O
Vdr	O
(	O
R270L	O
)	O
and	O
Vdr	O
-	O
KO	O
rats	O
compared	O
to	O
that	O
of	O
WT	O
rats	O
,	O
whereas	O
no	O
animals	O
died	O
at	O
15	O
weeks	O
of	O
age	O
among	O
the	O
Cyp27b1	B
-	O
KO	O
rats	O
fed	O
the	O
CE	O
-	O
2	O
diet	O
.	O

Thus	O
,	O
subsequent	O
analyses	O
were	O
performed	O
with	O
the	O
F	O
-	O
2	O
diet	O
for	O
mutant	O
Vdr	O
(	O
R270L	O
)	O
and	O
Vdr	O
-	O
KO	O
rats	O
,	O
while	O
a	O
CE	O
-	O
2	O
diet	O
containing	O
1	O
.	O
15	O
%	O
calcium	O
was	O
used	O
for	O
Cyp27b1	B
-	O
KO	O
rats	O
.	O

The	O
femur	O
lengths	O
of	O
Cyp27b1	B
-	O
KO	O
,	O
mutant	O
Vdr	O
(	O
R270L	O
)	O
and	O
Vdr	O
-	O
KO	O
rats	O
were	O
shorter	O
than	O
those	O
of	O
WT	O
rats	O
.	O

Although	O
Vdr	O
(	O
R270L	O
)	O
and	O
Vdr	O
-	O
KO	O
rats	O
did	O
not	O
show	O
clear	O
changes	O
in	O
total	O
bone	O
mineral	O
density	O
,	O
the	O
Bone	O
Mineral	O
Density	O
of	O
cortical	O
bone	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
was	O
significantly	O
decreased	O
(	O
t	O
=	O
21	O
.	O
108	O
,	O
df	O
=	O
3	O
.	O
245	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
resulting	O
in	O
decreased	O
total	O
Bone	O
Mineral	O
Density	O
(	O
t	O
=	O
13	O
.	O
782	O
,	O
df	O
=	O
6	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
rats	O
and	O
Vdr	O
-	O
KO	O
rats	O
at	O
15	O
weeks	O
of	O
age	O
,	O
as	O
evidenced	O
by	O
toluidine	O
blue	O
staining	O
,	O
indicating	O
the	O
histological	O
features	O
of	O
rickets	O
rats	O
but	O
not	O
in	O
Vdr	O
-	O
KO	O
rats	O
at	O
15	O
weeks	O
of	O
age	O
.	O

Although	O
all	O
Genetically	O
Modified	O
rats	O
showed	O
abnormal	O
bone	O
morphology	O
,	O
Cyp27b1	B
-	O
KO	O
rats	O
showed	O
more	O
severe	O
bone	O
disorders	O
than	O
the	O
other	O
Genetically	O
Modified	O
rats	O
rats	O
(	O
t	O
=	O
3	O
.	O
881	O
,	O
df	O
=	O
12	O
,	O
p	O
=	O
0	O
.	O
002	O
)	O
and	O
Cyp27b1	B
-	O
KO	O
rats	O
(	O
t	O
=	O
7	O
.	O
584	O
,	O
df	O
=	O
7	O
.	O
845	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
whose	O
secretion	O
is	O
induced	O
by	O
the	O
reduced	O
plasma	O
calcium	O
level	O
via	O
calcium	O
-	O
sensing	O
receptor	O
in	O
the	O
parathyroid	O
,	O
was	O
significantly	O
increased	O
in	O
Vdr	O
(	O
R270L	O
)	O
rats	O
(	O
t	O
=	O
4	O
.	O
295	O
,	O
df	O
=	O
5	O
.	O
026	O
,	O
p	O
=	O
0	O
.	O
008	O
)	O
and	O
Cyp27b1	B
-	O
KO	O
rats	O
(	O
t	O
=	O
8	O
.	O
448	O
,	O
df	O
=	O
8	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
whereas	O
the	O
plasma	O
calcium	O
level	O
in	O
Vdr	O
-	O
KO	O
mice	O
was	O
much	O
lower	O
than	O
that	O
in	O
wild	O
-	O
type	O
mice	O
^	O
,	O
.	O

As	O
shown	O
in	O
Fig	O
,	O
the	O
plasma	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
level	O
was	O
significantly	O
increased	O
in	O
Vdr	O
(	O
R270L	O
)	O
(	O
t	O
=	O
4	O
.	O
024	O
,	O
df	O
=	O
8	O
,	O
p	O
=	O
0	O
.	O
004	O
)	O
and	O
Vdr	O
-	O
KO	O
rats	O
(	O
t	O
=	O
2	O
.	O
723	O
,	O
df	O
=	O
5	O
,	O
p	O
=	O
0	O
.	O
042	O
)	O
but	O
was	O
significantly	O
decreased	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
(	O
8	O
.	O
0	O
3	O
.	O
2	O
pg	O
/	O
mL	O
(	O
mean	O
SEM	O
,	O
n	O
=	O
7	O
)	O
)	O
compared	O
to	O
that	O
in	O
WT	O
rats	O
(	O
24	O
.	O
8	O
5	O
.	O
2	O
pg	O
/	O
mL	O
,	O
(	O
mean	O
SEM	O
,	O
n	O
=	O
7	O
)	O
)	O
(	O
t	O
=	O
2	O
.	O
771	O
,	O
df	O
=	O
12	O
,	O
p	O
=	O
0	O
.	O
017	O
)	O
.	O

This	O
result	O
was	O
somewhat	O
different	O
from	O
that	O
in	O
Cyp27b1	B
-	O
KO	O
mice	O
^	O
,	O
which	O
showed	O
no	O
detectable	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
(	O
<	O
5	O
pg	O
/	O
mL	O
)	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
dietary	O
administration	O
of	O
25	O
(	O
OH	O
)	O
D_3	O
to	O
Cyp27b1	B
-	O
KO	O
mice	O
reversed	O
type	O
I	O
rickets	O
hallmarks	O
,	O
such	O
as	O
growth	O
failure	O
,	O
skeletal	O
disorders	O
and	O
hypocalcemia	O
^	O
.	O

Dietary	O
administration	O
of	O
25	O
(	O
OH	O
)	O
D_3	O
to	O
Cyp27b1	B
-	O
KO	O
rats	O
at	O
200	O
gkg	O
^	O
1day	O
^	O
1	O
also	O
significantly	O
reversed	O
growth	O
failure	O
(	O
see	O
Supplementary	O
Fig	O
.	O

Histological	O
analysis	O
of	O
the	O
femoral	O
sections	O
demonstrated	O
a	O
normalized	O
structure	O
of	O
the	O
cortex	O
and	O
trabecular	O
bone	O
by	O
25	O
(	O
OH	O
)	O
D_3	O
administration	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
.	O

In	O
addition	O
,	O
25	O
(	O
OH	O
)	O
D_3	O
administration	O
dramatically	O
corrected	O
the	O
osteomalacic	O
features	O
of	O
the	O
Cyp27b1	B
-	O
KO	O
rats	O
(	O
see	O
Supplementary	O
Fig	O
.	O

The	O
plasma	O
calcium	O
level	O
of	O
Cyp27b1	B
-	O
KO	O
rats	O
was	O
fully	O
restored	O
by	O
25	O
(	O
OH	O
)	O
D_3	O
administration	O
(	O
F	O
(	O
1	O
,	O
21	O
)	O
=	O
45	O
.	O
6	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
the	O
markedly	O
elevated	O
plasma	O
Parathyroid	O
Hormone	O
level	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
(	O
F	O
(	O
1	O
,	O
11	O
)	O
=	O
90	O
.	O
6	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
was	O
normalized	O
after	O
25	O
(	O
OH	O
)	O
D_3	O
administration	O
(	O
F	O
(	O
1	O
,	O
11	O
)	O
=	O
62	O
.	O
2	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
_2D_3	O
deficiency	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
was	O
normalized	O
by	O
25	O
(	O
OH	O
)	O
D_3	O
administration	O
(	O
F	O
(	O
1	O
,	O
16	O
)	O
=	O
15	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
D_3	O
^	O
.	O

Liver	O
mitochondrial	O
fractions	O
prepared	O
from	O
Cyp27b1	B
-	O
KO	O
rats	O
showed	O
1ALPHA	O
-	O
hydroxylation	O
activity	O
toward	O
25	O
(	O
OH	O
)	O
D_3	O
.	O

These	O
results	O
were	O
also	O
quite	O
similar	O
to	O
those	O
in	O
Cyp27b1	B
-	O
KO	O
mice	O
,	O
suggesting	O
that	O
the	O
most	O
likely	O
candidate	O
for	O
the	O
other	O
1ALPHA	O
-	O
hydroxylase	O
is	O
Cyp27a1	O
^	O
.	O

When	O
wild	O
-	O
type	O
and	O
Vdr	O
(	O
R270L	O
)	O
rats	O
were	O
compared	O
,	O
a	O
difference	O
was	O
seen	O
in	O
(	O
1	O
)	O
VDR	O
-	O
dependent	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
effects	O
and	O
Cyp27b1	B
-	O
KO	O
rats	O
may	O
reveal	O
(	O
2	O
)	O
VDR	O
-	O
independent	O
effects	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
.	O

The	O
plasma	O
level	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
was	O
dramatically	O
reduced	O
,	O
probably	O
by	O
the	O
reduction	O
in	O
Cyp27b1	B
expression	O
resulting	O
from	O
the	O
decrease	O
in	O
plasma	O
Parathyroid	O
Hormone	O
content	O
.	O

Growth	O
failure	O
and	O
rickets	O
were	O
observed	O
in	O
both	O
Vdr	O
(	O
R270L	O
)	O
and	O
Cyp27b1	B
-	O
KO	O
rats	O
.	O

The	O
morphological	O
abnormalities	O
observed	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
appeared	O
to	O
be	O
closely	O
linked	O
with	O
a	O
decrease	O
in	O
cortical	O
bone	O
density	O
and	O
an	O
increase	O
in	O
femoral	O
cancellous	O
bone	O
density	O
.	O

Comparisons	O
of	O
growth	O
rates	O
and	O
plasma	O
calcium	O
levels	O
revealed	O
more	O
severe	O
symptoms	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
than	O
in	O
Vdr	O
(	O
R270L	O
)	O
rats	O
.	O

It	O
is	O
most	O
likely	O
that	O
Cyp27b1	B
-	O
KO	O
rats	O
showed	O
more	O
severe	O
rickets	O
symptoms	O
than	O
mutant	O
Vdr	O
(	O
R270L	O
)	O
rats	O
because	O
of	O
the	O
absence	O
of	O
Vdr	O
-	O
independent	O
effects	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
.	O

Membrane	O
-	O
associated	O
rapid	O
response	O
steroid	O
-	O
binding	O
proteins	O
,	O
such	O
as	O
GRP58	O
,	O
ERp57	O
,	O
ERp60	O
,	O
and	O
Pdia3	O
^	O
,	O
could	O
be	O
involved	O
in	O
calcium	O
absorption	O
in	O
the	O
small	O
intestine	O
,	O
and	O
it	O
is	O
presumed	O
that	O
the	O
remarkable	O
difference	O
in	O
the	O
plasma	O
calcium	O
concentration	O
between	O
Vdr	O
(	O
R270L	O
)	O
rats	O
and	O
Cyp27b1	B
-	O
KO	O
rats	O
was	O
based	O
on	O
the	O
Vdr	O
-	O
independent	O
effects	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
.	O

As	O
with	O
Vdr	O
(	O
R270L	O
)	O
rats	O
,	O
administration	O
of	O
25	O
(	O
OH	O
)	O
D_3	O
exerted	O
pronounced	O
effects	O
on	O
Cyp27b1	B
-	O
KO	O
rats	O
,	O
resulting	O
in	O
normalization	O
of	O
plasma	O
calcium	O
and	O
Parathyroid	O
Hormone	O
levels	O
,	O
osteogenesis	O
,	O
and	O
infertility	O
in	O
females	O
.	O

However	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
was	O
detected	O
in	O
the	O
blood	O
of	O
Cyp27b1	B
-	O
KO	O
rats	O
at	O
the	O
same	O
levels	O
as	O
in	O
wild	O
-	O
type	O
rats	O
.	O

As	O
described	O
in	O
our	O
previous	O
study	O
,	O
the	O
generation	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
following	O
25	O
(	O
OH	O
)	O
D_3	O
administration	O
was	O
also	O
observed	O
in	O
Cyp27b1	B
-	O
KO	O
mice	O
^	O
.	O

1ALPHA	O
-	O
Hydroxylase	O
activity	O
toward	O
25	O
(	O
OH	O
)	O
D_3	O
in	O
a	O
liver	O
mitochondrial	O
fraction	O
prepared	O
from	O
Cyp27b1	B
-	O
KO	O
rats	O
suggested	O
that	O
Cyp27a1	O
,	O
a	O
1ALPHA	O
-	O
hydroxylase	O
abundant	O
in	O
the	O
liver	O
,	O
is	O
most	O
likely	O
responsible	O
for	O
the	O
generation	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
.	O

It	O
should	O
be	O
noted	O
that	O
25	O
(	O
OH	O
)	O
D_3	O
administration	O
is	O
highly	O
effective	O
in	O
type	O
I	O
rickets	O
models	O
,	O
such	O
as	O
Cyp27b1	B
-	O
KO	O
rats	O
.	O

By	O
contrast	O
,	O
the	O
Cyp27b1	B
-	O
KO	O
rats	O
for	O
analysis	O
were	O
continuously	O
fed	O
the	O
CE	O
-	O
2	O
diet	O
because	O
most	O
male	O
Cyp27b1	B
-	O
Knockout	O
rats	O
were	O
not	O
able	O
to	O
survive	O
more	O
than	O
10	O
weeks	O
when	O
fed	O
the	O
F	O
-	O
2	O
diet	O
(	O
data	O
not	O
shown	O
)	O
.	O

A	O
history	O
of	O
the	O
roles	O
of	O
cytochrome	B
P450	I
enzymes	I
in	O
the	O
toxicity	O
of	O
drugs	O
.	O

In	O
the	O
mid	O
-	O
20th	O
Century	O
the	O
relationship	O
between	O
drug	O
metabolism	O
and	O
toxicity	O
became	O
appreciated	O
,	O
and	O
the	O
roles	O
of	O
cytochrome	B
P450	I
(	O
P450	O
)	O
enzymes	O
began	O
to	O
be	O
defined	O
in	O
the	O
1960s	O
.	O

Much	O
has	O
been	O
written	O
about	O
cytochrome	B
P450	I
(	O
P450	O
,	O
CYP	O
)	O
.	O

In	O
1976	O
,	O
an	O
international	O
series	O
of	O
biennial	O
meetings	O
on	O
the	O
cytochrome	B
P450	I
enzymes	I
was	O
established	O
as	O
a	O
means	O
of	O
facilitating	O
contact	O
of	O
scientists	O
in	O
this	O
area	O
working	O
in	O
Eastern	O
Bloc	O
and	O
western	O
countries	O
but	O
has	O
developed	O
into	O
a	O
timely	O
international	O
biennial	O
series	O
with	O
meetings	O
rotating	O
among	O
Europe	O
,	O
Asia	O
,	O
North	O
America	O
,	O
and	O
Australia	O
.	O

Another	O
DDI	O
grading	O
difference	O
relates	O
to	O
strong	O
enzyme	O
inducers	O
(	O
eg	O
carbamazepine	O
,	O
phenytoin	O
,	O
St	O
Johns	O
Wort	O
)	O
which	O
are	O
contraindicated	O
in	O
the	O
COVID	O
-	O
19	O
website	O
with	O
drugs	O
metabolized	O
by	O
cytochrome	B
P450	I
,	O
given	O
the	O
risk	O
of	O
treatment	O
failure	O
and	O
difficulty	O
of	O
managing	O
the	O
DDI	O
.	O

COVID	O
-	O
19	O
drugs	O
are	O
also	O
potential	O
victims	O
of	O
a	O
DDI	O
when	O
co	O
-	O
administered	O
with	O
strong	O
cytochrome	B
P450	I
inducers	O
,	O
as	O
are	O
chloroquine	O
,	O
hydroxychloroquine	O
and	O
remdesivir	O
.	O

In	O
addition	O
to	O
mitochondria	O
-	O
that	O
are	O
considered	O
the	O
most	O
relevant	O
source	O
of	O
ROS	O
-	O
and	O
to	O
peroxisomes	O
and	O
microsomes	O
,	O
the	O
endoplasmic	O
reticulum	O
stress	O
and	O
enzymes	O
as	O
NADPH	O
oxidase	O
,	O
cytochrome	B
P450	I
2E1	O
,	O
cyclooxygenases	O
,	O
and	O
lipoxygenases	O
also	O
produce	O
Reactive	O
Oxidative	O
Species	O
.	O

In	O
addition	O
,	O
the	O
wild	O
F	O
.	O
filiformis	O
genome	O
contained	O
107	O
cytochrome	B
P450	I
family	O
genes	O
and	O
674	O
genes	O
encoding	O
secretory	O
proteins	O
.	O

Two	O
putative	O
cytochrome	B
P450	I
genes	O
(	O
gene	O
9114	O
and	O
gene	O
7212	O
)	O
were	O
also	O
significantly	O
upregulated	O
in	O
the	O
dikaryotic	O
mycelium	O
compared	O
to	O
the	O
monokaryotic	O
mycelium	O
of	O
the	O
wild	O
strain	O
(	O
7	O
.	O
61	O
-	O
and	O
7	O
.	O
50	O
-	O
fold	O
change	O
,	O
respectively	O
)	O
and	O
the	O
cultivar	O
strain	O
mycelium	O
(	O
2	O
.	O
1	O
-	O
and	O
1	O
.	O
7	O
-	O
fold	O
change	O
,	O
respectively	O
)	O
.	O

We	O
identified	O
107	O
genes	O
in	O
the	O
cytochrome	B
P450	I
family	O
,	O
including	O
nine	O
putative	O
trichodiene	O
oxygenases	O
,	O
31	O
O	O
-	O
methylsterigmatocystin	O
oxidoreductases	O
,	O
five	O
benzoate	O
4	O
-	O
monooxygenases	O
,	O
two	O
linoleate	O
10R	O
-	O
lipoxygenases	O
,	O
two	O
ent	O
-	O
kaurene	O
oxidases	O
,	O
lanosterol	O
14	O
-	O
alpha	O
and	O
flavonoid	O
hydroxylases	O
and	O
other	O
candidate	O
cytochrome	O
P450s	O
.	O

Twenty	O
-	O
six	O
CYP450	O
genes	O
were	O
upregulated	O
in	O
the	O
mycelium	O
of	O
the	O
wild	O
strain	O
compared	O
to	O
the	O
cultivar	O
strain	O
and	O
the	O
cytochrome	B
P450	I
(	O
gene	O
5820	O
-	O
D3	O
)	O
had	O
the	O
highest	O
expression	O
level	O
,	O
with	O
more	O
than	O
a	O
500	O
-	O
fold	O
change	O
.	O

It	O
has	O
been	O
reported	O
that	O
a	O
more	O
divergent	O
cytochrome	B
P450	I
oxidase	O
could	O
be	O
involved	O
in	O
secondary	O
biosynthesis	O
.	O

a	O
=	O
view	O
)	O
to	O
obtain	O
the	O
annotated	O
gene	O
for	O
cytochrome	B
P450	I
.	O

This	O
highly	O
regulated	O
pathway	O
involves	O
several	O
cytochrome	B
P450	I
,	O
as	O
well	O
as	O
different	O
dehydrogenases	O
and	O
reductases	O
.	O

After	O
phylogenetic	O
analysis	O
,	O
domain	O
prediction	O
,	O
and	O
molecular	O
docking	O
studies	O
,	O
22	O
candidates	O
encoding	O
2	O
,	O
3	O
-	O
oxidosqualene	O
cyclase	O
,	O
alcohol	O
dehydrogenase	O
,	O
cytochrome	B
P450	I
,	O
acyltransferase	O
,	O
and	O
esterase	O
were	O
proposed	O
to	O
be	O
potential	O
genes	O
involved	O
in	O
azadirachtin	O
A	O
biosynthesis	O
.	O

Five	O
kinds	O
of	O
putative	O
enzymes	O
,	O
oxidosqualene	O
cyclase	O
,	O
cytochrome	B
P450	I
,	O
alcohol	O
dehydrogenase	O
,	O
acyltransferase	O
,	O
and	O
esterase	O
were	O
proposed	O
in	O
the	O
putative	O
biosynthetic	O
pathway	O
.	O

One	O
of	O
them	O
(	O
transcript	O
/	O
14554	O
)	O
was	O
annotated	O
as	O
the	O
neem	O
NADPH	O
-	O
cytochrome	B
P450	I
reductase	O
2	O
.	O

All	O
three	O
kratom	O
alkaloids	O
tested	O
inhibited	O
select	O
cytochrome	B
P450	I
enzymes	I
,	O
suggesting	O
a	O
potential	O
risk	O
for	O
adverse	O
interactions	O
when	O
kratom	O
is	O
co	O
-	O
consumed	O
with	O
drugs	O
metabolized	O
by	O
these	O
enzymes	O
.	O

Mitragynine	O
has	O
been	O
reported	O
to	O
inhibit	O
several	O
cytochrome	O
P450s	O
(	O
CYPs	O
)	O
^	O
,	O
-	O
-	O
,	O
which	O
could	O
lead	O
to	O
increased	O
systemic	O
exposure	O
to	O
co	O
-	O
consumed	O
drugs	O
,	O
including	O
opioids	O
,	O
and	O
potential	O
adverse	O
effects	O
.	O

Consistent	O
with	O
previous	O
literature	O
,	O
our	O
results	O
raise	O
concern	O
about	O
potential	O
drug	O
interactions	O
that	O
may	O
occur	O
when	O
kratom	O
is	O
consumed	O
concurrently	O
with	O
opiates	O
or	O
other	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P450s	O
.	O

For	O
example	O
,	O
in	O
Arabidopsis	O
thaliana	O
,	O
gene	O
groups	O
including	O
two	O
to	O
five	O
terpene	O
synthases	O
clustered	O
together	O
with	O
prenyltransferase	O
-	O
,	O
cytochrome	B
P450	I
-	O
and	O
glycosyltransferase	O
genes	O
^	O
.	O

Degradation	O
of	O
polychlorinated	O
biphenyls	O
(	O
PCBs	O
)	O
is	O
initiated	O
by	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
and	O
includes	O
PCB	O
oxidation	O
to	O
OH	O
-	O
metabolites	O
,	O
which	O
often	O
display	O
a	O
higher	O
toxicity	O
than	O
their	O
parental	O
compounds	O
.	O

Taking	O
these	O
results	O
into	O
account	O
,	O
we	O
decided	O
to	O
subject	O
PCB	O
28	O
to	O
in	O
vitro	O
metabolism	O
by	O
a	O
human	O
liver	O
-	O
like	O
cytochrome	B
P450	I
cocktail	O
(	O
rhCYP	O
cocktail	O
)	O
^	O
,	O
.	O

Metabolization	O
takes	O
place	O
by	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
,	O
which	O
are	O
very	O
well	O
conserved	O
between	O
invertebrates	O
and	O
vertebrates	O
.	O

The	O
expression	O
level	O
of	O
nitronate	O
monooxygenase	O
(	O
NMO	O
)	O
,	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
and	O
cytochrome	O
P450s	O
(	O
CYP72A1	O
and	O
CYP72A2	O
)	O
varied	O
broadly	O
among	O
populations	O
and	O
individual	O
plants	O
within	O
the	O
populations	O
.	O

EMR	O
is	O
considered	O
to	O
be	O
polygenically	O
inherited	O
,	O
involving	O
multiple	O
genes	O
encoding	O
for	O
metabolic	O
enzymes	O
such	O
as	O
cytochrome	B
P450	I
monooxygenase	O
(	O
P450	O
)	O
,	O
glucosyl	O
transferases	O
(	O
GT	O
)	O
,	O
glutathione	O
S	O
-	O
transferases	O
(	O
GST	O
)	O
,	O
esterases	O
and	O
ABC	O
transporters	O
(	O
;	O
.	O

Two	O
cytochrome	B
P450	I
genes	O
(	O
CYP81A12	O
and	O
CYP81A21	O
)	O
were	O
found	O
to	O
be	O
overexpressed	O
and	O
associated	O
with	O
resistance	O
to	O
ALS	O
inhibitors	O
in	O
Echinochloa	O
phyllopogon	O
.	O

The	O
metabolism	O
of	O
this	O
polycyclic	O
aromatic	O
hydrocarbon	O
molecule	O
by	O
oxidation	O
reaction	O
through	O
cytochrome	B
P450	I
enzyme	I
from	O
human	O
host	O
and	O
monooxygenases	O
and	O
dioxygenase	O
enzymes	O
from	O
bacterial	O
species	O
of	O
skin	O
microbiome	O
is	O
known	O
from	O
experimental	O
studies	O
,	O
and	O
reference	O
databases	O
such	O
as	O
the	O
University	O
of	O
Minnesota	O
Biocatalysis	O
/	O
Biodegradation	O
Database	O
(	O
;	O
.	O

The	O
ingestion	O
of	O
BaP	O
is	O
known	O
to	O
be	O
toxic	O
due	O
to	O
its	O
metabolism	O
by	O
human	O
cytochrome	B
P450	I
enzyme	I
and	O
the	O
products	O
of	O
its	O
oxidation	O
are	O
known	O
to	O
cause	O
carcinogenicity	O
and	O
other	O
adverse	O
health	O
effects	O
by	O
reacting	O
with	O
the	O
host	O
DNA	O
(	O
;	O
.	O

In	O
separate	O
experiments	O
,	O
3	O
,	O
5	O
-	O
DCNB	O
cytotoxicity	O
was	O
reduced	O
by	O
pretreating	O
IKC	O
with	O
antioxidants	O
and	O
cytochrome	B
P450	I
,	O
flavin	O
monooxygenase	O
and	O
peroxidase	O
inhibitors	O
,	O
while	O
3	O
,	O
5	O
-	O
DCPHA	O
cytotoxicity	O
was	O
attenuated	O
by	O
two	O
nucleophilic	O
antioxidants	O
(	O
glutathione	O
and	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
)	O
.	O

Stipitaldehyde	O
8	O
represents	O
a	O
branching	O
point	O
in	O
Tropolone	O
Sesquiterpenoids	O
biosynthesis	O
(	O
Scheme	O
)	O
:	O
in	O
the	O
case	O
of	O
xenovulene	O
A	O
2	O
,	O
stipitaldehyde	O
8	O
is	O
oxidised	O
by	O
the	O
cytochrome	B
P450	I
AsR2	O
to	O
the	O
corresponding	O
hemiacetal	O
9	O
and	O
subsequent	O
elimination	O
of	O
water	O
yields	O
the	O
reactive	O
quinomethide	O
10	O
that	O
undergoes	O
an	O
enzymecatalyzed	O
hetero	O
Diels	O
-	O
Alder	O
reaction	O
with	O
ALPHAhumulene	O
6	O
,	O
synthesised	O
by	O
an	O
unusual	O
terpene	O
cyclase	O
,	O
yielding	O
xenovulene	O
B	O
11	O
(	O
Scheme	O
.	O

Unique	O
to	O
the	O
eup2	O
Biosynthetic	O
Gene	O
Clusters	O
and	O
pyc	O
Biosynthetic	O
Gene	O
Clusters	O
are	O
shortchain	O
dehydrogenase	O
encoding	O
genes	O
(	O
eupL4	O
and	O
pycL2	O
;	O
homologous	O
to	O
eupfE	O
)	O
and	O
a	O
cytochrome	B
P450	I
(	O
eupR6	O
,	O
pycR5	O
)	O
homologous	O
to	O
eupfD	O
,	O
previously	O
shown	O
to	O
be	O
responsible	O
for	O
C10	O
hydroxylation	O
of	O
the	O
terpene	O
moiety	O
.	O

Cytochromes	O
are	O
classified	O
based	O
on	O
their	O
lowest	O
electronic	O
energy	O
absorption	O
band	O
in	O
their	O
reduced	O
state	O
:	O
cytochrome	B
P450	I
(	O
450	O
nm	O
)	O
,	O
cytochrome	O
c	O
(	O
550	O
nm	O
)	O
,	O
cytochromes	O
b	O
(	O
565	O
nm	O
)	O
,	O
cytochromes	O
a	O
(	O
605	O
nm	O
)	O
.	O

Notably	O
,	O
in	O
doing	O
so	O
we	O
have	O
identified	O
a	O
non	O
-	O
canonical	O
cytochrome	B
P450	I
that	O
catalyzes	O
the	O
remarkable	O
ring	O
expansion	O
reaction	O
required	O
to	O
produce	O
the	O
distinct	O
carbon	O
scaffold	O
of	O
colchicine	O
.	O

For	O
yeast	O
expression	O
of	O
CYP	O
genes	O
,	O
we	O
utilized	O
S	O
.	O
cerevisiae	O
strain	O
WAT11	O
(	O
ade2	O
)	O
,	O
which	O
harbors	O
a	O
chromosomal	O
copy	O
of	O
the	O
Arabidopsis	O
thaliana	O
NADPH	O
-	O
cytochrome	B
P450	I
reductase	O
1	O
gene	O
.	O

Comparison	O
of	O
two	O
human	O
cell	O
lines	O
(	O
HepG2	O
and	O
HepaRG	O
)	O
with	O
different	O
activities	O
of	O
cytochrome	B
P450	I
enzymes	I
revealed	O
that	O
Ze	O
339	O
and	O
its	O
single	O
constituents	O
petasin	O
,	O
isopetasin	O
,	O
neopetasin	O
,	O
isopetasol	O
,	O
and	O
petasol	O
exerted	O
higher	O
toxicity	O
in	O
cells	O
having	O
a	O
higher	O
cytochrome	O
activity	O
.	O

Celastrol	O
biosynthesis	O
likely	O
adheres	O
to	O
the	O
common	O
triterpenoid	O
scheme	O
that	O
starts	O
with	O
cycloisomerization	O
of	O
2	O
,	O
3	O
-	O
oxidosqualene	O
by	O
an	O
oxidosqualene	O
cyclase	O
(	O
OSC	O
)	O
and	O
continues	O
with	O
oxidative	O
decoration	O
(	O
s	O
)	O
of	O
the	O
30	O
-	O
carbon	O
triterpenoid	O
core	O
structure	O
by	O
cytochrome	O
P450	B
enzymes	I
[	O
,	O
.	O

These	O
results	O
suggest	O
that	O
these	O
P450	B
enzymes	I
likely	O
catalyze	O
three	O
sequential	O
oxygenations	O
of	O
friedelin	O
into	O
an	O
alcohol	O
,	O
and	O
further	O
to	O
a	O
carboxylic	O
acid	O
via	O
an	O
aldehyde	O
.	O

In	O
triterpenoid	O
biosynthesis	O
,	O
the	O
formation	O
of	O
a	O
triterpene	O
backbone	O
is	O
usually	O
followed	O
by	O
oxidations	O
catalyzed	O
by	O
P450	B
enzymes	I
.	O

Output	O
includes	O
metabolism	O
to	O
oxysterols	O
by	O
the	O
cytochrome	O
P450	B
enzymes	I
Cytochromes	O
P450	O
27a1	O
and	O
CYP46A1	O
,	O
the	O
photoreceptor	O
phagocytosis	O
,	O
and	O
efflux	O
to	O
lipoprotein	O
particles	O
,	O
which	O
circulate	O
in	O
the	O
intraretinal	O
space	O
.	O

Furthermore	O
,	O
different	O
reconstituted	O
fractions	O
of	O
extract	O
(	O
petasins	O
and	O
fatty	O
acid	O
fraction	O
)	O
were	O
examined	O
in	O
three	O
in	O
vitro	O
test	O
systems	O
using	O
hepatocytes	O
:	O
Two	O
human	O
cell	O
lines	O
,	O
with	O
lower	O
and	O
higher	O
activity	O
of	O
cytochrome	O
P450	B
enzymes	I
(	O
HepG2	O
,	O
HepaRG	O
)	O
as	O
well	O
as	O
a	O
rodent	O
cell	O
line	O
with	O
high	O
cytochrome	O
P450	O
activity	O
(	O
H4IIE	O
)	O
,	O
were	O
used	O
.	O

The	O
analysis	O
focused	O
on	O
three	O
different	O
in	O
vitro	O
test	O
systems	O
of	O
hepatocytes	O
:	O
two	O
human	O
hepatic	O
cell	O
lines	O
,	O
with	O
lower	O
and	O
higher	O
activity	O
of	O
cytochrome	O
P450	B
enzymes	I
(	O
HepG2	O
and	O
HepaRG	O
,	O
respectively	O
,	O
(	O
Andersson	O
,	O
Kanebratt	O
,	O
&	O
Kenna	O
,	O
;	O
Guillouzo	O
et	O
al	O
.	O
,	O
)	O
)	O
and	O
a	O
rat	O
cell	O
line	O
(	O
H4IIE	O
[	O
Fujimura	O
,	O
Murakami	O
,	O
Miwa	O
,	O
Aruga	O
,	O
&	O
Toriumi	O
,	O
;	O
Westerink	O
,	O
Stevenson	O
,	O
&	O
Schoonen	O
,	O
]	O
)	O
were	O
used	O
.	O

Isolated	O
cytochrome	O
P450	B
enzymes	I
and	O
phosphate	O
buffer	O
were	O
obtained	O
from	O
BD	O
Gentest	O
(	O
Switzerland	O
)	O
.	O

In	O
this	O
direction	O
,	O
this	O
study	O
is	O
an	O
attempt	O
to	O
provide	O
a	O
complete	O
picture	O
of	O
P450	B
enzymes	I
in	O
different	O
cyanobacterial	O
species	O
as	O
these	O
enzymes	O
are	O
the	O
key	O
players	O
in	O
primary	O
and	O
secondary	O
metabolism	O
of	O
organisms	O
,	O
including	O
the	O
production	O
of	O
different	O
secondary	O
metabolites	O
.	O

As	O
these	O
Cytochrome	B
P450	B
enzymes	I
differ	O
significantly	O
between	O
species	O
,	O
drug	O
biotransformation	O
and	O
hepatotoxicity	O
can	O
only	O
be	O
evaluated	O
in	O
freshly	O
isolated	O
primary	O
human	O
hepatocytes	O
^	O
.	O

Hepatocyte	O
-	O
Like	O
Cells	O
differ	O
from	O
Primary	O
Human	O
Hepatocytes	O
at	O
the	O
transcriptional	O
,	O
proteomic	O
,	O
and	O
epigenetical	O
level	O
,	O
and	O
specifically	O
express	O
low	O
levels	O
of	O
hepatic	O
transcription	O
factors	O
and	O
Cytochrome	B
P450	B
enzymes	I
^	O
,	O
,	O
,	O
.	O

We	O
also	O
show	O
that	O
extracellular	O
amino	O
acids	O
represent	O
a	O
tool	O
to	O
drive	O
both	O
metabolic	O
maturation	O
and	O
the	O
expression	O
of	O
Cytochrome	B
P450	B
enzymes	I
,	O
and	O
this	O
in	O
both	O
Hepatocyte	O
-	O
Like	O
Cells	O
and	O
HepG2	O
hepatoma	O
cells	O
.	O

As	O
aside	O
from	O
CYP3A4	B
,	O
also	O
other	O
Cytochrome	O
P450	O
isoforms	O
were	O
induced	O
in	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
medium	O
(	O
Supplementary	O
Fig	O
)	O
,	O
Amino	O
Acids	O
represent	O
a	O
valuable	O
tool	O
to	O
induce	O
Cytochrome	B
P450	B
enzymes	I
.	O

The	O
top	O
deregulated	O
pathways	O
when	O
comparing	O
HLC	O
Liver	O
Differentiation	O
Medium	O
D20	O
with	O
Primary	O
Human	O
Hepatocytes	O
contained	O
several	O
genes	O
involved	O
in	O
AA	O
catabolism	O
,	O
glucose	O
metabolism	O
,	O
metabolic	O
pathways	O
,	O
and	O
metabolism	O
of	O
xenobiotics	O
by	O
Cytochrome	B
P450	B
enzymes	I
and	O
AMP	O
-	O
activated	O
protein	O
kinase	O
)	O
,	O
we	O
next	O
stratified	O
these	O
into	O
four	O
quadrants	O
.	O

AOH	O
and	O
Alternariol	O
Monomethyl	O
Ether	O
were	O
reported	O
to	O
serve	O
as	O
substrates	O
for	O
different	O
Cytochrome	B
P450	B
enzymes	I
,	O
particularly	O
for	O
Cytochrome	B
P450	I
1A1	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
hydroxylated	O
metabolites	O
.	O

However	O
,	O
both	O
CYP2C8	B
3	O
and	O
6	O
LCPUFA	O
metabolites	O
are	O
proangiogenic	O
and	O
inhibition	O
of	O
CYP2C8	B
decreases	O
ocular	O
neovascularization	O
(	O
Shao	O
et	O
al	O
,	O
;	O
Gong	O
et	O
al	O
,	O
,	O
)	O
.	O

The	O
CYP2C19	O
gene	O
is	O
part	O
of	O
the	O
CYP2C	O
cluster	O
comprising	O
four	O
genes	O
(	O
CYP2C8	B
,	O
CYP2C9	O
,	O
CYP2C18	O
and	O
CYP2C19	O
)	O
.	O

For	O
human	O
cells	O
:	O
phenacetin	O
(	O
CYP1A2	B
)	O
,	O
efavirenz	O
(	O
CYP2B6	B
)	O
,	O
amodiaquine	O
(	O
CYP2C8	B
)	O
,	O
diclofenac	O
(	O
CYP2C9	B
)	O
,	O
dextromethorphan	O
(	O
CYP2D6	O
)	O
,	O
testosterone	O
(	O
CYP3A4	B
)	O
,	O
and	O
for	O
rat	O
cells	O
phenacetin	O
(	O
CYP1A2	B
)	O
,	O
testosterone	O
(	O
CYP2A1	O
,	O
CYP3A1	O
,	O
CYP3A2	O
)	O
,	O
diclofenac	O
(	O
CYP2C6	O
)	O
testosterone	O
(	O
CYP2C11	O
)	O
,	O
and	O
Pnitrophenol	O
(	O
CYP2E1	B
)	O
were	O
used	O
.	O

To	O
investigate	O
whether	O
metabolic	O
activation	O
by	O
human	O
phase	O
I	O
enzymes	O
-	O
at	O
least	O
in	O
part	O
-	O
contributes	O
to	O
the	O
cytotoxic	O
effect	O
,	O
Ze	O
339	O
(	O
concentrations	O
up	O
to	O
100	O
g	O
/	O
ml	O
)	O
was	O
coincubated	O
in	O
HepaRG	O
cells	O
for	O
4	O
hr	O
with	O
different	O
single	O
cytochromes	O
inhibitors	O
:	O
ketoconazole	O
(	O
CYP3A4	B
)	O
,	O
sulfaphenazole	O
(	O
CYP2C9	B
)	O
,	O
montelukast	O
(	O
CYP2C8	B
)	O
,	O
omeprazole	O
(	O
CYP2C19	B
)	O
,	O
ALPHAnaphthoflavone	O
(	O
CYP1A2	B
)	O
,	O
quinidine	O
(	O
CYP2D6	O
)	O
,	O
xanthotoxin	O
(	O
CYP2A6	O
)	O
,	O
chlormethiazole	O
(	O
CYP2E1	B
)	O
,	O
and	O
ticlopidine	O
(	O
CYP2B6	B
)	O
-	O
(	O
each	O
at	O
a	O
concentration	O
of	O
10	O
M	O
)	O
.	O

The	O
incubation	O
with	O
single	O
human	O
cytochromes	O
revealed	O
that	O
petasin	O
was	O
mainly	O
metabolized	O
by	O
CYP2D6	O
(	O
80	O
.	O
2	O
%	O
)	O
and	O
to	O
an	O
intermediate	O
extent	O
by	O
CYP3A4	B
(	O
34	O
%	O
)	O
,	O
CYP2B6	B
(	O
50	O
%	O
)	O
,	O
CYP2C8	B
(	O
54	O
%	O
)	O
,	O
and	O
CYP2C9	B
(	O
51	O
%	O
)	O
.	O

However	O
,	O
for	O
isopetasin	O
and	O
neopetasin	O
,	O
the	O
cytochromes	O
mainly	O
involved	O
in	O
their	O
metabolism	O
were	O
CYP3A4	B
(	O
87	O
%	O
and	O
86	O
%	O
)	O
,	O
CYP2D6	O
(	O
61	O
%	O
and	O
83	O
%	O
)	O
,	O
and	O
CYP2C8	B
(	O
44	O
%	O
and	O
71	O
%	O
)	O
.	O

Extend	O
of	O
metabolism	O
was	O
54	O
%	O
/	O
44	O
%	O
/	O
71	O
%	O
for	O
CYP2C8	B
(	O
human	O
)	O
and	O
51	O
%	O
/	O
8	O
%	O
/	O
58	O
%	O
for	O
CYP2C9	B
(	O
human	O
)	O
versus	O
94	O
%	O
/	O
72	O
%	O
/	O
75	O
%	O
for	O
CYP2C6	O
(	O
rat	O
)	O
and	O
55	O
%	O
/	O
74	O
%	O
/	O
84	O
%	O
for	O
CYP2C11	O
(	O
rat	O
)	O
.	O

In	O
HepaRG	O
cells	O
,	O
the	O
effect	O
of	O
cytochrome	O
inhibition	O
on	O
the	O
toxic	O
effects	O
of	O
Ze	O
339	O
was	O
investigated	O
;	O
addition	O
of	O
quinidine	O
(	O
CYP2D6	O
inhibitor	O
)	O
and	O
montelukast	O
(	O
CYP2C8	B
inhibitor	O
)	O
attenuated	O
(	O
p	O
<	O
.	O
001	O
and	O
p	O
=	O
.	O
041	O
,	O
respectively	O
)	O
;	O
most	O
of	O
the	O
cytotoxic	O
effect	O
of	O
Ze	O
339	O
demonstrated	O
for	O
the	O
highest	O
concentration	O
studied	O
(	O
100	O
g	O
/	O
ml	O
)	O
.	O

Inhibition	O
of	O
different	O
cytochromes	O
in	O
HepaRG	O
showed	O
an	O
attenuation	O
of	O
the	O
toxic	O
effects	O
,	O
which	O
was	O
pronounced	O
for	O
CYP2D6	O
and	O
to	O
a	O
minor	O
extend	O
CYP2C8	B
.	O

When	O
Cyp18a1	O
(	O
human	O
orthologues	O
:	O
CYP2C19	B
,	O
CYP2C8	B
,	O
CYP2C9	B
,	O
CYP2J2	O
,	O
CYP2R1	O
,	O
CYP21A2	O
,	O
CYP2A6	O
,	O
CYP2D6	B
,	O
CYP2	O
F1	O
,	O
CYP2S1	O
,	O
CYP2U1	O
and	O
CYP2E1	B
)	O
was	O
silenced	O
,	O
a	O
10	O
%	O
reduction	O
of	O
3	O
-	O
OHCB	O
28	O
and	O
a	O
70	O
%	O
reduction	O
of	O
3	O
-	O
OHCB	O
28	O
was	O
observed	O
compared	O
to	O
control	O
.	O

The	O
first	O
association	O
of	O
genetic	O
polymorphisms	O
with	O
the	O
metabolism	O
of	O
an	O
anti	O
-	O
epileptic	O
drug	O
has	O
been	O
reported	O
in	O
the	O
association	O
of	O
variation	O
in	O
drug	O
-	O
metabolizing	O
enzymes	O
CYP2C9	B
and	O
CYP2C19	B
with	O
phenytoin	O
dose	O
,	O
providing	O
hope	O
for	O
individualized	O
therapy	O
for	O
patients	O
.	O

In	O
patients	O
with	O
severe	O
INH	O
-	O
induced	O
liver	O
injury	O
,	O
not	O
only	O
serum	O
autoantibodies	O
to	O
CYP2E1	O
,	O
CYP3A4	B
and	O
CYP2C9	B
(	O
the	O
three	O
major	O
P450s	O
that	O
metabolize	O
and	O
/	O
or	O
interact	O
with	O
INH	O
)	O
,	O
but	O
also	O
serum	O
antibodies	O
to	O
INH	O
-	O
adducted	O
CYP2E1	O
and	O
other	O
INH	O
-	O
adducted	O
non	O
-	O
P450	O
proteins	O
are	O
detected	O
.	O

Similar	O
serum	O
antibodies	O
to	O
drug	O
-	O
modified	O
and	O
/	O
or	O
unmodified	O
P450s	O
and	O
other	O
native	O
cellular	O
proteins	O
have	O
also	O
been	O
detected	O
in	O
idiosyncratic	O
liver	O
injury	O
upon	O
halothane	O
-	O
exposure	O
(	O
anti	O
-	O
trifluoroacetyl	O
-	O
CYP2E1	O
)	O
,	O
aromatic	O
anti	O
-	O
convulsant	O
(	O
anti	O
-	O
CYP3A	B
)	O
,	O
dihydralazine	O
(	O
anti	O
-	O
CYP1A2	O
)	O
,	O
tienilic	O
acid	O
(	O
anti	O
-	O
tienilic	O
acid	O
-	O
CYP2C9	B
)	O
and	O
/	O
or	O
chronic	O
alcohol	O
intake	O
(	O
anti	O
-	O
acetaldehyde	O
-	O
CYP2E1	O
and	O
anti	O
-	O
hydroxyethyl	O
-	O
CYP2E1	O
)	O
,	O
.	O

For	O
CYP2C9	B
,	O
diverging	O
effects	O
were	O
observed	O
(	O
8	O
%	O
and	O
58	O
%	O
)	O
,	O
and	O
for	O
CYP2B6	B
,	O
virtually	O
no	O
metabolism	O
(	O
13	O
%	O
and	O
20	O
%	O
)	O
was	O
noted	O
.	O

CYP2B6	B
(	O
human	O
)	O
and	O
CYP2E1	B
(	O
rat	O
)	O
could	O
not	O
be	O
compared	O
between	O
species	O
because	O
the	O
respective	O
analogue	O
of	O
the	O
other	O
species	O
was	O
not	O
available	O
to	O
us	O
.	O
.	O
Positive	O
controls	O
for	O
each	O
of	O
the	O
isolated	O
cytochromes	O
showed	O
an	O
extent	O
of	O
metabolism	O
between	O
31	O
.	O
2	O
%	O
(	O
CYP1A2	B
)	O
and	O
100	O
%	O
(	O
CYP2C9	B
)	O
for	O
human	O
cytochromes	O
and	O
between	O
23	O
.	O
1	O
%	O
(	O
CYP2D2	O
)	O
and	O
100	O
%	O
(	O
CYP2B1	O
)	O
for	O
rat	O
cytochromes	O
(	O
data	O
not	O
shown	O
)	O
.	O

Studies	O
had	O
showed	O
that	O
the	O
metabolism	O
of	O
Valproic	O
Acid	O
and	O
DM	O
can	O
be	O
metabolically	O
and	O
pharmacokinetically	O
affected	O
by	O
the	O
same	O
enzymes	O
:	O
CYP2C9	B
and	O
CYP3A4	B
;	O
that	O
multiple	O
human	O
cytochromes	O
contribute	O
to	O
the	O
bio	O
-	O
transformation	O
of	O
DM	O
,	O
including	O
the	O
enzymes	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	O
,	O
and	O
CYP3A	B
;	O
and	O
that	O
Valproic	O
Acid	O
inhibits	O
CYP2C9	B
,	O
CYP3A4	B
or	O
induces	O
CYP3A4	B
gene	O
expression	O
in	O
vitro	O
which	O
support	O
the	O
possible	O
drug	O
interaction	O
of	O
these	O
two	O
drugs	O
.	O

Meanwhile	O
,	O
the	O
examined	O
series	O
inhibited	O
the	O
cytochrome	O
P450	O
isomers	O
,	O
ie	O
,	O
CYP2C19	B
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
-	O
except	O
for	O
Compound	O
2g	O
,	O
which	O
did	O
not	O
inhibit	O
CYP2C19	B
.	O

While	O
other	O
hepatic	O
cytochromes	O
contribute	O
to	O
metoprolol	O
metabolism	O
,	O
namely	O
CYP3A4	B
,	O
CYP2B6	B
,	O
and	O
CYP2C9	B
,	O
these	O
isoforms	O
contribute	O
to	O
less	O
than	O
20	O
%	O
of	O
the	O
drugs	O
metabolism	O
;	O
thus	O
,	O
we	O
have	O
focused	O
on	O
CYP2D6	B
since	O
it	O
is	O
the	O
primary	O
pathway	O
of	O
metabolism	O
.	O

More	O
specifically	O
,	O
midazolam	O
biotransformation	O
was	O
equal	O
to	O
that	O
of	O
Primary	O
Human	O
Hepatocytes	O
,	O
whereas	O
the	O
biotransformation	O
by	O
CYP2D6	B
,	O
CYP1A2	B
,	O
and	O
CYP2C9	B
were	O
found	O
to	O
be	O
in	O
the	O
range	O
of	O
1	O
-	O
10	O
%	O
of	O
the	O
best	O
PHH	O
donor	O
^	O
,	O
,	O
,	O
.	O

To	O
assess	O
the	O
respective	O
metabolization	O
capacities	O
,	O
models	O
were	O
treated	O
with	O
a	O
cocktail	O
consisting	O
of	O
the	O
probe	O
substrates	O
midazolam	O
(	O
10	O
M	O
)	O
,	O
dextromethorphan	O
(	O
20	O
M	O
)	O
,	O
phenacetin	O
(	O
100	O
M	O
)	O
,	O
and	O
tolbutamide	O
(	O
100	O
M	O
)	O
,	O
to	O
determine	O
the	O
activities	O
of	O
CYP3A4	B
,	O
CYP2D6	B
,	O
CYP1A2	B
,	O
and	O
CYP2C9	B
,	O
respectively	O
.	O

If	O
one	O
considers	O
that	O
the	O
metabolism	O
of	O
most	O
drugs	O
is	O
catalyzed	O
by	O
the	O
enzyme	O
group	O
of	O
Cytochrome	B
P450	I
,	O
composed	O
of	O
a	O
large	O
number	O
of	O
isoenzymes	O
,	O
the	O
most	O
important	O
of	O
which	O
in	O
the	O
metabolism	O
of	O
drugs	O
are	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
and	O
CYP3A4	B
.	O

Enzalutamide	O
,	O
recognized	O
as	O
a	O
strong	O
CYP3A4	B
and	O
a	O
moderate	O
CYP2C9	B
and	O
CYP2C19	B
inducer	O
,	O
significantly	O
reduces	O
concentrations	O
of	O
several	O
anti	O
-	O
HIV	O
agents	O
such	O
as	O
darunavir	O
,	O
ritonavir	O
,	O
etravirine	O
,	O
and	O
raltegravir	O
.	O

SIM	O
-	O
53B	O
may	O
inhibit	O
some	O
of	O
the	O
cytochrome	O
P450	O
isoforms	O
such	O
as	O
CYP1A2	B
,	O
CYP2C9	B
and	O
CYP3A4	B
.	O

On	O
the	O
other	O
hand	O
,	O
lopinavir	O
/	O
ritonavir	O
induces	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2C19	B
and	O
glucuronidation	O
.	O

For	O
the	O
determination	O
of	O
murine	O
CYP	O
activities	O
,	O
substrates	O
of	O
orthologous	O
human	O
CYP	O
forms	O
were	O
used	O
:	O
CYP1A1	B
/	O
2	O
,	O
ethoxyresorufin	O
(	O
murine	O
CYP1A2	B
)	O
;	O
CYP2C9	B
,	O
diclofenac	O
(	O
murine	O
2C	O
subfamily	O
)	O
;	O
CYP2C19	B
,	O
diazepam	O
(	O
murine	O
2C	O
subfamily	O
)	O
;	O
CYP2D6	B
,	O
bufuralol	O
(	O
murine	O
2D22	O
)	O
and	O
CYP3A4	B
,	O
midazolam	O
(	O
murine	O
CYP3A11	O
and	O
3A13	O
)	O
.	O

Kratom	O
extracts	O
^	O
and	O
mitragynine	O
^	O
,	O
have	O
been	O
tested	O
as	O
inhibitors	O
of	O
several	O
CYPs	O
,	O
including	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
.	O

We	O
evaluated	O
whether	O
the	O
observed	O
variability	O
in	O
alkaloid	O
profile	O
for	O
kratom	O
extracts	O
results	O
in	O
altered	O
inhibitory	O
effects	O
on	O
three	O
major	O
CYPs	O
,	O
specifically	O
CYP2C9	B
,	O
CYP2D6	B
,	O
and	O
CYP3A	B
.	O

All	O
three	O
kratom	O
extracts	O
tested	O
showed	O
concentration	O
-	O
dependent	O
inhibition	O
of	O
each	O
CYP	O
,	O
with	O
stronger	O
effects	O
on	O
CYP2D6	B
compared	O
to	O
CYP2C9	B
and	O
CYP3A	B
.	O

If	O
the	O
concentration	O
of	O
mitragynine	O
in	O
the	O
liver	O
upon	O
kratom	O
consumption	O
nears	O
the	O
IC_50	O
values	O
estimated	O
from	O
the	O
screening	O
assay	O
(	O
~	O
1	O
M	O
for	O
CYP2D6	B
;	O
10	O
-	O
100	O
M	O
for	O
CYP2C9	B
and	O
CYP3A	B
)	O
,	O
a	O
CYP	O
-	O
mediated	O
kratom	O
-	O
drug	O
interaction	O
is	O
possible	O
.	O

Mitragynine	O
and	O
7	O
-	O
hydroxymitragynine	O
(	O
purchased	O
)	O
,	O
speciofoline	O
(	O
the	O
isolated	O
alkaloid	O
)	O
,	O
and	O
three	O
methanolic	O
kratom	O
extracts	O
(	O
prepared	O
from	O
commercial	O
products	O
K50	O
,	O
K51	O
,	O
and	O
K52	O
;	O
Table	O
)	O
,	O
were	O
tested	O
as	O
inhibitors	O
of	O
CYP2C9	B
,	O
CYP2D6	B
,	O
and	O
CYP3A	B
activities	O
using	O
a	O
cocktail	O
approach	O
^	O
.	O

Diclofenac	O
(	O
4	O
M	O
)	O
,	O
dextromethorphan	O
(	O
4	O
M	O
)	O
,	O
and	O
midazolam	O
(	O
2	O
M	O
)	O
were	O
used	O
as	O
probe	O
substrates	O
for	O
CYP2C9	B
,	O
CYP2D6	B
,	O
and	O
CYP3A	B
activities	O
,	O
respectively	O
.	O

Positive	O
control	O
inhibitors	O
included	O
sulfaphenazole	O
(	O
1	O
M	O
;	O
CYP2C9	B
)	O
,	O
quinidine	O
(	O
2	O
M	O
;	O
CYP2D6	B
)	O
,	O
and	O
ketoconazole	O
(	O
0	O
.	O
1	O
M	O
;	O
CYP3A	B
)	O
.	O

After	O
equilibrating	O
the	O
mixtures	O
for	O
5	O
min	O
at	O
37	O
C	O
,	O
the	O
reaction	O
was	O
initiated	O
by	O
addition	O
of	O
NADPH	O
(	O
1	O
mM	O
final	O
concentration	O
)	O
and	O
incubated	O
for	O
10	O
min	O
(	O
CYP2C9	B
and	O
CYP2D6	B
activities	O
)	O
or	O
2	O
min	O
(	O
CYP3A	B
activity	O
)	O
at	O
37	O
C	O
.	O
Reactions	O
were	O
quenched	O
with	O
2	O
volumes	O
of	O
cold	O
methanol	O
containing	O
internal	O
standard	O
(	O
alprazolam	O
,	O
0	O
.	O
1	O
M	O
)	O
.	O

This	O
system	O
allowed	O
us	O
to	O
simultaneously	O
test	O
whether	O
the	O
human	O
orthologs	O
of	O
the	O
dCYP	O
enzymes	O
identified	O
within	O
our	O
in	O
vivo	O
screening	O
were	O
also	O
involved	O
in	O
metabolizing	O
PCB	O
28	O
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP2E1	B
(	O
drosophila	O
ortholog	O
:	O
Cyp18a1	O
)	O
and	O
CYP3A4	B
(	O
drosophila	O
ortholog	O
:	O
Cyp9f2	O
)	O
in	O
concentration	O
ranges	O
corresponding	O
to	O
their	O
endogenous	O
abundance	O
in	O
the	O
liver	O
^	O
.	O

In	O
vitro	O
,	O
PCB	O
28	O
could	O
be	O
converted	O
into	O
all	O
OH	O
-	O
metabolites	O
by	O
the	O
combination	O
of	O
six	O
recombinant	O
human	O
cytochromes	O
(	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP2E1	B
,	O
CYP3A4	B
)	O
,	O
which	O
are	O
strongly	O
expressed	O
in	O
the	O
liver	O
and	O
thus	O
reflect	O
its	O
metabolic	O
properties	O
.	O

Following	O
the	O
modification	O
of	O
pharmacotherapy	O
motivated	O
by	O
the	O
pharmacogenetic	O
study	O
,	O
these	O
interactions	O
were	O
reduced	O
to	O
135	O
(	O
CYP3A4	B
,	O
57	O
;	O
CYP2D6	B
,	O
22	O
;	O
CYP2C9	B
,	O
19	O
)	O
and	O
25	O
(	O
CYP3A4	B
,	O
10	O
;	O
CYP3A5	B
,	O
10	O
;	O
CYP1A2	B
,	O
5	O
)	O
,	O
achieving	O
a	O
reduction	O
in	O
pharmacological	O
interactions	O
of	O
26	O
.	O
10	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
.	O

The	O
presence	O
of	O
the	O
alleles	O
listed	O
in	O
of	O
the	O
CYP1A2	B
,	O
CYP2B6	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP3A4	B
,	O
and	O
CYP3A5	B
genes	O
was	O
analyzed	O
in	O
the	O
Pharmacogenetics	O
and	O
Precision	O
Medicine	O
Unit	O
of	O
the	O
University	O
Hospital	O
of	O
Salamanca	O
.	O

In	O
reference	O
to	O
the	O
CYP2C9	B
and	O
CYP2C19	B
genes	O
(	O
n	O
=	O
183	O
,	O
n	O
=	O
186	O
)	O
,	O
the	O
majority	O
phenotype	O
was	O
EM	O
(	O
57	O
.	O
38	O
%	O
,	O
n	O
=	O
105	O
;	O
47	O
.	O
85	O
%	O
,	O
n	O
=	O
89	O
)	O
.	O

However	O
,	O
of	O
the	O
total	O
number	O
of	O
57	O
human	O
Cytochromes	O
P450	O
coding	O
genes	O
with	O
putative	O
enzymatic	O
activities	O
,	O
only	O
15	O
seem	O
to	O
metabolize	O
drugs	O
to	O
date	O
,	O
and	O
genetic	O
polymorphisms	O
of	O
CYP2C9	B
,	O
CYP2C19	B
,	O
and	O
CYP2D6	B
belong	O
to	O
the	O
most	O
frequently	O
studied	O
in	O
pharmacogenomics	O
.	O

CYP1A1	B
*	O
2A	O
is	O
also	O
associated	O
with	O
some	O
hormone	O
-	O
related	O
diseases	O
due	O
to	O
its	O
involvement	O
in	O
the	O
biotransformation	O
of	O
sex	O
hormones	O
.	O

For	O
example	O
,	O
CYP1A1	B
*	O
2A	O
increases	O
the	O
risk	O
of	O
prostate	O
cancer	O
,	O
cervical	O
cancer	O
,	O
and	O
recurrent	O
pregnancy	O
loss	O
in	O
humans	O
,	O
^	O
,	O
.	O

CYP1A1	B
*	O
2C	O
(	O
SNP	O
ID	O
:	O
rs1048943	O
)	O
contains	O
an	O
A	O
to	O
G	O
transition	O
at	O
2455	O
,	O
which	O
results	O
in	O
the	O
modification	O
of	O
the	O
protein	O
from	O
isoleucine	O
to	O
valine	O
.	O

CYP1A1	B
*	O
2C	O
is	O
reported	O
to	O
be	O
associated	O
with	O
a	O
variety	O
of	O
cancers	O
and	O
hormone	O
-	O
related	O
diseases	O
,	O
including	O
prostate	O
cancer	O
,	O
breast	O
cancer	O
,	O
and	O
male	O
infertility	O
,	O
^	O
,	O
.	O

As	O
mentioned	O
earlier	O
,	O
CYP1A1	B
and	O
CYP1A2	O
are	O
involved	O
in	O
the	O
biotransformation	O
of	O
multiple	O
estrogens	O
,	O
and	O
thus	O
are	O
important	O
for	O
maintaining	O
the	O
balance	O
of	O
estrogens	O
.	O

Epidemiologic	O
studies	O
also	O
discussed	O
the	O
relationship	O
between	O
CYP1A1	B
polymorphisms	O
and	O
prostate	O
cancer	O
risk	O
^	O
,	O
.	O

It	O
was	O
reported	O
that	O
CYP1A1	B
Single	O
Nucleotide	O
Polymorphisms	O
(	O
rs4646903	O
and	O
rs1048943	O
)	O
were	O
positively	O
correlated	O
with	O
prostate	O
cancer	O
^	O
,	O
^	O
,	O
.	O

CYP1A1	B
hydroxylates	O
testosterone	O
at	O
the	O
C	O
-	O
6	O
site	O
,	O
which	O
produces	O
hydrophilic	O
metabolites	O
and	O
promotes	O
the	O
excretion	O
of	O
testosterone	O
.	O

Therefore	O
,	O
CYP1A1	B
mutants	O
may	O
interfere	O
with	O
the	O
normal	O
physiological	O
concentration	O
of	O
testosterone	O
,	O
and	O
eventually	O
lead	O
to	O
the	O
occurrence	O
and	O
development	O
of	O
prostate	O
cancer	O
.	O

In	O
fact	O
,	O
CYP1A1	B
*	O
4	O
(	O
2453C	O
>	O
A	O
)	O
and	O
rs1048943	O
(	O
2455A	O
>	O
G	O
)	O
may	O
interfere	O
with	O
the	O
metabolism	O
of	O
testosterone	O
and	O
estrogen	O
,	O
and	O
are	O
reported	O
to	O
be	O
positively	O
correlated	O
with	O
male	O
infertility	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
CYP1A1	B
may	O
affect	O
the	O
biological	O
function	O
of	O
placenta	O
,	O
which	O
may	O
be	O
due	O
to	O
its	O
estrogen	O
metabolism	O
^	O
,	O
.	O

In	O
fact	O
,	O
it	O
is	O
reported	O
that	O
the	O
CYP1A1	B
SNP	O
rs4646903	O
(	O
3801T	O
>	O
C	O
)	O
is	O
positively	O
correlated	O
with	O
the	O
risk	O
of	O
recurrent	O
pregnancy	O
loss	O
in	O
humans	O
.	O

Epidemiological	O
analysis	O
showed	O
that	O
genetic	O
polymorphisms	O
of	O
the	O
CYP1A1	B
(	O
rs4646903	O
,	O
rs1048943	O
,	O
rs4986883	O
,	O
and	O
rs1799814	O
)	O
were	O
not	O
associated	O
with	O
the	O
high	O
risk	O
of	O
coronary	O
artery	O
disease	O
.	O

However	O
,	O
CYP1A1	B
SNP	O
(	O
rs1048943	O
)	O
and	O
CYP1A2	O
Single	O
Nucleotide	O
Polymorphisms	O
(	O
rs762551	O
,	O
rs1133323	O
,	O
and	O
rs1378942	O
)	O
are	O
positively	O
correlated	O
with	O
hypertension	O
susceptibility	O
^	O
,	O
.	O

In	O
this	O
part	O
,	O
the	O
Single	O
Nucleotide	O
Polymorphisms	O
of	O
CYP1A	O
(	O
11	O
for	O
CYP1A1	B
and	O
9	O
for	O
CYP1A2	O
)	O
studied	O
most	O
in	O
recent	O
10	O
years	O
are	O
reviewed	O
for	O
the	O
first	O
time	O
,	O
and	O
the	O
relationship	O
between	O
CYP1A	O
Single	O
Nucleotide	O
Polymorphisms	O
and	O
human	O
diseases	O
is	O
summarized	O
.	O

Treatment	O
of	O
antioxidant	O
,	O
CYP1A1	B
and	O
CYP2A6	O
inhibitors	O
,	O
and	O
chemodietary	O
agents	O
with	O
antioxidant	O
properties	O
significantly	O
reduced	O
the	O
Cell	O
Culture	O
Supernatant	O
and	O
CCS	O
-	O
EVs	O
mediated	O
HIV	O
-	O
1	O
replication	O
in	O
U1	O
cells	O
.	O

We	O
used	O
the	O
following	O
specific	O
TaqMan	O
TM	O
probes	O
(	O
CYP1A1	B
(	O
Hs01054794_m1	O
)	O
,	O
CYP2A6	O
(	O
Hs00430021_m1	O
)	O
,	O
SOD1	O
(	O
Hs00533490_m1	O
)	O
,	O
SOD2	O
(	O
Hs00167309_m1	O
)	O
,	O
catalase	O
(	O
Hs00156308_m1	O
)	O
,	O
and	O
PRDX6	O
(	O
Hs00705355_s1	O
)	O
)	O
and	O
Glyceraldehyde	O
3	O
-	O
Phosphate	O
Dehydrogenase	O
as	O
an	O
endogenous	O
control	O
.	O

We	O
used	O
Western	O
blotting	O
to	O
identify	O
the	O
presence	O
of	O
CYPs	O
,	O
antioxidants	O
,	O
and	O
Human	O
Papillomavirus	O
proteins	O
in	O
Caski	O
-	O
derived	O
Extracellular	O
Vesicles	O
and	O
to	O
calculate	O
the	O
relative	O
protein	O
fold	O
expression	O
level	O
of	O
CYPs	O
and	O
Antioxidant	O
Enzymes	O
in	O
U1	O
cells	O
upon	O
treatment	O
with	O
CCS	O
/	O
CCS	O
-	O
Eversus	O
We	O
used	O
the	O
following	O
primary	O
antibodies	O
:	O
Glyceraldehyde	O
3	O
-	O
Phosphate	O
Dehydrogenase	O
Rabbit	O
Mab	O
,	O
1	O
:	O
2000	O
dilution	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
,	O
catalogue	O
#	O
2118	O
;	O
CYP1A1	B
rabbit	O
Mab	O
,	O
1	O
:	O
200	O
dilution	O
(	O
Proteintech	O
Group	O
,	O
Inc	O
.	O
,	O
Rosemont	O
,	O
IL	O
,	O
USA	O
)	O
,	O
catalogue	O
#	O
13241	O
-	O
1	O
-	O
AP	O
;	O
CYP1B1	O
Rabbit	O
Mab	O
,	O
1	O
:	O
500	O
dilution	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Dallas	O
,	O
TX	O
,	O
USA	O
)	O
,	O
catalogue	O
#	O
sc	O
-	O
32882	O
;	O
CYP2A6	O
Mouse	O
Mab	O
,	O
1	O
:	O
200	O
dilution	O
(	O
Abcam	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
,	O
catalogue	O
#	O
ab3570	O
;	O
SOD1	O
Mouse	O
Mab	O
,	O
1	O
:	O
1500	O
dilution	O
,	O
catalog	O
#	O
sc	O
-	O
101523	O
;	O
SOD2	O
Mouse	O
Mab	O
,	O
1	O
:	O
500	O
dilution	O
,	O
catalogue	O
#	O
sc	O
-	O
133254	O
;	O
Catalase	O
Mouse	O
Mab	O
,	O
1	O
:	O
1200	O
dilution	O
(	O
Santa	O
Cruz	O
Biotechnology	O
Inc	O
.	O
,	O
Dallas	O
,	O
TX	O
,	O
USA	O
)	O
,	O
catalog	O
#	O
21260	O
-	O
1	O
-	O
AP	O
;	O
PRDX6	O
Rabbit	O
Mab	O
,	O
1	O
:	O
500	O
dilution	O
(	O
LifeSpan	O
Biosciences	O
,	O
Inc	O
.	O
,	O
Seattle	O
,	O
WA	O
,	O
USA	O
)	O
,	O
catalog	O
#	O
LS	O
-	O
C162131	O
;	O
CD63	O
,	O
Rabbit	O
Pab	O
,	O
1	O
:	O
200	O
dilution	O
(	O
Proteintech	O
Group	O
,	O
Rosemont	O
,	O
IL	O
,	O
USA	O
)	O
,	O
catalog	O
#	O
25682	O
-	O
1	O
-	O
AP	O
.	O

The	O
four	O
-	O
day	O
exposure	O
of	O
Cell	O
Culture	O
Supernatant	O
significantly	O
increased	O
the	O
expression	O
of	O
CYP1A1	B
and	O
CYP2A6	O
at	O
the	O
mRNA	O
level	O
(	O
A	O
,	O
B	O
)	O
but	O
not	O
at	O
the	O
protein	O
level	O
(	O
C	O
,	O
D	O
;	O
.	O

To	O
confirm	O
that	O
HIV	O
-	O
1	O
replication	O
is	O
occurring	O
via	O
a	O
CYP	O
-	O
mediated	O
oxidative	O
stress	O
pathway	O
,	O
we	O
treated	O
the	O
CCS	O
-	O
EVs	O
exposed	O
U1	O
cells	O
with	O
an	O
antioxidant	O
(	O
resveratrol	O
)	O
CYP1A1	B
-	O
selective	O
inhibitor	O
(	O
ellipticine	O
)	O
,	O
and	O
CYP2A6	O
-	O
selective	O
inhibitor	O
(	O
tryptamine	O
)	O
.	O

We	O
particularly	O
examined	O
the	O
expression	O
of	O
CYP1A1	B
and	O
CYP2A6	O
,	O
because	O
these	O
enzymes	O
are	O
expressed	O
in	O
monocytic	O
cells	O
.	O

CYP1A1	B
and	O
CYP2A6	O
are	O
the	O
major	O
enzymes	O
for	O
metabolizing	O
polyaryl	O
hydrocarbons	O
and	O
nicotine	O
present	O
in	O
cigarette	O
smoke	O
,	O
respectively	O
,	O
as	O
well	O
as	O
environmental	O
contaminants	O
.	O

This	O
is	O
consistently	O
the	O
case	O
for	O
CYP1A1	B
expression	O
upon	O
exposure	O
to	O
cigarette	O
smoke	O
condensate	O
and	O
benzo	O
(	O
a	O
)	O
pyrene	O
.	O

Recently	O
,	O
we	O
confirmed	O
this	O
association	O
in	O
vitro	O
in	O
U1	O
cells	O
,	O
in	O
which	O
we	O
demonstrated	O
that	O
CYP1A1	B
metabolizes	O
benzo	O
(	O
a	O
)	O
pyrene	O
(	O
a	O
harmful	O
carcinogen	O
in	O
cigarette	O
smoke	O
)	O
and	O
causes	O
increased	O
production	O
of	O
Reactive	O
Oxygen	O
Species	O
,	O
which	O
subsequently	O
triggers	O
HIV	O
-	O
1	O
replication	O
in	O
the	O
U1	O
cells	O
.	O

In	O
flies	O
with	O
RNAi	O
-	O
mediated	O
silencing	O
of	O
Cyp307a2	O
(	O
human	O
orthologs	O
:	O
CYP1A1	B
and	O
CYP1A2	B
)	O
,	O
the	O
metabolite	O
3	O
-	O
OHCB	O
28	O
was	O
not	O
detected	O
and	O
3	O
-	O
OHCB	O
28	O
was	O
reduced	O
by	O
more	O
than	O
70	O
%	O
compared	O
to	O
control	O
levels	O
.	O

Feeding	O
experiments	O
on	O
rats	O
with	O
commercially	O
available	O
PCB	O
mixtures	O
such	O
as	O
Aroclor	O
1254	O
,	O
Fire	O
-	O
Master	O
Bp	O
-	O
6	O
or	O
individual	O
congeners	O
showed	O
the	O
induction	O
of	O
different	O
CYPs	O
depending	O
on	O
the	O
position	O
of	O
the	O
chlorine	O
atoms	O
on	O
the	O
phenyl	O
ring	O
^	O
:	O
Non	O
-	O
orthochlorinated	O
coplanar	O
PCBs	O
such	O
as	O
PCB	O
126	O
,	O
PCB	O
169	O
and	O
PCB	O
77	O
induce	O
the	O
expression	O
of	O
CYP1A1	B
and	O
CYP1A2	B
.	O

Other	O
structured	O
PCBs	O
such	O
as	O
PCB	O
118	O
,	O
PCB	O
138	O
and	O
PCB	O
170	O
induce	O
the	O
expression	O
of	O
both	O
CYP1A1	B
and	O
CYP2B	O
^	O
.	O

Virtually	O
no	O
metabolism	O
was	O
observed	O
for	O
CYP1A2	B
(	O
4	O
%	O
)	O
.	O

Incubation	O
with	O
rat	O
cytochromes	O
revealed	O
a	O
different	O
pattern	O
of	O
metabolism	O
compared	O
with	O
human	O
cytochromes	O
:	O
For	O
CYP1A2	B
,	O
petasin	O
was	O
higher	O
(	O
43	O
%	O
versus	O
4	O
%	O
)	O
,	O
and	O
neopetasin	O
(	O
22	O
%	O
versus	O
<	O
1	O
%	O
)	O
and	O
isopetasin	O
(	O
<	O
1	O
%	O
versus	O
21	O
%	O
)	O
lower	O
metabolized	O
,	O
respectively	O
.	O

On	O
the	O
other	O
hand	O
,	O
all	O
the	O
screened	O
molecules	O
emerged	O
as	O
non	O
-	O
inhibitors	O
of	O
the	O
cytochromes	O
CYP1A2	B
and	O
CYP2D6	O
.	O

Of	O
note	O
,	O
we	O
also	O
found	O
an	O
AAGLY	O
-	O
mediated	O
induction	O
of	O
CYP1A2	B
and	O
CYP2E1	B
in	O
the	O
embryonic	O
kidney	O
line	O
,	O
HEK293	O
(	O
Supplementary	O
Fig	O
.	O

Following	O
in	O
vitro	O
analysis	O
using	O
a	O
liver	O
-	O
like	O
CYP	O
-	O
cocktail	O
,	O
containing	O
human	O
orthologues	O
of	O
dCYP1A2	O
,	O
we	O
confirm	O
human	O
CYP1A2	B
as	O
a	O
PCB	O
28	O
metabolizing	O
enzyme	O
.	O

All	O
of	O
the	O
enzymatic	O
activity	O
on	O
PCB	O
28	O
was	O
found	O
in	O
the	O
fraction	O
containing	O
CYP1A2	B
,	O
CYP2E1	B
and	O
CYP3A4	B
.	O

Particularly	O
CYP1A2	B
as	O
a	O
single	O
enzyme	O
generated	O
high	O
levels	O
of	O
the	O
OH	O
-	O
CB28	O
metabolites	O
^	O
.	O

This	O
confirmed	O
CYP1A2	B
as	O
a	O
central	O
CYP	O
in	O
the	O
formation	O
of	O
reactive	O
OH	O
-	O
metabolites	O
from	O
PCB	O
28	O
.	O

Since	O
CYP1A2	B
is	O
a	O
human	O
orthologue	O
of	O
Drosophila	O
Cyp307a2	O
,	O
these	O
results	O
indicate	O
a	O
conservation	O
at	O
the	O
level	O
of	O
activity	O
against	O
PCB28	O
between	O
Drosophila	O
melanogaster	O
and	O
the	O
human	O
system	O
.	O

This	O
result	O
confirmed	O
CYP1A2	B
as	O
a	O
central	O
CYP	O
in	O
the	O
formation	O
of	O
reactive	O
OH	O
-	O
metabolites	O
from	O
PCB	O
28	O
,	O
since	O
CYP1A2	B
contained	O
in	O
the	O
liver	O
-	O
like	O
rhCYP	O
cocktail	O
is	O
a	O
human	O
orthologue	O
of	O
Cyp307a2	O
in	O
Drosophila	O
^	O
.	O

The	O
human	O
CYP1A2	B
,	O
identified	O
in	O
this	O
study	O
is	O
capable	O
of	O
oxidizing	O
estradiol	O
,	O
resulting	O
in	O
the	O
production	O
of	O
2	O
-	O
hydroxy	O
and	O
4	O
-	O
hydroxy	O
metabolites	O
^	O
.	O

Xenobiotic	O
substrates	O
of	O
CYP1A2	B
include	O
caffeine	O
^	O
,	O
aflatoxin	O
B1	O
^	O
and	O
paracetamol	O
^	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
increased	O
function	O
of	O
CYP1A2	B
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	O
cancer	O
^	O
,	O
which	O
could	O
ultimately	O
also	O
be	O
important	O
for	O
the	O
metabolism	O
of	O
PCBs	O
:	O
In	O
individual	O
cases	O
,	O
existing	O
exposure	O
of	O
PCBs	O
in	O
conjunction	O
with	O
genetic	O
polymorphisms	O
in	O
CYP1A2	B
could	O
lead	O
to	O
an	O
increase	O
in	O
biological	O
efficacy	O
of	O
PCBs	O
(	O
toxicity	O
/	O
mutagenicity	O
)	O
,	O
which	O
could	O
also	O
result	O
in	O
an	O
increased	O
risk	O
of	O
disease	O
.	O

Therefore	O
,	O
in	O
further	O
steps	O
,	O
CYP1A2	B
variants	O
might	O
be	O
identified	O
,	O
that	O
accelerate	O
the	O
metabolism	O
of	O
PCB	O
28	O
in	O
humans	O
.	O

Taking	O
only	O
neuroleptic	O
therapy	O
into	O
account	O
,	O
78	O
interactions	O
were	O
tested	O
,	O
most	O
of	O
which	O
occur	O
through	O
cytochromes	O
CYP3A4	B
(	O
n	O
=	O
27	O
)	O
,	O
CYP3A5	B
(	O
n	O
=	O
27	O
)	O
,	O
and	O
CYP1A2	B
(	O
n	O
=	O
17	O
)	O
.	O

The	O
CYP1A2	B
gene	O
was	O
studied	O
in	O
179	O
patients	O
,	O
with	O
the	O
most	O
prevalent	O
phenotype	O
being	O
HI	O
(	O
Higher	O
Inducibility	O
)	O
(	O
86	O
.	O
03	O
%	O
,	O
n	O
=	O
154	O
)	O
.	O

In	O
total	O
,	O
taking	O
into	O
account	O
the	O
liver	O
metabolism	O
,	O
mediated	O
through	O
the	O
previously	O
mentioned	O
CYP450	O
system	O
members	O
,	O
from	O
both	O
antipsychotic	O
therapy	O
and	O
concomitant	O
therapy	O
,	O
458	O
conflicts	O
were	O
discovered	O
between	O
the	O
patients	O
prescription	O
and	O
genotype	O
,	O
with	O
most	O
conflicts	O
associated	O
with	O
concomitant	O
therapy	O
occurring	O
through	O
cytochrome	O
CYP3A5	B
(	O
n	O
=	O
57	O
)	O
,	O
and	O
those	O
primarily	O
related	O
to	O
the	O
metabolism	O
of	O
neuroleptics	O
occurring	O
through	O
CYP1A2	B
(	O
n	O
=	O
80	O
)	O
;	O
taking	O
into	O
account	O
the	O
minor	O
metabolizers	O
of	O
the	O
studied	O
antipsychotics	O
,	O
the	O
cytochrome	O
with	O
the	O
highest	O
number	O
of	O
incidences	O
found	O
was	O
CYP3A5	B
(	O
n	O
=	O
93	O
)	O
.	O

The	O
pharmacogenetic	O
profile	O
of	O
the	O
population	O
(	O
CYP1A2	B
HI	O
:	O
0	O
.	O
86	O
;	O
CYP2D6	B
EM	O
:	O
0	O
.	O
85	O
;	O
CYP3A4	B
EM	O
:	O
0	O
.	O
91	O
)	O
could	O
explain	O
the	O
need	O
to	O
apply	O
a	O
higher	O
dose	O
with	O
its	O
consequent	O
adverse	O
effects	O
in	O
patients	O
treated	O
with	O
olanzapine	O
,	O
clozapine	O
,	O
or	O
asenapine	O
,	O
all	O
related	O
to	O
CYP1A2	B
,	O
while	O
favoring	O
the	O
use	O
of	O
aripiprazole	O
or	O
risperidone	O
in	O
those	O
who	O
have	O
a	O
wt	O
-	O
like	O
haplotype	O
in	O
CYP2D6	B
and	O
CYP3A4	B
cytochromes	O
,	O
a	O
situation	O
frequently	O
found	O
in	O
our	O
population	O
.	O

This	O
methodology	O
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
large	O
number	O
of	O
cases	O
in	O
which	O
there	O
was	O
a	O
problem	O
in	O
the	O
pharmacotherapy	O
due	O
to	O
the	O
metabolism	O
mainly	O
mediated	O
by	O
CYP1A2	B
.	O

For	O
CYP2C19	B
(	O
rs4244285	O
)	O
is	O
the	O
defining	O
polymorphism	O
of	O
the	O
CYP2C19	B
*	O
2	O
allele	O
and	O
is	O
a	O
synonymous	O
G	O
>	O
A	O
transition	O
in	O
exon	O
5	O
that	O
creates	O
an	O
aberrant	O
splice	O
site	O
,	O
and	O
this	O
change	O
alters	O
the	O
mRNA	O
reading	O
frame	O
,	O
which	O
results	O
in	O
a	O
truncated	O
,	O
non	O
-	O
functional	O
protein	O
.	O

This	O
CYP2C19	B
*	O
2	O
allele	O
is	O
the	O
most	O
common	O
CYP2C19	B
loss	O
-	O
of	O
-	O
function	O
allele	O
,	O
with	O
allele	O
frequencies	O
of	O
approximately	O
12	O
%	O
in	O
Caucasians	O
,	O
15	O
%	O
in	O
African	O
-	O
Americans	O
,	O
and	O
29	O
-	O
35	O
%	O
in	O
Asians	O
.	O

The	O
CYP2C19	B
poor	O
metabolism	O
phenotype	O
was	O
initially	O
discovered	O
by	O
studies	O
on	O
impaired	O
mephenytoin	O
metabolism	O
and	O
the	O
major	O
molecular	O
defect	O
responsible	O
for	O
the	O
trait	O
is	O
the	O
CYP2C19	B
*	O
2	O
(	O
rs4244285	O
)	O
loss	O
-	O
of	O
-	O
function	O
allele	O
.	O

For	O
CYP2C19	B
*	O
2	O
Single	O
Nucleotide	O
Polymorphisms	O
can	O
cause	O
a	O
40	O
-	O
nucleotide	O
deletion	O
and	O
a	O
frame	O
shift	O
which	O
leads	O
to	O
a	O
premature	O
stop	O
codon	O
,	O
result	O
in	O
the	O
production	O
of	O
a	O
truncated	O
protein	O
without	O
enzymatic	O
activity	O
.	O

For	O
CYP2C19	B
(	O
rs4986893	O
)	O
is	O
the	O
defining	O
polymorphism	O
of	O
the	O
CYP2C19	B
*	O
3	O
allele	O
and	O
is	O
a	O
G	O
>	O
A	O
transition	O
in	O
exon	O
4	O
that	O
results	O
in	O
a	O
premature	O
termination	O
codon	O
at	O
amino	O
acid	O
212	O
.	O

The	O
CYP2C19	B
*	O
3	O
allele	O
frequencies	O
in	O
most	O
populations	O
is	O
below	O
1	O
%	O
;	O
however	O
,	O
it	O
is	O
more	O
prevalent	O
among	O
Asians	O
(	O
2	O
-	O
9	O
%	O
)	O
.	O

Poor	O
CYP2C19	B
metabolizers	O
are	O
found	O
in	O
5	O
%	O
of	O
white	O
people	O
,	O
but	O
in	O
up	O
to	O
20	O
%	O
of	O
Asians	O
.	O

Here	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
the	O
number	O
of	O
miRNAs	O
that	O
targeting	O
the	O
CYP2C19	B
gene	O
,	O
which	O
includes	O
the	O
following	O
:	O
hsa	O
-	O
miR	O
-	O
1270	O
,	O
hsa	O
-	O
miR	O
-	O
455	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
4325	O
,	O
hsa	O
-	O
miR	O
-	O
7703	O
,	O
hsa	O
-	O
miR	O
-	O
6880	O
-	O
5p	O
,	O
hsa	O
-	O
miR	O
-	O
6851	O
-	O
5p	O
,	O
hsa	O
-	O
miR	O
-	O
3689d	O
,	O
hsa	O
-	O
miR	O
-	O
4683	O
,	O
hsa	O
-	O
miR	O
-	O
6499	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
767	O
-	O
5p	O
,	O
hsa	O
-	O
miR	O
-	O
6134	O
,	O
hsa	O
-	O
miR	O
-	O
4537	O
,	O
hsa	O
-	O
miR	O
-	O
5186	O
,	O
hsa	O
-	O
miR	O
-	O
665	O
,	O
hsa	O
-	O
miR	O
-	O
4459	O
,	O
hsa	O
-	O
miR	O
-	O
92b	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
92a	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
367	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
363	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
32	O
-	O
5p	O
,	O
hsa	O
-	O
miR	O
-	O
25	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
3180	O
-	O
5p	O
,	O
hsa	O
-	O
miR	O
-	O
3912	O
-	O
5p	O
,	O
hsa	O
-	O
miR	O
-	O
874	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
3157	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
5195	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
145	O
-	O
5p	O
,	O
and	O
hsa	O
-	O
miR	O
-	O
6886	O
-	O
3p	O
.	O

Since	O
,	O
about	O
28	O
miRNAs	O
can	O
target	O
the	O
CYP2C19	B
gene	O
,	O
we	O
believe	O
that	O
during	O
the	O
disease	O
status	O
in	O
children	O
with	O
epilepsy	O
,	O
or	O
during	O
treatment	O
with	O
phenobarbital	O
,	O
one	O
or	O
multiple	O
miRNA	O
may	O
be	O
involved	O
,	O
along	O
with	O
the	O
regulation	O
of	O
the	O
CYP2C19	B
gene	O
,	O
which	O
in	O
turn	O
up	O
-	O
regulates	O
or	O
down	O
regulates	O
the	O
genes	O
and	O
also	O
changes	O
the	O
genetic	O
variations	O
of	O
the	O
gene	O
.	O

Genomic	O
variation	O
of	O
CYP2C19	B
was	O
considered	O
in	O
drug	O
pharmacokinetic	O
proteins	O
,	O
in	O
drug	O
target	O
proteins	O
and	O
finally	O
across	O
multiple	O
candidate	O
genes	O
,	O
thus	O
providing	O
three	O
broad	O
hypotheses	O
as	O
sources	O
,	O
housing	O
potential	O
influential	O
genomic	O
variations	O
.	O

Metoprolol	O
metabolites	O
segregated	O
very	O
well	O
with	O
CYP2D6	B
phenotype	O
,	O
suggesting	O
that	O
drug	O
metabolism	O
can	O
be	O
predicted	O
based	O
upon	O
knowledge	O
of	O
CYP2D6	B
genotype	O
and	O
the	O
presence	O
of	O
drug	O
-	O
drug	O
interactions	O
.	O

This	O
may	O
have	O
contributed	O
to	O
our	O
inability	O
to	O
identify	O
endogenous	O
metabolites	O
predictive	O
of	O
clinical	O
effectiveness	O
,	O
if	O
CYP2D6	B
drug	O
metabolism	O
plays	O
a	O
major	O
role	O
in	O
drug	O
effectiveness	O
,	O
as	O
hypothesized	O
.	O

CYP2D6	B
was	O
genotyped	O
using	O
the	O
Multiplex	O
SNaPshot	O
technique	O
previously	O
described	O
.	O

This	O
assay	O
detects	O
20	O
CYP2D6	B
clinically	O
significant	O
variants	O
and	O
identifies	O
copy	O
number	O
variants	O
.	O

Genotyping	O
was	O
performed	O
after	O
subjects	O
completed	O
the	O
protocol	O
;	O
thus	O
,	O
the	O
investigators	O
were	O
blinded	O
to	O
the	O
CYP2D6	B
genotype	O
during	O
treatment	O
.	O

Predicted	O
phenotypes	O
were	O
determined	O
utilizing	O
CYP2D6	B
activity	O
score	O
,	O
as	O
described	O
by	O
Gaedigk	O
et	O
al	O
.	O
.	O
Each	O
identified	O
CYP2D6	B
SNV	O
was	O
assigned	O
a	O
predicted	O
enzyme	O
activity	O
score	O
[	O
,	O
.	O

Human	O
P450	O
polymorphisms	O
in	O
what	O
is	O
now	O
known	O
as	O
CYP2D6	B
were	O
identified	O
in	O
the	O
1970s	O
and	O
in	O
the	O
1980s	O
in	O
P450	O
2C19	O
[	O
,	O
.	O

(	O
Note	O
:	O
by	O
definition	O
a	O
polymorphism	O
is	O
present	O
at	O
1	O
%	O
incidence	O
in	O
a	O
population	O
,	O
and	O
the	O
term	O
variant	O
includes	O
not	O
only	O
polymorphisms	O
but	O
all	O
rare	O
changes	O
,	O
and	O
the	O
term	O
single	O
nucleotide	O
variant	O
(	O
SNV	O
)	O
is	O
probably	O
more	O
generally	O
appropriate	O
,	O
ie	O
,	O
160	O
CYP2D6	B
SNVs	O
are	O
known	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
pharmvar	O
.	O
org	O
/	O
gene	O
/	O
CYP2D6	B
)	O
.	O
)	O

Today	O
we	O
realize	O
that	O
SNVs	O
are	O
seen	O
in	O
all	O
human	O
P450s	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
pharmvar	O
.	O
org	O
/	O
gene	O
/	O
CYP2D6	B
)	O
.	O

This	O
is	O
,	O
for	O
instance	O
,	O
how	O
the	O
CYP2D6	B
polymorphism	O
was	O
discovered	O
,	O
in	O
that	O
Robert	O
Smith	O
(	O
personally	O
)	O
experienced	O
a	O
strong	O
hypotensive	O
effect	O
of	O
debrisoquine	O
.	O

Conversely	O
,	O
some	O
drugs	O
are	O
activated	O
by	O
P450s	O
,	O
and	O
there	O
are	O
SNVs	O
that	O
involve	O
higher	O
activity	O
than	O
wild	O
type	O
enzyme	O
,	O
eg	O
,	O
CYP2D6	B
*	O
53	O
[	O
,	O
.	O

One	O
deficiency	O
is	O
predicting	O
the	O
in	O
vivo	O
magnitude	O
of	O
P450	O
SNversus	O
For	O
instance	O
,	O
even	O
the	O
CYP2D6	B
*	O
3	O
polymorphism	O
,	O
which	O
results	O
in	O
loss	O
of	O
the	O
entire	O
enzyme	O
due	O
to	O
aberrant	O
mRNA	O
splicing	O
,	O
has	O
varying	O
effects	O
in	O
vivo	O
with	O
different	O
drugs	O
,	O
and	O
the	O
results	O
cannot	O
be	O
explained	O
simply	O
by	O
the	O
contribution	O
of	O
other	O
P450s	O
.	O

Tested	O
extracts	O
and	O
mitragynine	O
were	O
generally	O
stronger	O
inhibitors	O
of	O
CYP2D6	B
activity	O
relative	O
to	O
the	O
other	O
isoforms	O
^	O
,	O
.	O

Most	O
patients	O
had	O
an	O
EM	O
phenotype	O
(	O
85	O
.	O
95	O
%	O
,	O
n	O
=	O
159	O
;	O
91	O
.	O
49	O
%	O
,	O
n	O
=	O
172	O
)	O
with	O
respect	O
to	O
CYP2D6	B
cytochromes	O
(	O
n	O
=	O
183	O
)	O
and	O
CYP3A4	B
(	O
n	O
=	O
188	O
)	O
,	O
and	O
PM	O
(	O
Poor	O
Metabolizer	O
)	O
phenotype	O
(	O
87	O
.	O
85	O
%	O
,	O
n	O
=	O
159	O
)	O
was	O
the	O
most	O
frequent	O
with	O
respect	O
to	O
CYP3A5	B
cytochrome	O
(	O
n	O
=	O
187	O
)	O
.	O

Aripiprazole	O
is	O
a	O
neuroleptic	O
whose	O
metabolism	O
develops	O
predominantly	O
in	O
the	O
liver	O
,	O
through	O
the	O
CYP450	O
system	O
,	O
specifically	O
by	O
CYP2D6	B
and	O
CYP3A4	B
cytochromes	O
which	O
,	O
in	O
the	O
vast	O
majority	O
of	O
our	O
patients	O
(	O
more	O
than	O
80	O
%	O
)	O
,	O
presented	O
an	O
EM	O
phenotype	O
,	O
favoring	O
its	O
use	O
.	O

This	O
finding	O
strongly	O
suggests	O
that	O
hepatic	O
CYP2E1	B
-	O
dependent	O
ROS	O
-	O
elicited	O
lipid	O
peroxidation	O
with	O
consequent	O
JNK1	O
activation	O
and	O
insulin	O
resistance	O
occur	O
only	O
when	O
hepatic	O
lipid	O
is	O
markedly	O
elevated	O
and	O
available	O
for	O
peroxidation	O
.	O

and	O
Jiang	O
et	O
al	O
.	O
,	O
we	O
conclude	O
that	O
a	O
major	O
determinant	O
of	O
the	O
differential	O
responses	O
observed	O
upon	O
comparable	O
CYP2E1	B
-	O
functional	O
stabilization	O
in	O
Chip	O
-	O
KO	O
and	O
Gp78	O
-	O
KO	O
mouse	O
livers	O
is	O
the	O
ER	O
-	O
stability	O
of	O
the	O
Insig	O
-	O
SCAP	O
-	O
SREBP	O
-	O
1c	O
complex	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
Chip	O
-	O
KO	O
mice	O
,	O
although	O
the	O
adiponectin	O
-	O
AMPK1ALPHA	O
-	O
FOXO1	O
/	O
3	O
signaling	O
initially	O
protects	O
the	O
livers	O
,	O
this	O
beneficial	O
signaling	O
is	O
suppressed	O
as	O
progressively	O
augmented	O
CYP2E1	B
-	O
dependent	O
oxidative	O
injury	O
and	O
sustained	O
JNK	O
-	O
signaling	O
activation	O
trigger	O
hepatic	O
injury	O
and	O
hepatocyte	O
dropout	O
with	O
age	O
.	O

Thus	O
,	O
in	O
principle	O
,	O
ALD	O
-	O
targeted	O
CYP2E1	B
given	O
its	O
critical	O
role	O
in	O
acetaminophen	O
-	O
mediated	O
hepatotoxicity	O
and	O
contribution	O
to	O
alcoholic	O
liver	O
disease	O
could	O
be	O
a	O
prime	O
candidate	O
.	O

However	O
,	O
while	O
the	O
protective	O
effects	O
of	O
rapamycin	O
-	O
induced	O
Autophagic	O
-	O
Lysosomal	O
Degradation	O
and	O
the	O
worsening	O
effects	O
of	O
chloroquine	O
-	O
suppressed	O
Autophagic	O
-	O
Lysosomal	O
Degradation	O
on	O
acetaminophen	O
-	O
elicited	O
hepatotoxicity	O
seemingly	O
reflect	O
an	O
inherent	O
role	O
of	O
CYP2E1	B
in	O
acetaminophen	O
bioactivation	O
,	O
they	O
are	O
exerted	O
at	O
a	O
stage	O
beyond	O
CYP2E1	B
-	O
dependent	O
metabolic	O
activation	O
,	O
and	O
thus	O
,	O
quite	O
independent	O
of	O
corresponding	O
effects	O
on	O
CYP2E1	B
-	O
proteolytic	O
stability	O
.	O

This	O
apparent	O
discrepancy	O
is	O
due	O
not	O
only	O
to	O
reduced	O
CYP2E1	B
content	O
but	O
also	O
a	O
persistent	O
,	O
compensatory	O
activation	O
of	O
NRF2	O
that	O
triggers	O
the	O
transcriptional	O
activation	O
of	O
drug	O
detoxification	O
enzymes	O
and	O
GSH	O
synthesis	O
,	O
as	O
well	O
as	O
greater	O
hepatocyte	O
proliferation	O
in	O
the	O
liver	O
-	O
specific	O
Atg5	O
-	O
KO	O
mice	O
.	O

Interestingly	O
,	O
CYP2E1	B
-	O
stabilization	O
upon	O
chemically	O
-	O
induced	O
autophagic	O
disruption	O
in	O
HepG2	O
cells	O
promotes	O
,	O
as	O
expected	O
,	O
CYP2E1	B
-	O
dependent	O
oxidative	O
stress	O
,	O
mitochondrial	O
dysfunction	O
,	O
JNK	O
and	O
p38	O
MAPK	O
-	O
activation	O
,	O
and	O
consequent	O
cytotoxicity	O
.	O

Thus	O
,	O
CYP2E1	B
functional	O
stabilization	O
upon	O
Chip	O
-	O
KO	O
results	O
in	O
hepatic	O
oxidative	O
stress	O
,	O
JNK1	O
-	O
activation	O
,	O
insulin	O
resistance	O
,	O
FA	O
-	O
and	O
TG	O
-	O
accumulation	O
and	O
liver	O
injury	O
that	O
contribute	O
to	O
NASH	O
.	O

By	O
contrast	O
,	O
despite	O
comparable	O
CYP2E1	B
functional	O
stabilization	O
,	O
no	O
significant	O
hepatic	O
FA	O
-	O
and	O
TG	O
-	O
accumulation	O
is	O
observed	O
upon	O
Gp78	O
-	O
KO	O
due	O
to	O
the	O
ER	O
-	O
stabilization	O
of	O
the	O
Insig	O
proteins	O
that	O
prevents	O
SREBP	O
-	O
1c	O
-	O
elicited	O
transcriptional	O
activation	O
of	O
hepatic	O
lipogenesis	O
.	O

In	O
addition	O
,	O
the	O
hydroxylation	O
of	O
some	O
tri	O
-	O
and	O
tetrachlorobiphenyls	O
(	O
PCB	O
20	O
,	O
22	O
,	O
52	O
and	O
74	O
)	O
by	O
CYP2E1	B
^	O
and	O
the	O
formation	O
of	O
4	O
-	O
OHCB	O
101	O
from	O
PCB	O
101	O
by	O
CYP2A6	O
was	O
detected	O
in	O
vitro	O
^	O
.	O

were	O
altering	O
N	O
-	O
oxidation	O
of	O
3	O
,	O
5	O
-	O
DCA	O
,	O
the	O
ability	O
of	O
diethyldithiocarbamate	O
(	O
DEDTCA	O
)	O
,	O
an	O
inhibitor	O
of	O
CYP2C	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
CYP2E1	B
,	O
to	O
reduce	O
DCNB	O
formation	O
was	O
examined	O
.	O

Since	O
the	O
CYP2E1	B
inhibitor	O
isoniazid	O
had	O
no	O
effect	O
on	O
3	O
,	O
5	O
-	O
DCA	O
cytotoxicity	O
,	O
it	O
appears	O
that	O
CYP2C	O
enzymes	O
are	O
bioactivating	O
3	O
,	O
5	O
-	O
DCA	O
to	O
toxic	O
metabolites	O
via	O
3	O
,	O
5	O
-	O
DCPHA	O
formation	O
.	O

In	O
vitro	O
functional	O
reconstitution	O
studies	O
,	O
of	O
E1	O
/	O
E2	O
/	O
E3	O
-	O
mediated	O
CYP3A4	B
and	O
CYP2E1	O
ubiquitination	O
have	O
identified	O
UbcH5a	O
/	O
Hsc70	O
/	O
Hsp40	O
/	O
CHIP	O
and	O
UBC7	O
/	O
AMFR	O
/	O
gp78	O
complexes	O
as	O
two	O
relevant	O
E2	O
/	O
E3	O
systems	O
in	O
CYP3A4	B
and	O
CYP2E1	O
ubiquitination	O
:	O
(	O
i	O
)	O
CHIP	O
(	O
carboxy	O
-	O
terminus	O
of	O
Hsc70	O
-	O
interacting	O
protein	O
)	O
,	O
a	O
cytoplasmic	O
Hsc70	O
-	O
cochaperone	O
,	O
functions	O
with	O
its	O
cognate	O
UbcH5a	O
E2	O
and	O
Hsc70	O
/	O
Hsp40	O
co	O
-	O
chaperones	O
in	O
substrate	O
ubiquitination	O
,	O
.	O

The	O
individual	O
roles	O
of	O
CHIP	O
and	O
gp78	O
in	O
CYP3A	B
and	O
CYP2E1	O
ubiquitination	O
and	O
Endoplasmic	O
Reticulum	O
-	O
Associated	O
Degradation	O
were	O
verified	O
upon	O
lentiviral	O
shRNA	O
interference	O
analyses	O
targeted	O
individually	O
against	O
each	O
of	O
these	O
E3s	O
in	O
cultured	O
rat	O
hepatocytes	O
,	O
.	O

Thus	O
,	O
upon	O
CHIP	O
-	O
knockdown	O
,	O
CYP3A	B
was	O
stabilized	O
largely	O
as	O
the	O
parent	O
(	O
55	O
kDa	O
)	O
species	O
along	O
with	O
a	O
minor	O
CYP3A	B
fraction	O
consisting	O
of	O
its	O
high	O
molecular	O
mass	O
ubiquitinated	O
species	O
.	O

Upon	O
gp78	O
knockdown	O
,	O
CYP3A	B
was	O
largely	O
found	O
as	O
its	O
parent	O
species	O
along	O
with	O
a	O
significant	O
amount	O
of	O
its	O
ubiquitinated	O
species	O
.	O

However	O
,	O
upon	O
either	O
E3	O
-	O
knockdown	O
,	O
the	O
functionally	O
active	O
CYP3A	B
fraction	O
not	O
only	O
was	O
proportional	O
to	O
the	O
relative	O
amount	O
of	O
the	O
stabilized	O
unmodified	O
parent	O
species	O
,	O
but	O
also	O
considerably	O
greater	O
than	O
that	O
in	O
the	O
corresponding	O
non	O
-	O
targeting	O
shRNA	O
-	O
treated	O
control	O
hepatocytes	O
,	O
indicating	O
that	O
CYP3A	B
-	O
ERAD	O
disruption	O
could	O
be	O
therapeutically	O
relevant	O
.	O

Furthermore	O
,	O
each	O
system	O
by	O
itself	O
was	O
capable	O
of	O
CYP3A4	B
-	O
ubiquitination	O
as	O
determined	O
upon	O
in	O
vitro	O
reconstitution	O
studies	O
of	O
each	O
individual	O
CYP3A4	B
E2	O
/	O
E3	O
-	O
ubiquitination	O
system	O
.	O

However	O
,	O
CYP3A4	B
ubiquitination	O
was	O
both	O
greatly	O
accelerated	O
and	O
magnified	O
when	O
both	O
E2	O
/	O
E3	O
systems	O
were	O
present	O
simultaneously	O
.	O

The	O
CYP3A4	B
ubiquitination	O
profile	O
observed	O
upon	O
sequential	O
introduction	O
of	O
each	O
E2	O
/	O
E3	O
in	O
the	O
reconstituted	O
system	O
suggested	O
that	O
UbcH5a	O
/	O
CHIP	O
most	O
likely	O
serves	O
as	O
the	O
E3	O
,	O
with	O
UBC7	O
/	O
gp78	O
serving	O
as	O
the	O
E4	O
involved	O
in	O
the	O
elongation	O
of	O
CYP3A4	B
polyUb	O
chains	O
.	O

This	O
heterotrimeric	O
p97	O
-	O
complex	O
was	O
documented	O
to	O
be	O
required	O
for	O
CYP3A	B
Ubiquitin	O
-	O
Dependent	O
Proteasomal	O
Degradation	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Through	O
chemical	O
(	O
formaldehyde	O
)	O
-	O
crosslinking	O
,	O
immune	O
affinity	O
-	O
purification	O
and	O
LC	O
-	O
MS	O
/	O
MS	O
analyses	O
,	O
its	O
close	O
cellular	O
association	O
with	O
ubiquitinated	O
CYP3A23	O
in	O
cultured	O
rat	O
hepatocytes	O
was	O
also	O
documented	O
,	O
a	O
finding	O
subsequently	O
verified	O
by	O
p97	O
-	O
targeted	O
lentiviral	O
Shrna	O
Interference	O
analyses	O
in	O
cultured	O
rat	O
hepatocytes	O
.	O

Lentiviral	O
shRNAi	O
-	O
elicited	O
p97	O
-	O
knockdown	O
led	O
to	O
the	O
accumulation	O
of	O
parent	O
and	O
ubiquitinated	O
CYP3A23	O
species	O
that	O
remained	O
largely	O
anchored	O
to	O
the	O
ER	O
-	O
membrane	O
,	O
unlike	O
those	O
from	O
control	O
shRNA	O
-	O
treated	O
hepatocytes	O
that	O
were	O
largely	O
extracted	O
into	O
the	O
cytosol	O
.	O

The	O
serious	O
,	O
life	O
-	O
threatening	O
Drug	O
-	O
Drug	O
Interactions	O
observed	O
with	O
the	O
CYP3A4	B
mechanism	O
-	O
based	O
inactivators	O
grapefruit	O
juice	O
furanocoumarins	O
and	O
terfenadine	O
,	O
astemizole	O
or	O
amiodarone	O
are	O
some	O
illustrative	O
examples	O
,	O
.	O

Similar	O
hepatic	O
stabilization	O
of	O
CYP3A	B
-	O
enzymes	O
in	O
these	O
mice	O
can	O
significantly	O
enhance	O
the	O
bioactivation	O
of	O
the	O
breast	O
cancer	O
chemotherapeutic	O
prodrug	O
tamoxifen	O
to	O
its	O
pharmacologically	O
active	O
end	O
-	O
product	O
endoxifen	O
.	O

We	O
find	O
it	O
intriguing	O
that	O
serum	O
antibodies	O
to	O
one	O
of	O
the	O
CYP3A	B
peptides	O
detected	O
in	O
clinical	O
CBZ	O
-	O
elicited	O
acute	O
hypersensitivity	O
reactions	O
,	O
corresponds	O
to	O
the	O
same	O
CYP3A4	B
helix	O
K	O
-	O
region	O
that	O
is	O
heme	O
-	O
modified	O
upon	O
cumene	O
-	O
hydroperoxide	O
-	O
elicited	O
peroxidative	O
CYP3A4	B
heme	O
-	O
fragmentation	O
.	O

The	O
magnitude	O
of	O
CYP2E1	O
and	O
CYP3A	B
functional	O
stabilization	O
is	O
comparable	O
in	O
Gp78	O
-	O
KO	O
and	O
Chip	O
-	O
KO	O
mouse	O
livers	O
,	O
.	O

CYP3A	B
showed	O
a	O
similar	O
pattern	O
:	O
petasin	O
/	O
neopetasin	O
/	O
isopetasin	O
metabolism	O
with	O
CYP3A4	B
(	O
human	O
)	O
was	O
34	O
%	O
/	O
87	O
%	O
/	O
86	O
%	O
versus	O
CYP3A1	O
(	O
rat	O
)	O
:	O
37	O
%	O
/	O
78	O
%	O
/	O
86	O
%	O
versus	O
CYP3A2	O
(	O
rat	O
)	O
:	O
34	O
%	O
/	O
46	O
%	O
/	O
73	O
%	O
.	O

By	O
day	O
20	O
,	O
hepatic	O
transcripts	O
,	O
such	O
as	O
alpha1	O
-	O
antitrypsin	O
and	O
Na	O
^	O
+	O
-	O
taurocholate	O
cotransporting	O
polypeptide	O
,	O
reached	O
levels	O
found	O
in	O
PHHs4A	O
and	O
Alpha1	O
-	O
Antitrypsin	O
and	O
activity	O
of	O
mature	O
genes	O
such	O
as	O
albumin	O
or	O
CYP3A4	B
,	O
the	O
most	O
important	O
drug	O
-	O
biotransforming	O
enzyme	O
,	O
remained	O
lower	O
than	O
in	O
Primary	O
Human	O
Hepatocytes	O
or	O
even	O
12	O
h	O
plated	O
Primary	O
Human	O
Hepatocytes	O
(	O
PHH	O
12	O
h	O
)	O
.	O

Induction	O
of	O
HNF1A	O
,	O
FOXA3	O
,	O
and	O
PROX1	O
from	O
D4	O
until	O
D20	O
induced	O
their	O
expression	O
to	O
levels	O
near	O
those	O
of	O
Primary	O
Human	O
Hepatocytes	O
and	O
increased	O
both	O
Albumin	O
and	O
CYP3A4	B
mRNA	O
.	O

Transcript	O
levels	O
of	O
Albumin	O
now	O
reached	O
those	O
of	O
PHH	O
12	O
h	O
and	O
CYP3A4	B
expression	O
was	O
increased	O
50	O
-	O
fold	O
was	O
still	O
very	O
low	O
or	O
increased	O
OCR	O
was	O
observed	O
.	O

Surprisingly	O
,	O
despite	O
the	O
clear	O
correlation	O
between	O
metabolism	O
,	O
AA	O
catabolism	O
,	O
and	O
Cytochrome	O
P450	O
expression	O
observed	O
in	O
the	O
WGCNA	O
,	O
AA3	O
only	O
marginally	O
induced	O
the	O
expression	O
of	O
CYP3A4	B
when	O
exceeding	O
the	O
nutritional	O
need	O
(	O
Supplementary	O
Fig	O
,	O
C	O
)	O
.	O

We	O
observed	O
a	O
concentration	O
-	O
dependent	O
increase	O
in	O
CYP3A4	B
expression	O
when	O
HLC	O
D20	O
or	O
HC3X	O
D20	O
were	O
differentiated	O
in	O
AA3	O
medium	O
supplemented	O
with	O
2	O
%	O
glycine	O
present	O
in	O
the	O
media	O
was	O
replaced	O
by	O
2	O
%	O
of	O
a	O
single	O
AA	O
,	O
as	O
the	O
combination	O
increased	O
the	O
osmolarity	O
of	O
the	O
media	O
to	O
lethal	O
levels	O
(	O
Supplementary	O
Fig	O
.	O

Importantly	O
,	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
medium	O
induced	O
a	O
gradual	O
maturation	O
of	O
HLC	O
and	O
HC3X	O
progeny	O
,	O
as	O
extended	O
culture	O
resulted	O
in	O
a	O
continuous	O
increase	O
in	O
CYP3A4	B
expression	O
and	O
function	O
to	O
levels	O
that	O
were	O
in	O
the	O
range	O
of	O
gold	O
standard	O
,	O
freshly	O
thawed	O
Primary	O
Human	O
Hepatocytes	O
.	O

As	O
we	O
observed	O
for	O
Hepatocyte	O
-	O
Like	O
Cells	O
,	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
also	O
induced	O
a	O
gradual	O
increase	O
in	O
CYP3A4	B
expression	O
and	O
function	O
of	O
HepG2	O
cells	O
over	O
time	O
.	O

Based	O
on	O
the	O
Rna	O
-	O
Sequencing	O
data	O
,	O
we	O
next	O
analyzed	O
the	O
activity	O
of	O
the	O
AKT	O
-	O
mTORC1	O
,	O
Amp	O
-	O
Activated	O
Protein	O
Kinase	O
,	O
and	O
eIF2alpha	O
pathways	O
in	O
HepG2	O
cultured	O
with	O
AA3	O
ALA	O
or	O
AA3GLY	O
(	O
strong	O
inducers	O
of	O
CYP3A4	B
)	O
versus	O
AA3	O
VAL	O
(	O
weak	O
induction	O
of	O
CYP3A4	B
)	O
.	O

This	O
analysis	O
linked	O
induction	O
of	O
mature	O
hepatic	O
markers	O
such	O
as	O
CYP3A4	B
,	O
Phosphoenolpyruvate	O
Carboxykinase	O
,	O
and	O
glutamine	O
synthetase	O
to	O
an	O
increased	O
phosphorylation	O
of	O
S6	O
,	O
Amp	O
-	O
Activated	O
Protein	O
Kinase	O
,	O
and	O
AKT	O
.	O

From	O
these	O
pathways	O
,	O
we	O
were	O
able	O
to	O
specifically	O
link	O
mTORC1	O
signaling	O
to	O
the	O
induction	O
of	O
CYP3A4	B
,	O
as	O
addition	O
of	O
the	O
mTORC1	O
inhibitor	O
rapamycin	O
blocked	O
the	O
induction	O
of	O
CYP3A4	B
,	O
while	O
Amp	O
-	O
Activated	O
Protein	O
Kinase	O
phosphorylation	O
and	O
ATF4	O
levels	O
remained	O
unchanged	O
(	O
Supplementary	O
Fig	O
.	O

Furthermore	O
,	O
knockout	O
of	O
the	O
upstream	O
regulators	O
of	O
Amp	O
-	O
Activated	O
Protein	O
Kinase	O
and	O
eIF2alpha	O
,	O
LKB1	O
and	O
GCN2	O
,	O
did	O
not	O
affect	O
CYP3A4	B
levels	O
both	O
in	O
control	O
media	O
or	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
media	O
(	O
Supplementary	O
Fig	O
B	O
,	O
C	O
)	O
.	O

In	O
both	O
HepG2	O
,	O
HLC	O
and	O
HC3X	O
,	O
mTORC1	O
appeared	O
to	O
regulate	O
CYP3A4	B
expression	O
rather	O
than	O
translation	O
.	O

Finally	O
,	O
although	O
Knockout	O
of	O
the	O
mTORC1	O
inhibitor	O
Tuberous	O
sclerosis	O
(	O
TSC	O
)	O
1	O
was	O
not	O
sufficient	O
for	O
driving	O
maturation	O
in	O
HepG2	O
,	O
culture	O
of	O
TSC1	O
Knockout	O
HepG2	O
in	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
medium	O
yielded	O
an	O
even	O
greater	O
induction	O
of	O
CYP3A4	B
compared	O
with	O
wild	O
-	O
type	O
HepG2	O
^	O
.	O

However	O
,	O
we	O
only	O
found	O
an	O
increase	O
in	O
CYP3A4	B
and	O
the	O
gluconeogenic	O
genes	O
,	O
G6PC	O
and	O
Phosphoenolpyruvate	O
Carboxykinase	O
,	O
when	O
HC6X	O
were	O
also	O
cultured	O
with	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
,	O
indicating	O
that	O
mitochondrial	O
biogenesis	O
is	O
not	O
sufficient	O
to	O
drive	O
maturation	O
(	O
Supplementary	O
Fig	O
E	O
,	O
F	O
)	O
.	O

The	O
transcriptome	O
of	O
HC6X	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
D40	O
was	O
similar	O
to	O
that	O
of	O
HC3X	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
D40	O
,	O
even	O
if	O
perhaps	O
slightly	O
closer	O
to	O
that	O
of	O
Primary	O
Human	O
Hepatocytes	O
caused	O
a	O
significant	O
decrease	O
in	O
CYP3A4	B
activity	O
and	O
to	O
a	O
lesser	O
extent	O
also	O
decreased	O
global	O
maturity	O
(	O
Fig	O
.	O

In	O
accordance	O
,	O
we	O
found	O
that	O
HC6X	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
D40	O
stained	O
positive	O
for	O
CYP3A4	B
,	O
with	O
several	O
cells	O
displaying	O
a	O
binucleated	O
phenotype	O
(	O
Supplementary	O
Fig	O
.	O

Of	O
the	O
investigated	O
signaling	O
pathways	O
,	O
we	O
only	O
found	O
inhibition	O
of	O
mTORC1	O
to	O
be	O
able	O
to	O
prevent	O
the	O
induction	O
of	O
CYP3A4	B
under	O
conditions	O
of	O
AA	O
supplementation	O
.	O

Nevertheless	O
,	O
the	O
sole	O
activation	O
of	O
mTORC1	O
through	O
the	O
genetic	O
deletion	O
of	O
TSC1	O
was	O
not	O
sufficient	O
to	O
induce	O
CYP3A4	B
expression	O
.	O

CYP3A4	B
-	O
dependent	O
metabolization	O
was	O
determined	O
using	O
the	O
fluorometric	O
probe	O
BFC	O
as	O
previously	O
described	O
^	O
.	O

Moreover	O
it	O
is	O
important	O
to	O
emphasize	O
that	O
tocilizumab	O
decreases	O
the	O
concentration	O
of	O
several	O
medications	O
as	O
a	O
cytochrome	O
P450	O
,	O
isoenzyme	O
CYP3A4	B
inducer	O
in	O
terms	O
of	O
antagonisms	O
or	O
synergy	O
but	O
this	O
is	O
not	O
yet	O
entirely	O
clear	O
(	O
;	O
.	O

Several	O
drugs	O
,	O
such	O
as	O
CYP3A4	B
inhibitors	O
,	O
increase	O
concentration	O
of	O
colchicine	O
and	O
attention	O
should	O
be	O
paid	O
when	O
the	O
latter	O
is	O
used	O
with	O
cisplatin	O
or	O
vinca	O
alkaloids	O
.	O

One	O
main	O
source	O
of	O
risk	O
is	O
inhibition	O
of	O
CYP3A4	B
by	O
lopinavir	O
/	O
ritonavir	O
(	O
perpetrator	O
)	O
.	O

Given	O
that	O
ritonavir	O
irreversibly	O
inhibits	O
CYP3A4	B
,	O
the	O
inhibitory	O
effect	O
may	O
last	O
up	O
to	O
5	O
days	O
after	O
stopping	O
ritonavir	O
.	O

Interestingly	O
,	O
we	O
observed	O
the	O
same	O
trend	O
as	O
with	O
CYP3A	B
enzymes	O
:	O
a	O
diminished	O
difference	O
between	O
the	O
sexes	O
in	O
GF	O
mice	O
.	O

The	O
enzymatic	O
activity	O
of	O
CYP3A	B
was	O
significantly	O
decreased	O
in	O
GF	O
mice	O
compared	O
to	O
SPF	O
mice	O
.	O

In	O
the	O
female	O
groups	O
,	O
the	O
activity	O
of	O
CYP3A	B
did	O
not	O
differ	O
significantly	O
from	O
the	O
male	O
groups	O
but	O
had	O
a	O
tendency	O
to	O
decrease	O
.	O

Even	O
though	O
in	O
humans	O
the	O
differences	O
are	O
subtler	O
,	O
it	O
is	O
known	O
that	O
the	O
CYP3A4	B
activity	O
features	O
apparent	O
sexual	O
dimorphism	O
with	O
higher	O
activity	O
in	O
women	O
due	O
to	O
differences	O
in	O
growth	O
hormone	O
patterns	O
.	O

The	O
enzymatic	O
activity	O
of	O
CYP3A	B
(	O
using	O
midazolam	O
as	O
a	O
substrate	O
)	O
in	O
both	O
the	O
male	O
and	O
female	O
mice	O
lacking	O
the	O
microbiota	O
was	O
significantly	O
decreased	O
compared	O
to	O
their	O
SPF	O
counterparts	O
.	O

Further	O
we	O
have	O
found	O
that	O
the	O
activity	O
of	O
CYP3A	B
did	O
not	O
differ	O
significantly	O
in	O
female	O
groups	O
from	O
the	O
male	O
groups	O
,	O
but	O
had	O
a	O
tendency	O
to	O
decrease	O
.	O

This	O
data	O
suggests	O
that	O
the	O
down	O
-	O
regulation	O
of	O
CYP3A	B
enzymes	O
may	O
not	O
be	O
sex	O
-	O
specific	O
and	O
,	O
above	O
all	O
,	O
that	O
the	O
gut	O
microbiome	O
is	O
crucial	O
in	O
the	O
synthesis	O
of	O
CYP3A	B
in	O
both	O
sexes	O
.	O

Interestingly	O
,	O
we	O
observed	O
the	O
same	O
trend	O
as	O
with	O
CYP3A	B
enzymes	O
:	O
diminishing	O
the	O
changes	O
between	O
sexes	O
in	O
GF	O
mice	O
.	O

In	O
humans	O
,	O
CYP2C	O
and	O
CYP3A	B
enzymes	O
are	O
abundantly	O
present	O
in	O
the	O
liver	O
and	O
,	O
completely	O
or	O
partially	O
,	O
metabolize	O
a	O
large	O
fraction	O
of	O
all	O
prescribed	O
drugs	O
.	O

CYP3A4	B
contributes	O
to	O
the	O
oxidation	O
of	O
many	O
steroids	O
,	O
and	O
its	O
activity	O
in	O
humans	O
is	O
sexually	O
dimorphic	O
.	O

The	O
exact	O
mechanism	O
for	O
sex	O
differences	O
in	O
CYP3A4	B
(	O
and	O
other	O
CYPs	O
)	O
remains	O
elusive	O
but	O
may	O
include	O
altered	O
growth	O
hormone	O
signalling	O
.	O

In	O
addition	O
,	O
because	O
CYP3A	B
is	O
also	O
expressed	O
in	O
the	O
intestine	O
,	O
mitragynine	O
concentrations	O
in	O
the	O
intestine	O
could	O
well	O
exceed	O
10	O
M	O
,	O
increasing	O
the	O
possibility	O
of	O
CYP3A	B
-	O
mediated	O
kratom	O
-	O
drug	O
interactions	O
.	O

In	O
the	O
context	O
of	O
Hepatocellular	O
Carcinoma	O
,	O
treatment	O
with	O
5	O
-	O
AZA	O
conduced	O
to	O
tumor	O
regression	O
and	O
a	O
shift	O
to	O
a	O
more	O
differentiated	O
phenotype	O
,	O
which	O
was	O
associated	O
with	O
regional	O
demethylation	O
of	O
CpG	O
regions	O
upstream	O
of	O
the	O
liver	O
-	O
specific	O
genes	O
SLC10A1	O
,	O
CYP3A4	B
,	O
ALB	O
,	O
and	O
miR	O
-	O
122	O
,	O
which	O
were	O
downregulated	O
pretreatments	O
.	O

The	O
cytochrome	O
through	O
which	O
more	O
conflicts	O
occur	O
was	O
CYP3A4	B
(	O
n	O
=	O
67	O
)	O
,	O
followed	O
by	O
3A5	O
(	O
n	O
=	O
27	O
)	O
and	O
1A2	O
(	O
n	O
=	O
27	O
)	O
.	O

As	O
can	O
be	O
seen	O
,	O
the	O
prescription	O
of	O
oral	O
drugs	O
whose	O
metabolism	O
is	O
related	O
to	O
enzymes	O
frequently	O
altered	O
in	O
the	O
study	O
population	O
,	O
is	O
reduced	O
by	O
between	O
20	O
and	O
100	O
%	O
,	O
in	O
favor	O
of	O
intramuscular	O
prescriptions	O
that	O
either	O
do	O
not	O
have	O
liver	O
metabolism	O
,	O
such	O
as	O
Paliperidone	O
,	O
which	O
increases	O
by	O
186	O
.	O
95	O
%	O
,	O
or	O
whose	O
main	O
route	O
of	O
metabolism	O
is	O
associated	O
with	O
an	O
enzyme	O
that	O
usually	O
has	O
no	O
alterations	O
,	O
such	O
as	O
Aripiprazole	O
,	O
whose	O
prescriptions	O
increase	O
by	O
100	O
%	O
,	O
predominantly	O
metabolized	O
by	O
CYP3A4	B
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
use	O
of	O
DEPOT	O
presentations	O
of	O
drugs	O
such	O
as	O
paliperidone	O
(	O
not	O
metabolized	O
by	O
the	O
CYP450	O
system	O
)	O
or	O
aripiprazole	O
(	O
whose	O
predominant	O
pathway	O
within	O
the	O
CYP450	O
system	O
is	O
CYP3A4	B
,	O
which	O
presents	O
a	O
wt	O
-	O
like	O
genotype	O
in	O
the	O
vast	O
majority	O
of	O
the	O
study	O
population	O
)	O
has	O
been	O
the	O
solution	O
for	O
the	O
majority	O
of	O
problematic	O
cases	O
,	O
because	O
of	O
the	O
pharmacogenetic	O
profile	O
of	O
the	O
sample	O
,	O
even	O
considering	O
that	O
each	O
patient	O
was	O
studied	O
individually	O
attending	O
its	O
personal	O
genetic	O
implications	O
.	O

The	O
lowest	O
counts	O
of	O
variants	O
were	O
found	O
in	O
CYP21A2	O
(	O
one	O
variant	O
)	O
,	O
CYP26C1	O
(	O
seven	O
)	O
,	O
CYP3A4	B
,	O
and	O
CYP19A1	O
(	O
both	O
eight	O
variants	O
)	O
.	O

CYP3A5	B
catalyzes	O
a	O
comparable	O
range	O
of	O
reactions	O
as	O
CYP3A4	B
but	O
its	O
role	O
in	O
drug	O
and	O
steroid	O
metabolism	O
is	O
limited	O
due	O
to	O
its	O
generally	O
low	O
activity	O
and	O
expression	O
in	O
a	O
relatively	O
small	O
percentage	O
of	O
individuals	O
[	O
,	O
.	O

CYP3A7	O
is	O
the	O
major	O
CYP3A	O
isoform	O
in	O
prenatal	O
and	O
early	O
postnatal	O
life	O
and	O
differs	O
from	O
CYP3A4	B
in	O
terms	O
of	O
expression	O
and	O
function	O
.	O

CYP3A4	B
-	O
catalyzed	O
6BETA	O
-	O
hydroxylation	O
is	O
the	O
most	O
common	O
hydroxylation	O
for	O
^	O
4	O
steroids	O
,	O
eg	O
cortisol	O
(	O
(	O
e	O
)	O
)	O
,	O
while	O
6ALPHA	O
-	O
hydroxylated	O
pregnanolones	O
are	O
quantitatively	O
important	O
urine	O
steroid	O
metabolites	O
during	O
pregnancy	O
.	O

The	O
differential	O
substrate	O
specificity	O
,	O
regioselectivity	O
and	O
catalytic	O
activity	O
of	O
CYP3A4	B
and	O
CYP3A7	O
and	O
the	O
dynamic	O
expression	O
pattern	O
of	O
the	O
two	O
isoforms	O
throughout	O
fetal	O
development	O
and	O
the	O
first	O
year	O
of	O
life	O
lead	O
to	O
substantial	O
changes	O
in	O
the	O
hepatic	O
steroid	O
metabolome	O
during	O
this	O
period	O
of	O
life	O
.	O

CYP3A4	B
levels	O
are	O
low	O
in	O
the	O
fetus	O
and	O
newborn	O
compared	O
to	O
the	O
adult	O
.	O

Thus	O
,	O
there	O
is	O
a	O
switch	O
from	O
CYP3A7	O
to	O
CYP3A4	B
during	O
the	O
first	O
months	O
after	O
birth	O
.	O

In	O
fact	O
,	O
CYP2C19	O
and	O
CYP3A4	B
can	O
21	O
-	O
hydroxylate	O
progesterone	O
and	O
pregnenolone	O
,	O
possibly	O
partially	O
compensating	O
mineralocorticoid	O
deficiency	O
in	O
CAH	O
due	O
to	O
21	O
-	O
hydroxylase	O
deficiency	O
;	O
however	O
,	O
the	O
two	O
enzymes	O
are	O
not	O
capable	O
of	O
catalyzing	O
the	O
21	O
-	O
hydroxylation	O
of	O
17OHP	O
to	O
11	O
-	O
deoxycortisol	O
.	O

Cortisol	O
can	O
also	O
be	O
6BETA	O
-	O
hydroxylated	O
by	O
CYP3A4	B
expressed	O
in	O
the	O
liver	O
,	O
resulting	O
in	O
6BETA	O
-	O
hydroxycortisol	O
(	O
6BETA	O
-	O
OHF	O
)	O
.	O

Circulating	O
Dehydroepiandrosterone	O
is	O
readily	O
16ALPHA	O
-	O
hydroxylated	O
by	O
CYP3A4	B
/	O
7	O
within	O
the	O
liver	O
.	O

CYP3A4	B
is	O
the	O
major	O
enzyme	O
responsible	O
for	O
the	O
16ALPHA	O
-	O
hydroxylation	O
of	O
estrone	O
in	O
adults	O
,	O
though	O
CYP1A1	O
,	O
CYP2C19	O
and	O
CYP3A5	B
can	O
also	O
catalyze	O
the	O
reaction	O
.	O

Conversely	O
,	O
CYP1A2	O
is	O
the	O
dominant	O
enzyme	O
catalyzing	O
the	O
16ALPHA	O
-	O
hydroxylation	O
of	O
17BETA	O
-	O
estradiol	O
,	O
with	O
CYP3A4	B
,	O
CYP1A1	O
and	O
CYP1B1	O
also	O
demonstrating	O
this	O
activity	O
.	O

These	O
reactions	O
are	O
catalyzed	O
by	O
a	O
variety	O
of	O
CYPs	O
,	O
including	O
CYP3A4	B
and	O
CYP1A2	O
in	O
the	O
liver	O
,	O
or	O
CYP1A1	O
and	O
CYP3A4	B
in	O
peripheral	O
tissues	O
.	O

There	O
are	O
more	O
than	O
50	O
Cytochrome	O
P450	O
enzymes	O
,	O
but	O
the	O
CYP1A2	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2D6	O
,	O
CYP3A4	B
,	O
and	O
CYP3A5	B
enzymes	O
metabolize	O
90	O
percent	O
of	O
drugs	O
.	O

Accordingly	O
,	O
the	O
dominant	O
human	O
liver	O
/	O
intestinal	O
CYP3A4	B
and	O
human	O
liver	O
CYP2E1	O
are	O
found	O
to	O
be	O
prototypic	O
ERAD	O
-	O
C	O
substrates	O
.	O

CYP3A4	B
,	O
accounting	O
for	O
30	O
%	O
of	O
the	O
hepatic	O
P450	O
content	O
,	O
is	O
engaged	O
in	O
the	O
metabolism	O
of	O
>	O
50	O
%	O
of	O
clinically	O
relevant	O
drugs	O
and	O
other	O
xenobiotics	O
,	O
whereas	O
CYP2E1	O
biotransforms	O
clinically	O
relevant	O
drugs	O
(	O
acetaminophen	O
,	O
halothane	O
)	O
,	O
EtOH	O
,	O
and	O
other	O
xenobiotics	O
,	O
carcinogens	O
(	O
nitrosamines	O
)	O
,	O
endogenous	O
acetone	O
and	O
fatty	O
acids	O
(	O
arachidonic	O
acid	O
)	O
to	O
toxic	O
/	O
reactive	O
intermediates	O
,	O
.	O

Therefore	O
,	O
further	O
elucidation	O
of	O
the	O
function	O
of	O
rs17102977	O
and	O
mainly	O
the	O
whole	O
gene	O
locus	O
1p33	O
containing	O
also	O
CYP4B1	O
,	O
CYP4A11	O
,	O
CYP4Z1	O
,	O
and	O
CYP4A22	O
genes	O
is	O
needed	O
.	O

Thus	O
,	O
although	O
previous	O
studies	O
identified	O
Amino	O
Acids	O
as	O
important	O
for	O
hepatocyte	O
survival	O
,	O
proliferation	O
,	O
and	O
protein	O
synthesis	O
^	O
,	O
,	O
we	O
here	O
demonstrate	O
that	O
increasing	O
Amino	O
Acids	O
to	O
levels	O
30	O
-	O
fold	O
above	O
that	O
of	O
typical	O
hepatocyte	O
media	O
,	O
actively	O
induces	O
a	O
metabolic	O
switch	O
,	O
as	O
well	O
as	O
Cytochrome	B
P450	I
enzyme	O
expression	O
and	O
function	O
(	O
Supplementary	O
Table	O
.	O

Comparative	O
Cytochrome	B
P450	I
biotransformation	O
studies	O
were	O
performed	O
to	O
assess	O
functionality	O
across	O
a	O
number	O
of	O
gold	O
standard	O
primary	O
hepatocyte	O
models	O
.	O

Tocilizumab	O
decreases	O
concentrations	O
of	O
many	O
anticancer	O
drugs	O
due	O
to	O
interference	O
with	O
Cytochrome	B
P450	I
.	O

Cytochrome	B
P450	I
monooxygenases	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
biosynthesis	O
of	O
numerous	O
secondary	O
metabolites	O
and	O
stress	O
responses	O
of	O
plants	O
to	O
herbicides	O
and	O
pathogens	O
^	O
-	O
.	O

Previous	O
studies	O
reported	O
that	O
Mycophenolic	O
Acid	O
metabolized	O
in	O
inactive	O
MPAG	O
and	O
AcMPAG	O
metabolites	O
by	O
Cytochrome	B
P450	I
.	O

Meanwhile	O
QC	O
further	O
improved	O
the	O
therapeutic	O
efficacy	O
by	O
increasing	O
the	O
bioavailability	O
of	O
Mycophenolic	O
Acid	O
through	O
inhibiting	O
Cytochrome	B
P450	I
enzyme	I
.	O

Thus	O
,	O
we	O
investigated	O
the	O
potential	O
of	O
naturally	O
occurring	O
Alternaria	O
toxin	O
mixtures	O
to	O
induce	O
Cytochrome	B
P450	I
1A1	O
/	O
1A2	O
/	O
1B1	O
activity	O
.	O

Sub	O
-	O
cytotoxic	O
concentrations	O
of	O
the	O
two	O
toxin	O
mixtures	O
,	O
as	O
well	O
as	O
ATX	O
-	O
I	O
,	O
ATX	O
-	O
II	O
and	O
AOH	O
,	O
exhibited	O
dose	O
-	O
dependent	O
enhancements	O
of	O
Cytochrome	B
P450	I
1	O
activity	O
.	O

Besides	O
,	O
several	O
Cytochrome	B
P450	I
isoforms	O
are	O
frequently	O
induced	O
by	O
their	O
own	O
substrates	O
.	O

Hence	O
,	O
prominent	O
ligands	O
of	O
the	O
Aryl	O
Hydrocarbon	O
Receptor	O
behave	O
also	O
as	O
inducers	O
of	O
Cytochrome	B
P450	I
1A1	O
activity	O
,	O
such	O
as	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
and	O
benzo	O
[	O
a	O
]	O
pyrene	O
(	O
B	O
[	O
a	O
]	O
P	O
)	O
,	O
which	O
are	O
suggested	O
to	O
be	O
involved	O
in	O
increased	O
breast	O
cancer	O
risk	O
.	O

Furthermore	O
,	O
distinctively	O
elevated	O
Cytochrome	B
P450	I
1A1	O
and	O
Cytochrome	B
P450	I
1B1	O
protein	O
expression	O
as	O
well	O
as	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
activity	O
were	O
previously	O
reported	O
for	O
breast	O
cancer	O
tissues	O
in	O
comparison	O
to	O
adjacent	O
non	O
-	O
tumor	O
tissues	O
.	O

A	O
standard	O
method	O
used	O
to	O
determine	O
Cytochrome	B
P450	I
1A1	O
enzyme	O
activity	O
induction	O
upon	O
exposure	O
to	O
Aryl	O
Hydrocarbon	O
Receptor	O
ligands	O
is	O
the	O
7	O
-	O
ethoxyresorufin	O
-	O
O	O
-	O
deethylase	O
assay	O
.	O

The	O
dealkylation	O
of	O
7	O
-	O
ethoxyresorufin	O
(	O
7	O
-	O
ER	O
)	O
yielding	O
the	O
fluorescent	O
substance	O
resorufin	O
was	O
shown	O
to	O
be	O
primarily	O
exerted	O
through	O
Cytochrome	B
P450	I
1A1	O
,	O
followed	O
by	O
Cytochrome	B
P450	I
1A2	O
and	O
Cytochrome	B
P450	I
1B1	O
.	O

Previous	O
studiesuncovered	O
the	O
induction	O
of	O
Cytochrome	B
P450	I
1A1	O
expression	O
to	O
be	O
Aryl	O
Hydrocarbon	O
Receptor	O
dependent	O
for	O
both	O
dibenzo	O
-	O
ALPHA	O
-	O
pyrones	O
in	O
murine	O
hepatoma	O
cells	O
and	O
AOH	O
in	O
human	O
esophageal	O
cancer	O
cells	O
,	O
whereas	O
the	O
latter	O
turned	O
out	O
to	O
be	O
irrelevant	O
for	O
the	O
genotoxic	O
capabilities	O
of	O
AOH	O
.	O

Although	O
data	O
on	O
the	O
metabolism	O
of	O
altertoxins	O
is	O
scarce	O
,	O
ATX	O
-	O
II	O
was	O
reported	O
to	O
induce	O
Cytochrome	B
P450	I
1A1	O
activity	O
and	O
raise	O
Cytochrome	B
P450	I
1A1	O
transcript	O
levels	O
in	O
KYSE	O
510	O
cells	O
.	O

Hence	O
,	O
this	O
study	O
aimed	O
to	O
uncover	O
the	O
potential	O
of	O
naturally	O
occurring	O
mixtures	O
of	O
Alternaria	O
toxins	O
to	O
enhance	O
Cytochrome	B
P450	I
1	O
activity	O
and	O
their	O
combinatory	O
effects	O
in	O
this	O
respect	O
applying	O
the	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
assay	O
.	O

Further	O
,	O
the	O
Cytochrome	B
P450	I
1	O
activating	O
potential	O
of	O
single	O
Alternaria	O
toxins	O
,	O
as	O
well	O
as	O
binary	O
mixtures	O
according	O
to	O
the	O
complex	O
extracts	O
,	O
was	O
investigated	O
utilizing	O
the	O
estrogen	O
-	O
sensitive	O
mammary	O
adenocarcinoma	O
cell	O
line	O
MCF	O
-	O
7	O
.	O

Thus	O
,	O
the	O
study	O
at	O
hand	O
investigated	O
the	O
potential	O
of	O
complex	O
Alternaria	O
toxin	O
mixtures	O
as	O
well	O
as	O
selected	O
single	O
toxins	O
in	O
corresponding	O
binary	O
mixtures	O
to	O
affect	O
Cytochrome	B
P450	I
1	O
enzyme	O
activity	O
in	O
estrogen	O
-	O
sensitive	O
MCF	O
-	O
7	O
mammary	O
cancer	O
cells	O
.	O

The	O
induction	O
of	O
both	O
Cytochrome	B
P450	I
1A1	O
mRNA	O
transcription	O
and	O
the	O
according	O
enzymatic	O
activity	O
was	O
reported	O
to	O
serve	O
as	O
indicators	O
for	O
Aryl	O
Hydrocarbon	O
Receptor	O
activation	O
.	O

In	O
contrast	O
,	O
E2	O
showed	O
no	O
estrogen	O
-	O
related	O
induction	O
of	O
Cytochrome	B
P450	I
1	O
activity	O
in	O
our	O
MCF	O
-	O
7	O
cell	O
model	O
(	O
a	O
)	O
,	O
which	O
was	O
suggested	O
in	O
a	O
previously	O
published	O
study	O
.	O

Both	O
,	O
the	O
Complete	O
Extract	O
and	O
the	O
Reduced	O
Extract	O
(	O
stripped	O
from	O
the	O
two	O
perylene	O
quinones	O
ATX	O
-	O
II	O
and	O
STTX	O
-	O
III	O
)	O
,	O
led	O
to	O
dose	O
-	O
dependent	O
enhancements	O
of	O
Cytochrome	B
P450	I
1A1	O
activity	O
(	O
a	O
)	O
.	O

This	O
is	O
in	O
line	O
with	O
a	O
previous	O
report	O
of	O
the	O
Complete	O
Extract	O
to	O
increase	O
Cytochrome	B
P450	I
1A1	O
expression	O
levels	O
in	O
Ishikawa	O
cells	O
at	O
concentrations	O
comparable	O
to	O
the	O
extracts	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
enzyme	O
activity	O
induction	O
in	O
MCF	O
-	O
7	O
.	O

Notably	O
,	O
the	O
REs	O
capability	O
to	O
induce	O
Cytochrome	B
P450	I
1	O
activity	O
surpassed	O
the	O
potent	O
activity	O
of	O
the	O
Complete	O
Extract	O
at	O
higher	O
concentrations	O
.	O

Single	O
known	O
extracts	O
constituents	O
,	O
such	O
as	O
ATX	O
-	O
II	O
and	O
AOH	O
were	O
previously	O
shown	O
to	O
activate	O
the	O
Aryl	O
Hydrocarbon	O
Receptor	O
,	O
increase	O
Cytochrome	B
P450	I
1A1	O
enzyme	O
activity	O
,	O
which	O
was	O
shown	O
via	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
assay	O
and	O
impact	O
Cytochrome	B
P450	I
1A1	O
mRNA	O
transcription	O
at	O
corresponding	O
concentrations	O
in	O
KYSE	O
510	O
oesophageal	O
cancer	O
cells	O
,	O
while	O
Alternariol	O
Monomethyl	O
Ether	O
exhibited	O
its	O
potency	O
primarily	O
in	O
HepG2	O
cells	O
.	O

Testing	O
single	O
toxins	O
revealed	O
dose	O
-	O
dependent	O
enzyme	O
activation	O
for	O
ATX	O
-	O
I	O
,	O
ATX	O
-	O
II	O
and	O
AOH	O
;	O
in	O
contrast	O
,	O
no	O
evident	O
induction	O
of	O
Cytochrome	B
P450	I
1	O
enzyme	O
activity	O
was	O
exerted	O
by	O
Alternariol	O
Monomethyl	O
Ether	O
(	O
b	O
)	O
.	O

Previously	O
,	O
ATX	O
-	O
II	O
was	O
found	O
to	O
increase	O
Cytochrome	B
P450	I
1	O
transcription	O
and	O
activity	O
in	O
oesophageal	O
cancer	O
cells	O
starting	O
at	O
a	O
concentration	O
of	O
0	O
.	O
05	O
M	O
and	O
0	O
.	O
1	O
M	O
,	O
respectively	O
,	O
indicating	O
a	O
higher	O
sensitivity	O
to	O
Aryl	O
Hydrocarbon	O
Receptor	O
activation	O
compared	O
to	O
the	O
breast	O
cancer	O
cell	O
line	O
MCF	O
-	O
7	O
.	O

This	O
enhancement	O
of	O
Cytochrome	B
P450	I
1	O
enzyme	O
activity	O
was	O
linked	O
to	O
Aryl	O
Hydrocarbon	O
Receptor	O
activation	O
.	O

Preceding	O
published	O
experiments	O
showed	O
inconclusive	O
efficacy	O
of	O
Alternariol	O
Monomethyl	O
Ether	O
towards	O
Cytochrome	B
P450	I
1	O
enzyme	O
activity	O
alteration	O
,	O
increasing	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
activity	O
in	O
HepG2	O
cells	O
at	O
10	O
M	O
and	O
in	O
KYSE	O
510	O
at	O
50	O
M	O
.	O
This	O
effect	O
was	O
diminished	O
again	O
at	O
50	O
M	O
in	O
HepG2	O
,	O
possibly	O
due	O
to	O
the	O
onset	O
of	O
cytotoxicity	O
.	O

Of	O
note	O
,	O
B	O
[	O
a	O
]	O
P	O
was	O
shown	O
to	O
elevate	O
Cytochrome	B
P450	I
1A1	O
and	O
Cytochrome	B
P450	I
1B1	O
mRNA	O
in	O
MCF	O
-	O
7	O
cells	O
;	O
therefore	O
,	O
enhanced	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
enzyme	O
activity	O
cannot	O
exclusively	O
be	O
ascribed	O
to	O
a	O
single	O
Cytochrome	B
P450	I
1	O
enzyme	O
as	O
7	O
-	O
ER	O
poses	O
a	O
substrate	O
for	O
several	O
above	O
mentioned	O
isoforms	O
.	O

Nonetheless	O
,	O
previous	O
studies	O
on	O
AOH	O
,	O
Alternariol	O
Monomethyl	O
Ether	O
,	O
and	O
ATX	O
-	O
II	O
as	O
well	O
as	O
on	O
the	O
Alternaria	O
extracts	O
used	O
showed	O
Cytochrome	B
P450	I
1A1	O
mRNA	O
enhancements	O
in	O
various	O
cell	O
lines	O
.	O

Therefore	O
,	O
a	O
high	O
correlation	O
of	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
enzyme	O
activity	O
towards	O
Cytochrome	B
P450	I
1A1	O
could	O
be	O
assumed	O
for	O
the	O
toxins	O
and	O
mixtures	O
applied	O
here	O
as	O
well	O
.	O

Nonetheless	O
,	O
further	O
interference	O
by	O
other	O
compounds	O
not	O
tested	O
(	O
or	O
not	O
identified	O
)	O
within	O
the	O
complex	O
mixture	O
affecting	O
the	O
Cytochrome	B
P450	I
1	O
enzyme	O
activity	O
needs	O
to	O
be	O
considered	O
for	O
interpretation	O
of	O
the	O
current	O
data	O
.	O

We	O
could	O
decipher	O
the	O
two	O
perylene	O
quinone	O
derivates	O
ATX	O
-	O
I	O
and	O
ATX	O
-	O
II	O
,	O
as	O
well	O
as	O
the	O
dibenzo	O
-	O
ALPHA	O
-	O
pyrone	O
AOH	O
,	O
as	O
participants	O
towards	O
the	O
Cytochrome	B
P450	I
1A1	O
activity	O
induction	O
exerted	O
by	O
complex	O
Alternaria	O
extracts	O
in	O
mammary	O
cancer	O
cells	O
and	O
their	O
combinatory	O
effects	O
to	O
be	O
major	O
contributors	O
.	O

Issues	O
addressed	O
at	O
these	O
research	O
meetings	O
(	O
International	O
Conferences	O
on	O
Cytochrome	B
P450	I
,	O
https	O
:	O
/	O
/	O
www	O
.	O
p450meetings	O
.	O
com	O
)	O
include	O
biochemistry	O
,	O
biophysics	O
,	O
gene	O
regulation	O
,	O
and	O
pharmaceutical	O
and	O
biotechnology	O
applications	O
.	O

Increase	O
in	O
Cytochrome	B
P450	I
activity	O
has	O
been	O
observed	O
even	O
after	O
short	O
-	O
course	O
treatment	O
with	O
lopinavir	O
/	O
ritonavir	O
.	O

Cytochrome	B
P450	I
genes	O
,	O
which	O
are	O
involved	O
in	O
plant	O
development	O
,	O
antioxidant	O
,	O
and	O
detoxification	O
of	O
pollutants	O
,	O
are	O
also	O
involved	O
in	O
plant	O
defense	O
by	O
protecting	O
from	O
various	O
biotic	O
and	O
abiotic	O
stresses	O
.	O

Therefore	O
,	O
we	O
searched	O
the	O
genome	O
of	O
F	O
.	O
filiformis	O
for	O
proteins	O
with	O
a	O
P450	O
conserved	O
domain	O
using	O
the	O
NCBI	O
CDD	O
tool	O
and	O
BLASTp	O
and	O
also	O
by	O
homology	O
BLAST	O
in	O
the	O
Fungal	O
Cytochrome	B
P450	I
Database	O
(	O
p450	O
.	O
riceblast	O
.	O
snu	O
.	O
ac	O
.	O
kr	O
/	O
index	O
.	O
php	O
?	O

The	O
homolog	O
of	O
MaCYP71CD2	O
in	O
neem	O
(	O
AiCYP71CD2	O
)	O
was	O
identified	O
,	O
the	O
homolog	O
of	O
MaCYP71BQ5	O
(	O
a	O
characterized	O
Cytochrome	B
P450	I
from	O
M	O
.	O
azedarach	O
)	O
in	O
neem	O
was	O
fragmented	O
.	O

Extensive	O
bioinformatic	O
analysis	O
of	O
unigenes	O
involving	O
phylogenetic	O
analysis	O
,	O
domain	O
prediction	O
,	O
and	O
molecular	O
docking	O
further	O
provided	O
22	O
candidates	O
for	O
the	O
putative	O
biosynthetic	O
pathway	O
,	O
including	O
1	O
2	O
,	O
3	O
-	O
Oxidosqualene	O
Cyclase	O
unigene	O
,	O
2	O
Alcohol	O
Dehydrogenase	O
unigenes	O
,	O
12	O
Cytochrome	B
P450	I
unigenes	O
,	O
2	O
Acyltransferase	O
unigenes	O
,	O
and	O
5	O
Esterase	O
unigenes	O
.	O

The	O
length	O
of	O
two	O
Cytochrome	B
P450	I
unigenes	O
(	O
transcript	O
/	O
16971	O
and	O
transcript	O
/	O
16742	O
)	O
was	O
1536	O
bp	O
and	O
1527	O
bp	O
,	O
and	O
they	O
encoded	O
proteins	O
consisting	O
of	O
511	O
and	O
508	O
amino	O
acids	O
,	O
respectively	O
.	O

Alcohol	O
Dehydrogenase	O
,	O
Cytochrome	B
P450	I
,	O
Acyltransferase	O
,	O
and	O
Esterase	O
are	O
supposed	O
to	O
be	O
involved	O
in	O
azadirachtin	O
downstream	O
pathway	O
and	O
thus	O
their	O
encoding	O
-	O
unigenes	O
were	O
chosen	O
as	O
candidates	O
.	O

Among	O
all	O
the	O
Differentially	O
Expressed	O
Genes	O
in	O
fruit	O
and	O
leaf	O
transcriptome	O
data	O
,	O
Differentially	O
Expressed	O
Genes	O
encoding	O
Alcohol	O
Dehydrogenase	O
,	O
Cytochrome	B
P450	I
,	O
Acyltransferase	O
and	O
Esterase	O
were	O
discovered	O
.	O

As	O
for	O
Cytochrome	B
P450	I
,	O
sixteen	O
Differentially	O
Expressed	O
Genes	O
encoded	O
Cytochrome	B
P450	I
and	O
ten	O
Differentially	O
Expressed	O
Genes	O
were	O
selected	O
.	O

Among	O
all	O
the	O
Differentially	O
Expressed	O
Genes	O
in	O
fruit	O
and	O
leaf	O
transcriptome	O
data	O
,	O
Differentially	O
Expressed	O
Genes	O
encoding	O
Alcohol	O
Dehydrogenase	O
,	O
Cytochrome	B
P450	I
,	O
Acyltransferase	O
,	O
and	O
Esterase	O
were	O
identified	O
.	O

There	O
were	O
16	O
Differentially	O
Expressed	O
Genes	O
encoding	O
Cytochrome	B
P450	I
,	O
10	O
out	O
of	O
these	O
Differentially	O
Expressed	O
Genes	O
were	O
selected	O
.	O

According	O
to	O
the	O
phylogenetic	O
analysis	O
of	O
unigenes	O
encoding	O
Cytochrome	B
P450	I
,	O
5	O
transcripts	O
(	O
transcript	O
/	O
16057	O
,	O
transcript	O
/	O
16577	O
,	O
transcript	O
/	O
16950	O
,	O
transcript	O
/	O
16777	O
,	O
and	O
transcript	O
/	O
17001	O
)	O
were	O
grouped	O
with	O
members	O
in	O
CYP71	O
and	O
CYP72	O
clades	O
,	O
whose	O
members	O
are	O
reported	O
to	O
be	O
involved	O
in	O
terpenoid	O
biosynthesis	O
.	O

According	O
to	O
Cytochrome	B
P450	I
domain	O
analysis	O
,	O
transcript	O
/	O
17636	O
and	O
transcript	O
/	O
16971	O
contained	O
the	O
same	O
CypX	O
domain	O
as	O
CYP81B1	O
.	O

Therefore	O
,	O
5	O
Differentially	O
Expressed	O
Genes	O
(	O
transcript	O
/	O
16057	O
,	O
transcript	O
/	O
16	O
,	O
577	O
,	O
transcript	O
/	O
17057	O
,	O
transcript	O
/	O
16777	O
,	O
and	O
transcript	O
/	O
17001	O
)	O
contained	O
domains	O
found	O
within	O
Cytochrome	B
P450	I
oxidases	O
and	O
the	O
others	O
contained	O
domain	O
found	O
within	O
Cytochrome	B
P450	I
hydroxylase	O
.	O

Upon	O
bioinformatic	O
analysis	O
of	O
these	O
Differentially	O
Expressed	O
Genes	O
,	O
2	O
transcripts	O
(	O
transcript	O
/	O
18833	O
and	O
transcript	O
/	O
19291	O
)	O
encoding	O
Alcohol	O
Dehydrogenase	O
,	O
12	O
transcripts	O
encoding	O
Cytochrome	B
P450	I
,	O
2	O
Acyltransferase	O
transcripts	O
(	O
transcript	O
/	O
17792	O
and	O
transcript	O
/	O
18214	O
)	O
,	O
and	O
5	O
transcripts	O
encoding	O
Esterase	O
,	O
were	O
selected	O
as	O
candidates	O
in	O
the	O
azadirachtin	O
A	O
downstream	O
pathway	O
.	O

MaCYP71BQ5	O
is	O
the	O
Cytochrome	B
P450	I
found	O
to	O
be	O
involved	O
in	O
melianol	O
formation	O
.	O

Finally	O
,	O
22	O
unigenes	O
encoding	O
enzymes	O
including	O
2	O
,	O
3	O
-	O
Oxidosqualene	O
Cyclase	O
,	O
Alcohol	O
Dehydrogenase	O
,	O
Cytochrome	B
P450	I
,	O
Acyltransferase	O
,	O
and	O
Esterase	O
were	O
selected	O
as	O
candidates	O
involved	O
in	O
azadirachtin	O
A	O
downstream	O
pathway	O
.	O

The	O
SwissProt	O
database	O
was	O
queried	O
to	O
retrieve	O
all	O
reviewed	O
sequences	O
of	O
alcohol	O
dehydrogenase	O
,	O
Cytochrome	B
P450	I
,	O
acyltransferase	O
,	O
and	O
esterase	O
.	O

Next	O
,	O
molecular	O
docking	O
was	O
performed	O
with	O
Autodock	O
4	O
.	O
0	O
to	O
predict	O
the	O
interactions	O
of	O
four	O
triterpenoids	O
(	O
tirucalla	O
-	O
7	O
,	O
24	O
-	O
dien	O
-	O
3BETA	O
-	O
ol	O
,	O
azadirone	O
,	O
nimbin	O
,	O
and	O
nimbolide	O
)	O
as	O
substrates	O
for	O
the	O
Cytochrome	B
P450	I
proteins	O
.	O

For	O
covering	O
acting	O
domains	O
present	O
in	O
Cytochrome	B
P450	I
protein	O
,	O
grid	O
spacing	O
was	O
maintained	O
at	O
0	O
.	O
375	O
.	O

In	O
addition	O
to	O
the	O
conjugation	O
pathway	O
and	O
17	O
-	O
ketosteroid	O
pathway	O
,	O
hydroxylation	O
and	O
oxidation	O
of	O
hepatic	O
Cytochrome	B
P450	I
enzymes	I
are	O
additional	O
pathways	O
for	O
testosterone	O
metabolism	O
.	O

The	O
expression	O
of	O
additional	O
CYPs	O
(	O
Cyp1a1	O
,	O
Cyp1b1	O
,	O
Cyp2e1	B
)	O
was	O
observed	O
in	O
the	O
skin	O
of	O
C57BL	O
/	O
6J	O
mice	O
by	O
Flowers	O
et	O
al	O
.	O
.	O
In	O
the	O
mouse	O
skin	O
the	O
expression	O
of	O
several	O
Cyp	O
genes	O
was	O
demonstrated	O
on	O
the	O
RNA	O
level	O
.	O

Determination	O
of	O
(	O
CD	O
-	O
1	O
)	O
mouse	O
cutaneous	O
RNA	O
levels	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
showed	O
transcripts	O
arising	O
from	O
Cyp4f13	O
and	O
4f16	O
(	O
most	O
abundant	O
)	O
,	O
Cyp4f18	O
and	O
4f39	O
(	O
intermediate	O
)	O
,	O
Cyp4f14	O
,	O
4f17	O
,	O
and	O
4f37	O
(	O
low	O
)	O
,	O
and	O
from	O
Cyp4f15	O
and	O
Cyp4f40	O
(	O
highly	O
variable	O
or	O
too	O
low	O
to	O
measure	O
in	O
some	O
animals	O
)	O
(	O
Du	O
et	O
al	O
.	O
.	O
In	O
addition	O
,	O
the	O
expression	O
of	O
the	O
Cyp1a1	O
,	O
Cyp1b1	O
,	O
Cyp2e1	B
genes	O
was	O
observed	O
in	O
(	O
C57BL	O
/	O
6J	O
)	O
mouse	O
skin	O
(	O
Flowers	O
et	O
al	O
.	O
.	O
Interestingly	O
,	O
recent	O
studies	O
by	O
Borland	O
et	O
al	O
.	O

Expression	O
of	O
Cyp1b1	O
and	O
Cyp1a1	B
mRNAs	O
peaked	O
at	O
4	O
h	O
,	O
expression	O
of	O
Cyp3a11	O
mRNA	O
peaked	O
at	O
24	O
h	O
(	O
upregulation	O
of	O
Pregnane	O
X	O
Receptor	O
in	O
the	O
DMBA	O
-	O
treated	O
skin	O
was	O
confirmed	O
at	O
the	O
protein	O
level	O
)	O
.	O

Western	O
diet	O
and	O
benzo	O
[	O
a	O
]	O
pyrene	O
can	O
induce	O
fatty	O
liver	O
in	O
Cyp1a1	B
deficiency	O
mice	O
,	O
but	O
not	O
in	O
Wild	O
Type	O
mice	O
.	O

In	O
agreement	O
with	O
previous	O
studies	O
,	O
the	O
mRNA	O
levels	O
of	O
Cyp4a12	O
and	O
Cyp4a14	O
were	O
below	O
the	O
levels	O
of	O
detection	O
in	O
the	O
hearts	O
of	O
both	O
male	O
and	O
female	O
mice	O
in	O
the	O
current	O
study	O
(	O
data	O
not	O
shown	O
)	O
.	O

ZHX2	O
,	O
described	O
earlier	O
as	O
the	O
repressor	O
that	O
targets	O
H19	O
for	O
silencing	O
in	O
postnatal	O
liver	O
,	O
also	O
regulates	O
sexually	O
dimorphic	O
,	O
developmentally	O
-	O
regulated	O
P450	O
genes	O
in	O
the	O
liver	O
,	O
including	O
Cyp2a4	O
,	O
Cyp2b13	O
and	O
Cyp4a12	O
.	O

showed	O
that	O
the	O
metabolism	O
of	O
a	O
particular	O
drug	O
could	O
be	O
dominated	O
by	O
a	O
single	O
(	O
putative	O
)	O
P450	B
enzyme	I
.	O

The	O
gene	O
CYP4X1	O
encodes	O
an	O
orphan	O
Cytochromes	O
P450	B
enzyme	I
expressed	O
mainly	O
in	O
the	O
brain	O
,	O
aorta	O
,	O
or	O
breast	O
.	O

Detailed	O
stopped	O
-	O
flow	O
kinetics	O
of	O
binding	O
of	O
camphor	O
to	O
cytochrome	O
P450cam	B
have	O
been	O
studied	O
for	O
site	O
-	O
directed	O
mutants	O
of	O
P450cam	B
.	O

In	O
regard	O
to	O
results	O
presented	O
for	O
ellagic	O
acid	O
,	O
and	O
since	O
it	O
is	O
known	O
to	O
exert	O
inhibition	O
on	O
CYP2C9	O
,	O
its	O
effect	O
may	O
be	O
due	O
to	O
a	O
decrease	O
in	O
hepatic	O
first	O
-	O
pass	O
metabolism	O
of	O
warfarin	O
due	O
to	O
its	O
ability	O
to	O
inhibit	O
such	O
Cytochrome	B
P450	I
Enzymes	I
isoform	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
guava	O
leaves	O
extract	O
and	O
quercetin	O
to	O
inhibit	O
some	O
of	O
hepatic	O
Cytochrome	B
P450	I
Enzymes	I
isoforms	O
associated	O
with	O
warfarin	O
metabolism	O
such	O
as	O
CYP2C9	O
,	O
2C8	O
and	O
3A4	O
may	O
be	O
responsible	O
for	O
increasing	O
warfarin	O
plasma	O
concentration	O
[	O
,	O
.	O

In	O
vitro	O
warfarin	O
-	O
herb	O
interactions	O
and	O
their	O
effects	O
on	O
hepatic	O
Cytochrome	B
P450	I
Enzymes	I
isoforms	O
showed	O
that	O
CYP2C9	O
,	O
2C8	O
and	O
3A4	O
activities	O
in	O
primary	O
isolated	O
and	O
cultured	O
rat	O
hepatocytes	O
were	O
not	O
affected	O
by	O
warfarin	O
.	O

Since	O
Cytochrome	B
P450	I
Enzymes	I
isoforms	O
other	O
than	O
2C9	O
,	O
2C8	O
and	O
3A4	O
are	O
involved	O
in	O
warfarin	O
metabolism	O
,	O
further	O
study	O
with	O
more	O
focus	O
on	O
pomegranate	O
peel	O
and	O
its	O
constituents	O
is	O
therefore	O
suggested	O
.	O

To	O
achieve	O
this	O
,	O
the	O
hit	O
compounds	O
evaluated	O
for	O
either	O
substrate	O
or	O
inhibitors	O
of	O
Cytochrome	B
P450	I
Enzymes	I
along	O
with	O
Cytochrome	B
P450	I
Enzymes	I
of	O
Human	O
Liver	O
Microsomes	O
.	O

These	O
metabolism	O
properties	O
were	O
explored	O
in	O
silico	O
and	O
summarized	O
by	O
predicting	O
the	O
metabolic	O
sites	O
as	O
well	O
as	O
metabolites	O
,	O
and	O
type	O
of	O
Cytochrome	B
P450	I
Enzymes	I
involved	O
enzymes	O
,	O
which	O
catalyzes	O
xenobiotics	O
/	O
drugs	O
in	O
phase	O
II	O
metabolism	O
and	O
transform	O
the	O
small	O
molecules	O
to	O
water	O
-	O
soluble	O
form	O
,	O
which	O
may	O
lead	O
to	O
the	O
easy	O
elimination	O
of	O
xenobiotics	O
.	O

It	O
indicates	O
that	O
cytochrome	B
c	I
can	O
be	O
used	O
for	O
pathology	O
assessment	O
for	O
living	O
cells	O
.	O

Thus	O
,	O
the	O
peak	O
at	O
1337	O
cm	O
^	O
1	O
can	O
be	O
useful	O
to	O
distinguish	O
between	O
cytochrome	B
c	I
and	O
b	O
,	O
as	O
the	O
vibration	O
at	O
1337	O
cm	O
^	O
1	O
represents	O
a	O
unique	O
peak	O
of	O
the	O
reduced	O
cyt	O
b	O
(	O
ferrous	O
(	O
Fe	O
^	O
2	O
+	O
)	O
cytochrome	O
)	O
.	O

Hence	O
,	O
the	O
ratio	O
of	O
intensities	O
750	O
/	O
1126	O
can	O
be	O
used	O
to	O
estimate	O
the	O
relative	O
amount	O
of	O
reduced	O
cytochromes	O
c	O
,	O
c_1	O
versus	O
reduced	O
cytochromes	O
b	O
.	O
The	O
vibrations	O
of	O
cytochrome	B
c	I
that	O
are	O
resonance	O
Raman	O
enhanced	O
in	O
the	O
brain	O
and	O
breast	O
tissues	O
are	O
demonstrated	O
(	O
with	O
green	O
arrows	O
)	O
in	O
,	O
and	O
.	O

Symmetric	O
vibrational	O
modes	O
of	O
the	O
porphyrin	O
ligand	O
in	O
cytochrome	B
c	I
are	O
resonance	O
Raman	O
enhanced	O
to	O
a	O
greater	O
degree	O
using	O
excitation	O
wavelengths	O
within	O
the	O
Soret	O
absorption	O
peaks	O
at	O
408	O
nm	O
(	O
ferric	O
,	O
Fe	O
^	O
3	O
+	O
)	O
,	O
416	O
nm	O
(	O
ferrous	O
,	O
Fe	O
^	O
2	O
+	O
)	O
states	O
,	O
whereas	O
asymmetric	O
modes	O
are	O
enhanced	O
to	O
a	O
greater	O
degree	O
using	O
excitation	O
wavelengths	O
within	O
the	O
Q	O
absorption	O
peak	O
at	O
500	O
-	O
550	O
nm	O
.	O

Detailed	O
vibrational	O
assignment	O
of	O
cytochrome	B
c	I
can	O
be	O
found	O
in	O
ref	O
Q	O
-	O
resonant	O
Raman	O
spectra	O
contain	O
unusually	O
strong	O
depolarized	O
bands	O
.	O

The	O
bands	O
of	O
cytochrome	B
c	I
at	O
750	O
,	O
1126	O
,	O
1248	O
,	O
1310	O
,	O
1363	O
cm	O
^	O
1	O
are	O
depolarized	O
and	O
represent	O
the	O
reduced	O
form	O
.	O

The	O
band	O
at	O
1584	O
cm	O
^	O
1	O
represents	O
the	O
reduced	O
form	O
of	O
cytochrome	B
c	I
and	O
it	O
is	O
not	O
observed	O
in	O
the	O
oxidized	O
form	O
.	O

Some	O
of	O
the	O
peaks	O
of	O
the	O
oxidized	O
form	O
of	O
cytochrome	B
c	I
(	O
around	O
750	O
,	O
1130	O
,	O
1172	O
,	O
1314	O
,	O
1374	O
,	O
1570	O
-	O
1573	O
and	O
1634	O
cm	O
^	O
1	O
)	O
have	O
the	O
same	O
positions	O
as	O
the	O
reduced	O
form	O
,	O
but	O
their	O
intensities	O
are	O
significantly	O
lower	O
except	O
the	O
band	O
1634	O
cm	O
^	O
1	O
corresponding	O
to	O
the	O
ferric	O
cytochrome	B
c	I
as	O
presented	O
in	O
.	O

Our	O
results	O
in	O
show	O
that	O
the	O
Raman	O
intensities	O
of	O
the	O
reduced	O
form	O
of	O
cytochrome	B
c	I
(	O
cyt	O
c	O
Fe	O
^	O
2	O
+	O
)	O
are	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
oxidized	O
form	O
(	O
cyt	O
c	O
Fe	O
^	O
3	O
+	O
)	O
and	O
they	O
support	O
earlier	O
results	O
presented	O
in	O
the	O
literature	O
.	O

We	O
used	O
1584	O
cm	O
^	O
1	O
vibrational	O
mode	O
(	O
_19	O
)	O
as	O
a	O
marker	O
band	O
of	O
ferrous	O
cyt	O
c	O
in	O
brain	O
and	O
breast	O
cancer	O
tissues	O
,	O
_19	O
of	O
ferrous	O
heme	O
c	O
(	O
1582	O
cm	O
^	O
1	O
)	O
,	O
_2	O
of	O
ferric	O
heme	O
c	O
(	O
1585	O
cm	O
^	O
1	O
)	O
,	O
_19	O
of	O
ferrous	O
heme	O
cyt	O
b	O
(	O
1586	O
cm	O
^	O
1	O
)	O
and	O
_2	O
of	O
ferrous	O
heme	O
b	O
(	O
1583	O
cm	O
^	O
1	O
)	O
we	O
can	O
eliminate	O
from	O
our	O
discussion	O
all	O
ferric	O
modes	O
due	O
to	O
the	O
fact	O
that	O
the	O
resonance	O
Raman	O
intensities	O
of	O
the	O
ferric	O
modes	O
are	O
very	O
weak	O
in	O
comparison	O
to	O
the	O
ferrous	O
bands	O
except	O
the	O
band	O
1634	O
cm	O
^	O
1	O
corresponding	O
to	O
the	O
ferric	O
cytochrome	B
c	I
.	O
Thus	O
,	O
the	O
bands	O
at	O
1584	O
cm	O
^	O
1	O
(	O
reduced	O
cyt	O
c	O
)	O
and	O
at	O
1634	O
cm	O
^	O
1	O
(	O
oxidized	O
cyt	O
c	O
)	O
of	O
cytochrome	B
c	I
can	O
be	O
used	O
as	O
a	O
very	O
important	O
parameter	O
controlling	O
the	O
level	O
of	O
reduction	O
in	O
cancer	O
tissues	O
.	O

The	O
Raman	O
spectra	O
in	O
,	O
and	O
do	O
not	O
provide	O
information	O
about	O
the	O
distribution	O
of	O
cytochrome	B
c	I
in	O
the	O
cancer	O
tissue	O
.	O

To	O
learn	O
about	O
the	O
distribution	O
of	O
cytochrome	B
c	I
we	O
used	O
Raman	O
polarized	O
imaging	O
.	O

The	O
anomalously	O
polarized	O
band	O
at	O
1584	O
cm	O
^	O
1	O
appearing	O
in	O
the	O
Q	O
-	O
resonant	O
Raman	O
spectra	O
is	O
characteristic	O
of	O
cytochrome	B
c	I
.	O
This	O
result	O
additionally	O
supports	O
our	O
previous	O
findings	O
from	O
and	O
that	O
the	O
Q	O
-	O
resonant	O
Raman	O
band	O
at	O
1584	O
cm	O
^	O
1	O
in	O
the	O
breast	O
and	O
brain	O
tissues	O
represents	O
cytochrome	B
c	I
.	O
shows	O
microscopy	O
image	O
,	O
Raman	O
image	O
,	O
and	O
the	O
average	O
Raman	O
spectra	O
of	O
lipids	O
(	O
blue	O
)	O
,	O
proteins	O
(	O
red	O
)	O
,	O
cytochrome	O
(	O
green	O
)	O
,	O
mitochondrion	O
(	O
magenta	O
)	O
at	O
532	O
nm	O
at	O
different	O
experimental	O
geometries	O
for	O
Raman	O
scattering	O
:	O
without	O
polarization	O
analyzer	O
,	O
at	O
parallel	O
and	O
perpendicular	O
polarizations	O
of	O
the	O
incident	O
and	O
Raman	O
scattered	O
beams	O
for	O
infiltrating	O
ductal	O
cancer	O
(	O
malignancy	O
grade	O
G2	O
)	O
.	O

Since	O
Raman	O
scattering	O
at	O
1584	O
cm	O
^	O
1	O
is	O
not	O
observed	O
in	O
the	O
oxidized	O
form	O
of	O
cytochrome	B
c	I
the	O
band	O
at	O
1584	O
cm	O
^	O
1	O
originates	O
from	O
the	O
reduced	O
form	O
of	O
cytochromes	O
c	O
.	O
Our	O
results	O
demonstrate	O
that	O
the	O
Raman	O
intensity	O
of	O
1584	O
cm	O
^	O
1	O
peak	O
is	O
the	O
most	O
sensitive	O
vibration	O
of	O
redox	O
status	O
in	O
the	O
cell	O
and	O
is	O
related	O
to	O
the	O
amount	O
of	O
the	O
reduced	O
cytochromes	O
c	O
.	O
Therefore	O
,	O
we	O
used	O
1584	O
cm	O
^	O
1	O
to	O
study	O
the	O
redox	O
state	O
of	O
mitochondrial	O
cytochrome	B
c	I
in	O
brain	O
and	O
breast	O
ex	O
vivo	O
human	O
tissues	O
.	O

To	O
check	O
whether	O
the	O
redox	O
state	O
of	O
cytochrome	B
c	I
is	O
related	O
to	O
cancer	O
aggressiveness	O
we	O
used	O
the	O
Raman	O
redox	O
state	O
biomarker	O
represented	O
by	O
the	O
Raman	O
intensity	O
of	O
1584	O
cm	O
^	O
1	O
peak	O
.	O

A	O
shows	O
the	O
intensity	O
of	O
the	O
750	O
,	O
1126	O
,	O
1337	O
and	O
1584	O
cm	O
^	O
1	O
Raman	O
peak	O
of	O
cytochrome	B
c	I
as	O
a	O
function	O
of	O
grade	O
.	O

B	O
shows	O
the	O
data	O
for	O
1584	O
cm	O
^	O
1	O
band	O
of	O
reduced	O
cytochrome	B
c	I
for	O
breast	O
normal	O
(	O
G0	O
)	O
and	O
cancer	O
(	O
invasive	O
ductal	O
cancer	O
)	O
human	O
tissue	O
(	O
G1	O
,	O
G2	O
,	O
G3	O
)	O
.	O

Based	O
on	O
the	O
average	O
values	O
(	O
number	O
of	O
patients	O
n	O
=	O
39	O
)	O
obtained	O
for	O
the	O
Raman	O
biomarker	O
of	O
cytochrome	B
c	I
I_1584	O
we	O
obtained	O
a	O
plot	O
as	O
a	O
function	O
of	O
cancer	O
grade	O
malignancy	O
.	O

In	O
the	O
view	O
of	O
the	O
results	O
presented	O
in	O
it	O
is	O
evident	O
that	O
the	O
Raman	O
biomarker	O
I_1584	O
measuring	O
contribution	O
of	O
cytochrome	B
c	I
in	O
the	O
human	O
breast	O
tissues	O
correlates	O
with	O
breast	O
cancer	O
aggressiveness	O
.	O

The	O
intensity	O
of	O
the	O
1584	O
cm	O
^	O
1	O
Raman	O
signal	O
corresponding	O
to	O
the	O
amount	O
of	O
reduced	O
cytochrome	B
c	I
increases	O
with	O
increasing	O
cancer	O
aggressiveness	O
.	O

It	O
indicates	O
that	O
cytochrome	B
c	I
plays	O
a	O
crucial	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
cancer	O
.	O

The	O
parabolic	O
dependence	O
of	O
the	O
Raman	O
biomarker	O
I_1584	O
of	O
the	O
reduced	O
cytochrome	B
c	I
in	O
vs	O
cancer	O
malignancy	O
shows	O
that	O
the	O
optimal	O
concentration	O
of	O
cytochrome	B
c	I
that	O
are	O
needed	O
to	O
maintain	O
cellular	O
homeostasis	O
corresponds	O
to	O
the	O
normalized	O
intensity	O
of	O
0	O
.	O
006	O
0	O
.	O
003	O
for	O
the	O
breast	O
tissues	O
.	O

The	O
concentrations	O
of	O
the	O
reduced	O
cytochrome	B
c	I
at	O
this	O
level	O
modulate	O
protective	O
,	O
signaling	O
-	O
response	O
pathways	O
,	O
resulting	O
in	O
positive	O
effects	O
on	O
life	O
-	O
history	O
traits	O
.	O

The	O
reduced	O
cytochrome	B
c	I
level	O
above	O
the	O
value	O
of	O
0	O
.	O
06	O
0	O
.	O
02	O
triggers	O
a	O
toxic	O
runaway	O
process	O
and	O
aggressive	O
breast	O
cancer	O
development	O
.	O

The	O
plot	O
provides	O
an	O
important	O
cell	O
-	O
physiologic	O
response	O
,	O
normally	O
the	O
reduced	O
cytochrome	B
c	I
operates	O
at	O
low	O
,	O
basal	O
level	O
in	O
normal	O
cells	O
,	O
but	O
it	O
is	O
strongly	O
induced	O
to	O
very	O
high	O
levels	O
in	O
pathological	O
cancer	O
states	O
.	O

It	O
is	O
interesting	O
to	O
check	O
if	O
the	O
other	O
characteristic	O
bands	O
of	O
cytochrome	B
c	I
and	O
cytochrome	B
b	I
correlate	O
with	O
breast	O
cancer	O
grade	O
malignancy	O
G0	O
-	O
G3	O
.	O

We	O
analyzed	O
the	O
Raman	O
intensity	O
ratio	O
of	O
the	O
peaks	O
at	O
750	O
cm	O
^	O
1	O
and	O
1126	O
cm	O
^	O
1	O
to	O
evaluated	O
the	O
relative	O
contribution	O
of	O
cytochrome	B
c	I
and	O
b	O
(	O
see	O
B	O
,	O
C	O
)	O
.	O

It	O
indicates	O
that	O
the	O
relative	O
contribution	O
of	O
cytochrome	B
c	I
is	O
higher	O
than	O
cytochrome	B
b	I
when	O
the	O
grade	O
of	O
malignancy	O
increases	O
.	O

C	O
,	O
F	O
show	O
that	O
the	O
intensity	O
of	O
the	O
1584	O
cm	O
^	O
1	O
Raman	O
signal	O
corresponding	O
to	O
the	O
concentration	O
of	O
reduced	O
cytochrome	B
c	I
increases	O
with	O
increasing	O
brain	O
tumor	O
aggressiveness	O
.	O

To	O
check	O
whether	O
cytochromes	O
c	O
is	O
upregulated	O
in	O
brain	O
tumors	O
we	O
studied	O
the	O
Raman	O
signals	O
at	O
1584	O
cm	O
^	O
1	O
corresponding	O
to	O
concertation	O
of	O
cytochrome	B
c	I
as	O
a	O
function	O
of	O
brain	O
tumor	O
malignancy	O
by	O
using	O
WHO	O
grade	O
.	O

shows	O
the	O
Raman	O
intensities	O
of	O
characteristic	O
vibrations	O
in	O
brain	O
tissue	O
corresponding	O
to	O
concentration	O
of	O
reduced	O
cytochrome	B
c	I
.	O
One	O
can	O
see	O
that	O
for	O
the	O
brain	O
tumors	O
the	O
Raman	O
intensity	O
of	O
all	O
characteristic	O
vibrations	O
of	O
cytochrome	B
c	I
increases	O
with	O
increasing	O
cancer	O
aggressiveness	O
up	O
to	O
G3	O
and	O
then	O
slightly	O
decreases	O
for	O
G4	O
.	O

The	O
results	O
presented	O
in	O
the	O
paper	O
suggest	O
that	O
the	O
redox	O
-	O
sensitive	O
peak	O
observed	O
at	O
1584	O
cm	O
^	O
1	O
with	O
excitation	O
at	O
532	O
nm	O
is	O
specifically	O
linked	O
to	O
cytochrome	B
c	I
.	O
and	O
can	O
be	O
considered	O
to	O
be	O
a	O
redox	O
state	O
marker	O
of	O
the	O
ferric	O
low	O
spin	O
heme	O
in	O
cyt	O
c	O
,	O
assigned	O
to	O
the	O
v_19	O
mode	O
,	O
vibrations	O
of	O
methine	O
bridges	O
(	O
CALPHAC	O
,	O
CALPHACH	O
bonds	O
)	O
and	O
the	O
CALPHACBETA	O
bond	O
.	O

We	O
found	O
that	O
concentration	O
of	O
cytochrome	B
c	I
is	O
upregulated	O
in	O
brain	O
and	O
breast	O
cancers	O
.	O

The	O
intensities	O
of	O
the	O
1584	O
cm	O
^	O
1	O
Raman	O
signal	O
corresponding	O
to	O
the	O
amount	O
of	O
the	O
reduced	O
cytochrome	B
c	I
increases	O
with	O
increasing	O
cancer	O
aggressiveness	O
.	O

We	O
found	O
the	O
dependence	O
of	O
the	O
Raman	O
biomarker	O
I_1584	O
of	O
the	O
reduced	O
cytochrome	B
c	I
vs	O
grade	O
of	O
cancer	O
malignancy	O
which	O
shows	O
that	O
the	O
optimal	O
concentration	O
of	O
cytochrome	B
c	I
that	O
are	O
needed	O
to	O
maintain	O
cellular	O
homeostasis	O
corresponds	O
to	O
the	O
normalized	O
Raman	O
intensity	O
of	O
0	O
.	O
006	O
0	O
.	O
003	O
for	O
the	O
breast	O
tissue	O
and	O
0	O
.	O
074	O
0	O
.	O
005	O
for	O
the	O
brain	O
tissue	O
.	O

The	O
reduced	O
cytochrome	B
c	I
level	O
above	O
these	O
values	O
triggers	O
a	O
toxic	O
runaway	O
process	O
and	O
aggressive	O
cancer	O
development	O
.	O

The	O
relation	O
between	O
the	O
Raman	O
signal	O
intensity	O
at	O
1584	O
cm	O
^	O
1	O
of	O
the	O
reduced	O
cytochrome	B
c	I
vs	O
cancer	O
grade	O
provides	O
an	O
important	O
cell	O
-	O
physiologic	O
response	O
demonstrating	O
that	O
the	O
reduced	O
cytochrome	B
c	I
operates	O
at	O
low	O
,	O
basal	O
level	O
in	O
normal	O
cells	O
,	O
but	O
it	O
is	O
strongly	O
induced	O
to	O
very	O
high	O
levels	O
in	O
pathological	O
cancer	O
states	O
.	O

We	O
analyzed	O
the	O
Raman	O
intensity	O
ratio	O
of	O
the	O
peaks	O
at	O
750	O
cm	O
^	O
1	O
and	O
1126	O
cm	O
^	O
1	O
to	O
evaluate	O
the	O
relative	O
contribution	O
of	O
cytochrome	B
c	I
and	O
b	O
in	O
human	O
breast	O
tissue	O
as	O
a	O
function	O
of	O
breast	O
cancer	O
grade	O
malignancy	O
G0	O
-	O
G3	O
at	O
excitation	O
532	O
nm	O
.	O

We	O
found	O
that	O
the	O
relative	O
contribution	O
of	O
cytochrome	B
c	I
is	O
higher	O
than	O
cytochrome	B
b	I
when	O
the	O
grade	O
of	O
malignancy	O
increases	O
.	O

Given	O
that	O
the	O
Raman	O
spectra	O
underling	O
the	O
relRI	O
trends	O
were	O
recorded	O
from	O
individual	O
cells	O
in	O
a	O
monolayer	O
of	O
cells	O
,	O
this	O
indicated	O
a	O
significantly	O
higher	O
active	O
cytochrome	B
-	I
c	I
content	O
per	O
cell	O
for	O
N	O
.	O
eutropha	O
and	O
Nitrosospira	O
grown	O
under	O
oxygen	O
-	O
deprived	O
conditions	O
than	O
was	O
seen	O
in	O
cells	O
grown	O
in	O
oxygen	O
abundance	O
.	O

The	O
ER	O
-	O
bound	O
enzyme	O
complex	O
belongs	O
to	O
the	O
cytochrome	B
P450	I
superfamily	I
.	O

The	O
metabolic	O
activation	O
of	O
PCBs	O
is	O
initiated	O
by	O
cytochrome	B
p450	I
(	O
CYP	O
)	O
family	O
members	O
and	O
includes	O
the	O
oxidation	O
of	O
PCBs	O
to	O
OH	O
-	O
PCBs	O
.	O

As	O
synthetic	O
OH	O
-	O
metabolites	O
of	O
PCB	O
28	O
-	O
induced	O
cytotoxicity	O
in	O
a	O
model	O
cell	O
culture	O
system	O
^	O
,	O
we	O
conclude	O
that	O
PCB	O
28	O
bioactivation	O
by	O
cytochrome	B
p450	I
(	O
Cyp	O
)	O
enzymes	O
leads	O
to	O
toxicity	O
in	O
Drosophila	O
.	O

However	O
,	O
several	O
factors	O
,	O
including	O
differences	O
in	O
intracellular	O
pH	O
,	O
membrane	O
lipid	O
composition	O
of	O
the	O
ER	O
(	O
relevant	O
for	O
ER	O
-	O
membrane	O
-	O
anchored	O
OSCs	O
and	O
P450s	O
)	O
,	O
and	O
availability	O
of	O
dedicated	O
co	O
-	O
factors	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
specialized	O
cytochrome	B
b5	I
enzymes	O
,	O
are	O
generally	O
regarded	O
to	O
cause	O
a	O
plant	O
enzyme	O
not	O
to	O
function	O
properly	O
in	O
a	O
yeast	O
cell	O
.	O

The	O
Photosynthetic	O
Electron	O
Transfer	O
Chain	O
employs	O
three	O
membrane	O
protein	O
complexes	O
:	O
PSI	O
,	O
PSII	O
,	O
their	O
respective	O
light	O
-	O
harvesting	O
complexes	O
(	O
LHCI	O
and	O
LHCII	O
)	O
,	O
and	O
the	O
cytochrome	O
b6	O
/	O
f	O
complex	O
(	O
Cyt	O
b6f	O
,	O
a	O
plastoquinol	O
-	O
plastocyanin	O
-	O
oxidoreductase	O
)	O
.	O

Formation	O
of	O
21	O
mol	O
O_2	O
^	O
(	O
mg	O
Chl	O
)	O
^	O
1	O
h	O
^	O
1	O
,	O
measured	O
as	O
an	O
SOD	O
-	O
dependent	O
cytochrome	O
c	O
reduction	O
,	O
was	O
observed	O
in	O
D1	O
/	O
D2	O
/	O
cytochrome	O
b559	O
complexes	O
illuminated	O
at	O
200	O
W	O
m	O
^	O
2	O
in	O
the	O
presence	O
of	O
an	O
artificial	O
electron	O
donor	O
.	O

Subcellular	O
localization	O
of	O
Carbon	O
Monoxide	O
can	O
also	O
regulate	O
ROS	O
production	O
,	O
for	O
instance	O
Taill	O
and	O
colleagues	O
have	O
demonstrated	O
that	O
CORM	O
-	O
2	O
treatment	O
inhibited	O
the	O
activity	O
of	O
NAD	O
(	O
P	O
)	O
H	O
oxidase	O
cytochrome	O
b_558	O
,	O
which	O
decreases	O
plasmatic	O
membrane	O
ROS	O
production	O
,	O
while	O
there	O
is	O
an	O
increase	O
on	O
mitochondrial	O
ROS	O
generation	O
by	O
targeting	O
cytochrome	O
c	O
oxidase	O
.	O

Under	O
Coos1	O
Is	O
Frame	O
-	O
Shifted	O
conditions	O
,	O
the	O
expression	O
levels	O
of	O
hyd	O
-	O
3b	O
genes	O
(	O
KKC1_RS10620	O
-	O
KKC1_RS10635	O
)	O
encoding	O
group	O
3b	O
[	O
NiFe	O
]	O
hydrogenase	O
catalytic	O
subunits	O
and	O
their	O
maturation	O
protease	O
were	O
upregulated	O
,	O
whereas	O
those	O
of	O
hyd	O
-	O
1a	O
genes	O
(	O
KKC1_RS00385	O
-	O
KKC1_RS00400	O
)	O
encoding	O
group	O
1a	O
[	O
NiFe	O
]	O
hydrogenase	O
catalytic	O
subunits	O
,	O
a	O
cytochrome	B
b	I
subunit	O
,	O
and	O
their	O
maturation	O
protease	O
were	O
downregulated	O
.	O

Conversely	O
,	O
the	O
group	O
1a	O
[	O
NiFe	O
]	O
hydrogenase	O
is	O
a	O
periplasmic	O
,	O
unidirectional	O
H_2	O
-	O
uptake	O
hydrogenase	O
,	O
and	O
the	O
cytochrome	B
b	I
subunit	O
is	O
considered	O
a	O
putative	O
electron	O
carrier	O
,	O
as	O
are	O
other	O
group	O
1	O
hydrogenases	O
(	O
Greening	O
et	O
al	O
.	O

One	O
of	O
these	O
peaks	O
characterizes	O
more	O
than	O
1	O
,	O
000	O
different	O
sequences	O
of	O
mitochondrial	O
cytochrome	B
b	I
molecules	O
at	O
p	O
=	O
379	O
.	O

However	O
,	O
in	O
the	O
case	O
p	O
=	O
379	O
,	O
out	O
of	O
1	O
,	O
889	O
proteins	O
,	O
1	O
,	O
048	O
(	O
two	O
-	O
thirds	O
)	O
are	O
mitochondrial	O
cytochrome	B
b	I
.	O
This	O
value	O
is	O
approximately	O
equal	O
to	O
that	O
part	O
of	O
the	O
peak	O
that	O
rises	O
above	O
the	O
total	O
mass	O
of	O
protein	O
lengths	O
in	O
.	O

For	O
a	O
large	O
number	O
of	O
differing	O
amino	O
acid	O
residue	O
sequences	O
,	O
but	O
with	O
the	O
same	O
p	O
-	O
value	O
,	O
cytochrome	B
b	I
is	O
precisely	O
typical	O
as	O
being	O
representative	O
of	O
animals	O
.	O

Some	O
of	O
the	O
major	O
topics	O
that	O
the	O
speakers	O
discussed	O
were	O
whether	O
P450	O
was	O
synthesized	O
in	O
the	O
rough	O
or	O
smooth	O
endoplasmic	O
reticulum	O
,	O
whether	O
there	O
were	O
one	O
or	O
two	O
P450s	O
(	O
some	O
questioned	O
whether	O
changes	O
in	O
phospholipids	O
might	O
be	O
responsible	O
for	O
the	O
altered	O
activities	O
)	O
,	O
the	O
role	O
of	O
cytochrome	B
b_5	I
(	O
Estabrook	O
,	O
Mannering	O
)	O
,	O
the	O
purification	O
of	O
P450	O
from	O
rabbit	O
liver	O
(	O
Coon	O
,	O
Sato	O
)	O
,	O
the	O
chemical	O
mechanism	O
(	O
s	O
)	O
of	O
catalysis	O
(	O
Ullrich	O
,	O
McMahon	O
,	O
Udenfriend	O
,	O
Daly	O
,	O
Witkop	O
,	O
Jerina	O
)	O
,	O
and	O
the	O
biological	O
basis	O
of	O
P450	O
induction	O
.	O

Curiously	O
,	O
plant	O
-	O
like	O
hallmark	O
electron	O
transfer	O
enzymes	O
and	O
transporters	O
are	O
found	O
throughout	O
the	O
genome	O
,	O
such	O
as	O
a	O
cytochrome	O
b6c1	O
complex	O
and	O
a	O
CO2	O
-	O
concentrating	O
transporter	O
.	O

In	O
the	O
previous	O
genome	O
an	O
operon	O
annotated	O
as	O
a	O
cytochrome	O
b_6f	O
was	O
annotated	O
.	O

However	O
,	O
while	O
genes	O
indeed	O
include	O
a	O
cytochrome	O
b_6	O
,	O
there	O
is	O
no	O
homology	O
to	O
a	O
cytochrome	O
f	O
,	O
but	O
there	O
is	O
to	O
a	O
cytochrome	O
c_1	O
.	O

This	O
leads	O
us	O
to	O
believe	O
that	O
this	O
organism	O
has	O
a	O
cytochrome	O
b_6c_1	O
,	O
which	O
is	O
a	O
novel	O
-	O
hybrid	O
type	O
complex	O
III	O
also	O
found	O
in	O
G	O
.	O
stearothermophilus	O
(	O
Sone	O
et	O
al	O
.	O
.	O
Curiously	O
,	O
the	O
iron	O
-	O
sulfur	O
cluster	O
of	O
C	O
.	O
thermarum	O
TA2	O
.	O

Supporting	O
this	O
proposition	O
,	O
while	O
a	O
b_6c_1	O
has	O
not	O
been	O
examined	O
,	O
a	O
synthetically	O
constructed	O
b_6c_1	O
was	O
constructed	O
and	O
was	O
able	O
to	O
functionally	O
replace	O
a	O
cytochrome	O
b_6f	O
in	O
Rhodobacter	O
capsulatus	O
in	O
the	O
process	O
of	O
cellular	O
photosynthesis	O
(	O
Saribas	O
et	O
al	O
.	O
.	O
At	O
the	O
electron	O
-	O
accepting	O
end	O
of	O
the	O
respiratory	O
chain	O
,	O
C	O
.	O
thermarum	O
TA2	O
.	O

These	O
similarities	O
include	O
a	O
cytochrome	O
b_6c_1	O
complex	O
that	O
is	O
a	O
possible	O
homolog	O
of	O
the	O
plant	O
cytochrome	O
b_6f	O
,	O
the	O
similarity	O
in	O
F_1F_O	O
-	O
ATP	O
synthase	O
c	O
-	O
subunit	O
rotor	O
ring	O
size	O
,	O
and	O
the	O
means	O
to	O
capture	O
inorganic	O
carbon	O
.	O

The	O
family	O
of	O
cytochromes	O
are	O
localized	O
in	O
the	O
third	O
complex	O
in	O
the	O
electron	O
transport	O
chain	O
,	O
also	O
known	O
as	O
complex	O
III	O
or	O
Coenzyme	O
Q	O
-	O
Cyt	O
c	O
reductase	O
,	O
sometimes	O
called	O
the	O
cytochrome	O
bc_1	O
complex	O
(	O
cytochrome	B
b	I
,	O
cytochrome	O
c_1	O
)	O
,	O
as	O
well	O
as	O
in	O
cytochrome	O
c	O
loosely	O
associated	O
with	O
the	O
inner	O
membrane	O
of	O
the	O
mitochondrion	O
.	O

Using	O
different	O
excitations	O
,	O
we	O
are	O
able	O
to	O
monitor	O
contribution	O
of	O
cytochrome	O
family	O
in	O
the	O
electron	O
transfer	O
chain	O
in	O
the	O
mitochondrial	O
respiration	O
originating	O
from	O
cytochrome	B
b	I
,	O
c_1	O
in	O
complex	O
III	O
,	O
cytochrome	O
c	O
,	O
and	O
a	O
,	O
a_3	O
cytochromes	O
in	O
complex	O
IV	O
.	O

The	O
amount	O
of	O
cytochrome	B
b	I
is	O
practically	O
the	O
same	O
for	O
all	O
grades	O
of	O
brain	O
tumor	O
.	O

(	O
presence	O
of	O
CYP	O
and	O
cytochrome	B
b5	I
)	O
.	O

In	O
addition	O
,	O
plants	O
express	O
redox	O
co	O
-	O
factors	O
dedicated	O
to	O
secondary	O
metabolism	O
,	O
such	O
as	O
specialized	O
cytochrome	B
b5	I
proteins	O
,	O
and	O
many	O
CYPs	O
depend	O
on	O
such	O
co	O
-	O
factors	O
for	O
optimal	O
activity	O
.	O

EROD	B
activity	O
was	O
determined	O
using	O
the	O
methods	O
of	O
Peters	O
et	O
al	O
.	O
,	O
with	O
mild	O
modifications	O
.	O

EROD	B
enzyme	O
activity	O
assay	O
was	O
conducted	O
applying	O
the	O
complex	O
mixtures	O
of	O
Alternaria	O
toxins	O
to	O
test	O
their	O
potential	O
to	O
activate	O
the	O
Aryl	O
Hydrocarbon	O
Receptor	O
signalling	O
pathway	O
.	O

Progestin	O
receptor	O
membrane	O
component	O
1	O
is	O
a	O
single	O
transmembrane	O
heme	O
-	O
binding	O
protein	O
containing	O
a	O
cytochrome	B
b_5	I
motif	O
,	O
which	O
has	O
been	O
proposed	O
as	O
a	O
progesterone	O
binding	O
protein	O
in	O
vertebrates	O
(	O
,	O
.	O

For	O
example	O
,	O
Progestin	O
Receptor	O
Membrane	O
Component	O
1	O
is	O
a	O
heme	O
-	O
binding	O
protein	O
with	O
a	O
cytochrome	B
b_5	I
motif	O
,	O
which	O
binds	O
and	O
activates	O
P450	O
proteins	O
and	O
is	O
involved	O
in	O
steroidogenesis	O
and	O
drug	O
metabolism	O
.	O

Pgrmc1	O
has	O
a	O
role	O
in	O
the	O
regulation	O
of	O
cholesterol	O
and	O
steroid	O
synthesis	O
because	O
of	O
its	O
cytochrome	B
b_5	I
motif	O
and	O
its	O
ability	O
to	O
bind	O
and	O
activate	O
P450	O
proteins	O
(	O
,	O
.	O

The	O
recombinant	O
baculosomes	O
with	O
hyperexpressed	O
CYP3A4	O
and	O
coexpressed	O
NADPH	O
cytochrome	O
P450	O
reductase	O
and	O
cytochrome	B
b_5	I
,	O
was	O
used	O
as	O
source	O
of	O
enzyme	O
.	O

Progesterone	O
receptor	O
membrane	O
component	O
1	O
is	O
a	O
multifunctional	O
protein	O
with	O
a	O
C	O
-	O
terminal	O
cytochrome	B
b_5	I
domain	O
^	O
.	O

Progesterone	O
Receptor	O
Membrane	O
Component1	O
regulates	O
cell	O
proliferation	O
and	O
apoptosis	O
in	O
granulosa	O
and	O
luteal	O
cells	O
via	O
interaction	O
between	O
its	O
cytoplasmic	O
cytochrome	B
b_5	I
binding	O
domain	O
(	O
amino	O
acids	O
70	O
-	O
130	O
)	O
and	O
plasminogen	O
activator	O
inhibitor	O
RNA	O
-	O
binding	O
protein	O
-	O
1	O
(	O
PAIR	O
-	O
BP1	O
)	O
^	O
,	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
17	O
,	O
20	O
-	O
lyase	O
activity	O
of	O
CYP17A1	O
is	O
dependent	O
on	O
augmentation	O
by	O
cytochrome	B
b_5	I
(	O
CYB5A	O
)	O
in	O
addition	O
to	O
electron	O
transfer	O
from	O
P450	O
Oxidoreductase	O
.	O

In	O
the	O
mammalian	O
liver	O
,	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-	O
anchored	O
P450s	O
function	O
together	O
with	O
their	O
redox	O
partners	O
cytochrome	O
P450	O
reductase	O
and	O
cytochrome	B
b_5	I
in	O
the	O
oxidative	O
metabolism	O
and	O
elimination	O
of	O
numerous	O
endobiotics	O
(	O
arachidonic	O
acid	O
,	O
retinoic	O
acid	O
,	O
steroids	O
,	O
vitamin	O
D	O
)	O
as	O
well	O
as	O
xenobiotics	O
(	O
pharmacological	O
and	O
recreational	O
drugs	O
,	O
carcinogens	O
,	O
toxins	O
and	O
other	O
foreign	O
substances	O
of	O
dietary	O
or	O
environmental	O
origin	O
)	O
,	O
.	O

Hepatocyte	O
spheroids	O
formed	O
in	O
this	O
device	O
were	O
subjected	O
to	O
different	O
flow	O
rates	O
,	O
of	O
which	O
a	O
flow	O
rate	O
of	O
50	O
L	O
/	O
min	O
provided	O
the	O
optimal	O
microenvironment	O
for	O
spheroid	O
formation	O
,	O
maintained	O
significantly	O
higher	O
rates	O
of	O
albumin	O
and	O
urea	O
synthesis	O
,	O
yielded	O
higher	O
CYP3A1	O
(	O
cytochrome	O
P450	O
3A1	O
)	O
and	O
CYP2C11	O
(	O
cytochrome	O
P450	O
2C11	O
)	O
enzyme	O
activities	O
for	O
metabolism	O
,	O
and	O
demonstrated	O
higher	O
expression	O
levels	O
of	O
liver	O
-	O
specific	O
genes	O
.	O

Markers	O
of	O
pharmacokinetics	O
/	O
toxicity	O
:	O
(	O
1	O
)	O
Sofarenib	O
metabolism	O
:	O
The	O
metabolism	O
of	O
sorafenib	O
is	O
well	O
-	O
established	O
and	O
occurs	O
mainly	O
in	O
the	O
liver	O
through	O
two	O
pathways	O
:	O
Phase	O
I	O
oxidation	O
mediated	O
by	O
cytochrome	B
P450	I
3A4	I
,	O
and	O
phase	O
II	O
conjugation	O
mediated	O
by	O
UDP	O
glucuronosyltransferase	O
1A9	O
.	O

Moreover	O
,	O
up	O
-	O
regulation	O
of	O
genes	O
coding	O
for	O
cytochrome	B
P	I
-	I
450	I
and	O
monooxygenase	O
by	O
the	O
red	O
and	O
blue	O
light	O
,	O
respectively	O
,	O
which	O
was	O
observed	O
in	O
our	O
analysis	O
,	O
seem	O
to	O
support	O
the	O
role	O
of	O
putative	O
white	O
collar	O
proteins	O
or	O
phytochromes	O
in	O
AMPK	O
and	O
MAPK	O
based	O
signal	O
transduction	O
.	O

The	O
low	O
-	O
spin	O
soluble	O
cyt	O
c	O
of	O
mitochondria	O
in	O
which	O
the	O
heme	O
-	O
attachment	O
site	O
is	O
located	O
towards	O
the	O
N	O
-	O
terminus	O
,	O
and	O
the	O
sixth	O
ligand	O
located	O
towards	O
the	O
C	O
-	O
terminus	O
belongs	O
to	O
class	O
I	O
.	O
Cytochrome	B
c	I
transfers	O
electrons	O
from	O
complex	O
III	O
to	O
complex	O
IV	O
,	O
also	O
known	O
as	O
cytochrome	O
oxidase	O
,	O
which	O
is	O
the	O
final	O
enzyme	O
of	O
the	O
electron	O
transport	O
system	O
.	O

Cytochrome	B
c	I
,	O
which	O
is	O
reduced	O
to	O
cyt	O
c	O
Fe	O
^	O
2	O
+	O
(	O
ferrous	O
)	O
by	O
the	O
electron	O
from	O
the	O
complex	O
III	O
,	O
passes	O
an	O
electron	O
to	O
the	O
copper	O
binuclear	O
center	O
,	O
being	O
oxidized	O
back	O
to	O
cytochrome	O
c	O
(	O
cyt	O
c	O
Fe	O
^	O
3	O
+	O
(	O
ferric	O
)	O
)	O
.	O

The	O
overall	O
human	O
brain	O
samples	O
statistic	O
was	O
:	O
n	O
(	O
G0	O
)	O
=	O
1	O
,	O
n	O
(	O
G1	O
)	O
=	O
17	O
,	O
n	O
(	O
G2	O
)	O
=	O
9	O
,	O
n	O
(	O
G3	O
)	O
=	O
4	O
,	O
n	O
(	O
G4	O
)	O
=	O
13	O
,	O
where	O
G0	O
describes	O
healthy	O
tissue	O
,	O
G1	O
,	O
G2	O
,	O
G3	O
,	O
G4	O
the	O
cancer	O
tissues	O
with	O
increasing	O
malignancy	O
grade	O
Cytochrome	B
c	I
from	O
the	O
equine	O
heart	O
(	O
C7752	O
,	O
Sigma	O
-	O
Aldrich	O
,	O
Pozna	O
,	O
Poland	O
)	O
was	O
used	O
without	O
additional	O
purification	O
.	O

In	O
summary	O
,	O
we	O
conclude	O
that	O
nicotine	O
metabolism	O
by	O
CYP2B6	B
is	O
stereoselective	O
,	O
and	O
common	O
polymorphisms	O
in	O
CYP2B6	B
significantly	O
influence	O
the	O
oxidation	O
of	O
both	O
(	O
S	O
)	O
and	O
(	O
R	O
)	O
nicotine	O
to	O
nicotine	O
iminium	O
and	O
nornicotine	O
.	O

However	O
,	O
the	O
small	O
contribution	O
of	O
CYP2B6	B
to	O
nicotine	O
metabolism	O
in	O
the	O
liver	O
,	O
and	O
its	O
undetectable	O
activity	O
in	O
human	O
brain	O
tissue	O
,	O
make	O
it	O
highly	O
unlikely	O
that	O
this	O
genetic	O
variation	O
influences	O
complex	O
smoking	O
behaviors	O
.	O

Moreover	O
,	O
even	O
if	O
sorafenib	O
is	O
not	O
a	O
substrate	O
for	O
the	O
cytochrome	O
isoforms	O
CYP2B6	B
,	O
CYP2C8	O
,	O
and	O
CYP2C9	O
and	O
the	O
UDP	O
glucuronosyltransferase	O
UGT1A1	O
,	O
the	O
biological	O
agent	O
in	O
vivo	O
inhibits	O
activity	O
of	O
these	O
enzymes	O
with	O
potential	O
pharmacological	O
consequences	O
and	O
drug	O
-	O
interaction	O
events	O
.	O

Regorafenib	O
and	O
its	O
major	O
metabolites	O
are	O
also	O
reported	O
to	O
inhibit	O
a	O
number	O
of	O
cytochromes	O
(	O
CYP2C8	O
,	O
CYP2C9	O
,	O
CYP2B6	B
,	O
Cytochrome	O
P450	O
3a4	O
,	O
CYP2D6	O
)	O
,	O
UGT1A	O
enzymes	O
(	O
UGT1A9	O
,	O
UGT1A1	O
)	O
,	O
and	O
transporters	O
(	O
BCRP	O
)	O
and	O
induce	O
others	O
(	O
CYP1A2	O
,	O
CYP2B6	B
,	O
CYP2C19	O
,	O
CYP3A4	O
)	O
with	O
potential	O
alteration	O
in	O
the	O
exposure	O
of	O
co	O
-	O
administered	O
drugs	O
.	O

One	O
knockdown	O
(	O
CYP303a1	O
,	O
human	O
orthologue	O
CYP2B6	B
)	O
never	O
showed	O
the	O
uptake	O
of	O
PCB	O
28	O
and	O
was	O
therefore	O
excluded	O
from	O
further	O
analysis	O
.	O

Among	O
the	O
166	O
patients	O
who	O
were	O
tested	O
for	O
the	O
CYP2B6	B
gene	O
,	O
the	O
most	O
common	O
phenotype	O
was	O
EM	O
(	O
Extensive	O
Metabolizer	O
)	O
(	O
50	O
.	O
00	O
%	O
,	O
n	O
.	O

The	O
genes	O
that	O
are	O
overexpressed	O
in	O
Theca	O
cells	O
(	O
cluster	O
4	O
)	O
are	O
particularly	O
involved	O
in	O
cholesterol	O
import	O
(	O
SCARB1	O
,	O
STARD5	O
)	O
,	O
bile	O
acid	O
metabolism	O
(	O
CH25H	O
)	O
,	O
HDL	O
-	O
mediated	O
lipid	O
transport	O
(	O
APOA1	O
,	O
PLTP	O
,	O
SCARB1	O
)	O
,	O
lipid	O
degradation	O
(	O
LPL	O
,	O
PLIN5	O
)	O
,	O
and	O
steroidogenesis	O
(	O
CYP27A	O
,	O
CYP7B1	O
,	O
TM7SF2	O
)	O
.	O

Further	O
analysis	O
showed	O
a	O
significant	O
negative	O
correlation	O
between	O
LC3II	O
/	O
I	O
ratio	O
and	O
cell	O
viability	O
(	O
P	O
<	O
.	O
01	O
)	O
,	O
and	O
apoptosis	O
rate	O
,	O
cytochrome	B
C	I
and	O
cleaved	O
caspase3	O
correlated	O
positively	O
with	O
LC3II	O
/	O
I	O
ratio	O
.	O

As	O
shown	O
in	O
Figure	O
BE	O
,	O
cell	O
viability	O
was	O
significantly	O
increased	O
,	O
apoptosis	O
rate	O
,	O
expressions	O
of	O
cytochrome	B
C	I
and	O
cleaved	O
caspase3	O
were	O
remarkably	O
decreased	O
by	O
3MA	O
pretreatment	O
compared	O
with	O
the	O
corresponding	O
bubble	O
alone	O
groups	O
of	O
10	O
,	O
20	O
and	O
30	O
minutes	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

3MA	O
induced	O
a	O
significant	O
decrease	O
in	O
cell	O
viability	O
as	O
well	O
increases	O
in	O
apoptosis	O
rate	O
,	O
cytochrome	B
C	I
and	O
cleaved	O
caspase3	O
in	O
1	O
or	O
5	O
minutes	O
groups	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

A	O
descriptive	O
study	O
assessed	O
Cytochrome	B
P450	I
3a4	I
and	O
Udp	O
Glucuronosyltransferase	O
1a9	O
genetic	O
variability	O
by	O
sequencing	O
the	O
germline	O
DNA	O
of	O
three	O
patients	O
with	O
metastatic	O
colorectal	O
cancer	O
experiencing	O
severe	O
toxic	O
hepatitis	O
after	O
sorafenib	O
treatment	O
and	O
reported	O
that	O
two	O
patients	O
were	O
heterozygous	O
for	O
the	O
UGT1A9	O
*	O
22	O
(	O
rs3832043	O
)	O
polymorphism	O
.	O

This	O
drug	O
undergoes	O
hepatic	O
metabolism	O
by	O
Cytochrome	B
P450	I
3a4	I
and	O
,	O
to	O
a	O
minor	O
extent	O
,	O
by	O
CYP2C9	O
.	O

Lenvatinib	O
is	O
metabolized	O
in	O
liver	O
microsomes	O
mostly	O
through	O
Cytochrome	B
P450	I
3a4	I
(	O
>	O
80	O
%	O
)	O
and	O
,	O
to	O
a	O
minor	O
extent	O
,	O
by	O
aldehyde	O
oxidase	O
and	O
acts	O
as	O
a	O
substrate	O
for	O
Atp	O
-	O
Binding	O
Cassette	O
transporters	O
,	O
encoded	O
by	O
the	O
ABCB1	O
and	O
ABCG2	O
genes	O
,	O
such	O
as	O
BCRP	O
and	O
P	O
-	O
glycoprotein	O
.	O

The	O
results	O
demonstrate	O
that	O
cytochrome	B
b	I
5	I
plays	O
a	O
dual	O
role	O
in	O
the	O
CYP3A4	O
-	O
catalyzed	O
oxidation	O
of	O
ellipticine	O
:	O
(	O
1	O
)	O
cytochrome	B
b	I
5	I
mediates	O
CYP3A4	O
catalytic	O
activities	O
by	O
donating	O
the	O
first	O
and	O
second	O
electron	O
to	O
this	O
enzyme	O
in	O
its	O
catalytic	O
cycle	O
,	O
indicating	O
that	O
NADH	O
:	O
cytochrome	B
b	I
5	I
reductase	O
can	O
substitute	O
NADPH	O
-	O
dependent	O
POR	O
in	O
this	O
enzymatic	O
reaction	O
and	O
(	O
2	O
)	O
cytochrome	B
b	I
5	I
can	O
act	O
as	O
an	O
allosteric	O
modifier	O
of	O
the	O
CYP3A4	O
oxygenase	O
.	O

However	O
,	O
because	O
they	O
are	O
microsomes	O
(	O
particles	O
of	O
broken	O
endoplasmic	O
reticulum	O
)	O
,	O
other	O
enzymes	O
(	O
proteins	O
)	O
of	O
the	O
endoplasmic	O
reticulum	O
membrane	O
(	O
ie	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
and	O
cytochrome	B
b	I
_5	I
)	O
are	O
also	O
expressed	O
at	O
basal	O
levels	O
in	O
these	O
Supersomes	O
(	O
Gentest	O
Corp	O
.	O
,	O
Woburn	O
,	O
MI	O
,	O
USA	O
)	O
.	O

We	O
also	O
utilized	O
CYP3A4	O
-	O
Supersomes	O
which	O
also	O
contained	O
over	O
-	O
expressed	O
cytochrome	B
b	I
_5	I
,	O
in	O
a	O
molar	O
ratio	O
of	O
CYP3A4	O
to	O
cytochrome	B
b	I
_5	I
of	O
1	O
-	O
5	O
(	O
Gentest	O
Corp	O
.	O
,	O
Woburn	O
,	O
MI	O
,	O
USA	O
)	O
.	O

Incubation	O
mixtures	O
used	O
to	O
study	O
the	O
ellipticine	O
metabolism	O
by	O
human	O
hepatic	O
microsomes	O
or	O
Supersomes	O
contained	O
in	O
a	O
final	O
volume	O
of	O
0	O
.	O
5	O
cm	O
^	O
3	O
100	O
mmol	O
dm	O
^	O
3	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
mmol	O
dm	O
^	O
3	O
NADPH	O
or	O
NADH	O
,	O
0	O
.	O
025	O
mmol	O
dm	O
^	O
3	O
ellipticine	O
(	O
dissolved	O
in	O
0	O
.	O
005	O
cm	O
^	O
3	O
dimethyl	O
sulfoxide	O
,	O
DMSO	O
)	O
and	O
0	O
.	O
5	O
mg	O
protein	O
of	O
human	O
hepatic	O
microsomes	O
or	O
100	O
nmol	O
dm	O
^	O
3	O
human	O
recombinant	O
CYP3A4	O
in	O
Supersomes	O
either	O
with	O
or	O
without	O
cytochrome	B
b	I
_5	I
.	O

The	O
incubation	O
mixtures	O
for	O
measuring	O
the	O
testosterone	O
metabolism	O
contained	O
in	O
a	O
final	O
volume	O
of	O
0	O
.	O
5	O
cm	O
^	O
3	O
:	O
100	O
mmol	O
dm	O
^	O
3	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
50	O
mol	O
dm	O
^	O
3	O
testosterone	O
(	O
0	O
.	O
0025	O
cm	O
^	O
3	O
of	O
stock	O
methanol	O
solution	O
per	O
incubation	O
)	O
,	O
1	O
mmol	O
dm	O
^	O
3	O
NADPH	O
or	O
NADH	O
,	O
and	O
100	O
nmol	O
dm	O
^	O
3	O
human	O
recombinant	O
CYP3A4	O
in	O
Supersomes	O
either	O
with	O
or	O
without	O
cytochrome	B
b	I
_5	I
.	O

Incubation	O
mixtures	O
used	O
to	O
assess	O
DNA	O
adduct	O
formation	O
by	O
ellipticine	O
contained	O
0	O
.	O
5	O
mg	O
protein	O
of	O
human	O
hepatic	O
microsomes	O
or	O
100	O
nmol	O
dm	O
^	O
3	O
human	O
recombinant	O
CYP3A4	O
in	O
Supersomes	O
either	O
with	O
or	O
without	O
cytochrome	B
b	I
_5	I
,	O
0	O
.	O
1	O
mmol	O
dm	O
^	O
3	O
ellipticine	O
(	O
dissolved	O
in	O
0	O
.	O
0075	O
cm	O
^	O
3	O
methanol	O
)	O
,	O
and	O
0	O
.	O
5	O
mg	O
of	O
calf	O
thymus	O
DNA	O
in	O
a	O
final	O
volume	O
of	O
0	O
.	O
75	O
cm	O
^	O
3	O
as	O
described	O
previously	O
[	O
,	O
.	O

CYP2B6	O
variants	O
,	O
reference	O
allele	O
P450	O
oxidoreductase	O
(	O
POR	O
)	O
,	O
and	O
reference	O
allele	O
cytochrome	B
b	I
_5	I
vectors	O
were	O
previously	O
generated	O
,	O
and	O
recombinant	O
proteins	O
previously	O
expressed	O
in	O
insect	O
cells	O
,	O
as	O
described	O
.	O
,	O
Haplotype	O
selection	O
was	O
based	O
on	O
the	O
known	O
clinical	O
significance	O
and	O
frequency	O
of	O
the	O
polymorphism	O
,	O
and	O
a	O
desire	O
to	O
inform	O
the	O
mechanistic	O
basis	O
for	O
the	O
influence	O
of	O
these	O
polymorphisms	O
on	O
metabolism	O
.	O

In	O
the	O
case	O
of	O
the	O
Cyp1a2	B
and	O
Cyp2c29	O
,	O
the	O
mRNA	O
expression	O
was	O
significantly	O
decreased	O
in	O
SPF	O
and	O
GF	O
female	O
mice	O
compared	O
to	O
the	O
control	O
.	O

Interestingly	O
,	O
the	O
sex	O
differences	O
were	O
erased	O
in	O
GF	O
mice	O
,	O
and	O
the	O
expression	O
of	O
Cyp3a11	O
was	O
about	O
the	O
same	O
in	O
both	O
sexes	O
.	O

In	O
other	O
words	O
,	O
there	O
is	O
significant	O
interaction	O
between	O
the	O
gender	O
and	O
presence	O
of	O
the	O
gut	O
microbiome	O
,	O
which	O
together	O
influence	O
the	O
Cyp3a11	O
mRNA	O
expression	O
.	O

Sort	O
=	O
Bait	O
interacts	O
with	O
cytochrome	O
P450	O
CYP2E1	O
and	O
CYP11B2	B
,	O
while	O
the	O
affinity	O
of	O
TBXAS1CYP2E1	O
complex	O
formation	O
is	O
fivefold	O
higher	O
in	O
the	O
presence	O
of	O
low	O
-	O
molecular	O
-	O
weight	O
non	O
-	O
peptide	O
endogenous	O
bioregulator	O
isatin	O
(	O
2	O
,	O
3	O
-	O
dioxindole	O
)	O
.	O

CYP11B2	B
,	O
which	O
is	O
also	O
known	O
as	O
aldosterone	O
synthase	O
,	O
additionally	O
exhibits	O
18	O
-	O
hydroxylase	O
and	O
18	O
-	O
methyl	O
oxidase	O
activity	O
,	O
which	O
are	O
required	O
to	O
convert	O
corticosterone	O
to	O
aldosterone	O
via	O
the	O
18	O
-	O
hydroxycorticosterone	O
intermediate	O
.	O

In	O
CYP90B1	O
,	O
the	O
active	O
site	O
is	O
characterized	O
by	O
the	O
conformations	O
side	O
-	O
chain	O
in	O
and	O
steroid	O
-	O
core	O
out	O
,	O
similar	O
to	O
CYP11A1	B
,	O
and	O
for	O
CYP90B1	O
the	O
3	O
-	O
hydroxy	O
group	O
hydrogen	O
is	O
bonded	O
with	O
H385	O
and	O
the	O
carbonyl	O
oxygen	O
of	O
V216	O
via	O
a	O
water	O
molecule	O
.	O

However	O
,	O
due	O
to	O
the	O
perpendicular	O
position	O
of	O
the	O
CYP90B1	O
steroid	O
core	O
,	O
the	O
C	O
-	O
22	O
is	O
located	O
closer	O
to	O
the	O
heme	O
iron	O
(	O
4	O
.	O
1	O
)	O
and	O
gets	O
hydrolyzed	O
,	O
whereas	O
20	O
-	O
C	O
is	O
too	O
far	O
from	O
the	O
heme	O
group	O
(	O
4	O
.	O
9	O
)	O
to	O
get	O
hydrolyzed	O
,	O
unlike	O
in	O
CYP11A1	B
where	O
both	O
positions	O
are	O
hydroxylated	O
.	O

Within	O
the	O
adrenal	O
,	O
A4	O
can	O
serve	O
as	O
a	O
substrate	O
for	O
CYP11B1	B
,	O
yielding	O
the	O
11	O
-	O
oxygenated	O
androgen	O
precursor	O
,	O
11OHA4	O
,	O
with	O
conversion	O
of	O
testosterone	O
to	O
11BETA	O
-	O
hydroxytestosterone	O
(	O
11OHT	O
)	O
,	O
also	O
occurring	O
.	O

The	O
EV	O
CYPs	O
(	O
CYP	B
1A1	I
and	O
2A6	O
)	O
exert	O
an	O
additive	O
effect	O
on	O
the	O
basal	O
CYPs	O
of	O
the	O
recipient	O
cells	O
.	O

The	O
genetic	O
variation	O
of	O
cytochrome	B
B	I
and	O
MHC	O
-	O
DRB	O
differed	O
in	O
Chinese	O
woodchucks	O
with	O
different	O
susceptibility	O
to	O
WHV	O
infection	O
.	O

These	O
data	O
will	O
be	O
benefit	O
for	O
understanding	O
the	O
pathogenesis	O
of	O
hepadnavirus	O
infection	O
,	O
and	O
cytochrome	B
B	I
and	O
MHC	O
-	O
DRB	O
alleles	O
will	O
be	O
helpful	O
for	O
selection	O
suitable	O
animals	O
for	O
WHV	O
infection	O
.	O

5	O
per	O
species	O
)	O
for	O
the	O
cytochrome	O
oxidase	O
subunit	O
1	O
(	O
CO1	O
)	O
and	O
cytochrome	B
B	I
(	O
CytB	O
)	O
gene	O
regions	O
for	O
the	O
shark	O
and	O
teleost	O
species	O
commonly	O
encountered	O
in	O
the	O
West	O
Coast	O
and	O
Gascoyne	O
Coast	O
bioregions	O
of	O
Western	O
Australia	O
were	O
downloaded	O
from	O
GenBank	O
/	O
BOLD	O
databases	O
where	O
available	O
.	O

Orthochlorinated	O
PCBs	O
such	O
as	O
PCB	O
128	O
,	O
PCB	O
153	O
,	O
PCB	O
155	O
and	O
PCB	O
180	O
induce	O
the	O
expression	O
of	O
CYP2B1	B
.	O

While	O
berberine	O
increased	O
CYP1A1	O
mRNA	O
to	O
a	O
level	O
approaching	O
that	O
of	O
TCDD	O
-	O
exposed	O
HepG2	O
cells	O
,	O
our	O
findings	O
suggested	O
that	O
an	O
increase	O
in	O
miR	O
-	O
21	O
-	O
3p	O
might	O
be	O
the	O
reason	O
for	O
the	O
mild	O
increase	O
in	O
CYP1A1	B
protein	I
level	O
by	O
berberine	O
as	O
compared	O
to	O
that	O
induced	O
by	O
TCDD	O
.	O

While	O
the	O
CYP1A1	O
mRNA	O
was	O
increased	O
,	O
berberine	O
-	O
induced	O
miR	O
-	O
21	O
-	O
3p	O
suppressed	O
the	O
increase	O
in	O
CYP1A1	B
protein	I
and	O
function	O
.	O

Likewise	O
Guth	O
did	O
not	O
detect	O
PROD	B
activity	O
in	O
StrataTest	O
^	O
(	O
LOD	O
4	O
pmol	O
/	O
min	O
/	O
mg	O
protein	O
)	O
.	O

Attempts	O
to	O
induce	O
PROD	B
activities	O
in	O
the	O
human	O
reconstructed	O
skin	O
model	O
EpiDerm	O
^	O
using	O
quite	O
a	O
number	O
of	O
CYP2B6	O
inducers	O
(	O
phenobarbital	O
,	O
rifampicin	O
,	O
6	O
-	O
(	O
4	O
-	O
chlorophenyl	O
)	O
imidazo	O
[	O
2	O
,	O
1	O
-	O
b	O
]	O
[	O
1	O
,	O
3	O
]	O
thiazole	O
-	O
5	O
-	O
carbaldehyde	O
-	O
O	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorobenzyl	O
)	O
oxime	O
(	O
CITCO	O
)	O
as	O
well	O
as	O
cyclophosphamide	O
)	O
also	O
failed	O
(	O
Gtz	O
et	O
al	O
.	O
.	O
In	O
contrast	O
to	O
these	O
negative	O
findings	O
Baron	O
et	O
al	O
.	O

report	O
detection	O
of	O
PROD	B
activity	O
in	O
proliferating	O
human	O
keratinocytes	O
in	O
culture	O
and	O
its	O
induction	O
by	O
phenobarbital	O
.	O

reported	O
that	O
native	O
human	O
skin	O
had	O
a	O
low	O
level	O
of	O
CYP3A4	O
protein	O
,	O
moderately	O
induced	O
after	O
24	O
h	O
by	O
2	O
mM	O
phenobarbital	O
,	O
which	O
,	O
however	O
,	O
was	O
not	O
accompanied	O
by	O
an	O
increase	O
in	O
CYP3A4	O
-	O
dependent	O
BROD	B
activity	O
by	O
phenobarbital	O
(	O
0	O
.	O
5	O
-	O
2	O
mM	O
for	O
24	O
,	O
48	O
and	O
72	O
h	O
)	O
nor	O
by	O
rifampicin	O
(	O
50	O
and	O
100	O
M	O
for	O
24	O
h	O
)	O
nor	O
by	O
dexamethasone	O
(	O
10	O
and	O
50	O
M	O
for	O
24	O
,	O
48	O
and	O
72	O
h	O
)	O
.	O

It	O
is	O
unclear	O
why	O
our	O
patient	O
did	O
not	O
exhibit	O
any	O
side	O
or	O
adverse	O
effects	O
;	O
however	O
,	O
it	O
could	O
be	O
that	O
the	O
Carbamazepine	O
he	O
received	O
played	O
a	O
role	O
,	O
although	O
studies	O
have	O
shown	O
that	O
there	O
is	O
little	O
or	O
no	O
in	O
vivo	O
effects	O
of	O
CYP	B
2D6	I
on	O
Paliperidone	O
.	O

CYP26B1	B
metabolizes	O
retinoic	O
acid	O
,	O
a	O
compound	O
with	O
potential	O
anticancer	O
abilities	O
.	O

In	O
this	O
regard	O
,	O
a	O
recent	O
Genome	O
-	O
Wide	O
Association	O
Study	O
revealed	O
an	O
association	O
of	O
CYP26B1	B
with	O
esophageal	O
squamous	O
cell	O
carcinoma	O
risk	O
.	O

In	O
isolated	O
RCs	O
of	O
PSII	O
,	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
was	O
found	O
to	O
exhibit	O
SOD	O
activity	O
.	O

As	O
proposed	O
by	O
Pospil	O
,	O
the	O
catalytic	O
formation	O
of	O
H_2O_2	O
by	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
proceeds	O
as	O
a	O
two	O
-	O
step	O
reduction	O
-	O
oxidation	O
reaction	O
involving	O
two	O
molecules	O
of	O
O_2	O
^	O
.	O

The	O
first	O
step	O
is	O
reduction	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
(	O
Fe	O
^	O
3	O
+	O
)	O
to	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
(	O
Fe	O
^	O
2	O
+	O
)	O
,	O
Reaction	O
(	O
106	O
)	O
.	O

The	O
second	O
step	O
is	O
the	O
oxidation	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
(	O
Fe	O
^	O
2	O
+	O
)	O
by	O
HO_2	O
^	O
,	O
the	O
protonated	O
form	O
of	O
O_2	O
^	O
,	O
with	O
formation	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
(	O
Fe	O
^	O
3	O
+	O
)	O
and	O
H_2O_2	O
,	O
Reaction	O
(	O
107	O
)	O
.	O

In	O
addition	O
,	O
they	O
isolated	O
mitochondrial	O
and	O
cytosol	O
fractions	O
and	O
observed	O
a	O
time	O
-	O
dependent	O
release	O
of	O
Cytochrome	B
C	I
to	O
cytosol	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
release	O
of	O
Cytochrome	B
C	I
from	O
the	O
mitochondria	O
was	O
simultaneous	O
with	O
Aif1p	O
(	O
apoptosis	O
-	O
inducing	O
factor	O
)	O
release	O
;	O
Aif1p	O
is	O
involved	O
in	O
chromatin	O
condensation	O
and	O
DNA	O
degradation	O
;	O
these	O
are	O
related	O
to	O
a	O
function	O
of	O
mitochondrial	O
permeabilization	O
induced	O
by	O
Human	O
Lf	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
kinetics	O
of	O
human	O
CYP17A1	O
favors	O
the	O
conversion	O
of	O
17OH	O
-	O
pregnenolone	O
to	O
dehydroepiandrosterone	O
over	O
that	O
of	O
17OH	O
-	O
progesterone	O
to	O
androstenedione	O
.	O

The	O
apparent	O
K_m	O
and	O
v_max	O
of	O
CYP17A1	O
for	O
17OH	O
-	O
progesterone	O
are	O
10	O
-	O
fold	O
higher	O
(	O
K_m	O
)	O
and	O
10	O
-	O
fold	O
lower	O
(	O
v_max	O
)	O
than	O
those	O
for	O
17OH	O
-	O
pregnenolone	O
.	O

Thus	O
,	O
the	O
catalytic	O
efficiency	O
(	O
k_cat	O
/	O
K_m	O
)	O
for	O
the	O
17	B
,	I
20	I
-	I
lyase	I
reaction	O
by	O
one	O
mole	O
of	O
CYP71A1	O
is	O
about	O
100	O
-	O
fold	O
higher	O
for	O
17OH	O
-	O
pregnenolone	O
than	O
for	O
17OH	O
-	O
progesterone	O
.	O

The	O
absence	O
of	O
SOAT1	O
can	O
increase	O
the	O
availability	O
for	O
the	O
retina	O
of	O
fatty	O
acids	O
,	O
which	O
are	O
used	O
as	O
the	O
enzyme	O
substrates	O
,	O
whereas	O
the	O
absence	O
of	O
Cytochromes	O
P450	O
27a1	O
and	O
CYP46A1	B
abolishes	O
the	O
production	O
of	O
27	O
-	O
hydroxycholesterol	O
and	O
24	O
-	O
hydroxycholesterol	O
,	O
which	O
are	O
activating	O
ligands	O
for	O
LXRs	O
.	O

The	O
present	O
work	O
provides	O
insights	O
into	O
potential	O
mechanisms	O
that	O
could	O
underlie	O
the	O
deteriorations	O
in	O
retinal	O
function	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
.	O

Further	O
studies	O
are	O
required	O
to	O
target	O
more	O
precisely	O
the	O
major	O
contributors	O
to	O
changes	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
.	O

In	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
,	O
retinal	O
function	O
was	O
dependent	O
on	O
sex	O
and	O
was	O
normal	O
in	O
female	O
animals	O
,	O
in	O
agreement	O
with	O
our	O
previous	O
findings	O
that	O
Apolipoprotein	O
E	O
absence	O
elicits	O
strong	O
compensatory	O
mechanisms	O
that	O
minimize	O
retinal	O
impact	O
of	O
this	O
protein	O
absence	O
.	O

Future	O
work	O
will	O
map	O
these	O
responses	O
by	O
retinal	O
proteomics	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
for	O
comparison	O
to	O
Apoe	O
^	O
/	O
results	O
.	O

We	O
propose	O
the	O
following	O
model	O
to	O
unify	O
the	O
available	O
data	O
and	O
to	O
identify	O
the	O
questions	O
that	O
remain	O
unanswered	O
to	O
completely	O
explain	O
changes	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
.	O

Accordingly	O
,	O
glucose	O
utilization	O
and	O
fatty	O
acid	O
BETA	O
-	O
oxidation	O
could	O
be	O
increased	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
as	O
a	O
compensatory	O
response	O
to	O
decreased	O
LXR	O
activation	O
and	O
/	O
or	O
increased	O
fatty	O
acid	O
availability	O
.	O

Apparently	O
,	O
other	O
processes	O
could	O
also	O
become	O
affected	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
as	O
suggested	O
by	O
retinal	O
proteomics	O
.	O

We	O
comprehensively	O
characterized	O
the	O
retina	O
of	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
and	O
identified	O
some	O
of	O
the	O
homeostatic	O
responses	O
to	O
the	O
blockage	O
of	O
the	O
major	O
pathways	O
of	O
retinal	O
cholesterol	O
output	O
and	O
storage	O
.	O

Cyp27b1	B
-	O
KO	O
rats	O
and	O
Vdr	O
(	O
R270L	O
)	O
rats	O
were	O
fed	O
25	O
(	O
OH	O
)	O
D_3	O
for	O
comparison	O
of	O
its	O
effects	O
on	O
rickets	O
symptoms	O
.	O

During	O
25D	O
-	O
F	O
-	O
2	O
feeding	O
,	O
the	O
average	O
daily	O
food	O
intake	O
was	O
18	O
.	O
6	O
3	O
.	O
7	O
g	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
and	O
18	O
.	O
1	O
0	O
.	O
7	O
g	O
in	O
Vdr	O
(	O
R270L	O
)	O
rats	O
,	O
whereas	O
the	O
body	O
weight	O
of	O
Cyp27b1	B
-	O
KO	O
rats	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
Vdr	O
(	O
R270L	O
)	O
rats	O
.	O

Consequently	O
,	O
the	O
food	O
intake	O
per	O
kg	O
body	O
weight	O
was	O
calculated	O
to	O
be	O
113	O
.	O
2	O
16	O
.	O
9	O
g	O
/	O
kg	O
bw	O
/	O
day	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
and	O
56	O
.	O
0	O
6	O
.	O
4	O
g	O
/	O
kg	O
bw	O
/	O
day	O
in	O
Vdr	O
(	O
R270L	O
)	O
rats	O
.	O

Thus	O
,	O
the	O
dose	O
of	O
25	O
(	O
OH	O
)	O
D_3	O
was	O
calculated	O
to	O
be	O
168	O
.	O
9	O
25	O
.	O
1	O
g	O
/	O
kg	O
bw	O
/	O
day	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
and	O
80	O
.	O
9	O
7	O
.	O
7	O
g	O
/	O
kg	O
bw	O
/	O
day	O
in	O
Vdr	O
(	O
R270L	O
)	O
rats	O
(	O
the	O
values	O
are	O
shown	O
as	O
the	O
means	O
SEMs	O
(	O
n	O
=	O
2	O
-	O
3	O
animals	O
/	O
group	O
)	O
)	O
.	O

Liver	O
mitochondrial	O
and	O
microsomal	O
fractions	O
were	O
prepared	O
from	O
Cyp27b1	B
-	O
KO	O
rats	O
using	O
the	O
same	O
methods	O
as	O
described	O
in	O
our	O
previous	O
study	O
^	O
.	O

Two	O
-	O
way	O
ANOVA	O
was	O
performed	O
for	O
the	O
analysis	O
of	O
the	O
bone	O
mineral	O
density	O
and	O
levels	O
of	O
plasma	O
Ca	O
,	O
Parathyroid	O
Hormone	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
,	O
25	O
(	O
OH	O
)	O
D_3	O
and	O
its	O
metabolites	O
in	O
Cyp27b1	B
-	O
KO	O
and	O
mutant	O
Vdr	O
(	O
R270L	O
)	O
rats	O
fed	O
the	O
F	O
-	O
2	O
or	O
25D	O
-	O
F	O
-	O
2	O
diet	O
.	O

